PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Betts, CD; Astarloa, L; Bloch, C; Zacarias, F; Chelala, C				Betts, CD; Astarloa, L; Bloch, C; Zacarias, F; Chelala, C			The changing face of AIDS in Argentina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MINIST HLTH & SOCIAL ACT ARGENTINA,NATL PROGRAM AGAINST HUMAN RETROVIRUS & AIDS,BUENOS AIRES,DF,ARGENTINA; PAN AMER HLTH ORG,WHO,REG AIDS STD PROGRAM,BUENOS AIRES,DF,ARGENTINA	Pan American Health Organization; World Health Organization								ASTARLOA L, 1995, P 10 LAT AM STD C 4; AVOLIO J, 1993, 9 INT C AIDS JUN 6 1; CAHN P, 1989, 5 INT C AIDS JUN 4 9; CASIRO A, 1989, 5 INT C AIDS JUN 4 9; FAY O, 1989, 5 INT C AIDS JUN 4 9; MULTARE S, 1992, 8 INT C AIDS JUL 19; *PAN AM HLTH ORG, 1995, AIDS SURV AM Q REP; *PAN AM HLTH ORG, 1994, 1992 AIDS HIV STD AN; RIOMOLDI I, 1992, 8 INT C AIDS JUL 19; *US BUR CENS, 1995, HIV AIDS SURV DAT BA	10	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					94	96		10.1001/jama.276.2.94	http://dx.doi.org/10.1001/jama.276.2.94			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656518				2022-12-24	WOS:A1996UV48500007
J	Andrews, K; Murphy, L; Munday, R; Littlewood, C				Andrews, K; Murphy, L; Munday, R; Littlewood, C			Misdiagnosis of the vegetative state: Retrospective study in a rehabilitation unit	BRITISH MEDICAL JOURNAL			English	Article							PERSISTENT	Objective-To identify the number of patients who were misdiagnosed as being in the vegetative state and their characteristics. Design-Retrospective study of the clinical records of the medical, occupational therapy, and clinical psychology departments. Setting-20 bed unit specialising in the rehabilitation of patients with profound brain damage, including the vegetative state. Subjects-40 patients admitted between 1992 and 1995 with a referral diagnosis of vegetative state. Outcome measures-Patients who showed an ability to communicate consistently using eye pointing or a touch sensitive single switch buzzer. Results-Of the 40 patients referred as being in the vegetative state, 17 (43%) were considered as having been misdiagnosed; seven of these had been presumed to be vegetative for longer than one year, including three for over four years. Most of the misdiagnosed patients were blind or severely visually impaired. All patients remained severely physically disabled, but nearly all were able to communicate their preference in quality of life issues-some to a high level. Conclusions-The vegetative state needs considerable skill to diagnose, requiring assessment over a period of time; diagnosis cannot be made, even by the most experienced clinician, from a bedside assessment. Accurate diagnosis is possible but requires the skills of a multidisciplinary team experienced in the management of people with complex disabilities. Recognition of awareness is essential if an optimal quality of life is to be achieved and to avoid inappropriate approaches to the courts for a declaration for withdrawal of tube feeding.			Andrews, K (corresponding author), ROYAL HOSP NEURODISABIL,LONDON SW15 3SW,ENGLAND.							ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Hagen C., 1980, REHABILITATION HEAD, P87; JENNETT B, 1991, BMJ-BRIT MED J, V302, P1256, DOI 10.1136/bmj.302.6787.1256; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; 1996, J R COLL PHYSICIANS, V30, P119; 1994, NEW ENGL J MED, V330, P1499; [No title captured]	11	558	572	2	40	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					13	16		10.1136/bmj.313.7048.13	http://dx.doi.org/10.1136/bmj.313.7048.13			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664760	Green Published			2022-12-24	WOS:A1996UW66700022
J	Goldsborough, AS; Kornberg, TB				Goldsborough, AS; Kornberg, TB			Reduction of transcription by homologue asynapsis in Drosophila imaginal discs	NATURE			English	Article							GENE-COMPLEX; MELANOGASTER; TRANSVECTION; TRANS; EXPRESSION; MUTATIONS	THE interactions between enhancers and promoter elements that control gene expression are generally considered to act in cis only, but genetic studies suggest that they can also function in trans between non-contiguous DNA molecules. Termed transvection(1), such trans interactions have been proposed to be responsible for several examples of intragenic complementation in Drosophila(1-9). Transvection is thought to depend on the physical proximity of sister chromosomes(10,11), because it is inhibited when chromosome rearrangements reduce the pairing of homologues(1,3,5). This led to the suggestion that transvection occurs enhancer elements on one chromosome regulate expression on the other(7,12), with the pairing dependence resulting from a need for proximity between the two copies of the gene. Here we have analysed the levels of transcription from both alleles of the Drosophila Ultra-bithorax (Ubx) gene, and report that the predictions of this simple model are not supported. Our findings indicate a more complex level of trans regulation that may have implications for the aetiology of genetic disorders that are influenced by chromosome rearrangements.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								ASHBURNE.M, 1967, NATURE, V214, P1159, DOI 10.1038/2141159b0; BABU P, 1980, DEV NEUROBIOLOGY DRO, P35; CASTELLIGAIR JE, 1990, GENETICS, V126, P177; DREESEN TD, 1991, GENE DEV, V5, P331, DOI 10.1101/gad.5.3.331; GELBART WM, 1982, P NATL ACAD SCI-BIOL, V79, P2636, DOI 10.1073/pnas.79.8.2636; GELBART WM, 1982, GENETICS, V102, P179; GEYER P, 1990, EMBO J, V9, P224; GOLDSBOROUGH AS, 1994, P NATL ACAD SCI USA, V91, P12696, DOI 10.1073/pnas.91.26.12696; JACK JW, 1979, P NATL ACAD SCI USA, V76, P1368, DOI 10.1073/pnas.76.3.1368; JUDD BH, 1988, CELL, V53, P841, DOI 10.1016/S0092-8674(88)90209-7; KORNHER JS, 1986, CELL, V44, P879, DOI 10.1016/0092-8674(86)90010-3; LEISERSON WM, 1994, GENETICS, V138, P1171; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MULLER HP, 1990, TRENDS GENET, V6, P300, DOI 10.1016/0168-9525(90)90236-Y; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; WHITE RAH, 1985, NATURE, V318, P567, DOI 10.1038/318567a0; ZACHAR Z, 1985, COLD SPRING HARB SYM, V50, P337, DOI 10.1101/SQB.1985.050.01.043	18	53	54	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					807	810		10.1038/381807a0	http://dx.doi.org/10.1038/381807a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657287				2022-12-24	WOS:A1996UU35600066
J	Liu, F; Hata, A; Baker, JC; Doody, J; Carcamo, J; Harland, RM; Massague, J				Liu, F; Hata, A; Baker, JC; Doody, J; Carcamo, J; Harland, RM; Massague, J			A human Mad protein acting as a BMP-regulated transcriptional activator	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; VENTRALIZING FACTOR; MAMMALIAN-CELLS; INDUCTION; MESODERM	THE TGF-beta/activin/BMP cytokine family signals through serine/threonine kinase receptors, but how the receptors transduce the signal is unknown. The Mad (Mothers against decapentaplegic) gene from Drosophila(1) and the related Sma genes from Caenorhabditis elegans(2) have been genetically implicated in signalling by members of the bone-morphogenetic-protein (BMP) subfamily. We have cloned Smad1, a human homologue of Mad and Sma. Microinjection of Smad1 messenger RNA into Xenopus embryo animal caps mimics the mesoderm-ventralizing effects of BMP4. Smad1 moves into the nucleus in response to BMP4. Smad1 has transcriptional activity when fused to a heterologous DNA-binding domain, and this activity is increased by BMP4 acting through BMP-receptor types I and II. The transactivating activity resides in the conserved carboxy-terminal domain of Smad1 and is disrupted by a nonsense mutation that corresponds to null mutations found in Mad and in the related gene DPC4, a candidate tumour-suppressor gene in human pancreatic cancer(3), Additionally, we show that DPC4 contains a transcriptional activation domain. The results suggests that the Smad proteins are a new class of transcription factors that mediate responses to the TGF-beta family.	MEM SLOAN KETTERING CANC CTR,CELL BIOL PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94709	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; University of California System; University of California Berkeley				Massague, Joan/0000-0001-9324-8408				CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DALE L, 1992, DEVELOPMENT, V115, P573; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; JONES CM, 1992, DEVELOPMENT, V115, P639; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LENNON GG, IN PRESS GENOMICS; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU F, 1995, MOL CELL BIOL, V15, P3479; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	23	570	601	1	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					620	623		10.1038/381620a0	http://dx.doi.org/10.1038/381620a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637600				2022-12-24	WOS:A1996UQ65700055
J	Csink, AK; Henikoff, S				Csink, AK; Henikoff, S			Genetic modification of heterochromatic association and nuclear organization in Drosophila	NATURE			English	Article							POSITION-EFFECT VARIEGATION; MELANOGASTER; EXPRESSION	HETEROCHROMATIN is the highly compact, usually pericentromeric, region of eukaryotic chromosomes. Unlike the more gene-rich euchromatin, heterochromatin remains condensed during interphase, when it is sequestered to the periphery of the nucleus(1-3). Here we show, by using fluorescent in situ hybridization to interphase diploid nuclei of Drosophila, that the insertion of heterochromatin into a euchromatic gene, which results in position-effect variegation (PEV), also causes the aberrant association of the gene and its homologous copy with heterochromatin. In correlation with the gene's mutant variegating phenotype, the cytological association of the heterochromatic region is affected by chromosomal distance from heterochromatin and by genic modifiers of PEV. Proteins that are thought to be involved in the formation of heterochromatin can therefore influence the interphase nuclear position of a chromosomal region. This suggests that heterochromatin and proteins involved in its formation provide a structural framework for the interphase nucleus.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute				Henikoff, Steven/0000-0002-7621-8685				Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; EBERL DF, 1993, GENETICS, V134, P277; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Heitz E, 1928, JAHRB WISS BOT, V69, P762; HENIKOFF S, 1989, P NATL ACAD SCI USA, V86, P6704, DOI 10.1073/pnas.86.17.6704; HENIKOFF S, 1995, GENETICS, V140, P1007; KELLUM R, 1995, J CELL SCI, V108, P1407; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOCKE J, 1988, GENETICS, V120, P181; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; MAKUNIN IV, 1995, DOKL AKAD NAUK+, V344, P266; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Marshall WF, 1996, MOL BIOL CELL, V7, P825, DOI 10.1091/mbc.7.5.825; MAYFIELD JE, 1975, CHROMOSOMA, V52, P37, DOI 10.1007/BF00285787; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; Sokal R. R, 1981, BIOMETRY; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; Swedlow JR, 1993, CURR OPIN CELL BIOL, V5, P412, DOI 10.1016/0955-0674(93)90005-B; TALBERT PB, 1994, GENETICS, V136, P559; VOURCH C, 1993, EXP CELL RES, V205, P142, DOI 10.1006/excr.1993.1068; WAKIMOTO BT, 1990, GENETICS, V125, P141; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3	23	269	279	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					529	531		10.1038/381529a0	http://dx.doi.org/10.1038/381529a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632827				2022-12-24	WOS:A1996UP43500062
J	Douglas, AS; Allan, TM; Helms, PJ				Douglas, AS; Allan, TM; Helms, PJ			Seasonality and the sudden infant death syndrome during 1987-9 and 1991-3 in Australia and Britain	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SLEEPING POSITION	Objective-To determine whether seasonality of the sudden infant death syndrome persists now that rates have fallen, mostly after widespread adoption of the ''face upwards' sleeping position. Design-Monthly data on the sudden infant death syndrome during 1987-9 were compared for seasonality with those of 1991-3; rates were studied as deaths per 1000 live births. Setting-Australia and Britain (England,Wales, and Scotland). Subjects-Infants under 1 year dying of the syndrome (2401 for Australia and 6630 for Britain). Main outcome measure-Extent of seasonal variation (amplitude) was established by cosinor analysis; amplitudes for the earlier and later years were compared. Results-The rate fell in every month, and, though it did so relatively more in winter than summer, seasonality remained a distinctive feature. In the comparison of amplitudes the ratio between the earlier and later years was 1.4 in both Australia and Britain. Some differences between the hemispheres were noted. Conclusions-Seasonality of the sudden infant death syndrome remains to be explained and continues to be an important aetiological lead. Studies from other countries are needed.	UNIV ABERDEEN, WELLCOME RES LIB, SCH MED, ABERDEEN AB9 2ZD, SCOTLAND; UNIV ABERDEEN, DEPT CHILD HLTH, SCH MED, ABERDEEN AB9 2ZD, SCOTLAND	University of Aberdeen; University of Aberdeen	Douglas, AS (corresponding author), UNIV ABERDEEN, DEPT MED & THERAPEUT, SCH MED, FORESTERHILL, ABERDEEN AB9 2ZD, SCOTLAND.							Abramson H, 1944, J PEDIATR-US, V25, P404, DOI 10.1016/S0022-3476(44)80005-1; ALLAN TM, 1994, SEASONAL VARIATION H; ARENDT J, 1995, MELATONIN MAMMALIAN, P207; Arrundale J., 1993, Health Bulletin (Edinburgh), V51, P106; BEAL S, 1994, MED J AUSTRALIA, V160, P660; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BOLTON DPG, 1993, ARCH DIS CHILD, V69, P187, DOI 10.1136/adc.69.2.187; CAMPBELL MJ, 1994, J ROY STAT SOC A STA, V157, P191, DOI 10.2307/2983358; DOUGLAS AS, 1991, LANCET, V337, P1393, DOI 10.1016/0140-6736(91)93069-L; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FLEMING PJ, 1993, ACTA PAEDIATR, V82, P57, DOI 10.1111/j.1651-2227.1993.tb12878.x; GILMAN EA, 1995, BRIT MED J, V310, P631, DOI 10.1136/bmj.310.6980.631; KAADA B, 1994, ACTA PAEDIATR, V83, P548, DOI 10.1111/j.1651-2227.1994.tb13079.x; MINORS DS, 1989, BIOL RHYTHMS CLIN PR, P172; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; NELSON EAS, 1989, LANCET, V1, P199; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; PEARCE EA, 1993, WORLD WEATHER GUIDE; Sothern R., 1972, PHYSIOL TEACH, V1, P1; WAKLEY T, 1855, LANCET, V1, P103; WEISSBLUTH L, 1994, J THEOR BIOL, V167, P13, DOI 10.1006/jtbi.1994.1046; WIGFIELD R, 1994, EARLY HUM DEV, V38, P161, DOI 10.1016/0378-3782(94)90208-9; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282	25	34	35	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 1	1996	312	7043					1381	1383						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP434	8646093	Green Published			2022-12-24	WOS:A1996UP43400017
J	Zhu, X; Jiang, MS; Peyton, M; Boulay, G; Hurst, R; Stefani, E; Birnbaumer, L				Zhu, X; Jiang, MS; Peyton, M; Boulay, G; Hurst, R; Stefani, E; Birnbaumer, L			trp, a novel mammalian gene family essential for agonist-activated capacitative Ca2+ entry	CELL			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; MOLECULAR-CLONING; DROSOPHILA PHOTORECEPTORS; INTRACELLULAR CALCIUM; ACINAR-CELLS; MAST-CELLS; INFLUX; PHOTOTRANSDUCTION; MOBILIZATION; EXCITATION	Capacitative calcium entry (CCE) describes Ca2+ influx into cells that replenishes Ca2+ stores emptied through the action of IP3 and other agents. It is an essential component of cellular responses to many hormones and growth factors. The molecular basis of this form of Ca2+ entry is complex and may involve more than one type of channel. Studies on visual signal transduction in Drosophila led to the hypothesis that a protein encoded in frp may be a component of CCE channels. We report the existence of six trp-related genes in the mouse genome. Expression in L cells of small portions of these genes in antisense orientation suppressed CCE. Expression in COS cells of two full-length cDNAs encoding human trp homologs, Htrp1 and Htrp3, increased CCE. This identifies mammalian gene products that participate in CCE. We propose that trp homologs are subunits of CCE channels, not unlike those of classical voltage-gated ion channels.			Zhu, X (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT ANESTHESIOL,DEPT BIOL CHEM,LOS ANGELES,CA 90095, USA.		Boulay, Guylain/D-9773-2010; Peyton, Michael/A-8728-2008		NHLBI NIH HHS [HL-45198] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERVEN LA, 1994, BIOCHEM J, V299, P399, DOI 10.1042/bj2990399; BERVEN LA, 1995, J BIOL CHEM, V270, P25893, DOI 10.1074/jbc.270.43.25893; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BYRON KL, 1995, J PHYSIOL-LONDON, V485, P455, DOI 10.1113/jphysiol.1995.sp020742; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOW TW, 1992, BLOOD, V80, P113; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; FOSKETT JK, 1994, J BIOL CHEM, V269, P31525; GILON P, 1995, J BIOL CHEM, V270, P8050, DOI 10.1074/jbc.270.14.8050; Grudt TJ, 1996, MOL BRAIN RES, V36, P93, DOI 10.1016/0169-328X(95)00248-Q; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HARDIE RC, 1994, J GEN PHYSIOL, V103, P409, DOI 10.1085/jgp.103.3.409; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HARTENECK C, 1995, FEBS LETT, V358, P297, DOI 10.1016/0014-5793(94)01455-A; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU Y, 1994, BIOCHEM BIOPH RES CO, V132, P346; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; JAMESKRACKE MR, 1994, J PHARMACOL EXP THER, V271, P824; KASS GEN, 1993, BIOCHIM BIOPHYS ACTA, V1223, P226; KUHN LC, 1984, CELL, V37, P95, DOI 10.1016/0092-8674(84)90304-0; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LEVY FO, 1992, J BIOL CHEM, V267, P7553; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIAO CF, 1990, J BIOL CHEM, V265, P11273; MATHES C, 1994, J GEN PHYSIOL, V104, P107, DOI 10.1085/jgp.104.1.107; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MONTERO M, 1994, J BIOL CHEM, V269, P29451; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RANDRIAMAMPITA C, 1994, J BIOL CHEM, V269, P29; RUDOLPH U, 1993, TRANSGENIC RES, V2, P345, DOI 10.1007/BF01976176; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILLING WP, 1992, BIOCHEM J, V284, P521, DOI 10.1042/bj2840521; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUSS E, 1989, J GEN PHYSIOL, V94, P465, DOI 10.1085/jgp.94.3.465; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	64	580	610	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1996	85	5					661	671		10.1016/S0092-8674(00)81233-7	http://dx.doi.org/10.1016/S0092-8674(00)81233-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646775	Bronze			2022-12-24	WOS:A1996UP34400007
J	Derrick, BE; Martinez, JL				Derrick, BE; Martinez, JL			Associative, bidirectional modifications at the hippocampal mossy fibre-CA3 synapse	NATURE			English	Article							LONG-TERM POTENTIATION; FIBER SYNAPSES; AREA CA1; DEPRESSION; INDUCTION; NEURONS; PLASTICITY; FORMS; CELLS	LONG-TERM potentiation (LTP) and long-term depression (LTD) are activity-dependent changes in synaptic strength that may serve as the cellular mechanisms of information storage in the vertebrate brain(1-4). The messy fibre-CA3 synapse displays NMDA (N-methyl-D-aspartate) receptor-independent forms of LTP(5-8) and LTD(9-11) that were thought to be non-associative(9-11). Here we report that the messy fibre-CA3 synapse displays each of the known types of LTD in vivo, including associative, heterosynaptic acid homosynaptic LTD. These types of LTD are induced when only two of the three conditions necessary for messy fibre LTP induction are provided. Because some of these conditions can be provided by convergent CA3 afferents, each type of LTD can be induced in an associative manner, which suggests that LTD is involved in associative information storage. Similar to the induction of NMDA receptor-dependent LTD and LTP at other cortical synapses, messy fibre LTD occurs when synaptic conditions are insufficient to induce LTP, and both LTP and LTD induction are influenced by previous synaptic activity, consistent with the view that common principles govern activity-dependent plasticity at cortical synapses(2,12,22).			Derrick, BE (corresponding author), UNIV TEXAS,DIV LIFE SCI,SAN ANTONIO,TX 78249, USA.							ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADLER JE, 1990, NEUROSCIENCE, V35, P265, DOI 10.1016/0306-4522(90)90080-N; CAUDLE RM, 1991, J PHARMACOL EXP THER, V258, P18; CHATTARJI S, 1989, BRAIN RES, V495, P145, DOI 10.1016/0006-8993(89)91228-6; DERRICK BE, 1994, P NATL ACAD SCI USA, V91, P10290, DOI 10.1073/pnas.91.22.10290; DERRICK BE, 1994, J NEUROSCI, V14, P4359; DERRICK BE, 1992, J PHARMACOL EXP THER, V263, P725; DRAKE CT, 1994, J NEUROSCI, V14, P3736; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; Intrator Nathan, 1993, P147; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; LAW CC, 1994, P NATL ACAD SCI USA, V91, P7797, DOI 10.1073/pnas.91.16.7797; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; MARTINEZ JL, 1995, A REV PSYCHOL, V47, P173; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MONTAGUE PR, 1994, LEARN MEMORY, V1, P1; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; WAGNER JJ, 1990, NEUROSCIENCE, V37, P45, DOI 10.1016/0306-4522(90)90190-F; WELSSKOPF M, 1993, NATURE, V362, P423; WHITE G, 1990, J NEUROPHYSIOL, V64, P1186, DOI 10.1152/jn.1990.64.4.1186; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; WILSHAW D, 1990, NEURAL COMPUT, V2, P85; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	29	34	35	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					429	434		10.1038/381429a0	http://dx.doi.org/10.1038/381429a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632800				2022-12-24	WOS:A1996UN47900053
J	Larsen, CP; Elwood, ET; Alexander, DZ; Ritchie, SC; Hendrix, R; TuckerBurden, C; Cho, HR; Aruffo, A; Hollenbaugh, D; Linsley, PS; Winn, KJ; Pearson, TC				Larsen, CP; Elwood, ET; Alexander, DZ; Ritchie, SC; Hendrix, R; TuckerBurden, C; Cho, HR; Aruffo, A; Hollenbaugh, D; Linsley, PS; Winn, KJ; Pearson, TC			Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways	NATURE			English	Article							TRANSPLANTATION TOLERANCE; MONOCLONAL-ANTIBODIES; CELL ACTIVATION; LYMPHOCYTES-T; RECEPTOR; ANTIGEN; INVIVO; COSTIMULATION; ALLOANTIGEN; EXPRESSION	THE receptor-ligand pairs CD28-B7 and CD40-gp39 are essential For the initiation and amplification of T-cell-dependent immune responses(1,2). CD28-B7 interactions provide 'second signals' necessary for optimal T-cell activation and IL-2 production(3-5), whereas CD40-gp39 signals co-stimulate B-cell, macrophage, endothelial cell and T-cell activation(6-12). Nonetheless, blockade of either of these pathways alone is not sufficient to permit engraftment of highly immunogenic allografts(13-15). Here we report that simultaneous but not independent blockade of the CD28 and CD40 pathways effectively aborts T-cell clonal expansion in vitro and in vivo, promotes long-term survival of fully allogeneic skin grafts, and inhibits the development of chronic vascular rejection of primarily vascularized cardiac allografts. The requirement for simultaneous blockade of these pathways for effective inhibition of alloimmunity indicates that, although they are interrelated, the CD28 and CD40 pathways are critical independent regulators of T-cell-dependent immune responses.	EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,CARLOS & MARGUERITE MASON TRANSPLANTAT RES CTR,ATLANTA,GA 30322; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Emory University; Emory University; Bristol-Myers Squibb	Larsen, CP (corresponding author), EMORY UNIV,SCH MED,DEPT SURG,1639 PIERCE DR,ATLANTA,GA 30322, USA.		Larsen, Christian P./B-6906-2012	Larsen, Christian P./0000-0001-6573-2649				ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; JENKINS MK, 1991, J IMMUNOL, V147, P2461; KAYE J, 1988, NATURE, V336, P580, DOI 10.1038/336580a0; Larsen CP, 1996, TRANSPLANTATION, V61, P4, DOI 10.1097/00007890-199601150-00002; LARSEN CP, 1994, J IMMUNOL, V152, P5208; LIDSTAD ST, 1984, NATURE, V307, P168; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MAYUMI H, 1989, J EXP MED, V169, P213, DOI 10.1084/jem.169.1.213; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; Pearson TC, 1996, TRANSPLANTATION, V61, P997, DOI 10.1097/00007890-199604150-00002; PEARSON TC, 1993, TRANSPLANTATION, V55, P361, DOI 10.1097/00007890-199302000-00025; PEREIRA GMB, 1990, J IMMUNOL, V144, P2109; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0	29	1217	1283	2	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					434	438		10.1038/381434a0	http://dx.doi.org/10.1038/381434a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632801				2022-12-24	WOS:A1996UN47900054
J	Paunio, M; Virtamo, J; Gref, CG; Heinonen, OP				Paunio, M; Virtamo, J; Gref, CG; Heinonen, OP			Serum high density lipoprotein cholesterol, alcohol, and coronary mortality in male smokers	BRITISH MEDICAL JOURNAL			English	Article							RESEARCH CLINICS PREVALENCE; ACUTE MYOCARDIAL-INFARCTION; HEART-DISEASE; CARDIOVASCULAR-DISEASE; ETHANOL INTOXICATION; BRAIN INFARCTION; MEN; RISK; CONSUMPTION; SUBFRACTIONS	Objective-To determine whether the increase in mortality from coronary heart disease with high concentrations (>1.75 mmol/1) of high density Lipoprotein cholesterol could be due to alcohol intake. Design-Cohort study. Setting-Placebo group of the alpha tocopherol, beta carotene cancer prevention (ATBC) study of south western population in Finland. Participants-7052 male smokers aged 50-69 years enrolled to the ATBC study in the 1980s. Main outcome measures-The relative and absolute rates for clinically or pathologically verified deaths from coronary heart disease for different concentrations of high density lipoprotein cholesterol with and without stratification for alcohol intake. Similar rates were also calculated for different alcohol consumption groups. Results-During the average follow up period of 6.7 years 258 men died from verified coronary heart disease. Coronary death rate steadily decreased with increasing concentration of high density Lipoprotein cholesterol until a high concentration. An increase in the rate was observed above 1.75 mol/1. This increase occurred among those who reported alcohol intake. Mortality was associated with alcohol intake in a J shaped dose response, and those who reported consuming more than five drinks a day (heavy drinkers) had the highest death rate. Mortality was higher in heavy drinkers than in non-drinkers or light or moderate drinkers in all high density lipoprotein categories from 0.91 mmol/1 upward. Conclusions-Mortality from coronary heart disease increases at concentrations of high density lipoprotein cholesterol over 1.75 mmol/1. The mortality was highest among heavy drinkers, but an increase was found among light drinkers also.	HELSINKI NATL PUBL HLTH INST,HELSINKI,FINLAND		Paunio, M (corresponding author), HELSINKI UNIV,DEPT PUBL HLTH,POB 21,SF-00014 HELSINKI,FINLAND.				DIVISION OF CANCER PREVENTION AND CONTROL [N01CN045165] Funding Source: NIH RePORTER; NCI NIH HHS [N0I-CN-45165] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, Ann Epidemiol, V4, P1, DOI 10.1016/1047-2797(94)90036-1; Barrett-Connor E, 1992, Ann Epidemiol, V2, P77, DOI 10.1016/1047-2797(92)90040-W; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; FRIEDMAN GD, 1993, NEW ENGL J MED, V329, P1882, DOI 10.1056/NEJM199312163292510; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GOLDBOURT U, 1990, ARTERIOSCLEROSIS, V10, P512, DOI 10.1161/01.ATV.10.4.512; GOLDBOURT U, 1979, AM J EPIDEMIOL, V109, P296, DOI 10.1093/oxfordjournals.aje.a112683; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON DJ, 1986, CIRCULATION, V74, P1217, DOI 10.1161/01.CIR.74.6.1217; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HILLBOM M, 1983, NEUROLOGY, V33, P381, DOI 10.1212/WNL.33.3.381; HILLBOM M, 1985, STROKE, V16, P19, DOI 10.1161/01.STR.16.1.19; HILLBOM M, 1990, ANN MED, V22, P347, DOI 10.3109/07853899009147918; HILLBOM ME, 1983, EUR J CLIN INVEST, V13, P45, DOI 10.1111/j.1365-2362.1983.tb00063.x; JACKSON R, 1992, AM J EPIDEMIOL, V136, P819, DOI 10.1093/aje/136.7.819; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; KAPRIO J, 1982, INT J EPIDEMIOL, V11, P378, DOI 10.1093/ije/11.4.378; KATTERMANN R, 1984, J CLIN CHEM CLIN BIO, V22, P245; KUSTNER GM, 1976, CLIN CHEM, V22, P695; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LEE ET, 1980, STATISTICAL METHODS; MCGARRY GW, 1994, BRIT MED J, V309, P640, DOI 10.1136/bmj.309.6955.640; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; MOREYRA AE, 1982, CLIN CARDIOL, V5, P425, DOI 10.1002/clc.4960050707; PAUNIO M, 1994, CIRCULATION, V90, P2909, DOI 10.1161/01.CIR.90.6.2909; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PIETINEN P, 1988, AM J EPIDEMIOL, V128, P655, DOI 10.1093/oxfordjournals.aje.a115013; REED D, 1986, AM J MED, V80, P871, DOI 10.1016/0002-9343(86)90631-5; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Romanov K, 1987, Alcohol Alcohol Suppl, V1, P619; ROSSII KZ, 1994, GOSUDARSTVENNY NAUCH; *SAS STAT SOFTW, 1991, PHREG PROC PREL DOC; SHESTOV DB, 1993, CIRCULATION, V88, P846, DOI 10.1161/01.CIR.88.3.846; SHESTOV DB, 1982, NIH831966 US DEP HLT, P391; SIMPURA J, 1995, ADDICTION, V90, P673, DOI 10.1111/j.1360-0443.1995.tb02205.x; STENSVOLD I, 1992, EUR HEART J, V13, P1155, DOI 10.1093/oxfordjournals.eurheartj.a060331; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; TASKINEN MR, 1982, METABOLISM, V31, P1168, DOI 10.1016/0026-0495(82)90169-X; WANNAMETHEE G, 1988, J ROY COLL GEN PRACT, V38, P440; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; 1986, PREV MED, V15, P254; 1994, NEW ENGL J MED, V330, P1029	43	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1200	1203						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634563				2022-12-24	WOS:A1996UL05800019
J	Olson, KE; Higgs, S; Gaines, PJ; Powers, AM; Davis, BS; Kamrud, KI; Carlson, JO; Blair, CD; Beaty, BJ				Olson, KE; Higgs, S; Gaines, PJ; Powers, AM; Davis, BS; Kamrud, KI; Carlson, JO; Blair, CD; Beaty, BJ			Genetically engineered resistance to dengue-2 virus transmission in mosquitoes	SCIENCE			English	Article							AMINO-ACID SEQUENCE; YELLOW-FEVER VIRUS; NUCLEOTIDE-SEQUENCE; MONOCLONAL-ANTIBODIES; JAMAICA GENOTYPE; TYPE-2 VIRUS; PROTEINS; EXPRESSION; GENOME; RNA	The control of arthropod-borne virus diseases such as dengue may ultimately require the genetic manipulation of mosquito vectors to disrupt virus transmission to human populations. To reduce the ability of mosquitoes to transmit dengue viruses, a recombinant Sindbis virus was used to transduce female Aedes aegypti with a 567-base antisense RNA targeted to the premembrane coding region of dengue type 2 (DEN-2) virus. The transduced mosquitoes were unable to support replication of DEN-P virus in their salivary glands and therefore were not able to transmit the virus.			Olson, KE (corresponding author), COLORADO STATE UNIV,DEPT MICROBIOL,ARTHROPAD BARNE & INFECT DIS LAB,FT COLLINS,CO 80523, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034014] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07352, AI34014] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHBURNER M, 1995, SCIENCE, V270, P1941, DOI 10.1126/science.270.5244.1941; BEATY BJ, 1979, MOSQ NEWS, V39, P232; BESANSKY NJ, 1995, PARASITOL TODAY, V270, P1941; CARLSON J, 1995, ANNU REV ENTOMOL, V40, P359, DOI 10.1146/annurev.en.40.010195.002043; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHANAS AC, 1982, J GEN VIROL, V58, P37, DOI 10.1099/0022-1317-58-1-37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAMPTON J, 1990, PARASITOL TODAY, V6, P31, DOI 10.1016/0169-4758(90)90057-B; DEUBEL V, 1986, VIROLOGY, V155, P365, DOI 10.1016/0042-6822(86)90200-X; DEUBEL V, 1988, VIROLOGY, V165, P234, DOI 10.1016/0042-6822(88)90677-0; FALLON AM, 1991, NATURE, V352, P828, DOI 10.1038/352828a0; Gaines PJ, 1996, J VIROL, V70, P2132, DOI 10.1128/JVI.70.4.2132-2137.1996; GOULD EA, 1985, J GEN VIROL, V66, P1369, DOI 10.1099/0022-1317-66-7-1369; GUBLER DJ, 1994, INFECT AGENT DIS, V2, P383; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HAHN YS, 1988, VIROLOGY, V162, P167, DOI 10.1016/0042-6822(88)90406-0; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HIGGS S, 1993, PARASITOL TODAY, V9, P444, DOI 10.1016/0169-4758(93)90098-Z; KARBER G, 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914; MARCHUK D, 1990, NUCLEIC ACIDS RES, V19, P1154; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; MURRAY JM, 1993, J GEN VIROL, V74, P175, DOI 10.1099/0022-1317-74-2-175; OLSON KE, 1994, INSECT BIOCHEM MOLEC, V24, P39, DOI 10.1016/0965-1748(94)90121-X; POWERS AM, 1994, VIRUS RES, V32, P57, DOI 10.1016/0168-1702(94)90061-2; POWERS AM, UNPUB; POWERS AM, IN PRESS P NATL ACAD; RaymsKeller A, 1995, INSECT MOL BIOL, V4, P245, DOI 10.1111/j.1365-2583.1995.tb00030.x; RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987; ROSEN L, 1974, AM J TROP MED HYG, V23, P1153, DOI 10.4269/ajtmh.1974.23.1153; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SANFORD JC, 1985, J THEOR BIOL, V113, P395, DOI 10.1016/S0022-5193(85)80234-4; WHITEHEAD RH, 1971, T ROY SOC TROP MED H, V65, P661, DOI 10.1016/0035-9203(71)90051-4	32	156	161	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					884	886		10.1126/science.272.5263.884	http://dx.doi.org/10.1126/science.272.5263.884			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629025				2022-12-24	WOS:A1996UK75700062
J	Xanthoudakis, S; Viola, JPB; Shaw, KTY; Luo, C; Wallace, JD; Bozza, PT; Curran, T; Rao, A				Xanthoudakis, S; Viola, JPB; Shaw, KTY; Luo, C; Wallace, JD; Bozza, PT; Curran, T; Rao, A			An enhanced immune response in mice lacking the transcription factor NFAT1	SCIENCE			English	Article							ACTIVATED T-CELLS; CYCLOSPORINE-A; NUCLEAR FACTOR; GENE; IDENTIFICATION; LYMPHOCYTE; COMPLEX; DISEASE	Transcription factors of the NFAT family are thought to play a major role in regulating the expression of cytokine genes and other inducible genes during the immune response. The role of NFAT1 was investigated by targeted disruption of the NFAT1 gene. Unexpectedly, cells from NFAT1(-/-) mice showed increased primary responses to Leishmania major and mounted increased secondary responses to ovalbumin in vitro. In an in vivo model of allergic inflammation, the accumulation of eosinophils and levels of serum immunoglobulin E were increased in NFAT1(-/-) mice. These results suggest that NFAT1 exerts a negative regulatory influence on the immune response.	ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA; HOFFMANN LA ROCHE INC, DEPT CNS RES, NEUROGENET PROGRAM, NUTLEY, NJ 07110 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, HARVARD THORNDIKE LAB, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,CHARLES A DANA RES INST, SCH MED, BOSTON, MA 02115 USA	St Jude Children's Research Hospital; Roche Holding; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Curran, Tom/C-1164-2008; Bozza, Patricia T./AAE-2933-2021; Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Viola, Joao P.B./AAP-4125-2020; Curran, Tom/F-5234-2018; Bozza, Patricia T./AAM-4537-2021	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Viola, Joao P.B./0000-0002-0698-3146; Curran, Tom/0000-0003-1444-7551; Bozza, Patricia T./0000-0001-8349-9529	NATIONAL CANCER INSTITUTE [P30CA021765, R37CA042471, R01CA042471] Funding Source: NIH RePORTER; NCI NIH HHS [CA42471, P30 CA21765] Funding Source: Medline; NIGMS NIH HHS [GM46227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; BACHMANN MF, 1995, J VIROL, V69, P4842, DOI 10.1128/JVI.69.8.4842-4846.1995; BOZZA PT, 1994, IMMUNOPHARMACOLOGY, V27, P131, DOI 10.1016/0162-3109(94)90047-7; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRADLEY LM, 1995, J IMMUNOL, V155, P1713; BROMBERG JS, 1995, CURR OPIN IMMUNOL, V7, P639, DOI 10.1016/0952-7915(95)80070-0; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Daser A, 1995, CURR OPIN IMMUNOL, V7, P762, DOI 10.1016/0952-7915(95)80045-X; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1993, J IMMUNOL, V151, P837; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LUO C, UNPUB; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SADLACK B, 1994, EUR J IMMUNOL, V24, P281, DOI 10.1002/eji.1830240144; SADLACK B, 1995, EUR J IMMUNOL, V25, P3053, DOI 10.1002/eji.1830251111; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHUBERT LA, 1995, J BIOL CHEM, V270, P29624; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHANKAR AH, 1993, J EXP MED, V178, P101, DOI 10.1084/jem.178.1.101; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STROBER W, 1993, CELL, V75, P203, DOI 10.1016/0092-8674(93)80062-J; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tsytsykova AV, 1996, J BIOL CHEM, V271, P3763; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang DZ, 1995, ANN NY ACAD SCI, V766, P182, DOI 10.1111/j.1749-6632.1995.tb26661.x; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; YASEEN NR, 1993, J BIOL CHEM, V268, P14285; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845	54	310	317	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					892	895		10.1126/science.272.5263.892	http://dx.doi.org/10.1126/science.272.5263.892			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629027				2022-12-24	WOS:A1996UK75700065
J	Qu, DQ; Ludwig, DS; Gammeltoft, S; Piper, M; Pelleymounter, MA; Cullen, MJ; Mathes, WF; Przypek, J; Kanarek, R; MaratosFlier, E				Qu, DQ; Ludwig, DS; Gammeltoft, S; Piper, M; Pelleymounter, MA; Cullen, MJ; Mathes, WF; Przypek, J; Kanarek, R; MaratosFlier, E			A role for melanin-concentrating hormone in the central regulation of feeding behaviour	NATURE			English	Article							MESSENGER-RIBONUCLEIC-ACID; RAT-BRAIN; PUTATIVE NEUROPEPTIDES; HYPOTHALAMUS; PEPTIDE; GENE; LOCALIZATION; STIMULATION; SYSTEM; RNA	THE hypothalamus plays a central role in the integrated regulation of energy homeostasis and body weight, and a number of hypothalamic neuropeptides, such as neuropeptide Y (ref. 1), galanin(2), CRH (ref. 3), and GLP-1 (ref. 4), have been implicated in the mediation of these effects. To discover new hypothalamic peptides involved in the regulation of body weight, we used differential display polymerase chain reaction(5) to identify messenger RNAs that are differentially expressed in the hypothalamus of ob/+ compared with ob/ob C57Bl/6J mice. We show here that one mRNA that is overexpressed in the hypothalamus of ob/ob mice encodes the neuropeptide melanin-concentrating hormone (MCH). Fasting further increased expression of MCH mRNA in both normal and obese animals. Neurons containing MCH are located in the zona incerta and in the lateral hypothalamus. These areas are involved in regulation of ingestive behaviour, but the role of MCH in mammalian physiology is unknown. To determine whether MCH is involved in the regulation of feeding, we injected MCH into the lateral ventricles of rats and found that their food consumption increased. These findings suggest that MCH participates in the hypothalamic regulation of body weight.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,ELLIOT P JOSLIN RES LAB,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02215; AMGEN INC,DEPT NEUROBIOL,THOUSAND OAKS,CA 91320; TUFTS UNIV,DEPT PSYCHOL,MEDFORD,MA 02155	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Amgen; Tufts University				Ludwig, David/0000-0003-3307-8544				ARASE K, 1988, AM J PHYSIOL, V255, pE255, DOI 10.1152/ajpendo.1988.255.3.E255; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRETON C, 1993, MOL CELL NEUROSCI, V4, P271, DOI 10.1006/mcne.1993.1035; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CECHETTO DF, 1988, J COMP NEUROL, V272, P579, DOI 10.1002/cne.902720410; CONE RD, 1993, ANN NY ACAD SCI, V680, P342, DOI 10.1111/j.1749-6632.1993.tb19694.x; JAKUBOWSKI M, 1991, J NEUROENDOCRIN; KAWAUCHI H, 1993, ANN NY ACAD SCI, V680, P64, DOI 10.1111/j.1749-6632.1993.tb19675.x; KAWAUCHI H, 1983, NATURE, V305, P423; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; KYRKOULI SE, 1986, EUR J PHARMACOL, V122, P159, DOI 10.1016/0014-2999(86)90175-5; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MATSUNAGA TO, 1989, PEPTIDES, V10, P773, DOI 10.1016/0196-9781(89)90112-5; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; NAHON JL, 1993, ANN NY ACAD SCI, V680, P111, DOI 10.1111/j.1749-6632.1993.tb19678.x; NAITO N, 1988, CELL TISSUE RES, V253, P291; OOMURA Y, 1987, NEWS PHYSIOL SCI, V2, P199; PARKES D, 1992, ENDOCRINOLOGY, V131, P1826, DOI 10.1210/en.131.4.1826; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RANCE T, 1979, GEN COMP ENDOCR, V37, P64, DOI 10.1016/0016-6480(79)90047-9; RISOLD PY, 1992, NEUROSCI LETT, V136, P145, DOI 10.1016/0304-3940(92)90035-6; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; SKOFITSCH G, 1985, BRAIN RES BULL, V15, P635, DOI 10.1016/0361-9230(85)90213-8; STANLEY BG, 1989, PHYSIOL BEHAV, V46, P173, DOI 10.1016/0031-9384(89)90251-5; TEMPEL DL, 1990, BRAIN RES BULL, V25, P821, DOI 10.1016/0361-9230(90)90177-2; THOMPSON RC, 1990, DNA CELL BIOL, V9, P637, DOI 10.1089/dna.1990.9.637; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; ZAMIR N, 1986, P NATL ACAD SCI USA, V83, P1528, DOI 10.1073/pnas.83.5.1528; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	1099	1153	0	58	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					243	247		10.1038/380243a0	http://dx.doi.org/10.1038/380243a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637571				2022-12-24	WOS:A1996UB11700050
J	Dikstein, R; Ruppert, S; Tjian, R				Dikstein, R; Ruppert, S; Tjian, R			TAF(11)250 is a bipartite protein kinase that phosphorylates the basal transcription factor RAP74	CELL			English	Article							RNA POLYMERASE-II; MOLECULAR-CLONING; INITIATION-FACTOR; BINDING PROTEIN; TERMINAL DOMAIN; COACTIVATORS; GENE; ACTIVATION; PROMOTER; HELICASE	Some TAF subunits of transcription factor TFIID play a pivotal role in transcriptional activation by mediating protein-protein interactions, whereas other TAFs direct promoter selectivity via protein-DNA recognition. Here, we report that purified recombinant TAF(II)250 is a protein serine kinase that selectively phosphorylates RAP74 but not other basal transcription factors or common phosphoacceptor proteins. The phosphorylation of RAP74 also occurs in the context of the complete TFIID complex. Deletion analysis revealed that TAF(II)250 contains two distinct kinase domains each capable of autophosphorylation. However, both the N- and C-terminal kinase domains of TAF(II)250 are required for efficient transphosphorylation of RAP74 on serine residues. These findings suggest that the targeted phosphorylation of RAP74 by TAF(II)250 may provide a mechanism for signaling between components within the initiation complex to regulate transcription.			Dikstein, R (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,401 BARKER HALL,BERKELEY,CA 94720, USA.							BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; NOGUCHI E, 1994, SOMAT CELL MOLEC GEN, V20, P505, DOI 10.1007/BF02255841; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OREILLEY DR, 1994, BACULOVIRUS EXPRESSI; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SOPTA M, 1985, J BIOL CHEM, V260, P353; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER P, 1995, CELL, V81, P1115; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351	40	179	185	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					781	790		10.1016/S0092-8674(00)81055-7	http://dx.doi.org/10.1016/S0092-8674(00)81055-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625415	Bronze			2022-12-24	WOS:A1996TZ99000015
J	Wang, G; Seidman, MM; Glazer, PM				Wang, G; Seidman, MM; Glazer, PM			Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair	SCIENCE			English	Article							C-MYC GENE; FORMING OLIGONUCLEOTIDES; SACCHAROMYCES-CEREVISIAE; TARGETED MUTAGENESIS; TELOMERIC DNA; FREE-EXTRACTS; BINDING; INHIBITION; MUTATIONS; CLEAVAGE	When mammalian cells were treated with tripler-forming oligonucleotides of sufficient binding affinity, mutations were specifically induced in a simian virus 40 vector contained within the cells. Tripler-induced mutagenesis was not detected in xeroderma pigmentosum group A cells nor in Cockayne's syndrome group B cells, indicating a requirement for excision repair and for transcription-coupled repair, respectively, in the process. Tripler formation was also found to stimulate DNA repair synthesis in human cell extracts, in a pattern correlating with the inhibition of transcription in such extracts. These findings may have implications for therapeutic applications of tripler DNA and raise the possibility that naturally occurring triple helices are a source of genetic instability.	YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, NEW HAVEN, CT 06520 USA; ONCORPHARM, GAITHERSBURG, MD 20877 USA	Yale University			Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560	NATIONAL CANCER INSTITUTE [R01CA064186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005775, R01ES005775] Funding Source: NIH RePORTER; NCI NIH HHS [CA64186] Funding Source: Medline; NIEHS NIH HHS [ES05775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GLAZER PM, 1987, MOL CELL BIOL, V7, P218, DOI 10.1128/MCB.7.1.218; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HAVRE PA, 1993, P NATL ACAD SCI USA, V90, P7879, DOI 10.1073/pnas.90.16.7879; HAVRE PA, 1993, J VIROL, V67, P7324, DOI 10.1128/JVI.67.12.7324-7331.1993; Helene Claude, 1993, Current Opinion in Biotechnology, V4, P29, DOI 10.1016/0958-1669(93)90028-U; ING NH, 1993, NUCLEIC ACIDS RES, V21, P2789, DOI 10.1093/nar/21.12.2789; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LAWRENCE CW, 1984, MOL GEN GENET, V195, P487, DOI 10.1007/BF00341451; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; LEVY DD, 1995, CARCINOGENESIS, V16, P1557, DOI 10.1093/carcin/16.7.1557; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PRAKASH L, 1976, GENETICS, V83, P285; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; QUAH SK, 1980, GENETICS, V96, P819; READ GS, 1982, P NATL ACAD SCI-BIOL, V79, P5215, DOI 10.1073/pnas.79.17.5215; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; WANG G, 1995, MOL CELL BIOL, V15, P1759; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	45	291	309	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					802	805		10.1126/science.271.5250.802	http://dx.doi.org/10.1126/science.271.5250.802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628995				2022-12-24	WOS:A1996TU69400044
J	Choi, JW; Chen, J; Schreiber, SL; Clardy, J				Choi, JW; Chen, J; Schreiber, SL; Clardy, J			Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP	SCIENCE			English	Article							PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; RAPAMYCIN AY-22,989; CYCLOPHILIN; CHEMISTRY; LIGANDS	Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-associated protein (FRAP). A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resolution of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously. The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins. The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects observed for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasia mutant gene product, and it illustrates how a small cell-permeable molecule can mediate protein dimerization.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University	Choi, JW (corresponding author), CORNELL UNIV,BAKER LAB,DEPT CHEM,ITHACA,NY 14853, USA.			Chen, Jie/0000-0002-7887-3747	NATIONAL CANCER INSTITUTE [R01CA059021] Funding Source: NIH RePORTER; NCI NIH HHS [CA59021] Funding Source: Medline; NIGMS NIH HHS [GM38625] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; FINDLAY JA, 1980, CAN J CHEM, V58, P579, DOI 10.1139/v80-090; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; LEDERER F, 1981, J MOL BIOL, V148, P427, DOI 10.1016/0022-2836(81)90185-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; NICHOLLS A, 1992, GRASP MANUAL; RIVERA VM, IN PRESS NATURE MED; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SWINDELLS DCN, 1978, CAN J CHEM, V56, P2491, DOI 10.1139/v78-407; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	35	606	647	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					239	242		10.1126/science.273.5272.239	http://dx.doi.org/10.1126/science.273.5272.239			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8662507				2022-12-24	WOS:A1996UW78700041
J	Navarro, B; Kennedy, ME; Velimirovic, B; Bhat, D; Peterson, AS; Clapham, DE				Navarro, B; Kennedy, ME; Velimirovic, B; Bhat, D; Peterson, AS; Clapham, DE			Nonselective and G(beta gamma)-insensitive weaver K+ channels	SCIENCE			English	Article							MUTANT	Homozygous weaver mice are profoundly ataxic because of the loss of granule cell neurons during cerebellar development. This granule cell loss appears to be caused by a genetic defect in the pore region (Gly(156) --> Ser) of the heterotrimeric guanine nucleotide-binding protein (G protein)-gated inwardly rectifying potassium (K+) channel subunit (GIRK2). A related subunit, GIRK1, associates with GIRK2 to constitute a neuronal G protein-gated inward rectifier K+ channel. The weaver allele of the GIRK2 subunit (wvGIRK2) caused loss of K+ selectivity when expressed either as wvGIRK2 homomultimers or as GIRK1-wvGIRK2 heteromultimers. The mutation also led to loss of sensitivity to G protein beta gamma dimers. Expression of wvGIRK2 subunits led to increased cell death, presumably as a result of basal nonselective channel opening.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Mayo Clinic; Duke University; Duke University			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	17	143	146	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1996	272	5270					1950	1953		10.1126/science.272.5270.1950	http://dx.doi.org/10.1126/science.272.5270.1950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658170				2022-12-24	WOS:A1996UV29400052
J	MunozJordan, JL; Davies, KP; Cross, GAM				MunozJordan, JL; Davies, KP; Cross, GAM			Stable expression of mosaic coats of variant surface glycoproteins in Trypanosoma brucei	SCIENCE			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; SITE-ASSOCIATED GENE; BLOOD-STREAM-FORM; ANTIGENIC VARIATION; AFRICAN TRYPANOSOMES; PHOSPHOLIPASE-C; MEMBRANE-FORM; VSG 117; PURIFICATION; SEQUENCE	The paradigm of antigenic variation in parasites is the variant surface glycoprotein (VSG) of Af rican trypanosomes. Only one VSG is expressed at any time, except for short periods during switching, The reasons for this pattern of expression and the consequences of expressing more than one VSG are unknown. Trypanosoma brucei was genetically manipulated to generate cell lines that expressed two VSGs simultaneously. These VSGs were produced in equal amounts and were homogeneously distributed on the trypanosome surface. The double-expressor cells had similar population doubling times and were as infective as wild-type cells. Thus, the simultaneous expression of two VSGs is not intrinsically harmful.	ROCKEFELLER UNIV,MOLEC PARASITOL LAB,NEW YORK,NY 10021	Rockefeller University			Cross, George A M/B-7444-2011	Cross, George A M/0000-0003-1374-6955; Davies, Kelvin/0000-0002-0201-9210	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021531] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUR Z, 1989, P NATL ACAD SCI USA, V86, P9626, DOI 10.1073/pnas.86.23.9626; AGUR Z, 1992, PARASITOL TODAY, V8, P128, DOI 10.1016/0169-4758(92)90280-F; AGUR Z, 1995, PARASITOL TODAY, V11, P24, DOI 10.1016/0169-4758(95)80103-0; ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; ALINE RF, 1989, MOL BIOCHEM PARASIT, V32, P169, DOI 10.1016/0166-6851(89)90068-6; ALLEN G, 1982, J MOL BIOL, V157, P527, DOI 10.1016/0022-2836(82)90474-0; ALLEN G, 1983, BIOCHEM J, V209, P481, DOI 10.1042/bj2090481; BALTZ T, 1986, NATURE, V319, P602, DOI 10.1038/319602a0; BARRY D, 1992, PARASITOL TODAY, V8, P128; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BOOTHROYD JC, 1982, J MOL BIOL, V157, P547, DOI 10.1016/0022-2836(82)90475-2; BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; BULOW R, 1989, MOL BIOCHEM PARASIT, V32, P85, DOI 10.1016/0166-6851(89)90132-1; BULOW R, 1986, J BIOL CHEM, V261, P1918; CARRINGTON M, 1991, J MOL BIOL, V221, P823, DOI 10.1016/0022-2836(91)80178-W; CARRINGTON M, 1989, MOL BIOCHEM PARASIT, V33, P289, DOI 10.1016/0166-6851(89)90091-1; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CORNELISSEN AWCA, 1985, CELL, V41, P825, DOI 10.1016/S0092-8674(85)80063-5; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CROZATIER M, 1990, MOL BIOCHEM PARASIT, V42, P1, DOI 10.1016/0166-6851(90)90107-W; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DEALMEIDA MLC, 1984, J PROTOZOOL, V31, P53, DOI 10.1111/j.1550-7408.1984.tb04289.x; DUSZENKO M, 1993, ADV CELL MOL BIOL M, V2, P227; EHLERS B, 1987, MOL CELL BIOL, V7, P1242, DOI 10.1128/MCB.7.3.1242; ESSER KM, 1985, SCIENCE, V229, P190, DOI 10.1126/science.3892689; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FOX JA, 1986, J BIOL CHEM, V261, P5767; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; GRAHAM SV, 1991, MOL BIOCHEM PARASIT, V47, P31, DOI 10.1016/0166-6851(91)90145-V; GRAHAM SV, 1990, PARASITOLOGY, V101, P361, DOI 10.1017/S0031182000060558; GRAY AR, 1976, BIOLOGY KINETOPLASTI, V1, P493; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; JOHNSON JG, 1977, J PROTOZOOL, V24, P587, DOI 10.1111/j.1550-7408.1977.tb01020.x; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; KOSINSKI RJ, 1980, PARASITOLOGY, V80, P343, DOI 10.1017/S0031182000000809; LAMONT GS, 1986, PARASITOLOGY, V92, P355, DOI 10.1017/S003118200006412X; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; LIPS S, 1993, MOL BIOCHEM PARASIT, V62, P135, DOI 10.1016/0166-6851(93)90189-5; LIU AYC, 1983, J MOL BIOL, V167, P57, DOI 10.1016/S0022-2836(83)80034-5; MILLER EN, 1981, PARASITOLOGY, V82, P63, DOI 10.1017/S0031182000041871; MYLER PJ, 1985, INFECT IMMUN, V47, P684, DOI 10.1128/IAI.47.3.684-690.1985; NAVARRO M, IN PRESS MOL CELL BI, V16; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; SCHOLLER JK, 1988, MOL BIOCHEM PARASIT, V29, P89, DOI 10.1016/0166-6851(88)90123-5; SEYFANG A, 1990, J PROTOZOOL, V37, P546, DOI 10.1111/j.1550-7408.1990.tb01263.x; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; STRANG AM, 1993, BIOCHEM BIOPH RES CO, V196, P1430, DOI 10.1006/bbrc.1993.2412; TIMMERS HTM, 1987, J MOL BIOL, V184, P81; TURNER CMR, 1989, PARASITOLOGY, V99, P67, DOI 10.1017/S0031182000061035; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; WILLIAMS BG, 1995, TRYP LEISHM SEM GLAS; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244; ZAMZE SE, 1990, EUR J BIOCHEM, V187, P657, DOI 10.1111/j.1432-1033.1990.tb15350.x	62	48	48	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1795	1797		10.1126/science.272.5269.1795	http://dx.doi.org/10.1126/science.272.5269.1795			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650579				2022-12-24	WOS:A1996UT11000045
J	Nudo, RJ; Wise, BM; SiFuentes, F; Milliken, GW				Nudo, RJ; Wise, BM; SiFuentes, F; Milliken, GW			Neural substrates for the effects of rehabilitative training on motor recovery after ischemic infarct	SCIENCE			English	Article							OWL MONKEYS; CORTEX; ORGANIZATION; AREA; REORGANIZATION; REPRESENTATION; STIMULATION; STROKE; HAND; MAPS	Substantial functional reorganization lakes place in the motor cortex of adult primates after a focal ischemic infarct, as might occur in stroke. A subtotal lesion confined to a small portion of the representation of one hand was previously shown to result in a further loss of hand territory in the adjacent, undamaged cortex of adult squirrel monkeys. In the present study, retraining of skilled hand use after similar infarcts resulted in prevention of the loss of hand territory adjacent to the infarct. In some instances, the hand representations expanded into regions formerly occupied by representations of the elbow and shoulder. Functional reorganization in the undamaged motor cortex was accompanied by behavioral recovery of skilled hand function. These results suggest that, after local damage to the motor cortex, rehabilitative training can shape subsequent reorganization in the adjacent intact cortex, and that the undamaged motor cortex may play an important role in motor recovery.			Nudo, RJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROBIOL & ANAT,HOUSTON,TX 77030, USA.		Nudo, Randolph/B-1623-2009		NINDS NIH HHS [NS27974, NS30853] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030853, R29NS027974] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bach-y-Rita P., 1980, RECOVERY FUNCTION TH, P225; BENECKE R, 1991, EXP BRAIN RES, V83, P419; Black P, 1970, Trans Am Neurol Assoc, V95, P207; BLACK P, 1975, OUTCOME SEVERE DAMAG, P65; BUCY PC, 1944, PRECENTRAL MOTOR COR, P353; CASTROALAMANCOS MA, 1992, EUR J NEUROSCI, V4, P853, DOI 10.1111/j.1460-9568.1992.tb00195.x; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; DONOGHUE JP, 1988, J NEUROSCI, V8, P3221; DONOGHUE JP, 1992, EXP BRAIN RES, V89, P1; GLEES P, 1950, J NEUROPHYSIOL, V13, P137, DOI 10.1152/jn.1950.13.2.137; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; Gowland C, 1987, STROKE REHABILITATIO, P217; HOFFMAN DS, 1995, J NEUROPHYSIOL, V73, P891, DOI 10.1152/jn.1995.73.2.891; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; KARNI A, 1995, NATURE, V377, P155; Lashley KS, 1924, ARCH NEURO PSYCHIATR, V12, P249, DOI 10.1001/archneurpsyc.1924.02200030002001; Nudo R. J., 1995, Society for Neuroscience Abstracts, V21, P517; NUDO RJ, 1992, J NEUROSCI, V12, P2918, DOI 10.1523/JNEUROSCI.12-08-02918.1992; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144, DOI 10.1152/jn.1996.75.5.2144; Nudo RJ, 1996, J NEUROSCI, V16, P785; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PASSINGHAM RE, 1983, BRAIN, V106, P675, DOI 10.1093/brain/106.3.675; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1015, DOI 10.1152/jn.1992.67.5.1015; RIDDING MC, 1995, CAN J PHYSIOL PHARM, V73, P218, DOI 10.1139/y95-032; SANES JN, 1995, SCIENCE, V268, P1775, DOI 10.1126/science.7792606; SCHLAUG G, 1994, EXP BRAIN RES, V98, P523; SEITZ RJ, 1995, NEUROREPORT, V6, P742, DOI 10.1097/00001756-199503270-00009; STRICK PL, 1982, J NEUROPHYSIOL, V48, P139, DOI 10.1152/jn.1982.48.1.139; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; TRAVIS A M, 1956, Am J Phys Med, V35, P273; TWITCHELL TE, 1951, BRAIN, V74, P443, DOI 10.1093/brain/74.4.443; WANG XQ, 1995, NATURE, V378, P71, DOI 10.1038/378071a0	34	1312	1397	6	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1791	1794		10.1126/science.272.5269.1791	http://dx.doi.org/10.1126/science.272.5269.1791			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650578				2022-12-24	WOS:A1996UT11000044
J	Glickman, S; Kamm, MA				Glickman, S; Kamm, MA			Bowel dysfunction in spinal-card-injury patients	LANCET			English	Article							CORD INJURY; STIMULATION	Background This study aimed to determine the prevalence, nature, and effects-both physical and psychological-of spinal-cord-injury (SCI) on bower function. Methods 115 consecutive hospital outpatients (89 male, median age 38 years) with chronic SCI (median duration 62 months, range 9-491 months, 48% cervical, 47% thoracic, 5% lumbar) completed a questionnaire about pre and post injury bowel function, the Hospital Anxiety and Depression Scale (HADS), and self assessment of the impact of their disabilities and symptoms. Findings Nausea, diarrhoea, constipation, and faecal incontinence were all much more common (p<0 . 0001) after SCI. 95% of patients required at least one therapeutic method to initiate defaecation. Half the patients became dependent on others for toileting. 49% took more than 30 min to complete their toilet procedure. Bowel function was a source of distress in 54% of patients and this was significantly (p=0 . 005) associated with the time required for bowel management and frequency of incontinence (p=0 . 001). There was a highly significant correlation between the HADS scores and the time taken for bower management. On a scale of 0 (for no perceived problem) to 10 (maximum perceived problem), patients rated their loss of mobility as a mean of 6 . 8 (SD 3 . 3) and their bowel management as 5 . 1(SD 3 . 6). Interpretation Dowel function is a major physical and psychological problem in SCI patients.	CHARING CROSS HOSP,DEPT REHABIL MED,LONDON,ENGLAND; ST MARKS HOSP,MED PHYSIOL UNIT,LONDON EC1V 2PS,ENGLAND	Imperial College London; Imperial College London				Glickman, Scott/0000-0002-8084-9949				DEVROEDE G, 1979, GASTROENTEROLOGY, V77, P1258; FROST F, 1993, ARCH PHYS MED REHAB, V74, P696, DOI 10.1016/0003-9993(93)90027-8; GLICK ME, 1986, PARAPLEGIA, V24, P129, DOI 10.1038/sc.1986.17; HILL J, 1994, BRIT J SURG, V81, P1490, DOI 10.1002/bjs.1800811030; MACDONAGH RP, 1990, BRIT MED J, V300, P1494, DOI 10.1136/bmj.300.6738.1494; MACINTYRE AS, 1992, GUT, V33, P1062; MENARDO G, 1987, DIS COLON RECTUM, V30, P924, DOI 10.1007/BF02554277; STONE JM, 1990, ARCH PHYS MED REHAB, V71, P514; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	9	255	258	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1651	1653		10.1016/S0140-6736(96)91487-7	http://dx.doi.org/10.1016/S0140-6736(96)91487-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642958				2022-12-24	WOS:A1996UQ70100010
J	Mead, GM				Mead, GM			Raltitrexed, a new drug for advanced colorectal cancer	LANCET			English	Editorial Material											Mead, GM (corresponding author), ROYAL S HANTS HOSP,WESSEX MED ONCOL UNIT,SOUTHAMPTON SO14 0YG,HANTS,ENGLAND.							Conti JA, 1996, J CLIN ONCOL, V14, P709, DOI 10.1200/JCO.1996.14.3.709; Cunningham D, 1995, EUR J CANCER, V31A, P1945, DOI 10.1016/0959-8049(95)00502-1; Cunningham D, 1996, ANN ONCOL, V7, P179; HERRMANN R, 1994, EUR J CANCER, V30A, P404, DOI 10.1016/0959-8049(94)90266-6; HILL M, 1995, J CLIN ONCOL, V13, P1297, DOI 10.1200/JCO.1995.13.6.1297; LEICHMAN CG, 1995, J CLIN ONCOL, V13, P1303, DOI 10.1200/JCO.1995.13.6.1303; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; Slevin ML, 1996, BMJ-BRIT MED J, V312, P392; 1992, J CLIN ONCOL, V10, P904; 1992, J CLIN ONCOL, V10, P896	10	6	6	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1568	1569		10.1016/S0140-6736(96)91068-5	http://dx.doi.org/10.1016/S0140-6736(96)91068-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667859				2022-12-24	WOS:A1996UP66100002
J	Krause, PJ; Telford, SR; Spielman, A; Sikand, V; Ryan, R; Christianson, D; Burke, G; Brassard, P; Pollack, R; Peck, J; Persing, DH				Krause, PJ; Telford, SR; Spielman, A; Sikand, V; Ryan, R; Christianson, D; Burke, G; Brassard, P; Pollack, R; Peck, J; Persing, DH			Concurrent lyme disease and babesiosis - Evidence for increased severity and duration of illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BORRELIA-BURGDORFERI; MICROTI	Objective.-To determine whether patients coinfected with Lyme disease and babesiosis in sites where both diseases are zoonotic experience a greater number of symptoms for a longer period of time than those with either infection alone. Design.-Community-based, yearly serosurvey and clinic-based cohort study. Setting.-Island community in Rhode Island and 2 Connecticut medical clinics from 1990 to 1994. Study Participants.-Long-term residents of the island community and patients seeking treatment at the clinics. Main Outcome Measures.-Seroreactivity to the agents of Lyme disease and babesiosis and number and duration of symptoms. Results.-Of 1156 serosurvey subjects, 97 (8.4%) were seroreactive against Lyme disease spirochete antigen, of whom 14 (14%) also were seroreactive against babesial antigen. Of 240 patients diagnosed with Lyme disease, 26 (11%) were coinfected with babesiosis. Coinfected patients experienced fatigue (P=.002), headache (P<.001), sweats (P<.001), chills (P=.03), anorexia (P=.04), emotional lability (P=.02), nausea (P=.004), conjunctivitis (P=.04), and splenomegaly (P=.01) more frequently than those with Lyme disease alone. Thirteen (50%) of 26 coinfected patients were symptomatic for 3 months or longer compared with 7 (4%) of the 184 patients with Lyme disease alone from whom follow-up data were available (P<.001), Patients coinfected with Lyme disease experienced more symptoms and a more persistent episode of illness than did those (n=10) experiencing babesial infection alone. Circulating spirochetal DNA was detected more than 3 times as often in coinfected patients as in those with Lyme disease alone (P=.06). Conclusions.-Approximately 10% of patients with Lyme disease in southern New England are coinfected with babesiosis in sites where both diseases are zoonotic. The number of symptoms and duration of illness in patients with concurrent Lyme disease and babesiosis are greater than in patients with either infection alone. In areas where both Lyme disease and babesiosis have been reported, the possibility of concomitant babesial infection should be considered when moderate to severe Lyme disease has been diagnosed.	UNIV CONNECTICUT,SCH MED,DEPT LAB MED,FARMINGTON,CT 06030; HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115; MAYO CLIN,DEPT MED,ROCHESTER,MN; MAYO CLIN,DEPT PATHOL,ROCHESTER,MN	University of Connecticut; Harvard University; Harvard T.H. Chan School of Public Health; Mayo Clinic; Mayo Clinic	Krause, PJ (corresponding author), UNIV CONNECTICUT,SCH MED,DEPT PEDIAT,FARMINGTON,CT 06030, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019693, R01AI032403, P01AI030548, R01AI019693] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19693, AI 30548, AI 32403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG AL, 1992, AM J TROP MED HYG, V47, P249, DOI 10.4269/ajtmh.1992.47.249; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BENACH JL, 1981, J INFECT DIS, V144, P473; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; GOLIGHTLY LM, 1989, REV INFECT DIS, V11, P629; GRUNWALDT E, 1983, NEW ENGL J MED, V308, P1166; KIMSEY PB, 1990, CLIN RES, V38, P596; KRAUSE PJ, 1994, J INFECT DIS, V169, P923, DOI 10.1093/infdis/169.4.923; KRAUSE PJ, 1991, J CLIN MICROBIOL, V29, P1; KRAUSE PJ, 1992, PEDIATRICS, V89, P1045; MALAWISTA SE, 1994, J INFECT DIS, V170, P1312, DOI 10.1093/infdis/170.5.1312; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MELDRUM SC, 1992, CLIN INFECT DIS, V15, P1019, DOI 10.1093/clind/15.6.1019; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; PERSING DH, 1994, J INFECT DIS, V169, P668, DOI 10.1093/infdis/169.3.668; PURVIS AC, 1977, PARASITOLOGY, V75, P197, DOI 10.1017/S003118200006234X; RUEBUSH TK, 1977, ANN INTERN MED, V86, P6, DOI 10.7326/0003-4819-86-1-6; SPIELMAN A, 1985, ANNU REV ENTOMOL, V30, P439, DOI 10.1146/annurev.en.30.010185.002255; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; TELFORD SR, 1995, ANN INTERN MED, V123, P277, DOI 10.7326/0003-4819-123-4-199508150-00006; TELFORD SR, IN PRESS TOPLEY WILS; Vos A. J. de, 1987, Immune responses in parasitic infections: immunology, immunopathology, and immunoprophylaxis. Volume III: Protozoa, P183; 1991, LYME DIS SURVEILL SU, V2, P1	24	326	340	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1657	1660		10.1001/jama.275.21.1657	http://dx.doi.org/10.1001/jama.275.21.1657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637139				2022-12-24	WOS:A1996UN25200028
J	Gautam, M; Noakes, PG; Moscoso, L; Rupp, F; Scheller, RH; Merlie, JP; Sanes, JR				Gautam, M; Noakes, PG; Moscoso, L; Rupp, F; Scheller, RH; Merlie, JP; Sanes, JR			Defective neuromuscular synaptogenesis in agrin-deficient mutant mice	CELL			English	Article							CULTURED MUSCLE-CELLS; ACETYLCHOLINE-RECEPTOR CLUSTERS; TORPEDO ELECTRIC ORGAN; EXTRACELLULAR-MATRIX; PROTEIN; MOLECULES; INDUCTION; JUNCTION; REDISTRIBUTION; LOCALIZATION	During neuromuscular synapse formation, motor axons induce clustering of acetylcholine receptors (AChRs) in the muscle fiber membrane. The protein agrin, originally isolated from the basal lamina of the synaptic cleft, is synthesized and secreted by motoneurons and triggers formation of AChR clusters on cultured myotubes. We show here that postsynaptic AChR aggregates are markedly reduced in number, size, and density in muscles of agrin-deficient mutant mice. These results support the hypothesis that agrin is a critical organizer of postsynaptic differentiation. However, some postsynaptic differentiation does occur in the mutant, suggesting the existence of a second nerve-derived synaptic organizing signal. In addition, we show that intramuscular nerve branching and presynaptic differentiation are abnormal in the mutant, phenotypes which may reflect either a distinct effect of agrin or impaired retrograde signaling from a defective postsynaptic apparatus.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOL & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Stanford University	Gautam, M (corresponding author), WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA.		Noakes, Peter/X-9825-2019	Noakes, Peter/0000-0001-9821-8478; Gautam, Medha/0000-0002-5418-4322				ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P757, DOI 10.1113/jphysiol.1977.sp011880; BENNETT MR, 1975, COLD SPRING HARB SYM, V40, P409, DOI 10.1101/SQB.1976.040.01.039; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; BURG MA, 1995, J NEUROSCI RES, V41, P49, DOI 10.1002/jnr.490410107; Campagna JA, 1995, NEURON, V15, P1365, DOI 10.1016/0896-6273(95)90014-4; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; COHEN MW, 1992, J NEUROSCI, V12, P2982, DOI 10.1523/JNEUROSCI.12-08-02982.1992; DAVEY DF, 1986, J NEUROSCI, V6, P673; DECHIARA TM, 1996, IN PRESS CELL; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; FALLON JR, 1989, J CELL BIOL, V108, P1527, DOI 10.1083/jcb.108.4.1527; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HARRIS A J, 1981, Philosophical Transactions of the Royal Society of London B Biological Sciences, V293, P287, DOI 10.1098/rstb.1981.0078; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; HOUENOU LJ, 1990, J NEUROBIOL, V21, P1249, DOI 10.1002/neu.480210809; KUROMI H, 1984, DEV BIOL, V103, P53, DOI 10.1016/0012-1606(84)90006-X; LUPA MT, 1989, J NEUROSCI, V9, P3937; MA E, 1994, J NEUROSCI, V14, P2943; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MOSCOSO LM, 1995, MOL CELL NEUROSCI, V6, P80, DOI 10.1006/mcne.1995.1008; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; PENG HB, 1995, J NEUROSCI, V15, P3027; PENG HB, 1991, NEURON, V6, P237; PENG HB, 1982, J NEUROSCI, V2, P1760; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1992, J NEUROSCI, V12, P3535; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANES JR, 1991, DEVELOPMENT, V113, P1181; SMITH MA, 1992, MOL CELL NEUROSCI, V3, P406, DOI 10.1016/1044-7431(92)90052-4; SMITH MA, 1994, NEURON, V12, P795, DOI 10.1016/0896-6273(94)90332-8; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WALLACE BG, 1989, J NEUROSCI, V9, P1294; ZISKINDCONHAIM L, 1984, J NEUROSCI, V4, P2346	53	756	771	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1996	85	4					525	535		10.1016/S0092-8674(00)81253-2	http://dx.doi.org/10.1016/S0092-8674(00)81253-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653788	hybrid			2022-12-24	WOS:A1996UM41500010
J	Jia, L; Bonaventura, C; Bonaventura, J; Stamler, JS				Jia, L; Bonaventura, C; Bonaventura, J; Stamler, JS			S-nitrosohaemoglobin: A dynamic activity of blood involved in vascular control	NATURE			English	Article							HUMAN-HEMOGLOBIN; NITRIC-OXIDE; BINDING	A dynamic cycle exists in which haemoglobin is S-nitrosylated in the lung when red blood cells are oxygenated, and the NO group is released during arterial-venous transit. The vasoactivity of S-nitrosohaemoglobin is promoted by the erythrocytic export of S-nitrosothiols. These findings highlight newly discovered allosteric and electronic properties of haemoglobin that appear to be involved in the control of blood pressure and which may facilitate efficient delivery of oxygen to tissues. The role of S-nitrosohaemoglobin in the transduction of NO-related activities may have therapeutic applications.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE MARINE BIOMED CTR,NICHOLAS SCH ENVIRONM,PIVERS ISL,NC 28516	Duke University; Duke University	Jia, L (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV RESP & CARDIOVASC MED,MSRB BLDG,ROOM 321,BOX 2612,DURHAM,NC 27710, USA.			JIA, LEE/0000-0001-6839-5545; Stamler, Jonathan/0000-0002-6866-1572				AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P29; BECKMAN JS, 1996, METHODS NITRIC OXIDE; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; CRAESCU CT, 1986, J BIOL CHEM, V261, P4710; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; JOCELYN PC, 1972, BIOCH SH GROUP, P243; KILBOURN RG, 1994, BIOCHEM BIOPH RES CO, V199, P155, DOI 10.1006/bbrc.1994.1208; KONDO T, 1995, METHOD ENZYMOL, V252, P72; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; MANSOURI A, 1979, BIOCHEM BIOPH RES CO, V89, P441, DOI 10.1016/0006-291X(79)90649-1; OLSEN SB, 1996, CIRCULATION, V93, P329; Olson J S, 1981, Methods Enzymol, V76, P631; SALHANY JM, 1981, TRENDS BIOCH SCI JAN, P1; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; SHEN WQ, 1995, CIRCULATION, V92, P3505, DOI 10.1161/01.CIR.92.12.3505; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TOOTHILL C, 1967, BRIT J ANAESTH, V39, P405, DOI 10.1093/bja/39.5.405; VOGEL WM, 1986, AM J PHYSIOL, V251, pH413, DOI 10.1152/ajpheart.1986.251.2.H413; WENNMALM A, 1992, BRIT J PHARMACOL, V106, P6507; WOOD J, 1994, NEUROPHARMACOLOGY, V33, P1235, DOI 10.1016/0028-3908(94)90022-1	26	1384	1442	1	40	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					221	226		10.1038/380221a0	http://dx.doi.org/10.1038/380221a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637569				2022-12-24	WOS:A1996UB11700043
J	Mahon, BE; Mintz, ED; Greene, KD; Wells, JG; Tauxe, RV				Mahon, BE; Mintz, ED; Greene, KD; Wells, JG; Tauxe, RV			Reported cholera in the United States, 1992-1994 - A reflection of global changes in cholera epidemiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIBRIO-CHOLERAE; OUTBREAK; AMERICA; STRAIN; VCA-3	Objective.-To describe US cholera surveillance data from 1992 to 1994 and the domestic impact of the epidemics of Vibrio cholerae O1 in Latin America and V cholerae O139 in Asia. Design, Setting, and Participants.-Retrospective review of surveillance data from all cases of cholera reported to the Centers for Disease Control and Prevention (CDC) from January 1, 1992, through December 31, 1994, in the United States and its territories. Main Outcome Measures.-Clinical, epidemiologic, and laboratory surveillance data. Results.-From 1992 through 1994, 160 cases of cholera were reported to CDC by 20 states and 1 territory. This is a marked increase: only 136 cases were reported from 1965 through 1991. Outbreaks affecting 75 passengers on an airplane from Latin America and 5 passengers on a cruise ship in Southeast Asia accounted for 50% of cases. Vibrio cholerae O139 caused 6 cases (4%). The proportion of V cholerae O1 isolates resistant to at least 1 antimicrobial agent rose from 3% in 1992 to 93% in 1994. Of 158 patients whose location of exposure was known, 151 (96%) acquired infection abroad (125 in Latin America, 26 in Asia). Of 105 persons whose reason for travel was known, 31 (30%) were US residents who had returned to their country of origin to visit family or friends, and 65 (62%) were non-US residents visiting the United States from cholera-affected countries. The cholera rate among persons arriving in the United States from cholera-affected regions was 0.27 case per 100 000 air travelers, not substantially increased from earlier estimates. Conclusions.-Cholera has increased in the United States since 1991, reflecting global changes in cholera epidemiology, and is now primarily travel associated and antimicrobial resistant. Most travelers were not traditional tourists; reaching them with prevention measures may be difficult. The risk of cholera to the individual traveler remains extremely low.			Mahon, BE (corresponding author), CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333, USA.							ALBERT MJ, 1993, LANCET, V341, P704; ALMEIDA RJ, 1992, J CLIN MICROBIOL, V30, P300, DOI 10.1128/JCM.30.2.300-304.1992; BART KJ, 1970, J INFECT DIS, V121, pS17, DOI 10.1093/infdis/121.Supplement.S17; BESSER RE, 1994, JAMA-J AM MED ASSOC, V272, P1203, DOI 10.1001/jama.272.15.1203; BLAKE PA, 1980, NEW ENGL J MED, V302, P305, DOI 10.1056/NEJM198002073020601; BOYCE TG, 1995, J INFECT DIS, V172, P1401, DOI 10.1093/infdis/172.5.1401; *CDCP, 1995, HLTH INF INT TRAV 19; CHONGSANGUAN M, 1993, LANCET, V342, P430, DOI 10.1016/0140-6736(93)92841-G; EberhartPhillips J, 1996, EPIDEMIOL INFECT, V116, P9, DOI 10.1017/S0950268800058891; EVINS GM, 1995, J INFECT DIS, V172, P173, DOI 10.1093/infdis/172.1.173; FINELLI L, 1992, J INFECT DIS, V166, P1433, DOI 10.1093/infdis/166.6.1433; GOLDBERG S, 1983, INFECT IMMUN, V42, P224, DOI 10.1128/IAI.42.1.224-230.1983; JOHNSTON JM, 1983, NEW ENGL J MED, V309, P523, DOI 10.1056/NEJM198309013090903; KLONTZ KC, 1987, ANN INTERN MED, V107, P846, DOI 10.7326/0003-4819-107-6-846; Levine Myron M., 1994, P395; LOWRY PW, 1989, ARCH INTERN MED, V149, P2079, DOI 10.1001/archinte.149.9.2079; MACPHERSON DW, 1992, CAN MED ASSOC J, V146, P1947; MEKALANOS JJ, 1994, SCIENCE, V265, P1387, DOI 10.1126/science.8073279; *NAT COMM CLIN LAB, 1993, M2A5 NAT COMM CLIN L; RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5; SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2; SHIMADA T, 1993, LANCET, V341, P1347; SNYDER JD, 1982, JAMA-J AM MED ASSOC, V247, P2268, DOI 10.1001/jama.1982.03320410050031; SWERDLOW DL, 1992, JAMA-J AM MED ASSOC, V267, P1495, DOI 10.1001/jama.267.11.1495; TAUXE RV, 1992, JAMA-J AM MED ASSOC, V267, P1388, DOI 10.1001/jama.267.10.1388; TAYLOR JL, 1993, J INFECT DIS, V167, P1330, DOI 10.1093/infdis/167.6.1330; *US DEP TRANSP, 1995, INT AIR TRAV STAT 19; WEBER JT, 1994, ARCH INTERN MED, V154, P551, DOI 10.1001/archinte.154.5.551; WEISSMAN JB, 1975, AM J EPIDEMIOL, V100, P487; *WHO, 1991, WHO PROGR CONTR DIAR; WOODWARD WE, 1970, J INFECT DIS, V121, pS10, DOI 10.1093/infdis/121.Supplement.S10; 1991, MMWR-MORBID MORTAL W, V40, P516; 1991, MMWR-MORBID MORTAL W, V40, P108; 1995, WKLY EPIDEMIOL REC, V70, P201; 1977, MMWR-MORBID MORTAL W, V26, P307; 1995, EPIDEMIOL B PAN AM H, V16, P11; 1993, LANCET, V342, P387; 1990, MMWR-MORBID MORTAL W, V39, P9; 1993, MMWR-MORBID MORTAL W, V42, P501; 1995, MMWR-MORBID MORTAL W, V44, P385; 1992, MMWR-MORBID MORTAL W, V41, P664; 1977, MMWR-MORBID MORTAL W, V26, P302; 1988, MMWR-MORBID MORTAL W, V37, P617; 1995, MMWR-MORBID MORTAL W, V44, P215	44	34	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1996	276	4					307	312		10.1001/jama.276.4.307	http://dx.doi.org/10.1001/jama.276.4.307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX583	8656543				2022-12-24	WOS:A1996UX58300036
J	Petitti, DB; Sidney, S; Bernstein, A; Wolf, S; Quesenberry, C; Ziel, HK				Petitti, DB; Sidney, S; Bernstein, A; Wolf, S; Quesenberry, C; Ziel, HK			Stroke in users of low-dose oral contraceptives	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THROMBOEMBOLIC DISEASE; RISK; PROGESTOGENS; SAFETY	Background Previous studies have linked the use of oral contraceptive agents to an increased risk of stroke, but those studies have been limited to oral contraceptives containing more estrogen than is now generally used. Methods In a population-based, case-control study, we identified fatal and nonfatal strokes in female members of the California Kaiser Permanente Medical Care Program who were 15 through 44 years of age. Matched controls were randomly selected from female members who had not had strokes. Information about the use of oral contraceptives (essentially limited to low-estrogen preparations) was obtained in interviews. Results-A total of 408 confirmed strokes occurred in a total of 1.1 million women during 3.6 million woman-years of observation. The incidence of stroke was thus 11.3 per 100,000 woman-years. On the basis of data from 295 women with stroke who were interviewed and their controls, the odds ratio for ischemic stroke among current users of oral contraceptives, as compared with former users and women who had never used such drugs, was 1.18 (95 percent confidence interval, 0.54 to 2.59) after adjustment for other risk factors for stroke. The adjusted odds ratio for hemorrhagic stroke was 1.14 (95 percent confidence interval, 0.60 to 2.16). With respect to the risk of hemorrhagic stroke, there was a positive interaction between the current use of oral contraceptives and smoking (odds ratio for women with both these factors, 3.64; 95 percent confidence interval, 0.95 to 13.87). Conclusions Stroke is rare among women of childbearing age. Low-estrogen oral-contraceptive preparations do not appear to increase the risk of stroke. (C)1996, Massachusetts Medical Society.	KAISER PERMANENTE MED CARE PROGRAM,PASADENA,CA; KAISER PERMANENTE MED CARE PROGRAM,OAKLAND,CA	Kaiser Permanente; Kaiser Permanente					NICHD NIH HHS [N01-HD-3108] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1995, LANCET, V346, P1575; DYKEN ML, 1984, STROKE, V15, P1105; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JORDAN WM, 1961, LANCET, V2, P1146, DOI DOI 10.1016/S0140-6736(61)91061-3; KAY CR, 1982, AM J OBSTET GYNECOL, V142, P762; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; Lorentz IT, 1962, BRIT MED J, V2, P1191; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; ORY HW, 1983, MAKING CHOICES; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; STOLLEY PD, 1975, AM J EPIDEMIOL, V102, P197, DOI 10.1093/oxfordjournals.aje.a112148; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; 1975, JAMA-J AM MED ASSOC, V231, P718	19	268	274	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					8	15		10.1056/NEJM199607043350102	http://dx.doi.org/10.1056/NEJM199607043350102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637557				2022-12-24	WOS:A1996UU47900002
J	Tough, DF; Borrow, P; Sprent, J				Tough, DF; Borrow, P; Sprent, J			Induction of bystander T cell proliferation by viruses and type I interferon in vivo	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; INFECTION; ANTIGEN; MEMORY; MICE; STIMULATION; EXPRESSION; EXPANSION; TOLERANCE; RESPONSES	T cell proliferation in vivo is presumed to reflect a T cell receptor (TCR)-mediated polyclonal response directed to various environmental antigens, However, the massive proliferation of T cells seen in viral infections is suggestive of a bystander reaction driven by cytokines instead of the TCR. In mice, T cell proliferation in viral infections preferentially affected the CD44(hi) subset of CD8(+) cells and was mimicked by injection of polyinosinic-polycytidylic acid [poly(I:C)], an inducer of type I interferon (IFN I), and also by purified IFN I; such proliferation was not associated with up-regulation of CD69 or CD25 expression, which implies that TCR signaling was not involved, IFN I [poly(I:C)]-stimulated CD8(+) cells survived for prolonged periods in vivo and displayed the same phenotype as did long-lived antigen-specific CD8(+) cells, IFN I also potentiated the clonal expansion and survival of CD8(+) cells responding to specific antigen, Production of IFN I may thus play an important role in the generation and maintenance of specific memory.	Scripps Res Inst, DEPT IMMUNOL, IMM4, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, IMM6, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute				Borrow, Persephone/0000-0002-3877-9780	NCI NIH HHS [CA38355, CA25803] Funding Source: Medline; NIAID NIH HHS [AI21487] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038355, P01CA025803, R37CA038355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021487] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELL EB, 1987, J IMMUNOL, V139, P1379; BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; BRUNO L, 1995, IMMUNITY, V2, P37, DOI 10.1016/1074-7613(95)90077-2; DUMONT FJ, 1986, EUR J IMMUNOL, V16, P735, DOI 10.1002/eji.1830160704; DUTKO FJ, 1983, J GEN VIROL, V64, P1689, DOI 10.1099/0022-1317-64-8-1689; FIELD AK, 1967, P NATL ACAD SCI USA, V58, P1004, DOI 10.1073/pnas.58.3.1004; GAO EK, 1990, J EXP MED, V171, P1101, DOI 10.1084/jem.171.4.1101; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRESSER I, 1976, J EXP MED, V144, P1305, DOI 10.1084/jem.144.5.1305; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; KORNGOLD R, 1983, J IMMUNOL, V130, P2236; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KYBURZ D, 1993, EUR J IMMUNOL, V23, P1956, DOI 10.1002/eji.1830230834; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; MERIGAN TC, 1977, NATURE, V268, P67, DOI 10.1038/268067a0; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; RAZVI ES, 1995, ADV VIRUS RES, V45, P1, DOI 10.1016/S0065-3527(08)60057-3; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; ROEDERER M, 1995, NAT MED, V1, P621, DOI 10.1038/nm0795-621; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SPRENT J, 1985, J EXP MED, V162, P2068, DOI 10.1084/jem.162.6.2068; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; TOUGH D, UNPUB; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; TRIPP RA, 1995, J IMMUNOL, V154, P6013; TRIPP RA, 1995, J IMMUNOL, V154, P5870; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; WHITTON JL, 1988, VIROLOGY, V162, P321, DOI 10.1016/0042-6822(88)90471-0; YANG HY, 1989, J IMMUNOL, V142, P1710; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	32	898	921	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1996	272	5270					1947	1950		10.1126/science.272.5270.1947	http://dx.doi.org/10.1126/science.272.5270.1947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658169				2022-12-24	WOS:A1996UV29400051
J	Wesson, DR; Ling, W				Wesson, DR; Ling, W			Addiction medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL DEPENDENCE; BUPRENORPHINE; NALTREXONE		SUMMIT MED CTR, OAKLAND, CA USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	Wesson, DR (corresponding author), UNIV CALIF SAN FRANCISCO, OAKLAND, CA USA.			, Walter/0000-0003-0664-5099				ALTERMAN AI, 1994, J NERV MENT DIS, V182, P157, DOI 10.1097/00005053-199403000-00005; CALHOUN S, IN PRESS PSYCHOACTIV; DOLE VP, 1995, JAMA-J AM MED ASSOC, V274, P1307; FRATTOLA L, 1990, DRUG EXP CLIN RES, V16, P371; HOLLANDER JE, 1995, ANN EMERG MED, V26, P671, DOI 10.1016/S0196-0644(95)70035-8; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; LESHNER A, 1995, NIDA NOTES, V10, P3; Ling W, 1996, ARCH GEN PSYCHIAT, V53, P401; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; ROBINSON GM, 1993, DRUG ALCOHOL DEPEN, V33, P81, DOI 10.1016/0376-8716(93)90036-P; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876	11	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1792	1793		10.1001/jama.275.23.1792	http://dx.doi.org/10.1001/jama.275.23.1792			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642712				2022-12-24	WOS:A1996UQ15200011
J	Davenport, RJ; Dennis, MS; Warlow, CP				Davenport, RJ; Dennis, MS; Warlow, CP			Effect of correcting outcome data for case mix: An example from stroke medicine	BRITISH MEDICAL JOURNAL			English	Article							INTENSIVE-CARE	Objective-To show the influence of variations in case mix on clinical outcome indicators for patients admitted to hospital with acute stroke. Design-''Before and after'' cohort study, with prospective, consecutive identification of patients and prospective follow up; multiple logistic regression analyses to correct for case mix variations. Setting-University teaching hospital. Subjects-216 patients with stroke identified before the introduction of an organised stroke service, and 252 patients with stroke identified after its introduction. Main outcome measures-Case fatality at 30 days and 12 months; for survivors at 12 months, proportions of patients who were independent (according to the Oxford handicap scale) and of those living at home. Results-Crude outcome data suggested that patients in the cohort identified after the introduction of the stroke service were significantly more likely to be alive, independent, and living at home than patients managed before the stroke service. After adjustment for age and sex these ''improvements'' were less impressive but still significant. After adjustment for many other possible prognostic indicators, however, the differences between the two groups for all four outcomes were non-significant, suggesting that the ''improvements'' may have been entirely due to differences in case mix between the two cohorts, rather than the new stroke service. Conclusions-Variations in case mix have a crucial influence on the interpretation of outcome data, and this is particularly important in non-randomised comparative studies. Such studies, comparing performance within and between different provider units, are likely to become increasingly common in the new reformed NHS. To allow meaningful interpretation, these studies must try to correct for case mix.			Davenport, RJ (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BION J, 1993, BRIT MED J, V307, P953, DOI 10.1136/bmj.307.6910.953; Carstairs V, 1991, DEPRIVATION HLTH; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; *SCOTT OFF, 1994, CLIN OUTC IND; *SCOTT OFF, 1995, CLIN OUTC IND; WARLOW C, 1995, STROKE MODULE COCHRA; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539	15	87	87	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1503	1505		10.1136/bmj.312.7045.1503	http://dx.doi.org/10.1136/bmj.312.7045.1503			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR823	8646140	Green Published			2022-12-24	WOS:A1996UR82300018
J	Kirkwood, A; Rioult, MG; Bear, MF				Kirkwood, A; Rioult, MG; Bear, MF			Experience-dependent modification of synaptic plasticity in visual cortex	NATURE			English	Article							LONG-TERM DEPRESSION; AREA CA1; HIPPOCAMPUS; NEURONS; RAT	IN many regions of the cerebral cortex, Ca2+ influx through NMDA (N-methyl-D-aspartate) sensitive glutamate receptors (NMDA receptors) can trigger two forms of synaptic plasticity: long-term depression (LTD) and long-term potentiation (LTP)(1). LTD is induced by low levels of postsynaptic NMDA-receptor activation, for instance in response to low-frequency stimulation, whereas LTP is induced by the stronger activation that occurs following high-frequency stimulation(2-4). Theoretical studies have shown that the properties of synaptic LTD and LTP can account for many aspects of experience-dependent plasticity in the developing visual cortex, provided that the LTD-LTP crossover point (the modification threshold, theta(m)) varies as a function of the history of cortical activity(5-7). Here we provide direct experimental evidence that the value of theta(m) depends on sensory experience. We find in visual cortex of light-deprived rats that LTP is enhanced and LTD diminished over a range of stimulation frequencies, and that these effects can be reversed by as little as two days of light exposure. Our findings support the idea that a variable synaptic-modification threshold allows synaptic weights in neural networks to achieve a stable equilibrium.	BROWN UNIV,DEPT NEUROSCI,PROVIDENCE,RI 02912; BROWN UNIV,HOWARD HUGHES MED INST,PROVIDENCE,RI 02912	Brown University; Brown University; Howard Hughes Medical Institute				Bear, Mark/0000-0002-9903-2541; Rioult, Marika G/0000-0002-7473-2664				Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BUISSERET P, 1976, J PHYSIOL-LONDON, V255, P511, DOI 10.1113/jphysiol.1976.sp011293; BUISSERET P, 1978, NATURE, V272, P816, DOI 10.1038/272816a0; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CLOTHIAUX EE, 1991, J NEUROPHYSIOL, V66, P1785, DOI 10.1152/jn.1991.66.5.1785; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FREGNAC Y, 1994, J NEUROPHYSIOL, V71, P1403, DOI 10.1152/jn.1994.71.4.1403; GABBOTT PLA, 1986, EXP BRAIN RES, V64, P225; KERR DS, 1996, P NATL ACAD SCI USA, V62, P11637; Kimura F, 1990, Neuroreport, V1, P65, DOI 10.1097/00001756-199009000-00018; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; MAYFORD M, 1905, CELL, V81, P1; Mulkey R. M., 1992, Society for Neuroscience Abstracts, V18, P1498; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; SEJNOWSKI IJ, 1977, J THEOR BIOL, V69, P385, DOI 10.1016/0022-5193(77)90146-1; SELIG DK, 1995, NEURON, V15, P417, DOI 10.1016/0896-6273(95)90045-4; SHOUVAL H, IN PRESS NEURAL COMP; Steele P. M., 1994, Society for Neuroscience Abstracts, V20, P1514; WAGNER JJ, 1995, J NEUROSCI, V15, P1577; WEXLER EM, 1993, NEUROREPORT, V4, P591, DOI 10.1097/00001756-199305000-00034	30	445	454	1	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					526	528		10.1038/381526a0	http://dx.doi.org/10.1038/381526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632826				2022-12-24	WOS:A1996UP43500061
J	Brooks, PC; Stromblad, S; Sanders, LC; vonSchalscha, TL; Aimes, RT; StetlerStevenson, WG; Quigley, JP; Cheresh, DA				Brooks, PC; Stromblad, S; Sanders, LC; vonSchalscha, TL; Aimes, RT; StetlerStevenson, WG; Quigley, JP; Cheresh, DA			Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3	CELL			English	Article							EXTRACELLULAR-MATRIX; IV COLLAGENASE; ADHESION MOLECULES; UROKINASE RECEPTOR; TUMOR PROGRESSION; METASTASIS; VITRONECTIN; BINDING; EXPRESSION; INHIBITOR	Cellular invasion depends on cooperation between adhesive and proteolytic mechanisms. Evidence is provided that the matrix metalloproteinase MMP-2 can be localized in a proteolytically active form on the surface of invasive cells, based on its ability to bind directly integrin alpha v beta 3. MMP-2 and alpha v beta 3 were specifically colocalized on angiogenic blood vessels and melanoma cells in vivo. Expression of alpha v beta 3 on cultured melanoma cells enabled their binding to MMP-2 in a proteolytically active form, facilitating cell-mediated collagen degradation. In vitro, these proteins formed an SDS-stable complex that depended on the noncatalytic C-terminus of MMP-2, since a truncation mutant lost the ability to bind alpha v beta 3. These findings define a single cell-surface receptor that regulates both matrix degradation and motility, thereby facilitating directed cellular invasion.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA; NCI, PATHOL LAB, NIH, BETHESDA, MD 20892 USA	Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brooks, PC (corresponding author), Scripps Res Inst, DEPT IMMUNOL, IMM24 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Stetler-Stevenson, William G/H-6956-2012; Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William G/0000-0002-5500-5808; Stetler-Stevenson, William/0000-0002-5500-5808; Stromblad, Staffan/0000-0002-1236-6339	NCI NIH HHS [CA-50286, CA-45726] Funding Source: Medline; NHLBI NIH HHS [HL-54444] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA050286, R01CA045726, R01CA050286] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054444] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBELDA SM, 1990, CANCER RES, V50, P6757; AMES RT, 1994, BIOCHEM J, V300, P729, DOI 10.1042/bj3000729; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN PD, 1990, CANCER RES, V50, P6184; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; EMONARD HP, 1992, CANCER RES, V52, P5845; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FILARDO EJ, 1996, IN PRESS J CELL SCI; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GREVIN D, 1993, INT J DEV BIOL, V37, P519; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ITO A, 1995, BRIT J CANCER, V71, P1039, DOI 10.1038/bjc.1995.200; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; KLEINER DE, 1993, BIOCHEMISTRY-US, V32, P1583, DOI 10.1021/bi00057a024; KNUDSEN KA, 1982, J CELL BIOCHEM, V18, P157, DOI 10.1002/jcb.1982.240180204; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONSKY WL, 1993, CANCER RES, V53, P3159; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MOSES MA, 1991, J CELL BIOCHEM, V47, P230, DOI 10.1002/jcb.240470308; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MUELLER SC, 1991, J CELL SCI, V99, P213; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; NEWMAN PJ, 1985, BLOOD, V65, P227; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PEPPER MS, 1994, J CELL BIOCHEM, V55, P419, DOI 10.1002/jcb.240550403; PFAFF M, 1994, J BIOL CHEM, V269, P20233; REINARTZ J, 1994, EXP CELL RES, V214, P486, DOI 10.1006/excr.1994.1286; RUCKLIDGE GJ, 1994, BIOCHEM SOC T, V22, P63, DOI 10.1042/bst0220063; RUOSLAHTI E, 1992, BRIT J CANCER, V66, P239, DOI 10.1038/bjc.1992.250; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1988, J BIOL CHEM, V263, P18726; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; THOMAS L, 1993, J CELL SCI, V105, P191; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YAN HC, 1993, J CLIN INVEST, V91, P986, DOI 10.1172/JCI116320	59	1371	1414	0	76	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1996	85	5					683	693		10.1016/S0092-8674(00)81235-0	http://dx.doi.org/10.1016/S0092-8674(00)81235-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646777	Bronze			2022-12-24	WOS:A1996UP34400009
J	Fero, ML; Rivkin, M; Tasch, M; Porter, P; Carow, CE; Firpo, E; Polyak, K; Tsai, LH; Broudy, V; Perlmutter, RM; Kaushansky, K; Roberts, JM				Fero, ML; Rivkin, M; Tasch, M; Porter, P; Carow, CE; Firpo, E; Polyak, K; Tsai, LH; Broudy, V; Perlmutter, RM; Kaushansky, K; Roberts, JM			A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice	CELL			English	Article							CYCLIN-DEPENDENT KINASES; GROWTH FACTOR-I; TRANSGENIC MICE; FUSION GENES; INHIBITION; PROTOONCOGENE; FIBROBLASTS; DISRUPTION; SUBUNIT; HORMONE	Targeted disruption of the murine p27(Kip1) gene caused a gene dose-dependent increase in animal size without other gross morphologic abnormalities. All tissues were enlarged and contained more cells, although endocrine abnormalities were not evident. Thymic hyperplasia was associated with increased T lymphocyte proliferation, and T cells showed enhanced IL-2 responsiveness in vitro. Thus, p27 deficiency may cause a Cell-autonomous defect resulting in enhanced proliferation in response to mitogens. In the spleen, the absence of p27 selectively enhanced proliferation of hematopoietic progenitor cells. p27 deletion, like deletion of the Rb gene, uniquely caused neoplastic growth of the pituitary pars intermedia, Suggesting that p27 and Rb function in the same regulatory pathway. The absence of p27 also caused an ovulatory defect and female sterility. Maturation of secondary ovarian follicles into corpora lutea, which express high levels of p27, was markedly impaired.	FRED HUTCHINSON CANC RES CTR, PROGRAM CANC BIOL, DIV PUBL HLTH, SEATTLE, WA 98104 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; UNIV WASHINGTON, DEPT MED, DIV HEMATOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT IMMUNOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; JOHNS HOPKINS ONCOL CTR, HOWARD HUGHES MED INST, BALTIMORE, MD 21231 USA	Fred Hutchinson Cancer Center; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine	Fero, ML (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, DIV PUBL HLTH, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.			Fero, Matthew/0000-0002-9967-4659	NCI NIH HHS [R01 CA 31615] Funding Source: Medline; NIDDK NIH HHS [R01 DK 49855] Funding Source: Medline; NIGMS NIH HHS [GM53049] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053049] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; BROUDY VC, 1988, ARCH BIOCHEM BIOPHYS, V265, P329, DOI 10.1016/0003-9861(88)90135-X; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHRONWALL BM, 1987, ENDOCRINOLOGY, V120, P1201, DOI 10.1210/endo-120-3-1201; COATS S, 1996, IN PRESS SCIENCE; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GARY KA, 1992, INT J DEV NEUROSCI, V10, P131, DOI 10.1016/0736-5748(92)90041-W; Gehlert D R, 1988, Peptides, V9 Suppl 1, P161, DOI 10.1016/0196-9781(88)90240-9; GERDES J, 1992, J PATHOL, V168, P85, DOI 10.1002/path.1711680114; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; HU NP, 1994, ONCOGENE, V9, P1021; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KAWAMATA N, 1995, CANCER RES, V55, P2266; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANBUULOFFERS SC, 1995, J ENDOCRINOL, V144, P491, DOI 10.1677/joe.0.1440491; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARD A, 1994, P NATL ACAD SCI USA, V91, P10365, DOI 10.1073/pnas.91.22.10365; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WOLF E, 1994, ENDOCRINOLOGY, V135, P1877, DOI 10.1210/en.135.5.1877; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	59	1304	1340	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1996	85	5					733	744		10.1016/S0092-8674(00)81239-8	http://dx.doi.org/10.1016/S0092-8674(00)81239-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646781	hybrid			2022-12-24	WOS:A1996UP34400013
J	Seol, W; Choi, HS; Moore, DD				Seol, W; Choi, HS; Moore, DD			An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors	SCIENCE			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; RESPONSE ELEMENT; X-RECEPTOR; BETA-GENE; PROTEIN; ALPHA	SHP is an orphan member of the nuclear hormone receptor superfamily that contains the dimerization and ligand-binding domain found in other;family members but lacks the conserved DNA binding domain. In the yeast two-hybrid system, SHP interacted with several conventional and orphan members of the receptor superfamily, including retinoid receptors, the thyroid hormone receptor, and the orphan receptor MB67. SHP also interacted directly with these receptors in vitro. In mammalian cells, SHP specifically inhibited transactivation by the superfamily members with which it interacted. These results suggest that SHP functions as a negative regulator of receptor-dependent signaling pathways.	MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital					NIDDK NIH HHS [DK46546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; Choi H. W., UNPUB; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Moore DD, 1995, GLOB MOB SURV; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	33	431	448	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1996	272	5266					1336	1339		10.1126/science.272.5266.1336	http://dx.doi.org/10.1126/science.272.5266.1336			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650544				2022-12-24	WOS:A1996UN47200046
J	Yang, HY; Bard, M; Bruner, DA; Gleeson, A; Deckelbaum, RJ; Aljinovic, G; Pohl, TM; Rothstein, R; Sturley, SL				Yang, HY; Bard, M; Bruner, DA; Gleeson, A; Deckelbaum, RJ; Aljinovic, G; Pohl, TM; Rothstein, R; Sturley, SL			Sterol esterification in yeast: A two-gene process	SCIENCE			English	Article							ACYL-COENZYME-A; CHOLESTEROL ACYLTRANSFERASE; RAT-LIVER; TRANSFORMATION; METABOLISM; CELLS; DNA	Unesterified sterol modulates the function of eukaryotic membranes. In human cells, sterol is esterified to a storage form by acyl-coenzyme A (CoA): cholesterol acyl transferase (ACAT). Here, two genes are identified, ARE1 and ARE2, that encode ACAT-related enzymes in yeast. The yeast enzymes are 49 percent identical to each other and exhibit 23 percent identity to human ACAT. Deletion of ARE2 reduced sterol ester levels to approximately 25 percent of normal levels, whereas disruption of ARE1 did not affect sterol ester biosynthesis. Deletion of both genes resulted in a viable cell with undetectable esterified sterol. Measurements of [C-14]acetate incorporation into saponified lipids indicated down-regulation of sterol biosynthesis in the are1 are2 mutant cells. With the use of a consensus sequence to the yeast and human genes, an additional member of the ACAT gene family was identified in humans.	COLUMBIA UNIV COLL PHYS & SURG, INST HUMAN NUTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PEDIAT, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MOLEC BIOPHYS, NEW YORK, NY 10032 USA; INDIANA UNIV PURDUE UNIV, DEPT BIOL, INDIANAPOLIS, IN 46202 USA; GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Indiana University System; Indiana University-Purdue University Indianapolis; Columbia University			Yang, Hongyuan/AAR-1326-2020	Yang, Hongyuan/0000-0002-8482-6031	NHGRI NIH HHS [HG00861] Funding Source: Medline; NIAID NIH HHS [R01 AI38598] Funding Source: Medline; NIGMS NIH HHS [GM 50237] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050237, R37GM050237] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BILLHEIMER JT, 1992, ADV CHOLESTEROL RES; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1274, DOI 10.1161/01.ATV.12.11.1274; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1983, ENZYMES, V16, P523; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIMSTERDENK D, 1994, MOL BIOL CELL, V5, P655, DOI 10.1091/mbc.5.6.655; DOOLITTLE GM, 1982, BIOCHEMISTRY-US, V21, P674, DOI 10.1021/bi00533a014; ERICKSON SK, 1994, J LIPID RES, V35, P763; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; OKPODU CM, 1994, BIOTECHNIQUES, V16, P154; PARKS LW, 1985, METHOD ENZYMOL, V111, P333; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHIRATOR.T, 1965, BIOCHIM BIOPHYS ACTA, V106, P625, DOI 10.1016/0005-2760(65)90078-0; STURLEY SL, 1994, J BIOL CHEM, V269, P21670; STURLEY SL, UNPUB; TABAS I, 1986, J BIOL CHEM, V261, P3147; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMPSON SL, 1987, J BIOL CHEM, V262, P17420; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Yang H., UNPUB	36	215	228	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1996	272	5266					1353	1356		10.1126/science.272.5266.1353	http://dx.doi.org/10.1126/science.272.5266.1353			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650549				2022-12-24	WOS:A1996UN47200051
J	Clouthier, DE; Avarbock, MR; Maika, SD; Hammer, RE; Brinster, RL				Clouthier, DE; Avarbock, MR; Maika, SD; Hammer, RE; Brinster, RL			Rat spermatogenesis in mouse testis	NATURE			English	Article								RECENTLY, transplantation of mouse donor spermatogonial stem cells from a fertile testis to an infertile recipient mouse testis was described(1,2). The donor tells established spermatogenesis in the seminiferous tubules of the host, and normal spermatozoa were produced. In the most successful transplants, the recipient mice were fertile and sired up to 80 per cent of progeny from donor cells(2). Here we examine the feasibility of transplanting spermatogonial stem cells from other species to the mouse seminiferous tubule to generate spermatogenesis. Marked testis cells from transgenic rats sere transplanted to the testes of immunodeficient mice, and in all of 10 recipient mice (in 19 of 20 testes), rat spermatogenesis occurred. Epididymides of eight mice were examined, and the three from mice with the longest transplants (greater than or equal to 110 days) contained rat spermatozoa with normal morphology. The generation of rat spermatogenesis in mouse testes suggests that spermatogonial stem cells of many species could be transplanted, and opens the possibility of xenogeneic spermatogenesis for other species.	UNIV PENN, SCH VET MED, REPROD PHYSIOL LAB, PHILADELPHIA, PA 19104 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Clouthier, David/A-7062-2009	Hammer, Robert E./0000-0001-5487-7551; Brinster, Ralph/0000-0003-1408-7656	NICHD NIH HHS [R01 HD036504] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036504] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVARBOCK MR, IN PRESS NATURE MED; Baker TG., 1972, REPROD BIOL, P398; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; BUCCI LR, 1987, MUTAT RES, V176, P259, DOI 10.1016/0027-5107(87)90057-1; CAMPER SA, 1995, BIOL REPROD, V52, P246, DOI 10.1095/biolreprod52.2.246; CATZEFLIS FM, 1993, MAMMAL PHYLOGENY : PLACENTALS, P159; DEKRETSER DM, 1988, PHYSL REPROD, P932; ENDERS GC, 1993, SERTOLI CELL, P447; FISHEL S, 1995, LANCET, V345, P1641, DOI 10.1016/S0140-6736(95)90149-3; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Hogan B, 1994, MANIPULATING MOUSE E; Jiang FX, 1995, INT J ANDROL, V18, P326, DOI 10.1111/j.1365-2605.1995.tb00570.x; KIMURA Y, 1995, DEVELOPMENT, V121, P2397; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; Russell LD, 1993, SERTOLI CELL, P365; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; TESARIK JN, 1995, NEW ENGL J MED, V333, P525, DOI 10.1056/NEJM199508243330819	22	285	320	2	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 30	1996	381	6581					418	421		10.1038/381418a0	http://dx.doi.org/10.1038/381418a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632797	Green Accepted			2022-12-24	WOS:A1996UN47900050
J	Newton, R; Ferlay, J; Reeves, G; Beral, V; Parkin, DM				Newton, R; Ferlay, J; Reeves, G; Beral, V; Parkin, DM			Effect of ambient solar ultraviolet radiation on incidence of squamous-cell carcinoma of the eye	LANCET			English	Article								Background We have investigated the geographic distribution of squamous-cell carcinoma of the eye to assess whether solar ultraviolet light is a risk factor for this disease. Methods We used routinely collected population-based cancer incidence data and published measurements of ambient solar ultraviolet light in our analysis. Findings The incidence of squamous-cell carcinoma of the eye declined by 49% for each 10 degrees increase in latitude (p<0.0001), falling from more than 12 cases per million per year in Uganda (latitude 0.3 degrees) to less than 0.2 per million per year in the UK (latitude >50 degrees). Solar ultraviolet radiation decreases with increasing latitude, and the incidence of squamous-cell carcinoma of the eye decreased by 29% per unit reduction in ultraviolet exposure (p<0.0001). Interpretation Our results are compatible with the hypothesis that exposure to solar ultraviolet light is an important cause of squamous-cell carcinoma of the eye.	INT AGCY RES CANC,F-69372 LYON,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC)	Newton, R (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.		Ferlay, Jacques/ABD-5058-2021					ATEENYIAGABA C, 1995, LANCET, V345, P695, DOI 10.1016/S0140-6736(95)90870-6; DIFFEY BL, 1993, MELANOMA EPIDEMIOLOG, P81; *EUR NETW CANC REG, 1995, EUROCIM US MAN; GOEDERT JJ, 1995, LANCET, V346, P257, DOI 10.1016/S0140-6736(95)91309-2; *INT AG CANC RES, 1992, INT AG CANC RES MON, V55; KESTELYN P, 1990, LANCET, V336, P51, DOI 10.1016/0140-6736(90)91562-O; LEE GA, 1994, OPHTHALMOLOGY, V101, P360; MCDONNELL JM, 1989, NEW ENGL J MED, V320, P1442, DOI 10.1056/NEJM198906013202202; *NCI SURV PROGR, 1994, SURV EP END RES SEER; NEWTON R, 1995, LANCET, V345, P1378, DOI 10.1016/S0140-6736(95)92583-X; Parkin DM, 1992, CANC INCIDENCE 5 CON, VVI; Templeton A C, 1973, Recent Results Cancer Res, V41, P203; *WHO, 1976, MAN INT CLASS DIS ON	13	109	115	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1450	1451		10.1016/S0140-6736(96)91685-2	http://dx.doi.org/10.1016/S0140-6736(96)91685-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676629				2022-12-24	WOS:A1996UM48500012
J	Yunus, MB; Aldag, JC				Yunus, MB; Aldag, JC			Restless legs syndrome and leg cramps in fibromyalgia syndrome: A controlled study	BRITISH MEDICAL JOURNAL			English	Article											Yunus, MB (corresponding author), UNIV ILLINOIS,COLL MED,DEPT MED,BOX 1649,PEORIA,IL 61656, USA.							CLOUGH C, 1987, BRIT MED J, V294, P262, DOI 10.1136/bmj.294.6567.262; MONTPLAISIR J, 1986, CLIN NEUROPHARMACOL, V9, P456, DOI 10.1097/00002826-198610000-00006; REYNOLDS G, 1986, BRIT MED J, V292, P659, DOI 10.1136/bmj.292.6521.659; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; Yunus Muhammad B., 1993, P1383	5	108	114	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1339	1339		10.1136/bmj.312.7042.1339	http://dx.doi.org/10.1136/bmj.312.7042.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646049	Green Published			2022-12-24	WOS:A1996UN47600024
J	Lalvani, A; Shastri, JS				Lalvani, A; Shastri, JS			HIV epidemic in India: Opportunity to learn from the past	LANCET			English	Editorial Material									RN COOPER HOSP,AIDS SURVEILLANCE & ZONAL BLOOD TESTING CTR,BOMBAY,MAHARASHTRA,INDIA		Lalvani, A (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND.			Lalvani, Ajit/0000-0002-2396-246X				BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; ESSEX M, 1996, 8 ANN M NAT COOP VAC; GREZ M, 1994, J VIROL, V68, P2161, DOI 10.1128/JVI.68.4.2161-2168.1994; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; JACOB KS, 1989, BRIT MED J, V299, P721, DOI 10.1136/bmj.299.6701.721; JAIN MK, 1994, J ACQ IMMUN DEF SYND, V7, P1185; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; 1995, WKLY EPIDEMIOL REC, V70, P353	10	28	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1349	1350		10.1016/S0140-6736(96)91007-7	http://dx.doi.org/10.1016/S0140-6736(96)91007-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637338				2022-12-24	WOS:A1996UL90400006
J	Hoodless, PA; Haerry, T; Abdollah, S; Stapleton, M; OConnor, MB; Attisano, L; Wrana, JL				Hoodless, PA; Haerry, T; Abdollah, S; Stapleton, M; OConnor, MB; Attisano, L; Wrana, JL			MADR1, a MAD-related protein that functions in BMP2 signaling pathways	CELL			English	Article							BONE MORPHOGENETIC PROTEINS; FACTOR-BETA FAMILY; GENE; EXPRESSION; RECEPTOR; COMPLEX; INDUCE; CELLS	Components of the signaling pathways that lie downstream of Ser/Thr kinase receptors and are required for signaling by the TGF beta superfamily have been poorly defined. The Drosophila gene Mothers against dpp (Mad) and the C. elegans sma genes are implicated in these signaling pathways. We show that MAD functions downstream of DPP receptors and is required for receptor signaling. Phosphorylation of MADR1, a human homolog of MAD, is tightly regulated and rapidly induced by BMP2, but not TGF beta or activin. This phosphorylation is necessary for function, since a point mutant that yields a null phenotype in Drosophila is not phosphorylated. BMP2 treatment results in accumulation of MADR1 in the nucleus. MAD proteins may thus define a novel class of signaling molecules with nuclear function in Ser/Thr kinase receptor signaling pathways.	HOSP SICK CHILDREN,PROGRAM DEV BIOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DIV GASTROENTEROL,TORONTO,ON M5G 1X8,CANADA; UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of California System; University of California Irvine; University of California System; University of California Irvine			Wrana, Jeffrey/F-8857-2013; O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506; Hoodless, Pamela/0000-0003-1371-0725	NIGMS NIH HHS [GM47462] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Attisano L, 1996, MOL CELL BIOL, V16, P1066; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LENNON GG, 1996, IN PRESS GENOMICS; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIU F, 1995, MOL CELL BIOL, V15, P3479; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; NOLL R, 1994, DEVELOPMENT, V120, P2329; OHTA S, 1992, FEBS LETT, V314, P356, DOI 10.1016/0014-5793(92)81505-G; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RAFTERY LA, 1995, GENETICS, V139, P241; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEKELSKY JJ, 1995, GENETICS, V139, P1347; STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217	57	628	665	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					489	500		10.1016/S0092-8674(00)81250-7	http://dx.doi.org/10.1016/S0092-8674(00)81250-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653785	Bronze			2022-12-24	WOS:A1996UM41500007
J	Lee, GH; Proenca, R; Montez, JM; Carroll, KM; Darvishzadeh, JG; Lee, JI; Friedman, JM				Lee, GH; Proenca, R; Montez, JM; Carroll, KM; Darvishzadeh, JG; Lee, JI; Friedman, JM			Abnormal splicing of the leptin receptor in diabetic mice	NATURE			English	Article							YEAST; FRAGMENTS; MUTATION; CLONING; GENES; DNA	MUTATIONS in the mouse diabetes (db) gene result in obesity and diabetes in a syndrome resembling morbid human obesity(1), Previous data suggest that the db gene encodes the receptor for the obese (ob) gene product, leptin(2-7). A leptin receptor was recently cloned from choroid plexus and shown to map to the same 6-cM interval on mouse chromosome 4 as db(8). This receptor maps to the same 300-kilobase interval as db, and has at least six alternatively spliced forms. One of these splice variants is expressed at a high level in the hypothalamus, and is abnormally spliced in C57BL/Ks db/db mice, The mutant protein is missing the cytoplasmic region, and is likely to be defective in signal transduction. This suggests that the weight-reducing effects of leptin may be mediated by signal transduction through a leptin receptor in the hypothalamus.	ROCKEFELLER UNIV, DEPT MOLEC GENET, NEW YORK, NY 10021 USA	Rockefeller University	Lee, GH (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Friedman, Jeffrey M/E-5784-2011					BAHARY N, 1990, P NATL ACAD SCI USA, V87, P8642, DOI 10.1073/pnas.87.21.8642; BAHARY N, 1993, MAMM GENOME, V4, P511, DOI 10.1007/BF00364786; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; Lodish H, 1986, MOL CELL BIOL; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MILATOVICH A, 1994, SOMAT CELL MOLEC GEN, V20, P75, DOI 10.1007/BF02290677; MODI WS, 1995, CYTOGENET CELL GENET, V69, P232, DOI 10.1159/000133971; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NURMINSKY DI, 1993, BIOTECHNIQUES, V15, P201; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TARTON MD, 1996, NATURE, V379, P69; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	27	1988	2081	0	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					632	635		10.1038/379632a0	http://dx.doi.org/10.1038/379632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628397				2022-12-24	WOS:A1996TV68800050
J	Rubin, DM; Coux, O; Wefes, I; Hengartner, C; Young, RA; Goldberg, AL; Finley, D				Rubin, DM; Coux, O; Wefes, I; Hengartner, C; Young, RA; Goldberg, AL; Finley, D			Identification of the gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome	NATURE			English	Article							TAT-MEDIATED TRANSACTIVATION; BINDING-PROTEIN; 26-S PROTEASE; MODULATOR; FAMILY; GENES	THE SUG1 gene of Saccharomyces cerevisiae encodes a putative ATPase. Mutations in SUG1 were isolated(1) as suppressors of a mutation in the transcriptional activation domain of GAL4. Sug1 was recently proposed to be a subunit of the RNA polymerase II holoenzyme and to mediate the association of transcriptional activators with holoenzyme(2). We show here that Sug1 is not a subunit of the holoenzyme, at least in its purified form, but of the 26S proteasome(3,4), a large complex of relative molecular-mass 2,000K that catalyses the ATP-dependent degradation of ubiquitin-protein conjugates. Sug1 co-purifies with the proteasome in both conventional and nickel-chelate affinity chromatography. Our observations account for the reduced ubiquitin-dependent proteolysis in sug1 mutants(5) and suggest that the effects of sug1 mutations on transcription are indirect results of defective proteolysis.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Coux, Olivier/P-6847-2019; Hengartner, Christoph/AAF-5132-2021; Young, Richard A/F-6495-2012; Coux, Olivier/B-3406-2010	Coux, Olivier/0000-0001-8455-3849; Young, Richard A/0000-0001-8855-8647; Coux, Olivier/0000-0001-8455-3849				AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; Crowe J, 1994, Methods Mol Biol, V31, P371; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PETERS JM, 1994, J BIOL CHEM, V269, P7709; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; XU QL, 1995, MOL CELL BIOL, V15, P6025; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	28	146	147	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					655	657		10.1038/379655a0	http://dx.doi.org/10.1038/379655a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628401				2022-12-24	WOS:A1996TV68800057
J	Smith, SB; Cui, YJ; Bustamante, C				Smith, SB; Cui, YJ; Bustamante, C			Overstretching B-DNA: The elastic response of individual double-stranded and single-stranded DNA molecules	SCIENCE			English	Article								Single molecules of double-stranded DNA (dsDNA) were stretched with force-measuring laser tweezers. Under a longitudinal stress of similar to 65 piconewtons (pN), dsDNA molecules in aqueous buffer undergo a highly cooperative transition into a stable form with 5.8 angstroms rise per base pair, that is, 70% longer than B-form dsDNA. When the stress was relaxed below 65 pN, the molecules rapidly and reversibly contracted to their normal contour lengths. This transition was affected by changes in the ionic strength of the medium and the water activity or by cross-linking of the two strands of dsDNA. Individual molecules of single-stranded DNA were also stretched giving a persistence length of 7.5 angstroms and a stretch modulus of 800 pN. The overstretched form may play a significant role in the energetics of DNA recombination.	UNIV OREGON,INST MOLEC BIOL,DEPT CHEM,EUGENE,OR 97403; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403	University of Oregon; Howard Hughes Medical Institute; University of Oregon; University of Oregon				Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032543, R37GM032543] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-32543] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHTER EK, 1971, BIOPOLYMERS, V10, P1625, DOI 10.1002/bip.360100916; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; BERMAN HM, 1994, CURR OPIN STRUC BIOL, V4, P345, DOI 10.1016/S0959-440X(94)90102-3; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CALLADINE CR, 1992, UNDERSTANDING DNA MO; Callen H.B., 1985, THERMODYNAMICS INTRO; DAVIDSON N, 1971, BACTERIOPHAGE LAMBDA, P56; GHISLAIN LP, 1994, REV SCI INSTRUM, V65, P2762, DOI 10.1063/1.1144613; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1503, DOI 10.1002/bip.1981.360200710; HEARST JE, 1984, Q REV BIOPHYS, V17, P1, DOI 10.1017/S0033583500005242; KLUG A, 1975, NATURE, V255, P530; LANDAU LD, 1986, THEORY ELASTICITY, P67; LANDAU LD, 1980, STATISTICAL PHYSIC 1; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHELLMAN JA, 1995, BIOPHYS CHEM, V55, P95, DOI 10.1016/0301-4622(94)00144-9; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Smith Steven B., 1995, Biophysical Journal, V68, pA250; SOBEL ES, 1991, BIOPOLYMERS, V31, P1559, DOI 10.1002/bip.360311311; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; THUNDAT T, 1994, NUCLEIC ACIDS RES, V22, P4224, DOI 10.1093/nar/22.20.4224; Trifonov E.N., 1987, STRUCTURE EXPRESSION, P243; USSERY DW, 1992, METHOD ENZYMOL, V212, P242; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	29	2226	2327	14	384	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					795	799		10.1126/science.271.5250.795	http://dx.doi.org/10.1126/science.271.5250.795			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628994				2022-12-24	WOS:A1996TU69400042
J	MacMillan, LB; Hein, L; Smith, MS; Piascik, MT; Limbird, LE				MacMillan, LB; Hein, L; Smith, MS; Piascik, MT; Limbird, LE			Central hypotensive effects of the alpha(2a)-adrenergic receptor subtype	SCIENCE			English	Article							RAT-BRAIN; MESSENGER-RNAS; EXPRESSION; GENE; ADRENOCEPTORS; DISRUPTION; MUTATION	alpha 2-Adrenergic receptors (alpha(2)ARs) present in the brainstem decrease blood pressure and are targets for clinically effective antihypertensive drugs. The existence of three alpha(2)AR subtypes, the lack of subtype-specific ligands, and the cross-reactivity of alpha(2)AR agonists with imidazoline receptors has precluded an understanding of the role of individual alpha(2)AR subtypes in the hypotensive response. Gene targeting was used to introduce a point mutation into the alpha 2 alpha AR subtype in the mouse genome. The hypotensive response to alpha(2)AR agonists was lost in the mutant mice, demonstrating that the alpha(2a)AR subtype plays a principal role in this response.	VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; STANFORD UNIV, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT CELLULAR & MOL PHYSIOL, STANFORD, CA 94305 USA; UNIV KENTUCKY, DEPT PHARMACOL, LEXINGTON, KY 40536 USA	Vanderbilt University; Stanford University; Stanford University; University of Kentucky					NHLBI NIH HHS [HL38120, HL43671, HL48638] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038120, R01HL038120, R01HL043671, P01HL048638, R37HL043671] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel F, 1989, MOL REPROD DEV, V1, P146; BOUSQUET P, 1992, AM J HYPERTENS, V5, pS47, DOI 10.1093/ajh/5.4.47S; BYLUND DB, 1994, PHARMACOL REV, V46, P121; CERESA BP, 1994, J BIOL CHEM, V269, P29557; CHABRE O, 1994, J BIOL CHEM, V269, P5730; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; HIEBLE JP, 1995, J MED CHEM, V38, P3415, DOI 10.1021/jm00018a001; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MACMILLAN LB, UNPUB; MCCUNE SK, 1993, NEUROSCIENCE, V57, P143, DOI 10.1016/0306-4522(93)90116-W; NICHOLAS AP, 1993, J COMP NEUROL, V328, P575, DOI 10.1002/cne.903280409; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; SCHEININ M, 1994, MOL BRAIN RES, V21, P133, DOI 10.1016/0169-328X(94)90386-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; WANG R, IN PRESS NEUROSCIENC	20	409	427	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					801	803		10.1126/science.273.5276.801	http://dx.doi.org/10.1126/science.273.5276.801			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670421				2022-12-24	WOS:A1996VB42900044
J	Cockett, NE; Jackson, SP; Shay, TL; Farnir, F; Berghmans, S; Snowder, GD; Nielsen, DM; Georges, M				Cockett, NE; Jackson, SP; Shay, TL; Farnir, F; Berghmans, S; Snowder, GD; Nielsen, DM; Georges, M			Polar overdominance at the Ovine callipyge locus	SCIENCE			English	Article							CHROMOSOME-14	An inheritable muscular hypertrophy was recently described in sheep and shown to be determined by the callipyge gene mapped to ovine chromosome 18. Here, the callipyge phenotype was found to be characterized by a nonmendelian inheritance pattern, referred to as polar overdominance, where only heterozygous individuals having inherited the callipyge mutation from their sire express the phenotype. The possible role of parental imprinting in the determinism of polar overdominance is envisaged.	UTAH STATE UNIV,DEPT ANIM DAIRY & VET SCI,LOGAN,UT 84322; TEXAS TECH UNIV,DEPT ANIM SCI & FOOD TECHNOL,LUBBOCK,TX 79409; UNIV LIEGE B43,FAC VET MED,DEPT GENET,B-4000 LIEGE,BELGIUM; ARS,USDA,US SHEEP EXPT STN,DUBOIS,ID 83423	Utah System of Higher Education; Utah State University; Texas Tech University System; Texas Tech University; University of Liege; United States Department of Agriculture (USDA)				Nielsen, Dahlia/0000-0003-0123-6085; Berghmans, Stephane/0000-0001-5414-8674; Georges, Michel/0000-0003-4124-2375				ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; APIENZA C, 1990, DEV S, P107; BALDACCI PA, 1992, MAMM GENOME, V2, P100, DOI 10.1007/BF00353857; BEECHEY CV, 1994, MOUSE GENOME, V92, P505; BREGLIANO JC, 1983, MOBILE GENETIC ELEME, P363; CATTANACH BM, 1993, MOUSE GENOME, V91, P858; COCKETT NE, 1994, P NATL ACAD SCI USA, V91, P3019, DOI 10.1073/pnas.91.8.3019; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FARNIR F, UNPUB; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; GEORGES M, 1995, GENETICS, V139, P907; LATHROP GM, 1984, AM J HUM GENET, V36, P460; MORTON NE, 1956, AM J HUM GENET, V8, P80; NIELSEN DJ, UNPUB; SAPIENZA C, 1992, GENETICS, V132, P241; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TEMPLE IK, 1991, J MED GENET, V28, P511, DOI 10.1136/jmg.28.8.511; WAKASUGI N, 1974, J REPROD FERTIL, V41, P85, DOI 10.1530/jrf.0.0410085; WANG JCC, 1991, AM J HUM GENET, V48, P1069	21	215	240	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					236	238		10.1126/science.273.5272.236	http://dx.doi.org/10.1126/science.273.5272.236			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8662506				2022-12-24	WOS:A1996UW78700040
J	Pichel, JG; Shen, LY; Sheng, HZ; Granholm, AC; Drago, J; Grinberg, A; Lee, EJ; Huang, SP; Saarma, M; Hoffer, BJ; Sariola, H; Westphal, H				Pichel, JG; Shen, LY; Sheng, HZ; Granholm, AC; Drago, J; Grinberg, A; Lee, EJ; Huang, SP; Saarma, M; Hoffer, BJ; Sariola, H; Westphal, H			Defects in enteric innervation and kidney development in mice lacking GDNF	NATURE			English	Article							EMBRYONIC STEM-CELLS; LETHALITY; GENE	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF) has been isolated as a neurotrophic factor for midbrain dopaminergic neurons(1). Because of its neurotrophic activity on a wide range of neuronal populations in vitro and in vivo(2-11), GDNF is being considered as a potential therapeutic agent for neuronal disorders(2,3,12). During mammalian development, it is expressed not only in the nervous system, but also very prominently in the metanephric kidney and the gastrointestinal tract, suggesting possible functions during organogenesis(7,11,13,14). We have investigated the role of GDNF during development by generating a null mutation in the murine GDNF locus, and found that mutant mice show kidney agenesis or dysgenesis and defective enteric innervation. We demonstrate that GDNF induces ureter bud formation and branching during metanephros development, and is essential for proper innervation of the gastrointestinal tract.	NIH,LAB MAMMALIAN GENET & DEV,BETHESDA,MD 20892; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BASIC DENT SCI,DENVER,CO 80262; MONASH UNIV,DEPT ANAT,CLAYTON,VIC 3168,AUSTRALIA; UNIV HELSINKI,BIOCTR 1,PROGRAM MOL NEUROBIOL,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,BIOCTR 1,PROGRAM DEV BIOL,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,CHILDRENS HOSP,LAB PEDIAT PATHOL,FIN-00380 HELSINKI,FINLAND	National Institutes of Health (NIH) - USA; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Monash University; University of Helsinki; University of Helsinki; University of Helsinki			Pichel, Jose G/AAF-2255-2019	Pichel, Jose G/0000-0001-8580-0952				Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; Durbec PL, 1996, DEVELOPMENT, V122, P349; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Harlow E, 1988, ANTIBODIES LAB MANUA; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; LEDOUARI.NM, 1973, J EMBRYOL EXP MORPH, V30, P31; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LOVE PE, 1992, P NATL ACAD SCI USA, V89, P9929, DOI 10.1073/pnas.89.20.9929; MOUNT HTJ, 1995, P NATL ACAD SCI USA, V92, P9092, DOI 10.1073/pnas.92.20.9092; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; OSATHANO.V, 1966, ARCH PATHOL, V82, P391; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; SARIOLA H, 1988, DEVELOPMENT, V104, P589; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Suvanto P, 1996, EUR J NEUROSCI, V8, P816, DOI 10.1111/j.1460-9568.1996.tb01267.x; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YNTEMA CL, 1954, J COMP NEUROL, V101, P515, DOI 10.1002/cne.901010212	30	949	977	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1996	382	6586					73	76		10.1038/382073a0	http://dx.doi.org/10.1038/382073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV473	8657307				2022-12-24	WOS:A1996UV47300056
J	Winkelmann, BR; Nauck, M; Klein, B; Russ, AP; Bohm, BO; Siekmeier, R; Ihnken, K; Verho, M; Gross, W; Marz, W				Winkelmann, BR; Nauck, M; Klein, B; Russ, AP; Bohm, BO; Siekmeier, R; Ihnken, K; Verho, M; Gross, W; Marz, W			Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease	ANNALS OF INTERNAL MEDICINE			English	Article						coronary disease; myocardial infarction; peptidyl-dipeptidase A; polymorphism (genetics)		Background: Previous research has shown that the insertion/deletion (I/D) polymorphism of the angiotensin I-converting enzyme (ACE) gene is a major determinant of plasma ACE activity. It has been suggested that persons with the DD genotype (those who express, on average, the highest levels of circulating ACE) have an increased risk for myocardial infarction and coronary artery disease, particularly if they are otherwise at low risk. Subsequent studies, however, have not confirmed that ACE I/D gene polymorphism is a risk factor for coronary artery disease and myocardial infarction. Objective: To investigate the association between the I/D polymorphism of the ACE gene and the risk for coronary artery disease and myocardial infarction in patients in whom coronary artery disease status was documented by angiography. Design: Cross-sectional study. Setting: University medical center. Patients: 209 male case-patients with coronary artery disease and 92 male controls without coronary artery disease, as documented by coronary angiography. Measurements: Assessment of the cardiac risk profile by questionnaire; classification of patients by the degree of coronary artery stenosis; levels of lipoproteins, apolipoproteins, and fibrinogen; and ACE I/D gene polymorphism assessed by polymerase chain reaction amplification. Results: Plasma ACE activity was significantly associated with ACE I/D gene polymorphism. The ACE genotype was not associated with the presence of coronary artery disease or myocardial infarction. If a recessive effect of the D allele was assumed (DD compared with DI and II), the relative risk was 1.00 (95% CI, 0.76 to 1.30) for coronary artery disease and 1.03 (CI, 0.77 to 1.38) for myocardial infarction. Results of analyses were also negative when a dominant effect of the D allele was assumed and when low-risk subgroups were examined. The established risk factors age and apolipoprotein B level emerged as the most important risk predictors in multivariate analyses, followed by diastolic blood pressure and fasting glucose levels. Conclusions: In an angiographically defined study sample, ACE I/D gene polymorphism was not associated with an increased risk for coronary artery disease or myocardial infarction, despite its effects on plasma ACE activity.	UNIV FRANKFURT, GUSTAV EMBDEN CTR BIOL CHEM, D-60590 FRANKFURT, GERMANY	Goethe University Frankfurt			Nauck, Michael Albrecht/ABA-9752-2021; Boehm, Bernhard Otto/F-8750-2015	Nauck, Michael Albrecht/0000-0002-5749-6954; 				AGERHOLMLARSEN B, 1996, CIRCULATION S1, V92, P800; AHNVE S, 1995, J AM COLL CARDIOL, V26, P277; Andersson B., 1995, European Heart Journal, V16, P113; ARBUSTINI E, 1995, BRIT HEART J, V74, P584; ASSMANN G, 1994, ATHEROSCLEROSIS, V110, pS11, DOI 10.1016/0021-9150(94)05386-W; Austen W G, 1975, Circulation, V51, P5; BEOHAR N, 1995, J INVEST MED, V43, P275; BOHN M, 1993, CLIN GENET, V44, P292; BOLIBAR I, 1995, ARTERIOSCL THROM VAS, V15, P1035, DOI 10.1161/01.ATV.15.8.1035; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; FRIEDL W, 1995, ATHEROSCLEROSIS, V112, P137, DOI 10.1016/0021-9150(94)05406-9; GARDEMANN A, 1995, CIRCULATION, V92, P2796, DOI 10.1161/01.CIR.92.10.2796; GLASER C, 1994, CIRCULATION, V90, P364; HARRAP SB, 1993, HYPERTENSION, V21, P455, DOI 10.1161/01.HYP.21.4.455; HUANG HM, 1994, CIRC RES, V75, P454, DOI 10.1161/01.RES.75.3.454; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; JAMIESON A, 1994, UNPUB COUNC ART 67 S, P120; KATSUYA T, 1995, LANCET, V345, P1600, DOI 10.1016/S0140-6736(95)90115-9; LACHURIE ML, 1995, CIRCULATION, V91, P2933, DOI 10.1161/01.CIR.91.12.2933; LEATHAM E, 1994, J HUM HYPERTENS, V8, P635; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; LUDWIG E, 1995, CIRCULATION, V91, P2120, DOI 10.1161/01.CIR.91.8.2120; MARSHALL HW, 1994, CIRCULATION, V89, P567, DOI 10.1161/01.CIR.89.2.567; MARZ W, 1986, CLIN CHIM ACTA, V160, P1, DOI 10.1016/0009-8981(86)90330-X; MATTU RK, 1995, CIRCULATION, V91, P270, DOI 10.1161/01.CIR.91.2.270; MIETTINEN HE, 1994, HUM GENET, V94, P189; MORRIS BJ, 1994, J CLIN INVEST, V94, P1085, DOI 10.1172/JCI117423; Moussard C., 1995, European Heart Journal, V16, P370; OKAMURA T, 1990, J CARDIOVASC PHARM, V15, P353, DOI 10.1097/00005344-199003000-00002; PAYNE MN, 1994, CIRCULATION, V90, P2566, DOI 10.1161/circ.90.5.7955223; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; ROBITAILLE NM, 1994, CIRCULATION, V90, P110; RUIZ J, 1994, P NATL ACAD SCI USA, V91, P3662, DOI 10.1073/pnas.91.9.3662; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHUNKERT H, 1993, CIRC RES, V72, P312, DOI 10.1161/01.RES.72.2.312; SHANMUGAM V, 1993, PCR METH APPL, V3, P120; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SOUBRIER F, 1993, J HYPERTENS, V11, P471, DOI 10.1097/00004872-199305000-00001; TIRET L, 1992, AM J HUM GENET, V51, P197; URATA H, 1990, J BIOL CHEM, V265, P22348; WESOLOWSKA EB, 1994, UNPUB COUNC ART 67 S, P78; *WHO STUD GROUP DI, 1985, DIAB MELL	44	94	94	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1996	125	1					19	+		10.7326/0003-4819-125-1-199607010-00004	http://dx.doi.org/10.7326/0003-4819-125-1-199607010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT399	8644984				2022-12-24	WOS:A1996UT39900003
J	Turner, G				Turner, G			Intelligence and the X chromosome	LANCET			English	Article							MAJOR INTELLECTUAL TRAITS; LINKED MENTAL-RETARDATION; 4 HYPOTHESES; LINKAGE; LEHRKES; GENES				Turner, G (corresponding author), HUNTER GENET,POB 84,NEWCASTLE,NSW 2298,AUSTRALIA.							ANASTASI A, 1972, AM J MENT DEF, V76, P620; BOUCHARD TJ, 1990, SCIENCE, V250, P223, DOI 10.1126/science.2218526; GEDEON AK, IN PRESS AM J MED GE; GLASS IA, 1991, J MED GENET, V28, P361, DOI 10.1136/jmg.28.6.361; HERBST DS, 1980, AM J MED GENET, V7, P461, DOI 10.1002/ajmg.1320070407; LEHRKE R, 1972, AM J MENT DEF, V76, P611; LEHRKE R, 1994, BIRTH DEFECTS ORIG A, V10; MORTON NE, 1992, J MED GENET, V29, P71, DOI 10.1136/jmg.29.1.71; NANCE WE, 1972, AM J MENT DEF, V76, P623; Ohno S., 1967, SEX CHROMOSOMES SEX; OPITZ JM, 1986, AM J MED GENET, V23, P1, DOI 10.1002/ajmg.1320230102; RESTA RG, 1995, AM J MED GENET, V59, P131, DOI 10.1002/ajmg.1320590202; TURNER G, 1974, J MED GENET, V11, P109, DOI 10.1136/jmg.11.2.109; TURNER G, 1991, J MED GENET, V28, P429, DOI 10.1136/jmg.28.6.429; TURNER G, IN PRESS AM J MED GE; WILSON R, 1987, ENCY NEUROSCIENCE, V1, P539	16	33	34	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1814	1815		10.1016/S0140-6736(96)91623-2	http://dx.doi.org/10.1016/S0140-6736(96)91623-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667929				2022-12-24	WOS:A1996UU46900016
J	Bone, LI				Bone, LI			As I was dying - An examination of classic literature and dying	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Bone, LI (corresponding author), MED COLL OHIO, 3000 ARLINGTON AVE, TOLEDO, OH 43699 USA.								0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1091	1093		10.7326/0003-4819-124-12-199606150-00013	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633826				2022-12-24	WOS:A1996UQ65800012
J	Kimball, AM; Tant, M				Kimball, AM; Tant, M			A role for businesses in HIV prevention in Asia	LANCET			English	Editorial Material									ASIAN DEV BANK,MANILA,PHILIPPINES	Asian Development Bank	Kimball, AM (corresponding author), UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98195, USA.							ALBERS C, 1991, 10 INT C AIDS; BEHRAVESH N, 1993, DRI MCGRAW HILL INSI, P1; BLOOM DE, 1991, SCIENCE, V252, P1798, DOI 10.1126/science.1829547; CHEN D, 1991, NAT SEM AIDS SOC IMP; Goss D., 1993, EMPL RELAT, V15, P25, DOI [10.1108/01425459310031804, DOI 10.1108/01425459310031804]; HANKINS C, 1995, CAN MED ASSOC J, V153, P1613; JANJAREEON WS, 1995, REG AIDS C AS PAC CH; SINGH YN, 1994, INT J STD AIDS, V5, P137, DOI 10.1177/095646249400500212; TANG S, 1992, REPORT SURVEY AIDS W; *UN, 1993, DEM YB, P200; WEIL J, 1992, WALL STREET J   0702, pB1; *WHO, 1993, WORLD DEV REP EST HI; 1994, FAR E EC REV, V158, P5	13	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1670	1672		10.1016/S0140-6736(96)91493-2	http://dx.doi.org/10.1016/S0140-6736(96)91493-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642964				2022-12-24	WOS:A1996UQ70100016
J	Danielian, PJ; Wang, J; Hall, MH				Danielian, PJ; Wang, J; Hall, MH			Long term outcome by method of delivery of fetuses in breech presentation at term: Population based follow up	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Objective-To compare the long term outcome of infants delivered in breech presentation at term by intended mode of delivery. Design-A population based comparison of outcomes up to school age. Data obtained from maternity, health visitor, and school medical records and handicap register. Setting-Grampian region 1981-90. Subjects-1645 infants delivered alive at term after breech presentation. Main outcome measures-Handicap, developmental delay, neurological deficit, psychiatric referral. Results-Elective caesarean section was performed in 590 (35.9%) cases. The remainder (1055; 64.1%) were intended vaginal deliveries, Handicap or other health problem was recorded in 269 (19.4%) of 1387 infants for whom records were available. Proportions of elective caesarean sections and intended vaginal deliveries in this group were 37.2% (100 cases) and 62.8% (169) respectively, almost the same as in the total cohort. There were no significant differences between elective caesarean section and planned vaginal delivery in terms of severe handicap or any other outcome measure. Case records were obtained for 23 of 27 infants with severe handicap. 11 (47.8%) were delivered by elective caesarean section. Of these, three had undiagnosed congenital abnormalities and seven were unexplained. Of the 12 (52.2%) planned vaginal deliveries, in only one was handicap possibly attributable to delivery and four cases were unavoidable even if elective caesarean section had been planned. Conclusion-In selected cases of breech presentation at term planned vaginal delivery with caesarean section if necessary remains as safe as elective caesarean section in terms of long term handicap. It was not possible to determine whether particular babies would have fared better had they been delivered by elective caesarean section.	UNIV ABERDEEN,SCH MED,ABERDEEN AB9 1FX,SCOTLAND	University of Aberdeen	Danielian, PJ (corresponding author), ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZA,SCOTLAND.							BINGHAM P, 1987, OBSTET GYNECOL, V69, P965; BISTOLETTI P, 1981, ACTA OBSTET GYN SCAN, V60, P165; BYRNE P, 1992, BRIT MED J, V305, P1092, DOI 10.1136/bmj.305.6861.1092; CHENG M, 1993, OBSTET GYNECOL, V82, P605; COLLEA JV, 1980, AM J OBSTET GYNECOL, V137, P235, DOI 10.1016/0002-9378(80)90780-2; FABERNIJHOLT R, 1983, BRIT MED J, V286, P9, DOI 10.1136/bmj.286.6358.9; HALL MH, 1993, BRIT MED J, V306, P718, DOI 10.1136/bmj.306.6879.718-b; HALL MH, 1982, BRIT MED J, V285, P701; LYONS ER, 1978, AM J OBSTET GYNECOL, V130, P558, DOI 10.1016/0002-9378(78)90076-5; MYERS SA, 1986, AM J OBSTET GYNECOL, V155, P6; OHLSEN H, 1975, ACTA OBSTET GYNECOL, V54, P165; ROSEN MG, 1984, AM J OBSTET GYNECOL, V148, P909, DOI 10.1016/0002-9378(84)90533-7; SAVAGE W, 1992, BRIT MED J, V305, P1092, DOI 10.1136/bmj.305.6861.1092-a; SVENNINGSEN NW, 1985, J PERINAT MED, V13, P117, DOI 10.1515/jpme.1985.13.3.117; WRIGHT RC, 1959, OBSTET GYNECOL, V14, P758	15	86	88	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1451	1453		10.1136/bmj.312.7044.1451	http://dx.doi.org/10.1136/bmj.312.7044.1451			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664622	Green Published			2022-12-24	WOS:A1996UQ29600024
J	Risold, PY; Swanson, LW				Risold, PY; Swanson, LW			Structural evidence for functional domains in the rat hippocampus	SCIENCE			English	Article							INSITU HYBRIDIZATION; MESSENGER-RNA; AMMONS HORN; NEURONS; NUCLEUS; BRAIN; LOCALIZATION; ORGANIZATION; CONNECTIONS; PROJECTIONS	The hippocampus has two major outputs: multisynaptic pathways to the cerebral cortex and a massive descending projection directly to the lateral septal part of the basal ganglia. Here it is shown that the descending output is organized in such a way that different hippocampal regions map in an orderly way onto hypothalamic systems mediating the expression of different classes of goal-oriented behavior. This mapping is characterized by a unidirectional hippocampo-lateral septal projection and then by bidirectional lateral septo-hypothalamic projections, all topographically organized. The connectional evidence predicts that information processing in different regions of the hippocampus selectively influences the expression of different classes of behavior.	UNIV SO CALIF,PROGRAM NEURAL INFORMAT & BEHAV SCI,LOS ANGELES,CA 90089; UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089	University of Southern California; University of Southern California			Risold, Pierre-Yves/M-7730-2018; Risold, Pierre-Yves/AAJ-9535-2021	Risold, Pierre-Yves/0000-0001-6801-591X; 				CANTERAS NS, 1994, J COMP NEUROL, V348, P41, DOI 10.1002/cne.903480103; CANTERAS NS, UNPUB; COHEN RS, 1992, PROG NEUROBIOL, V38, P423, DOI 10.1016/0301-0082(92)90045-G; ESCLAPEZ M, 1993, J COMP NEUROL, V331, P339, DOI 10.1002/cne.903310305; HAGLUND L, 1984, J COMP NEUROL, V229, P171, DOI 10.1002/cne.902290204; HANSEN S, 1982, BRAIN RES, V239, P213, DOI 10.1016/0006-8993(82)90843-5; HARLAN RE, 1987, J COMP NEUROL, V258, P159, DOI 10.1002/cne.902580202; KOHLER C, 1984, ANAT EMBRYOL, V170, P1, DOI 10.1007/BF00319452; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Ramon y Cajal S., 1897, HISTOLOGY NERVOUS SY, V1; RISOLD PY, 1995, P NATL ACAD SCI USA, V92, P3898, DOI 10.1073/pnas.92.9.3898; RISOLD PY, 1994, J COMP NEUROL, V348, P1, DOI 10.1002/cne.903480102; RISOLD PY, UNPUB; SIEGEL A, 1988, PROG NEUROBIOL, V31, P261, DOI 10.1016/0301-0082(88)90015-9; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; SIMERLY RB, 1988, J COMP NEUROL, V270, P209, DOI 10.1002/cne.902700205; Squire L. R., 1987, MEMORY BRAIN; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; SWANSON LW, 1989, J COMP NEUROL, V285, P413, DOI 10.1002/cne.902850402; SWANSON LW, 1981, J NEUROSCI, V1, P548; SWANSON LW, 1975, SCIENCE, V189, P303, DOI 10.1126/science.49928; SWANSON LW, 1978, J COMP NEUROL, V181, P681, DOI 10.1002/cne.901810402; SWANSON LW, 1977, J COMP NEUROL, V172, P49, DOI 10.1002/cne.901720104; Swanson LW, 1987, HDB CHEM NEUROANATOM, P125; TAUBE JS, 1995, J NEUROSCI, V15, P70; [No title captured]	26	282	283	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1484	1486		10.1126/science.272.5267.1484	http://dx.doi.org/10.1126/science.272.5267.1484			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633241				2022-12-24	WOS:A1996UP89900048
J	Wang, XZ; Ron, D				Wang, XZ; Ron, D			Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase	SCIENCE			English	Article							PROTEIN-KINASE; GROWTH ARREST; DNA DAMAGE; AGENTS; ONCOGENE; C/EBP; CELLS	CHOP, a member of the C/EBP family of transcription factors, mediates effects of cellular stress on growth and differentiation, It accumulates under conditions of stress and undergoes inducible phosphorylation on two adjacent serine residues (78 and 81). In vitro, CHOP is phosphorylated on these residues by p38 mitogen-activated protein kinase (MAP kinase). A specific inhibitor of p38 MAP kinase, SB203580, abolished the stress-inducible in vivo phosphorylation of CHOP. Phosphorylation of CHOP on these residues enhanced its ability to function as a transcriptional activator and was also required for the full inhibitory effect of CHOP on adipose cell differentiation. CHOP thus serves as a link between a specific stress-activated protein kinase, p38, and cellular growth and differentiation.	NYU, MED CTR, SKIRBALL INST BIOMOL MED, DEPT MED, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University; New York University; New York University				Ron, David/0000-0002-3014-5636				BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERLJARD B, 1994, CELL, V76, P1025; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LUETHY JD, 1992, CANCER RES, V52, P5; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PRICE BD, 1992, CANCER RES, V52, P3814; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; WANG X, UNPUB; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	29	721	745	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1996	272	5266					1347	1349		10.1126/science.272.5266.1347	http://dx.doi.org/10.1126/science.272.5266.1347			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650547				2022-12-24	WOS:A1996UN47200049
J	Seymour, CA				Seymour, CA			Controversies in management - Screening asymptomatic people at high risk for hepatitis C - The case for	BRITISH MEDICAL JOURNAL			English	Article							VIRUS				Seymour, CA (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,LONDON SW17 0RE,ENGLAND.							ALTER HJ, 1995, SEMIN LIVER DIS, V15, P5; ASCHER NL, 1994, HEPATOLOGY, V20, P245; BRESTERS D, 1993, LANCET, V342, P210, DOI 10.1016/0140-6736(93)92300-I; BRUNO S, 1994, BRIT MED J, V308, P697, DOI 10.1136/bmj.308.6930.697; CUCKLE HS, 1995, BRIT MED J, V311, P1460, DOI 10.1136/bmj.311.7018.1460; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; GOODRICK MJ, 1994, TRANSFUSION MED, V4, P113, DOI 10.1111/j.1365-3148.1994.tb00251.x; MACLENNAN S, 1994, TRANSFUSION MED, V4, P130; MORADPOUR D, 1995, NEW ENGL J MED, V332, P1092, DOI 10.1056/NEJM199504203321610; POLYNARD T, 1995, NEW ENGL J MED, V332, P1457; SARACCO G, 1993, HEPATOLOGY, V18, P1300, DOI 10.1002/hep.1840180603; SEYMOUR CA, 1994, BRIT MED J, V308, P670, DOI 10.1136/bmj.308.6930.670; SHIELL A, 1994, MED J AUSTRALIA, V160, P268, DOI 10.5694/j.1326-5377.1994.tb125830.x; TERRAULT N, 1995, NEW ENGL J MED, V332, P1509, DOI 10.1056/NEJM199506013322211; TINE F, 1991, J HEPATOL, V13, P192, DOI 10.1016/0168-8278(91)90814-R; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; UYTTENDAELE S, 1994, VOX SANG, V66, P122, DOI 10.1111/j.1423-0410.1994.tb00293.x; VANDERPOEL CL, 1994, LANCET, V344, P1475, DOI 10.1016/S0140-6736(94)90293-3; Watson JP, 1996, GUT, V38, P269, DOI 10.1136/gut.38.2.269; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3	20	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1347	1348		10.1136/bmj.312.7042.1347	http://dx.doi.org/10.1136/bmj.312.7042.1347			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646052	Green Published			2022-12-24	WOS:A1996UN47600027
J	Marengere, LEM; Waterhouse, P; Duncan, GS; Mittrucker, HW; Feng, GS; Mak, TW				Marengere, LEM; Waterhouse, P; Duncan, GS; Mittrucker, HW; Feng, GS; Mak, TW			Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4	SCIENCE			English	Article							ANTIGEN RECEPTOR; ZETA-CHAIN; LYMPHOCYTES-T; TCR ZETA; KINASE; CD28; PHOSPHORYLATION; CLONING; ZAP-70	The absence of CTLA-4 results in uncontrolled T cell proliferation. The T cell receptor-specific kinases FYN, LCK, and ZAP-70 as well as the RAS pathway were found to be activated in T cells of Ctla-4(-/-) mutant mice. In addition, CTLA-4 specifically associated with the tyrosine phosphatase SYP, an interaction mediated by the SRC homology 2 (SH2) domains SYP and phosphotyrosine sequence Tyr-Val-Lys-Met within the CTLA-4 cytoplasmic tail. The CTLA-4-associated SYP had phosphatase activity toward the RAS regulator p52(SHC). Thus, the RAS pathway and T cell activation through the T cell receptor are regulated by CTLA-4-associated SYP.	UNIV TORONTO, AMGEN INST, ONTARIO CANC INST, DEPT IMMUNOL, TORONTO, ON M5G 2C1, CANADA; UNIV TORONTO, AMGEN INST, ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO, ON M5G 2C1, CANADA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute			Duncan, Gordon/AIE-7011-2022	Waterhouse, Paul/0000-0001-8745-5224				ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; GROSS JA, 1992, J IMMUNOL, V149, P380; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; OKUMURA M, 1995, CURR OPIN IMMUNOL, V7, P312, DOI 10.1016/0952-7915(95)80104-9; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WANG LM, 1995, STEM CELLS, V13, P360, DOI 10.1002/stem.5530130407; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	53	438	449	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1996	272	5265					1170	1173		10.1126/science.272.5265.1170	http://dx.doi.org/10.1126/science.272.5265.1170			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638161				2022-12-24	WOS:A1996UM88900050
J	Attenburrow, MEJ; Dowling, BA; Sharpley, AL; Cowen, PJ				Attenburrow, MEJ; Dowling, BA; Sharpley, AL; Cowen, PJ			Case-control study of evening melatonin concentration in primary insomnia	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,LITTLEMORE HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND	University of Oxford				Sharpley, Ann L/0000-0002-0623-1067; Cowen, Philip/0000-0001-5518-6138				DEMENT WC, 1982, J AM GERIATR SOC, V30, P25, DOI 10.1111/j.1532-5415.1982.tb03700.x; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; HAIMOV I, 1994, BRIT MED J, V309, P167, DOI 10.1136/bmj.309.6948.167; IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem-55-1-27; ZHDANOVA IV, 1995, CLIN PHARMACOL THER, V57, P552, DOI 10.1016/0009-9236(95)90040-3	5	18	18	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1263	1264		10.1136/bmj.312.7041.1263	http://dx.doi.org/10.1136/bmj.312.7041.1263			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UM404	8634615	Green Published			2022-12-24	WOS:A1996UM40400020
J	Li, W; Whaley, CD; Mondino, A; Mueller, DL				Li, W; Whaley, CD; Mondino, A; Mueller, DL			Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4(+) T cells	SCIENCE			English	Article							COSTIMULATORY SIGNAL; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODY; REGULATED KINASES; ACTIVATION DOMAIN; CLONAL ANERGY; GROWTH-FACTOR; C ACTIVATION; PROLIFERATION; STIMULATION	T cells activated by antigen receptor stimulation in the absence of accessory cell-derived costimulatory signals lose the capacity to synthesize the growth factor interleukin-2 (IL-2), a state called clonal anergy. An analysis of CD3- and CD28-induced signal transduction revealed reduced ERK and JNK enzyme activities in murine anergic T cells. The amounts of ERK and JNK proteins were unchanged, and the kinases could be fully activated in the presence of phorbol 12-myristrate 13-acetate. Dephosphorylation of the calcineurin substrate NFATp (preexisting nuclear factor of activated T cells) also remained inducible. These results suggest that a specific block in the activation of ERK and JNK contributes to defective IL-2 production in clonal anergy.	UNIV MINNESOTA, SCH MED, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, CTR IMMUNOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Mondino, Anna/K-9434-2016	Mondino, Anna/0000-0003-0833-6927; Mueller, Daniel/0000-0003-1621-0419	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031669] Funding Source: NIH RePORTER; NIAID NIH HHS [R29 AI 31669] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHO EA, 1993, J IMMUNOL, V151, P20; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HECHT TT, 1983, J IMMUNOL, V131, P1049; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; JENKINS MK, 1990, J IMMUNOL, V144, P16; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI W, UNPUB; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONDINO A, UNPUB; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUELLER DL, 1991, J IMMUNOL, V147, P4118; MUELLER DL, 1990, J IMMUNOL, V144, P3701; MUELLER DL, 1995, CURR OPIN IMMUNOL, V7, P375, DOI 10.1016/0952-7915(95)80113-8; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MUELLER DL, 1989, J IMMUNOL, V142, P2617; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; OWAKI H, 1992, BIOCHEM BIOPH RES CO, V182, P1416, DOI 10.1016/0006-291X(92)91891-S; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; QUILL H, 1992, J IMMUNOL, V149, P2887; Sambrook J., 1989, MOL CLONING; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHALEY CD, UNPUB; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798	49	403	415	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 1	1996	271	5253					1272	1276		10.1126/science.271.5253.1272	http://dx.doi.org/10.1126/science.271.5253.1272			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638107				2022-12-24	WOS:A1996TX69500034
J	Eliasson, L; Renstrom, E; Ammala, C; Berggren, PO; Bertorello, AM; Bokvist, K; Chibalin, A; Deeney, JT; Flatt, PR; Gabel, J; Gromada, J; Larsson, O; Lindstrom, P; Rhodes, CJ; Rorsman, P				Eliasson, L; Renstrom, E; Ammala, C; Berggren, PO; Bertorello, AM; Bokvist, K; Chibalin, A; Deeney, JT; Flatt, PR; Gabel, J; Gromada, J; Larsson, O; Lindstrom, P; Rhodes, CJ; Rorsman, P			PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells	SCIENCE			English	Article							DIAZOXIDE; GLIBENCLAMIDE; TOLBUTAMIDE; ACTIVATION; CHANNELS; CURRENTS; RELEASE	Hypoglycemic sulfonylureas represent a group of clinically useful antidiabetic compounds that stimulate insulin secretion from pancreatic beta cells. The molecular mechanisms involved are not fully understood but are believed to involve inhibition of potassium channels sensitive to adenosine triphosphate (K-ATP channels) in the beta cell membrane, causing membrane depolarization, calcium influx, and activation of the secretory machinery. In addition to these effects, sulfonylureas also promoted exocytosis by direct interaction with the secretory machinery not involving closure of the plasma membrane K-ATP channels. This effect was dependent on protein kinase C (PKC) and was observed at therapeutic concentrations of sulfonylureas, which suggests that it contributes to their hypoglycemic action in diabetics.	NOVO NORDISK AS,DEPT ISLET CELL PHYSIOL,DK-2100 COPENHAGEN,DENMARK; GOTHENBURG UNIV,DEPT PHYSIOL & PHARMACOL,DIV BIOPHYS,S-41390 GOTHENBURG,SWEDEN; KAROLINSKA INST,ROLF LUFT CTR DIABET RES,DEPT MOLEC MED,S-17176 STOCKHOLM,SWEDEN; BOSTON UNIV,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV ULSTER,DEPT BIOL & BIOMED SCI,COLERAINE BT52 1SA,LONDONDERRY,NORTH IRELAND; UMEA UNIV,DEPT HISTOL & CELL BIOL,S-90187 UMEA,SWEDEN; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215	Novo Nordisk; University of Gothenburg; Karolinska Institutet; Boston University; Boston University; Ulster University; Umea University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.			Rorsman, Patrik/A-4331-2016; Eliasson, Lena/E-9294-2012; Tuluc, Petronel/C-2527-2011	Rorsman, Patrik/0000-0001-7578-0767; Eliasson, Lena/0000-0002-6467-5029; Deeney, Jude/0000-0003-0988-9419; Berggren, Per-Olof/0000-0001-8991-413X; Flatt, Peter/0000-0001-8548-7943; Chibalin, Alexander/0000-0002-6339-6271				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8214; AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BERNARDI H, 1993, P NATL ACAD SCI USA, V90, P1340, DOI 10.1073/pnas.90.4.1340; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; CARPENTIER JL, 1986, DIABETOLOGIA, V29, P259, DOI 10.1007/BF00454887; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; LINDAU M, 1986, NATURE, V319, P150, DOI 10.1038/319150a0; MEISSNER HP, 1976, FEBS LETT, V67, P37; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OZANNE SE, 1995, DIABETOLOGIA, V38, P277; PANTEN U, 1992, HORM METAB RES, V24, P549, DOI 10.1055/s-2007-1003387; PHILIPSON LH, 1995, SCIENCE, V270, P1159, DOI 10.1126/science.270.5239.1159; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RENSTROM E, UNPUB; THEVENOD F, 1992, J MEMBRANE BIOL, V129, P253; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; ZUNKLER BJ, 1988, N-S ARCH PHARMACOL, V337, P225	28	172	174	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					813	815		10.1126/science.271.5250.813	http://dx.doi.org/10.1126/science.271.5250.813			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628999				2022-12-24	WOS:A1996TU69400048
J	Pronk, GJ; Ramer, K; Amiri, P; Williams, LT				Pronk, GJ; Ramer, K; Amiri, P; Williams, LT			Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER	SCIENCE			English	Article							DEATH GENE CED-3; INHIBITION; ENZYME; ENCODES	Genetic studies indicated that the Drosophila melanogaster protein REAPER (RPR) controls apoptosis during embryo development. Induction of RPR expression in Drosophila Schneider cells rapidly stimulated apoptosis. RPR-mediated apoptosis was blocked by N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk) which suggests that an interleukin-1 beta converting enzyme (ICE)-like protease is required for RPR function. RPR-induced apoptosis was associated with increased ceramide production that was also blocked by Z-VAD-fmk, which suggests that ceramide generation requires an ICE-like protease as well. Thus, the intracellular RPR protein uses cell death signaling pathways similar to those used by the vertebrate transmembrane receptors Fas (CD95) and tumor necrosis factor receptor type 1.	UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Pronk, GJ (corresponding author), CHIRON CORP,ROOM M348,4560 HORTON ST,EMERYVILLE,CA 94608, USA.							ASHBURNER M, 1989, DROSOPHILA LABORATOR, P142; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; INOUE S, 1991, J BIOL CHEM, V266, P13311; JACOBSON MD, 1994, CURR BIOL, V4, P337, DOI 10.1016/S0960-9822(00)00073-7; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOS M, 1995, NATURE, V376, P37; MARTIN JM, 1995, CELL, V82, P349; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICHOLSON DW, 1995, NATURE, V376, P379; NITATORI T, 1995, J NEUROSCI, V15, P1001; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PRONK GJ, UNPUB; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SCHLEGEL J, 1995, FEBS LETT, V364, P139, DOI 10.1016/0014-5793(95)00374-I; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WNAG L, 1994, CELL, V78, P739; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	45	253	259	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					808	810		10.1126/science.271.5250.808	http://dx.doi.org/10.1126/science.271.5250.808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628997				2022-12-24	WOS:A1996TU69400046
J	Blower, SM; Small, PM; Hopewell, PC				Blower, SM; Small, PM; Hopewell, PC			Control strategies for tuberculosis epidemics: New models for old problems	SCIENCE			English	Article							PULMONARY TUBERCULOSIS; SAN-FRANCISCO; RESISTANT; RIFAMPIN; VACCINES; THERAPY; HIV	Tuberculosis, although preventable and curable, causes more adult deaths than any other infectious disease. A theoretical framework for designing effective control strategies is developed and used to determine treatment levels for eradication, to assess the effects of noneradicating control, and to examine the global goals of the World Health Organization. The theory is extended to assess how suboptimal control programs contribute to the evolution of drug resistance. A new evaluation criterion is defined and used to suggest how control strategies can be improved. In order to control tuberculosis, treatment failure rates must be lower in developing countries than in developed countries.	STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94143 USA	Stanford University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Blower, SM (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO GEN HOSP, BOX 1347, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033831, U01AI035969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA008153] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33831, AI35969] Funding Source: Medline; NIDA NIH HHS [1R29DA08153] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERSON R M, 1991; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; BLOWER SM, UNPUB; BLOWR SM, 1996, P 1996 W MULT SIM ME, P71; BROEKMANS JF, 1993, TUBERCULOSIS COMPREH, P641; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CHAULET P, 1993, TUBERCULOSIS COMPREH, P601; COSTELLO HD, 1980, AM REV RESPIR DIS, V121, P313; Frost WH, 1937, AM J PUBLIC HEALTH N, V27, P759, DOI 10.2105/AJPH.27.8.759; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GRZYBOWSKI S, 1978, Bulletin of the International Union Against Tuberculosis, V53, P70; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LIETMAN TM, UNPUB; MCLEAN AR, 1993, P ROY SOC B-BIOL SCI, V253, P9, DOI 10.1098/rspb.1993.0075; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P419, DOI 10.1017/S0950268800067170; Park MM, 1996, AM J RESP CRIT CARE, V153, P317, DOI 10.1164/ajrccm.153.1.8542137; PORCO TC, UNPUB; SLUTKIN G, 1988, AM REV RESPIR DIS, V138, P1622, DOI 10.1164/ajrccm/138.6.1622; 1994, AM J RESP CRIT CARE, V149, P1623	22	257	266	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1996	273	5274					497	500		10.1126/science.273.5274.497	http://dx.doi.org/10.1126/science.273.5274.497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8662538				2022-12-24	WOS:A1996UY98300040
J	Schrock, E; duManoir, S; Veldman, T; Schoell, B; Wienberg, J; FergusonSmith, MA; Ning, Y; Ledbetter, DH; BarAm, I; Soenksen, D; Garini, Y; Ried, T				Schrock, E; duManoir, S; Veldman, T; Schoell, B; Wienberg, J; FergusonSmith, MA; Ning, Y; Ledbetter, DH; BarAm, I; Soenksen, D; Garini, Y; Ried, T			Multicolor spectral karyotyping of human chromosomes	SCIENCE			English	Article							HYBRIDIZATION	The simultaneous and unequivocal discernment of all human chromosomes in different colors would be of significant clinical and biologic importance. Whole-genome scanning by spectral karyotyping allowed instantaneous visualization of defined emission spectra for each human chromosome after fluorescence in situ hybridization, By means of computer separation (classification) of spectra, spectrally overlapping chromosome-specific DNA probes could be resolved, and all human chromosomes were simultaneously identified.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; TEL AVIV UNIV,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL; APPL SPECTRAL IMAGING INC,CARLSBAD,CA 92009; APPL SPECTRAL IMAGING LTD,IL-10551 MIGDAL HAEMEQ,ISRAEL; NIH,DIAGNOST DEV BRANCH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892	University of Cambridge; Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			du manoir, stan p/O-8677-2017	du manoir, stan p/0000-0002-2200-2651; Ferguson-Smith, Malcolm/0000-0001-9372-1381; Garini, Yuval/0000-0002-8783-2015				Brigham E. O, 1988, FAST FOURIER TRANSFO; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KOEHLER U, 1995, GENOMICS, V30, P287, DOI 10.1006/geno.1995.9875; Le Beau M M, 1993, Important Adv Oncol, P29; MALIK Z, 1996, FLUORESCENCE IMAGING, V137, P87; MELTZER P, 1992, NAT GENET, V1, P2; NING Y, IN PRESS NATURE GENE; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; SCHROCK E, UNPUB; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Telenius H, 1992, GENE CHROMOSOME CANC, V4, P267; VANTUINEN P, 1983, AM J PHYS ANTHROPOL, V61, P453, DOI 10.1002/ajpa.1330610408	12	1348	1449	2	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1996	273	5274					494	497		10.1126/science.273.5274.494	http://dx.doi.org/10.1126/science.273.5274.494			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8662537				2022-12-24	WOS:A1996UY98300039
J	Jones, DC; Hayslett, JP				Jones, DC; Hayslett, JP			Outcome of pregnancy in women with moderate or severe renal insufficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR-DISEASE; FAILURE	Background Pregnant women with mild preexisting renal disease have relatively few complications of pregnancy, but the risks of maternal and obstetrical complications in women with moderate or severe renal insufficiency remain uncertain. Methods We determined the frequency and types of maternal and obstetrical complications and the outcomes of pregnancy in 67 women with primary renal disease (82 pregnancies). All the women had initial serum creatinine concentrations of at least 1.4 mg per deciliter (124 mu mol per liter) and gestations that continued beyond the first trimester. Results The mean (+/-SD) serum creatinine con concentration increased from 1.9+/-0.8 mg per deciliter (168+/-71 mu mol per liter) in early pregnancy to 2.5+/-1.3 mg per deciliter (221+/-115 mu mol per liter) in the third trimester. The frequency of hypertension rose from 28 percent at base line to 48 percent in the third trimester, and that of high-grade proteinuria (urinary protein excretion, >3000 mg per liter) from 23 percent to 41 percent. For the 70 pregnancies (57 women) for which data were available during pregnancy and immediately post partum, pregnancy-related loss of maternal renal function occurred in 43 percent. Eight of these pregnancies (10 percent of the total) were associated with rapid acceleration of maternal renal insufficiency. Obstetrical complications included a high rate of preterm delivery (59 percent) and growth retardation (37 percent). The infant survival rate was 93 percent. Conclusions Among pregnant women with moderate or severe renal insufficiency, the rates of complications due to worsening renal function, hypertension, and obstetrical complications are increased, but fetal survival is high. (C) 1996, Massachusetts Medical Society.	YALE UNIV,DEPT INTERNAL MED,NEW HAVEN,CT 06520	Yale University	Jones, DC (corresponding author), YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,POB 208063,NEW HAVEN,CT 06520, USA.							ABE S, 1985, AM J OBSTET GYNECOL, V153, P508, DOI 10.1016/0002-9378(85)90463-6; AMINI SB, 1994, OBSTET GYNECOL, V83, P342; [Anonymous], 1975, LANCET, V2, P801; BARCELO P, 1986, KIDNEY INT, V30, P914, DOI 10.1038/ki.1986.272; BEAR RA, 1978, CAN MED ASSOC J, V118, P663; CUNNINGHAM FG, 1990, AM J OBSTET GYNECOL, V163, P453, DOI 10.1016/0002-9378(90)91175-C; HAYCOCK KA, 1994, STATVIEW; HOU S, 1985, NEW ENGL J MED, V312, P836, DOI 10.1056/NEJM198503283121306; Hughes EC, 1972, OBSTETRIC GYNECOLOGI, P423; IMBASCIATI E, 1986, AM J NEPHROL, V6, P193, DOI 10.1159/000167114; JUNGERS P, 1991, AM J KIDNEY DIS, V17, P116, DOI 10.1016/S0272-6386(12)81114-0; Jungers P, 1986, Adv Nephrol Necker Hosp, V15, P103; KATZ AI, 1980, KIDNEY INT, V18, P192, DOI 10.1038/ki.1980.128; Mackay EV, 1963, AUST NZ J OBSTET GYN, V3, P21; MITCH WE, 1976, LANCET, V2, P1326; PACKHAM DK, 1989, Q J MED, V71, P537; SURIAN M, 1984, NEPHRON, V36, P101, DOI 10.1159/000183126; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4	18	236	258	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1996	335	4					226	232		10.1056/NEJM199607253350402	http://dx.doi.org/10.1056/NEJM199607253350402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ532	8657238				2022-12-24	WOS:A1996UZ53200002
J	Tofler, IR; Stryer, BK; Micheli, LJ; Herman, LR				Tofler, IR; Stryer, BK; Micheli, LJ; Herman, LR			Physical and emotional problems of elite female gymnasts	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ATHLETE TRIAD; AMENORRHEA; INJURIES; OSTEOPOROSIS; SWIMMERS; GROWTH		UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024; CHILDRENS HOSP,MED CTR,BOSTON,MA 02115; FLORIDA STATE UNIV,TALLAHASSEE,FL 32306	University of California System; University of California Los Angeles; Harvard University; Boston Children's Hospital; State University System of Florida; Florida State University	Tofler, IR (corresponding author), LOUISIANA STATE UNIV,CHILDRENS HOSP NEW ORLEANS,DEPT PSYCHIAT,200 HENRY CLAY AVE,NEW ORLEANS,LA 70118, USA.							BAKER R, 1996, NY TIMES        0420, pA17; CLAESSENS AL, 1992, MED SCI SPORT EXER, V24, P755; COAKLEY J, 1993, INTENSIVE PARTICIPATION IN CHILDRENS SPORTS, P77; COOK PC, 1995, ORTHOP CLIN N AM, V26, P453; DONNELLY P, 1993, INTENSIVE PARTICIPATION IN CHILDRENS SPORTS, P95; DRINKWATER BL, 1990, JAMA-J AM MED ASSOC, V263, P545, DOI 10.1001/jama.263.4.545; DUMMER GM, 1987, PHYSICIAN SPORTSMED, V15, P75, DOI 10.1080/00913847.1987.11709350; EMANS SJ, 1990, OBSTET GYNECOL, V76, P585; FRISCH RE, 1984, BIOL REV, V59, P161, DOI 10.1111/j.1469-185X.1984.tb00406.x; GARRICK JG, 1980, AM J SPORT MED, V8, P261, DOI 10.1177/036354658000800409; GOLDSTEIN JD, 1991, AM J SPORT MED, V19, P463, DOI 10.1177/036354659101900507; GOULD D, 1993, INTENSIVE PARTICIPATION IN CHILDRENS SPORTS, P19; KAPLAN HI, 1988, SYNOPSIS PSYCHIAT BE, P598; KIBLER WB, 1993, INTENSIVE PARTICIPATION IN CHILDRENS SPORTS, P203; LOUCKS AB, 1985, MED SCI SPORT EXER, V17, P56, DOI 10.1249/00005768-198502000-00010; MANDELBAUM BR, 1989, AM J SPORT MED, V17, P305, DOI 10.1177/036354658901700301; MANDELBAUM BR, 1993, INTENSIVE PARTICIPATION IN CHILDRENS SPORTS, P217; MICHELI LJ, 1989, PEDIAT EXERC SCI, V1, P329; NASH H L, 1987, Physician and Sportsmedicine, V15, P129; NATTIV A, 1994, CLIN SPORT MED, V13, P405; NATTIV A, 1993, PHYSICIAN SPORTSMED, V21, P66, DOI 10.1080/00913847.1993.11710401; OPIC H, 1995, REPORT INDEPENDENT I; OTIS CL, 1992, CLIN SPORT MED, V11, P351; PILLEMER FG, 1988, CLIN SPORT MED, V7, P679; POWERS SK, 1994, EXERCISE PHYSL THEOR, P480; ROBERTS GAF, 1992, ADVANCES IN CHITIN AND CHITOSAN, P179; ROSEN LW, 1986, PHYSICIAN SPORTSMED, V14, P79, DOI 10.1080/00913847.1986.11708966; ROSEN LW, 1988, PHYSICIAN SPORTSMED, V16, P140, DOI 10.1080/00913847.1988.11709603; ROWLAND TW, 1993, INTENSIVE PARTICIPAT, P177; Ryan J., 1995, LITTLE GIRLS PRETTY; Seefeldt V, 1978, J PHYS ED RECREATION, V49, P38; SINGER D, 1995, REHABIL MANAGE   DEC, P121; Skolnick AA, 1996, JAMA-J AM MED ASSOC, V275, P22, DOI 10.1001/jama.275.1.22; SKOLNICK AA, 1993, JAMA-J AM MED ASSOC, V270, P921, DOI 10.1001/jama.270.8.921; THEINTZ GE, 1993, J PEDIATR-US, V122, P306, DOI 10.1016/S0022-3476(06)80139-3; TOFLER I, 1995, INT J SPORTS PSYCHIA; TOFLER I, 1996, INT SOC SPORT SCI RE; TOFLER I, 1996, INT SOC SPORTS  0506; WEISS M, 1995, SPORTS PSYCHOL INTER, P41; Weiss M R, 1990, Exerc Sport Sci Rev, V18, P331; WILDER RT, 1992, J BONE JOINT SURG AM, V74A, P910, DOI 10.2106/00004623-199274060-00013; YEAGER KK, 1993, MED SCI SPORT EXER, V25, P775, DOI 10.1249/00005768-199307000-00003; 1996, NBS SPORTS      0302; 1994, TECHNIQUE, V15, P18; 1994, REUTERS NEWS SE 1128	45	94	94	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1996	335	4					281	283		10.1056/NEJM199607253350412	http://dx.doi.org/10.1056/NEJM199607253350412			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ532	8657248				2022-12-24	WOS:A1996UZ53200012
J	Gitti, RK; Lee, BM; Walker, J; Summers, MF; Yoo, S; Sundquist, WI				Gitti, RK; Lee, BM; Walker, J; Summers, MF; Yoo, S; Sundquist, WI			Structure of the amino-terminal core domain of the HIV-1 capsid protein	SCIENCE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIPLE-RESONANCE NMR; SIDE-CHAIN RESONANCES; ALPHA-CHYMOTRYPSIN; POSTTRANSLATIONAL MODIFICATIONS; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; C-13 MAGNETIZATION; PARTICLE FORMATION; LARGER PROTEINS	The three-dimensional structure of the amino-terminal core domain (residues 1 through 151) of the human immunodeficiency virus-type 1 (HIV-1) capsid protein has been solved by multidimensional heteronuclear magnetic resonance spectroscopy. The structure is unlike those of previously characterized viral coat proteins and is composed of seven alpha helices, two beta hairpins, and an exposed partially ordered loop. The domain is shaped like an arrowhead, with the beta hairpins and loop exposed at the trailing edge and the carboxyl-terminal helix projecting from the tip. The proline residue Pro(1) forms a salt bridge with a conserved, buried aspartate residue (Asp(51)), which suggests that the amino terminus of the protein rearranges upon proteolytic maturation. The binding site for cyclophilin A, a cellular rotamase that is packaged into the HIV-1 virion, is located on the exposed loop and encompasses the essential proline residue Pro(90). In the free monomeric domain, Pro(90) adopts kinetically trapped cis and trans conformations, raising the possibility that cyclophilin A catalyzes interconversion of the cis- and trans-Pro(90) loop structures.	UNIV MARYLAND BALTIMORE CTY,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21228; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	University System of Maryland; University of Maryland Baltimore County; Utah System of Higher Education; University of Utah	Gitti, RK (corresponding author), UNIV MARYLAND BALTIMORE CTY,HOWARD HUGHES MED INST,BALTIMORE,MD 21228, USA.		Lee, Brian/F-8380-2013	Lee, Brian/0000-0002-0269-7812	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030917, R37AI030917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042561, R29GM042561] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42014] Funding Source: Medline; NIAID NIH HHS [AI30917] Funding Source: Medline; NIGMS NIH HHS [GM 42561] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; Aberham C, 1996, J VIROL, V70, P3536, DOI 10.1128/JVI.70.6.3536-3544.1996; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARGOS P, 1989, EMBO J, V8, P779, DOI 10.1002/j.1460-2075.1989.tb03438.x; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Basak AK, 1996, J VIROL, V70, P3797, DOI 10.1128/JVI.70.6.3797-3806.1996; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; BIRKTOFT JJ, 1976, BIOCHEMISTRY-US, V15, P4481, DOI 10.1021/bi00665a023; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; BRAATEN D, IN PRESS J VIROL; BROOKS I, 1994, METHOD ENZYMOL, V240, P459; CHAZAL N, 1994, J VIROL, V68, P111, DOI 10.1128/JVI.68.1.111-122.1994; COATES ARM, 1987, NATURE, V326, P549, DOI 10.1038/326549c0; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; EHRLICH LS, 1992, J VIROL, V66, P4874, DOI 10.1128/JVI.66.8.4874-4883.1992; EHRLICH LS, 1994, VIROLOGY, V204, P515, DOI 10.1006/viro.1994.1565; FELHAMMER H, 1977, J MOL BIOL, V111, P415; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRANKE EK, 1994, J VIROL, V68, P5300, DOI 10.1128/JVI.68.8.5300-5305.1994; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; GELDERBLOM HR, 1992, MEMBRANE INTERACTION, P33; GEMMECKER G, 1993, J AM CHEM SOC, V115, P11620, DOI 10.1021/ja00077a080; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRIMES J, 1995, NATURE, V373, P167, DOI 10.1038/373167a0; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; Hedstrom L, 1996, BIOCHEMISTRY-US, V35, P4515, DOI 10.1021/bi951928k; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HONG SS, 1993, J VIROL, V67, P2787, DOI 10.1128/JVI.67.5.2787-2798.1993; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JOWETT JBM, 1992, J GEN VIROL, V73, P3079, DOI 10.1099/0022-1317-73-12-3079; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; KOIDE S, 1995, J BIOMOL NMR, V6, P306; KOLATKAR PR, 1992, ACTA CRYSTALLOGR B, V48, P191, DOI 10.1107/S0108768191012363; KOSSIAKOFF AA, 1977, BIOCHEMISTRY-US, V16, P654, DOI 10.1021/bi00623a016; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGEDIJK JPM, 1990, J GEN VIROL, V71, P2609, DOI 10.1099/0022-1317-71-11-2609; LILJAS L, 1982, J MOL BIOL, V159, P93, DOI 10.1016/0022-2836(82)90033-X; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MASSIAH MA, 1994, J MOL BIOL, V244, P198, DOI 10.1006/jmbi.1994.1719; MATHEWS S, 1994, NATURE, V370, P666; MCCONN J, 1969, J MOL BIOL, V39, P551, DOI 10.1016/0022-2836(69)90145-4; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MEYERS R, 1995, HUAN RETROVIRUSES AI; MODROW S, 1994, MED MICROBIOL IMMUN, V184, P177; MUHANDIRAM DR, 1993, J BIOMOL NMR, V3, P463; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; OTT DE, 1995, AIDS RES HUM RETROV, V11, P1003, DOI 10.1089/aid.1995.11.1003; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PRONGAY AJ, 1990, P NATL ACAD SCI USA, V87, P9980, DOI 10.1073/pnas.87.24.9980; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; REICIN AS, 1995, J VIROL, V69, P642, DOI 10.1128/JVI.69.2.642-650.1995; ROBERTHEBMANN V, 1992, MOL IMMUNOL, V29, P729, DOI 10.1016/0161-5890(92)90183-X; ROSE S, 1992, PROTEINS, V13, P112, DOI 10.1002/prot.340130204; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1988, P NATL ACAD SCI USA, V85, P4625, DOI 10.1073/pnas.85.13.4625; SIGLER PB, 1968, J MOL BIOL, V35, P143, DOI 10.1016/S0022-2836(68)80043-9; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; STEINKASSERER A, 1995, J VIROL, V69, P814, DOI 10.1128/JVI.69.2.814-824.1995; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; VONPOBLOTZKI A, 1993, VIROLOGY, V193, P981, DOI 10.1006/viro.1993.1210; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; WANG CT, 1993, J VIROL, V67, P4264, DOI 10.1128/JVI.67.7.4264-4273.1993; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YOO SJ, UNPUB; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	103	401	412	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					231	235		10.1126/science.273.5272.231	http://dx.doi.org/10.1126/science.273.5272.231			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8662505				2022-12-24	WOS:A1996UW78700039
J	French, JK; Williams, BF; Hart, HH; Wyatt, S; Poole, JE; Ingram, C; Ellis, CJ; Williams, MG; White, HD				French, JK; Williams, BF; Hart, HH; Wyatt, S; Poole, JE; Ingram, C; Ellis, CJ; Williams, MG; White, HD			Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; CARDIOPULMONARY-RESUSCITATION; INTRAVENOUS STREPTOKINASE; RANDOMIZED TRIAL; FREQUENCY; SURVIVAL	Objective-To determine the proportion of patients presenting with acute myocardial infarction who are eligible for thrombolytic therapy. Design-Cohort follow up study. Setting-The four coronary care units in Auckland, New Zealand. Subjects-All 3014 patients presenting to the units with suspected myocardial infarction in 1993. Main outcome measures-Eligibility for reperfusion with thrombolytic therapy (presentation within 12 hours of the onset of ischaemic chest pain with ST elevation greater than or equal to 2 mm in leads V1-V3, ST elevation greater than or equal to 1 mm in any other two contiguous leads, or new left bundle branch block); proportions of (a) patients eligible for reperfusion and (b) patients with contraindications to thrombolysis; death (including causes); definite myocardial infarction. Results-948 patients had definite myocardial infarction, 124 probable myocardial infarction, and nine ST elevation but no infarction; 1274 patients had unstable angina and 659 chest pain of other causes. Of patients with definite or probable myocardial infarction, 576 (53.3%) were eligible for reperfusion, 39 had definite contraindications to thrombolysis (risk of bleeding). Hence 49.7% of patients (537/1081) were eligible for thrombolysis and 43.5% (470) received this treatment. Hospital mortality among patients eligible for reperfusion was 11.7% (55/470 cases) among those who received thrombolysis and 17.0% (18/106) among those who did not. Conclusions-On current criteria about half of patients admitted to coronary care units with definite or probable myocardial infarction are eligible for thrombolytic therapy. Few eligible patients have definite contraindications to thrombolytic therapy. Mortality for all community admissions for myocardial infarction remains high.	GREEN LANE HOSP, CORONARY CARE UNIT, AUCKLAND 3, NEW ZEALAND; N SHORE HOSP, CORONARY CARE UNIT, AUCKLAND, NEW ZEALAND; MIDDLEMORE HOSP, CORONARY CARE UNIT, AUCKLAND 6, NEW ZEALAND; AUCKLAND HOSP, CORONARY CARE UNIT, AUCKLAND, NEW ZEALAND	Auckland City Hospital								[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1993, Lancet, V342, P767; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BARBASH GI, 1993, J AM COLL CARDIOL, V22, P707, DOI 10.1016/0735-1097(93)90180-9; BEHAR S, 1991, AM J CARDIOL, V68, P1291, DOI 10.1016/0002-9149(91)90233-B; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1995, LANCET, V345, P669; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; Gottlieb S., 1995, European Heart Journal, V16, P9; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; HAMPTON J, 1993, LANCET, V342, P759; KARNASH SL, 1995, J AM COLL CARDIOL, V26, P1651, DOI 10.1016/0735-1097(95)00386-X; KENNEDY JW, 1985, NEW ENGL J MED, V312, P1073, DOI 10.1056/NEJM198504253121701; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; NECHES RB, 1991, CLIN CARDIOL, V14, P616, DOI 10.1002/clc.4960140715; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROSSI P, 1991, AM J CARDIOL, V68, P585, DOI 10.1016/0002-9149(91)90348-O; Rustige J., 1995, European Heart Journal, V16, P9; SCHOLZ KH, 1992, AM J CARDIOL, V69, P724, DOI 10.1016/0002-9149(92)90494-J; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1985, LANCET, V2, P578; TENAGLIA AN, 1991, AM J CARDIOL, V68, P1015, DOI 10.1016/0002-9149(91)90488-7; THOMPSON JT, 1987, ARCH OPHTHALMOL-CHIC, V105, P191; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; WARD H, 1995, BMJ-BRIT MED J, V310, P3, DOI 10.1136/bmj.310.6971.3; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WHITE HD, 1989, NEW ENGL J MED, V320, P817, DOI 10.1056/NEJM198903303201301; WILCOX RG, 1988, LANCET, V2, P525; WOODS KL, 1994, LANCET, V343, P232, DOI 10.1016/S0140-6736(94)91016-2	32	84	84	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	1996	312	7047					1637	1641		10.1136/bmj.312.7047.1637	http://dx.doi.org/10.1136/bmj.312.7047.1637			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664716	Green Published			2022-12-24	WOS:A1996UV48900021
J	Grierson, I				Grierson, I			Glaucoma and nitric oxide	LANCET			English	Editorial Material							TRABECULAR MESHWORK				Grierson, I (corresponding author), UNIV LIVERPOOL,DEPT MED,UNIT OPHTHALMOL ST PAULS,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							LEPPLEWIENHUES A, 1991, EXP EYE RES, V53, P33, DOI 10.1016/0014-4835(91)90141-Z; MAEPEA O, 1989, EXP EYE RES, V49, P645, DOI 10.1016/S0014-4835(89)80060-0; NATHANSON JA, 1995, INVEST OPHTH VIS SCI, V36, P1774; NATHANSON JA, 1995, INVEST OPHTH VIS SCI, V36, P1765; WIEDERHOLT M, 1994, INVEST OPHTH VIS SCI, V35, P1515	5	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1781	1782		10.1016/S0140-6736(96)91613-X	http://dx.doi.org/10.1016/S0140-6736(96)91613-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667919				2022-12-24	WOS:A1996UU46900006
J	Ho, IC; Hodge, MR; Rooney, JW; Glimcher, LH				Ho, IC; Hodge, MR; Rooney, JW; Glimcher, LH			The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4	CELL			English	Article							T-CELL ACTIVATION; GENE-EXPRESSION; CYCLOSPORINE-A; V-MAF; TRANSCRIPTION; PROTEINS; MOTIF; PROMOTER; ELEMENTS; COMPLEX	The molecular basis for the distinctive cytokine expression of CD4+ T helper 1 (Th1) and T helper 2 (Th2) subsets remains elusive. Here, we report that the proto-oncogene c-maf, a basic region/leucine zipper transcription factor, controls tissue-specific expression of IL-4. c-Maf is expressed in Th2 but not Th1 clones and is induced during normal precursor cell differentiation along a Th2 but not Th1 lineage. c-Maf binds to a c-Maf response element (MARE) in the proximal IL-4 promoter adjacent to a site footprinted by extracts from Th2 but not Th1 clones. Ectopic expression of c-Maf transactivates the IL-4 promoter in Th1 cells, B cells, and nonlymphoid cells, a function that maps to the MARE and Th2-specific footprint. Furthermore, c-Maf acts in synergy with the nuclear factor of activated T cells (NF-ATp) to initiate endogeneous IL-4 production by B cells. Manipulation of c-Maf may alter Th subset ratios in human disease.			Ho, IC (corresponding author), HARVARD UNIV,SCH MED,HARVARD SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI37650] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; BARVE SS, 1994, J IMMUNOL, V152, P1171; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; DAVYDOV IV, 1995, J IMMUNOL, V155, P5273; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; HAVRAN WL, 1987, NATURE, V325, P65, DOI 10.1038/325065a0; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HODGE MR, 1995, J IMMUNOL, V154, P6397; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; LANE RD, 1986, METHOD ENZYMOL, V121, P183; LEDERER JA, 1994, J IMMUNOL, V152, P77; Lederer JA, 1996, J IMMUNOL, V156, P56; LEONARD JP, 1995, J EXP MED, V181, P381, DOI 10.1084/jem.181.1.381; LEWEBER M, 1993, J IMMUNOL, V151, P1371; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOUZAKI A, 1991, EMBO J, V10, P1399, DOI 10.1002/j.1460-2075.1991.tb07660.x; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SUDA T, 1995, J IMMUNOL, V154, P3806; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4228, DOI 10.1128/MCB.11.8.4228; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X	52	560	571	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					973	983		10.1016/S0092-8674(00)81299-4	http://dx.doi.org/10.1016/S0092-8674(00)81299-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674125	Bronze			2022-12-24	WOS:A1996UV48400005
J	KissLaszlo, Z; Henry, Y; Bachellerie, JP; CaizerguesFerrer, M; Kiss, T				KissLaszlo, Z; Henry, Y; Bachellerie, JP; CaizerguesFerrer, M; Kiss, T			Site-specific ribose methylation of preribosomal RNA: A novel function for small nucleolar RNAs	CELL			English	Article							EXTERNAL TRANSCRIBED SPACER; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; PREMESSENGER RNA; U3 SNRNA; BOX-C; YEAST; FIBRILLARIN; GENE; EXPRESSION	Eukaryotic cells contain many fibrillarin-associated small nucleolar RNAs (snoRNAs) that possess long complementarities to mature rRNAs. Characterization of 21 novel antisense snoRNAs from human cells followed by genetic depletion and reconstitution studies on yeast U24 snoRNA provides evidence that this class of snoRNAs is required for site-specific 2'-O-methylation of preribosomal RNA (pre-rRNA). Antisense snoRNAs function through direct base-pairing interactions with pre-rRNA. The antisense element, together with the D or D' box of the snoRNA, provide the information necessary to select the target nucleotide for the methyltransfer reaction. The conclusion that snoRNAs function in covalent modification of the sugar moieties of ribonucleotides demonstrates that eukaryotic small nuclear RNAs have a more versatile cellular function than earlier anticipated.			KissLaszlo, Z (corresponding author), UNIV TOULOUSE 3, LAB BIOL MOL EUCARYOTE, CNRS, F-31062 TOULOUSE, FRANCE.			Kiss, Tamas/0000-0003-0293-3093				ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; Bachellerie JP, 1995, BIOCHEM CELL BIOL, V73, P835, DOI 10.1139/o95-091; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BAKIN A, 1995, NUCLEIC ACIDS RES, V23, P3290, DOI 10.1093/nar/23.16.3290; Baserga S., 1993, RNA WORLD, P359; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BELTRAME M, 1995, EMBO J, V14, P4350, DOI 10.1002/j.1460-2075.1995.tb00109.x; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BRIMACOMBE R, 1993, FASEB J, V7, P161, DOI 10.1096/fasebj.7.1.8422963; CABOCHE M, 1977, EUR J BIOCHEM, V74, P19, DOI 10.1111/j.1432-1033.1977.tb11362.x; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; DAVIES B, 1993, GENOMICS, V15, P68, DOI 10.1006/geno.1993.1011; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; DWOMICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181; EICHLER DC, 1987, BIOCHEMISTRY-US, V26, P1639, DOI 10.1021/bi00380a023; EICHLER DC, 1994, BIOCHIMIE, V76, P1115, DOI 10.1016/0300-9084(94)90039-6; EICHLER DC, 1995, PROG NUCL ACID RES M, V49, P179; England T E, 1980, Methods Enzymol, V65, P65; FILIPOWICZ W, 1993, MOL BIOL REP, V18, P149, DOI 10.1007/BF00986770; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; FRAGAPANE P, 1993, EMBO J, V12, P2921, DOI 10.1002/j.1460-2075.1993.tb05954.x; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; HADJIOLOV AA, 1985, CELL BIOL MONOGRAPHS; HUANG GM, 1992, MOL CELL BIOL, V12, P4456, DOI 10.1128/MCB.12.10.4456; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kiss T, 1996, MOL CELL BIOL, V16, P1391; KISS T, 1993, EMBO J, V12, P2913, DOI 10.1002/j.1460-2075.1993.tb05953.x; KISS T, 1995, GENE DEV, V9, P1411, DOI 10.1101/gad.9.11.1411; LANE BG, 1995, BIOCHIMIE, V77, P7, DOI 10.1016/0300-9084(96)88098-9; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIANG WQ, 1995, GENE DEV, V9, P2433, DOI 10.1101/gad.9.19.2433; LONG TW, 1983, BIOCHIM BIOPHYS ACTA, V740, P29, DOI 10.1016/0167-4781(83)90117-3; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1974, J MOL BIOL, V88, P133, DOI 10.1016/0022-2836(74)90299-X; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MADEN BEH, 1988, J MOL BIOL, V201, P289, DOI 10.1016/0022-2836(88)90139-8; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; PELLIZZONI L, 1994, NUCLEIC ACIDS RES, V22, P4607, DOI 10.1093/nar/22.22.4607; PRISLEI S, 1993, NUCLEIC ACIDS RES, V21, P5824, DOI 10.1093/nar/21.25.5824; QU LH, 1995, NUCLEIC ACIDS RES, V23, P2669, DOI 10.1093/nar/23.14.2669; QU LH, 1994, NUCLEIC ACIDS RES, V22, P4073, DOI 10.1093/nar/22.20.4073; Sambrook JFE, 1989, MOL CLONING LAB MANU; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SEGAL DM, 1991, J BIOL CHEM, V266, P24358; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; SMITH JD, 1959, BIOCHIM BIOPHYS ACTA, V31, P573, DOI 10.1016/0006-3002(59)90045-9; SOLLNERWEBB B, 1996, RIBOSOMAL RNA STRUCT, P469; STEITZ JA, 1995, SCIENCE, V270, P1626, DOI 10.1126/science.270.5242.1626; SWANN PF, 1975, BIOCHEM J, V150, P335, DOI 10.1042/bj1500335; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; TRINHROHLIK Q, 1988, NUCLEIC ACIDS RES, V16, P6041, DOI 10.1093/nar/16.13.6041; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; TYCOWSKI KT, 1993, GENE DEV, V6, P1120; VAUGHAN MH, 1967, P NATL ACAD SCI USA, V58, P1527, DOI 10.1073/pnas.58.4.1527; VELDMAN GM, 1981, NUCLEIC ACIDS RES, V9, P6935, DOI 10.1093/nar/9.24.6935; WATKINS NJ, 1996, IN PRESS ELEMENTS ES; WOLF SF, 1977, BIOCHEMISTRY-US, V16, P2783, DOI 10.1021/bi00631a031; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; ZAGORSKI J, 1988, MOL CELL BIOL, V8, P3282, DOI 10.1128/MCB.8.8.3282	72	654	681	1	39	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1996	85	7					1077	1088		10.1016/S0092-8674(00)81308-2	http://dx.doi.org/10.1016/S0092-8674(00)81308-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674114	Bronze			2022-12-24	WOS:A1996UV48400014
J	Miller, FG; Fins, JJ				Miller, FG; Fins, JJ			A proposal to restructure hospital care for dying patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									CORNELL UNIV,COLL MED,NEW YORK,NY 10021; UNIV VIRGINIA,CHARLOTTESVILLE,VA 22908; NEW YORK HOSP,CORNELL MED CTR,NEW YORK,NY 10021	Cornell University; University of Virginia; Cornell University; NewYork-Presbyterian Hospital			Ram, Prem/K-4511-2012	Fins, Joseph/0000-0002-7221-0053				COLBURN D, 1995, WASHINGTON POST 1122, pA1; COLBURN D, 1995, WASHINGTON POST 1205, P7; COWLEY G, 1995, NEWSWEEK        1204, P74; Gilbert Susan, 1995, N Y Times Web, pC7; GOMEZ CF, 1996, CARING DYING IDENTIF, P27; GOODMAN E, 1995, JAMA-J AM MED ASSOC, V273, P1039; HORSBURGH CR, 1995, NEW ENGL J MED, V333, P735, DOI 10.1056/NEJM199509143331117; JAMES N, 1992, SOC SCI MED, V34, P1363, DOI 10.1016/0277-9536(92)90145-G; JECKER NS, 1991, J MED PHILOS, V16, P285, DOI 10.1093/jmp/16.3.285; Konner M., 1987, BECOMING DOCTOR JOUR; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; MATHEWS JJ, 1991, WOMEN HEALTH, V17, P39, DOI 10.1300/J013v17n01_03; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; NULAND SB, 1994, HOW WE DIE RELFECTIO; Quill TE, 1993, DEATH DIGNITY MAKING; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SCOTT JR, 1976, NEW ENGL J MED, V294, P1205, DOI 10.1056/NEJM197605272942203; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Solomon MZ, 1995, HASTINGS CENT REP, V25, pS28, DOI 10.2307/3527856; STODDARD S, 1992, HOSPICE MOVEMENT; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WINSLOW R, 1995, WALL STREET J   0721, pB1; 1995, JAMA-J AM MED ASSOC, V274, P1591	24	57	57	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1740	1742		10.1056/NEJM199606273342612	http://dx.doi.org/10.1056/NEJM199606273342612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UT400	8637523				2022-12-24	WOS:A1996UT40000012
J	Elena, SF; Cooper, VS; Lenski, RE				Elena, SF; Cooper, VS; Lenski, RE			Punctuated evolution caused by selection of rare beneficial mutations	SCIENCE			English	Article							EQUILIBRIA; RATES	For more than two decades there has been intense debate over the hypothesis that most morphological evolution occurs during relatively brief episodes of rapid change that punctuate much longer periods of stasis, A clear and unambiguous case of punctuated evolution is presented for cell size in a population of Escherichia coli evolving for 3000 generations in a constant environment, The punctuation is caused by natural selection as rare, beneficial mutations sweep successively through the population, This experiment shows that the most elementary processes in population genetics can give rise to punctuated evolutionary dynamics.			Elena, SF (corresponding author), MICHIGAN STATE UNIV,CTR MICROBIAL ECOL,E LANSING,MI 48824, USA.		Elena, Santiago F./A-4191-2011	Elena, Santiago F./0000-0001-8249-5593; Cooper, Vaughn/0000-0001-7726-0765; Lenski, Richard/0000-0002-1064-8375				ARNOLD SJ, 1983, AM ZOOL, V23, P347, DOI 10.1093/icb/23.2.347; BOOKSTEIN FL, 1978, PALEOBIOLOGY, V4, P120, DOI 10.1017/S0094837300005807; CHARLESWORTH B, 1982, EVOLUTION, V36, P474, DOI 10.1111/j.1558-5646.1982.tb05068.x; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; DYKHUIZEN DE, 1983, MICROBIOL REV, V47, P150, DOI 10.1128/MMBR.47.2.150-168.1983; Eldredge N., 1972, P82; Falconer D. S., 1981, INTRO QUANTITATIVE G; GINGERICH PD, 1984, SYST ZOOL, V33, P335, DOI 10.2307/2413079; GINGERICH PD, 1983, SCIENCE, V222, P159, DOI 10.1126/science.222.4620.159; GINZBURG LR, 1981, PALEOBIOLOGY, V7, P426, DOI 10.1017/S0094837300025483; Gould S.J., 1982, P83; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; Haldane JBS, 1927, P CAMB PHILOS SOC, V23, P838, DOI 10.1017/S0305004100015644; JOHNSON PA, 1995, P ROY SOC B-BIOL SCI, V259, P125, DOI 10.1098/rspb.1995.0019; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Levinton J. S., 1988, GENETICS PALEONTOLOG; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; NEWMAN CM, 1985, NATURE, V315, P400, DOI 10.1038/315400a0; Travisano M, 1996, GENETICS, V143, P15; Turner J., 1986, PATTERNS PROCESSES H, P183; VASI F, 1994, AM NAT, V144, P432, DOI 10.1086/285685; WILLIAMSON PG, 1981, NATURE, V293, P437, DOI 10.1038/293437a0	25	198	205	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1802	1804		10.1126/science.272.5269.1802	http://dx.doi.org/10.1126/science.272.5269.1802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650581				2022-12-24	WOS:A1996UT11000047
J	Waldman, T; Lengauer, C; Kinzler, KW; Vogelstein, B				Waldman, T; Lengauer, C; Kinzler, KW; Vogelstein, B			Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21	NATURE			English	Article							CYCLE; INSITU	PRECISE coordination of the S and M phases of the eukaryotic cell cycle is critical not only for normal cell division, but also for effective growth arrest under conditions of stress. When damaged, a cell must communicate signals to both the mitotic and DNA synthesis machineries so that a mitotic block is not followed by an extra S phase, or vice versa. The biochemical mechanisms regulating this coordination, termed checkpoints, have been identified in lower eukaryotes, but are largely unknown in mammalian cells(1-3). Here we show that p21(WAF1/CIP1), the prototype inhibitor of cyclin-dependent kinases (CDKs)(4), is required for this coordination in human cells. In the absence of p21, DNA-damaged cells arrest in a G2-like state, but then undergo additional S phases without intervening normal mitoses. They thereby acquire grossly deformed, polyploid nuclei and subsequently die through apoptosis. Perhaps not by coincidence, the DNA-damaging agents that can cause S/M uncoupling are used in the clinic to kill cancer cells preferentially.	JOHNS HOPKINS ONCOL CTR,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; PROGRAM HUMAN GENET,BALTIMORE,MD 21231	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine								CARDER P, 1993, ONCOGENE, V8, P1397; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GAO X, 1995, ONCOGENE, V11, P1395; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIBERSON RT, 1995, MICROSC RES TECHNIQ, V32, P246, DOI 10.1002/jemt.1070320307; GORCZYCA W, 1993, CANCER RES, V53, P1945; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2457; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; KUNG AL, 1990, CANCER RES, V50, P7307; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LENGAUER C, 1994, GENET ANAL-BIOMOL E, V11, P140, DOI 10.1016/1050-3862(94)90034-5; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LICHTER P, 1992, HUMAN CYTOGENETICS P, P157; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MORROW CS, 1993, CANCER MED, P618; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NURSE P, 1994, CELL, V79, P5474; RIED T, 1992, GENE CHROMOSOME CANC, V4, P69, DOI 10.1002/gcc.2870040109; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; WALDMAN T, 1995, CANCER RES, V55, P5187	28	708	732	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					713	716		10.1038/381713a0	http://dx.doi.org/10.1038/381713a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649519				2022-12-24	WOS:A1996UR97900057
J	Rhodes, JM				Rhodes, JM			Cholesterol crystal embolism: An important ''new'' diagnosis for the general physician	LANCET			English	Editorial Material							EMBOLIZATION				Rhodes, JM (corresponding author), UNIV LIVERPOOL,DEPT MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.		Rhodes, Jonathan M/C-2496-2009					BLANKENSHIP JC, 1995, CHEST, V107, P662, DOI 10.1378/chest.107.3.662; CABILI S, 1993, ANGIOLOGY, V44, P821, DOI 10.1177/000331979304401010; CROSS SS, 1991, J CLIN PATHOL, V44, P859, DOI 10.1136/jcp.44.10.859; DAHLBERG PJ, 1989, SURGERY, V105, P737; FINE MJ, 1987, ANGIOLOGY, V38, P769, DOI 10.1177/000331978703801007; GAINES PA, 1988, LANCET, V1, P168; Moolenaar W, 1996, GUT, V38, P196, DOI 10.1136/gut.38.2.196; RICHARDS AM, 1965, AM J CARDIOL, V15, P696, DOI 10.1016/0002-9149(65)90359-0; WONG FKM, 1995, AM J KIDNEY DIS, V26, P508	9	29	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1641	1641		10.1016/S0140-6736(96)91482-8	http://dx.doi.org/10.1016/S0140-6736(96)91482-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642953				2022-12-24	WOS:A1996UQ70100005
J	Cascalho, M; Ma, A; Lee, S; Masat, L; Wabl, M				Cascalho, M; Ma, A; Lee, S; Masat, L; Wabl, M			A quasi-monoclonal mouse	SCIENCE			English	Article							LAMBDA-LIGHT CHAIN; B-CELL LYMPHOMA; GENE REPLACEMENT; VARIABLE REGION; VH; SEGMENTS; IMMUNOGLOBULINS; RECOMBINATION; REARRANGEMENT; ASSOCIATION	As a model for studying the generation of antibody diversity, a gene-targeted mouse was produced that is hemizygous for a rearranged V(D)J segment at the immunoglobulin (Ig) heavy chain locus, the other allele being nonfunctional. The mouse also has no functional kappa light chain allele. The heavy chain, when paired with any lambda light chain, is specific for the hapten (4-hydroxy-3-nitrophenyl) acetyl (NP). The primary repertoire of this quasi-monoclonal mouse is monospecific, but somatic hypermutation and secondary rearrangements change the specificity of 20 percent of the antigen receptors on B cells. The serum concentrations of the Ig isotypes are similar to those in nontransgenic littermates, but less than half of the serum IgM binds to NP, and none of the other isotypes do. Thus, neither network interactions nor random activation of a small fraction of the B cell population can account for serum is concentrations.			Cascalho, M (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.			Cascalho, Marilia/0000-0002-2695-3921	NIAMS NIH HHS [P60 AR20684] Funding Source: Medline; NIGMS NIH HHS [1R01 GM37699] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037699] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELLA E, 1971, P NATL ACAD SCI USA, V68, P590, DOI 10.1073/pnas.68.3.590; AZUMA T, 1981, P NATL ACAD SCI-BIOL, V78, P569, DOI 10.1073/pnas.78.1.569; BECKENGESER G, 1987, P NATL ACAD SCI USA, V84, P1060, DOI 10.1073/pnas.84.4.1060; BLOMBERG B, 1981, P NATL ACAD SCI-BIOL, V78, P3765, DOI 10.1073/pnas.78.6.3765; CARSON S, 1989, IMMUNOGENETICS, V29, P173, DOI 10.1007/BF00373642; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; CHEN JZ, 1993, EMBO J, V12, P821, DOI 10.1002/j.1460-2075.1993.tb05722.x; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; COUTINHO A, 1995, SCAND J IMMUNOL, V42, P3, DOI 10.1111/j.1365-3083.1995.tb03619.x; COVEY LR, 1990, INT IMMUNOL, V2, P579, DOI 10.1093/intimm/2.6.579; DILDROP R, 1987, EUR J IMMUNOL, V17, P731, DOI 10.1002/eji.1830170525; ELLIOTT BW, 1982, NATURE, V299, P559, DOI 10.1038/299559a0; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GROSSCHEDL R, 1984, CELL, V38, P67; IMANISHI T, 1974, J EXP MED, V140, P1498, DOI 10.1084/jem.140.6.1498; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Kabat EA, 1991, SEQUENCES PROTEINS I; KARJALAINEN K, 1980, EUR J IMMUNOL, V10, P132, DOI 10.1002/eji.1830100212; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; KLEINFIELD RW, 1989, J IMMUNOL, V142, P4475; KOMORI T, 1993, EUR J IMMUNOL, V23, P517, DOI 10.1002/eji.1830230233; LOH DY, 1983, CELL, V33, P85, DOI 10.1016/0092-8674(83)90337-9; MILLER J, 1981, P NATL ACAD SCI-BIOL, V78, P3829, DOI 10.1073/pnas.78.6.3829; RAMSDEN DA, 1991, P NATL ACAD SCI USA, V88, P10721, DOI 10.1073/pnas.88.23.10721; REILLY EB, 1984, P NATL ACAD SCI-BIOL, V81, P2484, DOI 10.1073/pnas.81.8.2484; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; SANCHEZ P, 1987, J EXP MED, V166, P265, DOI 10.1084/jem.166.1.265; SCHULENBERG EP, 1971, P NATL ACAD SCI USA, V66, P2623; SELSING E, 1982, P NATL ACAD SCI-BIOL, V79, P4681, DOI 10.1073/pnas.79.15.4681; SHIRASAWA T, 1992, J EXP MED, V176, P1209, DOI 10.1084/jem.176.4.1209; STEENBERGEN EJ, 1993, BLOOD, V82, P581, DOI 10.1182/blood.V82.2.581.bloodjournal822581; TAKI S, 1993, SCIENCE, V262, P1268, DOI 10.1126/science.8235657; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; USUDA S, 1992, EMBO J, V11, P611, DOI 10.1002/j.1460-2075.1992.tb05093.x; VARELA F, 1991, P NATL ACAD SCI USA, V88, P5917, DOI 10.1073/pnas.88.13.5917; WEISS S, 1985, EUR J IMMUNOL, V15, P765, DOI 10.1002/eji.1830150805; WHITESCHARF ME, 1981, EUR J IMMUNOL, V11, P897, DOI 10.1002/eji.1830111109; WHITESCHARF ME, 1982, EUR J IMMUNOL, V12, P935, DOI 10.1002/eji.1830121108	38	159	174	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 14	1996	272	5268					1649	1652		10.1126/science.272.5268.1649	http://dx.doi.org/10.1126/science.272.5268.1649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658139				2022-12-24	WOS:A1996UR09300046
J	Zhu, XT; Zhao, X; Burkholder, WF; Gragerov, A; Ogata, CM; Gottesman, ME; Hendrickson, WA				Zhu, XT; Zhao, X; Burkholder, WF; Gragerov, A; Ogata, CM; Gottesman, ME; Hendrickson, WA			Structural analysis of substrate binding by the molecular chaperone DnaK	SCIENCE			English	Article							HEAT-SHOCK; 3-DIMENSIONAL STRUCTURE; PEPTIDE-BINDING; ANOMALOUS DIFFRACTION; UNCOATING PROTEIN; ESCHERICHIA-COLI; ATP HYDROLYSIS; CALMODULIN; HSP70; NUCLEOTIDES	DnaK and other members of the 70-kilodalton heat-shock protein (hsp70) family promote protein folding, interaction, and translocation, both constitutively and in response to stress, by binding to unfolded polypeptide segments. These proteins have two functional units: a substrate-binding portion binds the polypeptide, and an adenosine triphosphatase portion facilitates substrate exchange. The crystal structure of a peptide complex with the substrate-binding unit of DnaK has now been determined at 2.0 Angstrom resolution. The structure consists of a beta-sandwich subdomain followed by alpha-helical segments. The peptide is bound to DnaK in an extended conformation through a channel defined by loops from the beta sandwich. An alpha-helical domain stabilizes the complex, but does not contact the peptide directly. This domain is rotated in the molecules of a second crystal lattice, which suggests a model of conformation-dependent substrate binding that features a latch mechanism for maintaining long lifetime complexes.	COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; COLUMBIA UNIV, CANC RES INST, NEW YORK, NY 10032 USA; BROOKHAVEN NATL LAB, NATL SYNCHROTRON LIGHT SOURCE, HOWARD HUGHES MED INST, STONY BROOK, NY USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Howard Hughes Medical Institute; United States Department of Energy (DOE); Brookhaven National Laboratory	Zhu, XT (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.				NIGMS NIH HHS [GM 37219, R01 GM034102, GM 34102] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM037219, R37GM034102, R01GM037219, R01GM034102] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; BURKHOLDER WF, UNPUB; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FARR CD, 1995, BIOCHEMISTRY-US, V34, P15574, DOI 10.1021/bi00047a024; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INOUE A, 1995, J BIOL CHEM, V270, P22571, DOI 10.1074/jbc.270.38.22571; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MCKAY DBW, 1994, BIOL HEAT SHOCK PROT, P209; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRASA K, 1994, J BIOL CHEM, V269, P6831; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; RENSING SA, 1994, J MOL EVOL, V39, P80, DOI 10.1007/BF00178252; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROMAN E, 1994, EUR J BIOCHEM, V222, P65, DOI 10.1111/j.1432-1033.1994.tb18842.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAITO H, 1978, MOL GEN GENET, V164, P1, DOI 10.1007/BF00267592; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; Shi L, 1996, BIOCHEMISTRY-US, V35, P3297, DOI 10.1021/bi951984l; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TWERWILIGER T, 1979, CCP4 SUITE PROGRAMS; WANG TF, 1993, J BIOL CHEM, V268, P26409; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; YOCHEM J, 1978, MOL GEN GENET, V164, P9, DOI 10.1007/BF00267593; Zhao X., UNPUB; [No title captured]	68	1005	1059	2	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	1996	272	5268					1606	1614		10.1126/science.272.5268.1606	http://dx.doi.org/10.1126/science.272.5268.1606			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658133	Green Accepted			2022-12-24	WOS:A1996UR09300034
J	Sinauer, N; Annest, JL; Mercy, JA				Sinauer, N; Annest, JL; Mercy, JA			Unintentional, nonfatal firearm-related injuries - A preventable public health burden	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUNSHOT WOUNDS; NORTH-CAROLINA; FATALITIES; CHILDREN; CALIFORNIA; DEATHS	Objective.-To describe the magnitude and characteristics of unintentional, nonfatal firearm-related injuries treated in US hospital emergency departments. Design.-Data were obtained from medical records for all firearm-related injury cases identified using the National Electronic Injury Surveillance System (NEISS) from June 1, 1992, through May 31, 1994. We report on cases classified as unintentional gunshot wounds. Setting.-NEISS comprises 91 hospitals that are a stratified probability sample of all hospitals in the United States and its territories that have at least 6 beds and provide 24-hour emergency service. Main Outcome Measures.-Number of and population rates for unintentional, nonfatal firearm-related injuries. Results.-An estimated 34 485 (95% confidence interval [CI], 25 225-43 745) persons (6.7 per 100 000 population; 95% CI, 4.9-8.5) were treated for unintentional, nonfatal firearm-related injuries in US emergency departments during the 2-year study period. The majority of patients were male (87%) and aged 15 to 34 years (61%); 38% required hospitalization. Injuries were most often to an extremity (73%), were self-inflicted (70%), involved a handgun (57%), and resulted during common gun-related activities. Conclusions.-Further development of effective interventions are needed to reduce the risk of injury from unintentional discharge of a firearm during routine gun-handling practices by those who own and use firearms. These injuries often occur during common gun-related activities such as gun cleaning, loading/unloading, hunting, target shooting, and showing, handling, or carrying. Studies are needed to evaluate the efficacy of existing gun safety training courses and assess the potential role of various gun safety devices (eg, trigger locks and loading indicators) in future prevention strategies.	NATL CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,OFF STAT & PROGRAMMING,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA								American Academy of Pediatrics, 1994, STOP FIR INJ; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BAKER SP, 1992, INJURY FACT BOOK, P149; CARTER GL, 1989, ANN EMERG MED, V18, P406, DOI 10.1016/S0196-0644(89)80581-5; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; COLE TB, 1988, AM J PUBLIC HEALTH, V78, P1585, DOI 10.2105/AJPH.78.12.1585; Davis Y, 1996, J SAFETY RES, V27, P83, DOI 10.1016/0022-4375(96)00002-3; DOWD MD, 1994, PEDIATRICS, V94, P867; Go Bette K., 1995, P21; *HANDG CONTR INC, 1995, STAT WHICH REQ SAF T; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; HEMENWAY D, 1990, J POLICY ANAL MANAG, V9, P94, DOI 10.2307/3325116; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; LEE RK, 1993, AM J PREV MED, V9, P16, DOI 10.1016/S0749-3797(18)30673-1; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MARTIN JR, 1991, ANN EMERG MED, V20, P58, DOI 10.1016/S0196-0644(05)81120-5; MORROW PL, 1986, AM J PUBLIC HEALTH, V76, P1120, DOI 10.2105/AJPH.76.9.1120; *NATL CTR INJ, 1995, INJ MORT NAT SUMM IN; *OUTD EMP PUBL, 1993, 1993 HUNT ED PROGR P; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Senturia YD, 1996, ARCH PEDIAT ADOL MED, V150, P265, DOI 10.1001/archpedi.1996.02170280035006; STUCKY W, 1991, J PEDIATR ORTHOPED, V11, P64, DOI 10.1097/01241398-199101000-00013; *US BUR CENS, 1993, CURR POP REP P25, V1104, P12; *US CONS PROD SAF, 1994, NAT EL INJ SURV SYST; *US DEP JUST, 1993, CRIM VICT US; WALLER J A, 1973, Accident Analysis and Prevention, V5, P351, DOI 10.1016/0001-4575(73)90033-X; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; WINTEMUTE GJ, 1989, J TRAUMA, V29, P457, DOI 10.1097/00005373-198904000-00007; Zawitz MW, 1996, NCJ160093 US DEP JUS; Zimring F. E., 1987, CITIZENS GUIDE GUN C; 1992, MMWR-MORBID MORTAL W, V41, P442	31	53	54	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1740	1743						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP307	8637171				2022-12-24	WOS:A1996UP30700027
J	Connolly, AJ; Ishihara, H; Kahn, ML; Farese, RV; Coughlin, SR				Connolly, AJ; Ishihara, H; Kahn, ML; Farese, RV; Coughlin, SR			Role of the thrombin receptor In development and evidence for a second receptor	NATURE			English	Article							ACTIVATION; DOMAIN; MICE	THROMBIN, a coagulation protease generated at sites of vascular injury, activates platelets, endothelial cells, leukocytes and mesenchymal cells(1,2). A G-protein-coupled receptor that is proteolytically activated by thrombin(3) is a target for drug development aimed at blocking thrombosis, inflammation and proliferation. Here we show that although disruption of the thrombin-receptor (tr) gene in mice causes about half the tr(-/-) embryos to die at embryonic day 9-10, half survive to become grossly normal adult mice with no bleeding diathesis. Strikingly, tr(-/-) platelets respond strongly to thrombin, whereas tr(-/-) fibroblasts lose their ability to respond to thrombin. We conclude that the thrombin receptor plays an unexpected role in embryonic development, suggesting a possible new function for the 'coagulation' proteases themselves. Moreover, a second platelet thrombin receptor exists, and different thrombin receptors have tissue-specific roles. This may allow development of therapeutics that will selectively block thrombin's different cellular actions.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes								BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BEVIGLIA L, 1993, THROMB RES, V71, P3001; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; CONNOLLY TM, 1994, THROMB HAEMOSTASIS, V72, P627; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; DERIAN CK, 1995, THROMB RES, V78, P505, DOI 10.1016/0049-3848(95)00084-5; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FENTON JZ, 1983, HEMAT ONVOL CLIN N A, V7, P1107; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GOODWIN CA, 1994, BIOCHEM BIOPH RES CO, V202, P321, DOI 10.1006/bbrc.1994.1930; HOGAN B, 1994, MANIPULATING MOUSE E, P1; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kahn M, 1996, MOL MED, V2, P349, DOI 10.1007/BF03401632; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KINLOUGHRATHBONE RL, 1993, THROMB HAEMOSTASIS, V70, P1019; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LAGES B, 1994, BLOOD, V83, P2549, DOI 10.1182/blood.V83.9.2549.bloodjournal8392549; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; RYDEL TJ, 1994, J BIOL CHEM, V269, P22000; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; SOIFER SJ, 1994, AM J PATHOL, V144, P60; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	30	433	446	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					516	519		10.1038/381516a0	http://dx.doi.org/10.1038/381516a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632823				2022-12-24	WOS:A1996UP43500058
J	Kanopka, A; Muhlemann, O; Akusjarvi, G				Kanopka, A; Muhlemann, O; Akusjarvi, G			Inhibition by SR proteins of splicing of a regulated adenovirus pre-mRNA	NATURE			English	Article							RNA; BINDING; INVITRO; SITE; TERMINATION; EXPRESSION; SELECTION; ENHANCER; SF2	THE adenovirus L1 unit(1) represents an example of an alternatively spliced precursor messenger (pre-mRNA) where one 5' splice can be joined to one of two alternative 3' splice sites, producing the 52,55K or the IIIa mRNAs (Fig, 1a). Efficient usage of the distal IIIa 3' splice site requires late viral protein synthesis and is therefore confined to the late phase of virus infection(2-4). Here we show that, in extracts from uninfected cells, the classical SR proteins(5), which are essential splicing factors(5-7), inhibit IIIa pre-mRNA splicing by binding to an intronic repressor element and preventing recruitment of the U2 small nuclear ribonucleoprotein particle to the spliceosome. We further show that the viral repressor element has splicing-enhancer activity when appropriately placed in the pre-mRNA. Together, our results demonstrate that SR proteins function as activators or repressors of splicing depending on where on the pre-mRNA they bind.	UNIV UPPSALA,DEPT IMMUNOL & MED MICROBIOL,BMC,S-75123 UPPSALA,SWEDEN	Uppsala University				Muhlemann, Oliver/0000-0003-0657-1368				AKUSJARVI G, 1981, NATURE, V292, P420, DOI 10.1038/292420a0; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; FU XD, 1995, RNA, V1, P663; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; HIMMELSPACH M, 1995, RNA, V1, P794; HORNIG H, 1986, NATURE, V324, P589, DOI 10.1038/324589a0; IMPERIALE M, 1995, CURR TOP MICROBIOL, P139; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P2379, DOI 10.1093/nar/19.9.2379; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P6956, DOI 10.1093/nar/19.24.6956; KREIVI JP, 1994, NUCLEIC ACIDS RES, V22, P332, DOI 10.1093/nar/22.3.332; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Moore DD, 1995, GLOB MOB SURV; Moore M., 1993, RNA WORLD, P303; NEVINS JR, 1981, NATURE, V290, P113, DOI 10.1038/290113a0; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; SVENSSON C, 1986, P NATL ACAD SCI USA, V83, P4690, DOI 10.1073/pnas.83.13.4690; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363	30	208	211	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					535	538		10.1038/381535a0	http://dx.doi.org/10.1038/381535a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632829				2022-12-24	WOS:A1996UP43500064
J	Nennig, ME; Shinefield, HR; Edwards, KM; Black, SB; Fireman, BH				Nennig, ME; Shinefield, HR; Edwards, KM; Black, SB; Fireman, BH			Prevalence and incidence of adult pertussis in an urban population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTION; OUTBREAK	Objectives.-To determine the prevalence of Bordetella pertussis infection among adults who have prolonged cough for 2 weeks or longer and to estimate the incidence of B pertussis infection in adults in a defined urban population. Design.-A prospective clinical study. Setting.-Kaiser Permanente, San Francisco (Calif) Medical Center. Participants.-One hundred fifty-three referred and participating health plan members 18 years old or older with the complaint of cough:persisting for 2 weeks or longer and 154 health plan members 18 years old or older with no cough for the past 3 months (controls) were enrolled. Medical records for an additional 100 patients randomly sampled from 676 patients 18 years old or older with an ambulatory diagnosis of cough (60 with prolonged cough) were also reviewed. Main Outcome Measures.-Prevalence of adult pertussis as determined by enzyme-linked immunosorbent assay IgG antibody levers to pertussis toxin in individuals with prolonged cough for 2 weeks or longer and the incidence of adult pertussis in San Francisco Kaiser health plan members. Results.-The prevalence of adult pertussis was 12.4% of the participating referrals. The incidence of adult pertussis was estimated to be 176 cases per 100 000 person-years (95% confidence interval, 97 to 255 cases). Conclusions.-Adult pertussis is a significantly greater public health threat than previously suspected, Booster doses of acellular pertussis vaccine after 7 years of age may bean effective approach to minimize transmission and infection.	KAISER PERMANENTE MED GRP,KAISER PERMANENTE PEDIAT VACCINE STUDY CTR,OAKLAND,CA; KAISER PERMANENTE MED GRP,DIV RES,OAKLAND,CA; VANDERBILT UNIV,MED CTR,DEPT PEDIAT,DIV INFECT DIS,NASHVILLE,TN 37232	Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups; Vanderbilt University								ADDISS DG, 1991, J INFECT DIS, V164, P704, DOI 10.1093/infdis/164.4.704; AOYAMA T, 1992, AM J DIS CHILD, V146, P163, DOI 10.1001/archpedi.1992.02160140029015; BASS JW, 1987, PEDIATR INFECT DIS J, V6, P141, DOI 10.1097/00006454-198702000-00001; Cherry J D, 1984, Curr Probl Pediatr, V14, P1; CHERRY JD, 1995, CLIN INFECT DIS, V20, P1271, DOI 10.1093/clinids/20.5.1271; CROMER BA, 1993, AM J DIS CHILD, V147, P575, DOI 10.1001/archpedi.1993.02160290081031; EDWARDS KM, 1993, JAMA-J AM MED ASSOC, V269, P53, DOI 10.1001/jama.269.1.53; FARIZO KM, 1992, CLIN INFECT DIS, V14, P708, DOI 10.1093/clinids/14.3.708; HERWALDT LA, 1991, ARCH INTERN MED, V151, P1510, DOI 10.1001/archinte.151.8.1510; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; MORTIMER EA, 1990, J INFECT DIS, V161, P473, DOI 10.1093/infdis/161.3.473; MORTIMER EA, 1994, VACCINES, P91; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; PATRIARCA PA, 1988, AM J PUBLIC HEALTH, V78, P833, DOI 10.2105/AJPH.78.7.833; ROBERTSON PW, 1987, MED J AUSTRALIA, V147, P522; SCHMITTGROHE S, 1995, CLIN INFECT DIS, V21, P860, DOI 10.1093/clinids/21.4.860; STEKETEE RW, 1988, J INFECT DIS, V157, P441, DOI 10.1093/infdis/157.3.441; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044; 1993, MMWR-MORBID MORTAL W, V42, P959; 1993, MMWR-MORBID MORTAL W, V42, P952; 1982, MMWR-MORBID MORTAL W, V30, P1; 1995, MMWR-MORBID MORTAL W, V44, P525	25	183	188	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1672	1674		10.1001/jama.275.21.1672	http://dx.doi.org/10.1001/jama.275.21.1672			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637142				2022-12-24	WOS:A1996UN25200031
J	Dernburg, AF; Broman, KW; Fung, JC; Marshall, WF; Philips, J; Agard, DA; Sedat, JW				Dernburg, AF; Broman, KW; Fung, JC; Marshall, WF; Philips, J; Agard, DA; Sedat, JW			Perturbation of nuclear architecture by long-distance chromosome interactions	CELL			English	Article							SALIVARY-GLAND NUCLEI; DROSOPHILA-MELANOGASTER; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; EMBRYOGENESIS; DNA; HETEROCHROMATIN; RECOMBINATION; ORGANIZATION; MICROSCOPY	Position-effect variegation (PEV) describes the stochastic transcriptional silencing of a gene positioned adjacent to heterochromatin. Using FISH, we have tested whether variegated expression of the eye-color gene brown in Drosophila is influenced by its nuclear localization. In embryonic nuclei, a heterochromatic insertion at the brown locus is always spatially isolated from other heterochromatin. However, during larval development this insertion physically associates with other heterochromatic regions on the same chromosome in a stochastic manner. These observations indicate that the brown gene is silenced by specific contact with centromeric heterochromatin. Moreover, they provide direct evidence for long-range chromosome interactions and their impact on three-dimensional nuclear architecture, while providing a cohesive explanation for the phenomenon of PEV.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, DEPT STAT, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, GRAD GRP BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California San Francisco				Dernburg, Abby/0000-0001-8037-1079; Broman, Karl/0000-0002-4914-6671				ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ASHBRUNER M, 1989, DROSOPHILA LAB MANUA; BLACKMAN RK, 1987, CELL, V49, P497, DOI 10.1016/0092-8674(87)90452-1; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CARMENA M, 1993, J CELL SCI, V105, P41; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; CREMER T, 1993, COLD SPRING HARB SYM, V58, P777, DOI 10.1101/SQB.1993.058.01.085; DERNBURG AF, 1996, IN PRESS GENETICS, V143; Doi M., 1986, THEORY POLYM DYNAMIC; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; DREESEN TD, 1991, GENE DEV, V5, P331, DOI 10.1101/gad.5.3.331; DREIBIN RA, 1986, COMPUT GRAPH, V22, P65; Efron Bradley., 1994, INTRO BOOTSTRAP; ENGELS WR, 1994, SCIENCE, V263, P1623, DOI 10.1126/science.8128250; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; FOE VE, 1983, J CELL SCI, V61, P31; FREIFELDER D, 1976, PHYSICAL BIOCH; FUCHS JP, 1983, J CELL SCI, V64, P331; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; HAAF T, 1991, EXP CELL RES, V192, P325, DOI 10.1016/0014-4827(91)90048-Y; HABER JE, 1981, MOL CELL BIOL, V1, P1106, DOI 10.1128/MCB.1.12.1106; HARTL DL, 1994, P NATL ACAD SCI USA, V91, P6824, DOI 10.1073/pnas.91.15.6824; HAWLEY RS, 1992, DEV GENET, V13, P440, DOI 10.1002/dvg.1020130608; HELLGREN D, 1992, MUTAT RES, V284, P37, DOI 10.1016/0027-5107(92)90023-U; HENIKOFF S, 1995, GENETICS, V140, P1007; HENIKOFF S, 1994, GENETICS, V138, P1; HENIKOFF S, 1996, IN PRESS GENOMES; HILLIKER AJ, 1986, GENET RES, V47, P13, DOI 10.1017/S0016672300024459; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HIRAOKA Y, 1990, J CELL BIOL, V111, P2815, DOI 10.1083/jcb.111.6.2815; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; HSIEH T, 1979, J MOL BIOL, V135, P465, DOI 10.1016/0022-2836(79)90447-9; KARPEN GH, 1990, CELL, V63, P97; KAUFFMAN BP, 1963, ACTA BIOL PORT, V7, P225; LICHTEN M, 1989, GENETICS, V123, P261; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOHE AR, 1993, GENETICS, V134, P1149; MAKUNIN IV, 1995, DOKL AKAD NAUK+, V344, P266; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; MARSHALL WF, 1996, IN PRESS MOL CELL BI, V7; MATHOG D, 1984, NATURE, V308, P414, DOI 10.1038/308414a0; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; Merriam J., 1968, DROS INFORM SERV, V43, P64; PALLADINO F, 1994, CURR OPIN CELL BIOL, V6, P373, DOI 10.1016/0955-0674(94)90029-9; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; RILES L, 1993, GENETICS, V134, P81; RINE J, 1980, MOL GEN GENET, V180, P99, DOI 10.1007/BF00267357; SACHS RK, 1995, P NATL ACAD SCI USA, V92, P2710, DOI 10.1073/pnas.92.7.2710; SLATIS HM, 1955, GENETICS, V40, P246; SMITH AV, 1991, DEVELOPMENT, V112, P997; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; TALBERT PB, 1994, GENETICS, V136, P559; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; Titterington DM., 1985, STAT ANAL FINITE MIX; VANSCHAIK NW, 1959, GENETICS, V44, P725; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEILER KS, 1992, GENETICS, V132, P929; Wolff Tanya, 1993, P1277; YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239	62	326	332	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1996	85	5					745	759		10.1016/S0092-8674(00)81240-4	http://dx.doi.org/10.1016/S0092-8674(00)81240-4			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646782	Bronze			2022-12-24	WOS:A1996UP34400014
J	Mochizuki, T; Wu, GQ; Hayashi, T; Xenophontos, SL; Veldhuisen, B; Saris, JJ; Reynolds, DM; Cai, YQ; Gabow, PA; Pierides, A; Kimberling, WJ; Breuning, MH; Deltas, CC; Peters, DJM; Somlo, S				Mochizuki, T; Wu, GQ; Hayashi, T; Xenophontos, SL; Veldhuisen, B; Saris, JJ; Reynolds, DM; Cai, YQ; Gabow, PA; Pierides, A; Kimberling, WJ; Breuning, MH; Deltas, CC; Peters, DJM; Somlo, S			PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein	SCIENCE			English	Article							INTRACRANIAL ANEURYSMS; FUNCTIONAL EXPRESSION; SPANNING PROTEINS; CALCIUM-CHANNEL; HETEROGENEITY; SEQUENCES	A second gene for autosomal dominant polycystic kidney disease was identified by positional cloning. Nonsense mutations in this gene (PKD2) segregated with the disease in three PKD2 families. The predicted 968-amino acid sequence of the PKD2 gene product has six transmembrane spans with intracellular amino- and carboxyl-termini. The PKD2 protein has amino acid similarity with PKD1, the Caenorhabditis elegans homolog of PKD1, and the family of voltage-activated calcium (and sodium) channels, and it contains a potential calcium-binding domain.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED & MOLEC GENET, DIV RENAL, BRONX, NY 10461 USA; CYPRUS INST NEUROL & GENET, AGIOS DHOMENTIOS 2012, NICOSIA, CYPRUS; LEIDEN UNIV, DEPT HUMAN GENET, SYLVIUS LABS, 2333 AL LEIDEN, NETHERLANDS; UNIV COLORADO, HLTH SCI CTR, DEPT INTERNAL MED, DENVER, CO 80220 USA; NICOSIA GEN HOSP, DEPT NEPHROL, NICOSIA 1311, CYPRUS; BOYS TOWN NATL RES HOSP, DEPT PATHOL, OMAHA, NE 68131 USA; BOYS TOWN NATL RES HOSP, DEPT OTOLARYNGOL, OMAHA, NE 68131 USA	Yeshiva University; Albert Einstein College of Medicine; Leiden University; Leiden University - Excl LUMC; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Boys Town National Research Hospital; Boys Town National Research Hospital			Deltas, Constantinos/J-9345-2013; Breuning, Martijn H/E-3429-2010; Deltas, Constantinos/A-4936-2013; Peters, Dorien/AFH-8507-2022	Deltas, Constantinos/0000-0001-5549-9169; Deltas, Constantinos/0000-0001-5549-9169; Peters, Dorien/0000-0001-6974-7143	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002015, R01DK048383] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48383, DK02015] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; *BESTFIT, 1994, PROGR MAN WISC PACK; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; CHAPMAN AB, 1992, NEW ENGL J MED, V327, P916, DOI 10.1056/NEJM199209243271303; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; CONSTANTINOUDELTAS CD, 1995, HUM GENET, V95, P416; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DEALMEIDA S, 1995, HUM GENET, V96, P83, DOI 10.1007/BF00214191; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GABOW PA, 1990, KIDNEY INT, V38, P1177, DOI 10.1038/ki.1990.330; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GULATI J, 1992, J BIOL CHEM, V267, P25073; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HILLE B, 1992, IONIC CHANNELS EXCIT, P250; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; HOSSACK KF, 1988, NEW ENGL J MED, V319, P907, DOI 10.1056/NEJM198810063191404; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; HUSTON J, 1993, J AM SOC NEPHROL, V3, P1871; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KIMBERLING WJ, 1988, NEW ENGL J MED, V319, P913, DOI 10.1056/NEJM198810063191405; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOCHIZUKI T, UNPUB; MOCHIZUKI T, 1994, J AM SOC NEPHROL, V5, pA631; NAKASHIMA H, 1992, FEBS LETT, V303, P141, DOI 10.1016/0014-5793(92)80506-C; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; PETERS DJM, 1995, AM J HUM GENET, V57, pA200; RAVINE D, 1992, LANCET, V340, P1330, DOI 10.1016/0140-6736(92)92503-8; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; RIESS O, 1994, CYTOGENET CELL GENET, V65, P238, DOI 10.1159/000133638; ROMEO G, 1988, LANCET, V2, P8; ROST B, 1995, PROTEIN SCI, V4, P521; SANMILLAN JL, 1995, AM J HUM GENET, V56, P248; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; SOMIO S, 1993, J AM SOC NEPHROL, V4, P1371; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; TORRES VE, 1993, AM J KIDNEY DIS, V22, P513, DOI 10.1016/S0272-6386(12)80922-X; VELDHUISEN B, UNPUB; WARD CJ, 1994, CELL, V77, P881; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347	54	1086	1140	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1996	272	5266					1339	1342		10.1126/science.272.5266.1339	http://dx.doi.org/10.1126/science.272.5266.1339			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650545				2022-12-24	WOS:A1996UN47200047
J	Briggs, AH; Sculpher, MJ; Logan, RPH; Aldous, J; Ramsay, ME; Baron, JH				Briggs, AH; Sculpher, MJ; Logan, RPH; Aldous, J; Ramsay, ME; Baron, JH			Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age	BRITISH MEDICAL JOURNAL			English	Article							DUODENAL-ULCER; DISEASE	Objective-To assess the cost effectiveness of screening for and eradicating Helicobacter pylori in patients under 45 years of age presenting with dyspepsia. Design-A decision analytic model composed of a decision tree to represent the epidemiology of dyspepsia and a Markov process to model the outcomes of treatment. Patients-Patients under the age of 45 years presenting to their general practitioner with (peptic type) dyspepsia. Interventions-Conventional empirical treatment with healing and maintenance doses of cimetidine v eradication treatment solely in patients with confirmed peptic ulcer; and conventional empirical treatment for all dyspeptic patients compared with the use of a serology test to identify patients with H pylori, who then receive endoscopy to investigate the presence of peptic ulcer disease and, when disease is found, are given eradication treatment with a breath test to confirm successful eradication. Main outcome measures-Expected cumulative costs over a period of 10 years. The proportion of time patients spend without a recurrent ulcer. Results-After receiving eradication treatment, patients with confirmed ulcer spend an average of 99% of their time free fi om recurrent ulcer disease compared with 95% after treatment with cimetidine. Eradication treatment costs less than that with cimetidine. When the initial cost of identifying appropriate patients to receive eradication treatment is added to the analysis, however, these cost savings take almost eight years to accrue. Conclusions-Enthusiasm for introducing testing for and eradication of H pylori for dyspeptic patients in general practice should be tempered by an awareness that cost savings may take many years to realise.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT GASTROENTEROL,NOTTINGHAM NG7 2UH,ENGLAND; ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,DEPT GASTROENTEROL,LONDON W2 1NY,ENGLAND	University of Nottingham; Imperial College London; Imperial College London	Briggs, AH (corresponding author), BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND.		Briggs, Andrew/ABA-9009-2020	Briggs, Andrew/0000-0002-0777-1997; Sculpher, Mark/0000-0003-3746-9913				ALDOUS J, 1994, PILOT STUDY EFFECTS; ATHERTON JC, 1994, GUT, V35, P723, DOI 10.1136/gut.35.6.723; AXON ATR, 1995, BMJ-BRIT MED J, V310, P853, DOI 10.1136/bmj.310.6983.853; BARDHAN KD, 1984, GUT, V25, P711, DOI 10.1136/gut.25.7.711; BECK JR, 1983, MED DECIS MAKING, V3, P411; BELL GD, 1993, Q J MED, V86, P375; BELL GD, 1993, BR J MED EC, V6, P45; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; *BRIT MED ASS ROYA, 1995, BRIT NAT FORM; CAMPBELL LM, 1994, BR J MED EC, V7, P147; *CHART I PUBL FIN, 1990, HLTH DAT HLTH SERV T, V2; CLAUSEN MR, 1992, SCAND J GASTROENTERO, V27, P421, DOI 10.3109/00365529209000099; Duggan A. E., 1995, Gut, V37, pA58; EDENHOLM M, 1985, SCAND J GASTROENTERO, V20, P163, DOI 10.3109/00365528509103953; FORRESTER E, 1994, GASTROENTEROL PR FEB, P6; GRIBBLE EJ, 1994, GASTROENTEROLOGY INT, V7, P90; HASTINGS L, 1995, GUT, V37, pA6; *HM TREAS, 1991, EC APPR CENTR GOV TE; KATZ KD, 1992, AM J SURG, V163, P349, DOI 10.1016/0002-9610(92)90021-I; KEMMER TP, 1994, EUR J GASTROEN HEPAT, V6, P571, DOI 10.1097/00042737-199407000-00002; LABENZ J, 1994, AM J GASTROENTEROL, V89, P1785; LOGAN RPH, 1992, HELICOBACTER PYLORI, P88; MOORE RA, 1995, HELICOBACTER PYLORI; NETTEN A, 1994, UNIT COSTS COMMUNITY; NOVELL, 1995, QUATTRO PRO V6 0; PATEL P, 1994, LANCET, V344, P511, DOI 10.1016/S0140-6736(94)91899-6; PYM B, 1990, GASTROENTEROLOGY, V99, P27, DOI 10.1016/0016-5085(90)91225-U; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; SONNENBERG A, 1995, EUR J GASTROEN HEPAT, V7, P655; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; *TREEW SOFTW, 1995, DATA V2 6; TYTGAT GNJ, 1994, ALIMENT PHARM THERAP, V8, P359; VANZANTEN SJOV, 1994, CAN MED ASSOC J, V150, P189; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; 1994, JAMA-J AM MED ASSOC, V272, P65; 1991, GUT, V32, P95	36	127	127	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1321	1325		10.1136/bmj.312.7042.1321	http://dx.doi.org/10.1136/bmj.312.7042.1321			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646042	Green Published			2022-12-24	WOS:A1996UN47600016
J	Skinner, R; Cole, M; Pearson, ADJ; Coulthard, MG; Craft, AW				Skinner, R; Cole, M; Pearson, ADJ; Coulthard, MG; Craft, AW			Specificity of pH and osmolality of early morning urine sample in assessing distal renal tubular function in children: Results in healthy children	BRITISH MEDICAL JOURNAL			English	Article											Skinner, R (corresponding author), UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,SIR JAMES SPENCE INST CHILD HLTH,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							EDELMANN CM, 1967, AM J DIS CHILD, V114, P639, DOI 10.1001/archpedi.1967.02090270095009; RODRIGUEZSORIANO J, 1990, PEDIATR NEPHROL, V4, P268, DOI 10.1007/BF00857675; Silverman BW, 1986, DENSITY ESTIMATION S; SWIFT PGF, 1991, CURRENT PAEDIAT, V1, P177	4	10	10	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1337	1338		10.1136/bmj.312.7042.1337	http://dx.doi.org/10.1136/bmj.312.7042.1337			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646047	Green Published			2022-12-24	WOS:A1996UN47600022
J	Iijima, T; Witter, MP; Ichikawa, M; Tominaga, T; Kajiwara, R; Matsumoto, G				Iijima, T; Witter, MP; Ichikawa, M; Tominaga, T; Kajiwara, R; Matsumoto, G			Entorhinal-hippocampal interactions revealed by real-time imaging	SCIENCE			English	Article							FREQUENCY-DEPENDENT DEPRESSION; SUBICULAR COMPLEX; MEMORY SYSTEM; RAT; CONNECTIONS; CORTEX; INVITRO; ORGANIZATION; INHIBITION; IPSPS	The entorhinal cortex provides the major cortical input to the hippocampus, and both structures have been implicated in memory processes. The dynamics of neuronal circuits in the entorhinal-hippocampal system were studied in slices by optical imaging with high spatial and temporal resolution. Reverberation of neural activity was detected in the entorhinal cortex and was more prominent when the inhibition due to gamma-aminobutyric acid was slightly suppressed. Neural activity was transferred in a frequency-dependent way from the entorhinal cortex to the hippocampus. The entorhinal neuronal circuit could contribute to memory processes by holding information and selectively gating the entry of information into the hippocampus.	VRIJE UNIV AMSTERDAM,GRAD SCH NEUROSCI,NEUROSCI RES INST,DEPT ANAT & EMBRYOL,1081 BT AMSTERDAM,NETHERLANDS; TOHOKU UNIV,SENDAI,MIYAGI 980,JAPAN	Vrije Universiteit Amsterdam; Tohoku University	Iijima, T (corresponding author), ELECTROTECH LAB,MOL & CELLULAR NEUROSCI SECT,1-1-4 UMEZONO,TSUKUBA,IBARAKI 305,JAPAN.		Tominaga, Takashi/C-5332-2012	Tominaga, Takashi/0000-0003-1078-7989				BENARDO LS, 1993, BRAIN RES, V607, P81, DOI 10.1016/0006-8993(93)91491-A; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTON CL, 1992, HIPPOCAMPUS, V2, P99, DOI 10.1002/hipo.450020203; CHROBAK JJ, 1994, J NEUROSCI, V14, P6160; DEADWYLER SA, 1975, EXP NEUROL, V49, P35, DOI 10.1016/0014-4886(75)90194-6; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; Edelman G.M., 1989, REMEMBERED PRESENT B; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; FINCH DM, 1988, J NEUROSCI, V8, P2213; FINCH DM, 1986, BRAIN RES, V397, P205, DOI 10.1016/0006-8993(86)90621-9; FRANESIC I, 1994, P NATL ACAD SCI USA, V91, P13014; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; HEBB DO, 1949, ORG BEHAVIOR; HEINEMANN U, 1992, DENTATE GYRUS ITS S, V7, P273; HUGUENARD JR, 1986, J NEUROPHYSIOL, V56, P1; ICHIKAWA M, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P638; IIJIMA T, 1992, NEUROSCIENCE, V51, P211, DOI 10.1016/0306-4522(92)90486-L; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; JONES RSG, 1993, TRENDS NEUROSCI, V16, P58, DOI 10.1016/0166-2236(93)90018-H; JONES RSG, 1995, HIPPOCAMPUS, V5, P125, DOI 10.1002/hipo.450050207; LOTHMAN EW, 1991, PROG NEUROBIOL, V37, P1, DOI 10.1016/0301-0082(91)90011-O; MALINOW R, 1994, SCIENCE, V266, P1195, DOI 10.1126/science.7973700; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557, DOI 10.1152/jn.1985.53.2.557; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; TSUKAHARA N, 1972, BRAIN RES, V40, P67, DOI 10.1016/0006-8993(72)90108-4; VANHOESEN GW, 1982, TRENDS NEUROSCI, V5, P345, DOI 10.1016/0166-2236(82)90201-6; WITTER MP, 1993, HIPPOCAMPUS, V3, P33; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155	34	183	184	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1996	272	5265					1176	1179		10.1126/science.272.5265.1176	http://dx.doi.org/10.1126/science.272.5265.1176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638163				2022-12-24	WOS:A1996UM88900052
J	Lakowski, B; Hekimi, S				Lakowski, B; Hekimi, S			Determination of life-span in Caenorhabditis elegans by four clock genes	SCIENCE			English	Article							OXIDATIVE STRESS	The nematode worm Caenorhabditis elegans is a model system for the study of the genetic basis of aging. Maternal-effect mutations in four genes-clk-1, clk-2, clk-3, and gro-1-interact genetically to determine both the duration of development and life-span. Analysis of the phenotypes of these mutants suggests the existence of a general physiological clock in the worm. Mutations in certain genes involved in dauer formation (an alternative larval stage induced by adverse conditions in which development is arrested) can also extend life-span, but the life extension of Clock mutants appears to be independent of these genes. The daf-2(e1370) clk-1(e2519) worms, which carry life-span-extending mutations from two different pathways, live nearly five times as long as wild-type worms.	MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA	McGill University								BJORKSTEN J, 1968, J AM GERIATR SOC, V16, P408, DOI 10.1111/j.1532-5415.1968.tb02821.x; Comfort A., 1979, BIOL SENESCENCE; Curtis H.J., 1966, BIOL MECH AGING; DORMAN JB, 1995, GENETICS, V141, P1399; FINCH DL, 1990, LONGEVITY SENESCENCE; FLEMING JE, 1992, MUTAT RES, V275, P267, DOI 10.1016/0921-8734(92)90031-J; FRIEDMAN DB, 1988, GENETICS, V118, P75; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HEKIMI S, 1995, GENETICS, V141, P1351; ISHII N, 1994, J GERONTOL, V49, pB117, DOI 10.1093/geronj/49.3.B117; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; LARSEN PK, COMMUNICATION; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; MEDVEDEV ZA, 1961, SOWJETWISS NATURWISS, V12, P1273; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Pearl R., 1928, RATE LIVING; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; SACHER GA, 1966, PERSPECTIVES EXPT GE, pCH26; SZILARD L, 1959, P NATL ACAD SCI USA, V45, P30, DOI 10.1073/pnas.45.1.30; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; WONG A, 1995, GENETICS, V139, P1247	25	401	425	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1010	1013		10.1126/science.272.5264.1010	http://dx.doi.org/10.1126/science.272.5264.1010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638122				2022-12-24	WOS:A1996UL61900045
J	Paris, N; Stanley, CM; Jones, RL; Rogers, JC				Paris, N; Stanley, CM; Jones, RL; Rogers, JC			Plant cells contain two functionally distinct vacuolar compartments	CELL			English	Article							TONOPLAST INTRINSIC PROTEIN; GRAIN ASPARTIC PROTEINASE; DEVELOPING PEA COTYLEDONS; THIOL PROTEASE; ARABIDOPSIS-THALIANA; STRUCTURAL ASPECTS; BARLEY LECTIN; ALEURAIN; ACCUMULATION; PRECURSOR	The plant cell vacuole has multiple functions, including storage of proteins and maintenance of an acidic pH where proteases will have maximal activity. It has been assumed that these diverse functions occur in the same compartment. Here, we demonstrate that antibodies to two different tonoplast intrinsic proteins, alpha-TIP and TIP-Ma27, label vacuole membranes of two different compartments within the same cell. These compartments are functionally distinct, because barley lectin, a protein stored in root tips, is exclusively contained within the alpha-TIP compartment, while aleurain, a protease that serves as a marker for an acidified vacuolar environment, is exclusively contained within the TIP-Ma27 compartment. As cells develop large vacuoles, the two compartments merge; this may represent a process by which storage products in the alpha-TIP compartment are exposed to the acidic lytic TIP-Ma27 compartment for degradation.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211; UNIV MISSOURI,MOL CYTOL CORE FACIL,COLUMBIA,MO 65211; UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of California System; University of California Berkeley				PARIS, Nadine/0000-0001-5818-9318	NIGMS NIH HHS [GM52427] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052427] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bethke PC, 1996, PLANT PHYSIOL, V110, P521, DOI 10.1104/pp.110.2.521; BOLLER T, 1986, ANNU REV PLANT PHYS, V37, P137, DOI 10.1146/annurev.pp.37.060186.001033; CHRISPEELS MJ, 1992, CELL, V68, P613, DOI 10.1016/0092-8674(92)90134-X; CHRISPEELS MJ, 1991, PLANT MOL BIOL, V42, P21; CRAIG S, 1979, AUST J PLANT PHYSIOL, V6, P81, DOI 10.1071/PP9790081; CRAIG S, 1980, AUST J PLANT PHYSIOL, V7, P329, DOI 10.1071/PP9800329; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; Harlow E, 1988, ANTIBODIES LAB MANUA; HERMAN EM, 1994, PLANT PHYSIOL, V106, P1313, DOI 10.1104/pp.106.4.1313; HERMAN EM, 1994, ADV STRUCTURAL BIOL, P243; HOFTE H, 1992, PLANT PHYSIOL, V99, P561, DOI 10.1104/pp.99.2.561; HOH B, 1995, J CELL SCI, V108, P299; HOLWERDA BC, 1993, J EXP BOT, V44, P321; HOLWERDA BC, 1990, PLANT CELL, V2, P1091, DOI 10.1105/tpc.2.11.1091; HOLWERDA BC, 1992, PLANT CELL, V4, P307, DOI 10.1105/tpc.4.3.307; HOLWERDA BC, 1992, PLANT PHYSIOL, V99, P848, DOI 10.1104/pp.99.3.848; JOHNSON KD, 1989, PLANT PHYSIOL, V91, P1006, DOI 10.1104/pp.91.3.1006; KERVINEN J, 1993, PHYTOCHEMISTRY, V32, P799, DOI 10.1016/0031-9422(93)85208-9; KIRSCH T, 1994, P NATL ACAD SCI USA, V91, P3403, DOI 10.1073/pnas.91.8.3403; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LERNER DR, 1989, PLANT PHYSIOL, V91, P124, DOI 10.1104/pp.91.1.124; LUDEVID D, 1992, PLANT PHYSIOL, V100, P1633, DOI 10.1104/pp.100.4.1633; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MARTYMAZARS D, 1995, EUR J CELL BIOL, V66, P106; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; NAKAMURA K, 1993, J EXP BOT, V44, P331; NAKAMURA K, 1993, PLANT PHYSIOL, V101, P1, DOI 10.1104/pp.101.1.1; Okita TW, 1996, ANNU REV PLANT PHYS, V47, P327, DOI 10.1146/annurev.arplant.47.1.327; ROST TL, 1988, AM J BOT, V75, P1571, DOI 10.2307/2444707; RUNEBERGROOS P, 1994, PLANT PHYSIOL, V105, P321, DOI 10.1104/pp.105.1.321; RUNEBERGROOS P, 1991, EUR J BIOCHEM, V202, P1021, DOI 10.1111/j.1432-1033.1991.tb16465.x; SCHROEDER MR, 1993, PLANT PHYSIOL, V101, P451, DOI 10.1104/pp.101.2.451; STAAB JF, 1994, J BIOL CHEM, V269, P23736; TORMAKANGAS K, 1994, PLANTA, V195, P116, DOI 10.1007/BF00206299; WICK SM, 1985, PROTOPLASMA, V126, P198, DOI 10.1007/BF01281795; WINK M, 1993, J EXP BOT, V44, P231; ZHU Y, 1994, J BIOL CHEM, V269, P3846	38	335	346	0	39	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					563	572		10.1016/S0092-8674(00)81256-8	http://dx.doi.org/10.1016/S0092-8674(00)81256-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653791	Bronze			2022-12-24	WOS:A1996UM41500013
J	Giffin, W; Torrance, H; Rodda, DJ; Prefontaine, GG; Pope, L; Hache, RJG				Giffin, W; Torrance, H; Rodda, DJ; Prefontaine, GG; Pope, L; Hache, RJG			Sequence-specific DNA binding by Ku autoantigen and its effects on transcription	NATURE			English	Article							MAMMARY-TUMOR VIRUS; ACTIVATED PROTEIN-KINASE; GLUCOCORTICOID RECEPTOR; REGULATORY ELEMENT; REGION; ANTIGEN; DOMAIN	DNA-DEPENDENT protein kinase (DNA-PK) has been implicated in several nuclear processes including transcription(1-3), DNA replication(4,5), double-stranded DNA break repair, and V(D)J recom bination(6-10). Linkage of kinase and substrate on DNA in cis is required for efficient phosphorylation(11). Recruitment of DNA-PK to DNA is by Ku autoantigen, a DNA-end-binding protein required for DNA-PK catalytic activity(11). Although Ku is known to translocate along naked DNA(12), how DNA-end binding by Ku might lead to DNA-PK-mediated phosphorylation of sequence-specific DNA-binding proteins in vivo has not been obvious. Here we report the identification of Ku as a transcription factor that recruits DNA-PK directly to specific DNA sequences. NRE1 (negative regulatory element 1) is a DNA sequence element (-394/ - 381) in the long terminal repeat of mouse mammary tumour virus (MMTV) that is important for repressing inappropriate viral expression(13-16). We show that direct binding of Ku/DNA-PK to NRE1 represses glucocorticoid-induced MMTV transcription.	UNIV OTTAWA,OTTAWA CIVIC HOSP,LOEB INST MED RES,DEPT MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,OTTAWA CIVIC HOSP,LOEB INST MED RES,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute								Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; FALZON M, 1993, J BIOL CHEM, V268, P10546; FINNIE N, 1993, BIOCHEM SOC T, V21, P930, DOI 10.1042/bst0210930; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEE JW, 1991, J BIOL CHEM, V266, P24101; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MAY G, 1991, J BIOL CHEM, V266, P3052; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; YANEVA M, 1989, J BIOL CHEM, V264, P13407	28	187	188	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					265	268		10.1038/380265a0	http://dx.doi.org/10.1038/380265a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637578				2022-12-24	WOS:A1996UB11700057
J	HunterEnsor, M; Ousley, A; Sehgal, A				HunterEnsor, M; Ousley, A; Sehgal, A			Regulation of the Drosophila protein timeless suggests a mechanism for resetting the circadian clock by light	CELL			English	Article							PERIOD GENE-PRODUCT; VISUAL-SYSTEM; MELANOGASTER; EXPRESSION	Circadian behavioral rhythms in Drosophila depend on the appropriate regulation of at least two genes, period (per) and timeless (tim). Previous studies demonstrated that levels of PER and TIM RNA cycle with the same phase and that the PER and TIM proteins interact directly. Here we show the cyclic expression of TIM protein in adult heads and report that it lags behind peak levels of TIM RNA by several hours. We also show that nuclear expression of TIM depends upon the expression of PER protein. Finally, we report that the expression of TIM, but not PER, is rapidly reduced by light, suggesting that TIM mediates light-induced resetting of the circadian clock. Since both PER and TIM RNA are unaffected by light treatment, the effects of light on TIM appear to be posttranscriptional.	UNIV PENN,SCH MED,CTR SLEEP & RESP NEUROBIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine	HunterEnsor, M (corresponding author), UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104, USA.							ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; ESKIN A, 1979, FED PROC, V38, P2570; EWER J, 1992, J NEUROSCI, V12, P3321; FELDMAN J F, 1973, Genetics, V75, P605; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; NASSEL DR, 1993, J COMP NEUROL, V331, P183, DOI 10.1002/cne.903310204; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; PITTENDRIGH CS, 1976, MOL BASIS CIRCADIAN, P11; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; REPPERT SM, 1994, NEURON, V13, P1167, DOI 10.1016/0896-6273(94)90054-X; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Worden, 1974, NEUROSCIENCES 3RD ST, P437; ZATZ M, 1992, DISCUSS NEUROSCI, V8, P67; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	40	324	333	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					677	685		10.1016/S0092-8674(00)81046-6	http://dx.doi.org/10.1016/S0092-8674(00)81046-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625406	hybrid			2022-12-24	WOS:A1996TZ99000006
J	Kallberg, E; Jainandunsing, S; Gray, D; Leanderson, T				Kallberg, E; Jainandunsing, S; Gray, D; Leanderson, T			Somatic mutation of immunoglobulin V genes in vitro	SCIENCE			English	Article							GERMINAL-CENTERS; IMMUNE-RESPONSE; B-CELLS; T-CELLS; MATURATION; GENERATION; ANTIGEN; MEMORY	The molecular mechanism behind affinity maturation is the introduction of point mutations in immunoglobulin (Ig) V genes, followed by the selective proliferation of B cells expressing mutants with increased affinity for antigen. An in vitro culture system was developed in which somatic hypermutation of Ig V genes was sustained in primed B cells. Cognate T cell help and cross-linking of the surface Ig were required, whereas the addition of lipopolysaccharide or a CD40 ligand to drive proliferation was insufficient. This system should facilitate understanding of the molecular and cellular mechanisms that regulate somatic mutation and B cell selection.	LUND UNIV,IMMUNOL UNIT,S-22362 LUND,SWEDEN; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0NN,ENGLAND	Lund University; Imperial College London			Gray, David/L-8295-2013	Gray, David/0000-0003-3785-4934	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; DECKER DJ, 1995, IMMUNITY, V2, P195, DOI 10.1016/S1074-7613(95)80092-1; FULLER KA, 1993, J IMMUNOL, V151, P4505; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KAARTINEN M, 1983, NATURE, V304, P320, DOI 10.1038/304320a0; Kabat EA, 1983, SEQUENCES PROTEINS I; KALLBERG E, 1995, EUR J IMMUNOL, V25, P2349, DOI 10.1002/eji.1830250834; KALLBERG E, UNPUB; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KAWABE T, 1994, IMMUNITY, V1, P423; MANSER T, 1987, J IMMUNOL, V139, P234; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; RAJASEKAR R, 1988, SCAND J IMMUNOL, V27, P653, DOI 10.1111/j.1365-3083.1988.tb02398.x; RAZANAJAONA D, 1995, 9TH INT C IMM SAN FR; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; WOHLLEBEN G, IN PRESS INT IMMUNOL; YELTON DE, 1981, HYBRIDOMA, V1, P5, DOI 10.1089/hyb.1.1981.1.5	25	56	58	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1285	1289		10.1126/science.271.5253.1285	http://dx.doi.org/10.1126/science.271.5253.1285			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638111				2022-12-24	WOS:A1996TX69500038
J	Martin, A; Wiggs, CL; Ungerleider, LG; Haxby, JV				Martin, A; Wiggs, CL; Ungerleider, LG; Haxby, JV			Neural correlates of category-specific knowledge	NATURE			English	Article							MENTAL-IMAGERY; VISUAL-CORTEX; RECOGNITION; IMPAIRMENT; PICTURES	AN intriguing and puzzling consequence of damage to the human brain is selective loss of knowledge about a specific category of objects, One patient may be unable to identify or name living things(1-3), whereas another may have selective difficulty identifying man-made objects(4-6). To investigate the neural correlates of this remarkable dissociation, we used positron emission tomography to map regions of the normal brain that are associated with naming animals and tools. We found that naming pictures of animals and tools was associated with bilateral activation of the ventral temporal lobes and Broca's area, In addition, naming animals selectively activated the left medial occipital lobe-a region involved in the earliest stages of visual processing. In contrast, naming tools selectively activated a left premotor area also activated by imagined hand movements(7), and an area in the left middle temporal gyrus also activated by the generation of action words(8-10). Thus the brain regions active during object identification are dependent, in part, on the intrinsic properties of the object presented.			Martin, A (corresponding author), NIMH, PSYCHOL & PSYCHOPATHOL LAB, BLDG 10, ROOM 3D-41, BETHESDA, MD 20892 USA.		martin, alex/B-6176-2009					CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DECETY J, 1994, NATURE, V371, P600, DOI 10.1038/371600a0; FARAH MJ, 1989, TRENDS NEUROSCI, V12, P395, DOI 10.1016/0166-2236(89)90079-9; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; HUMPHREYS GW, 1988, COGNITIVE NEUROPSYCH, V5, P67, DOI 10.1080/02643298808252927; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; KROLL JF, 1984, J VERB LEARN VERB BE, V23, P39, DOI 10.1016/S0022-5371(84)90499-7; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SACCHETT C, 1992, COGNITIVE NEUROPSYCH, V9, P73, DOI 10.1080/02643299208252053; SAFFRAN EM, 1994, ATTENTION PERFORM, V15, P507; SHERIDAN J, 1993, COGNITIVE NEUROPSYCH, V10, P143, DOI 10.1080/02643299308253459; SILVERI MC, 1988, COGNITIVE NEUROPSYCH, V5, P677, DOI 10.1080/02643298808253278; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Talairach J., 1988, COPLANAR STEREOTAXIC; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WARRINGTON EK, 1987, BRAIN, V110, P1273, DOI 10.1093/brain/110.5.1273; WARRINGTON EK, 1983, BRAIN, V106, P859, DOI 10.1093/brain/106.4.859; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; ZEKI S, 1991, J NEUROSCI, V11, P641	26	1192	1213	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					649	652		10.1038/379649a0	http://dx.doi.org/10.1038/379649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TV688	8628399	Green Submitted			2022-12-24	WOS:A1996TV68800055
J	Grodstein, F; Stampfer, MJ; Manson, JE; Colditz, GA; Willett, WC; Rosner, B; Speizer, FE; Hennekens, CH				Grodstein, F; Stampfer, MJ; Manson, JE; Colditz, GA; Willett, WC; Rosner, B; Speizer, FE; Hennekens, CH			Postmenopausal estrogen and progestin use and the risk of cardiovascular disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; MYOCARDIAL-INFARCTION; CORONARY-ARTERIES; FOLLOW-UP; WOMEN; COHORT; STROKE; REPRODUCIBILITY; LIPOPROTEINS; ACCUMULATION	Background Estrogen therapy in postmenopausal women has been associated with a decreased risk of heart disease. There is little information, however, about the effect of combined estrogen and progestin therapy on the risk of cardiovascular disease. Methods We examined the relation between cardiovascular disease and postmenopausal hormone therapy during up to 16 years of follow-up in 59,337 women from the Nurses' Health Study, who were 30 to 55 years of age at base line. Information on hormone use was ascertained with biennial questionnaires. From 1976 to 1992, we documented 770 cases of myocardial infarction or death from coronary disease in this group and 572 strokes. Proportional-hazards models were used to calculate relative risks and 95 percent confidence intervals, adjusted for confounding variables. Results We observed a marked decrease in the risk of major coronary heart disease among women who took estrogen with progestin, as compared with the risk among women who did not use hormones (multivariate adjusted relative risk, 0.39; 95 percent confidence interval, 0.19 to 0.78) or estrogen alone (relative risk, 0.60; 95 percent confidence interval, 0.43 to 0.83). However, there was no significant association between stroke and use of combined hormones (multivariate adjusted relative risk, 1.09; 95 percent confidence interval, 0.66 to 1.80) or estrogen alone (relative risk, 1.27; 95 percent confidence interval, 0.95 to 1.69). Conclusions The addition of progestin does not appear to attenuate the cardioprotective effects of postmenopausal estrogen therapy. (C) 1996, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 30594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1986, MENOPAUSE PHYSL PHAR, P187; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COLLINS P, 1993, LANCET, V341, P1264, DOI 10.1016/0140-6736(93)91158-I; COX DR, 1972, J R STAT SOC B, V34, P187; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GANGAR KF, 1991, LANCET, V338, P839; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; HAARBO J, 1991, J CLIN INVEST, V87, P1274, DOI 10.1172/JCI115129; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; MILLER VT, 1991, OBSTET GYNECOL, V77, P235, DOI 10.1097/00006250-199102000-00014; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PINES A, 1991, AM J OBSTET GYNECOL, V164, P806, DOI 10.1016/0002-9378(91)90520-2; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; Rothman KJ, 1979, NIH PUBLICATION, V79-1649, P31; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; Sarrel Philip M., 1994, P251; SARREL PM, 1992, AM J OBSTET GYNECOL, V167, P467, DOI 10.1016/S0002-9378(11)91431-8; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; WAGNER JD, 1991, J CLIN INVEST, V88, P1995, DOI 10.1172/JCI115526; Walker AE, 1981, STROKE S1, V12, P13; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; World Health Organization, 1971, IHD REG REP 5 WORK G; 1995, JAMA-J AM MED ASSOC, V273, P199	35	1090	1107	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					453	461		10.1056/NEJM199608153350701	http://dx.doi.org/10.1056/NEJM199608153350701			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672166				2022-12-24	WOS:A1996VB84900001
J	Patino, MM; Liu, JJ; Glover, JR; Lindquist, S				Patino, MM; Liu, JJ; Glover, JR; Lindquist, S			Support for the prion hypothesis for inheritance of a phenotypic trait in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SUP35 GENE; PROTEIN HSP104; DISEASES; BIOLOGY; PSI(+)	A cytoplasmically inherited genetic element in yeast, [PSI+], was confirmed to be a prionlike aggregate of the cellular protein Sup35 by differential centrifugation analysis and microscopic localization of a Sup35-green fluorescent protein fusion. Aggregation depended on the intracellular concentration and functional state of the chaperone protein Hsp104 in the same manner as did [PSI+] inheritance. The amino-terminal and carboxyterminal domains of Sup35 contributed to the unusual behavior of [PSI+]. [PSI+] altered the conformational slate of newly synthesized prion proteins, inducing them to aggregate as well, thus fulfilling a major tenet of the prion hypothesis.	UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COUGHEY B, 1995, CURR BIOL, V2, P807; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DOEL SM, 1994, GENETICS, V137, P659; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; LANSBURY PT, 1995, CHEM BIOL, V2, P1, DOI 10.1016/1074-5521(95)90074-8; Lindquist S, 1995, COLD SPRING HARB SYM, V60, P451, DOI 10.1101/SQB.1995.060.01.050; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PATINO M, UNPUB; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHIRMER E, UNPUB; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; TUITE M, IN PRESS TRENDS GENE; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; WARD WW, 1980, PHOTOCHEM PHOTOBIOL, V31, P611, DOI 10.1111/j.1751-1097.1980.tb03755.x; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	26	558	567	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1996	273	5275					622	626		10.1126/science.273.5275.622	http://dx.doi.org/10.1126/science.273.5275.622			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662547				2022-12-24	WOS:A1996VA24900039
J	Guarnieri, F; Fliss, M; Bancroft, C				Guarnieri, F; Fliss, M; Bancroft, C			Making DNA add	SCIENCE			English	Article								Recent studies have demonstrated the feasibility of using DNA-based experiments to compute solutions to combinatorial problems. However, a prerequisite for designing a computer useful in a wide range of applications is the ability to perform mathematical calculations. The development of a DNA-based algorithm for addition is presented. The DNA representation of two nonnegative binary numbers is presented in a form permitting a chain of primer extension reactions to carry out the addition operation. To demonstrate the feasibility of this algorithm, a simple example was executed biochemically.	MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai								ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; GUARNIERI F, 1996, IN PRESS P 2 ANN M D; LIPTON RJ, 1995, SCIENCE, V268, P542, DOI 10.1126/science.7725098; REIF JH, 1995, 7 ANN ACM S PAR ALG, P213; Sambrook J., 1989, MOL CLONING; YAN GZ, 1991, MOL ENDOCRINOL, V5, P535, DOI 10.1210/mend-5-4-535	7	125	157	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					220	223		10.1126/science.273.5272.220	http://dx.doi.org/10.1126/science.273.5272.220			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8662501				2022-12-24	WOS:A1996UW78700035
J	Sanchez, MP; SilosSantiago, I; Frisen, J; He, B; Lira, SA; Barbacid, M				Sanchez, MP; SilosSantiago, I; Frisen, J; He, B; Lira, SA; Barbacid, M			Renal agenesis and the absence of enteric neurons in mice lacking GDNF	NATURE			English	Article							LETHALITY	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF)(1) is a potent survival factor for dopaminergic neurons and motor neurons in culture(1,2). It also protects these neurons from degeneration in vitro(3-9), and improves symptoms like Parkinson's disease induced pharmacologically in rodents(10) and monkeys(11), Thus GDNF might have beneficial effects in the treatment of Parkinson's disease and amyotrophic lateral sclerosis, To examine the physiological role of GDNF in the development of the mammalian nervous system, we have generated mice defective in GDNF expression by using homologous recombination in embryonic stem cells to delete each of its two coding exons(1), GDNF-null mice, regardless of their targeted mutation, display complete renal agenesis owing to lack of induction of the ureteric bud, an early step in kidney development, These mice also have no enteric neurons, which probably explains the observed pyloric stenosis and dilation of their duodenum, However, ablation of the GDNF gene does not affect the differentiation and survival of dopaminergic neurons, at least during embryonic development.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC ONCOL,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,TRANSGEN UNIT,PRINCETON,NJ 08543	Bristol-Myers Squibb; Bristol-Myers Squibb			Sanchez, Marina P/A-2453-2011	Sanchez, Marina P/0000-0003-1905-3842				Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Blaugrund E, 1996, DEVELOPMENT, V122, P309; BUTCHER LL, 1984, HDB CHEM NEUROANATOM, V2; Durbec PL, 1996, DEVELOPMENT, V122, P349; GASH MD, 1966, NATURE, V380, P252; GOSSLER A, 1995, GENE TARGETING PRACT, P181; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PAPAIOANNOU V, 1995, GENE TARGETING PRACT, P107; Saxen L., 1987, ORGANOGENESIS KIDNEY, V19; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Torres M, 1995, DEVELOPMENT, V121, P4057; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WURST W, 1995, GENE TARGETING PRACT, P33; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; ZURN AD, 1994, NEUROREPORT, V6, P113, DOI 10.1097/00001756-199412300-00030	26	986	1011	0	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1996	382	6586					70	73		10.1038/382070a0	http://dx.doi.org/10.1038/382070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV473	8657306				2022-12-24	WOS:A1996UV47300055
J	White, RJ; Trouche, D; Martin, K; Jackson, SP; Kouzarides, T				White, RJ; Trouche, D; Martin, K; Jackson, SP; Kouzarides, T			Repression of RNA polymerase III transcription by the retinoblastoma protein	NATURE			English	Article							TRANSFORMED-CELLS; MESSENGER-RNA; GENE-PRODUCT; IN-VITRO; ACTIVATION; MOUSE; TBP; IDENTIFICATION; PROMOTERS; INVITRO	TRANSCRIPTION by RNA polymerase (pol) III is under cell-cycle control, being higher in S and G2 than in G0 and early G1 phases(1-4), Many transformed cell types have elevated pol III activity(4-9), presumably to sustain sufficient protein synthesis for unrestrained growth, The retinoblastoma tumour-suppressor protein (Rb) restricts cellular proliferation, and is often found mutated in transformed cells(10,11). Here we demonstrate that Rb can repress the level of transcription from pol III templates both in vitro and in vivo. Analysis of Rb-deficient SAOS2 cells and primary fibroblasts from Rb--/- mice demonstrates elevated levels of pol III activity in the abscence of functional Rb protein, Rb-induced repression of pol III activity is alleviated by mutations in the Rb pocket domain that occur naturally in tumours, and by viral transforming proteins that hind and inactivate Rb, These results implicate repression of pol III transcription as a mechanism for Rb-induced growth arrest, and suggest that restraining protein biosynthesis may be important in the prevention of tumour development.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge; University of Cambridge			Jackson, Stephen Philip/R-4548-2019; Trouche, Didier/B-2854-2008; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; Trouche, Didier/0000-0003-1398-6481; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAREY MF, 1986, MOL CELL BIOL, V6, P3068, DOI 10.1128/MCB.6.9.3068; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON LF, 1974, CELL, V1, P95, DOI 10.1016/0092-8674(74)90068-3; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KOUZARIDES T, 1995, CANC BIOL, V6, P91; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; MAJELLO B, 1985, NATURE, V314, P457, DOI 10.1038/314457a0; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MAUCK JC, 1974, CELL, V3, P171, DOI 10.1016/0092-8674(74)90122-6; PATEL G, 1990, NUCLEIC ACIDS RES, V18, P2909, DOI 10.1093/nar/18.10.2909; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; SINGH K, 1985, NATURE, V314, P553, DOI 10.1038/314553a0; TROUCHE D, 1993, BIOCHEM BIOPH RES CO, V196, P611, DOI 10.1006/bbrc.1993.2293; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WHITE RJ, 1994, RNA POLYMERASE 3 TRA	27	181	181	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1996	382	6586					88	90		10.1038/382088a0	http://dx.doi.org/10.1038/382088a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV473	8657311				2022-12-24	WOS:A1996UV47300060
J	Anderson, RM; Schwartlander, B; McCutchan, F; Hu, D				Anderson, RM; Schwartlander, B; McCutchan, F; Hu, D			Implications of genetic variability in HIV for epidemiology and public health	LANCET			English	Editorial Material									ROBERT KOCH INST,W-1000 BERLIN,GERMANY; HENRY JACKSON FDN,BETHESDA,MD; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	Robert Koch Institute; Centers for Disease Control & Prevention - USA	Anderson, RM (corresponding author), UNIV OXFORD,CTR EPIDEMIOL INFECT DIS,S PARKS RD,OXFORD OX1 3PS,ENGLAND.			Anderson, Roy/0000-0002-9528-3175				KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; Mastro T D, 1996, AIDS, V10 Suppl A, pS75, DOI 10.1097/00002030-199601001-00011; MYERS G, 1995, HUMAN RETROVIRUSES A; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; SHAFFER N, 1995, 3 INT C AIDS AS PAC; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; 1995, J ACQ IMMUN DEF SYND, V8, P506	9	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1778	1779		10.1016/S0140-6736(96)91609-8	http://dx.doi.org/10.1016/S0140-6736(96)91609-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667915				2022-12-24	WOS:A1996UU46900002
J	Sakai, J; Duncan, EA; Rawson, RB; Hua, XX; Brown, RS; Goldstein, JL				Sakai, J; Duncan, EA; Rawson, RB; Hua, XX; Brown, RS; Goldstein, JL			Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; MUTANT HAMSTER-CELLS; TRANSCRIPTION; REDUCTASE; BINDING; GENES	Sterol regulatory element binding proteins (SREBPs) are transcription factors attached to the endoplasmic reticulum. The NH2-segment, which activates transcription, is connected to membranes by a hairpin anchor formed by two transmembrane sequences and a short lumenal loop. Using H-Ras-SREBP-2 fusion proteins, we show that the NH2-segment is released from membranes by two sequential cleavages. The first, regulated by sterols, occurs in the lumenal loop. The second, not regulated by sterols, occurs within the first transmembrane domain. The liberated NH2-segment enters the nucleus and activates genes controlling cholesterol synthesis and uptake. Certain mutant Chinese hamster ovary cells are auxotrophic for cholesterol because they fail to carry out the second cleavage; the NH2-segment remains membrane-bound and transcription is not activated.			Sakai, J (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Sakai, Juro/0000-0003-4043-1035	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Bollag D.M., 1991, PROTEIN METHODS; CHIN J, 1981, J BIOL CHEM, V256, P6304; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HUA X, 1996, IN PRESS J BIOL CHEM; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; JAMES GL, 1994, J BIOL CHEM, V269, P27705; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; PAI JT, 1996, IN PRESS P NATL ACAD; SATO R, 1994, J BIOL CHEM, V269, P17267; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; WANG X, 1996, J BIOL CHEM, V270, P18044; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	27	426	440	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1037	1046		10.1016/S0092-8674(00)81304-5	http://dx.doi.org/10.1016/S0092-8674(00)81304-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674110	Bronze			2022-12-24	WOS:A1996UV48400010
J	Wong, GT; Gannon, KS; Margolskee, RF				Wong, GT; Gannon, KS; Margolskee, RF			Transduction of bitter and sweet taste by gustducin	NATURE			English	Article							RECEPTOR-CELLS; MICE; DISRUPTION; EXPRESSION; RESPONSES	SFVERAL lines of evidence suggest that both sweet and bitter tastes are transduced via receptors coupled to heterotrimeric guanine-nucleotide-binding proteins (G proteins) (reviewed in refs 1, 2). Gustducin is a taste receptor cell (TRC)-specific G protein that is closely related to the transducins(3). Gustducin and rod transducin, which is also expressed in TRCs (ref. 4), have been proposed to couple bitter-responsive receptors to TRC-specific phosphodiesterases to regulate intracellular cyclic nucleotides(2-5). Here we investigate gustducin's role in taste transduction by generating and characterizing mice deficient in the gustducin alpha-subunit (alpha gustducin). As predicted, the mutant mice showed reduced behavioural and electrophysiological responses to bitter compounds, whereas they were indistinguishable from wild-type controls in their responses to salty and sour stimuli. Unexpectedly, mutant mice also exhibited reduced behavioural and electrophysiological responses to sweet compounds. Our results suggest that gustducin is a principal mediator of both bitter and sweet signal transduction.	CUNY MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Alshali, Rasha A/K-8051-2012	Margolskee, Robert/0000-0002-9572-2887				AKABAS MH, 1988, SCIENCE, V242, P1047, DOI 10.1126/science.3194756; AVENET P, 1987, J MEMBRANE BIOL, V97, P223, DOI 10.1007/BF01869225; AVENET P, 1988, NATURE, V331, P351, DOI 10.1038/331351a0; GANNON KS, 1995, PHYSIOL BEHAV, V57, P231, DOI 10.1016/0031-9384(94)00279-E; HARDER DB, 1989, CHEM SENSES, V14, P547, DOI 10.1093/chemse/14.4.547; KINNAMON SC, 1992, ANNU REV PHYSIOL, V54, P715, DOI 10.1146/annurev.physiol.54.1.715; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KWEE L, 1995, DEVELOPMENT, V121, P489; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Margolskee Robert F., 1993, Current Opinion in Neurobiology, V3, P526, DOI 10.1016/0959-4388(93)90051-Y; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MISTRETTA CM, 1991, SMELL TASTE HLTH DIS, P35; NAIM M, 1991, COMP BIOCHEM PHYS B, V100, P455, DOI 10.1016/0305-0491(91)90203-P; NAIM M, 1994, BIOCHEM J, V297, P451, DOI 10.1042/bj2970451; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NINOMIYA Y, 1984, BRAIN RES, V302, P305, DOI 10.1016/0006-8993(84)90244-0; NINOMIYA Y, 1989, COMP BIOCHEM PHYS A, V92, P371; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Spielman AI, 1996, AM J PHYSIOL-CELL PH, V270, pC926, DOI 10.1152/ajpcell.1996.270.3.C926; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; SZABO P, 1994, DEVELOPMENT, V120, P1651; TINTI JM, 1991, ACS SYM SER, V450, P88; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0; ZYLSTRA MLE, 1989, NATURE, V342, P435	30	525	568	5	51	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 27	1996	381	6585					796	800		10.1038/381796a0	http://dx.doi.org/10.1038/381796a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657284				2022-12-24	WOS:A1996UU35600063
J	Kibota, TT; Lynch, M				Kibota, TT; Lynch, M			Estimate of the genomic mutation rate deleterious to overall fitness in E-coli	NATURE			English	Article							POPULATIONS; EVOLUTION	MUTATIONS are a double-edged sword: they are the ultimate source of genetic variation upon which evolution depends, yet most mutations affecting fitness (viability and reproductive success) appear to be harmful(1). Deleterious mutations of small effect can escape natural selection, and should accumulate in small populations(2-4). Reduced fitness from deleterious-mutation accumulation may be important in the evolution of sex(5-7), mate choice(8,9), and diploid life-cycles(10), and in the extinction of small populations(11,12). Few empirical data exist, however. Minimum estimates of the genomic deleterious-mutation rate for viability in Drosophila melanogaster are surprisingly high(1,13,14), leading to the conjecture that the rate for total fitness could exceed 1.0 mutation per individual per generation(5,6). Here we use Escherichia coli to provide an estimate of the genomic deleterious-mutation rate for total fitness in a microbe. We estimate that the per-microbe rate of deleterious mutations is in excess of 0.0002.	UNIV OREGON,DEPT BIOL,EUGENE,OR 97403	University of Oregon	Kibota, TT (corresponding author), CLARK COLL,DEPT BIOL,1800 E MCLOUGHLIN BLVD,VANCOUVER,WA 98663, USA.							BATEMAN AJ, 1959, INT J RADIAT BIOL, P170; Carlton BC, 1981, MANUAL METHODS GENER, P222; Cavalier-Smith T., 1985, P69; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; CHARLESWORTH D, 1993, GENET RES, V61, P39, DOI 10.1017/S0016672300031086; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; HALGH J, 1978, THEOR POPUL BIOL, V14, P251; HARTL DL, 1994, GENETICS, V138, P227; Herdman M., 1985, EVOLUTION GENOME SIZ, P37; JENKINS CD, 1995, EVOLUTION, V49, P512, DOI [10.1111/j.1558-5646.1995.tb02283.x, 10.2307/2410275]; KEIGHTLEY PD, 1994, GENETICS, V138, P1315; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; LANDE R, 1994, EVOLUTION, V48, P1460, DOI [10.2307/2410240, 10.1111/j.1558-5646.1994.tb02188.x]; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; LENSKI RE, 1991, AM NAT, V138, P315; LINDSLEY DL, 1980, GENETICS BIOL DROSOP, P226; LYNCH M, 1993, J HERED, V84, P339, DOI 10.1093/oxfordjournals.jhered.a111354; LYNCH M, 1990, EVOLUTION, V44, P1725, DOI 10.1111/j.1558-5646.1990.tb05244.x; Lynch Michael, 1994, P86; [No title captured]; [No title captured]	24	252	255	1	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					694	696		10.1038/381694a0	http://dx.doi.org/10.1038/381694a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649513				2022-12-24	WOS:A1996UR97900051
J	Offit, K; Gilewski, T; McGuire, P; Schluger, A; Hampel, H; Brown, K; Swensen, J; Neuhausen, S; Skolnick, M; Norton, L; Goldgar, D				Offit, K; Gilewski, T; McGuire, P; Schluger, A; Hampel, H; Brown, K; Swensen, J; Neuhausen, S; Skolnick, M; Norton, L; Goldgar, D			Germline BRCA1 185delAG mutations in Jewish women with breast cancer	LANCET			English	Article							POLYMERASE CHAIN-REACTION; ENZYMATIC AMPLIFICATION	Background We aimed to find out the proportion of breast cancers in Ashkenazi Jewish women attributable to the frameshift mutation at position 185 involving the deletion of adenine and guanine (185delAG) in the breast cancer gene BRCA1. Methods We studied 107 Ashkenazi Jewish women with breast cancer seen at medical oncology acid genetic counselling clinics in New York over a three and a half year period beginning in 1992. 80 of the women were diagnosed before age 42 years; the other 27 were diagnosed between 42 and 50 years and had a positive family history, Genomic DNA testing by PCR amplification was done to identify any 185delAG mutations of the BRCA1 gene. Findings Of the 80 women diagnosed before the age of 42 years, 16 (20%, 95% CI 11 . 2-28 . 8) were heterozygous for the mutation, All 16 women had at least one first-degree or second-degree relative with breast or ovarian cancer, Of 27 probands diagnosed with breast cancer between the ages of 42 and 50 years who had at least one first-degree relative affected with breast or ovarian cancer, 8 (30%, 95% CI 12-47) had 185delAG mutations, Interpretation These data suggest that screening for the 185delAG mutation may be useful in genetic counselling of these women where options for detection and prevention of possible cancers can be discussed.	MEM SLOAN KETTERING CANC CTR,DEPT MED,BREAST ONCOL SERV,NEW YORK,NY 10021; UNIV UTAH,SCH MED,DEPT MED INFORMAT,GENET EPIDEMIOL GRP,SALT LAKE CITY,UT; MYRIAD GENET INC,SALT LAKE CITY,UT; INT AGCY RES CANC,UNIT GENET EPIDEMIOL,F-69372 LYON,FRANCE	Memorial Sloan Kettering Cancer Center; Utah System of Higher Education; University of Utah; Myriad Genetics, Inc; World Health Organization; International Agency for Research on Cancer (IARC)	Offit, K (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,CLIN GENET SERV,NEW YORK,NY 10021, USA.		Hampel, Heather/AAV-4041-2020	Hampel, Heather/0000-0001-7558-9794	NCI NIH HHS [P20 CA 58232, R01 CA 65673, R01 CA 55914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065673, P20CA058232, R01CA055914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; OFFIT K, 1994, J CLIN ONCOL, V12, P1724, DOI 10.1200/JCO.1994.12.8.1724; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; TONIN P, 1995, AM J HUM GENET, V57, P189; WEBER JL, 1989, AM J HUM GENET, V44, P388	10	117	121	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1643	1645		10.1016/S0140-6736(96)91484-1	http://dx.doi.org/10.1016/S0140-6736(96)91484-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642955				2022-12-24	WOS:A1996UQ70100007
J	deCharms, RC; Merzenich, MM				deCharms, RC; Merzenich, MM			Primary cortical representation of sounds by the coordination of action-potential timing	NATURE			English	Article							AUDITORY-CORTEX; STRIATE CORTEX; MACAQUE MONKEY; NEURONS; RESPONSES; CAT; SYNCHRONIZATION	CORTICAL population coding could in principle rely on either the mean rate of neuronal action potentials, or the relative timing of action potentials, or both, When a single sensory stimulus drives many neurons to fire at elevated rates, the spikes of these neurons become tightly synchronized(1,2), which could be involved in 'binding' together individual firing-rate feature representations into a unified object percept(3), Here we demonstrate that the relative timing of cortical action potentials can signal stimulus features themselves, a function even more basic than feature grouping, Populations of neurons in the primary auditory cortex can coordinate the relative timing of their action potentials such that spikes occur closer together in time during continuous stimuli. In this way cortical neurons can signal stimuli even when their firing rates do not change, Population coding based on relative spike timing can systematically signal stimulus features, it is topographically mapped, and it follows the stimulus time course even where mean firing rate does not.	UNIV CALIF SAN FRANCISCO, KECK CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Abeles M, 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; ADRIAN ED, 1950, ELECTROEN CLIN NEURO, V2, P377, DOI 10.1016/0013-4694(50)90075-7; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; BEMANDER O, 1994, NEURAL COMPUT, V6, P622; BRUGGE JF, 1973, J NEUROPHYSIOL, V36, P1138, DOI 10.1152/jn.1973.36.6.1138; CREUTZFELDT O, 1980, EXP BRAIN RES, V39, P87; DICKSON JW, 1974, J NEUROPHYSIOL, V37, P1239, DOI 10.1152/jn.1974.37.6.1239; Efron B, 1982, JACKKNIFE BOOTSTRAP, P75, DOI [10.1137/1.9781611970319.ch10, DOI 10.1137/1.9781611970319.CH10]; EGGERMONT JJ, 1994, J NEUROPHYSIOL, V71, P246, DOI 10.1152/jn.1994.71.1.246; GABBOTT PLA, 1987, NEUROSCIENCE, V21, P833, DOI 10.1016/0306-4522(87)90040-6; GRANNAN ER, 1993, NEURAL COMPUT, V5, P550, DOI 10.1162/neco.1993.5.4.550; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LEHMANN EL, 1975, NONPARAMETRICS; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P374, DOI 10.1152/jn.1957.20.4.374; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; MOUNTCASTLE VB, 1969, J NEUROPHYSIOL, V32, P452, DOI 10.1152/jn.1969.32.3.452; MURTHY VN, 1994, NEURAL COMPUT, V6, P1111, DOI 10.1162/neco.1994.6.6.1111; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PERKEL DH, 1967, BIOPHYS J, V7, P391, DOI 10.1016/S0006-3495(67)86596-2; PFINGST BE, 1981, J NEUROPHYSIOL, V45, P16, DOI 10.1152/jn.1981.45.1.16; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; TSO DY, 1986, J NEUROSCI, V6, P1160; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; VONDERMALSBURG C, 1981, INTERNAL REPORT M PL	30	393	397	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					610	613		10.1038/381610a0	http://dx.doi.org/10.1038/381610a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637597				2022-12-24	WOS:A1996UQ65700052
J	Yuan, JM; Ross, RK; Wang, XL; Gao, YT; Henderson, BE; Yu, MC				Yuan, JM; Ross, RK; Wang, XL; Gao, YT; Henderson, BE; Yu, MC			Morbidity and mortality in relation to cigarette smoking in Shanghai, China - A prospective male cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MAJOR RISK-FACTORS; MIDDLE-AGED MEN; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; FOLLOW-UP; STROKE; CANCER; SMOKERS; WOMEN	Objective.-To evaluate prospectively the health risk of cigarette smoking in middle-aged men in Shanghai, China. Design.-Prospective cohort study with annual follow-up. Participants.-A total of 18244 male residents of Shanghai, China. enrolled in the study during January 1, 1986, through September 30, 1989, and actively followed via annual visits. Results.-By September 30, 1993, 852 deaths and 554 incident cancer cases were identified during the follow-up period, which averaged 5.4 years per subject. The overall incidence rate for cancer was 568 per 100 000 man-years, with the 3 leading sites being lung (146/100000), stomach (116/100000), and liver (81/100000). Forty-one percent of all deaths were from cancer. Stroke was the most frequent cause of death unrelated to cancer, with an age-adjusted rate 4.2 times higher than that of US white men (201/100000 vs 48/100000), followed by ischemic heart disease, with an age-adjusted rate one-fifth that of US white men (69/100000 vs 366/100000). Compared with lifelong nonsmokers, the relative risks in heavy smokers (20 or more cigarettes per day) after adjustment for alcohol consumption were 2.2 fdr any incident cancer, 9.4 for incident lung cancer, 6.7 for head and neck cancer, and 1.8 for liver cancer. In terms of mortality, heavy smokers were at a 60% greater risk of death relative to lifelong nonsmokers; there was a 2.3-fold excess risk of death gram cancer and 2-fold to 3-fold excess risk of death from heart disease. Conclusions.-Cigarette smoking is an important predictor of risk of cancer and mortality in men in Shanghai. Among the study subjects, 36% of all cases of cancer and 21% of all deaths could be attributed to cigarette smoking.	SHANGHAI CANC INST,SHANGHAI,PEOPLES R CHINA	Shanghai Jiao Tong University	Yuan, JM (corresponding author), UNIV SO CALIF,NORRIS COMPREHENS CANC CTR,1441 EASTLAKE AVE,LOS ANGELES,CA 90033, USA.		Gao, Yu/HGE-1937-2022	Yuan, Jian-Min/0000-0002-4620-3108	NCI NIH HHS [R35 CA53890, R01 CA043092, R01 CA43092, R01 CA043092-20] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA053890, R01CA043092] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BARON AE, 1993, CANCER EPIDEM BIOMAR, V2, P519; BRESLOW NE, 1987, INT AGENCY RES CANC, V82; CARSTENSEN JM, 1987, J EPIDEMIOL COMMUN H, V41, P166, DOI 10.1136/jech.41.2.166; *CDC, 1989, 898411 CDC US DEP HL; CHEN DY, 1992, NEUROEPIDEMIOLOGY, V11, P15, DOI 10.1159/000110902; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P59; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P274; DENG J, 1985, CHIN J PREV MED, V5, P271; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Freund K M, 1993, Ann Epidemiol, V3, P417, DOI 10.1016/1047-2797(93)90070-K; HAHEIM LL, 1993, STROKE, V24, P1484, DOI 10.1161/01.STR.24.10.1484; HAMMOND EC, 1961, J NATL CANCER I, V27, P419; HAMMOND EC, 1980, PREV MED, V9, P169, DOI 10.1016/0091-7435(80)90071-7; HARMSEN P, 1990, STROKE, V21, P223, DOI 10.1161/01.STR.21.2.223; Kodama K, 1993, Ann Epidemiol, V3, P524; LAM KC, 1982, CANCER RES, V42, P5246; LEUNG HM, 1981, BIOMETRICS, V37, P293, DOI 10.2307/2530418; MENOTTI A, 1990, PREV MED, V19, P270, DOI 10.1016/0091-7435(90)90027-H; *NAT CTR HLTH STAT, 1993, US DEP HLTH HUM SERV; NOVOTNY TE, 1988, PUBLIC HLTH REPORTS, V103, P552; PAGANINIHILL A, 1994, AM J PUBLIC HEALTH, V84, P992, DOI 10.2105/AJPH.84.6.992; PARKIN DM, 1992, INT AGENCY RES CANC, V120; PETO R, 1986, LANCET, V2, P1038; RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823; ROBBINS AS, 1994, ANN INTERN MED, V120, P458, DOI 10.7326/0003-4819-120-6-199403150-00002; ROGOT E, 1980, PUBLIC HLTH REP, V95, P218; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; ROSS RK, IN PRESS AM J EPIDEM; SEMENCIW RM, 1988, INT J EPIDEMIOL, V17, P317, DOI 10.1093/ije/17.2.317; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; Thom T J, 1993, Ann Epidemiol, V3, P509; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YU JJ, 1990, JAMA-J AM MED ASSOC, V264, P1575, DOI 10.1001/jama.264.12.1575; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; 1993, MMWR-MORBID MORTAL W, V42, P645; 1987, CHIN MED J, V67, P229	39	147	155	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1646	1650						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637137				2022-12-24	WOS:A1996UN25200026
J	FungLeung, WP; Surh, CD; Liljedahl, M; Pang, J; Leturcq, D; Peterson, PA; Webb, SR; Karlsson, L				FungLeung, WP; Surh, CD; Liljedahl, M; Pang, J; Leturcq, D; Peterson, PA; Webb, SR; Karlsson, L			Antigen presentation and T cell development in H2-M-deficient mice	SCIENCE			English	Article							INVARIANT CHAIN; I-A; PEPTIDE; MOLECULES; LACKING; REGION	HLA-DM (DM) facilitates peptide loading of major histocompatibility complex class II molecules in human cell lines. Mice lacking functional H2-M, the mouse equivalent of DM, have normal amounts of class II molecules at the cell surface, but most of these are associated with invariant chain-derived CLIP peptides. These mice contain large numbers of CD4(+) T cells, which is indicative of positive selection in the thymus. Their CD4(+) cells were unresponsive to self H2-M-deficient antigen-presenting cells (APCs) but were hyperreactive to wild-type APCs. H2-M-deficient APCs failed to elicit proliferative responses from wild-type T cells.	SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute			Pang, Jesse CS/H-3549-2013	Pang, Jesse CS/0000-0002-8716-4045; Fung-Leung, Wai-Ping/0000-0001-7013-8855				BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIJLMAKERS MJJE, 1994, EMBO J, V13, P2699, DOI 10.1002/j.1460-2075.1994.tb06560.x; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BROOKS AG, 1994, J IMMUNOL, V153, P5382; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FUNGLEUNG WP, 1994, J EXP MED, V180, P959, DOI 10.1084/jem.180.3.959; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; HASENKRUG KJ, 1987, IMMUNOGENETICS, V25, P136, DOI 10.1007/BF00364282; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KARLSSON L, UNPUB; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MORKOWSKI S, 1995, J EXP MED, V182, P1403, DOI 10.1084/jem.182.5.1403; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STEBBINS CC, 1995, J EXP MED, V181, P223, DOI 10.1084/jem.181.1.223; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495; SURH CD, 1993, J EXP MED, V177, P379, DOI 10.1084/jem.177.2.379; SURH CD, UNPUB; SYMINGTON FW, 1981, IMMUNOGENETICS, V14, P53, DOI 10.1007/BF00344299; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEBB SR, 1990, SCIENCE, V248, P1643	29	241	243	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1278	1281		10.1126/science.271.5253.1278	http://dx.doi.org/10.1126/science.271.5253.1278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638109				2022-12-24	WOS:A1996TX69500036
J	Pei, X; Moss, F				Pei, X; Moss, F			Characterization of low-dimensional dynamics in the crayfish caudal photoreceptor	NATURE			English	Article							STRANGE SETS; TIME-SERIES; CHAOS; ORBITS; SYSTEM	ATTEMPTS to detect and characterize chaos in biological systems are of considerable interest, especially in medical science, where successful demonstrations may lead to new diagnostic tools and therapies(1). Unfortunately, conventional methods for identifying chaos often yield equivocal results when applied to biological data(2-8), which are usually heavily contaminated with noise. For such applications, a new technique(1) based on the detection of unstable periodic orbits holds promise, Infinite sets of unstable periodic orbits underlie chaos in dissipative systems(4,9); accordingly, the new method searches a time series only for rare events(8) characteristic of these unstable orbits(10), rather than analysing the structure of the series as a whole. Here we demonstrate the efficacy of the method when applied to the dynamics of the crayfish caudal photoreceptor (subject to stimuli representative of the animal's natural habitat). Our findings confirm the existence of low-dimensional dynamics in the system, and strongly suggest the existence of deterministic chaos. More importantly, these results demonstrate the power of methods based on the detection of unstable periodic orbits for identifying low-dimensional dynamics-and, in particular, chaos-in biological systems.			Pei, X (corresponding author), UNIV MISSOURI, DEPT PHYS & ASTRON, LAB NEURODYNAM, ST LOUIS, MO 63121 USA.							Abraham NB, 1993, INT J BIFURCAT CHAOS, V3, P485, DOI 10.1142/S0218127493000398; ARTUSO R, 1990, NONLINEARITY, V3, P325, DOI 10.1088/0951-7715/3/2/005; ARTUSO R, 1990, NONLINEARITY, V3, P361, DOI 10.1088/0951-7715/3/2/006; BEVINGTON PR, 1969, DATA REDUCTION ERROR, P48; CHANG T, 1994, BIOPHYS J, V67, P671, DOI 10.1016/S0006-3495(94)80526-0; CHRISTINI DJ, 1995, PHYS REV LETT, V75, P2782, DOI 10.1103/PhysRevLett.75.2782; CVITANOVIC P, 1988, PHYS REV LETT, V61, P2729, DOI 10.1103/PhysRevLett.61.2729; CVITANOVIC P, 1991, PHYSICA D, V51, P138, DOI 10.1016/0167-2789(91)90227-Z; DITTO WL, 1990, PHYS REV LETT, V65, P3211, DOI 10.1103/PhysRevLett.65.3211; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; GRASSBERGER P, 1983, PHYSICA D, V9, P189, DOI 10.1016/0167-2789(83)90298-1; HAYASHI H, 1992, J THEOR BIOL, V156, P269, DOI 10.1016/S0022-5193(05)80676-9; HERMANN HT, 1968, J GEN PHYSIOL, V51, P534, DOI 10.1085/jgp.51.4.534; HUNT ER, 1991, PHYS REV LETT, V67, P1953, DOI 10.1103/PhysRevLett.67.1953; KAPLAN DT, 1994, PHYSICA D, V73, P38, DOI 10.1016/0167-2789(94)90224-0; KENNEDY DONALD, 1963, JOUR GEN PHYSIOL, V46, P551, DOI 10.1085/jgp.46.3.551; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MAY RM, 1979, ANN NY ACAD SCI, V316, P517; Moon F.C., 1987, CHAOTIC VIBRATIONS; PETROV V, 1993, NATURE, V361, P240, DOI 10.1038/361240a0; PIERSON D, 1995, PHYS REV LETT, V75, P2124, DOI 10.1103/PhysRevLett.75.2124; ROLLINS RW, 1993, PHYS REV E, V47, pR780, DOI 10.1103/PhysRevE.47.R780; ROY R, 1992, PHYS REV LETT, V68, P1259, DOI 10.1103/PhysRevLett.68.1259; RUELLE D, 1971, COMMUN MATH PHYS, V20, P167, DOI 10.1007/BF01646553; RUELLE D, 1990, P ROY SOC LOND A MAT, V427, P241, DOI 10.1098/rspa.1990.0010; RUELLE D, 1994, PHYS TODAY, V47, P24, DOI 10.1063/1.881395; RUELLE D, 1980, RECHERCHE, V11, P132; RUELLE D, 1987, 8TH INT C MATH PHYS, P273; SCHIFF SJ, 1994, NATURE, V370, P615, DOI 10.1038/370615a0; Scott DA, 1995, BIOPHYS J, V69, P1748, DOI 10.1016/S0006-3495(95)80044-5; SHINBROT T, 1993, NATURE, V363, P411, DOI 10.1038/363411a0; STROGATZ SH, 1994, NONLINEAR DYNAMICS C, pCH12; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; WILKENS LA, 1994, J EXP BIOL, V189, P263; WILKENS LA, 1988, COMP BIOCHEM PHYS C, V91, P61, DOI 10.1016/0742-8413(88)90169-7; WOLF A, 1985, PHYSICA D, V16, P285, DOI 10.1016/0167-2789(85)90011-9	37	104	106	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					618	621		10.1038/379618a0	http://dx.doi.org/10.1038/379618a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628396				2022-12-24	WOS:A1996TV68800045
J	Ronemus, MJ; Galbiati, M; Ticknor, C; Chen, JC; Dellaporta, SL				Ronemus, MJ; Galbiati, M; Ticknor, C; Chen, JC; Dellaporta, SL			Demethylation-induced developmental pleiotropy in Arabidopsis	SCIENCE			English	Article							DNA METHYLTRANSFERASE; GENE; THALIANA; METHYLATION; SEQUENCE; MUTANT; PLANTS; INACTIVATION; DOMAIN; MAIZE	The function of DNA methylation in higher plants was investigated by expression of a complementary DNA encoding a cytosine methyltransferase (MET1) from Arabidopsis thaliana as an antisense RNA in transgenic plants. This expression resulted in a 34 to 71 percent reduction in total genomic cytosine methylation. Loss of methylation was observed in both repetitive DNA and single-copy gene sequences. Developmental effects included altered heterochrony, changes in meristem identity and organ number, and female sterility. Cytosine demethylation prolonged both vegetative and reproductive phases of development. These findings implicate DNA methylation in establishing or maintaining epigenetic developmental states in the meristem.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Yale University			Galbiati, Massimo/AAV-7051-2020	Galbiati, Massimo/0000-0002-9827-4506	NIGMS NIH HHS [GM38148] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038148] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENDER J, 1995, CELL, V83, P725, DOI 10.1016/0092-8674(95)90185-X; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BRUTNELL TP, 1994, GENETICS, V138, P213; BURN JE, 1993, P NATL ACAD SCI USA, V90, P287, DOI 10.1073/pnas.90.1.287; CAMPELL BR, 1992, GENE, V112, P225, DOI 10.1016/0378-1119(92)90380-8; Chen J., 1994, MAIZE HDB, P526, DOI [10.1007/978-1-4612-2694-9_85, DOI 10.1007/978-1-4612-2694-9_85]; CHOMET PS, 1987, EMBO J, V6, P295, DOI 10.1002/j.1460-2075.1987.tb04753.x; Dellaporta Stephen L., 1994, P569; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; FINNEGAN EJ, 1993, NUCLEIC ACIDS RES, V21, P2383, DOI 10.1093/nar/21.10.2383; GEHRKE CW, 1984, J CHROMATOGR, V301, P199, DOI 10.1016/S0021-9673(01)89189-5; GRUENBAUM Y, 1981, NATURE, V292, P860, DOI 10.1038/292860a0; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARTIENSSEN R, 1990, GENE DEV, V4, P331, DOI 10.1101/gad.4.3.331; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; NELSON M, 1991, NUCLEIC ACIDS RES, V19, P2045, DOI 10.1093/nar/19.suppl.2045; POETHIG RS, 1990, SCIENCE, V250, P923, DOI 10.1126/science.250.4983.923; RODRIGUEZRODRIG.H, UNPUB; ROSE AB, 1992, PLANT PHYSIOL, V100, P582, DOI 10.1104/pp.100.2.582; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N	33	382	410	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					654	657		10.1126/science.273.5275.654	http://dx.doi.org/10.1126/science.273.5275.654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662558				2022-12-24	WOS:A1996VA24900050
J	Hinnebusch, BJ; Perry, RD; Schwan, TG				Hinnebusch, BJ; Perry, RD; Schwan, TG			Role of the Yersinia pestis hemin storage (hms) locus in the transmission of plague by fleas	SCIENCE			English	Article							AGGREGATIVE FIMBRIAE; ESCHERICHIA-COLI; SIPHONAPTERA; FIBRONECTIN; PHENOTYPE; BACILLUS; PROTEINS; DELETION; CUTICLE; BINDING	Yersinia pestis, the cause of bubonic plague, is transmitted by the bites of infected fleas. Biological transmission of plague depends on blockage of the foregut of the flea by a mass of plague bacilli. Blockage was found to be dependent on the hemin storage (hms) locus. Yersinia pestis hms mutants established long-term infection of the flea's midgut but failed to colonize the proventriculus, the site in the foregut where blockage normally develops. Thus, the hms locus markedly alters the course of Y. pestis infection in its insect vector, leading ro a change in blood-feeding behavior and to efficient transmission of plague.	UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536	University of Kentucky	Hinnebusch, BJ (corresponding author), NIAID,ROCKY MT LABS,MICROBIAL STRUCT & FUNCT LAB,NIH,HAMILTON,MT 59840, USA.							Bacot A. W., 1914, Journal of Hygiene Cambridge Plague Suppl, V3; BACOT AW, 1915, J HYG PLAGUE CAMB S3, V4, P774; BIBIKOVA VA, 1977, ANNU REV ENTOMOL, V22, P23, DOI 10.1146/annurev.en.22.010177.000323; BREY PT, 1993, P NATL ACAD SCI USA, V90, P6275, DOI 10.1073/pnas.90.13.6275; CAVANAUGH DC, 1971, AM J TROP MED HYG, V20, P264, DOI 10.4269/ajtmh.1971.20.264; COLLINSON SK, 1992, J BACTERIOL, V174, P4490, DOI 10.1128/JB.174.13.4490-4495.1992; COLLINSON SK, 1993, J BACTERIOL, V175, P12, DOI 10.1128/JB.175.1.12-18.1993; ESKEY CR, 1940, PUBLIC HLTH B, V254; FETHERSTON JD, 1995, J BACTERIOL, V177, P1824, DOI 10.1128/jb.177.7.1824-1833.1995; FETHERSTON JD, 1992, MOL MICROBIOL, V6, P2693, DOI 10.1111/j.1365-2958.1992.tb01446.x; FETHERSTON JD, 1994, MOL MICROBIOL, V13, P697, DOI 10.1111/j.1365-2958.1994.tb00463.x; Hammar M, 1995, MOL MICROBIOL, V18, P661, DOI 10.1111/j.1365-2958.1995.mmi_18040661.x; HOPKINS TL, 1992, ANNU REV ENTOMOL, V37, P273, DOI 10.1146/annurev.en.37.010192.001421; JACKSON S, 1956, BRIT J EXP PATHOL, V37, P570; KARTMAN LEO, 1964, TRANS ROY SOC TROP MED HGY, V58, P363, DOI 10.1016/0035-9203(64)90206-8; KUTYREV VV, 1992, MICROB PATHOGENESIS, V12, P177, DOI 10.1016/0882-4010(92)90051-O; LILLARD JW, UNPUB; LUCIER TS, 1992, J BACTERIOL, V174, P2078, DOI 10.1128/JB.174.7.2078-2086.1992; MARMARAS VJ, 1993, ARCH INSECT BIOCHEM, V23, P169, DOI 10.1002/arch.940230404; MCDONOUGH KA, 1993, J MED ENTOMOL, V30, P772, DOI 10.1093/jmedent/30.4.772; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; PENDRAK ML, 1993, MOL MICROBIOL, V8, P857, DOI 10.1111/j.1365-2958.1993.tb01632.x; PERRY RD, 1993, INFECT IMMUN, V61, P32, DOI 10.1128/IAI.61.1.32-39.1993; Pollitzer R., 1954, WHO MONOGRAPH SERIES, V22; QUAN SF, 1954, SCIENCE, V120, P1101, DOI 10.1126/science.120.3131.1101; SURGALLA MJ, 1969, APPL MICROBIOL, V18, P834, DOI 10.1128/AEM.18.5.834-837.1969; TERTTI R, 1992, INFECT IMMUN, V60, P3021, DOI 10.1128/IAI.60.7.3021-3024.1992; WADE SE, 1988, J MED ENTOMOL, V25, P186, DOI 10.1093/jmedent/25.3.186	28	280	291	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1996	273	5273					367	370		10.1126/science.273.5273.367	http://dx.doi.org/10.1126/science.273.5273.367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY202	8662526				2022-12-24	WOS:A1996UY20200043
J	Wu, JY; Wen, L; Zhang, WJ; Rao, Y				Wu, JY; Wen, L; Zhang, WJ; Rao, Y			The secreted product of Xenopus gene lunatic Fringe, a vertebrate signaling molecule	SCIENCE			English	Article							BONE MORPHOGENETIC PROTEIN-4; MESODERM-INDUCING ACTIVITY; TGF-BETA; VENTRALIZING FACTOR; TRUNCATED ACTIVIN; AXIAL MESODERM; EARLY EMBRYOS; GROWTH-FACTOR; REQUIRES FGF; CELL-LINE	Signaling molecules are essential for vertebrate embryonic development. Here, two Xenopus homologs of the Drosophila gene fringe, lunatic Fringe (IFng) and radical Fringe (rFng), were identified and the protein product of IFng further characterized. The messenger RNA of IFng is supplied as a maternal message, Its product is a precursor protein consisting of pre-, pro-, and mature regions. The mature lunatic Fringe protein is secreted extracellularly, and it induced mesodermal tissue formation in animal cap assays. These results indicate that secreted lunatic Fringe can induce mesoderm and reveal that the Fringe proteins are a family of vertebrate signaling molecules.	ST LOUIS UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Saint Louis University; Washington University (WUSTL); Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576, R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967-02, R01 GM070967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, BIOESSAYS, V16, P385; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; JONES CM, 1995, CURR BIOL, V5, P574, DOI 10.1016/S0960-9822(95)00112-6; JONES CM, 1992, DEVELOPMENT, V115, P639; JONES CM, 1995, DEVELOPMENT, V121, P3651; KESSLER DS, 1994, SCIENCE, V265, P598; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; LABONNE C, 1994, DEVELOPMENT, V120, P463; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; RAO Y, 1994, GENE DEV, V8, P939, DOI 10.1101/gad.8.8.939; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SLACK JMW, 1989, DEVELOPMENT, V107, P141; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7	38	57	62	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1996	273	5273					355	358		10.1126/science.273.5273.355	http://dx.doi.org/10.1126/science.273.5273.355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY202	8662522	Green Accepted			2022-12-24	WOS:A1996UY20200039
J	Dudley, J; Chambers, T				Dudley, J; Chambers, T			Why the resistance to diagnostic imaging in childhood urinary tract infections	LANCET			English	Editorial Material							VESICOURETERAL REFLUX; CHILDREN				Dudley, J (corresponding author), SOUTHMEAD GEN HOSP,DEPT PAEDIAT,BRISTOL BS10 5NB,AVON,ENGLAND.							ARANT BS, 1991, AM J KIDNEY DIS, V17, P491, DOI 10.1016/S0272-6386(12)80490-2; *CAN ORG REPL REG, 1994, 1992 CAN I HLTH INF; Dick PT, 1996, J PEDIATR-US, V128, P15, DOI 10.1016/S0022-3476(96)70422-5; ESBJORNER E, 1990, PEDIATR NEPHROL, V4, P249, DOI 10.1007/BF00857667; GORDON I, 1990, PEDIATR NEPHROL, V4, P604, DOI 10.1007/BF00858633; JODAL U, 1987, PEDIATR NEPHROL, V1, P647, DOI 10.1007/BF00853603; MARRA G, 1994, ARCH DIS CHILD-FETAL, V70, pF147, DOI 10.1136/fn.70.2.F147; Matsumoto T, 1996, LANCET, V347, P757, DOI 10.1016/S0140-6736(96)90106-3; ROLLESTON GL, 1971, RENAL FUNCTION RENAL, P246; 1991, J R COLL PHYSICIANS, V25, P36	10	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					71	72		10.1016/S0140-6736(05)64600-4	http://dx.doi.org/10.1016/S0140-6736(05)64600-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676716				2022-12-24	WOS:A1996UW67300004
J	Osawa, M; Hanada, K; Hamada, H; Nakauchi, H				Osawa, M; Hanada, K; Hamada, H; Nakauchi, H			Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell	SCIENCE			English	Article							ANTIGEN; INVIVO; CD34	Hematopoietic stem cells (HSCs) supply all blood cells throughout life by making use of their self-renewal and multilineage differentiation capabilities. A monoclonal antibody raised to the mouse homolog of CD34 (mCD34) was used to purify mouse HSCs to near homogeneity. Unlike in humans, primitive adult mouse bone marrow HSCs were detected in the mCD34 low to negative fraction. Injection of a single mCD34(lo/-), c-Kit(+), Sca-1(+), lineage markers negative (Lin(-)) cell resulted in long-term reconstitution of the lymphohematopoietic system in 21 percent of recipients. Thus, the purified HSC population should enable analysis of the self-renewal and multilineage differentiation of individual HSCs.	UNIV TSUKUBA, CTR TSUKUBA ADV RES ALLIANCE, TSUKUBA, IBARAKI 305, JAPAN; JAPANESE FDN CANC RES, CTR CANC CHEMOTHERAPY, DEPT MOL BIOTHERAPY, TOKYO 170, JAPAN	University of Tsukuba; Japanese Foundation for Cancer Research	Osawa, M (corresponding author), UNIV TSUKUBA, INST BASIC MED SCI, DEPT IMMUNOL, TSUKUBA SCI CITY, TSUKUBA, IBARAKI 305, JAPAN.		Hanada, Kenichi/L-2481-2013; Hanada, Ken-ichi/A-4642-2008	Hanada, Kenichi/0000-0003-2959-1257; Osawa, Masatake/0000-0002-5318-9826				BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; Cheng J, 1996, BLOOD, V87, P479, DOI 10.1182/blood.V87.2.479.bloodjournal872479; CIVIN CI, 1984, J IMMUNOL, V133, P157; JONES RJ, 1990, NATURE, V347, P188, DOI 10.1038/347188a0; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; KRAUSE DS, 1994, BLOOD, V84, P691; OKADA S, 1993, BLOOD, V81, P1720; OKADA S, 1992, BLOOD, V80, P3044; ONISHI M, 1993, BLOOD, V81, P3217; Osawa M, 1996, J IMMUNOL, V156, P3207; OSAWA M, UNPUB; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788; SROUR EF, 1993, BLOOD, V82, P3333; SUDA J, 1992, BLOOD, V79, P2288; TJONNFJORD GE, 1994, BLOOD, V84, P3584; WINEMAN JP, 1992, BLOOD, V80, P1717	17	1605	1712	1	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1996	273	5272					242	245		10.1126/science.273.5272.242	http://dx.doi.org/10.1126/science.273.5272.242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8662508	Green Submitted			2022-12-24	WOS:A1996UW78700042
J	Cook, GC				Cook, GC			Familial Mediterranean fever: Underlying defect clearer, but diagnostic problems persist	LANCET			English	Editorial Material							GENE				Cook, GC (corresponding author), HOSP TROP DIS,LONDON NW1 0PE,ENGLAND.							BRENNERULLMAN A, 1994, AM J MED GENET, V53, P172, DOI 10.1002/ajmg.1320530210; FISCHELGHODSIAN N, 1993, AM J MED GENET, V46, P689, DOI 10.1002/ajmg.1320460619; HAVENAAR EC, 1995, CLIN IMMUNOL IMMUNOP, V76, P279, DOI 10.1006/clin.1995.1126; PRAS E, 1992, NEW ENGL J MED, V326, P1509, DOI 10.1056/NEJM199206043262301; REISSMAN P, 1994, WORLD J SURG, V18, P139, DOI 10.1007/BF00348205; RIVAS AL, 1992, CLIN IMMUNOL IMMUNOP, V64, P36, DOI 10.1016/0090-1229(92)90057-U; SCHATTNER A, 1991, AM J MED, V90, P434; Schattner A, 1996, QJM-MON J ASSOC PHYS, V89, P205; SHOHAT M, 1992, AM J MED GENET, V44, P179, DOI 10.1002/ajmg.1320440212; SHOHAT M, 1992, AM J HUM GENET, V51, P1349; SUNGUR C, 1993, KIDNEY INT, V44, P834, DOI 10.1038/ki.1993.318; YUVAL Y, 1995, AM J MED GENET, V57, P455, DOI 10.1002/ajmg.1320570319	12	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1779	1780		10.1016/S0140-6736(96)91611-6	http://dx.doi.org/10.1016/S0140-6736(96)91611-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667917				2022-12-24	WOS:A1996UU46900004
J	Edelmann, W; Cohen, PE; Kane, M; Lau, K; Morrow, B; Bennett, S; Umar, A; Kunkel, T; Cattoretti, G; Chaganti, R; Pollard, JW; Kolodner, RD; Kucherlapati, R				Edelmann, W; Cohen, PE; Kane, M; Lau, K; Morrow, B; Bennett, S; Umar, A; Kunkel, T; Cattoretti, G; Chaganti, R; Pollard, JW; Kolodner, RD; Kucherlapati, R			Meiotic pachytene arrest in MLH1-deficient mice	CELL			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE; MISMATCH REPAIR; SYNAPTONEMAL COMPLEX; COLON-CANCER; GENES; MUTATIONS; LOCUS; IDENTIFICATION; HOMOLOG	Germ line mutations in DNA mismatch repair genes including MLH1 cause hereditary nonpolyposis colon cancer. To understand the role of MLH1 in normal growth and development, we generated mice that have a null mutation of this gene. Mice homozygous for this mutation show a replication error phenotype, and extracts of these cells are deficient in mismatch repair activity. Homozygous mutant males show normal mating behavior but have no detectable mature sperm. Examination of meiosis in these males reveals that the cells enter meiotic prophase and arrest at pachytene. Homozygous mutant females have normal estrous cycles and reproductive and mating behavior but are infertile. The phenotypes of the mlh1 mutant mice are distinct from those deficient in msh2 and pms2. The different phenotypes of the three types of mutant mice suggest that these three genes may have independent functions in mammalian meiosis.	ALBERT EINSTEIN COLL MED,DEPT DEV & MOL BIOL,BRONX,NY 10467; DANA FARBER CANC INST,BOSTON,MA 02115; NIEHS,RES TRIANGLE PK,NC 27709; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY; MEM SLOAN KETTERING CANC CTR,DEPT GENET,NEW YORK,NY 10021	Yeshiva University; Albert Einstein College of Medicine; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Columbia University; Memorial Sloan Kettering Cancer Center	Edelmann, W (corresponding author), ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,BRONX,NY 10467, USA.		Kucherlapati, Raju/ABC-8807-2021	Morrow, Bernice/0000-0002-8076-4726; Cattoretti, Giorgio/0000-0003-3799-3221	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030280] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA067944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67944] Funding Source: Medline; NICHD NIH HHS [HD/AI 30280] Funding Source: Medline; NIGMS NIH HHS [GM 50006] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOYER JC, 1995, CANCER RES, V55, P6062; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHAGANTI RSK, 1980, AM J HUM GENET, V32, P833; COHEN PE, 1996, IN PRESS BIOL REPROD, V55; COUNCE SJ, 1973, CHROMOSOMA, V44, P231, DOI 10.1007/BF00329119; Datta A, 1996, MOL CELL BIOL, V16, P1085; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRASER LR, 1983, J REPROD FERTIL, V69, P419, DOI 10.1530/jrf.0.0690419; GOODPASTURE C, 1975, CHROMOSOMA, V53, P37, DOI 10.1007/BF00329389; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAWN MT, 1995, CANCER RES, V55, P3721; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1996, EMBO J, V15, P1726, DOI 10.1002/j.1460-2075.1996.tb00518.x; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1994, COLD SPRING HARB SYM, V59, P331, DOI 10.1101/SQB.1994.059.01.037; KOLODNER RD, 1995, CANCER RES, V55, P242; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PROLLA TA, 1994, THESIS YALE U NEW HA; PSYCHOYOS A, 1961, CR HEBD ACAD SCI, V252, P1515; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; WILLIAMSON MS, 1985, GENETICS, V110, P609	58	467	494	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1125	1134		10.1016/S0092-8674(00)81312-4	http://dx.doi.org/10.1016/S0092-8674(00)81312-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674118	hybrid			2022-12-24	WOS:A1996UV48400018
J	Calkins, DJ; Sterling, P				Calkins, DJ; Sterling, P			Absence of spectrally specific lateral inputs to midget ganglion cells in primate retina	NATURE			English	Article							GENICULATE-NUCLEUS; CONE CONNECTIONS; HORIZONTAL CELLS; MONKEY RETINA; MACAQUE; MECHANISMS; OPPONENT	VISUAL information is conveyed to the brain by retinal ganglion cells. Midget ganglion cells serve fine spatial vision(1,2) by summing excitation from a receptive field 'centre', receiving input from a single cone in the central retina, with lateral inhibition from a receptive field 'surround', receiving input from many surrounding cones, Midget ganglion cells are also thought to serve colour opponent vision(1-6) because the centre excitation is from a cone of one spectral type, while the surround inhibition is from cones of the other type(4,6). The two major cone types, middle(M)- and long(L)wavelength sensitive, are equally numerous and randomly distributed in the primate central retina(7-9), so a spectrally homogeneous surround requires that the cells mediating lateral interactions (horizontal or amacrine cells) receive selective input from only one cone type. Horizontal cells cannot do this because they receive input indiscriminately from M and L cones(10-12). Here we report that the amacrine cells connected to midget ganglion cells are similarly indiscriminate, The absence of spectral specificity in the inhibitory wiring raises doubt about the involvement of midget ganglion cells in colour vision and suggests that colour opponency may instead be conveyed by a different type of ganglion cell.	UNIV PENN, DEPT NEUROSCI, PHILADELPHIA, PA 19104 USA	University of Pennsylvania				Calkins, David/0000-0002-8475-9959				[Anonymous], 1991, COMPUTATIONAL MODELS, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; BOYCOTT BB, 1991, EUR J NEUROSCI, V3, P1069, DOI 10.1111/j.1460-9568.1991.tb00043.x; BOYCOTT BB, 1987, PROC R SOC SER B-BIO, V229, P345, DOI 10.1098/rspb.1987.0001; CALKINS DJ, 1994, NATURE, V371, P70, DOI 10.1038/371070a0; CRONER LJ, 1995, VISION RES, V35, P7, DOI 10.1016/0042-6989(94)E0066-T; Dacey DM, 1996, SCIENCE, V271, P656, DOI 10.1126/science.271.5249.656; DEMONASTERIO FM, 1978, J NEUROPHYSIOL, V41, P1418, DOI 10.1152/jn.1978.41.6.1418; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P241, DOI 10.1113/jphysiol.1984.sp015499; DOWLING JE, 1966, PROC R SOC SER B-BIO, V166, P80, DOI 10.1098/rspb.1966.0086; GRUNERT U, 1990, J COMP NEUROL, V297, P509, DOI 10.1002/cne.902970405; Kaplan E., 1990, Progress in Retinal Research, V9, P273, DOI 10.1016/0278-4327(90)90009-7; KLUG K, 1992, SOC NEUR ABSTR, V18; KLUG KY, 1993, INVEST OPHTH VIS SCI, V34, pA1398; KOLB H, 1991, J COMP NEUROL, V303, P617, DOI 10.1002/cne.903030408; Lee BB, 1996, VISION RES, V36, P631, DOI 10.1016/0042-6989(95)00167-0; MERIGAN WH, 1991, J NEUROSCI, V11, P994; MOLLON JD, 1992, NATURE, V360, P677, DOI 10.1038/360677a0; Packer OS, 1996, J NEUROSCI, V16, P2251; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; RODIECK RW, 1991, NATO ADV SCI I A-LIF, V203, P83; SCHILLER PH, 1990, NATURE, V343, P68, DOI 10.1038/343068a0; TSUKAMOTO Y, 1992, VISION RES, V32, P1809, DOI 10.1016/0042-6989(92)90042-H; VARDI N, 1994, VISION RES, V34, P1235, DOI 10.1016/0042-6989(94)90198-8; VARDI N, 1994, VISUAL NEUROSCI, V11, P135, DOI 10.1017/S0952523800011172; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; ZRENNER E, 1983, NEUROPHYSIOLOGICAL A	28	81	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					613	615		10.1038/381613a0	http://dx.doi.org/10.1038/381613a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637598				2022-12-24	WOS:A1996UQ65700053
J	Ehrhardt, DW; Wais, R; Long, SR				Ehrhardt, DW; Wais, R; Long, SR			Calcium spiking in plant root hairs responding to Rhizobium nodulation signals	CELL			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; CYTOSOLIC FREE CALCIUM; CYTOPLASMIC CALCIUM; HOST SPECIFICITY; MELILOTI; ALFALFA; CELLS; ACID; OSCILLATIONS; CHANNELS	Rhizobium lipochitooligosaccharide signal molecules stimulate multiple responses in legume host plants, including changes in host gene expression, cell growth, and mitoses leading to root nodule development. The basis for signal transduction in the plant is not known. We examined cytoplasmic free calcium in host root hairs using calcium-sensitive reporter dyes. Image analysis of injected dyes revealed localized periodic spikes in cytoplasmic calcium levels that ensued after a characteristic lag following signal application. Structural features of the signal molecules required to cause nodulation responses in alfalfa are also essential for stimulating calcium spiking. A nonnodulating alfalfa mutant is defective in calcium spiking, consistent with the possibility that this mutant is blocked in an early stage of nodulation signal perception.			Ehrhardt, DW (corresponding author), STANFORD UNIV, HOWARD HUGHES MED INST, DEPT BIOL SCI, STANFORD, CA 94305 USA.							ALLEN NS, 1994, ADV MOL GENETICS PLA, V3, P107; ATKINSON EM, 1994, THESIS STANFORD U ST; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLARKSON DT, 1988, J CELL SCI, V91, P71; DENARIE J, 1993, CELL, V74, P951, DOI 10.1016/0092-8674(93)90717-5; DUDLEY ME, 1987, PLANTA, V171, P289, DOI 10.1007/BF00398674; DUDLEY ME, 1989, PLANT CELL, V1, P65, DOI 10.1105/tpc.1.1.65; EHRHARDT DW, 1995, J BACTERIOL, V177, P6237, DOI 10.1128/jb.177.21.6237-6245.1995; EHRHARDT DW, 1992, SCIENCE, V256, P998, DOI 10.1126/science.10744524; FELLE H, 1988, PLANTA, V174, P495, DOI 10.1007/BF00634478; FELLE HH, 1995, PLANT J, V7, P939, DOI 10.1046/j.1365-313X.1995.07060939.x; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.ph.55.030193.002235; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; GILROY S, 1992, P NATL ACAD SCI USA, V89, P3591, DOI 10.1073/pnas.89.8.3591; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; Kijne J.W., 1992, BIOL NITROGEN FIXATI, P349; KURKDJIAN AC, 1995, PLANT PHYSIOL, V107, P783, DOI 10.1104/pp.107.3.783; MCAINSH MR, 1995, PLANT CELL, V7, P1207, DOI 10.1105/tpc.7.8.1207; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; MILLER DD, 1992, J CELL SCI, V101, P7; MUNNS DN, 1970, PLANT SOIL, V32, P90, DOI 10.1007/BF01372849; MYLONA P, 1995, PLANT CELL, V7, P869, DOI 10.1105/tpc.7.7.869; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; PETERSON MA, 1981, CROP SCI, V21, P611, DOI 10.2135/cropsci1981.0011183X002100040033x; READ ND, 1992, J MICROSC-OXFORD, V166, P57, DOI 10.1111/j.1365-2818.1992.tb01507.x; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROCHE P, 1991, J BIOL CHEM, V266, P10933; SAUNDERS MJ, 1982, SCIENCE, V217, P943, DOI 10.1126/science.217.4563.943; SAUNDERS MJ, 1983, DEV BIOL, V99, P41, DOI 10.1016/0012-1606(83)90252-X; SCHROEDER JI, 1990, P NATL ACAD SCI USA, V87, P9305, DOI 10.1073/pnas.87.23.9305; SMITH JT, 1993, ELECTROPHORESIS, V14, P396, DOI 10.1002/elps.1150140165; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	39	447	481	3	68	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 31	1996	85	5					673	681		10.1016/S0092-8674(00)81234-9	http://dx.doi.org/10.1016/S0092-8674(00)81234-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646776	Bronze			2022-12-24	WOS:A1996UP34400008
J	Funabiki, H; Yamano, H; Kumada, K; Nagao, K; Hunt, T; Yanagida, M				Funabiki, H; Yamano, H; Kumada, K; Nagao, K; Hunt, T; Yanagida, M			Cut2 proteolysis required for sister-chromatid separation in fission yeast	NATURE			English	Article							MATURATION-PROMOTING FACTOR; CELL-DIVISION CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MUTANTS; MITOSIS; KINASE; GENE; DEGRADATION	ALTHOUGH mitotic cyclins are well-known substrates for ubiquitin-mediated proteolysis at the metaphase-anaphase transition(1-4), their degradation is not essential for separation of sister chromatids(5-8); several lines of evidence suggest that proteolysis of other protein(s) is required, however(4,6,9-11). Here we report the anaphase-specific proteolysis of the Schizosaccharomyces pombe Cut2 protein, which is essential for sister-chromatid separation(12,13). Cut2 is located in the nucleus, where it is concentrated along the short metaphase spindle. The rapid degradation of Cut2 at anaphase requires its amino-terminal region and the activity of Cut9 (ref. 14), a component of the 20S cyclosome/anaphase-promoting complex (APC), which is necessary for cyclin destruction(3,4,11). Expression of non-degradable Cut2 blocks sister-chromatid separation but not cell-cycle progression. This defect can be overcome by grafting the N terminus of cyclin B onto the truncated Cut2, demonstrating that the regulated proteolysis of Cut2 is essential for sister-chromatid separation.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND	Kyoto University			Nagao, Koji/F-5281-2011	Nagao, Koji/0000-0003-1418-6988; Funabiki, Hironori/0000-0003-4831-4087				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; CREANOR J, 1990, J CELL SCI, V96, P435; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HAGAN IM, 1988, J CELL SCI, V89, P343; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IMIGER S, 1995, CELL, V81, P269; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; RIMMINGTON G, 1994, J CELL SCI, V107, P2729; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H	27	407	414	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					438	441		10.1038/381438a0	http://dx.doi.org/10.1038/381438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632802				2022-12-24	WOS:A1996UN47900055
J	DeChiara, TM; Bowen, DC; Valenzuela, DM; Simmons, MV; Poueymirou, WT; Thomas, S; Kinetz, E; Compton, DL; Rojas, E; Park, JS; Smith, C; DiStefano, PS; Glass, DJ; Burden, SJ; Yancopoulos, GD				DeChiara, TM; Bowen, DC; Valenzuela, DM; Simmons, MV; Poueymirou, WT; Thomas, S; Kinetz, E; Compton, DL; Rojas, E; Park, JS; Smith, C; DiStefano, PS; Glass, DJ; Burden, SJ; Yancopoulos, GD			The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo	CELL			English	Article							ORIGINAL SYNAPTIC SITES; TORPEDO ELECTRIC ORGAN; ACETYLCHOLINE-RECEPTORS; BASAL LAMINA; REGENERATING MUSCLE; GROWTH-FACTOR; AGRIN; NERVE; EXPRESSION; PROTEIN	Formation of neuromuscular synapses requires a series of inductive interactions between growing motor axons and differentiating muscle cells, culminating in the precise juxtaposition of a highly specialized nerve terminal with a complex molecular structure on the postsynaptic muscle surface. The receptors and signaling pathways mediating these inductive interactions are not known. We have generated mice with a targeted disruption of the gene encoding MuSK, a receptor tyrosine kinase selectively localized to the postsynaptic muscle surface. Neuromuscular synapses do not form in these mice, suggesting a failure in the induction of synapse formation. Together with the results of an accompanying manuscript, our findings indicate that MuSK responds to a critical nerve-derived signal (agrin), and in turn activates signaling cascades responsible for all aspects of synapse formation, including organization of the postsynaptic membrane, synapse-specific transcription, and presynaptic differentiation.	NYU,MED CTR,MOL NEUROBIOL PROGRAM,NEW YORK,NY 10016	New York University	DeChiara, TM (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Smith, Cynthia/AAY-6219-2020; Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Smith, Cynthia/0000-0003-3691-0324; Glass, David/0000-0001-6187-4164; Burden, Steven/0000-0002-3550-6891	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021579, R01NS027963, R01NS036193] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS036193-01A1S1, NS21579, NS27963, R01 NS036193] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BARBACID M, 1993, ONCOGENE, V8, P2033; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; Burden Steven J., 1995, Seminars in Developmental Biology, V6, P59, DOI 10.1016/S1044-5781(06)80085-X; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CARTAUD J, 1993, EUR J NEUROSCI, V5, P191, DOI 10.1111/j.1460-9568.1993.tb00485.x; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; CONOVER JC, 1995, NATURE, V375, P35; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; FALLS DL, 1990, COLD SPRING HARB SYM, V55, P397; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GANJU P, 1995, ONCOGENE, V11, P281; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HARRIS DA, 1989, NATURE, V337, P173, DOI 10.1038/337173a0; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KARNOVSKY MJ, 1964, J CELL BIOL, V23, P217, DOI 10.1083/jcb.23.2.217; KUFFLER DP, 1986, J COMP NEUROL, V250, P228, DOI 10.1002/cne.902500209; LETINSKY MS, 1976, J NEUROCYTOL, V5, P691, DOI 10.1007/BF01181582; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCMAHAN UJ, 1984, J CELL BIOL, V98, P1453, DOI 10.1083/jcb.98.4.1453; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; QU Z, 1994, J NEUROSCI, V14, P6834; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; SANES JR, 1995, DEV BIOL, V6, P163; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEALOCK R, 1994, CELL, V77, P617, DOI 10.1016/0092-8674(94)90045-0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SIMON AM, 1992, DEVELOPMENT, V114, P545; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SON YJ, 1995, NEURON, V14, P133, DOI 10.1016/0896-6273(95)90247-3; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1995, J CELL BIOL, V128, P1121, DOI 10.1083/jcb.128.6.1121; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	65	715	732	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					501	512		10.1016/S0092-8674(00)81251-9	http://dx.doi.org/10.1016/S0092-8674(00)81251-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653786	hybrid			2022-12-24	WOS:A1996UM41500008
J	Hareven, D; Gutfinger, T; Parnis, A; Eshed, Y; Lifschitz, E				Hareven, D; Gutfinger, T; Parnis, A; Eshed, Y; Lifschitz, E			The making of a compound leaf: Genetic manipulation of leaf architecture in tomato	CELL			English	Article							PLANT DEVELOPMENT; CLONAL ANALYSIS; HOMEOBOX GENE; MAIZE; EXPRESSION; LEAVES; KNOTTED-1; MERISTEM; FATES	The most distinctive morphogenetic feature of leaves is their being either simple or compound. To study the basis for this dichotomy, we have exploited the maize homeobox-containing Knotted-1 (Kn1) gene in conjunction with mutations that alter the tomato compound leaf. We show that misexpression of Kn1 confers different phenotypes on simple and compound leaves. Up to 2000 leaflets, organized in compound reiterated units, are formed in tomato leaves expressing Kn1. In contrast, Kn1 induces leaf malformations but fails to elicit leaf ramification in plants with inherent simple leaves such as Arabidopsis or in tomato mutant plants with simple leaves. Moreover, the tomato Kn1 ortholog, unlike that of Arabidopsis, is expressed in the leaf primordia. Presumably, the two alternative leaf forms are conditioned by different developmental programs in the primary appendage that is common to all types of leaves.	HEBREW UNIV JERUSALEM, FAC AGR, DEPT GENET & FIELD CROPS, IL-70700 REHOVOT, ISRAEL	Hebrew University of Jerusalem	Hareven, D (corresponding author), TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL.			Eshed, Yuval/0000-0001-8290-0018				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BECRAFT PW, 1994, GENETICS, V136, P295; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CARUSO JL, 1968, AM J BOT, V55, P1169, DOI 10.2307/2440737; CUTTER EG, 1971, PLANT ANATOMY EXPT I, P117; DENGLER NG, 1984, BOT GAZ, V145, P66, DOI 10.1086/337428; DOLAN L, 1991, DEVELOPMENT, P39; FREELING M, 1992, DEV BIOL, V153, P44, DOI 10.1016/0012-1606(92)90090-4; FREELING M, 1985, GENETICS, V111, P617; HAKE S, 1992, TRENDS GENET, V8, P109, DOI 10.1016/0168-9525(92)90065-C; HAKE S, 1989, EMBO J, V8, P15, DOI 10.1002/j.1460-2075.1989.tb03343.x; HAREVEN D, 1994, EUPHYTICA, V79, P235, DOI 10.1007/BF00022524; HELM J., 1951, Zuchter, V21, P89, DOI 10.1007/BF00710588; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jackson D.P., 1991, MOL PLANT PATHOLOGY; KAPLAN D R, 1973, Cellule, V69, P251; KAPLAN DR, 1983, SCI AM, V249, P98, DOI 10.1038/scientificamerican0783-98; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MARKS GA, 1987, PLANT MOL BIOL REP, V5, P311; MATHAN DS, 1962, AM J BOT, V49, P504, DOI 10.2307/2439421; MATSUOKA M, 1993, PLANT CELL, V5, P1039, DOI 10.1105/tpc.5.9.1039; MCCORMICK S, 1991, PLANT TISSUE CULTU B, V6, P1; PNUELI L, 1994, PLANT CELL, V6, P175, DOI 10.1105/tpc.6.2.175; POETHIG RS, 1985, PLANTA, V165, P170, DOI 10.1007/BF00395039; POETHIG RS, 1987, AM J BOT, V74, P581, DOI 10.2307/2443838; PRIHADASH A, 1992, PLANT CELL, V4, P149, DOI 10.1105/tpc.4.2.149; SIHA N, 1994, DEV GENET, V15, P401; SINHA N, 1993, CURR TOP DEV BIOL, V28, P47, DOI 10.1016/S0070-2153(08)60209-4; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SMITH LG, 1992, PLANT CELL, V4, P1017, DOI 10.1105/tpc.4.9.1017; SMITH LG, 1992, DEVELOPMENT, V116, P21; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STETTLER RF, 1964, AM J BOT, V51, P253, DOI 10.2307/2440294; STEVENS AM, 1986, TOMATO CROP; SUSSEX IM, 1989, CELL, V56, P225, DOI 10.1016/0092-8674(89)90895-7; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0	41	328	356	3	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					735	744		10.1016/S0092-8674(00)81051-X	http://dx.doi.org/10.1016/S0092-8674(00)81051-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625411	Bronze			2022-12-24	WOS:A1996TZ99000011
J	Rowe, T				Rowe, T			Coevolution of the mammalian middle ear and neocortex	SCIENCE			English	Article							EVOLUTION; PHYLOGENY; DIDELPHIDAE; MECHANISMS; ONTOGENY	Phylogenetic analysis with x-ray computed tomography of fossilized and recent crania implicates differential growth of the neocortex in the evolution and development of the mammalian middle ear, In premammalian tetrapods, the middle ear evolved as a chain of bones attached to the mandible and cranium, but in adult mammals the chain is detached from the mandible and lies behind it, The neocortex evolved concurrently with detachment of the chain. In mammalian development the auditory chain arises connected to the mandible but later detaches, recapitulating the phylogenetic transformation. In modern didelphid development, the auditory chain reaches mature size by the third week after birth and is then separated from the jaw and displaced caudally as the neocortex grows for another 9 weeks.	UNIV TEXAS,VERTEBRATE PALEONTOL LAB,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	Rowe, T (corresponding author), UNIV TEXAS,DEPT GEOL SCI,AUSTIN,TX 78712, USA.							ALBERCH P, 1979, PALEOBIOLOGY, V5, P296, DOI 10.1017/S0094837300006588; Allin E.F., 1986, P283; ALLIN EF, 1975, J MORPHOL, V147, P403, DOI 10.1002/jmor.1051470404; Allman J., 1990, Seminars in the Neurosciences, V2, P257; Bottorff W., 1995, THRINAXODON DIGITAL; BRAMBLE DM, 1978, PALEOBIOLOGY, V4, P271, DOI 10.1017/S009483730000600X; BUTLER AB, 1994, BRAIN RES REV, V19, P66, DOI 10.1016/0165-0173(94)90004-3; CARTER DR, 1987, J BIOMECH, V20, P1095, DOI 10.1016/0021-9290(87)90027-3; CLARK CT, 1993, J MORPHOL, V215, P119, DOI 10.1002/jmor.1052150203; Crompton A.W., 1986, P263; CROMPTON AW, 1978, AM SCI, V66, P192; de Beer G., 1937, DEV VERTEBRATE SKULL; de Beer G., 1958, EMBRYOS ANCESTORS; DESMOND ME, 1977, DEV BIOL, V57, P188, DOI 10.1016/0012-1606(77)90364-5; FILAN SL, 1991, J ZOOL, V225, P577, DOI 10.1111/j.1469-7998.1991.tb04326.x; FINK WL, 1982, PALEOBIOLOGY, V8, P254, DOI 10.1017/S0094837300006977; Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545; GAUTHIER J, 1988, CLADISTICS, V4, P105, DOI 10.1111/j.1096-0031.1988.tb00514.x; GOODRICH ES, 1930, STUDIES STRUCTURE DE; Gould S. J., 1977, ONTOGENY PHYLOGENY; Hall B.K., 1999, EVOLUTIONARY DEV BIO; Hanken J., 1993, SKULL, V1; Hanken J., 1993, SKULL, V2; Hanken J., 1993, SKULL; HERRING SW, 1993, AM ZOOL, V33, P472; Hopson J.A., 1979, P39; Hoyte D. A. N., 1966, International Review of General and Experimental Zoology, V2, P345; JELINEK R, 1970, FOLIA MORPHOL, V17, P184; Jerison HJ., 1973, EVOLUTION BRAIN INTE; JERISON HJ, 1990, NEOCORTEX, P5; Kluge A.G., 1988, P57; Langworthy OR, 1928, J COMP NEUROL, V46, P201, DOI 10.1002/cne.900460107; Larsell O, 1935, J COMP NEUROL, V63, P95, DOI 10.1002/cne.900630107; LENDE RA, 1963, SCIENCE, V141, P730, DOI 10.1126/science.141.3582.730; Maier W., 1987, Gegenbaurs Morphologisches Jahrbuch, V133, P123; McCLAIN JOHN A., 1939, JOUR MORPH, V64, P211, DOI 10.1002/jmor.1050640204; McCrady E, 1937, J EXP ZOOL, V75, P503, DOI 10.1002/jez.1400750306; MCCRADY E, 1938, AM ANAT MEM, V16; NANAGAS IC, 1925, J PHILIPP ISL MED AS, V5, P251; NEWMAN SA, 1990, DEVELOPMENT, V110, P1; NORTHCUTT RG, 1984, AM ZOOL, V24, P710; OLSON EC, 1959, EVOLUTION, V13, P344, DOI 10.2307/2406111; ROSE T, NEW PERSPECTIVES HIS; ROWE T, 1992, SYST BIOL, V41, P372, DOI 10.2307/2992573; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; ROWE T, 1993, MAMMAL PHYLOGENY, P129; SIMPSON GG, 1959, EVOLUTION, V13, P405, DOI 10.2307/2406116; SIMPSON GG, 1927, AM J SCI, V214, P259; THATCH WT, 1992, ANNU REV NEUROSCI, V15, P403; Ulinski P.S., 1986, P149; ULINSKI PS, 1971, J COMP NEUROL, V142, P33, DOI 10.1002/cne.901420104; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WEED LH, 1920, CONTRIB EMBRYOL, V9, P425; Wible J.R., 1991, Journal of Vertebrate Paleontology, V11, P1	54	124	128	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					651	654		10.1126/science.273.5275.651	http://dx.doi.org/10.1126/science.273.5275.651			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662557				2022-12-24	WOS:A1996VA24900049
J	Sugita, M; Jackman, RM; vanDonselaar, E; Behar, SM; Rogers, RA; Peters, PJ; Brenner, MB; Porcelli, SA				Sugita, M; Jackman, RM; vanDonselaar, E; Behar, SM; Rogers, RA; Peters, PJ; Brenner, MB; Porcelli, SA			Cytoplasmic tail-dependent localization of CD1b antigen-presenting molecules to MIICs	SCIENCE			English	Article							INTRACELLULAR-TRANSPORT; INVARIANT CHAIN; LYMPHOCYTES-T; HLA-DM; COMPARTMENTS; MEMBRANE; EXPRESSION; LYSOSOMES; CDNA	CD1 proteins have been implicated as antigen-presenting molecules for T cell-mediated immune responses, but their intracellular localization and trafficking remain uncharacterized. CD1b, a member of this family that presents microbial lipid antigens of exogenous origin, was found to localize to endocytic compartments that included the same specialized subset of endosomes in which major histocompatibility complex (MHC) class II molecules are proposed to bind endocytosed antigens. Unlike MHC class II molecules, which traffic to antigen-loading endosomal compartments [MHC class II compartments (MIICs)] primarily as a consequence of their association with the invariant chain, localization of CD1b to these compartments was dependent on a tyrosine-based motif in its own cytoplasmic tail.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,LYMPHOCYTE BIOL SECT,DIV RHEUMATOL & IMMUNOL,BOSTON,MA 02115; UNIV UTRECHT,FAC MED,DEPT CELL BIOL,UTRECHT,NETHERLANDS; UNIV UTRECHT,FAC MED,INST BIOMEMBRANES,UTRECHT,NETHERLANDS; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Utrecht University; Utrecht University; Harvard University; Harvard T.H. Chan School of Public Health			Behar, Samuel M/C-3541-2009	Sugita, Masahiko/0000-0001-5511-1304; Behar, Samuel/0000-0002-3374-6699				ARUFFO A, 1989, J IMMUNOL, V143, P1723; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BEHAR SM, 1995, J EXP MED, V182, P2007, DOI 10.1084/jem.182.6.2007; BENDELAC A, 1995, SCIENCE, V269, P185, DOI 10.1126/science.7542402; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; LERCH PG, 1983, HUM IMMUNOL, V6, P13, DOI 10.1016/0198-8859(83)90070-8; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OLIVE D, 1984, IMMUNOGENETICS, V20, P253, DOI 10.1007/BF00364207; PETERS PJ, 1995, J EXP MED, V182, P325, DOI 10.1084/jem.182.2.325; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; ROGERS RA, 1993, J CELL SCI, V106, P485; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SUGITA M, 1995, J BIOL CHEM, V270, P1443, DOI 10.1074/jbc.270.3.1443; SUGITA M, UNPUB; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	31	200	203	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1996	273	5273					349	352		10.1126/science.273.5273.349	http://dx.doi.org/10.1126/science.273.5273.349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY202	8662520				2022-12-24	WOS:A1996UY20200037
J	Semenza, JC; Rubin, CH; Falter, KH; Selanikio, JD; Flanders, WD; Howe, HL; Wilhelm, JL				Semenza, JC; Rubin, CH; Falter, KH; Selanikio, JD; Flanders, WD; Howe, HL; Wilhelm, JL			Heat-related deaths during the July 1995 heat wave in Chicago	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							APPARENT TEMPERATURE; ST-LOUIS; SULTRINESS; MORTALITY	Background During a record-setting heat wave in Chicago in July 1995, there were at least 700 excess deaths, most of which were classified as heat-related. We sought to determine who was at greatest risk for heat-related death. Methods We conducted a case-control study in Chicago to identify risk factors associated with heat-related death and death from cardiovascular causes from July 14 through July 17, 1995. Beginning on July 21, we interviewed 339 relatives, neighbors, or friends of those who died and 339 controls matched to the case subjects according to neighborhood and age. Results The risk of heat-related death was increased for people with known medical problems who were confined to bed (odds ratio as compared with those who were not confined to bed, 5.5) or who were unable to care for themselves (odds ratio, 4.1). Also at increased risk were those who did not leave home each day (odds ratio, 6.7), who lived alone (odds ratio, 2.3), or who lived on the top floor of a building (odds ratio, 4.7). Having social contacts such as group activities or friends in the area was protective. In a multivariate analysis, the strongest risk factors for heat-related death were being confined to bed (odds ratio, 8.2) and living alone (odds ratio, 2.3); the risk of death was reduced for people with working air conditioners (odds ratio, 0.3) and those with access to transportation (odds ratio, 0.3). Deaths classified as due to cardiovascular causes had risk factors similar to those for heat-related death. Conclusions In this study of the 1995 Chicago heat wave, those at greatest risk of dying from the heat were people with medical illnesses who were socially isolated and did not have access to air conditioning. In future heat emergencies, interventions directed to such persons should reduce deaths related to the heat. (C) 1996, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,ATLANTA,GA 30341; ILLINOIS DEPT PUBL HLTH,SPRINGFIELD,IL 62761; DEPT PUBL HLTH,CHICAGO,IL	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Chicago Department of Public Health								AGRESTI A, 1990, CATEGORICAL DATA ANA, P56; ALDERSON MR, 1967, BRIT J PREV SOC MED, V21, P22; APPLEGATE WB, 1981, J AM GERIATR SOC, V29, P337, DOI 10.1111/j.1532-5415.1981.tb01238.x; BAROR O, 1969, J APPL PHYSIOL, V26, P403, DOI 10.1152/jappl.1969.26.4.403; BEADENKOPF WG, 1963, J CHRON DIS, V16, P249, DOI 10.1016/0021-9681(63)90030-4; Bridger C A, 1968, Int J Biometeorol, V12, P51, DOI 10.1007/BF01552978; CLARKE JF, 1972, ENVIRON RES, V5, P93, DOI 10.1016/0013-9351(72)90023-0; ELLIS FP, 1980, Q J MED, V49, P1; ELLIS FP, 1972, ENVIRON RES, V5, P1, DOI 10.1016/0013-9351(72)90019-9; GOVER MARY, 1938, PUBL HEALTH REPTS, V53, P1122, DOI 10.2307/4582590; GWYNNE JF, 1974, NEW ZEAL MED J, V80, P336; HAYMES EM, 1975, J APPL PHYSIOL, V39, P457, DOI 10.1152/jappl.1975.39.3.457; HENSCHEL A, 1969, AM J PUBLIC HEALTH N, V59, P2232, DOI 10.2105/AJPH.59.12.2232; JONES TS, 1982, JAMA-J AM MED ASSOC, V247, P3327, DOI 10.1001/jama.247.24.3327; KILBOURNE EM, 1982, JAMA-J AM MED ASSOC, V247, P3332, DOI 10.1001/jama.247.24.3332; KILBOURNE EM, 1986, MAXCY ROSENAU PUBLIC, P703; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KOLLIAS J, 1964, J PHARMACOL EXP THER, V145, P373; MARTINEZ BF, 1989, JAMA-J AM MED ASSOC, V262, P2246, DOI 10.1001/jama.262.16.2246; *NAT CTR HLTH STAT, 1992, MORT PUBL US COMP DA; *NAT OC ATM ADM, 1995, 1995 NAT OC ATM ADM; ROGOT E, 1992, AM J EPIDEMIOL, V136, P106, DOI 10.1093/oxfordjournals.aje.a116413; SAS Institute, 1992, SAS STAT SOFTW CHANG; SCHUMAN SH, 1972, ENVIRON RES, V5, P59, DOI 10.1016/0013-9351(72)90020-5; SCHUMAN SH, 1964, JAMA-J AM MED ASSOC, V189, P733; STEADMAN RG, 1979, J APPL METEOROL, V18, P861, DOI 10.1175/1520-0450(1979)018<0861:TAOSPI>2.0.CO;2; STEADMAN RG, 1984, J CLIM APPL METEOROL, V23, P1674, DOI 10.1175/1520-0450(1984)023<1674:AUSOAT>2.0.CO;2; STEADMAN RG, 1979, J APPL METEOROL, V18, P874, DOI 10.1175/1520-0450(1979)018<0874:TAOSPI>2.0.CO;2; YAGLOU C. P., 1927, JOUR IND HYG, V9, P297; 1981, MMWR-MORBID MORTAL W, V30, P277; 1995, MMWR-MORBID MORTAL W, V44, P577	31	850	892	3	114	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	1996	335	2					84	90		10.1056/NEJM199607113350203	http://dx.doi.org/10.1056/NEJM199607113350203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW353	8649494	Bronze			2022-12-24	WOS:A1996UW35300003
J	Hatanaka, H; Ogura, K; Moriyama, K; Ichikawa, S; Yahara, I; Inagaki, F				Hatanaka, H; Ogura, K; Moriyama, K; Ichikawa, S; Yahara, I; Inagaki, F			Tertiary structure of destrin and structural similarity between two actin-regulating protein families	CELL			English	Article							ISOTOPICALLY ENRICHED PROTEINS; LABEL FINGERPRINTINGS SHOW; SIDE-CHAIN H-1; DEPOLYMERIZING PROTEIN; BINDING PROTEIN; HEAT-SHOCK; F-ACTIN; NMR-SPECTROSCOPY; C-13/N-15-ENRICHED PROTEINS; BACKBONE AMIDE	Destrin is an isoprotein of cofilin that regulates actin cytoskeleton in various eukaryotes. We determined the tertiary structure of destrin by triple-resonance multidimensional nuclear magnetic resonance. In spite of there being no significant amino acid sequence homology, we found that the folding of destrin was strikingly similar to that of repeated segments in the gelsolin family, which resulted in a new protein fold group. Sequential dissimilarity of the actin-binding helix of destrin to that of gelsolin explains the Ca2+-independent actin-binding of destrin. Possible mechanisms of phosphorylation-sensitive phosphoinositide-competitive actin binding, of pH-dependent filament severing, and of nuclear translocation with actin in response to stresses, are discussed on the basis of the tertiary structure.			Hatanaka, H (corresponding author), TOKYO METROPOLITAN INST MED SCI,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.							ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; ABE H, 1989, J BIOCHEM-TOKYO, V106, P172, DOI 10.1093/oxfordjournals.jbchem.a122810; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; BERNSTEIN BW, 1982, CELL MOTIL CYTOSKEL, V2, P1, DOI 10.1002/cm.970020102; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Brunger A.T., 1993, X PLOR VERSION 3 1 S; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; COOPER JA, 1986, J BIOL CHEM, V261, P477; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUMMOND IAS, 1986, MOL CELL BIOL, V6, P1767, DOI 10.1128/MCB.6.5.1767; GIULIANO KA, 1988, BIOCHEMISTRY-US, V27, P8931, DOI 10.1021/bi00425a009; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HATANAKA H, 1994, J MOL BIOL, V240, P155, DOI 10.1006/jmbi.1994.1429; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HEGYI G, 1974, EUR J BIOCHEM, V44, P7, DOI 10.1111/j.1432-1033.1974.tb03452.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; IIDA K, 1993, GENE, V124, P115; IIDA K, 1986, EXP CELL RES, V165, P207, DOI 10.1016/0014-4827(86)90545-8; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; KANAMORI T, 1995, J BIOL CHEM, V270, P8061, DOI 10.1074/jbc.270.14.8061; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MARKUS MA, 1994, PROTEIN SCI, V3, P70; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MCLAUGHLIN PJ, 1995, ANNU REV BIOPH BIOM, V24, P643, DOI 10.1146/annurev.bb.24.060195.003235; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; MORIYAMA K, 1990, J BIOL CHEM, V265, P5768; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OHTA Y, 1989, J BIOL CHEM, V264, P16143; PALMER AG, 1992, J MAGN RESON, V96, P416, DOI 10.1016/0022-2364(92)90097-Q; POLLARD TD, 1994, ANNU REV CELL BIOL, V10, P207, DOI 10.1146/annurev.cellbio.10.1.207; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; SCHNUCHEL A, 1995, J MOL BIOL, V247, P21, DOI 10.1006/jmbi.1994.0118; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SEIP S, 1992, J MAGN RESON, V100, P406, DOI 10.1016/0022-2364(92)90274-B; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P6186, DOI 10.1021/bi00368a053; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P5269, DOI 10.1021/bi00438a052; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485	71	125	128	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1047	1055		10.1016/S0092-8674(00)81305-7	http://dx.doi.org/10.1016/S0092-8674(00)81305-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674111	Bronze			2022-12-24	WOS:A1996UV48400011
J	Stassinopoulos, A; Ji, J; Gao, XL; Goldberg, IH				Stassinopoulos, A; Ji, J; Gao, XL; Goldberg, IH			Solution structure of a two-base DNA bulge complexed with an enediyne cleaving analog	SCIENCE			English	Article							SITE-SPECIFIC CLEAVAGE; NEOCARZINOSTATIN CHROMOPHORE; TAT-PROTEIN; ACTIVATION; LOOP; NMR; CONFORMATION; SEQUENCES; BINDING; MODEL	Nucleic acid bulges have been implicated in a number of biological processes and are specific cleavage targets for the enediyne antitumor antibiotic neocarzinostatin chromophore in a base-catalyzed, radical-mediated reaction. The solution structure of the complex between an analog of the bulge-specific cleaving species and an oligodeoxynucleotide containing a two-base bulge was elucidated by nuclear magnetic resonance. An unusual binding mode involves major groove recognition by the drug carbohydrate unit and tight fitting of the wedge-shaped drug in the triangular prism pocket formed by the two looped-out bulge bases and the neighboring base pairs. The two drug rings mimic helical DNA bases, complementing the bent DNA structure. The putative abstracting drug radical is 2.2 +/- 0.1 angstroms from the pro-S H5' of the target bulge nucleotide. This structure clarifies the mechanism of bulge recognition and cleavage by a drug and provides insight into the design of bulge-specific nucleic acid binding molecules.	UNIV HOUSTON,DEPT CHEM,HOUSTON,TX 77204; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	University of Houston System; University of Houston; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R35CA044257] Funding Source: NIH RePORTER; NCI NIH HHS [CA44257] Funding Source: Medline; NIGMS NIH HHS [GM53793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; CaceresCortes J, 1996, BIOCHEMISTRY-US, V35, P616, DOI 10.1021/bi9518398; CRIPPEN GM, 1981, DISTANCE GEOMETRY CO; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; DURAND M, 1990, NUCLEIC ACIDS RES, V18, P6353, DOI 10.1093/nar/18.21.6353; ECKEL LM, 1994, BIOCHEMISTRY-US, V33, P13611, DOI 10.1021/bi00250a012; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; GAO XL, 1995, BIOCHEMISTRY-US, V34, P40, DOI 10.1021/bi00001a006; GAO XL, 1989, Q REV BIOPHYS, V22, P93, DOI 10.1017/S0033583500003814; GOLDBERG IH, 1994, ENEDIYNE ANTIBIOTICS, P327; HANSEN M, 1995, CHEM BIOL, V2, P229, DOI 10.1016/1074-5521(95)90273-2; HENSENS OD, 1993, J AM CHEM SOC, V115, P11030, DOI 10.1021/ja00076a087; HENSENS OD, 1994, P NATL ACAD SCI USA, V91, P4534, DOI 10.1073/pnas.91.10.4534; HJAALT TAH, 1995, NUCLEIC ACIDS RES, V23, P580; JAMES TL, 1994, CURR OPIN STRUC BIOL, V4, P275, DOI 10.1016/S0959-440X(94)90320-4; KAPPEN LS, 1993, SCIENCE, V261, P1319, DOI 10.1126/science.8362243; KAPPEN LS, 1995, BIOCHEMISTRY-US, V34, P5997, DOI 10.1021/bi00017a029; KAPPEN LS, 1993, BIOCHEMISTRY-US, V32, P13138, DOI 10.1021/bi00211a024; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LILLEY MJ, 1995, P NATL ACAD SCI USA, V92, P7140; Mao B, 1995, BIOCHEMISTRY-US, V34, P16641, DOI 10.1021/bi00051a012; MAO B, 1995, BIOCHEMISTRY-US, V34, P6226, DOI 10.1021/bi00018a027; NELSON JW, 1985, BIOCHEMISTRY-US, V24, P6416, DOI 10.1021/bi00344a016; NICOLAOU KC, 1992, SCIENCE, V256, P1172, DOI 10.1126/science.256.5060.1172; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; QUIGLEY GJ, 1980, P NATL ACAD SCI-BIOL, V77, P7204, DOI 10.1073/pnas.77.12.7204; RICE JA, 1989, BIOCHEMISTRY-US, V28, P4512, DOI 10.1021/bi00436a058; RIPLEY LS, 1982, P NATL ACAD SCI-BIOL, V79, P4128, DOI 10.1073/pnas.79.13.4128; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4004, DOI 10.1021/bi00131a016; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SLAMA-SCHWOK A, 1995, J AM CHEM SOC, V117, P6822, DOI 10.1021/ja00131a003; STASSINOPOULOS A, 1995, BIOCHEMISTRY-US, V34, P15359, DOI 10.1021/bi00046a045; Turner DH, 1992, CURR OPIN STRUC BIOL, V2, P334; WHITE SA, 1987, NUCLEIC ACIDS RES, V15, P4049, DOI 10.1093/nar/15.10.4049; WILLIAMS LD, 1988, BIOCHEMISTRY-US, V27, P3004, DOI 10.1021/bi00408a051; WILSON WD, 1994, NEW J CHEM, V18, P419; WOODSON SA, 1988, BIOCHEMISTRY-US, V27, P3130, DOI 10.1021/bi00409a004; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YANG CF, 1995, BIOCHEMISTRY-US, V34, P2267, DOI 10.1021/bi00007a022	44	63	68	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1996	272	5270					1943	1946		10.1126/science.272.5270.1943	http://dx.doi.org/10.1126/science.272.5270.1943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658168				2022-12-24	WOS:A1996UV29400050
J	vanderHoeven, F; Zakany, J; Duboule, D				vanderHoeven, F; Zakany, J; Duboule, D			Gene transpositions in the HoxD complex reveal a hierarchy of regulatory controls	CELL			English	Article							EXPRESSION PATTERNS; BITHORAX COMPLEX; HOMEOBOX GENES; MOUSE EMBRYOS; RETINOIC ACID; DROSOPHILA; MURINE; ELEMENTS; BODY; ORGANIZATION	Vertebrate Hox genes are activated following a temporal sequence that reflects their linear order in the clusters. We introduced two Herd transcription units, labeled with lacZ, to an ectopic 5' position in the HoxD complex. Early expression of the relocated genes was delayed and resembled that of the neighboring Hoxd-13. At later stages, locus-dependent expression in distal limbs and the genital eminence was observed, indicating that common regulatory mechanisms are used for several genes. These experiments also illustrated that neighboring genes can share the same cis-acting sequence and that moving genes around in the complex induces novel regulatory interferences. These results suggest that high order regulation controls the activation of Hox genes and highlight three important constraints responsible for the conservation of Hox gene clustering.			vanderHoeven, F (corresponding author), UNIV GENEVA, DEPT ZOOL & ANIM BIOL, QUAI ERNEST ANSERMET 30, CH-1211 GENEVA 4, SWITZERLAND.			duboule, denis/0000-0001-9961-2960				ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; CASTELLIGAIR J, 1995, DEVELOPMENT, V121, P2973; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DEKKER EJ, 1993, MECH DEVELOP, V40, P3, DOI 10.1016/0925-4773(93)90083-A; DESCHAMPS J, 1993, DEV BIOL, V156, P473, DOI 10.1006/dbio.1993.1093; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1994, DEVELOPMENT, P143; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUBOULE D, 1994, DEVELOPMENT, P135; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1991, BIOESSAYS, V13, P505, DOI 10.1002/bies.950131004; GAUNT SJ, 1994, DEV DYNAM, V199, P229, DOI 10.1002/aja.1001990307; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1990, TRENDS GENET, V6, P208; GERARD M, 1993, EMBO J, V12, P3539, DOI 10.1002/j.1460-2075.1993.tb06028.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GRAPINBOTTON A, 1995, DEVELOPMENT, V121, P2707; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; INOUYE M, 1976, Congenital Anomalies, V16, P171; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; Joyner AL, 1993, GENE TARGETING PRACT; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MULLER J, 1995, DEVELOPMENT, V121, P2847; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; RENUCCI A, 1992, EMBO J, V11, P1459, DOI 10.1002/j.1460-2075.1992.tb05190.x; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; Sordino P, 1996, TRENDS ECOL EVOL, V11, P114, DOI 10.1016/0169-5347(96)81089-5; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; STEWART A, 1995, TRENDS GENET, V11, P35; vanderHoeven F, 1996, MECH DEVELOP, V54, P9, DOI 10.1016/0925-4773(95)00455-6; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZAKANY J, 1988, NEURON, V1, P679, DOI 10.1016/0896-6273(88)90167-5	51	193	193	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1996	85	7					1025	1035		10.1016/S0092-8674(00)81303-3	http://dx.doi.org/10.1016/S0092-8674(00)81303-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674109	Bronze			2022-12-24	WOS:A1996UV48400009
J	Lerman, C; Narod, S; Schulman, K; Hughes, C; GomezCaminero, A; Bonney, G; Gold, K; Trock, B; Main, D; Lynch, J; Fulmore, C; Snyder, C; Lemon, SJ; Conway, T; Tonin, P; Lenoir, G; Lynch, H				Lerman, C; Narod, S; Schulman, K; Hughes, C; GomezCaminero, A; Bonney, G; Gold, K; Trock, B; Main, D; Lynch, J; Fulmore, C; Snyder, C; Lemon, SJ; Conway, T; Tonin, P; Lenoir, G; Lynch, H			BRCA1 testing in families with hereditary breast-ovarian cancer - A prospective study of patient decision making and outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUNTINGTONS-DISEASE; SUSCEPTIBILITY; RISK; MODELS	Objectives.-To identify predictors of utilization of breast-ovarian cancer susceptibility (BRCA1 gene) testing and to evaluate outcomes of participation in a testing program. Design.-Prospective cohort study with baseline interview assessment of predictor variables (eg, sociodemographic factors, knowledge about hereditary cancer and genetic testing, perceptions of testing benefits, limitations, and risks). BRCA1 test results were offered after an education and counseling session in a research setting. Outcome variables (including depression, functional health status, and prophylactic surgery plans [follow-up only]) were assessed at baseline and 1-month follow-up interviews. Participants.-Adult male and female members (n=279) of families with BRCA1-linked hereditary breast-ovarian cancer (HBOC). Results.-Of subjects who completed a baseline interview (n=192), 60% requested BRCA1 test results (43% of all study subjects requested results). Requests for results were more frequent for persons with health insurance (odds ratio [OR], 3.74; 95% confidence interval [CI], 2.06-6.80); more first-degree relatives affected with breast cancer (OR, 1.59; 95% CI, 1.16-2.16); more knowledge about BRCA1 testing (OR, 1.85; 95% CI, 1.36-2.50); and indicating that test benefits are important (OR, 1.45; 95% CI, 1.13-1.86). At follow-up, noncarriers of BRCA1 mutations showed statistically significant reductions in depressive symptoms and functional impairment compared with carriers and nontested individuals. individuals identified as mutation carriers did not exhibit increases in depression and functional impairment. Among unaffected women with no prior prophylactic surgery, 17% of carriers (2/12) intended to have mastectomies and 33% (4/12) to have oophorectomies. Conclusions.-Only a subset of HBOC family members are likely to request BRCA1 testing when available. Rates of test use may be higher in persons of a higher socioeconomic status and those with more relatives affected with breast cancer. For some high-risk individuals who receive test results in a research setting that includes counseling, there may be psychological benefits. More research is needed to assess the generalizability of these results and evaluate the long-term consequences of BRCA1 testing.	WOMENS COLL HOSP,DEPT MED,TORONTO,ON M5S 1B2,CANADA; FOX CHASE CANC CTR,DIV POPULAT SCI,PHILADELPHIA,PA 19111; CREIGHTON UNIV,MED CTR,DEPT PREVENT MED & PUBL HLTH,OMAHA,NE 68178; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 2T5,CANADA; INT AGCY RES CANC,UNIT MECHANISMS CARCINOGENESIS,F-69372 LYON,FRANCE	University of Toronto; University Toronto Affiliates; Womens College Hospital; Fox Chase Cancer Center; Creighton University; McGill University; World Health Organization; International Agency for Research on Cancer (IARC)	Lerman, C (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT MED,LOMBARDI CANC CTR,DIV CANC PREVENT & CONTROL,WASHINGTON,DC 20007, USA.		Lerman, Caryn/AHC-5180-2022; Narod, Steven A/AAA-6112-2022	Gomez-Caminero, Andres/0000-0002-8728-3124	NCI NIH HHS [CA01604] Funding Source: Medline; NIMH NIH HHS [MH54435] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA001604] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ajzen I., 1980, UNDERSTANDING ATTITU; BEKKER H, 1993, BRIT MED J, V306, P14; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BLOCH M, 1992, AM J MED GENET, V42, P499, DOI 10.1002/ajmg.1320420416; BONNEY GE, 1986, BIOMETRICS, V42, P611, DOI 10.2307/2531211; BONNEY GE, 1992, HUM HERED, V42, P28, DOI 10.1159/000154044; CHALIKI H, 1995, AM J PUBLIC HEALTH, V85, P1133, DOI 10.2105/AJPH.85.8_Pt_1.1133; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; CRAUFURD D, 1989, LANCET, V2, P603; EASTON DF, 1993, AM J HUM GENET, V52, P678; ENGEL JF, 1995, CONSUMER BEHAVIOR; EVERSKIEBOOMS G, 1989, CLIN GENET, V35, P29; FEUNTEUN J, 1993, AM J HUM GENET, V52, P736; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; KESSLER S, 1987, AM J MED GENET, V26, P259, DOI 10.1002/ajmg.1320260204; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; LERMAN C, 1994, J CLIN ONCOL, V12, P843, DOI 10.1200/JCO.1994.12.4.843; LERMAN C, 1994, ARCH INTERN MED, V154, P609, DOI 10.1001/archinte.154.6.609; LERMAN C, 1995, AM J MED GENET, V57, P385, DOI 10.1002/ajmg.1320570304; LYNCH HT, 1994, CANCER, V74, P1184, DOI 10.1002/1097-0142(19940801)74:3+<1184::AID-CNCR2820741530>3.0.CO;2-4; LYNCH HT, 1992, CANCER, V69, P1404, DOI 10.1002/1097-0142(19920315)69:6<1404::AID-CNCR2820690616>3.0.CO;2-R; LYNCH HT, 1993, ARCH INTERN MED, V153, P1979; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; NELSON N, 1995, J NATL CANCER I, V88, P70; *OFF TECHN ASS, 1992, OTABPBA98 PUBL; QUAID KA, 1993, AM J MED GENET, V45, P41, DOI 10.1002/ajmg.1320450112; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SEROVA O, 1996, AM J HUM GENET, V58, P51; Sherbourne CD, 1992, MEASURING FUNCTIONIN, P205; Sherbourne CD, 1992, MEASURING FUNCTIONIN, P194; STRUEWING JP, 1995, CANCER EPIDEM BIOMAR, V4, P169; STRUEWING JP, 1995, NAT GENET, V11, P196; TAMBOR ES, 1994, AM J HUM GENET, V55, P626; *US DEP HLTH HUM S, 1993, NIH PUBL; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1994, JAMA-J AM MED ASSOC, V271, P785; 1994, AM J HUM GENET, V55, pR2	43	637	638	2	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1996	275	24					1885	1892		10.1001/jama.275.24.1885	http://dx.doi.org/10.1001/jama.275.24.1885			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR975	8648868				2022-12-24	WOS:A1996UR97500033
J	Morrison, HI; Schaubel, D; Desmeules, M; Wigle, DT				Morrison, HI; Schaubel, D; Desmeules, M; Wigle, DT			Serum folate and risk of fatal coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAROTID ARTERIAL-DISEASE; CANADA SURVEY COHORT; FOLLOW-UP; DEFICIENCY; MORTALITY; ADULTS	Objective.-To assess the relationship between serum folate level and the risk of fatal coronary heart disease (CHD) among men and women. Design.-Retrospective cohort study with serum folate levels measured from September 1970 to December 1972, with follow-up through 1985. Setting.-Participants in the Nutrition Canada Survey. Participants.-A total of 5056 Canadian men and women aged 35 to 79 years with no history of self-reported CHD. Main Outcome Measure.-Fifteen-year CHD mortality. Results.-A total of 165 CHD deaths were observed. We found a statistically significant association between serum folate level and risk of fatal CHD, with rate ratios for individuals in the lowest serum folate level category (<6.8 nmol/L [3 ng/mL]) compared with the highest category (>13.6 nmol/L [6 ng/mL]) of 1.69 (95% confidence interval, 1.10-2.61). Conclusions.-These data indicate that low serum folate levels are associated with an increased risk of fatal CHD.			Morrison, HI (corresponding author), DEPT HLTH & WELF,CANC BUR,LAB CTR DIS CONTROL BLDG,TUNNEYS PASTURE,OTTAWA,ON K1A 0L2,CANADA.							ARONOW WS, 1992, NEW YORK STATE J MED, V92, P424; ARONOW WS, 1992, CORONARY ARTERY DIS, V3, P249, DOI 10.1097/00019501-199203000-00012; BAYLIS EM, 1971, LANCET, V1, P62; BLOCK G, 1993, J NATL CANCER I, V85, P846, DOI 10.1093/jnci/85.11.846; BUTTERWORTH CE, 1992, JAMA-J AM MED ASSOC, V267, P528, DOI 10.1001/jama.267.4.528; CHANARIN I, 1994, CLIN INVEST MED, V17, P253; *DEP NAT HLTH WELF, 1978, H58361973 DEP NAT HL; *DEP NAT HLTH WELF, 1973, H58361973 DEP NAT HL; FREUDENHEIM JL, 1991, INT J EPIDEMIOL, V20, P368, DOI 10.1093/ije/20.2.368; GABY SK, 1991, VITAMIN INTAKE HLTH; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; JOHANSEN H, 1987, CAN MED ASSOC J, V136, P823; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; Kannel WB, 1983, PREVENTION CORONARY, P1; MARTIN M, 1986, LANCET, V2, P923; MOJONNIER L, 1968, J AM DIET ASSOC, V52, P288; *NAT CTR HLTH STAT, 1967, INT CLASS DIS AD US; *NAT RES COUNC, 1989, REC DIET ALL; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; ROMANO PS, 1995, AM J PUBLIC HEALTH, V85, P667, DOI 10.2105/AJPH.85.5.667; SALONEN JT, 1991, ARTERIOSCLER THROMB, V11, P1245, DOI 10.1161/01.ATV.11.5.1245; SAUBERLICH HE, 1987, AM J CLIN NUTR, V46, P1016, DOI 10.1093/ajcn/46.6.1016; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; SEMENCIW RM, 1988, INT J EPIDEMIOL, V17, P317, DOI 10.1093/ije/17.2.317; SHANNON HS, 1989, CAN J PUBLIC HEALTH, V80, P54; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; [No title captured]; 1991, LANCET, V338, P131	32	263	271	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1996	275	24					1893	1896		10.1001/jama.275.24.1893	http://dx.doi.org/10.1001/jama.275.24.1893			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR975	8648869				2022-12-24	WOS:A1996UR97500034
J	Calder, SJ; Anderson, GH; Gregg, PJ				Calder, SJ; Anderson, GH; Gregg, PJ			Certification of cause of death in patients dying soon after proximal femoral fracture	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY		UNIV LEICESTER,GLENFIELD GEN HOSP,DEPT ORTHOPAED SURG,LEICESTER LE3 9QP,LEICS,ENGLAND; LEICESTER ROYAL INFIRM,DEPT ORTHOPAED SURG,LEICESTER LE1 5WW,LEICS,ENGLAND	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Leicester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		PARKER MJ, 1991, PUBLIC HEALTH, V105, P443, DOI 10.1016/S0033-3506(05)80614-6; WOOD DJ, 1992, J BONE JOINT SURG BR, V74, P199, DOI 10.1302/0301-620X.74B2.1544951; 1992, RIGHTS RESPONSIBILIT, P79	3	19	19	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1515	1515		10.1136/bmj.312.7045.1515	http://dx.doi.org/10.1136/bmj.312.7045.1515			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UR823	8646144	Green Published			2022-12-24	WOS:A1996UR82300022
J	Spicer, DB; Rhee, J; Cheung, WL; Lassar, AB				Spicer, DB; Rhee, J; Cheung, WL; Lassar, AB			Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein twist	SCIENCE			English	Article							MUSCLE-SPECIFIC ENHANCER; CREATINE-KINASE GENE; REGULATORY ELEMENTS; DROSOPHILA-TWIST; BINDING-FACTOR; HLH PROTEINS; CELLS; EXPRESSION; MYF-5; INACTIVATION	The myogenic basic helix-loop-helix (bHLH) and MEF2 transcription factors are expressed in the myotome of developing somites and cooperatively activate skeletal muscle gene expression. The bHLH protein Twist is expressed throughout the epithelial somite and is subsequently excluded from the myotome. Ectopically expressed mouse Twist (Mtwist) was shown to inhibit myogenesis by blocking DNA binding by MyoD, by titrating E proteins, and by inhibiting trans-activation by MEF2. For inhibition of MEF2, Mtwist required heterodimerization with E proteins and an intact basic domain and carboxyl-terminus. Thus, Mtwist inhibits both families of myogenic regulators and may regulate myotome formation temporally or spatially.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Rhee, James/V-9973-2019		NIAMS NIH HHS [5-F32-AR08214-02] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008214] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BATE M, 1991, DEVELOPMENT, V113, P79; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1994, J BIOL CHEM, V269, P16740; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FUCHTBAUER EM, 1995, DEV DYNAM, V204, P316; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; IP YT, 1992, GENE DEV, V6, P1516; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JANES J, 1988, MOL CELL BIOL, V8, P62; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; Lassar AB, 1996, CURR OPIN NEUROBIOL, V6, P57, DOI 10.1016/S0959-4388(96)80009-2; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LILY B, 1994, P NATL ACAD SCI USA, V91, P5662; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAIDU PS, 1995, MOL CELL BIOL, V15, P3703; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SIMPSON P, 1983, GENETICS, V105, P605; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; SPICER DB, UNPUB; STOETZEL C, 1995, MECH DEVELOP, V51, P251, DOI 10.1016/0925-4773(95)00369-X; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; TAYLOR MV, 1995, CURR BIOL, V5, P740, DOI 10.1016/S0960-9822(95)00149-7; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG W, 1995, GENE DEV, V9, P1386	62	268	272	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1476	1480		10.1126/science.272.5267.1476	http://dx.doi.org/10.1126/science.272.5267.1476			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633239				2022-12-24	WOS:A1996UP89900046
J	Tang, XJ; Halleck, MS; Schlegel, RA; Williamson, P				Tang, XJ; Halleck, MS; Schlegel, RA; Williamson, P			A subfamily of P-type ATPases with aminophospholipid transporting activity	SCIENCE			English	Article							TRANSBILAYER MOVEMENT; SENSITIVE ATPASE; PLASMA-MEMBRANE; PHOSPHATIDYLSERINE; PROTEIN; PURIFICATION; RECOGNITION; MACROPHAGES; ASYMMETRY; SURFACE	The appearance of phosphatidylserine on the surface of animal cells triggers phagocytosis and blood coagulation. Normally, phosphatidylserine is confined to the inner leaflet of the plasma membrane by an aminophospholipid translocase, which has now been cloned and sequenced. The bovine enzyme is a member of a previously unrecognized subfamily of P-type adenosine triphosphatases (ATPases) that may have diverged from the primordial enzyme before the separation of the known families of ion-translocating ATPases. Studies in Saccharomyces cerevisiae suggest that aminophospholipid translocation is a general function of members of this family.	AMHERST COLL,DEPT BIOL,AMHERST,MA 01002; PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Amherst College; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park								ALLEN TM, 1988, P NATL ACAD SCI USA, V85, P8067, DOI 10.1073/pnas.85.21.8067; AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; BOGDANOV A, 1993, BIOCHEM SOC T, V21, P271, DOI 10.1042/bst0210271; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAGAN MJ, 1994, J MOL EVOL, V38, P57; HICKS BW, 1992, J NEUROCHEM, V58, P1211, DOI 10.1111/j.1471-4159.1992.tb11331.x; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; KRISHNA S, 1994, EXP PARASITOL, V78, P113, DOI 10.1006/expr.1994.1011; LI HH, 1990, P NATL ACAD SCI USA, V87, P4580, DOI 10.1073/pnas.87.12.4580; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; MORROT G, 1990, FEBS LETT, V266, P29, DOI 10.1016/0014-5793(90)81498-D; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PRADHAN D, 1994, MOL MEMBR BIOL, V11, P181, DOI 10.3109/09687689409162237; RIPMASTER TL, 1993, MOL CELL BIOL, V13, P7901, DOI 10.1128/MCB.13.12.7901; SCHLEGEL RA, IN PRESS P 6 INT C L; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; TROTTEIN F, 1995, EUR J BIOCHEM, V227, P214, DOI 10.1111/j.1432-1033.1995.tb20379.x; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; XIE XS, 1989, J BIOL CHEM, V264, P1710; ZACHOWSKI A, 1989, NATURE, V340, P75, DOI 10.1038/340075a0; ZACHOWSKI A, 1987, BIOCHIM BIOPHYS ACTA, V897, P197, DOI 10.1016/0005-2736(87)90328-2; ZACHOWSKI A, 1990, J NEUROCHEM, V55, P1352, DOI 10.1111/j.1471-4159.1990.tb03146.x	30	405	412	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1495	1497		10.1126/science.272.5267.1495	http://dx.doi.org/10.1126/science.272.5267.1495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633245				2022-12-24	WOS:A1996UP89900052
J	Keystone, JS				Keystone, JS			Of bites and body odour	LANCET			English	Editorial Material							HOST				Keystone, JS (corresponding author), UNIV TORONTO, TROP DIS UNIT, 100 COLL ST, TORONTO, ON, CANADA.							ACREE F, 1968, SCIENCE, V161, P1346, DOI 10.1126/science.161.3848.1346; DAVIS EE, 1976, J COMP PHYSIOL, V105, P43, DOI 10.1007/BF01380052; GILBERT IH, 1996, FLORIDA ENTOMOL, V49, P53; Knols BGJ, 1995, T ROY SOC TROP MED H, V89, P604, DOI 10.1016/0035-9203(95)90406-9; KNOLS BGJ, 1994, MED VET ENTOMOL, V8, P386, DOI 10.1111/j.1365-2915.1994.tb00104.x; KNOLS BGJ, 1995, PROCEEDINGS OF THE SECTION EXPERIMENTAL AND APPLIED ENTOMOLOGY OF THE NETHERLANDS ENTOMOLOGICAL SOCIETY (N.E.V.), VOL 6, 1995, P201; PORT GR, 1980, B ENTOMOL RES, V70, P133, DOI 10.1017/S0007485300009834; SCHRECK CE, 1981, J CHEM ECOL, V8, P429; SUTCLIFFE JF, 1986, CAN J ZOOL, V64, P1041, DOI 10.1139/z86-156; THOMPSON BH, 1976, TROPENMED PARASITOL, V27, P83	10	10	11	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	1996	347	9013					1423	1423		10.1016/S0140-6736(96)91678-5	http://dx.doi.org/10.1016/S0140-6736(96)91678-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676622				2022-12-24	WOS:A1996UM48500005
J	Mal, A; Poon, RYC; Howe, PH; Toyoshima, H; Hunter, T; Harter, ML				Mal, A; Poon, RYC; Howe, PH; Toyoshima, H; Hunter, T; Harter, ML			Inactivation of p27(Kip1) by the viral E1A oncoprotein in TGF beta-treated cells	NATURE			English	Article							GROWTH ARREST; INHIBITION; KINASE; PHOSPHORYLATION; PROTEINS; P34CDC2; CYCLE	THE adenovirus oncoprotein E1A and the simian virus SV40 large T antigen can both reverse the strong growth-inhibitory effect of transforming growth factor(TGF)-beta on mink lung epithelial cells(1,2): exposure of TGF-beta causes these cells to arrest late in the G1 phase of the cell cycle (ref. 3). This arrest correlates with an increase in expression of the protein p15(Ink4B) (ref. 4), inactivation of the cyclin E/A-cdk2 complex by the inhibitory protein p27(Kip1) (refs 5-7), and with the accumulation of unphosphorylated retinoblastoma protein(8). The rescue by E1A of cells from TGF-beta arrest is partly independent of its binding to retinoblastoma protein(1). Here we show that E1A directly affects the cyclin-dependent kinase inhibitor p27(Kip1) in TGF-beta-treated cells by binding to it and blocking its inhibitory effect, thereby restoring the activity of the cyclin-cdk2 kinase complex. In this way, E1A can overcome the effect of TGF-beta and modulate the cell cycle. To our knowledge, E1A provides the first example of a viral oncoprotein that can disable a cellular protein whose function is to inhibit the activity of cyclin-dependent kinases.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,RES INST,DEPT CELL BIOL,CLEVELAND,OH 44195; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Salk Institute				Poon, Randy/0000-0001-5571-6231				ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; BANERJEE AC, 1994, ONCOGENE, V9, P1733; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOWE PH, 1993, J BIOL CHEM, V268, P21448; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; NEVINS JR, 1993, BIOCHEM SOC T, V21, P935, DOI 10.1042/bst0210935; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; REYNISDOTTIR I, 1995, J GENES DEV, V9, P1831; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; STACEY DW, 1994, EMBO J, V13, P6107, DOI 10.1002/j.1460-2075.1994.tb06957.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7	26	136	139	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					262	265		10.1038/380262a0	http://dx.doi.org/10.1038/380262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637577				2022-12-24	WOS:A1996UB11700056
J	Giros, B; Jaber, M; Jones, SR; Wightman, RM; Caron, MG				Giros, B; Jaber, M; Jones, SR; Wightman, RM; Caron, MG			Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter	NATURE			English	Article							NUCLEUS-ACCUMBENS; MESSENGER-RNA; RECEPTOR GENE; RAT STRIATUM; NEURONS; MECHANISMS; EXPRESSION; NEUROTRANSMISSION; INHIBITOR; RELEASE	Disruption of the mouse dopamine transporter gene results in spontaneous hyperlocomotion despite major adaptive changes, such as decreases in neurotransmitter and receptor levels. In homozygote mice, dopamine persists at least 100 times longer in the extracellular space, explaining the biochemical basis of the hyperdopaminergic phenotype and demonstrating the critical role of the transporter in regulating neurotransmission. The dopamine transporter is an obligatory target of cocaine and amphetamine, as these psychostimulants have no effect on locomotor activity or dopamine release and uptake in mice lacking the transporter.	DUKE UNIV, MED CTR, DEPT CELL BIOL, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; UNIV N CAROLINA, CURRICULUM NEUROBIOL, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27514 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Jones, Sara R/K-4816-2014; Jansen, Heiko T./A-5770-2008; GIROS, Bruno/ABD-5790-2021	Jones, Sara R/0000-0002-3424-7576; Jansen, Heiko T./0000-0003-0178-396X; GIROS, Bruno/0000-0001-5876-9822; Jaber, Mohamed/0000-0003-2536-1913				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BALK JH, 1995, NATURE, V377, P424; BARKER EL, 1994, MOL PHARMACOL, V46, P799; BAUMANN MH, 1993, BRAIN RES, V608, P175, DOI 10.1016/0006-8993(93)90792-L; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Byck R, 1977, NIDA Res Monogr, VSeries 13, P97; CERRUTI C, 1993, MOL BRAIN RES, V18, P181, DOI 10.1016/0169-328X(93)90187-T; CHIODO LA, 1992, NEUROCHEM INT, V20, pS81; CILIAX BJ, 1995, J NEUROSCI, V15, P1714, DOI 10.1523/JNEUROSCI.15-03-01714.1995; CROW TJ, 1980, BRIT J PSYCHIAT, V137, P383, DOI 10.1192/S0007125000071919; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; EHRINGER H, 1960, KLIN WOCHENSCHR, V38, P1236, DOI 10.1007/BF01485901; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; FISCHER JF, 1979, J PHARMACOL EXP THER, V208, P203; FULLER RW, 1991, MED RES REV, V11, P17, DOI 10.1002/med.2610110103; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GRAHAM JH, 1995, J PHARMACOL EXP THER, V274, P707; HITRI A, 1994, CLIN NEUROPHARMACOL, V17, P1, DOI 10.1097/00002826-199402000-00001; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JABER M, 1995, NEUROSCIENCE, V65, P1041, DOI 10.1016/0306-4522(94)00537-F; JACOCKS HM, 1992, J PHARMACOL EXP THER, V262, P356; JONES SR, 1995, J NEUROCHEM, V64, P2581; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4; KENNEDY RT, 1992, J NEUROCHEM, V59, P449, DOI 10.1111/j.1471-4159.1992.tb09391.x; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LEMOINE C, 1990, P NATL ACAD SCI USA, V87, P230, DOI 10.1073/pnas.87.1.230; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; MEISTER B, 1993, NEUROENDOCRINOLOGY, V58, P388, DOI 10.1159/000126568; PARKER EM, 1986, J PHARMACOL EXP THER, V237, P179; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; RAITERI M, 1979, J PHARMACOL EXP THER, V208, P195; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SULZER D, 1995, J NEUROSCI, V15, P4102; TISON F, 1994, NEUROSCI LETT, V166, P48, DOI 10.1016/0304-3940(94)90837-0; WALL SC, 1995, MOL PHARMACOL, V47, P544; WIGHTMAN RM, 1990, BRAIN RES REV, V15, P135, DOI 10.1016/0165-0173(90)90015-G; Wise R A, 1985, Psychiatr Med, V3, P445; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; ZIMMERBERG B, 1992, PHYSIOL BEHAV, V52, P379, DOI 10.1016/0031-9384(92)90287-C	48	1948	1989	2	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					606	612		10.1038/379606a0	http://dx.doi.org/10.1038/379606a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628395				2022-12-24	WOS:A1996TV68800042
J	Tiku, PE; Gracey, AY; Macartney, AI; Beynon, RJ; Cossins, AR				Tiku, PE; Gracey, AY; Macartney, AI; Beynon, RJ; Cossins, AR			Cold-induced expression of Delta(9)-desaturase in carp by transcriptional and posttranslational mechanisms	SCIENCE			English	Article							STEARYL-COA DESATURASE; LIVER; MEMBRANES	Poikilothermic animals respond to chronic cold by increasing phosphoglyceride unsaturation to restore the fluidity of cold-rigidified membranes. Despite the importance of this compensatory response,the enzymes involved have not-been clearly identified, and the mechanisms that control their activity are unknown. In carp liver, cold induces an 8- to 10-fold increase in specific activity of the microsomal stearoyl coenzyme A desaturase. Cold-induced up-regulation of gene transcription resulted in a 10-fold increase in desaturase transcript amounts after 48 to 60 hours. However, this increase was preceded by the activation of latent desaturase, probably by a posttranslational mechanism. These two mechanisms may act sequentially to match desaturase expression to the demands imposed by a progressive decrease in temperature.	UNIV LIVERPOOL,DEPT ENVIRONM & EVOLUTIONARY BIOL,ENVIRONM PHYSIOL RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV MANCHESTER,INST SCI & TECHNOL,DEPT BIOCHEM & APPL MOLEC BIOL,MANCHESTER M60 1QD,LANCS,ENGLAND	University of Liverpool; University of Manchester			Beynon, Robert J/K-1408-2014; Gracey, Andrew Y/A-3060-2008	Beynon, Robert J/0000-0003-0857-495X; Cossins, Andrew/0000-0002-0813-5212				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSSINS AR, 1982, BIOCHIM BIOPHYS ACTA, V687, P303, DOI 10.1016/0005-2736(82)90559-4; Cossins AR, 1994, TEMPERATURE ADAPTATI; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; HAZEL JR, 1995, ANNU REV PHYSIOL, V57, P19, DOI 10.1146/annurev.ph.57.030195.000315; LEIFKOWITH JB, 1990, BIOCHIM BIOPHYS ACTA, V1044, P13; Liu Z J, 1990, DNA Seq, V1, P125, DOI 10.3109/10425179009016040; Macartney A., 1994, TEMPERATURE ADAPTATI, P129; MACARTNEY AI, UNPUB; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SCHUNKE M, 1983, BIOCHIM BIOPHYS ACTA, V734, P70, DOI 10.1016/0005-2736(83)90076-7; STRITTMATTER P, 1988, J BIOL CHEM, V263, P2532; TAKAMURA H, 1986, LIPIDS, V21, P356, DOI 10.1007/BF02535701; WODTKE E, 1991, BIOCHIM BIOPHYS ACTA, V1064, P343, DOI 10.1016/0005-2736(91)90321-X	15	228	244	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					815	818		10.1126/science.271.5250.815	http://dx.doi.org/10.1126/science.271.5250.815			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8629000				2022-12-24	WOS:A1996TU69400049
J	Hooton, TM; Scholes, D; Hughes, JP; Winter, C; Roberts, PL; Stapleton, AE; Stergachis, A; Stamm, WE				Hooton, TM; Scholes, D; Hughes, JP; Winter, C; Roberts, PL; Stapleton, AE; Stergachis, A; Stamm, WE			A prospective study of risk factors for symptomatic urinary tract infection in young women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VAGINAL EPITHELIAL-CELLS; SEXUAL INTERCOURSE; DIAPHRAGM USE; BLOOD-GROUP; EPIDEMIOLOGY; ASSOCIATION; BACTERIURIA; BEHAVIOR	Background Although acute urinary tract infections are common in young women, the associated risk factors have not been defined prospectively. Methods We recruited sexually active young women who were starting a new method of contraception at a university health center or a health maintenance organization (HMO) and monitored them for six months for symptomatic urinary tract infections. Daily diaries and serial interviews were used to collect data on potential risk factors. Results Among 796 women, the incidence of urinary tract infections per person-year was 0.7 in the university cohort (mean age, 23 years; n=348) and 0.5 in the HMO cohort (mean age, 29; n=448). In both cohorts, there were strong dose-response relations between the risk of infection and both recent use of a diaphragm with spermicide (respective relative risks for one, three, and five days of use in the past week, 1.42, 2.83, and 5.68 in the university cohort, P<0.001; and 1.29, 2.14, and 3.54 in the HMO cohort, P=0.04) and recent sexual intercourse (respective relative risks for one, three, and five days with intercourse in the past week, 1.37, 2.56, and 4.81 in-the university cohort, P<0.001; and 1.24, 1.91, and 2.96 in the HMO cohort, P=0.002). The risk of acute infection was also associated with a history of recurrent infection (relative risk, 5.58 in the university cohort and 2.10 in the HMO cohort) but not with cervical-cap use, ABO-blood-group nonsecretor phenotype, or delayed postcoital voiding. Conclusions Among sexually active young women the incidence of symptomatic urinary tract infection is high, and the risk is strongly and independently associated with recent sexual intercourse, recent use of a diaphragm with spermicide, and a history of recurrent urinary tract infections. (C) 1996, Massachusetts Medical Society.	UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PHARM,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative			Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047549, R01DK040045] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47549, DK 40045] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADATTO K, 1979, JAMA-J AM MED ASSOC, V241, P2525, DOI 10.1001/jama.241.23.2525; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; COUNTS GW, 1982, REV INFECT DIS, V4, P484; COX DR, 1972, J R STAT SOC B, V34, P187; FIHN SD, 1985, JAMA-J AM MED ASSOC, V254, P240, DOI 10.1001/jama.254.2.240; FOXMAN B, 1990, J CLIN EPIDEMIOL, V43, P329, DOI 10.1016/0895-4356(90)90119-A; FOXMAN B, 1995, EPIDEMIOLOGY, V6, P162, DOI 10.1097/00001648-199503000-00013; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1314, DOI 10.2105/AJPH.75.11.1314; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1308, DOI 10.2105/AJPH.75.11.1308; HOOTEN TM, 1994, CLIN INFECT DIS, V19, P274, DOI 10.1093/clinids/19.2.274; Hooton Thomas M., 1996, P67; HOOTON TM, 1991, JAMA-J AM MED ASSOC, V265, P64, DOI 10.1001/jama.265.1.64; HOOTON TM, 1991, J INFECT DIS, V164, P1216, DOI 10.1093/infdis/164.6.1216; HOPKINS WJ, 1995, J INFECT DIS, V172, P1612, DOI 10.1093/infdis/172.6.1612; Johnson J R, 1987, Infect Dis Clin North Am, V1, P773; JOHNSON JR, 1990, INFECT DIS CLIN N AM, V4, pRA7; KINANE DF, 1982, BRIT MED J, V285, P7, DOI 10.1136/bmj.285.6334.7; KUNIN CM, 1980, JAMA-J AM MED ASSOC, V243, P134; LIN DY, 1994, STAT MED, V13, P2233, DOI 10.1002/sim.4780132105; NICOLLE LE, 1982, J INFECT DIS, V146, P579, DOI 10.1093/infdis/146.5.579; PEARSON DC, 1987, PREV MED, V16, P783, DOI 10.1016/0091-7435(87)90018-1; REMIS RS, 1987, AM J EPIDEMIOL, V126, P685, DOI 10.1093/oxfordjournals.aje.a114708; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; SCHAPPERT SM, 1994, ADV DATA VITAL HLTH, V253; SHEINFELD J, 1989, NEW ENGL J MED, V320, P773, DOI 10.1056/NEJM198903233201205; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; STROM BL, 1987, ANN INTERN MED, V107, P816, DOI 10.7326/0003-4819-107-6-816; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; *US BUR CENS, 1995, 1995 STAT ABSTR US, P82; WALKER RH, 1990, TECHNICAL MANUAL	31	420	452	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1996	335	7					468	474		10.1056/NEJM199608153350703	http://dx.doi.org/10.1056/NEJM199608153350703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB849	8672152				2022-12-24	WOS:A1996VB84900003
J	Danese, MD; Powe, NR; Sawin, CT; Ladenson, PW				Danese, MD; Powe, NR; Sawin, CT; Ladenson, PW			Screening for mild thyroid failure at the periodic health examination - A decision and cost-effectiveness analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE TREATMENT; QUALITY-OF-LIFE; SUBCLINICAL HYPOTHYROIDISM; AUTOIMMUNE-THYROIDITIS; MICROSOMAL ANTIBODIES; MYOCARDIAL-INFARCTION; REPLACEMENT THERAPY; DOUBLE-BLIND; FOLLOW-UP; DISEASE	Objective.-To estimate the cost-effectiveness of periodic screening for mild thyroid failure by measurement of serum thyroid stimulating hormone (TSH) concentration. Design.-Cost-utility analysis using a state-transition computer decision model that accounted for case finding, medical consequences of mild thyroid failure, and costs of care during 40 years of simulated follow-up. Setting.-Periodic health examinations in offices of primary care physicians. Patients.-Hypothetical cohorts of women and men screened every 5 years during the recommended periodic examination, beginning at age 35 years. Interventions.-Adding the serum TSH assay to total serum cholesterol screening was compared to cholesterol screening alone. Main Outcome Measures.-Discounted quality-adjusted life years (QALYs) and direct medical costs from a societal perspective. Results.-The cost-effectiveness of screening 35-year-old patients with a serum TSH assay every 5 years was $9223 per QALY for women and $22 595 per QALY for men. The cost-effectiveness became more favorable when age at first screening was increased for both sexes and was always more favorable for women than men. Reduced progression to overt hypothyroidism and relief of symptoms increased QALYs, but did not substantially reduce direct medical costs. Finding hypercholesterolemia induced by mild thyroid failure reduced direct medical costs, but did not substantially increase QALYs. The cost of a TSH assay and the importance to patients of symptoms associated with thyroid failure were the most influential factors in sensitivity analyses. Conclusions.-The cost-effectiveness of screening for mild thyroid failure compares favorably with other generally accepted preventive medical practices. Physicians should consider measuring serum TSH concentration in patients aged 35 years and older undergoing routine periodic health examinations. The cost-effectiveness of screening is most favorable in elderly women.	JOHNS HOPKINS MED INST,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DIV GEN INTERNAL MED,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,DIV ENDOCRINOL & METAB,BALTIMORE,MD 21218; DEPT VET AFFAIRS MED CTR,MED SERV,BOSTON,MA; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Boston University					NEI NIH HHS [T32 EY07127] Funding Source: Medline; NIA NIH HHS [K01 AG000561] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG000561] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM MED ASS, 1994, PHYS CURR PROC TECHN; [Anonymous], 1994, Circulation, V89, P1333; Arem R, 1995, METABOLISM, V44, P1559, DOI 10.1016/0026-0495(95)90075-6; AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; BELL GM, 1985, CLIN ENDOCRINOL, V22, P83, DOI 10.1111/j.1365-2265.1985.tb01068.x; BOGNER U, 1993, ACTA ENDOCRINOL-COP, V128, P202, DOI 10.1530/acta.0.1280202; CHEUNG AP, 1992, MED J AUSTRALIA, V156, P312, DOI 10.5694/j.1326-5377.1992.tb139784.x; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DENKE MA, 1994, ARCH INTERN MED, V154, P317, DOI 10.1001/archinte.154.3.317; DIEKMAN T, 1995, ARCH INTERN MED, V155, P1490, DOI 10.1001/archinte.155.14.1490; DOSREMEDIOS LV, 1980, ARCH INTERN MED, V140, P1045, DOI 10.1001/archinte.140.8.1045; DOUBILET P, 1984, NEW ENGL J MED, V310, P95, DOI 10.1056/NEJM198401123100206; EPSTEIN KA, 1981, J CHRON DIS, V34, P175, DOI 10.1016/0021-9681(81)90063-1; FALKENBERG M, 1983, ACTA MED SCAND, V214, P361; FRANKLYN J, 1995, CLIN ENDOCRINOL, V43, P443, DOI 10.1111/j.1365-2265.1995.tb02615.x; FRANKLYN JA, 1993, CLIN ENDOCRINOL, V38, P453, DOI 10.1111/j.1365-2265.1993.tb00339.x; GEUL KW, 1993, CLIN ENDOCRINOL, V39, P275, DOI 10.1111/j.1365-2265.1993.tb02366.x; GORDIN A, 1981, CLIN ENDOCRINOL, V15, P537, DOI 10.1111/j.1365-2265.1981.tb00699.x; HATZIANDREU EI, 1988, AM J PUBLIC HEALTH, V78, P1417, DOI 10.2105/AJPH.78.11.1417; HELFAND M, 1990, ANN INTERN MED, V112, P840, DOI 10.7326/0003-4819-112-11-840; HUNINK MGM, 1994, J VASC SURG, V19, P632, DOI 10.1016/S0741-5214(94)70036-2; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; KEATING FR, 1961, PROG CARDIOVASC DIS, V3, P364, DOI 10.1016/S0033-0620(61)90004-4; LADENSON PW, 1994, THYROID, V4, P5; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MILLER DK, 1994, MED DECIS MAKING, V14, P52, DOI 10.1177/0272989X9401400107; MIURA S, 1994, INTERNAL MED, V33, P413, DOI 10.2169/internalmedicine.33.413; MONZANI F, 1993, CLIN INVESTIGATOR, V71, P367; *NAT CTR HLTH STAT, 1993, VIT HLTH STAT, V11, P242; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; NYSTROM E, 1981, ACTA MED SCAND, V210, P89; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; RIDGWAY EC, 1981, J CLIN ENDOCR METAB, V53, P1238, DOI 10.1210/jcem-53-6-1238; RINIKER M, 1981, CLIN ENDOCRINOL, V14, P69, DOI 10.1111/j.1365-2265.1981.tb00366.x; ROSENTHAL MJ, 1987, JAMA-J AM MED ASSOC, V258, P209, DOI 10.1001/jama.258.2.209; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; SCHULMAN KA, 1990, JAMA-J AM MED ASSOC, V264, P3025, DOI 10.1001/jama.264.23.3025; SMURAWSKA LT, 1994, STROKE, V25, P1628, DOI 10.1161/01.STR.25.8.1628; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P170; STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7; TOFT AD, 1994, NEW ENGL J MED, V331, P174; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; TUNBRIDGE WMG, 1981, BRIT MED J, V282, P258, DOI 10.1136/bmj.282.6260.258; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; *US DEP HHS, 1988, FRAM STUD EP INV CAR; US Department of Health and Human Services National Institutes of Health, 1987, FRAM STUD EP INV CAR; *US DHEW, 1973, FRAM STUD EP INV CAR; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; WARTOFSKY L, 1991, THYROID FUNDAMENTAL, P1084; WITTELS EH, 1990, AM J CARDIOL, V65, P432, DOI 10.1016/0002-9149(90)90806-C; 1996, ANN INTERN MED, V124, P515; 1979, CAN MED ASSOC J, V121, P1; 1994, REDBOOK 1994; 1994, IMS AM; 1981, LANCET, V2, P128	61	161	168	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1996	276	4					285	292		10.1001/jama.276.4.285	http://dx.doi.org/10.1001/jama.276.4.285			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX583	8656540				2022-12-24	WOS:A1996UX58300033
J	Karon, JM; Rosenberg, PS; McQuillan, G; Khare, M; Gwinn, M; Petersen, LR				Karon, JM; Rosenberg, PS; McQuillan, G; Khare, M; Gwinn, M; Petersen, LR			Prevalence of HIV infection in the United States, 1984 to 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; AIDS; BACKCALCULATION	Objective.-To estimate the number of persons infected with the human immunodeficiency virus (HIV) living in the United States and the change in HIV infection prevalence since 1984. Design.-We estimated HIV prevalence from 3 data sources. We estimated past HIV infection rates from a statistical procedure based on national acquired immunodeficiency syndrome (AIDS) case surveillance data and estimates of the time from HIV infection to AIDS diagnosis. We also analyzed HIV prevalence data from 2 national surveys, a survey of childbearing women and a household survey of current health status. We used other data sources to adjust these survey estimates to include groups not covered in the surveys. Results.-Approximately 0.3% of US residents (650 000-900 000 persons) were infected with HIV in 1992, Approximately 0.6% of men (including adolescent boys greater than or equal to 13 years of age) were infected, including approximately 2% of non-Hispanic black men and 1% of Hispanic men, Approximately 0.1% of women (including adolescent girls greater than or equal to 13 years of age) were infected, including approximately 0.6% of non-Hispanic black women. Approximately half of all infected persons were men who had sex with men, and one fourth were injecting drug users. The prevalence of HIV infection increased from 1984 to 1992, with a greater relative increase among women than men. Conclusions.-The 3 different data sources and methods are consistent in estimating that 650 000 to 900 000 persons were infected with HIV in the United States in 1992. Among adolescents and adults of both sexes, the proportion infected was substantially higher among non-Hispanic blacks and Hispanics than among non-Hispanic whites, HIV-related illness will be a major clinical and public health problem in the United States for years to come.	CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,ATLANTA,GA 30333; NCI,NIH,ROCKVILLE,MD	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Karon, JM (corresponding author), CTR DIS CONTROL & PREVENT,DIV HIV AIDS PREVENT,NATL CTR HIV STD & TB PREVENT,MAILSTOP E-48,ATLANTA,GA 30333, USA.							BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; Brookmeyer R., 1994, AIDS EPIDEMIOLOGY QU; *CDCP, 1993, HIVNCID1193036 PUBL, V3; Chu SY, 1996, OBSTET GYNECOL, V87, P195, DOI 10.1016/0029-7844(95)00399-1; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; EDLIN BR, 1995, 2 NAT C HUM RETR REL; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HAY JW, 1994, APPL STAT-J ROY ST C, V43, P599, DOI 10.2307/2986260; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; HOOVER DR, 1995, DRUGS, V49, P20, DOI 10.2165/00003495-199549010-00003; KARON JM, IN PRESS US DEP HL D, V821; MCQUILLAN GM, 1994, J ACQ IMMUN DEF SYND, V7, P1195; NELSON KE, 1994, AIDS RES HUM RETROV, V10, pS201; NWANYANWU OC, 1993, AM J PUBLIC HEALTH, V83, P571, DOI 10.2105/AJPH.83.4.571; OSMOND DH, 1994, AM J PUBLIC HEALTH, V84, P1933, DOI 10.2105/AJPH.84.12.1933; Prevots DR, 1996, AM J EPIDEMIOL, V143, P733, DOI 10.1093/oxfordjournals.aje.a008807; Rosenberg Philip S., 1990, Annals of Epidemiology, V1, P105; ROSENBERG PS, 1994, STAT MED, V13, P1975, DOI 10.1002/sim.4780131909; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; ROSENBERG PS, 1991, STAT MED, V10, P1167, DOI 10.1002/sim.4780100802; ROSENBERG PS, 1991, APPL STAT-J ROY ST C, V40, P269; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; VANHAASTRECHT HJA, 1994, AIDS, V8, P363, DOI 10.1097/00002030-199403000-00011; WEINSTOCK HS, 1995, J ACQ IMMUN DEF SYND, V9, P514; ZACCARELLI M, 1994, AIDS, V8, P345, DOI 10.1097/00002030-199403000-00008; 1990, MMWR-MORBID MORTAL W, V39, P1; 1987, MMWR MORB MORTAL S1S, V36, pS1; 1990, MMWR-MORBID MORTAL W, V39, P117; 1986, PUBLIC HLTH REP, V101, P342; 1991, MMWR-MORBID MORTAL W, V40, P1; 1990, MMWR-MORBID MORTAL W, V39, P110; 1992, MMWR-MORBID MORTAL W, V41, P1; 1994, MMWR-MORBID MORTAL W, V43, P826	35	183	184	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					126	131		10.1001/jama.276.2.126	http://dx.doi.org/10.1001/jama.276.2.126			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV485	8656504				2022-12-24	WOS:A1996UV48500027
J	Ceska, TA; Sayers, JR; Stier, G; Suck, D				Ceska, TA; Sayers, JR; Stier, G; Suck, D			A helical arch allowing single-stranded DNA to thread through T5 5'-exonuclease	NATURE			English	Article							POLYMERASE-I; 5'-3' EXONUCLEASE; D15 EXONUCLEASE; MECHANISM; PROTEIN; MODELS	THE 5'-exonucleases are enzymes that are essential for DNA replication and repair(1). As well as their exonucleolytic action, removing nucleotides from the 5'-end of nucleic acid molecules such as Okazaki fragments(2), many 5'-3'-exonucleases have been Shown to possess endonucleolytic activities(3,4), T5 5'-3'-exonuclease shares many similarities with the amino termini of eubacterial DNA polymerases(5), although, unlike eubacteria, phages such as T5, T4 and T7 express polymerase and 5'-exonuclease proteins from separate genes, Here we report the 2.5-Angstrom crystal structure of the phage T5 5'-exonuclease, which reveals a helical arch for binding DNA, We propose a model consistent with a threading mechanism in which single-stranded DNA could slide through the arch, which is formed by two helices, one containing positively charged, and the other hydrophobic, residues. The active site is at the base of the arch, and contains two metal-binding sites.	UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,KREBS INST,SECT MOL MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	Ceska, TA (corresponding author), EUROPEAN MOLEC BIOL LAB,STRUCT BIOL PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Sayers, Jon R/I-8974-2012; Sayers, Jon R/AAP-6179-2020	Sayers, Jon R/0000-0002-5082-1443; Sayers, Jon R/0000-0002-5082-1443				[Anonymous], 1993, ACTA CRYSTALLOGR D, V50, P760; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BRUNGER AT, 1993, X PLOR VERSION 3 1; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CESKA TA, 1993, J MOL BIOL, V233, P179, DOI 10.1006/jmbi.1993.1496; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Kornberg A., 1992, DNA REPLICATION; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; OKAZAKI R, 1971, P NATL ACAD SCI USA, V68, P2954, DOI 10.1073/pnas.68.12.2954; OTWINOWSKI Z, 1993, DENZO; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SAYERS JR, 1990, J BIOL CHEM, V265, P18311; SAYERS JR, 1994, J THEOR BIOL, V170, P415, DOI 10.1006/jtbi.1994.1202; SAYERS JR, 1991, NUCLEIC ACIDS RES, V19, P4127, DOI 10.1093/nar/19.15.4127; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; VELLIEUX FMDAP, 1995, J APPL CRYSTALLOGR, V28, P347, DOI 10.1107/S0021889894012355; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	26	166	173	1	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1996	382	6586					90	93		10.1038/382090a0	http://dx.doi.org/10.1038/382090a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV473	8657312				2022-12-24	WOS:A1996UV47300061
J	Eden, GF; VanMeter, JW; Rumsey, JM; Maisog, JM; Woods, RP; Zeffiro, TA				Eden, GF; VanMeter, JW; Rumsey, JM; Maisog, JM; Woods, RP; Zeffiro, TA			Abnormal processing of visual motion In dyslexia revealed by functional brain imaging	NATURE			English	Article							DEVELOPMENTAL DYSLEXIA; CORTEX; ORGANIZATION; COLOR; CONNECTIONS; PERCEPTION; MOVEMENT; VISION	IT is widely accepted that dyslexics have deficits in reading and phonological awareness(1,2), but there is increasing evidence that they also exhibit visual processing abnormalities that may be confined to particular portions of the visual system(3,4). In primate visual pathways, inputs from parvocellular or magnocellular layers of the lateral geniculate nucleus remain partly segregated in projections to extrastriate cortical areas specialized for processing colour and form versus motion(5-10), In studies of dyslexia, psychophysical(3) and anatomical(4) evidence indicate an anomaly in the magnocellular visual subsystem, To investigate the pathophysiology of dyslexia, we used functional magnetic resonance imaging (fMRI) to study visual motion processing in normal and dyslexic men, In all dyslexics, presentation of moving stimuli failed to produce the same task-related functional activation in area V5/MT (part of the magnocellular visual subsystem) observed in controls, In contrast, presentation of stationary patterns resulted in equivalent activations in V1/V2 and extrastriate cortex in both groups, Although previous studies have emphasized language deficits, our data reveal differences in the regional functional organization of the cortical visual system in dyslexia.	NIMH, CHILD PSYCHIAT BRANCH, NIH, BETHESDA, MD 20892 USA; NIH, LAB DIAGNOST RADIOL RES, OD, BETHESDA, MD 20892 USA; SENSOR SYST INC, STERLING, VA 20164 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT NEUROL, LOS ANGELES, CA 90098 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Eden, GF (corresponding author), NIMH, SECT FUNCT BRAIN IMAGING, NIH, BETHESDA, MD 20892 USA.		Zeffiro, Thomas/AAE-3441-2019; VanMeter, John W/D-2589-2018	Zeffiro, Thomas/0000-0002-0846-4577; VanMeter, John W/0000-0002-7012-5197				BRADLEY L, 1978, NATURE, V271, P746, DOI 10.1038/271746a0; CHENG K, 1995, J NEUROPHYSIOL, V74, P413, DOI 10.1152/jn.1995.74.1.413; CLARKE S, 1990, J COMP NEUROL, V298, P188, DOI 10.1002/cne.902980205; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; CORNELISSEN P, 1995, VISION RES, V35, P1483, DOI 10.1016/0042-6989(95)98728-R; EDEN GF, 1994, VISION RES, V34, P1345, DOI 10.1016/0042-6989(94)90209-7; EDEN GF, 1995, CORTEX, V31, P451, DOI 10.1016/S0010-9452(13)80059-7; KAPLAN E, 1982, J PHYSIOL-LONDON, V330, P125, DOI 10.1113/jphysiol.1982.sp014333; KULIKOWSKI JJ, 1973, J PHYSIOL-LONDON, V232, P149, DOI 10.1113/jphysiol.1973.sp010261; KWONG A, 1992, SOC NEUR ABSTR, V80, P5676; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; LIVINGSTONE MS, 1991, P NATL ACAD SCI USA, V88, P7943, DOI 10.1073/pnas.88.18.7943; LOVEGROVE WJ, 1980, SCIENCE, V210, P439, DOI 10.1126/science.7433985; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; NEWSOME WT, 1988, J NEUROSCI, V8, P2201; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SHAPLEY R, 1986, TRENDS NEUROSCI, V9, P229, DOI 10.1016/0166-2236(86)90064-0; SNOWLING MJ, 1981, PSYCHOL RES-PSYCH FO, V43, P219, DOI 10.1007/BF00309831; Talairach J., 1988, COPLANAR STEREOTAXIC; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; ZEFFIRO TA, IN PRESS ADV EXP MED; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0; ZEKI SM, 1973, BRAIN RES, V53, P422, DOI 10.1016/0006-8993(73)90227-8; ZIHL J, 1983, BRAIN, V106, P313, DOI 10.1093/brain/106.2.313	29	493	505	0	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 4	1996	382	6586					66	69		10.1038/382066a0	http://dx.doi.org/10.1038/382066a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV473	8657305				2022-12-24	WOS:A1996UV47300054
J	Nightingale, SL				Nightingale, SL			Dexfenfluramine approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKLAND,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					14	14						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667525				2022-12-24	WOS:A1996UU43900006
J	Marley, MS; Saumon, D; Guillot, T; Freedman, RS; Hubbard, WB; Burrows, A; Lunine, JI				Marley, MS; Saumon, D; Guillot, T; Freedman, RS; Hubbard, WB; Burrows, A; Lunine, JI			Atmospheric, evolutionary, and spectral models of the brown dwarf Gliese 229 B	SCIENCE			English	Article							ABSORPTION	Theoretical spectra and evolutionary models that span the giant planet-brown dwarf continuum have been computed based on the recent discovery of the brown dwarf Gliese 229 B. A flux enhancement in the 4- to 5-micrometer wavelength window is a universal feature from jovian planets to brown dwarfs, Model results confirm the existence of methane and water in the spectrum of Gliese 229 B and indicate that its mass is 30 to 55 jovian masses, Although these calculations focus on Gliese 229 B, they are also meant to guide future searches for extrasolar giant planets and brown dwarfs.	UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; UNIV ARIZONA,DEPT PHYS,TUCSON,AZ 85721; UNIV ARIZONA,DEPT ASTRON,TUCSON,AZ 85721	University of Arizona; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Arizona; University of Arizona	Marley, MS (corresponding author), NEW MEXICO STATE UNIV,DEPT ASTRON,BOX 30001,DEPT 4500,LAS CRUCES,NM 88003, USA.		Marley, Mark S/I-4704-2013	Guillot, Tristan/0000-0002-7188-8428				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BELL KL, 1980, J PHYS B-AT MOL OPT, V13, P1859, DOI 10.1088/0022-3700/13/9/016; BERGERON P, 1991, ASTROPHYS J, V367, P253, DOI 10.1086/169624; BORYSOW A, 1990, ASTROPHYS J, V348, pL41, DOI 10.1086/185626; BURROWS A, 1995, NATURE, V375, P299, DOI 10.1038/375299a0; BURROWS A, 1993, ASTROPHYS J, V406, P158, DOI 10.1086/172427; BUTLER RP, IN PRESS ASTROPHYS J; FEGLEY B, 1994, ICARUS, V110, P117, DOI 10.1006/icar.1994.1111; Gatewood G., 1996, B AM ASTRON SOC, V28, P885; GOODY R, 1989, J QUANT SPECTROSC RA, V42, P539, DOI 10.1016/0022-4073(89)90044-7; GUILLOT T, 1994, ICARUS, V112, P337, DOI 10.1006/icar.1994.1188; HILICO JC, 1992, J MOL SPECTROSC, V152, P229, DOI 10.1016/0022-2852(92)90134-A; JOHN TL, 1988, ASTRON ASTROPHYS, V193, P189; LINDAL GF, 1992, ASTRON J, V103, P967, DOI 10.1086/116119; LODDERS K, COMMUNICATION; LUNINE JI, 1986, ASTROPHYS J, V310, P238, DOI 10.1086/164678; MARCY GW, IN PRESS ASTROPHYS J; MARLEY MS, UNPUB; MATTHEWS K, IN PRESS ASTROPHYS J; MATTHEWS K, 1995, 6280 INT ASTR UN; MAYOR M, 1995, NATURE, V378, P355, DOI 10.1038/378355a0; MCKAY CP, 1989, ICARUS, V80, P23, DOI 10.1016/0019-1035(89)90160-7; NAKAJIMA T, 1995, NATURE, V378, P463, DOI 10.1038/378463a0; OPPENHEIMER BR, 1995, SCIENCE, V270, P1478, DOI 10.1126/science.270.5241.1478; POLLACK JB, 1993, ICARUS, V103, P1, DOI 10.1006/icar.1993.1055; Saumon D, 1996, ASTROPHYS J, V460, P993, DOI 10.1086/177027; STRONG K, 1993, J QUANT SPECTROSC RA, V50, P363, DOI 10.1016/0022-4073(93)90072-P; WATTSON RB, 1992, J QUANT SPECTROSC RA, V48, P763, DOI 10.1016/0022-4073(92)90140-Y; WATTSON RB, COMMUNICATION; ZHENG C, 1995, ICARUS, V113, P84, DOI 10.1006/icar.1995.1006	30	238	238	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1996	272	5270					1919	1921		10.1126/science.272.5270.1919	http://dx.doi.org/10.1126/science.272.5270.1919			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658164	Green Submitted			2022-12-24	WOS:A1996UV29400041
J	Gu, JG; Albuquerque, C; Lee, CJ; MacDermott, AB				Gu, JG; Albuquerque, C; Lee, CJ; MacDermott, AB			Synaptic strengthening through activation of Ca2+-permeable AMPA receptors	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; CHANNELS; CALCIUM; CURRENTS; ENTRY	POSTSYNAPTIC Ca2+ elevation during synaptic transmission is an important trigger for short- and long-term changes in synaptic strength in the vertebrate central nervous system(1). The AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate) receptors, a subfamily of glutamate receptors, mediate much of the excitatory synaptic transmission in the brain and spinal cord(2). It has been shown that a subtype of the AMPA receptor is Ca2+ -permeable(3-6) and is present in subpopulations of neurons(7-12). When synaptically localized(13), these receptors should mediate postsynaptic Ca2+ influx, providing a trigger for changes in synaptic strength. Here we show that Ca2+-permeable AMPA receptors are synaptically localized on a subpopulation of dorsal horn neurons, that they provide a synaptically gated route of Ca2+ entry, and that activation of these receptors strengthens synaptic transmission mediated by AMPA receptors. This pathway for postsynaptic Ca2+ influx may provide a new form of activity-dependent modulation of synaptic strength.	COLUMBIA UNIV, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University; Columbia University				Lee, C Justin/0000-0002-3555-0980				ABE T, 1983, J PHYSIOL-LONDON, V339, P243, DOI 10.1113/jphysiol.1983.sp014714; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BLASCHKE M, 1993, P NATL ACAD SCI USA, V90, P6528, DOI 10.1073/pnas.90.14.6528; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; GOLDSTEIN PA, 1995, J NEUROPHYSIOL, V73, P2522, DOI 10.1152/jn.1995.73.6.2522; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; Jonas Peter, 1994, Current Opinion in Neurobiology, V4, P366, DOI 10.1016/0959-4388(94)90098-1; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; KYROZIS A, 1995, J PHYSIOL-LONDON, V485, P373, DOI 10.1113/jphysiol.1995.sp020736; LERMA J, 1994, EUR J NEUROSCI, V6, P1080, DOI 10.1111/j.1460-9568.1994.tb00605.x; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MAYER ML, 1987, J NEUROSCI, V7, P3230; MURPHY TH, 1995, NEURON, V15, P159, DOI 10.1016/0896-6273(95)90073-X; OTIS TS, 1995, J PHYSIOL-LONDON, V482, P309, DOI 10.1113/jphysiol.1995.sp020519; REICHLING DB, 1993, J PHYSIOL-LONDON, V469, P67, DOI 10.1113/jphysiol.1993.sp019805; SCHNEGGENBURGER R, 1993, NEURON, V11, P133, DOI 10.1016/0896-6273(93)90277-X; SMITH SJ, 1988, CALCIUM ION CHANNEL, P147; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; Yin H z, 1994, Neurobiol Dis, V1, P43, DOI 10.1006/nbdi.1994.0006	28	206	210	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	1996	381	6585					793	796		10.1038/381793a0	http://dx.doi.org/10.1038/381793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657283				2022-12-24	WOS:A1996UU35600062
J	Shim, J; Lee, H; Park, J; Kim, H; Choi, EJ				Shim, J; Lee, H; Park, J; Kim, H; Choi, EJ			A non-enzymatic p21 protein inhibitor of stress-activated protein kinases	NATURE			English	Article							TRANSFORMATION; CELLS; JUN	THE stress-activated protein kinases (SAPKs), which are identical to the c-Jun amino-terminal kinases (JNKs), are activated in response to a variety of cellular stresses, including DNA damage, heat shock or tumour-necrosis factor-alpha(1,2). SAPK, a subfamily of the mitogen-activated protein (MAP) kinases, is a major protein kinase that phosphorylates c-Jun and other transcription factors(2-5). SAPK phosphorylation of transcription factors is important in stress-activated signalling cascades(1-6). Here we report that the protein p21(WAF1/CIP1/Sdi1), a DNA-damage-inducible cell-cycle inhibitor(7-10), acts as an inhibitor of the SAPK group of mammalian MAP kinases. This highlights a new biochemical activity of p21, which may provide the first evidence for a non-enzymatic inhibitory protein for SAPK. We suggest that p21, by inhibiting SAPK, may participate in regulating signalling cascades that are activated by cellular stresses such as DNA damage.	HANHYO INST TECHNOL,CELL BIOL LAB,SIHUNG SHI 429010,KYONGKI DO,SOUTH KOREA									AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARPER JW, 1993, CELL, V75, P805; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HILBERG F, 1992, ONCOGENE, V7, P2371; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OSAWA Y, 1995, BIOCHEM BIOPH RES CO, V216, P429, DOI 10.1006/bbrc.1995.2641; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	29	239	244	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					804	807		10.1038/381804a0	http://dx.doi.org/10.1038/381804a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657286				2022-12-24	WOS:A1996UU35600065
J	Meade, TW; Cooper, JA; Chakrabarti, R; Miller, GJ; Stirling, Y; Howarth, DJ				Meade, TW; Cooper, JA; Chakrabarti, R; Miller, GJ; Stirling, Y; Howarth, DJ			Fibrinolytic activity and clotting factors in ischaemic heart disease in women	BRITISH MEDICAL JOURNAL			English	Article											Meade, TW (corresponding author), ST BARTHOLOMEWS & ROYAL LONDON HOSP,SCH MED & DENT,MRC EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND.							HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1994, BRIT J HAEMATOL, V88, P601, DOI 10.1111/j.1365-2141.1994.tb05079.x; MEADE TW, 1994, LANCET, V343, P1442, DOI 10.1016/S0140-6736(94)92572-0	5	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1581	1581						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664669				2022-12-24	WOS:A1996UU80600021
J	Nickel, JC; Siemens, DR; Lundie, MJ				Nickel, JC; Siemens, DR; Lundie, MJ			Allopurinol for prostatitis: Where is the evidence?	LANCET			English	Editorial Material											Nickel, JC (corresponding author), QUEENS UNIV,DEPT UROL,KINGSTON,ON,CANADA.							DOBLE A, 1991, BR J UROL, V65, P598; NEAL DE, 1994, UROLOGY, V43, P460, DOI 10.1016/0090-4295(94)90231-3; Nickel JC, 1996, J UROLOGY, V155, P1950, DOI 10.1016/S0022-5347(01)66056-7; NICKEL JC, 1996, CURR OPIN UROL, V6, P53; Persson BE, 1996, J UROLOGY, V155, P961, DOI 10.1016/S0022-5347(01)66358-4; Persson BE, 1996, J UROLOGY, V155, P958, DOI 10.1016/S0022-5347(01)66357-2	6	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1711	1712						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656902				2022-12-24	WOS:A1996UT39600006
J	Baylies, MK; Bate, M				Baylies, MK; Bate, M			twist: A myogenic switch in Drosophila	SCIENCE			English	Article							GENE FAMILY; DORSOVENTRAL PATTERN; ZYGOTIC GENE; MYOD FAMILY; EXPRESSION; MEMBER; SPECIFICATION; MESODERM; CELLS; INACTIVATION	Somatic muscle is derived from a subset of embryonic mesoderm. In Drosophila, Twist (Twi), a basic helix-loop-helix transcription factor, is a candidate regulator of mesodermal differentiation and myogenesis. Altering amounts of Twist after gastrulation revealed that high levels of Twist are required for somatic myogenesis and block the formation of other mesodermal derivatives. Expression of twist in the ectoderm drives these cells into myogenesis. Thus, after an initial role in gastrulation, twist regulates mesodermal differentiation and propels a specific subset of mesodermal cells into somatic myogenesis. Vertebrate homologs of twist may also participate in the subdivision of mesoderm.			Baylies, MK (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.							AZPLAZU N, 1993, GENE DEV, V7, P1325; BATE M, 1991, DEVELOPMENT, V113, P79; BATE M, 1993, CR ACAD SCI III-VIE, V316, P1055; BATE M, IN PRESS SEM DEV BIO; BATE M, UNPUB; Bate Michael, 1993, P1013; BAYLIES MK, 1995, DEVELOPMENT, V121, P3829; BAYLIES MK, 1992, NEURON, V9, P575, DOI 10.1016/0896-6273(92)90194-I; BAYLIES MK, UNPUB; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870, DOI 10.1073/pnas.92.13.5870; BODMER R, 1993, DEVELOPMENT, V118, P719; Borkowski OMD, 1995, DEVELOPMENT, V121, P4183; BRAND A, 1994, PRACTICAL USES CELL, P643; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUCKINGHAM M, 1994, CELL, V78, P15, DOI 10.1016/0092-8674(94)90568-1; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; IP YT, 1994, EMBO J, V13, P5826, DOI 10.1002/j.1460-2075.1994.tb06926.x; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; KLERMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; MICHELSON AM, 1994, DEVELOPMENT, V120, P755; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROHWEDEL J, 1995, EXP CELL RES, V220, P92, DOI 10.1006/excr.1995.1295; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SIMPSON P, 1983, GENETICS, V105, P615; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	52	272	279	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1481	1484		10.1126/science.272.5267.1481	http://dx.doi.org/10.1126/science.272.5267.1481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633240				2022-12-24	WOS:A1996UP89900047
J	Engholm, G; Palmgren, F; Lynge, E				Engholm, G; Palmgren, F; Lynge, E			Lung cancer, smoking, and environment: A cohort study of the Danish population	BRITISH MEDICAL JOURNAL			English	Article							AIR-POLLUTION	Objective-The almost twofold difference in lung cancer incidence between people living in Copenhagen and in the rural areas of Denmark in the 1980s led to public concern; this study was undertaken to assess the effects of air pollution and occupation on lung cancer in Denmark, with control for smoking habits. Design-Cohort study of national population. Subjects-People aged 30-64 and economically active in 1970 (927 470 men and 486 130 women). Main outcome measures-Relative risks for lung cancer estimated with multiplicative Poisson modelling of incidence rates. Results-Differences in smoking habit explained about 60% of the excess lung cancer risk in Copenhagen for men and 90% for women. After control for smoking, workers had double the lung cancer risk of teachers and academics. There was only a small independent effect of region. Conclusion-Smoking is the main factor behind the regional differences in lung cancer incidence in Denmark, and occupational risk factors also seem to have an important role. The outdoor air in Copenhagen around 1970 contained on average 50-80 mu g/m(3) of sulphur dioxide, 80-100 mu g/m(3) total suspended particulate matter, and up to 10 ng/m(3) benzo(a)pyrene and had peak values of daily smoke of 120 mu g/m(3). Region had only a small effect on incidence of lung cancer in the present study, which suggests that an influence of outdoor air pollution on lung cancer is identifiable only above this pollution level.	NATL ENVIRONM RES INST,DK-4000 ROSKILDE,DENMARK	Aarhus University	Engholm, G (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,BOX 839,DK-2100 COPENHAGEN O,DENMARK.			Lynge, Elsebeth/0000-0003-4785-5236				CARSTENSEN JM, 1988, INT J EPIDEMIOL, V17, P753, DOI 10.1093/ije/17.4.753; *DANM STAT, 1975, 1970 POP HOUS CENS, P72; FRIIS S, 1993, EUR J CANCER, V29A, P538, DOI 10.1016/S0959-8049(05)80147-9; HEMMINKI K, 1994, ENVIRON HEALTH PERSP, V102, P187, DOI 10.2307/3431951; *INT AG RES CANC, 1985, MON EV CARC RISK CHE, V38, P203; JEDRYCHOWSKI W, 1990, J EPIDEMIOL COMMUN H, V44, P114, DOI 10.1136/jech.44.2.114; JENSEN FP, 1994, ENVIRON HEALTH PERSP, V102, P55, DOI 10.2307/3431931; KATSOUYANNI K, 1991, PREV MED, V20, P271, DOI 10.1016/0091-7435(91)90026-Z; LYNGE E, 1990, Scandinavian Journal of Work Environment and Health, V16, P1; LYNGE E, 1979, 37 DENM STAT, P27; LYNGE E, IN PRESS SOCIOECONOM; NIELSEN P E, 1988, Ugeskrift for Laeger, V150, P2229; Nielsen T., 1995, TRAFFIC PAH OTHER MU; NOY D, 1990, ATMOS ENVIRON A-GEN, V24, P2903, DOI 10.1016/0960-1686(90)90470-8; PERSHAGEN G, 1994, NEW ENGL J MED, V330, P159, DOI 10.1056/NEJM199401203300302; Speizer FE, 1994, EPIDEMIOLOGY LUNG CA, P131; *STAT I STRAL, 1987, NAT RAD DAN DWELL, P94; VANLOON AJM, 1995, J EPIDEMIOL COMMUN H, V49, P65, DOI 10.1136/jech.49.1.65; XU ZY, 1989, J NATL CANCER I, V81, P1800, DOI 10.1093/jnci/81.23.1800	19	32	33	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1259	1263		10.1136/bmj.312.7041.1259	http://dx.doi.org/10.1136/bmj.312.7041.1259			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634614	Green Published			2022-12-24	WOS:A1996UM40400019
J	Ast, G; Weiner, AM				Ast, G; Weiner, AM			A U1/U4/U5 snRNP complex induced by a 2'-O-methyl-oligoribonucleotide complementary to U5 snRNA	SCIENCE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER-RNA; 3' SPLICE SITE; PREMESSENGER RNA; U6 SNRNA; U2; PROTEIN; ASSOCIATION; RECOGNIZES; DEPLETION	Nuclear messenger RNA splicing involves multiple interactions between the five spliceosomal small nuclear ribonucleoprotein particles (snRNPs) U1, U2, U4, U5, and U6 and numerous spliceosomal proteins. Here it is shown that binding of a 2'-O-methyl-oligoribonucleotide complementary to U5 small nuclear RNA (snRNA) nucleotides 68 to 88 (BU5Ae) disrupts the initial U4/U5/U6 tri-snRNP complex, enhances the U2/U6 interaction, and induces a U1/U4/U5 snRNP complex. The U1/U4/U5 snRNP complex interacts specifically with an RNA oligonucleotide containing the 5' splice site sequence and may therefore represent a transitional stage in the displacement of U1 from the 5' splice site by U5 snRNP.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031073] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AST G, UNPUB; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KONFORTI BB, 1994, GENE DEV, V8, P1962, DOI 10.1101/gad.8.16.1962; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1991, NUCLEIC ACIDS RES, V19, P3857, DOI 10.1093/nar/19.14.3857; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WILL CL, 1993, MOL BIOL REP, V18, P121, DOI 10.1007/BF00986766; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542	34	17	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					881	884		10.1126/science.272.5263.881	http://dx.doi.org/10.1126/science.272.5263.881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629024				2022-12-24	WOS:A1996UK75700061
J	Bobola, N; Jansen, RP; Shin, TH; Nasmyth, K				Bobola, N; Jansen, RP; Shin, TH; Nasmyth, K			Asymmetric accumulation of ASH1p in postanaphase nuclei depends on a myosin and restricts yeast mating-type switching to mother cells	CELL			English	Article							HO GENE; SACCHAROMYCES-CEREVISIAE; CYCLE REGULATION; PROTEIN-KINASE; TRANSCRIPTION; EXPRESSION; FINGER; SW15; REPRESSION; ACTIVATION	Cell division in haploid yeast gives rise to a ''mother'' cell capable of mating-type switching and a ''daughter'' cell that is not. Switching is initiated by the HO endonuclease, whose gene is only transcribed in cells that have previously given birth to a bud (mother cells). HO expression depends on a minimyosin, She1p/Myo4p, which accumulates preferentially in growing buds. We describe a gene, ASH1, that is necessary to repress HO in daughters. ASH1 encodes a zinc finger protein whose preferential accumulation in daughter cell nuclei at the end of anaphase depends on She1p/Myo4p. The greater abundance of Ash1p in daughter cells is responsible for restricting HO expression to mother cells.			Bobola, N (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; HAARER BK, 1994, J CELL SCI, V107, P1055; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOCH C, 1993, SCIENCE, V261, P1550; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517	38	285	287	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					699	709		10.1016/S0092-8674(00)81048-X	http://dx.doi.org/10.1016/S0092-8674(00)81048-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625408	Bronze			2022-12-24	WOS:A1996TZ99000008
J	Link, RE; Desai, K; Hein, L; Stevens, ME; Chruscinski, A; Bernstein, D; Barsh, GS; Kobilka, BK				Link, RE; Desai, K; Hein, L; Stevens, ME; Chruscinski, A; Bernstein, D; Barsh, GS; Kobilka, BK			Cardiovascular regulation in mice lacking alpha(2)-adrenergic receptor subtypes b and c	SCIENCE			English	Article							POSTSYNAPTIC ALPHA-ADRENOCEPTOR; 2 DISTINCT TYPES; ADRENERGIC-RECEPTOR; MESSENGER-RNAS; ALPHA-2-ADRENOCEPTOR SUBTYPES; IMIDAZOLINE RECEPTORS; BLOOD-PRESSURE; RAT-KIDNEY; EXPRESSION; DEXMEDETOMIDINE	alpha(2)-Adrenergic receptors (alpha(2)ARs) are essential components of the neural circuitry regulating cardiovascular function. The role of specific alpha(2)AR subtypes alpha(2a), alpha(2b), and alpha(2c) was characterized with hemodynamic measurements obtained from strains of genetically engineered mice deficient in either alpha(2b) or alpha(2c) receptors. Stimulation of alpha(2b) receptors in vascular smooth muscle produced hypertension and counteracted the clinically beneficial hypotensive effect of stimulating alpha(2a) receptors in the central nervous system. There were no hemodynamic effects produced by disruption of the alpha(2c) subtype. These results provide evidence for the clinical efficacy of more subtype-selective alpha(2)AR drugs.	STANFORD UNIV, HOWARD HUGHES MED INST, DEPT CELLULAR & MOL PHYSIOL, STANFORD, CA 94305 USA; STANFORD UNIV, DIV CARDIOVASC MED, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University				Bernstein, Daniel/0000-0001-7761-5853; Kobilka, Brian/0000-0001-5958-3990	NHLBI NIH HHS [HL48638] Funding Source: Medline; NIGMS NIH HHS [GM07365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048638] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL I, 1992, J PHARMACOL EXP THER, V263, P1327; BENTLEY SM, 1977, BRIT J PHARMACOL, V61, pP116; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; BLOOR BC, 1992, J PHARMACOL EXP THER, V263, P690; BOUSQUET P, 1992, AM J HYPERTENS, V5, pS47, DOI 10.1093/ajh/5.4.47S; CHEN DG, 1988, AM J PHYSIOL, V254, pH984, DOI 10.1152/ajpheart.1988.254.5.H984; CHRUSCINSKI AJ, 1992, BIOCHEM BIOPH RES CO, V186, P1280, DOI 10.1016/S0006-291X(05)81544-X; COFFMAN JD, 1988, EUR J CLIN INVEST, V18, P309, DOI 10.1111/j.1365-2362.1988.tb01264.x; DOCHERTY JR, 1979, BRIT J PHARMACOL, V67, pP421; DREW GM, 1979, BRIT J PHARMACOL, V67, P207, DOI 10.1111/j.1476-5381.1979.tb08668.x; DYCK JB, 1993, ANESTHESIOLOGY, V78, P813, DOI 10.1097/00000542-199305000-00002; Flacke W E, 1993, J Cardiothorac Vasc Anesth, V7, P41, DOI 10.1016/1053-0770(93)90117-4; HAMILTON CA, 1992, PHARMACOL THERAPEUT, V54, P231, DOI 10.1016/0163-7258(92)90001-G; HANDY DE, 1993, HYPERTENSION, V21, P861, DOI 10.1161/01.HYP.21.6.861; KALLIO A, 1989, CLIN PHARMACOL THER, V46, P33, DOI 10.1038/clpt.1989.103; LINK R, 1992, MOL PHARMACOL, V42, P16; LINK RE, 1995, MOL PHARMACOL, V48, P48; LORENZ W, 1990, MOL PHARMACOL, V38, P599; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; MEISTER B, 1994, J PHARMACOL EXP THER, V268, P1605; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NICHOLAS AP, 1993, J COMP NEUROL, V328, P575, DOI 10.1002/cne.903280409; OHGUSHI M, 1993, CARDIOVASC RES, V27, P779, DOI 10.1093/cvr/27.5.779; PERALA M, 1992, MOL BRAIN RES, V16, P57, DOI 10.1016/0169-328X(92)90193-F; RUFFOLO RR, 1993, ANNU REV PHARMACOL, V33, P243, DOI 10.1146/annurev.pharmtox.33.1.243; SAVOLA JM, 1989, ACTA VET SCAND, P39; SCHEININ H, 1989, PROG NEURO-PSYCHOPH, V13, P635, DOI 10.1016/0278-5846(89)90051-1; SCHEININ M, 1994, MOL BRAIN RES, V21, P133, DOI 10.1016/0169-328X(94)90386-7; SUN L, 1992, EUR J PHARM-MOLEC PH, V226, P367, DOI 10.1016/0922-4106(92)90055-Z; TIMMERMANS PBMWM, 1983, J CARDIOVASC PHARM, V5, P1, DOI 10.1097/00005344-198301000-00001; TIMMERMANS PBMWM, 1979, N-S ARCH PHARMACOL, V310, P189, DOI 10.1007/BF00500284; UHLEN S, 1991, BRIT J PHARMACOL, V104, P657, DOI 10.1111/j.1476-5381.1991.tb12485.x; VANMEEL JCA, 1982, J AUTON PHARMACOL, V2, P13, DOI 10.1111/j.1474-8673.1982.tb00465.x; VIRTANEN R, 1989, ACTA VET SCAND, P29; VIRTANEN R, 1989, ARCH INT PHARMACOD T, V297, P190; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YAMAGUCHI I, 1980, J PHARMACOL EXP THER, V214, P275; ZENG DW, 1991, MOL BRAIN RES, V10, P219, DOI 10.1016/0169-328X(91)90064-5	38	392	409	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					803	805		10.1126/science.273.5276.803	http://dx.doi.org/10.1126/science.273.5276.803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670422				2022-12-24	WOS:A1996VB42900045
J	Xu, XA; Sun, YL; Hoey, T				Xu, XA; Sun, YL; Hoey, T			Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; GENE; TRANSCRIPTION; PROTEIN; INTERLEUKIN-12; EXPRESSION; LYMPHOCYTES; ACTIVATION; CYTOKINE; MEMBERS	STAT proteins (signal transducers and activators of transcription) activate distinct target genes despite having similar DNA binding preferences. The transcriptional specificity of STAT proteins was investigated on natural STAT binding sites near the interferon-gamma gene. These sites are arranged in multiple copies and required cooperative interactions for STAT binding. The conserved amino-terminal domain of STAT proteins was required for cooperative DNA binding, although this domain was not essential for dimerization or binding to a single site. Cooperative binding interactions enabled the STAT proteins to recognize Variations of the consensus site. These sites can be specific for the different STAT proteins and may function to direct selective transcriptional activation.	TULARIK,S SAN FRANCISCO,CA 94080									BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CHAN SH, 1992, J IMMUNOL, V148, P92; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HARDY KJ, 1985, P NATL ACAD SCI USA, V82, P8173, DOI 10.1073/pnas.82.23.8173; HARDY KJ, 1989, J EXP MED, V170, P1021, DOI 10.1084/jem.170.3.1021; HELM MH, 1995, SCIENCE, V267, P1347; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HOEY T, UNPUB; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KAPLAN MH, 1996, NATURE, V382, P162; MIKITA T, UNPUB; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHINDLER U, UNPUB; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; WEN Z, 1995, CELL, V82, P24; Xu X.Y, UNPUB; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YOUNG HA, 1989, J IMMUNOL, V143, P2389; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	28	395	402	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					794	797		10.1126/science.273.5276.794	http://dx.doi.org/10.1126/science.273.5276.794			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670419				2022-12-24	WOS:A1996VB42900042
J	Sato, Y; Roman, M; Tighe, H; Lee, D; Corr, M; Nguyen, MD; Silverman, GJ; Lotz, M; Carson, DA; Raz, E				Sato, Y; Roman, M; Tighe, H; Lee, D; Corr, M; Nguyen, MD; Silverman, GJ; Lotz, M; Carson, DA; Raz, E			Immunostimulatory DNA sequences necessary for effective intradermal gene immunization	SCIENCE			English	Article							MYCOBACTERIUM-BOVIS BCG; NATURAL-KILLER ACTIVITY; CD4+ T-CELLS; SYNTHETIC OLIGONUCLEOTIDES; INTERFERON-PRODUCTION; ALPHA; PROTEINS; IFN; TH1	Vaccination with naked DNA elicits cellular and humoral immune responses that have a T helper cell type 1 bias. However, plasmid vectors expressing large amounts of gene product do not necessarily induce immune responses to the encoded antigens. instead, the immunogenicity of plasmid DNA (pDNA) requires short immunostimulatory DNA sequences (ISS) that contain a CpG dinucleotide in a particular base context. Human monocytes transfected with pDNA or double-stranded oligonucleotides containing the ISS, but not those transfected with ISS-deficient pDNA or oligonucleotides, transcribed large amounts of interferon-alpha, interferon-beta, and interleukin-12. Although ISS are necessary for gene vaccination, they down-regulate gene expression and thus may interfere with gene replacement therapy by inducing proinflammatory cytokines.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SAM & ROSE STEIN INST RES AGING,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, R01AI037305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041897] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37305, AI36214] Funding Source: Medline; NIAMS NIH HHS [AR41897] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655; FINKELMAN FD, 1991, J EXP MED, V174, P1179, DOI 10.1084/jem.174.5.1179; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GAVIN MA, 1993, J IMMUNOL, V151, P3971; Halpern MD, 1996, CELL IMMUNOL, V167, P72, DOI 10.1006/cimm.1996.0009; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; KIMURA Y, 1994, J BIOCHEM-TOKYO, V116, P991, DOI 10.1093/oxfordjournals.jbchem.a124658; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; MANETTI R, 1995, EUR J IMMUNOL, V25, P2656, DOI 10.1002/eji.1830250938; MANICKAN E, 1995, J IMMUNOL, V155, P259; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; SATO Y, UNPUB; TOKUNAGA T, 1984, J NATL CANCER I, V72, P955; TOKUNAGA T, 1992, MICROBIOL IMMUNOL, V36, P55, DOI 10.1111/j.1348-0421.1992.tb01642.x; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG JC, 1992, AM J HEMATOL, V40, P81, DOI 10.1002/ajh.2830400202; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; YAMAMOTO T, 1994, JPN J CANCER RES, V85, P775, DOI 10.1111/j.1349-7006.1994.tb02947.x; YAMAMOTO T, 1994, MICROBIOL IMMUNOL, V38, P831, DOI 10.1111/j.1348-0421.1994.tb01867.x; Yi AK, 1996, J IMMUNOL, V156, P558	27	903	1146	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1996	273	5273					352	354		10.1126/science.273.5273.352	http://dx.doi.org/10.1126/science.273.5273.352			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY202	8662521				2022-12-24	WOS:A1996UY20200038
J	Maron, BJ; Shirani, J; Poliac, LC; Mathenge, R; Roberts, WC; Mueller, FO				Maron, BJ; Shirani, J; Poliac, LC; Mathenge, R; Roberts, WC; Mueller, FO			Sudden death in young competitive athletes - Clinical, demographic, and pathological profiles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR HYPERTROPHY; RIGHT CORONARY-ARTERY; LONG-QT SYNDROME; CARDIAC DEATH; MITRAL-VALVE; CARDIOVASCULAR-DISEASE; PATHO-PHYSIOLOGY; LEFT MAIN; CARDIOMYOPATHY; SINUS	Objective.-To develop clinical, demographic, and pathological profiles of young competitive athletes who died suddenly, Design.-Systematic evaluation of clinical information and circumstances associated with sudden deaths; interviews with family members, witnesses, and coaches; and analyses of postmortem anatomic, microscopic, and toxicologic data. Participants and Setting.-A total of 158 sudden deaths that occurred in trained athletes throughout the United States from 1985 through 1995 were analyzed. Main Outcome Measures.-Characteristics and probable cause of death, Results.-Of 158 sudden deaths among athletes, 24 (15%) were explained by noncardiovascular causes, Among the 134 athletes who had cardiovascular causes of sudden death, the median age was 17 years (range, 12-40 years), 120 (90%) were male, 70 (52%) were white, and 59 (44%) were black. The most common competitive sports involved were basketball (47 cases) and football (45 cases), together accounting for 68% of sudden deaths, A total of 121 athletes (90%) collapsed during or immediately after a training session (78 cases) or a formal athletic contest (43 cases), with 80 deaths (63%) occurring between 3 PM and 9 PM, The most common structural cardiovascular diseases identified at autopsy as the primary cause of death were hypertrophic cardiomyopathy (48 athletes [36%]), which was disproportionately prevalent in black athletes compared with white athletes (48% vs 26% of deaths; P=.01), and malformations involving anomalous coronary artery origin (17 athletes [13%]), Of 115 athletes who had a standard preparticipation medical evaluation, only 4 (3%) were suspected of having cardiovascular disease, and the cardiovascular abnormality responsible for sudden death was correctly identified in only 1 athlete (0.9%). Conclusions.-Sudden death in young competitive athletes usually is precipitated by physical activity and may be due to a heterogeneous spectrum of cardiovascular disease, most commonly hypertrophic cardiomyopathy. Preparticipation screening appeared to be of limited value in identification of underlying cardiovascular abnormalities.	MINNEAPOLIS HEART INST FDN, DIV CARDIOVASC RES, 920 E 28TH ST, SUITE 40, MINNEAPOLIS, MN 55407 USA; ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; NATL CTR CATASTROPH SPORTS INJURY RES, CHAPEL HILL, NC USA; BAYLOR UNIV, MED CTR, DALLAS, TX USA	Minneapolis Heart Institute Foundation; Yeshiva University; Albert Einstein College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Baylor University; Baylor University Medical Center								Aretz T., 1986, AM J CARDIOVASC PATH, V1, P3; BARTH CW, 1986, J AM COLL CARDIOL, V7, P366, DOI 10.1016/S0735-1097(86)80507-1; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; BURKE AP, 1993, J AM COLL CARDIOL, V21, P117, DOI 10.1016/0735-1097(93)90725-G; CHEITLIN MD, 1974, CIRCULATION, V50, P780, DOI 10.1161/01.CIR.50.4.780; CHESLER E, 1983, CIRCULATION, V67, P632, DOI 10.1161/01.CIR.67.3.632; CORRADO D, 1992, BRIT HEART J, V68, P601; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; DALIENTO L, 1995, J AM COLL CARDIOL, V25, P655, DOI 10.1016/0735-1097(94)00433-Q; DOLLAR AL, 1991, J AM COLL CARDIOL, V17, P921, DOI 10.1016/0735-1097(91)90875-A; DRORY Y, 1991, AM J CARDIOL, V68, P1388, DOI 10.1016/0002-9149(91)90251-F; FURLANELLO F, 1984, ANN NY ACAD SCI, V427, P253, DOI 10.1111/j.1749-6632.1984.tb20789.x; GOODIN JC, 1991, MODERN PATHOL, V4, P702; HUSTON TP, 1985, NEW ENGL J MED, V313, P24, DOI 10.1056/NEJM198507043130106; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JAMES TN, 1967, ANN INTERN MED, V67, P1013, DOI 10.7326/0003-4819-67-5-1013; KARK JA, 1987, NEW ENGL J MED, V317, P781, DOI 10.1056/NEJM198709243171301; KLUES HG, 1995, J AM COLL CARDIOL, V26, P1699, DOI 10.1016/0735-1097(95)00390-8; KLUES HG, 1992, CIRCULATION, V85, P1651, DOI 10.1161/01.CIR.85.5.1651; LECOMTE D, 1993, J FORENSIC SCI, V38, P617; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; MARON BJ, 1990, BRIT HEART J, V63, P308; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; MARON BJ, 1994, J AM COLL CARDIOL, V24, P848, DOI 10.1016/0735-1097(94)90837-0; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1979, AM J CARDIOL, V43, P1242, DOI 10.1016/0002-9149(79)90160-7; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MARON BJ, 1986, NEW ENGL J MED, V315, P610, DOI 10.1056/NEJM198609043151003; MARON BJ, 1994, J AM COLL CARDIOL, V23, P1405, DOI 10.1016/0735-1097(94)90384-0; MARON BJ, 1981, CIRCULATION, V63, P882, DOI 10.1161/01.CIR.63.4.882; MCKENNA WJ, 1994, BRIT HEART J, V71, P215; MCKENNA WJ, 1990, BRIT HEART J, V63, P287; MENKE DM, 1985, CHEST, V88, P299, DOI 10.1378/chest.88.2.299; MORALES AR, 1980, CIRCULATION, V62, P230, DOI 10.1161/01.CIR.62.2.230; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; OLSEN EGJ, 1983, EUR HEART J, V4, P1; PELLICCIA A, 1991, NEW ENGL J MED, V324, P295, DOI 10.1056/NEJM199101313240504; RAMPAZZO A, 1994, HUM MOL GENET, V3, P959, DOI 10.1093/hmg/3.6.959; ROBERTS CS, 1989, PROGR CARDIOLOGY, V2, P3; ROBERTS WC, 1986, AM J CARDIOL, V57, P179, DOI 10.1016/0002-9149(86)90977-X; ROBERTS WC, 1992, AM J CARDIOL, V70, P121, DOI 10.1016/0002-9149(92)91407-U; ROBERTS WC, 1982, AM HEART J, V104, P303, DOI 10.1016/0002-8703(82)90206-X; ROBERTS WC, 1982, AM J CARDIOL, V49, P863, DOI 10.1016/0002-9149(82)91970-1; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; SPIRITO P, 1990, J AM COLL CARDIOL, V15, P1521, DOI 10.1016/0735-1097(90)92820-R; TAMBURRO P, 1992, AM HEART J, V124, P1035, DOI 10.1016/0002-8703(92)90989-9; THIENE G, 1983, HUM PATHOL, V14, P704, DOI 10.1016/S0046-8177(83)80143-9; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; TSUNG SH, 1982, ARCH PATHOL LAB MED, V106, P168; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; VIRMANI R, 1984, J AM COLL CARDIOL, V3, P766, DOI 10.1016/S0735-1097(84)80253-3; VIRMANI R, 1988, AM HEART J, V115, P1068, DOI 10.1016/0002-8703(88)90078-6; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; ZIPES DP, 1994, J AM COLL CARDIOL, V24, P892, DOI 10.1016/0735-1097(94)90847-8	62	1203	1242	6	110	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					199	204		10.1001/jama.276.3.199	http://dx.doi.org/10.1001/jama.276.3.199			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667563	Green Published			2022-12-24	WOS:A1996UW46900030
J	Viola, A; Lanzavecchia, A				Viola, A; Lanzavecchia, A			T cell activation determined by T cell receptor number and tunable thresholds	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; ANTIGEN; REQUIREMENTS; SUPERANTIGEN; RECOGNITION; STIMULATION; MOLECULES; INVITRO; BINDING; PEPTIDE	The requirements for T cell activation have been reported io vary widely depending on the state of the T cell, the type of antigen-presenting cell, and the nature of the T cell receptor (TCR) ligand. A unitary requirement for T cell responses was revealed by measurement of the number of triggered TCRs. Irrespective of the nature of the triggering ligand, T cells ''counted'' the number of triggered TCRs and responded when a threshold of similar to 8000 TCRs was reached. The capacity to reach the activation threshold was severely compromised by a reduction in the number of TCRs. Costimulatory signals lowered the activation threshold to similar to 1500 TCRs, thus making T cells more sensitive to antigenic stimulation.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND				Agatea, Lisa/L-8267-2016; Viola, Antonella/A-4321-2015	Viola, Antonella/0000-0002-0125-9271				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BHARDWAJ N, 1993, J EXP MED, V178, P633, DOI 10.1084/jem.178.2.633; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DOHRING C, 1994, INT J CANCER, V57, P754, DOI 10.1002/ijc.2910570524; FERBER I, 1994, SCIENCE, V263, P674, DOI 10.1126/science.8303275; FISCHER H, 1992, J IMMUNOL, V148, P1993; INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LANZAVECCHIA A, 1986, TOL WORKSH 1986, P293; LUQMAN M, 1992, J IMMUNOL, V149, P2300; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; PADOVAN E, 1995, J EXP MED, V181, P1587, DOI 10.1084/jem.181.4.1587; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; ROOSNEK E, 1989, J EXP MED, V170, P297, DOI 10.1084/jem.170.1.297; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; THIBODEAU J, 1994, SCIENCE, V266, P1874, DOI 10.1126/science.7997881; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; VIOLA A, UNPUB; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0	28	860	881	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1996	273	5271					104	106		10.1126/science.273.5271.104	http://dx.doi.org/10.1126/science.273.5271.104			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8658175				2022-12-24	WOS:A1996UV47800049
J	Treanor, JJS; Goodman, L; deSauvage, F; Stone, DM; Poulsen, KT; Beck, CD; Gray, C; Armanini, MP; Pollock, RA; Hefti, F; Phillips, HS; Goddard, A; Moore, MW; BujBello, A; Davies, AM; Asai, N; Takahashi, M; Vandlen, R; Henderson, CE; Rosenthal, A				Treanor, JJS; Goodman, L; deSauvage, F; Stone, DM; Poulsen, KT; Beck, CD; Gray, C; Armanini, MP; Pollock, RA; Hefti, F; Phillips, HS; Goddard, A; Moore, MW; BujBello, A; Davies, AM; Asai, N; Takahashi, M; Vandlen, R; Henderson, CE; Rosenthal, A			Characterization of a multicomponent receptor for GDNF	NATURE			English	Article							TRANSFORMING GENE; SUPERFAMILY; ACTIVATION; RESPONSES; PROTEIN; CELLS; CD14; RET	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF)(1) is a potent survival factor for central and peripheral neurons(2-6), and is essential for the development of kidneys and the enteric nervous system(7-9). Despite the potential clinical and physiological importance of GDNF, its mechanism of action is unknown. Here we show that physiological responses to GDNF require the presence of a novel glycosyl-phosphatidylinositol (GPI)-linked protein (designated GDNFR-alpha) that is expressed on GDNF-responsive cells and binds GDNF with a high affinity. We further demonstrate that GDNF promotes the formation of a physical complex between GDNFR-alpha and the orphan tyrosine kinase receptor Ret(10-12), thereby inducing its tyrosine phosphorylation. These findings support the hypothesis that GDNF uses a multi-subunit receptor system in which GDNFR-alpha and Ret function as the ligand-binding and signalling components, respectively.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT BIOCHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOL CANC RES,S SAN FRANCISCO,CA 94080; IBDM,INSERM,U382,F-13288 MARSEILLE 09,FRANCE; UNIV ST ANDREWS,ST ANDREWS KY16 9AT,FIFE,SCOTLAND; NAGOYA UNIV,DEPT PATHOL,NAGOYA,AICHI 466,JAPAN	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of St Andrews; Nagoya University			Davies, Alun M/A-4334-2010; BUJ-BELLO, Anna/J-7556-2013; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014; ASAI, Naoya/I-7377-2014	Davies, Alun M/0000-0001-5841-8176; Takahashi, Masahide/0000-0002-2803-2683; Henderson, Christopher/0000-0002-9936-3279	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; ATTISANO L, 1994, BIOCHIM BIOPHYS ACTA, V1222, P21; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Durbec PL, 1996, DEVELOPMENT, V122, P349; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TSUZUKI T, 1995, ONCOGENE, V10, P191	30	925	992	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1996	382	6586					80	83		10.1038/382080a0	http://dx.doi.org/10.1038/382080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV473	8657309				2022-12-24	WOS:A1996UV47300058
J	Cobbe, SM; Dalziel, K; Ford, I; Marsden, AK				Cobbe, SM; Dalziel, K; Ford, I; Marsden, AK			Survival of 1476 patients initially resuscitated from out of hospital cardiac arrest	BRITISH MEDICAL JOURNAL			English	Article							AUTOMATED EXTERNAL DEFIBRILLATORS; HEARTSTART-SCOTLAND PROJECT; LONG-TERM SURVIVAL; VENTRICULAR ARRHYTHMIAS; MYOCARDIAL-INFARCTION; EXPERIENCE; MORTALITY; DISEASE	Objectives-To determine the short and long term outcome of patients admitted to hospital after initially successful resuscitation from cardiac arrest out of hospital. Design-Review of ambulance and hospital records. Follow up of mortality by ''flagging'' with the registrar general. Cox proportional hazards analysis of predictors of mortality in patients discharged alive fi om hospital. Setting-Scottish Ambulance Service and acute hospitals throughout Scotland. Subjects-1476 patients admitted to a hospital ward, of whom 680 (46%) were discharged alive. Main outcome measures-Survival to hospital discharge, neurological status at discharge, time to death, and cause of death after discharge. Results-The median duration of hospital stay was 10 days (interquartile range 8-15) in patients discharged alive and 1 (1-4) day in those dying in hospital. Neurological status at discharge in survivors was normal or mildly impaired in 605 (89%), moderately impaired in 58 (8.5%), and severely impaired in 13 (2%); one patient was comatose. Direct discharge to home occurred in 622 (91%) cases. The 680 discharged survivors were followed up for a median of 25 (range 0-68) months. There were 176 deaths, of which 81 were sudden cardiac deaths, 55 were non-sudden cardiac deaths, and 40 were due to other causes. The product limit estimate of 4 year survival after discharge was 68%. The independent predictors of mortality on follow up were increased age, treatment for heart failure, and cardiac arrest not due to definite myocardial infarction. Conclusion-About 40% of initial survivors of resuscitation out of hospital are discharged home without major neurological disability. Patients at high risk of subsequent cardiac death can be identified and may benefit from further cardiological evaluation.	UNIV GLASGOW,ROBERTSON CTR BIOSTAT,GLASGOW G12 8QQ,LANARK,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G31 2ER,LANARK,SCOTLAND; SCOTTISH AMBULANCE SERV,EDINBURGH EH10 5UU,MIDLOTHIAN,SCOTLAND	University of Glasgow; University of Glasgow			Ford, Ian/ABE-6145-2020					COBB LA, 1975, CIRCULATION, V52, P223; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; Connolly SJ, 1993, AM J CARDIOL, V72, P103; CUMMINS RO, 1989, ANN EMERG MED, V18, P1269, DOI 10.1016/S0196-0644(89)80257-4; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; EVERY NR, 1992, J AM COLL CARDIOL, V19, P1435, DOI 10.1016/0735-1097(92)90599-I; GEDDES JS, 1967, LANCET, V2, P273; GOLDSTEIN S, 1985, CIRCULATION, V71, P873, DOI 10.1161/01.CIR.71.5.873; GOLDSTEIN S, 1981, CIRCULATION, V64, P977, DOI 10.1161/01.CIR.64.5.977; *GOV ACT DEP, 1992, SCOTT POP MAL FEM IN; HALLSTROM AP, 1991, AM J CARDIOL, V68, P1021; HUTTER AM, 1981, AM J CARDIOL, V48, P595, DOI 10.1016/0002-9149(81)90136-3; KELLY P, 1990, J AM COLL CARDIOL, V15, P267, DOI 10.1016/S0735-1097(10)80046-4; LEHMANN MH, 1991, PACE, V14, P969, DOI 10.1111/j.1540-8159.1991.tb04143.x; MACKINTOSH AF, 1978, BRIT MED J, V1, P1115, DOI 10.1136/bmj.1.6120.1115; MOOSVI AR, 1990, AM J CARDIOL, V65, P1192, DOI 10.1016/0002-9149(90)90972-4; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; SEDGWICK ML, 1992, RESUSCITATION, V24, P73, DOI 10.1016/0300-9572(92)90175-C; SHARMA B, 1987, AM J CARDIOL, V59, P740, DOI 10.1016/0002-9149(87)91084-8; SIEBELS J, 1993, PACE, V16, P552, DOI 10.1111/j.1540-8159.1993.tb01624.x; STEINBECK G, 1992, NEW ENGL J MED, V327, P987, DOI 10.1056/NEJM199210013271404; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1993, AM J CARDIOL, V72, P280	30	88	88	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1633	1637		10.1136/bmj.312.7047.1633	http://dx.doi.org/10.1136/bmj.312.7047.1633			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664715	Green Published			2022-12-24	WOS:A1996UV48900020
J	Rowen, L; Koop, BF; Hood, L				Rowen, L; Koop, BF; Hood, L			The complete 685-kilobase DNA sequence of the human beta T cell receptor locus	SCIENCE			English	Article							VARIABLE REGION GENES; V-BETA; ANTIGEN RECEPTOR; ALPHA-CHAIN; ORGANIZATION; DIVERSITY; REPERTOIRE; POLYMORPHISM; FAMILIES; IDENTIFICATION	The human beta T cell receptor (TCR) locus, comprising a complex family of genes, has been sequenced, The locus contains two types of coding elements-TCR elements (65 variable gene segments and two clusters of diversity, joining, and constant segments) and eight trypsinogen genes-that constitute 4.6 percent of the DNA. Genome-wide interspersed repeats and locus-specific repeats span 30 and 47 percent, respectively, of the 685-kilobase sequence. A comparison of the germline variable elements with their approximately 300 complementary DNA counterparts reveals marked differential patterns of variable gene expression, the importance of exonuclease activity in generating TCR diversity, and the predominant tendency for only functional variable elements to be present in complementary DNA libraries.	UNIV VICTORIA, DEPT BIOL, CTR ENVIRONM HLTH, VICTORIA, BC V8W 2Y2, CANADA	University of Victoria	Rowen, L (corresponding author), UNIV WASHINGTON, DEPT MOLEC BIOTECHNOL, SEATTLE, WA 98195 USA.		Koop, Ben F./A-8151-2008	Koop, Ben F./0000-0003-0045-5200				Adams M. D., 1994, AUTOMATED DNA SEQUEN; ADAMS MD, 1995, NATURE, V377, P3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON SJ, 1989, MOL CELL BIOL, V9, P4835, DOI 10.1128/MCB.9.11.4835; Arden Bernhard, 1995, Immunogenetics, V42, P455; BOLLUM FJ, 1986, ADV CANCER RES, V47, P37, DOI 10.1016/S0065-230X(08)60197-9; CHARMLEY P, 1993, J EXP MED, V177, P135, DOI 10.1084/jem.177.1.135; CHARMLEY P, 1990, TISSUE ANTIGENS, V35, P157, DOI 10.1111/j.1399-0039.1990.tb01773.x; CHARMLEY P, 1995, GENOMICS, V29, P760, DOI 10.1006/geno.1995.9940; CONCANNON P, 1986, COLD SPRING HARB SYM, V51, P785, DOI 10.1101/SQB.1986.051.01.091; CONCANNON P, 1986, P NATL ACAD SCI USA, V83, P6598, DOI 10.1073/pnas.83.17.6598; CONCANNON P, 1992, MANUAL CLIN LABORATO, P885; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEININGER PL, 1993, EVOL BIOL, V27, P157; DOHERTY PJ, 1991, MOL IMMUNOL, V28, P607, DOI 10.1016/0161-5890(91)90129-8; EMI M, 1986, GENE, V41, P305; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FUNKHOUSER SW, 1992, ARTHRITIS RHEUM, V35, P465, DOI 10.1002/art.1780350417; Green Paul, COMMUNICATION; HALL MA, 1995, HUM IMMUNOL, V43, P207, DOI 10.1016/0198-8859(95)00013-T; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; HOOD L, 1975, ANNU REV GENET, V9, P305, DOI 10.1146/annurev.ge.09.120175.001513; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JORES R, 1993, J IMMUNOL, V151, P6110; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KIMURA N, 1987, EUR J IMMUNOL, V17, P375, DOI 10.1002/eji.1830170312; KOOP BF, 1994, GENOMICS, V19, P478, DOI 10.1006/geno.1994.1097; LEVITT MH, COMMUNICATION; LI YX, 1991, J EXP MED, V174, P1537, DOI 10.1084/jem.174.6.1537; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; MAK TW, 1984, IMMUNOL REV, V81, P221, DOI 10.1111/j.1600-065X.1984.tb01112.x; MALHOTRA U, 1992, J IMMUNOL, V149, P1802; POSNETT DN, 1994, J EXP MED, V179, P1707, DOI 10.1084/jem.179.5.1707; ROACH J, COMMUNICATION; ROBINSON MA, 1985, HUM IMMUNOL, V14, P195, DOI 10.1016/0198-8859(85)90228-9; ROBINSON MA, 1993, P NATL ACAD SCI USA, V90, P2433, DOI 10.1073/pnas.90.6.2433; ROSENBERG WMC, 1992, EUR J IMMUNOL, V22, P541, DOI 10.1002/eji.1830220237; ROWEN L, UNPUB; ROYER HD, 1987, P NATL ACAD SCI USA, V84, P232, DOI 10.1073/pnas.84.1.232; SEBOUN E, 1989, J EXP MED, V170, P1263, DOI 10.1084/jem.170.4.1263; SIU G, 1986, J EXP MED, V164, P1600, DOI 10.1084/jem.164.5.1600; SLIGHTOM JL, 1994, GENOMICS, V20, P149, DOI 10.1006/geno.1994.1149; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; Smit AFA, 1996, P NATL ACAD SCI USA, V93, P1443, DOI 10.1073/pnas.93.4.1443; SMIT AFA, 1995, NUCLEIC ACIDS RES, V23, P98, DOI 10.1093/nar/23.1.98; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; SMIT AFA, COMMUNICATION; TANI T, 1990, NUCLEIC ACIDS RES, V18, P1631, DOI 10.1093/nar/18.6.1631; TILLINGHAST JP, 1986, SCIENCE, V233, P879, DOI 10.1126/science.3755549; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; VERLINDE CLM, COMMUNICATION; Wang K., COMMUNICATION; WEI S, 1994, IMMUNOGENETICS, V40, P27, DOI 10.1007/BF00163961; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; WILKINSON DA, 1994, RETROVIRIDAE, V3, P465; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; ZHAO TM, 1994, J EXP MED, V180, P1405, DOI 10.1084/jem.180.4.1405	59	361	424	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	1996	272	5269					1755	1762		10.1126/science.272.5269.1755	http://dx.doi.org/10.1126/science.272.5269.1755			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650574				2022-12-24	WOS:A1996UT11000034
J	Bichot, NP; Schall, JD; Thompson, KG				Bichot, NP; Schall, JD; Thompson, KG			Visual feature selectivity In frontal eye fields induced by experience in mature macaques	NATURE			English	Article							STRIATE CORTEX; SACCADES; MONKEY; ENHANCEMENT; ATTENTION; RESPONSES; NEURONS; SEARCH	WHEN examining a complex image, the eye movements of expert observers differ from those of novices; experts have learned to ignore features that are visually salient but are not relevant to the interpretation of the image(1-3). We have studied the neural basis of this form of perceptual-motor learning using monkeys that have learned to search for a visual target among distracters, Monkeys trained to search only for, say, a red stimulus among green distracters will ignore green stimuli even if they subsequently appear as targets in a complementary search array, that is, among red distracters, We recorded from neurons in the frontal eye field (FEF), a cortical area that responds to visual stimuli and controls purposive eye movements(4-6). Normally, FEF neurons do not exhibit feature selectivity, but their activity evolves to signal the target for an incipient eye movement(7). In monkeys trained exclusively on targets of one colour, however, FEF neurons show selectivity for stimuli of that colour, Because this selective response occurs so soon after presentation of the stimulus array, and is independent of location within the visual field, we propose that it reflects a form of experience-dependent plasticity that mediates the learning of arbitrary stimulus-response associations.	VANDERBILT UNIV, DEPT PSYCHOL, VANDERBILT VIS RES CTR, NASHVILLE, TN 37240 USA	Vanderbilt University								BRAVO MJ, 1992, PERCEPT PSYCHOPHYS, V51, P465, DOI 10.3758/BF03211642; BRUCE CJ, 1990, NEUROSCI IN, P261; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; FISHER D, 1981, EYE MOVEMENTS COGNIT; GOLDBERG ME, 1981, J NEUROPHYSIOL, V46, P773, DOI 10.1152/jn.1981.46.4.773; GOLDBERG ME, 1989, NEUROBIOLOGY SACCADI, V3, P283; GRONER R, 1985, EYE MOVEMENTS HUMAN; HANES DP, 1995, EXP BRAIN RES, V103, P85; LAMME VAF, 1995, J NEUROSCI, V15, P1605; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; MOHLER CW, 1973, BRAIN RES, V61, P385, DOI 10.1016/0006-8993(73)90543-X; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2178; NOWAK LG, 1995, VISUAL NEUROSCI, V12, P371, DOI 10.1017/S095252380000804X; OREGAN JK, 1987, EYE MOVEMENTS PHYSL; SCHALL JD, 1995, J NEUROSCI, V15, P6905; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P559, DOI 10.1152/jn.1991.66.2.559; SCHALL JD, 1995, J NEUROSCI, V15, P4464; SCHALL JD, 1991, NEURAL BASIS VISUAL, P388; Thompson K. G., 1995, Society for Neuroscience Abstracts, V21, P1270; WEINBERGER NM, 1995, ANNU REV NEUROSCI, V18, P129; WURTZ RH, 1976, J NEUROPHYSIOL, V39, P766, DOI 10.1152/jn.1976.39.4.766	24	179	180	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					697	699		10.1038/381697a0	http://dx.doi.org/10.1038/381697a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649514				2022-12-24	WOS:A1996UR97900052
J	Figurov, A; PozzoMiller, LD; Olafsson, P; Wang, T; Lu, B				Figurov, A; PozzoMiller, LD; Olafsson, P; Wang, T; Lu, B			Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus	NATURE			English	Article							LONG-TERM POTENTIATION; POSTNATAL RAT-BRAIN; MESSENGER-RNA; AREA CA1; BDNF; NT-3; ENHANCEMENT; EXPRESSION; PLASTICITY; INDUCTION	NEUROTROPHINS promote neuronal survival and differentiation, but the fact that their expression is modified by neuronal activity, suggests a role in regulating synapse development and plasticity(1-3). In developing hippocampus, the expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB(4-7) increases in parallel with the ability to undergo long-term potentiation (LTP)(8-10). Here me report a mechanism by which BDNF modulates hippocampal LTP. Exogenous BDNF promoted the induction of LTP by tetanic stimulation in young (postnatal day 12-13) hippocampal slices, which in the absence of BDNF show only short-term potentiation (STP), This effect was due to an enhanced ability of hippocampal synapses to respond to tetanic stimulation, rather than to a direct modulation of the LTP-triggering mechanism. A TrkB-IgG fusion protein, which scavenges endogenous BDNF11, reduced the synaptic responses to tetanus as well as the magnitude of LTP in adult hippocampus.	NICHHD,DEV NEUROBIOL LAB,NIH,BETHESDA,MD 20892; ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Lu, Bai/A-4018-2012	Lu, Bai/0000-0001-5418-9759; Pozzo-Miller, Lucas/0000-0001-6085-5527				ANIKSZTEJN L, 1991, NATURE, V349, P67, DOI 10.1038/349067a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CASTREN E, 1993, NEUROREPORT, V4, P895, DOI 10.1097/00001756-199307000-00014; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DUGICHDJORDJEVIC MM, 1993, NEUROREPORT, V4, P1091; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; FRIEDMAN WJ, 1991, EUR J NEUROSCI, V3, P688, DOI 10.1111/j.1460-9568.1991.tb00854.x; HARRIS KM, 1984, J PHYSIOL-LONDON, V346, P27, DOI 10.1113/jphysiol.1984.sp015005; HUANG YY, 1993, J NEUROSCI, V13, P568; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; ISACKSON PJ, 1995, CURR OPIN NEUROBIOL, V5, P350, DOI 10.1016/0959-4388(95)80048-4; JACKSON PS, 1993, J NEUROPHYSIOL, V70, P1412, DOI 10.1152/jn.1993.70.4.1412; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MULLER D, 1989, DEV BRAIN RES, V49, P105, DOI 10.1016/0165-3806(89)90063-1; PATTERSON S, 1992, NEURON, V9, P1981; PETROZZINO JJ, 1994, HIPPOCAMPUS, V4, P546, DOI 10.1002/hipo.450040504; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; RINGSTEDT T, 1993, DEV BRAIN RES, V72, P119, DOI 10.1016/0165-3806(93)90165-7; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; WANG T, 1995, J NEUROSCI, V15, P4796; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	925	948	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					706	709		10.1038/381706a0	http://dx.doi.org/10.1038/381706a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649517				2022-12-24	WOS:A1996UR97900055
J	Rosch, P; Willbold, D				Rosch, P; Willbold, D			Is EIAV tat protein a homeodomain?	SCIENCE			English	Article							ANEMIA VIRUS TAT				Rosch, P (corresponding author), UNIV BAYREUTH,DEPT BIOPOLYMERS,D-95440 BAYREUTH,GERMANY.		Rösch, Paul/I-5445-2014; Willbold, Dieter/A-6280-2013	Rösch, Paul/0000-0003-3330-2446; Willbold, Dieter/0000-0002-0065-7366				ADES SE, 1995, BIOCHEMISTRY-US, V34, P14601, DOI 10.1021/bi00044a040; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Higgins D G, 1994, Methods Mol Biol, V25, P307; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; Metzger AU, 1996, FEBS LETT, V384, P255, DOI 10.1016/0014-5793(96)00314-6; NOIMAN S, 1990, VIROLOGY, V176, P280, DOI 10.1016/0042-6822(90)90254-O; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; STEPHENS RM, 1990, J VIROL, V64, P3716, DOI 10.1128/JVI.64.8.3716-3725.1990; STICHT H, 1994, EUR J BIOCHEM, V225, P855, DOI 10.1111/j.1432-1033.1994.0855b.x; STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x; WILLBOLD D, 1994, SCIENCE, V264, P1584, DOI 10.1126/science.7515512; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6	17	10	10	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1996	272	5268					1672	1672						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658146				2022-12-24	WOS:A1996UR09300053
J	Treiman, A				Treiman, A			To see a world in 80 kilograms of rock	SCIENCE			English	Editorial Material							SNC				Treiman, A (corresponding author), LUNAR & PLANETARY INST,HOUSTON,TX 77058, USA.							Ash RD, 1996, NATURE, V380, P57, DOI 10.1038/380057a0; EUGSTER O, 1996, LUNAR PLANET SCI, V27, P345; Gladman BJ, 1996, SCIENCE, V271, P1387, DOI 10.1126/science.271.5254.1387; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; HARPER CL, 1995, SCIENCE, V267, P213, DOI 10.1126/science.7809625; HARVEY RP, 1996, LUNAR PLANET SCI, V27, P497; HARVEY RP, 1995, LUNAR PLANET SCI, V26, P555; JAGOUTZ E, 1996, LUNAR PLANET SCI, V27, P597; JAGOUTZ E, 1994, METEORITICS, V29, P479; KRING DA, 1996, LUNAR PLANET SCI, V27, P705; *LUN PLAN I, LUN PLAN I CONTR, V888; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; MITTLEFEHLDT DW, 1996, LUNAR PLANET SCI, V27, P1099; NYQUIST LE, 1995, LUNAR PLANET SCI, V26, P1065; ROMANEK CS, 1994, NATURE, V372, P665; SWINDLE TD, 1995, LUNAR PLANET SCI, V26, P1385; TREIMAN AH, 1993, METEORITICS, V28, P86, DOI 10.1111/j.1945-5100.1993.tb00251.x; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; TREIMAN AH, 1995, J GEOPHYS RES-PLANET, V100, P5329, DOI 10.1029/94JE02184; [No title captured]; [No title captured]	22	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1447	1448		10.1126/science.272.5267.1447	http://dx.doi.org/10.1126/science.272.5267.1447			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633232				2022-12-24	WOS:A1996UP89900034
J	Garrity, PA; Rao, Y; Salecker, I; McGlade, J; Pawson, T; Zipursky, SL				Garrity, PA; Rao, Y; Salecker, I; McGlade, J; Pawson, T; Zipursky, SL			Drosophila photoreceptor axon guidance and targeting requires the dreadlocks SH2/SH3 adapter protein	CELL			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; 1ST OPTIC GANGLION; TYROSINE PHOSPHORYLATION; INSERTIONAL MUTAGENESIS; GENETIC MOSAICS; NERVOUS-SYSTEM; COMPOUND EYE; MELANOGASTER; SH2; DOMAIN	Mutations in the Drosophila gene dreadlocks (dock) disrupt photoreceptor cell (R cell) axon guidance and targeting. Genetic mosaic analysis and cell-type-specific expression of dock transgenes demonstrate dock is required in R cells for proper innervation. Dock protein contains one SH2 and three SH3 domains, implicating it in tyrosine kinase signaling, and is highly related to the human proto-oncogene Nck. Dock expression is detected in R cell growth cones in the target region. We propose Dock transmits signals in the growth cone in response to guidance and targeting cues. These findings provide an important step for dissection of signaling pathways regulating growth cone motility.	UNIV CALIF LOS ANGELES, SCH MED, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Garrity, PA (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA.		Pawson, Tony J/E-4578-2013; Salecker, Iris/V-1228-2018	Zipursky, Stephen/0000-0001-5630-7181; Salecker, Iris/0000-0003-3775-7763; Garrity, Paul/0000-0002-8274-6564				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHBRUNER M, 1989, DROSOPHILA LAB MANUA; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; CAMPOS AR, 1992, DEVELOPMENT, V114, P355; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GARRITY PA, 1995, CELL, V83, P177, DOI 10.1016/0092-8674(95)90159-0; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRIS WA, 1987, DEVELOPMENT, V101, P123; HAY BA, 1994, DEVELOPMENT, V120, P2121; HU QJ, 1995, MOL CELL BIOL, V15, P1169; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; KANKEL DR, 1976, DEV BIOL, V48, P1, DOI 10.1016/0012-1606(76)90041-5; KARPEN GH, 1992, GENETICS, V132, P737; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LETOURNEAU PC, 1991, NERVE GROWTH CONE; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MARDON G, 1994, DEVELOPMENT, V120, P3473; MARTIN KA, 1995, NEURON, V14, P229, DOI 10.1016/0896-6273(95)90281-3; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; MELNERTZHAGEN IA, 1993, DEV DROSOPHILA MELAN, P1363; MISMER D, 1987, GENETICS, V116, P565; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; SALECKER I, 1995, J COMP NEUROL, V352, P33, DOI 10.1002/cne.903520104; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHLAEPFER DD, 1994, NATURE, V372, P786; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; TOROK T, 1993, GENETICS, V135, P71; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WINBERG ML, 1992, DEVELOPMENT, V115, P903; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653; XU T, 1993, DEVELOPMENT, V117, P1223; YAO KM, 1994, J NEUROCHEM, V63, P41	59	229	231	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1996	85	5					639	650		10.1016/S0092-8674(00)81231-3	http://dx.doi.org/10.1016/S0092-8674(00)81231-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646773	Bronze			2022-12-24	WOS:A1996UP34400005
J	Mumma, MJ; DiSanti, MA; DelloRusso, N; Fomenkova, M; MageeSauer, K; Kaminski, CD; Xie, DX				Mumma, MJ; DiSanti, MA; DelloRusso, N; Fomenkova, M; MageeSauer, K; Kaminski, CD; Xie, DX			Detection of abundant ethane and methane, along with carbon monoxide and water, in comet C/1996 B2 Hyakutake: Evidence for interstellar origin	SCIENCE			English	Article							MONOCARBOXYLIC ACIDS; HALLEYS-COMET; AUSTIN 1989C1; P-HALLEY; P/HALLEY; FORMALDEHYDE; EMISSION; IDENTIFICATION; EXCITATION; METEORITE	The saturated hydrocarbons ethane (C2H6) and methane (CH4) along with carbon monoxide (GO) and water (H2O) were detected in comet C/1996 B2 Hyakutake with the use of high-resolution infrared spectroscopy at the NASA Infrared Telescope Facility on Mauna Kea, Hawaii. The inferred production rates of molecular gases from the icy, cometary nucleus (in molecules per second) are 6.4 x 10(26) for C2H6, 1.2 x 10(27) for CH4, 9.8 x 10(27) for CO, and 1.7 x 10(29) for H2O. An abundance of C2H6 comparable to that of CH4 implies that ices in C/1996 B2 Hyakutake did not originate in a thermochemically equilibrated region of the solar nebula. The abundances are consistent with a kinetically controlled production process, but production of C2H6 by gas-phase ion molecule reactions in the natal cloud core is energetically forbidden. The high C2H6/CH4 ratio is consistent with production of C2H6 in icy grain mantles in the natal cloud, either by photolysis of CH4-rich ice or by hydrogen-addition reactions to acetylene condensed from the gas phase.	CATHOLIC UNIV AMER,DEPT PHYS,WASHINGTON,DC 20064; NASA,GODDARD SPACE FLIGHT CTR,WASHINGTON,DC 20064; UNIV CALIF SAN DIEGO,CTR ASTROPHYS & SPACE SCI,LA JOLLA,CA 92093; ROWAN COLL,DEPT CHEM & PHYS,GLASSBORO,NJ 08028; NASA,INFRARED TELESCOPE FACIL,HILO,HI 96720	Catholic University of America; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of California System; University of California San Diego; Rowan University; National Aeronautics & Space Administration (NASA)	Mumma, MJ (corresponding author), NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771, USA.		Russo, Neil Dello/G-2727-2015; mumma, michael j/I-2764-2013; Magee-Sauer, Karen/K-6061-2015	Russo, Neil Dello/0000-0002-8379-7304; mumma, michael j/0000-0003-4627-750X; Magee-Sauer, Karen/0000-0002-4979-9875				ALLAMANDOLA LJ, 1988, ICARUS, V76, P225, DOI 10.1016/0019-1035(88)90070-X; ALLEN M, 1987, ASTRON ASTROPHYS, V187, P502; [Anonymous], 2006, MOL SPECTRA MOL STRU; BOCKELEEMORVAN D, 1987, ASTRON ASTROPHYS, V187, P425; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; BOCKELEEMORVAN D, 1991, NATURE, V350, P318, DOI 10.1038/350318a0; BOICE DC, 1990, GEOPHYS RES LETT, V17, P1813, DOI 10.1029/GL017i011p01813; BROOKE TY, 1991, ASTROPHYS J, V372, pL113, DOI 10.1086/186036; CHAMLEY SB, 1995, ASTROPHYS J, V448, P232; Charlesby A., 1960, ATOMIC RAD POLYM; CHIN G, 1984, ASTROPHYS J, V285, P858, DOI 10.1086/162565; COMBES M, 1988, ICARUS, V76, P404, DOI 10.1016/0019-1035(88)90013-9; Cronin J.R., 1988, METEORITES EARLY SOL, P819; CROVISIER J, 1983, ASTRON ASTROPHYS, V126, P170; DAYHOFF MO, 1964, SCIENCE, V164, P1461; DELLORUSSO N, UNPUB; DISANTI MA, 1992, ICARUS, V96, P151, DOI 10.1016/0019-1035(92)90068-I; DISANTI MA, 1996, 6374 IAU; DRAPATZ S, 1987, ASTRON ASTROPHYS, V187, P497; EBERHARDT P, 1987, ASTRON ASTROPHYS, V187, P481; ECK RV, 1966, SCIENCE, V153, P628, DOI 10.1126/science.153.3736.628; Fegley B.J., 1989, FORMATION EVOLUTION, P171; FELDMAN PD, 1996, 6370 IAU; FESTOU M, 1996, 6355 IAU; GERAKINES PA, IN PRESS ASTRON ASTR; GOLDMAN A, 1989, J QUANT SPECTROSC RA, V41, P17, DOI 10.1016/0022-4073(89)90016-2; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P311; HERBST E, 1983, ASTROPHYS J, V269, P329, DOI 10.1086/161046; Herzberg G., 1945, INFRARED RAMAN SPECT, V2; HIRAOKA K, 1994, CHEM PHYS LETT, V229, P408, DOI 10.1016/0009-2614(94)01066-8; HOBAN S, 1991, ICARUS, V93, P122, DOI 10.1016/0019-1035(91)90168-S; KAWARA K, 1988, ASTRON ASTROPHYS, V207, P174; LACY JH, 1991, ASTROPHYS J, V376, P556, DOI 10.1086/170304; LAMMERZAHL P, 1987, ASTRON ASTROPHYS, V187, P169; LARSON HP, 1989, ASTROPHYS J, V338, P1106, DOI 10.1086/167260; LAWLESS JG, 1979, NATURE, V282, P396, DOI 10.1038/282396a0; LII JH, 1992, J COMPUT CHEM, V13, P1138, DOI 10.1002/jcc.540130914; LIVINGSTON W, 1991, 91001 NSO; MATTHEWS HE, 1996, 6353 IAU; MEIER R, 1993, ASTRON ASTROPHYS, V277, P677; MOORE MH, 1992, ASTROPHYS J, V401, P353, DOI 10.1086/172065; Mumma M. J., 1993, PROTOSTARS PLANETS, P1177; MUMMA MJ, 1986, SCIENCE, V232, P1523, DOI 10.1126/science.232.4757.1523; MUMMA MJ, 1989, ASTROPHYS J, V344, P940, DOI 10.1086/167862; MUMMA MJ, 1995, B AM ASTRON SOC, V27, P1144; MUMMA MJ, 1996, 6366 IAU; Prinn R.G.P., 1989, ORIGIN EVOLUTION PLA, P78; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; SCHLEICHER D, 1996, 6372 IAU; SCHLOERB FP, 1986, ASTROPHYS J, V310, pL55, DOI 10.1086/184781; SCHUTTE WA, 1991, ASTRON ASTROPHYS, V244, P190; SENAY M, 1996, 6335 IAU; SNYDER LE, 1989, ASTRON J, V97, P246, DOI 10.1086/114976; Stief LJ, 1965, J CHEM PHYS, V43, P2490, DOI 10.1063/1.1697148; STUDIER MH, 1965, SCIENCE, V149, P1455, DOI 10.1126/science.149.3691.1455; Tielens A.G.G.M., 1987, INTERSTELLAR PROCESS, P397; TOKUNAGA AT, 1996, 6378 IAU; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WEAVER HA, 1984, ASTROPHYS J, V276, P782, DOI 10.1086/161664; WEAVER HA, 1984, ASTROPHYS J, V285, P872, DOI 10.1086/162567; WEAVER HA, 1996, 6374 IAU; WEGMANN R, 1987, ASTRON ASTROPHYS, V187, P339; WOMACK M, 6345 IAU; YUEN G, 1984, NATURE, V307, P252, DOI 10.1038/307252a0	64	271	272	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1310	1314		10.1126/science.272.5266.1310	http://dx.doi.org/10.1126/science.272.5266.1310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650540				2022-12-24	WOS:A1996UN47200037
J	Casscells, W; Hathorn, B; David, M; Krabach, T; Vaughn, WK; McAllister, HA; Bearman, G; Willerson, JT				Casscells, W; Hathorn, B; David, M; Krabach, T; Vaughn, WK; McAllister, HA; Bearman, G; Willerson, JT			Thermal detection of cellular infiltrates in living atherosclerotic plaques: Possible implications for plaque rupture and thrombosis	LANCET			English	Article							CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION	Background Atherosclerotic lesions are heterogeneous and prognosis cannot easily be predicted, intracoronary ultrasound and angioscopy, angiographic and necropsy studies suggest that the risk of plaque rupture correlates only weakly with the degree of stenosis. Most ruptured plaques are characterised by a large pool of cholesterol or necrotic debris and a thin fibrous cap with a dense infiltration of macrophages. The release of matrix-digesting enzymes by these cells is thought to contribute to plaque rupture. Other thromboses are found on non-ruptured but inflamed plaque surfaces, We postulated that both types of thrombotic events may be predicted by heat released by activated macrophages either on the plaque surface or under a thin cap. Methods To test the hypothesis, we measured the intimal surface temperatures at 20 sites in each of 50 samples of carotid artery taken at endarterectomy from 48 patients. The living samples were probed with a thermistor (24-gauge needle-tip; accuracy 0.1 degrees C; time contrast 0.15 s), The tissues were then fixed and stained. Findings Plaques showed several regions in which the surface temperatures varied reproducibly by 0.2-0.3 degrees C, but 37% of plaques had substantially warmer regions (0.4-2.2 degrees C). Points with substantially different temperatures could not be distinguished from one another by the naked eye; such points could also be very close to one another (<1 mm apart). Temperature correlated positively with cell density (r=0.68, p=0.0001) and inversely with the distance of the cell clusters from the luminal surface (r=-0.38, p=0.0006), Most cells were macrophages, Infrared thermographic images also revealed heterogeneity in temperature among the plaques. Interpretation Living atherosclerotic plaques show thermal heterogeneity, which raises the possibility that an infrared catheter or other techniques that can localise heat or metabolic activity might be able to identify plaques at high risk of rupture or thrombosis.	ST LUKES EPISCOPAL HOSP,TEXAS HEART INST,HOUSTON,TX; HERMANN HOSP,HOUSTON,TX; CALTECH,JET PROP LAB,PASADENA,CA	Saint Lukes Episcopal Hospital; Texas Heart Institute; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Casscells, W (corresponding author), UNIV TEXAS,SCH MED,DEPT INTERNAL MED,DIV CARDIOL,6431 FANNIN,POB 20708,HOUSTON,TX 77225, USA.				NHLBI NIH HHS [91HL07] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN EL, 1993, J AM COLL CARDIOL, V22, P1141, DOI 10.1016/0735-1097(93)90429-5; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; BENARON DA, 1995, J CLIN MONITOR, V11, P109, DOI 10.1007/BF01617732; BUJA LM, 1994, CIRCULATION, V89, P503, DOI 10.1161/01.CIR.89.1.503; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEFEYTER PJ, 1995, CIRCULATION, V92, P1408, DOI 10.1161/01.CIR.92.6.1408; FALK E, 1995, CIRCULATION, V92, P2033, DOI 10.1161/01.CIR.92.8.2033; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; GERTZ SD, 1995, CIRCULATION S1, V92, P293; Kannel W B, 1994, J Cardiovasc Risk, V1, P333, DOI 10.1097/00043798-199412000-00009; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MACFALL J, 1995, INT J HYPERTHER, V11, P73, DOI 10.3109/02656739509004949; MORENO PR, 1995, CIRCULATION, V92, P161; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; Shah Prediman K., 1996, Cardiology Clinics, V14, P17; SKINNER MP, 1995, NAT MED, V1, P69, DOI 10.1038/nm0195-69; TOUSSAINT JF, 1995, ARTERIOSCL THROM VAS, V15, P1533; VANDAMME H, 1994, CARDIOVASC PATHOL, V3, P9, DOI 10.1016/1054-8807(94)90003-5; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36	19	268	301	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1996	347	9013					1447	1449		10.1016/S0140-6736(96)91684-0	http://dx.doi.org/10.1016/S0140-6736(96)91684-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM485	8676628				2022-12-24	WOS:A1996UM48500011
J	Perry, RJ; Moore, CA; Morgan, BDG; Plummer, DL				Perry, RJ; Moore, CA; Morgan, BDG; Plummer, DL			Determining the approximate area of a burn: An inconsistency investigated and re-evaluated	BRITISH MEDICAL JOURNAL			English	Article									UCL HOSP, DEPT PLAST SURG, LONDON WC1E 6BT, ENGLAND; UCL, DEPT MED PHYS & BIOENGN, LONDON WC1E 6BT, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London	Perry, RJ (corresponding author), UCL, SCH MED, CIN SCI OFF, ADM, LONDON WC1E 6BT, ENGLAND.							Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; ELLIS H, 1993, LECT NOTES GEN SURG, P12; GEHAN EA, 1970, CANCER CHEMOTH REP 1, V54, P225; Plummer DL., 1992, REV NEU RORADIOL, V5, P489, DOI 10.1177/197140099200500413; Proctor HJ., 1993, ADV TRAUMA LIFE SUPP	5	29	30	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1338	1338		10.1136/bmj.312.7042.1338	http://dx.doi.org/10.1136/bmj.312.7042.1338			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646048	Green Published			2022-12-24	WOS:A1996UN47600023
J	Lanske, B; Karaplis, AC; Lee, K; Luz, A; Vortkamp, A; Pirro, A; Karperien, M; Defize, LHK; Ho, C; Mulligan, RC; AbouSamra, AB; Juppner, H; Segre, GV; Kronenberg, HM				Lanske, B; Karaplis, AC; Lee, K; Luz, A; Vortkamp, A; Pirro, A; Karperien, M; Defize, LHK; Ho, C; Mulligan, RC; AbouSamra, AB; Juppner, H; Segre, GV; Kronenberg, HM			PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth	SCIENCE			English	Article							HORMONE-RELATED PEPTIDE; PARATHYROID-HORMONE; MESSENGER-RNA; EXPRESSION; PROTEIN; TISSUES; MOUSE; RAT; CARTILAGE; CELLS	The PTH/PTHrP receptor binds to two ligands with distinct functions: the calcium-regulating hormone, parathyroid hormone (PTH), and the paracrine factor, PTH-related protein (PTHrP). Each ligand, in turn, is likely to activate more than one receptor. The functions of the PTH/PTHrP receptor were investigated by deletion of the murine gene by homologous recombination. Most PTH/PTHrP receptor (-/-) mutant mice died in mid-gestation, a phenotype not observed in PTHrP (-/-) mice, perhaps because of the effects of maternal PTHrP. Mice that survived exhibited accelerated differentiation of chondrocytes in bone, and their bones, grown in explant culture, were resistant to the effects of PTHrP and Sonic hedgehog. These results suggest that the PTH/PTHrP receptor mediates the effects of Indian Hedgehog and PTHrP on chondrocyte differentiation.	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; MCGILL UNIV,SIR MORTIMER B DAVIS JEWISH GEN HOSP,MONTREAL,PQ H3T 1E2,CANADA; GSF MUNCHEN,INST PATHOL,D-85758 MUNICH,GERMANY; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,CAMBRIDGE,MA 02139	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; McGill University; Harvard University; Harvard Medical School; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Abou-Samra, Abdul/ABE-8723-2020; Karperien, Marcel/R-3270-2018	Abou-Samra, Abdul/0000-0001-8735-1142; Lanske, Beate/0000-0003-4638-804X; Karperien, Marcel/0000-0003-0751-0604	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047237, R01DK047038] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47038, DK 47237] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BECK F, 1993, J REPROD FERTIL, V99, P343; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Broadus Arthur E., 1994, P259; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; FUKAYAMA S, 1995, P NATL ACAD SCI USA, V92, P10182, DOI 10.1073/pnas.92.22.10182; INOMATA N, 1995, ENDOCRINOLOGY, V136, P4732, DOI 10.1210/en.136.11.4732; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KARPERIEN M, 1994, MECH DEVELOP, V47, P29, DOI 10.1016/0925-4773(94)90093-0; KARPERIEN M, IN PRESS INT J DEV B; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; ORLOFF JJ, 1992, AM J PHYSIOL, V262, pE599, DOI 10.1152/ajpendo.1992.262.5.E599; POTTS JT, 1995, ENDOCRINOLOGY, V2, P920; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; TIAN J, 1993, AM J NEPHROL, V13, P210, DOI 10.1159/000168620; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; VANDESTOLPE A, 1993, J CELL BIOL, V120, P235, DOI 10.1083/jcb.120.1.235; VORTKAMP A, 1996, SCIENCE, V273, pR30	23	1013	1047	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					663	666		10.1126/science.273.5275.663	http://dx.doi.org/10.1126/science.273.5275.663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662561				2022-12-24	WOS:A1996VA24900053
J	Maldonado, R; Blendy, JA; Tzavara, E; Gass, P; Roques, BP; Hanoune, J; Schutz, G				Maldonado, R; Blendy, JA; Tzavara, E; Gass, P; Roques, BP; Hanoune, J; Schutz, G			Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB	SCIENCE			English	Article							ELEMENT-BINDING PROTEIN; NERVE GROWTH-FACTOR; OPIATE WITHDRAWAL; TARGETED MUTATION; ADENYLATE-CYCLASE; LOCUS-CERULEUS; RAT-BRAIN; C-FOS; TRANSCRIPTION	Chronic morphine administration induces an up-regulation of several components of the cyclic adenosine 5'-monophosphate (cAMP) signal transduction cascade. The behavioral and biochemical consequences of opiate withdrawal were investigated in mice with a genetic disruption of the alpha and Delta isoforms of the cAMP-responsive element-binding protein (CREB). In CREB alpha Delta mutant mice the main symptoms of morphine withdrawal were strongly attenuated. No change in opioid binding sites or in morphine-induced analgesia was observed in these mutant mice, and the increase of adenylyl cyclase activity and immediate early gene expression after morphine withdrawal was normal. Thus, CREB-dependent gene transcription is a factor in the onset of behavioral manifestations of opiate dependence.	GERMAN CANC RES CTR,DIV MOL BIOL CELL 1,D-69120 HEIDELBERG,GERMANY; HOP HENRI MONDOR,INSERM,U99,UNITE REGULAT GENES & SIGNALISAT CELLULAIRE,F-94010 CRETEIL,FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Maldonado, R (corresponding author), UNIV PARIS 05,FAC PHARM,DEPT PHARMOCOCHIM MOL & STRUCT,INSERM,U266,CNRS,F-75270 PARIS 06,FRANCE.		Maldonado, Rafael/F-5657-2014	Maldonado, Rafael/0000-0002-4359-8773				Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DELAYGOYET P, 1987, LIFE SCI, V41, P723, DOI 10.1016/0024-3205(87)90452-8; DUMAN RS, 1988, J PHARMACOL EXP THER, V246, P1033; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GUITART X, 1992, J NEUROCHEM, V58, P1168, DOI 10.1111/j.1471-4159.1992.tb09377.x; HANOUNE J, 1977, J BIOL CHEM, V252, P2039; HAYWARD MD, 1990, BRAIN RES, V525, P256, DOI 10.1016/0006-8993(90)90872-9; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MATSUOKA I, 1994, EUR J PHARM-MOLEC PH, V268, P215, DOI 10.1016/0922-4106(94)90191-0; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; SCHMIDT C, 1991, EUR J PHARMACOL, V192, P253, DOI 10.1016/0014-2999(91)90050-Z; STORNETTA RL, 1993, BRAIN RES, V624, P19, DOI 10.1016/0006-8993(93)90055-R; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D	17	252	264	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					657	659		10.1126/science.273.5275.657	http://dx.doi.org/10.1126/science.273.5275.657			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662559				2022-12-24	WOS:A1996VA24900051
J	Morgan, TO; Jacobsen, SJ; McCarthy, WF; Jacobson, DJ; McLeod, DG; Moul, JW				Morgan, TO; Jacobsen, SJ; McCarthy, WF; Jacobson, DJ; McLeod, DG; Moul, JW			Age-specific reference ranges for serum prostate-specific antigen in black men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER; ADENOCARCINOMA; CARCINOMA	Background The detection of prostate cancer by screening for prostate-specific antigen (PSA) in serum is improved when age-specific reference ranges are used, but these ranges have been derived from white populations. We determined the distribution of PSA and age-specific reference ranges in black men both with and without prostate cancer. Methods From January 1991 through May 1995, we measured serum PSA in 3475 men with no clinical evidence of prostate cancer (1802 white and 1673 black) and 1783 men with prostate cancer (1372 white and 411 black). We studied the data asa function of age and race to determine the usefulness of measuring PSA in diagnosing prostate cancer. Results Serum PSA concentrations in black men (geometric mean in controls, 1.48 ng per milliliter; in patients, 7.46) were significantly higher than those in white men (geometric mean in controls, 1.33 ng per milliliter; in patients, 6.28). The values in the controls correlated directly with age. The area under the receiver-operating-characteristic curve was 0.91 for blacks and 0.94 for whites. If traditional age-specific reference ranges were used in screening black men, with the test specificity kept at 95 percent, 41 percent of cases of prostate cancer would be missed. For the test to have 95 percent sensitivity among black men, the following normal reference ranges should be used: for men in their 40s, 0 to 2.0 ng of PSA per milliliter (test specificity, 93 percent); for men in their 50s, 0 to 4.0 ng per milliliter (specificity, 88 percent); for men in their 60s, 0 to 4.5 ng per milliliter (specificity, 81 percent); and for men in their 70s, 0 to 5.5 ng per milliliter (specificity, 78 percent). Conclusions Serum PSA concentrations can be used to discriminate between men with prostate cancer and those without it among both blacks and whites. Over 40 percent of cases of prostate cancer in black men would not be detected by tests using traditional age-specific reference ranges, which maintain specificity at 95 percent. In this high-risk population, the alternative approach - maintaining sensitivity at 95 percent - may be used with acceptable decrements in specificity. (C) 1996, Massachusetts Medical Society.	UNIFORMED SERV UNIV HLTH SCI,DEPT SURG,BETHESDA,MD 20814; WALTER REED ARMY MED CTR,DEPT SURG,UROL SERV,WASHINGTON,DC 20307; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,CLIN EPIDEMIOL SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,BIOSTAT SECT,ROCHESTER,MN 55905; UNIFORMED SERV UNIV HLTH SCI,CTR PROSTATE DIS RES,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Mayo Clinic; Mayo Clinic; Uniformed Services University of the Health Sciences - USA				Jacobsen, Steven/0000-0002-8174-8533				*AM UR ASS, 1992, AM UR ASS 1992 POL S, V4, P20; ANDERSON JR, 1995, UROLOGY, V46, P54, DOI 10.1016/S0090-4295(99)80158-7; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; DALKIN BL, 1993, J UROLOGY, V150, P1837, DOI 10.1016/S0022-5347(17)35910-4; DEANTONI EP, 1995, CANCER, V75, P1874, DOI 10.1002/1097-0142(19950401)75:7+<1874::AID-CNCR2820751618>3.0.CO;2-I; ELGALLEY RES, 1995, UROLOGY, V46, P200, DOI 10.1016/S0090-4295(99)80194-0; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; KEETCH DW, 1994, J UROLOGY, V151, P1571, DOI 10.1016/S0022-5347(17)35304-1; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; MORTON RA, 1994, UROLOGY, V44, P637, DOI 10.1016/S0090-4295(94)80196-7; MOUL JW, 1995, JAMA-J AM MED ASSOC, V274, P1277, DOI 10.1001/jama.274.16.1277; OESTERLING JE, 1995, BRIT J UROL, V75, P347, DOI 10.1111/j.1464-410X.1995.tb07347.x; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PIENTA KJ, 1995, UROLOGY, V45, P93, DOI 10.1016/S0090-4295(95)96996-9; ROSS RK, 1992, LANCET, V339, P887, DOI 10.1016/0140-6736(92)90927-U; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; SAKR WA, 1995, PATHOL RES PRACT, V191, P838, DOI 10.1016/S0344-0338(11)80965-9; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; WALSH PC, 1993, ANN INTERN MED, V119, P948, DOI 10.7326/0003-4819-119-9-199311010-00015	21	330	341	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					304	310		10.1056/NEJM199608013350502	http://dx.doi.org/10.1056/NEJM199608013350502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8663870				2022-12-24	WOS:A1996UY98200002
J	Grant, D				Grant, D			Current results of intestinal transplantation	LANCET			English	Article								Background Intestinal transplantation is an alternative to total parenteral nutrition (TPN) for the treatment of chronic intestinal failure. To determine the current status of small-bowel transplantation, we have reviewed the world experience since 1985. Methods We built up an international registry by asking twenty-five intestinal transplantation programmes to submit standard data on their cases operated on between 1985 and June, 1995. Findings One centre (two transplantations) did not use our report form, and these cases were excluded. The remaining twenty-four programmes did 180 transplantations in 170 patients. Two-thirds of the recipients were children. The main indication (64%) was short-gut syndrome; another 13% had a tumour. Of the grafts, 38% were small-bowel with or without colon, 46% were intestine plus liver, and 16% were multivisceral. Graft/patients' survival (%) at 1 and 3 years under cyclosporin immunosuppression was, respectively: 17/57 and 11/50 for small bower only; 44/44 and 28/28 for intestine plus liver; and 41/41 and 41/41 for multiviscera. The corresponding figures under tacrolimus were: 65/83 and 29/47; 64/66 and 38/40; and 51/59 and 37/43. 78% of the 86 survivors had stopped TPN and resumed oral nutrition. Interpretation Our approach cannot give data on long-term outcome. The short-term results of intestinal transplantation are similar to those of lung grafting. We conclude that small-bowel transplantation has become a life-saving option for patients who cannot be maintained on TPN and for those who require massive abdominal evisceration for locally aggressive tumours.			Grant, D (corresponding author), LONDON HLTH SCI CTR,4-TU36,UNIV CAMPUS,LONDON,ON N6A 5A5,CANADA.							ASFAR S, 1994, SURG CLIN N AM, V74, P1197, DOI 10.1016/S0039-6109(16)46441-8; CANIANO DA, 1988, NEW ENGL J MED, V318, P703, DOI 10.1056/NEJM198803173181111; GRUESSNER RWG, 1995, TRANSPLANTATION, V59, P164, DOI 10.1097/00007890-199501270-00002; HOFFMAN AL, 1990, TRANSPLANTATION, V49, P483, DOI 10.1097/00007890-199003000-00001; HOWARD L, 1991, JPEN-PARENTER ENTER, V15, P384, DOI 10.1177/0148607191015004384; THOMPSON JS, 1995, ANN SURG, V222, P600; TODO S, 1995, ANN SURG, V222, P270, DOI 10.1097/00000658-199509000-00006	7	177	181	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1801	1803		10.1016/S0140-6736(96)91619-0	http://dx.doi.org/10.1016/S0140-6736(96)91619-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667925				2022-12-24	WOS:A1996UU46900012
J	Shaheen, SO; Aaby, P; Hall, AJ; Barker, DJP; Heyes, CB; Shiell, AW; Goudiaby, A				Shaheen, SO; Aaby, P; Hall, AJ; Barker, DJP; Heyes, CB; Shiell, AW; Goudiaby, A			Measles and atopy in Guinea-Bissau	LANCET			English	Article							SKIN-TEST REACTIVITY; RESPIRATORY-INFECTIONS; CHILD-MORTALITY; VACCINATION; PREVALENCE; POPULATION; NUTRITION; COMMUNITY; ASTHMA; HEALTH	Background Epidemiological studies have led to speculation that infections in early childhood may prevent allergic sensitisation but evidence to support this hypothesis is lacking. We investigated whether measles infection protects against the development of atopy in children of Guinea-Bissau, West Africa. Methods We conducted a historical cohort study in Bandim, a semi-rural district of Bissau, the capital of Guinea-Bissau. 395 young adults, first surveyed in 1978-80 aged 0-6 years, were followed up in 1994. Our analyses were restricted to 262 individuals still living in Bandim for whom a measles history, documented in childhood, was judged to be reliable. We defined atopy as skin-prick test positivity (greater than or equal to 3 mm weal) to one OF more of seven allergens. Findings 17 (12.8%) of 133 participants who had had measles infection were atopic compared with 33 (25.6%) of 129 of those who had been vaccinated and not had measles (odds ratio, adjusted for potential confounding variables 0.36 [95% CI 0.17-0.78], p=0.01). Participants who had been breastfed for more than a year were less likely to have a positive skin test to housedust mite. After adjustment for breastfeeding and other variables, measles infection was associated with a large reduction in the risk of shin-prick test positivity to housedust mite (odds ratio for Dermatophagoides pteronyssinus 0.20 [0.05-0.81], p=0.02; D farinae 0.20 [0.06-0.71], p=0.01). Interpretation Measles infection may prevent the development of atopy in African children.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,HANTS,ENGLAND; STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,EPIDEMIOL RES UNIT,DK-2300 COPENHAGEN,DENMARK; UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,LONDON WC1E 7HT,ENGLAND; MINIST PUBL HLTH,BISSAU,GUINEA BISSAU	University of Southampton; Aarhus University; Statens Serum Institut; University of London; London School of Hygiene & Tropical Medicine				Aaby, Peter/0000-0001-8331-1389	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AABY P, 1989, PEDIATR INFECT DIS J, V8, P197; AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; AABY P, 1983, J INFECT DIS, V147, P693, DOI 10.1093/infdis/147.4.693; AABY P, 1984, AM J EPIDEMIOL, V120, P49, DOI 10.1093/oxfordjournals.aje.a113874; AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X; AABY P, 1995, CROWDING HLTH LOW IN; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; Burnet M., 1972, NATURAL HIST INFECT; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; COGSWELL JJ, 1982, BRIT MED J, V284, P1011, DOI 10.1136/bmj.284.6321.1011; Gardner M. J., 1989, STAT CONFIDENCE; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; GOLDING J, 1986, BIRTH 5 STUDY HLTH B, P295; GOLDING J, 1986, BIRTH 5 STUDY HLTH B, P171; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; HAGEL I, 1993, INT ARCH ALLERGY IMM, V101, P209, DOI 10.1159/000236521; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; MAGGI E, 1992, J IMMUNOL, V148, P2142; MEINERT R, 1994, ALLERGY, V49, P526, DOI 10.1111/j.1398-9995.1994.tb01124.x; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Pepys J., 1975, BR J HOSP MED, V14, P412; Peters T J, 1987, Paediatr Perinat Epidemiol, V1, P80, DOI 10.1111/j.1365-3016.1987.tb00092.x; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SHAHEEN SO, 1995, CLIN EXP ALLERGY, V25, P1034; SIGURS N, 1995, PEDIATRICS, V95, P500; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573	34	461	472	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1792	1796		10.1016/S0140-6736(96)91617-7	http://dx.doi.org/10.1016/S0140-6736(96)91617-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667923				2022-12-24	WOS:A1996UU46900010
J	Richman, DD				Richman, DD			HIV therapeutics	SCIENCE			English	Editorial Material									UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92092; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92092	University of California System; University of California San Diego; University of California System; University of California San Diego	Richman, DD (corresponding author), SAN DIEGO VET AFFAIRS MED CTR,CLIN SCI BLDG,ROOM 327,9500 GILMAN DR,LA JOLLA,CA 92092, USA.							CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARPENTER CCJ, IN PRESS J AM MED AS; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; COOMBS RW, IN PRESS J INFECT DI; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Gazzard Brian, 1996, P161; Gulick R., 1996, P162; HAMMER S, 1995, 35 INT C ANT AG CHEM; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MOUTOUH L, IN PRESS P NATL ACAD; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; RICHMAN DD, 1996, IN PRESS ANTIVIRAL D	18	75	78	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1996	272	5270					1886	1888		10.1126/science.272.5270.1886	http://dx.doi.org/10.1126/science.272.5270.1886			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658159				2022-12-24	WOS:A1996UV29400028
J	Hellman, S; Weichselbaum, RR				Hellman, S; Weichselbaum, RR			Radiation oncology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Hellman, S (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.							AKAKURA K, 1993, CANCER, V71, P2782, DOI 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; HANKS GE, 1995, CANCER, V75, P1972, DOI 10.1002/1097-0142(19950401)75:7+<1972::AID-CNCR2820751636>3.0.CO;2-P; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; SANDLER HM, 1995, INT J RADIAT ONCOL, V33, P797, DOI 10.1016/0360-3016(95)00219-7; Zelefsky M J, 1995, Cancer J Sci Am, V1, P142	7	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1852	1853		10.1001/jama.275.23.1852	http://dx.doi.org/10.1001/jama.275.23.1852			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642748				2022-12-24	WOS:A1996UQ15200047
J	Radestad, I; Steineck, G; Nordin, C; Sjogren, B				Radestad, I; Steineck, G; Nordin, C; Sjogren, B			Psychological complications after stillbirth - Influence of memories and immediate management: Population based study	BRITISH MEDICAL JOURNAL			English	Article							PERINATAL DEATH; FOLLOW-UP; GRIEF; FAMILIES	Objective-To identify factors that may predict long term psychological complications among women who have had a stillborn child, Design-Nationwide population based study using epidemiological methods, Subjects-380 subjects and 379 controls who had had a stillborn or non-deformed live child in Sweden in 1991. Results-Information was provided by 636 (84%) women, The ratio (95% confidence interval) of proportions of women with symptoms related to anxiety above the 90th centile for women who had had a stillborn child compared with those who had not was 2.1 (1.2 to 3.9), An interval of 25 hours or more from the diagnosis of death in utero to the start of delivery gave a ratio of 4.8 (1.5 to 15.9). The ratio was 2.3 (1.1 to 5.3) for not seeing the child as long as the mother had wished and 3.1 (1.6 to 6.0) for no possession of a token of remembrance, Conclusion-It is advisable to induce the delivery as soon as feasible after the diagnosis of death in utero, A calm environment for the woman to spend as much time as she wants with her stillborn child is beneficial, and tokens of remembrance should be collected.	KAROLINSKA INST,CTR CARING SCI N,STOCKHOLM,SWEDEN; KAROLINSKA INST,RADIUMHEMMET,CANC EPIDEMIOL UNIT,STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT WOMENS & CHILDRENS HLTH,STOCKHOLM,SWEDEN; LINKOPING UNIV HOSP,DEPT PSYCHIAT,S-58185 LINKOPING,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Linkoping University			Steineck, Gunnar/W-1515-2019	Steineck, Gunnar/0000-0002-0787-3969				Beckey R D, 1985, J Obstet Gynecol Neonatal Nurs, V14, P194, DOI 10.1111/j.1552-6909.1985.tb02227.x; BOURNE P, 1983, BRIT MED J, V286, P144; Bourne S, 1968, J R Coll Gen Pract, V16, P103; COHEN L, 1978, AM J ORTHOPSYCHIAT, V48, P727, DOI 10.1111/j.1939-0025.1978.tb02577.x; Cullberg J, 1966, Lakartidningen, V63, P3980; GILES PFH, 1970, AUST NZ J OBSTET GYN, V10, P207, DOI 10.1111/j.1479-828X.1970.tb00431.x; KELLNER KR, 1981, DEATH EDUC, V5, P29, DOI 10.1080/07481188108252075; Kennel JH, 1978, CONTEMP OBSTET GYNEC, V12, P53; KENNELL JH, 1970, NEW ENGL J MED, V283, P344, DOI 10.1056/NEJM197008132830706; KIRKLEYBEST E, 1982, AM J ORTHOPSYCHIAT, V52, P420, DOI 10.1111/j.1939-0025.1982.tb01428.x; KOWALSKI K, 1980, Clinical Obstetrics and Gynecology, V23, P1113, DOI 10.1097/00003081-198012000-00015; LAROCHE C, 1984, CAN J PSYCHIAT, V29, P14, DOI 10.1177/070674378402900104; LEON IG, 1992, CLIN PEDIATR, V31, P366, DOI 10.1177/000992289203100611; LEWIS E, 1976, LANCET, V2, P619; Long J, 1992, Midwives Chron, V105, P51; NICOL MT, 1986, MED J AUSTRALIA, V144, P287, DOI 10.5694/j.1326-5377.1986.tb128375.x; RADLOFF LS, 1994, APPL PSYCH MEAS, V1, P385; ROWE J, 1978, PEDIATRICS, V62, P166; *SAS I, 1993, P243 SAS; SPECK WT, 1980, PEDIATR REV, V2, P59; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; TOEDTER LJ, 1988, AM J ORTHOPSYCHIAT, V58, P435, DOI 10.1111/j.1939-0025.1988.tb01604.x; TUDEHOPE DI, 1986, MED J AUSTRALIA, V144, P290, DOI 10.5694/j.1326-5377.1986.tb128376.x; Welch I D, 1991, Neonatal Netw, V9, P53; ZEANAH CH, 1989, J AM ACAD CHILD PSY, V28, P467, DOI 10.1097/00004583-198907000-00001	25	136	138	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1505	1508		10.1136/bmj.312.7045.1505	http://dx.doi.org/10.1136/bmj.312.7045.1505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UR823	8646141	Green Published			2022-12-24	WOS:A1996UR82300019
J	Erkman, L; McEvilly, RJ; Luo, L; Ryan, AK; Hooshmand, F; OConnell, SM; Keithley, EM; Rapaport, DH; Ryan, AF; Rosenfeld, MG				Erkman, L; McEvilly, RJ; Luo, L; Ryan, AK; Hooshmand, F; OConnell, SM; Keithley, EM; Rapaport, DH; Ryan, AF; Rosenfeld, MG			Role of transcription factors Brn-3.1 and Brn-3.2 in auditory and visual system development	NATURE			English	Article							CELL LINEAGE; CAT RETINA; C-ELEGANS; GENE; MOUSE; DIFFERENTIATION; HOMEODOMAIN; EXPRESSION; DISTINCT; IDENTITY	THE neurally expressed genes Brn-3.1 and Brn-3.2 (refs 1-6) are mammalian orthologues of the Caenorhabditis elegans unc-86 gene(7) that constitute, with Brn-3.0 (refs 1-3,8,9), the class IV POU-domain transcription factors(10), Brn-3.1 and Brn-3.2 provide a means of exploring the potentially distinct biological functions of expanded gene families in neural development, The highly related members of the Brn-3 family have similar DNA-binding preferences(1,2) and overlapping expression patterns in the sensory nervous system, midbrain and hindbrain(1-6,8,9), suggesting functional redundancy, Here we report that Brn-3.1 and Brn-3.2 critically modulate the terminal differentiation of distinct sensorineural cells in which they exhibit selective spatial and temporal expression patterns, Deletion of the Brn-3.2 gene causes the loss of most retinal ganglion cells, defining distinct ganglion cell populations, Mutation of Brn-3.1 results in complete deafness, owing to a failure of hair cells to appear in the inner ear, with subsequent loss of cochlear and vestibular ganglia.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT SURG, DIV ANAT, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, VET ADM MED CTR, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT SURG OTOLARYNGOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego					BLRD VA [I01 BX001205] Funding Source: Medline; Veterans Affairs [I01BX001205] Funding Source: NIH RePORTER	BLRD VA; Veterans Affairs(US Department of Veterans Affairs)		COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; CRENSHAW EB, 1991, J NEUROSCI, V11, P1524; DRAGER UC, 1981, INVEST OPHTH VIS SCI, V20, P285; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1995, NEURON, V14, P1153, DOI 10.1016/0896-6273(95)90263-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; KELLEY MW, 1993, DEVELOPMENT, V119, P1041; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LUO L, 1993, HEARING RES, V69, P182; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; RAPAPORT DH, 1991, J COMP NEUROL, V312, P341, DOI 10.1002/cne.903120303; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; Sidman R.L., 1961, STRUCTURE EYE; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Stone J., 1981, WHOLEMOUNT HDB; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; WASSLE H, 1987, J COMP NEUROL, V265, P391, DOI 10.1002/cne.902650308; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WONG ROL, 1987, J COMP NEUROL, V255, P159, DOI 10.1002/cne.902550202; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIA YR, 1993, GENOMICS, V18, P126, DOI 10.1006/geno.1993.1435; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; XIANG MQ, 1995, J NEUROSCI, V15, P4762; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	30	419	435	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					603	606		10.1038/381603a0	http://dx.doi.org/10.1038/381603a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637595				2022-12-24	WOS:A1996UQ65700050
J	Frydman, J; Hartl, FU				Frydman, J; Hartl, FU			Principles of chaperone-assisted protein folding: Differences between in vitro and in vivo mechanisms	SCIENCE			English	Article							T-COMPLEX POLYPEPTIDE-1; MOLECULAR CHAPERONES; MESSENGER-RNA; IN-VIVO; ACTIN; DEGRADATION	Molecular chaperones in the eukaryotic cytosol were shown to interact differently with chemically denatured proteins and their newly translated counterparts. During refolding from denaturant, actin partitioned freely between 70-kilodalton heat shock protein, the bulk cytosol, and the chaperonin TCP1-ring complex. In contrast, during cell-free translation, the chaperones were recruited to the elongating polypeptide and protected it from exposure to the bulk cytosol during folding. Posttranslational cycling between chaperone-bound and free states was observed with subunits of oligomeric proteins and with aberrant polypeptides; this cycling allowed the subunits to assemble and the aberrant polypeptides to be degraded. Thus, folding, oligomerization, and degradation are linked hierarchically to ensure the correct fate of newly synthesized polypeptides.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019	, judith/0000-0003-2302-6943				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS J, 1994, CURR OPIN STRUC BIOL, V4, P117; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; Freedman Robert B., 1992, P455; FREEMAN BC, 1996, EMBO J, V12, P2969; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SOLOMON JM, 1991, NEW BIOL, V3, P1106; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; URSIC D, 1994, MOL BIOL CELL, V5, P1065, DOI 10.1091/mbc.5.10.1065; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WALDMANN T, 1995, BIOL CHEM H-S, V376, P119, DOI 10.1515/bchm3.1995.376.2.119; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; ZECHEL K, 1980, EUR J BIOCHEM, V110, P343, DOI 10.1111/j.1432-1033.1980.tb04873.x	43	210	224	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1497	1502		10.1126/science.272.5267.1497	http://dx.doi.org/10.1126/science.272.5267.1497			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633246				2022-12-24	WOS:A1996UP89900053
J	Gilmore, AP; Burridge, K				Gilmore, AP; Burridge, K			Regulation of vinculin binding to talin and actin by phosphatidyl-inositol-4-5-bisphosphate	NATURE			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; PURIFICATION; PROTEINS	VINCULIN, a prominent cytoskeletal protein at cell-substrate adhesions (focal adhesions) and cell-cell adhesions (adherens junctions)(1), interacts with other cytoskeletal proteins, including talin and actin(2,3). An intramolecular interaction between the head and tail domains of vinculin masks the binding sites for both proteins(4,5). The exposure of cryptic binding sites may be important for promoting focal adhesion assembly. Several agents that induce the formation of focal adhesions act through the GTP-binding protein Rho(6-9), which elevates phosphatidylinositol-4,5-bisphosphate (PtdInsP(2)) levels by activating phosphatidylinositol-4-phosphate-5-OH kinase (PtdIns-5-OH kinase)(10). PtdInsP(2) regulates several actin-binding proteins, including profilin(11), gelsolin(12) and alpha-actinin(13), and interacts with vinculin(14,15). Here we report that PtdInsP(2) dissociates vinculin's head-tail interaction, unmasking its talin- and actin-binding sites. Microinjection of antibodies against PtdInsP(2) inhibit assembly of stress fibres and focal adhesions.			Gilmore, AP (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599, USA.							BARRY ST, 1994, J CELL SCI, V107, P2033; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHRZANOWSKAWODN.M, 1994, J CELL SCI, V107, P3543; EVANS RR, 1984, J BIOL CHEM, V259, P3916; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; WOOD CK, 1994, J CELL SCI, V107, P709	30	442	450	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					531	535		10.1038/381531a0	http://dx.doi.org/10.1038/381531a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632828				2022-12-24	WOS:A1996UP43500063
J	deCelis, JF; Barrio, R; Kafatos, FC				deCelis, JF; Barrio, R; Kafatos, FC			A gene complex acting downstream of dpp in Drosophila wing morphogenesis	NATURE			English	Article							EXPRESSION; DISK	LOCALIZED expression of the transforming growth factor-beta (TGF-beta) homologue decapentaplegic (dpp) is crucial for Drosophila wing development(1-4). Here we show that spalt and spalt-related (sal and salr), two closely related genes that encode transcription factors, are expressed in response to dpp in a central territory of the wing imaginal disc, where they are required for the patterning of the wing. They are among the first identified elements that act downstream of dpp in wing development. The phenotypic consequences of misexpression of sal and salr suggest that an important outcome of dpp activity is the subdivision of the wing disc into territories smaller than lineage compartments, through the regulation of transcription-factor-encoding genes such as sal and salr.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 4TH,ENGLAND; INST MOLEC BIOL & BIOTECHNOL,GR-71110 IRAKLION,CRETE,GREECE	European Molecular Biology Laboratory (EMBL); University of Cambridge			de+Celis, Jose/AAE-8142-2019; Barrio, Rosa/F-8712-2011	Barrio, Rosa/0000-0002-9663-0669; de Celis, Jose F./0000-0003-4808-9844				BAKER NE, 1988, DEVELOPMENT, V102, P489; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1995, DEVELOPMENT, V121, P3467; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOMEZSKARMETA JL, 1995, GENE DEV, V9, P1869, DOI 10.1101/gad.9.15.1869; HOCH M, 1993, CURR OPIN GENET DEV, V3, P566, DOI 10.1016/0959-437X(93)90092-4; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; Reuter D, 1996, CHROMOSOMA, V104, P445, DOI 10.1007/BF00352268; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SWEENEY ST, 1985, NEURON, V14, P342; TABATA T, 1995, DEVELOPMENT, V121, P3359	21	197	199	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					421	424		10.1038/381421a0	http://dx.doi.org/10.1038/381421a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632798				2022-12-24	WOS:A1996UN47900051
J	Erickson, JC; Clegg, KE; Palmiter, RD				Erickson, JC; Clegg, KE; Palmiter, RD			Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y	NATURE			English	Article							RAT HIPPOCAMPAL SLICE; PRESYNAPTIC INHIBITION; FOOD-DEPRIVATION; FEEDING-BEHAVIOR; RECEPTOR; NEURONS; MECHANISM; INVITRO; BRAIN	NEUROPEPTIDE Y (NPY), a 36-amino-acid transmitter distributed throughout the nervous system(1,2), is thought to function as a central stimulator of feeding behaviour(1-4). NPY has also been implicated in the modulation of mood(5), cerebrocortical excitability(6), hypothalamic-pituitary signalling(7), cardiovascular physiology(1,8) and sympathetic function(9,10). However, the biological significance of NPY has been difficult to establish owing to a lack of pharmacological antagonists, We report here that mice deficient for NPY have normal food intake and body weight, and become hyperphagic following food deprivation. Mutant mice decrease their food intake and lose weight, initially to a greater extent than controls, when treated with recombinant leptin. Occasional, mild seizures occur in NPY-deficient mice and mutants are more susceptible to seizures induced by a GABA (gamma-aminobutyric acid) antagonist, These results indicate that NPY is not essential for certain feeding responses or leptin actions but is an important modulator of excitability in the central nervous system.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								BECK B, 1990, BRAIN RES, V528, P245, DOI 10.1016/0006-8993(90)91664-3; BLEAKMAN D, 1992, BRIT J PHARMACOL, V107, P334, DOI 10.1111/j.1476-5381.1992.tb12747.x; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; COLMERS WF, 1987, J PHYSIOL-LONDON, V383, P285; COLMERS WF, 1991, BRIT J PHARMACOL, V102, P41, DOI 10.1111/j.1476-5381.1991.tb12129.x; COLMERS WF, 1994, TRENDS NEUROSCI, V17, P373, DOI 10.1016/0166-2236(94)90046-9; COLMERS WF, 1988, J NEUROSCI, V8, P3827; COLMERS WF, 1993, BIOL NEUROPEPTIDE Y; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; HAAS HL, 1987, J COMP NEUROL, V257, P208, DOI 10.1002/cne.902570207; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; KLAPSTEIN GJ, 1993, HIPPOCAMPUS, V3, P103, DOI 10.1002/hipo.450030111; LEIBOWITZ SF, 1991, BRAIN RES BULL, V27, P333, DOI 10.1016/0361-9230(91)90121-Y; MCDERMOTT BJ, 1993, CARDIOVASC RES, V27, P893, DOI 10.1093/cvr/27.6.893; MCDONALD JK, 1993, BIOL NEUROPEPTIDE Y, P457; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; ORLOFF MJ, 1949, P SOC EXP BIOL MED, V70, P254; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; SCHWARTZ MW, IN PRESS DIABETES; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STJARNE L, 1986, NEUROSCIENCE, V18, P151, DOI 10.1016/0306-4522(86)90184-3; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; TOTH PT, 1993, NATURE, V364, P635, DOI 10.1038/364635a0; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	894	911	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					415	418		10.1038/381415a0	http://dx.doi.org/10.1038/381415a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632796				2022-12-24	WOS:A1996UN47900049
J	Chou, MM; Blenis, J				Chou, MM; Blenis, J			The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1	CELL			English	Article							DISTINCT MECHANISMS; RAF-1 KINASE; RAPAMYCIN; DOMAIN; RAS; FIBROBLASTS; INHIBITION; ONCOGENE; LYMPHOMA; MEMBRANE	The 70 kDa ribosomal S6 kinase (pp70(S6k)) plays an important role in the progression of cells through G1 phase of the cell cycle. However, little is known of the signaling molecules that mediate its activation. We demonstrate that Rho family G proteins regulate pp70(S6k) activity in vivo. Activated alleles of Cdc42 and Rac1, but not RhoA, stimulate pp70(S6k) activity in multiple cell types. Activation requires an intact effector domain and isoprenylation of Cdc42 and Rac1. Coexpression of Dbl, an exchange factor for Cdc42, also activates pp70(S6k). Growth factor-induced activation of pp70(S6k) is abrogated by dominant negative alleles of Cdc42 and Rad. In addition, Cdc42 and Rad form a GTP-dependent complex with the catalytically inactive form of pp70(S6k) in vitro and in vivo, suggesting a mechanism by which these G proteins activate pp70(S6k).	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SELF AJ, 1993, ONCOGENE, V8, P655; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	61	261	263	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					573	583		10.1016/S0092-8674(00)81257-X	http://dx.doi.org/10.1016/S0092-8674(00)81257-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653792	Bronze			2022-12-24	WOS:A1996UM41500014
J	Young, RE; Smith, MA; Sobeck, CK				Young, RE; Smith, MA; Sobeck, CK			Galileo probe: In situ observations of Jupiter's atmosphere	SCIENCE			English	Article							VOYAGER-2; WINDS; BELT	The Galileo probe performed the first in situ measurements of the atmosphere of Jupiter on 7 December 1995, The probe returned data until it reached a depth corresponding to an atmospheric pressure of similar to 24 bars. This report presents a brief overview of the origins and purpose of the mission. Science objectives, entry parameters and mission events, and results are described. The remaining reports address in more detail the individual experiments summarized here.			Young, RE (corresponding author), NASA,AMES RES CTR,MOFFETT FIELD,CA 94035, USA.							Atkinson DH, 1996, SCIENCE, V272, P842, DOI 10.1126/science.272.5263.842; Atreya S. K., 1985, Recent Advances in Planetary Meteorology. Seymour Hess Memorial Symposium at the 1983 IUGG General Assembly, P17; Beebe RF, 1996, SCIENCE, V272, P841, DOI 10.1126/science.272.5263.841; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; CONRATH B, 1987, J GEOPHYS RES, V92, P15006; DEPATER I, 1986, ICARUS, V68, P344, DOI 10.1016/0019-1035(86)90027-8; Fischer HM, 1996, SCIENCE, V272, P856, DOI 10.1126/science.272.5263.856; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; INGERSOLL AP, 1981, J GEOPHYS RES-SPACE, V86, P8733, DOI 10.1029/JA086iA10p08733; Lanzerotti LJ, 1996, SCIENCE, V272, P858, DOI 10.1126/science.272.5263.858; LIMAYE SS, 1982, J ATMOS SCI, V39, P1413, DOI 10.1175/1520-0469(1982)039<1413:JWFVPI>2.0.CO;2; LIMAYE SS, 1991, J GEOPHYS RES-PLANET, V96, P18941, DOI 10.1029/91JA01701; NEFF J, 1990, GLLMDT90195 JPL IOM; NEFF J, 1996, GLLNAV965 JPL IOM; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; Ragent B, 1996, SCIENCE, V272, P854, DOI 10.1126/science.272.5263.854; RUSSELL CT, 1992, SPACE SCI REV, V60; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; SMITH BA, 1981, SCIENCE, V212, P163, DOI 10.1126/science.212.4491.163; SMITH BA, 1986, SCIENCE, V233, P43, DOI 10.1126/science.233.4759.43; Sromovsky LA, 1996, SCIENCE, V272, P851, DOI 10.1126/science.272.5263.851; vonZahn U, 1996, SCIENCE, V272, P849, DOI 10.1126/science.272.5263.849; WEST RA, 1986, ICARUS, V65, P161, DOI 10.1016/0019-1035(86)90135-1; [No title captured]	25	47	47	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					837	838		10.1126/science.272.5263.837	http://dx.doi.org/10.1126/science.272.5263.837			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629015				2022-12-24	WOS:A1996UK75700044
J	Ferster, D; Chung, S; Wheat, H				Ferster, D; Chung, S; Wheat, H			Orientation selectivity of thalamic input to simple cells of cat visual cortex	NATURE			English	Article							RESPONSE PROPERTIES; RECEPTIVE-FIELDS; STRIATE CORTEX; AREA 17; NEURONS; PROJECTIONS; INHIBITION	MORE than 30 years after Hubel and Wiesel(1) first described orientation selectivity in the mammalian visual cortex, the mechanism that gives rise to this property is still controversial. Hubel and Wiesel(1) proposed a simple model for the origin of orientation tuning, in which the circularly symmetrical receptive fields of neurons in the lateral geniculate nucleus that excite a cortical simple cell are arranged in rows. Since this model was proposed, several experiments(2-6) and neuronal simulations(7,8) have suggested that the connectivity between the lateral geniculate nucleus and the cortex is not well organized in an orientation-specific fashion, and that orientation tuning arises instead from extensive interactions within the cortex. To test these models we have recorded visually evoked synaptic potentials in simple cells while cooling the cortex(9), which largely inactivates the cortical network, but leaves geniculate synaptic input functional. We report that the orientation tuning of these potentials is almost unaffected by cooling the cortex, in agreement with Hubel and Wiesel's original proposal(1).			Ferster, D (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,2153 N CAMPUS DR,EVANSTON,IL 60208, USA.							BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CREUTZFELDT OD, 1974, EXP BRAIN RES, V21, P251; CROOK JM, 1991, NEUROSCIENCE, V40, P1, DOI 10.1016/0306-4522(91)90169-O; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; FERSTER D, 1986, J NEUROSCI, V6, P1284; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P233, DOI 10.1113/jphysiol.1985.sp015822; FERSTER D, 1992, J NEUROSCI, V12, P1262; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1975, J COMP NEUROL, V163, P81, DOI 10.1002/cne.901630106; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; KALIL RE, 1970, J NEUROPHYSIOL, V33, P459, DOI 10.1152/jn.1970.33.3.459; KISVARDAY ZF, 1994, EUR J NEUROSCI, V6, P1619, DOI 10.1111/j.1460-9568.1994.tb00553.x; LEVAY S, 1976, BRAIN RES, V113, P1, DOI 10.1016/0006-8993(76)90002-0; MAEX R, 1994, THESIS KATHOLIEKE U; MILLER KD, 1994, J NEUROSCI, V14, P409; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; SAUL AB, 1990, J NEUROPHYSIOL, V64, P206, DOI 10.1152/jn.1990.64.1.206; SCHWARK HD, 1986, J NEUROPHYSIOL, V56, P1074, DOI 10.1152/jn.1986.56.4.1074; SHATZ CJ, 1977, J COMP NEUROL, V173, P497, DOI 10.1002/cne.901730307; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SOMERS DC, 1995, J NEUROSCI, V15, P5448; SUAREZ H, 1995, J NEUROSCI, V15, P6700; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303	30	412	416	0	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					249	252		10.1038/380249a0	http://dx.doi.org/10.1038/380249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637573				2022-12-24	WOS:A1996UB11700052
J	Sil, A; Herskowitz, I				Sil, A; Herskowitz, I			Identification of an asymmetrically localized determinant, Ash1p, required for lineage-specific transcription of the yeast HO gene	CELL			English	Article							CELL-CYCLE REGULATION; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; LIFE-CYCLE; EXPRESSION; DNA; SW15; INTERCONVERSION; ENCODES; START	S. cerevisiae cells exhibit asymmetric determination of cell fate. Cell division yields a mother cell, which is competent to transcribe the HO gene and switch mating type, and a daughter cell, which is not. We have isolated a mutant in which daughters transcribe HO and switch mating type. This mutation defines the ASH1 gene (asymmetric synthesis of HO). Deletion and overexpression of ASH1 cause reciprocal cell fate transformations: in ash1 Delta strains, daughters switch mating type as efficiently as mothers. Conversely, overexpression of ASH1 inhibits switching in mother cells. Ash1p has a zinc finger motif related to those of GATA transcriptional regulators. Ash1p is localized to the daughter nucleus in cells that have undergone nuclear division. Thus, Ash1p is a cell fate determinant that is asymmetrically localized to the daughter nucleus where it inhibits HO transcription.			Sil, A (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018738, R01AI018738] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18738] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; HADWIGER JA, 1990, NUCLEIC ACIDS RES, V18, P4025, DOI 10.1093/nar/18.13.4025; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HERSKOWITZ I, 1992, TRANSCRIPTIONAL REGU, P949; HICKS JB, 1976, GENETICS, V83, P245; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRUGER WD, 1991, THESIS U CALFORNIA S; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; ORKIN SH, 1992, BLOOD, V80, P575; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHULTZ LD, 1983, J BACTERIOL, V155, P8, DOI 10.1128/JB.155.1.8-14.1983; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERN M, 1985, THESIS U CALIFORNIA; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091	49	216	219	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					711	722		10.1016/S0092-8674(00)81049-1	http://dx.doi.org/10.1016/S0092-8674(00)81049-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625409	Bronze			2022-12-24	WOS:A1996TZ99000009
J	Terada, S; Nakata, T; Peterson, AC; Hirokawa, N				Terada, S; Nakata, T; Peterson, AC; Hirokawa, N			Visualization of slow axonal transport in vivo	SCIENCE			English	Article							RECOMBINANT ADENOVIRUSES IMPROVES; NEURONAL INTERMEDIATE FILAMENTS; INVIVO GENE-TRANSFER; NF-M; NEUROFILAMENT PROTEIN; CYSTIC-FIBROSIS; MODEL SYSTEM; CYTOSKELETON; SEQUENCE; VECTOR	In axons, cytoskeletal constituents move by slow transport, However, it remains controversial whether axonal neurofilaments are dynamic structures in which only subunits are transported or whether filaments assemble in the proximal axon and are transported intact as polymers to the axon terminus. To investigate the form neurofilament proteins rake during transport, neurons of transgenic mice lacking axonal neurofilaments were infected with a recombinant adenoviral vector encoding epitope-tagged neurofilament M. Confocal and electron microscopy revealed that the vitally encoded neurofilament M was transported in unpolymerized form along axonal microtubules. Thus, neurofilament proteins are probably transported as subunits or small oligomers along microtubules, which are major routes for slow axonal transport.	UNIV TOKYO, BRAIN RES INST, FAC MED, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT ANAT & CELL BIOL, BUNKYO KU, TOKYO 113, JAPAN; MCGILL UNIV, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA	University of Tokyo; University of Tokyo; McGill University				Terada, Sumio/0000-0001-5689-0186				AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BLUM JJ, 1989, CELL MOTIL CYTOSKEL, V12, P53, DOI 10.1002/cm.970120107; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CLEVELAND DW, 1991, CELL, V67, P453, DOI 10.1016/0092-8674(91)90518-4; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; GEISLER N, 1984, EMBO J, V3, P2701, DOI 10.1002/j.1460-2075.1984.tb02196.x; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; Hayat M.A., 1989, PRINCIPLES TECHNIQUE, DOI DOI 10.1007/978-1-349-09857-6; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; HIROKAWA N, 1985, J CELL BIOL, V101, P227, DOI 10.1083/jcb.101.1.227; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; HOLLENBECK PJ, 1990, NATURE, V343, P408, DOI 10.1038/343408a0; JOSHI HC, 1993, J CELL BIOL, V121, P1191, DOI 10.1083/jcb.121.6.1191; JULIEN JP, UNPUB; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KOMIYA Y, 1986, BIOMED RES-TOKYO, V7, P359; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; LASEK RJ, 1984, J CELL BIOL, V99, pS212, DOI 10.1083/jcb.99.1.212s; LASEK RJ, 1982, PHILOS T ROY SOC B, V299, P313, DOI 10.1098/rstb.1982.0135; LASEK RJ, 1986, J CELL SCI, P161; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1986, J CELL BIOL, V102, P647, DOI 10.1083/jcb.102.2.647; NIXON RA, 1991, NEURONAL CYTOSKELETO; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; OKABE S, 1993, J CELL BIOL, V121, P375, DOI 10.1083/jcb.121.2.375; SAITO I, 1985, J VIROL, V54, P711, DOI 10.1128/JVI.54.3.711-719.1985; STAUFENBIEL M, 1986, J VIROL, V60, P1186, DOI 10.1128/JVI.60.3.1186-1191.1986; TAKEDA S, 1994, J CELL BIOL, V127, P173, DOI 10.1083/jcb.127.1.173; TASHIRO T, 1989, J NEUROSCI, V9, P760; YAMASAKI H, 1992, LAB INVEST, V66, P734; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	45	82	82	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					784	788		10.1126/science.273.5276.784	http://dx.doi.org/10.1126/science.273.5276.784			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670416				2022-12-24	WOS:A1996VB42900039
J	Livnah, O; Stura, EA; Johnson, DL; Middleton, SA; Mulcahy, LS; Wrighton, NC; Dower, WJ; Jolliffe, LK; Wilson, IA				Livnah, O; Stura, EA; Johnson, DL; Middleton, SA; Mulcahy, LS; Wrighton, NC; Dower, WJ; Jolliffe, LK; Wilson, IA			Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 angstrom	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; ANTIBODY-ANTIGEN COMPLEXES; HUMAN TISSUE FACTOR; CRYSTAL-STRUCTURE; ERYTHROPOIETIN RECEPTOR; LIGAND-BINDING; EXTRACELLULAR DOMAIN; IMMUNOGLOBULIN FOLD; SIGNAL TRANSDUCTION; HUMAN CD4	The functional mimicry of a protein by an unrelated small molecule has been a formidable challenge. Now, however, th biological activity of a 166-residue hematopoietic growth hormone, erythropoietin (EPO), with is class 1 cytokine receptor has been mimicked by a 20-residue cyclic peptide unrelated in sequence to the natural ligand. The crystal structure at 2.8 Angstrom resolution of a complex of this agonist peptide with the extracellular domain of EPO receptor reveals that a peptide dimer induces an almost perfect twofold dimerization of the receptor. The dimer assembly differs from that of the human growth hormone (hGH) receptor complex and suggests that more than one mode of dimerization may be able to indue signal transduction and cell proliferation. The EPO receptor binding site, defined by peptide interaction, corresponds to the smaller functional epitope identified for hGH receptor. Similarly, the EPO mimetic peptide ligand can be considered as a minimal hormone, and suggests the design of nonpeptidic small molecule mimetics for EPO and other cytokines may indeed be achievable.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST, DRUG DISCOVERY RES, RARITAN, NJ 08869 USA; AFFYMAX RES INST, PALO ALTO, CA 94304 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute			Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118	NIGMS NIH HHS [GM-49497] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNSTEIN FC, 1978, ARCH BIOCHEM BIOPHYS, V185, P584, DOI 10.1016/0003-9861(78)90204-7; BOISSEL JP, 1993, J BIOL CHEM, V268, P15983; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; FOA P, 1991, ACTA HAEMATOL-BASEL, V86, P162, DOI 10.1159/000204826; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUREY WJ, 1990, AM CRYST ASS 40 ANN; GUSTCHINA A, 1995, PROTEINS, V21, P140, DOI 10.1002/prot.340210208; HANSEN JN, 1993, ANNU REV MICROBIOL, V47, P535, DOI 10.1146/annurev.micro.47.1.535; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; Johnson D. B., UNPUB; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; JOLLIFFE LK, 1995, NEPHROL DIAL TRANSPL, V10, P28, DOI 10.1093/ndt/10.supp2.28; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM H, 1993, BIOCHEMISTRY-US, V32, P8465, DOI 10.1021/bi00084a011; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRANTZ SB, 1991, BLOOD, V77, P419; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RONCO LV, 1994, J BIOL CHEM, V269, P277; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPIVAK JL, 1994, ERYTHROPOIETIN BASIC, V8, P863; STURA EA, UNPUB; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WILSON IA, 1991, CIBA F SYMP, V159, P13; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619	69	533	605	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1996	273	5274					464	471		10.1126/science.273.5274.464	http://dx.doi.org/10.1126/science.273.5274.464			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8662530				2022-12-24	WOS:A1996UY98300032
J	Lyons, SF				Lyons, SF			Shadow bands	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					98	98						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656519				2022-12-24	WOS:A1996UV48500009
J	Harvey, RP; McSween, HY				Harvey, RP; McSween, HY			A possible high-temperature origin for the carbonates in the Martian meteorite ALH84001	NATURE			English	Article							NORWAY	THE meteorite Allan Hills (ALH) 84001, commonly accepted to be of martian origin, is unique among known martian meteorites in containing abundant, zoned, pre-terrestrial carbonate minerals(1-9). Previous studies of the oxygen isotope compositions of these minerals(5,6,8) have suggested that they precipitated from a low-temperature (0-80 degrees C) aqueous fluid in the martian crust-perhaps in a near-surface hydrothermal system, Here we report analyses of the major-element compositions of the carbonates, which provide an independent constraint on the composition and temperature of the fluid from which they formed. We argue that the most likely explanation for the observed compositions, and for the absence of co-existing hydrous minerals, is that the carbonates were formed by reactions between hot (>650 degrees C), CO2-rich fluids and the ultramafic host rock during an impact event, Impact processes on the martian surface can produce both the hot, CO2-rich fluid (by volatilization of surface carbonates or other CO2 sources) and-by brecciation-the conduits through which it flowed, Impact metasomatism is also consistent with the observed oxygen isotope disequilibrium, sequence of mineral formation, and carbonate mineral zoning, reflecting carbonate formation during rapid cooling from high temperatures rather than prolonged exposure to low-temperature fluids(6,8).	UNIV TENNESSEE,DEPT GEOL SCI,KNOXVILLE,TN 37996	University of Tennessee System; University of Tennessee Knoxville	Harvey, RP (corresponding author), CASE WESTERN RESERVE UNIV,DEPT GEOL SCI,CLEVELAND,OH 44106, USA.							ANOVITZ LM, 1987, J PETROL, V28, P389, DOI 10.1093/petrology/28.2.389; ASH RA, 1995, METEORITICS, V30, P485; Baker V.R., 1992, CHANNELS VALLEY NETW, P493; CRIBB SJ, 1982, NORSK GEOL TIDSSKR, V62, P161; GRIFFITH LL, 1995, NATURE, V377, P406, DOI 10.1038/377406a0; HARVEY RP, 1994, METEORITICS, V29, P472; JAMES PB, 1992, MARS, P934; JOHANNES W, 1969, AM J SCI, V267, P1083, DOI 10.2475/ajs.267.9.1083; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; MARTINEZ I, 1994, EARTH PLANET SC LETT, V121, P559, DOI 10.1016/0012-821X(94)90091-4; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; OHNMACHT W, 1974, J PETROL, V15, P303, DOI 10.1093/petrology/15.2.303; RIDLEY WI, 1995, METEORITICS, V30, P565; ROMANEK CS, 1995, METEORITICS, V30, P567; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; Schreyer W, 1972, LITHOS, V5, P345, DOI 10.1016/0024-4937(72)90089-8; SCORE R, 1995, ANT METEORITE NEWSL, V18, P20; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; TROMMSDORFF V, 1990, CONTRIB MINERAL PETR, V104, P1, DOI 10.1007/BF00310641; WENTWORTH SJ, 1995, P LUN PLAN SCI C, V26, P1489; WOODS TL, 1992, GEOCHIM COSMOCHIM AC, V56, P3031, DOI 10.1016/0016-7037(92)90288-T	22	160	164	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1996	382	6586					49	51		10.1038/382049a0	http://dx.doi.org/10.1038/382049a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV473	8657303				2022-12-24	WOS:A1996UV47300048
J	Masters, PW; Lawson, N; Marenah, CB; Maile, LJ				Masters, PW; Lawson, N; Marenah, CB; Maile, LJ			High ambient temperature: A spurious cause of hypokalaemia	BRITISH MEDICAL JOURNAL			English	Article							SERUM POTASSIUM		THE SURGERY,CALVERTON NG14 4FP,ENGLAND		Masters, PW (corresponding author), CITY HOSP NOTTINGHAM,DEPT CLIN CHEM,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.		Masters, Paul/AAL-9303-2021					GOODMAN JR, 1954, AM J CLIN PATHOL, V24, P111, DOI 10.1093/ajcp/24.1_ts.111; KALSHEKER N, 1984, CLIN CHEM, V30, P1581; MOORE D, 1989, PRACTITIONER, V233, P395; Tietz N., 1986, TXB CLIN CHEM, P1176; VERRESEN L, 1986, CLIN CHEM, V32, P698	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1652	1653		10.1136/bmj.312.7047.1652	http://dx.doi.org/10.1136/bmj.312.7047.1652			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664721	Green Published			2022-12-24	WOS:A1996UV48900027
J	Choe, H; Farzan, M; Sun, Y; Sullivan, N; Rollins, B; Ponath, PD; Wu, LJ; Mackay, CR; LaRosa, G; Newman, W; Gerard, N; Gerard, C; Sodroski, J				Choe, H; Farzan, M; Sun, Y; Sullivan, N; Rollins, B; Ponath, PD; Wu, LJ; Mackay, CR; LaRosa, G; Newman, W; Gerard, N; Gerard, C; Sodroski, J			The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates	CELL			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HAMSTER OVARY CELLS; ENVELOPE GLYCOPROTEIN; T-CELL; HTLV-III/LAV; MONONUCLEAR PHAGOCYTES; CD4-MEDIATED FUSION; MACROPHAGE TROPISM; MOLECULAR-CLONING; MEMBRANE-FUSION	We examined the ability of chemokine receptors and related G protein-coupled receptors to facilitate infection by primary, clinical HIV-1 isolates. CCR5, when expressed along with CD4, the HIV-1 receptor, allowed cell lines resistant to most primary HIV-1 isolates to be infected. CCR3 facilitated infection by a more restricted subset of primary viruses, and binding of the CCR3 ligand, eotaxin, inhibited infection by these isolates. Utilization of CCR3 and CCR5 on the target cell depended upon the sequence of the third variable (V3) region of the HIV-1 gp120 exterior envelope glycoprotein. The ability of various members of the chemokine receptor family to support the early stages of HIV-1 infection helps to explain viral tropism and beta-chemokine inhibition of primary HIV-1 isolates.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; LEUKOSITE INC,CAMBRIDGE,MA 02142; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,PERLMUTTER LAB,DEPT PEDIAT,DEPT MED,CHILDRENS HOSP,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Boston Children's Hospital; Harvard Medical School	Choe, H (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HUMAN RETROVIROL,44 BINNEY ST,BOSTON,MA 02115, USA.		Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340; Farzan, Michael/0000-0002-2990-5319	NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024755, P30AI028691, R01AI024755] Funding Source: NIH RePORTER; NCI NIH HHS [CA06516] Funding Source: Medline; NIAID NIH HHS [AI28691, AI24755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; ASJO B, 1986, LANCET, V2, P660; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERGERON L, 1992, J VIROL, V66, P2389, DOI 10.1128/JVI.66.4.2389-2397.1992; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BOUHABIB DC, 1994, J VIROL, V68, P6006, DOI 10.1128/JVI.68.9.6006-6013.1994; BRAND D, 1995, J VIROL, V69, P166, DOI 10.1128/JVI.69.1.166-171.1995; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; CARRILLO A, 1993, VIROLOGY, V197, P817, DOI 10.1006/viro.1993.1664; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHESEBRO B, 1991, J VIROL, V65, P5782, DOI 10.1128/JVI.65.11.5782-5789.1991; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CULLEN BR, 1989, METHOD ENZYMOL, V152, P64; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FENYO EM, 1988, J VIROL, V62, P4414; FISHER AG, 1985, NATURE, V316, P262, DOI 10.1038/316262a0; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; FREEDMAN AR, 1991, J EXP MED, V174, P1661, DOI 10.1084/jem.174.6.1661; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GRIMAILA RJ, 1992, J VIROL, V66, P1875, DOI 10.1128/JVI.66.4.1875-1883.1992; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; IVANOFF LA, 1991, AIDS RES HUM RETROV, V7, P595, DOI 10.1089/aid.1991.7.595; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KARLSSON G, IN PRESS J VIROL; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MONTEFIORI DC, 1991, VIROLOGY, V182, P635, DOI 10.1016/0042-6822(91)90604-A; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MYERS G, 1994, HUMAN RETROVIRUSES A; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PALERMO DP, 1991, J BIOTECHNOL, V19, P35, DOI 10.1016/0168-1656(91)90073-5; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; PONATH P, 1996, J EXP MED, V183, P1; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; RAPORT C, 1996, IN PRESS J BIOL CHEM; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SKINNER MA, 1988, AIDS RES HUM RETROV, V4, P187, DOI 10.1089/aid.1988.4.187; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SOZZANI S, 1995, J IMMUNOL, V155, P3292; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TRAVIS BM, 1992, VIROLOGY, V186, P313, DOI 10.1016/0042-6822(92)90088-7; VALENTIN A, 1994, J VIROL, V68, P6684, DOI 10.1128/JVI.68.10.6684-6689.1994; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WEISSMAN D, 1995, P NATL ACAD SCI USA, V92, P826, DOI 10.1073/pnas.92.3.826; WELLER P, 1995, AM J RESPIR CELL MOL, V10, P610; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; WILLEY RL, 1994, J VIROL, V68, P4409, DOI 10.1128/JVI.68.7.4409-4419.1994; WRIN T, 1995, J VIROL, V69, P39, DOI 10.1128/JVI.69.1.39-48.1995	108	2063	2167	2	129	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1135	1148		10.1016/S0092-8674(00)81313-6	http://dx.doi.org/10.1016/S0092-8674(00)81313-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674119	Bronze			2022-12-24	WOS:A1996UV48400019
J	Doranz, BJ; Rucker, J; Yi, YJ; Smyth, RJ; Samson, M; Peiper, SC; Parmentier, M; Collman, RG; Doms, RW				Doranz, BJ; Rucker, J; Yi, YJ; Smyth, RJ; Samson, M; Peiper, SC; Parmentier, M; Collman, RG; Doms, RW			A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; MOLECULAR-CLONING; CELL-LINE; CD4-MEDIATED FUSION; HUMAN HOMOLOG; NPY BINDING; INFECTION; MACROPHAGE; VARIANTS	Here, we show that the beta-chemokine receptor CKR-5 serves as a cofactor for M-tropic HIV viruses. Expression of CKR-5 with CD4 enables nonpermissive cells to form syncytia with cells expressing M-tropic, but not T-tropic, HIV-1 env proteins. Expression of CKR-5 and CD4 enables entry of a M-tropic, but not a T-tropic, virus strain. A dual-tropic primary HIV-1 isolate (89.6) utilizes both Fusin and CKR-5 as entry cofactors. Cells expressing the 89.6 env protein form syncytia with QT6 cells expressing CD4 and either Fusin or CKR-5. The beta-chemokine receptors CKR-3 and CKR-2b support HIV-1 89.6 env-mediated syncytia formation but do not support fusion by any of the T-tropic or M-tropic strains tested. Our results suggest that the T-tropic viruses characteristic of disease progression may evolve from purely M-tropic viruses prevalent early in virus infection through changes in the env protein that enable the virus to use multiple entry cofactors.	UNIV PENN,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104; FREE UNIV BRUSSELS,IRIBHN,B-1070 BRUSSELS,BELGIUM; UNIV LOUISVILLE,JAMES GRAHAM BROWN CANC CTR,DEPT PATHOL,LOUISVILLE,KY 40202	University of Pennsylvania; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Louisville	Doranz, BJ (corresponding author), UNIV PENN,DEPT MED,DEPT LAB MED & PATHOL,PHILADELPHIA,PA 19104, USA.		Samson, Michel/F-8356-2013	Parmentier, Marc/0000-0001-8081-4685	NIAID NIH HHS [AI-35383, AI-38225] Funding Source: Medline; NINDS NIH HHS [NS27405] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035383, R01AI038225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS027405] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BERSON JF, 1996, IN PRESS J VIROL; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CHENGMAYER C, 1991, J VIROL, V65, P6931, DOI 10.1128/JVI.65.12.6931-6941.1991; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HARRINGTON RD, 1993, J VIROL, V67, P5939, DOI 10.1128/JVI.67.10.5939-5947.1993; HERZOG H, 1993, DNA CELL BIOL, V12, P465, DOI 10.1089/dna.1993.12.465; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; KIM FM, 1995, J VIROL, V69, P1755, DOI 10.1128/JVI.69.3.1755-1761.1995; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; LIU ZQ, 1990, J VIROL, V64, P6148, DOI 10.1128/JVI.64.12.6148-6153.1990; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Puri A, 1996, VIROLOGY, V219, P262, DOI 10.1006/viro.1996.0244; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; ZHO T, 1993, SCIENCE, V261, P1179	53	1705	1806	0	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1149	1158		10.1016/S0092-8674(00)81314-8	http://dx.doi.org/10.1016/S0092-8674(00)81314-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674120	hybrid			2022-12-24	WOS:A1996UV48400020
J	Tanaka, K; Oikawa, K; Ohta, N; Kuroiwa, H; Kuroiwa, T; Takahashi, H				Tanaka, K; Oikawa, K; Ohta, N; Kuroiwa, H; Kuroiwa, T; Takahashi, H			Nuclear encoding of a chloroplast RNA polymerase sigma subunit in a red alga	SCIENCE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; SP STRAIN PCC-7120; EVOLUTIONARY RELATIONSHIPS; GENE ORGANIZATION; RPOC1 GENE; DNA; EUBACTERIA; GENOME; CYANOBACTERIA; POLYPEPTIDES	A chloroplast RNA polymerase sigma factor is encoded by a nuclear gene, sigA, in the red alga Cyanidium caldarium RK-1. The encoded protein functions as an RNA polymerase sigma factor in vitro and it is localized to the chloroplast in vivo. SigA shows high sequence similarity to the sigma factors of cyanobacteria, which is indicative of the ancestral endosymbiotic event and subsequent transfer of the sigA gene to the nuclear genome.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; WASEDA UNIV, DEPT BASIC HUMAN SCI, TOKOROZAWA, SAITAMA 359, JAPAN; UNIV TOKYO, GRAD SCH SCI, DEPT PLANT SCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; Waseda University; University of Tokyo			Tanaka, Kan/E-3724-2015	Tanaka, Kan/0000-0001-7560-7884				BERGSLAND KJ, 1991, J BACTERIOL, V173, P3446, DOI 10.1128/jb.173.11.3446-3455.1991; BRAHAMSHA B, 1991, J BACTERIOL, V173, P2442, DOI 10.1128/jb.173.8.2442-2450.1991; HALLICK RB, 1993, NUCLEIC ACIDS RES, V21, P3537, DOI 10.1093/nar/21.15.3537; HARLOW H, 1988, ANTIBODIES LAB MANUA; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HU J, 1991, NUCLEIC ACIDS RES, V19, P3431, DOI 10.1093/nar/19.12.3431; HU J, 1990, P NATL ACAD SCI USA, V87, P1531, DOI 10.1073/pnas.87.4.1531; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; JOHNSON KA, 1990, CELL, V62, P615, DOI 10.1016/0092-8674(90)90105-N; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; LERBS S, 1988, MOL GEN GENET, V211, P459, DOI 10.1007/BF00425701; Liu B, 1996, P NATL ACAD SCI USA, V93, P3313, DOI 10.1073/pnas.93.8.3313; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; NOMURA T, 1986, NUCLEIC ACIDS RES, V14, P6857, DOI 10.1093/nar/14.17.6857; NOZAKI H, 1994, J PHYCOL, V30, P279, DOI 10.1111/j.0022-3646.1994.00279.x; OHTA N, 1992, PLANT CELL PHYSIOL, V33, P657; OHTA N, 1994, CURR GENET, V25, P357, DOI 10.1007/BF00351490; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; REITH M, 1995, ANNU REV PLANT PHYS, V46, P549, DOI 10.1146/annurev.arplant.46.1.549; REITH M, 1993, PLANT CELL, V5, P465, DOI 10.1105/tpc.5.4.465; SCHNEIDER GJ, 1988, J BACTERIOL, V170, P4136, DOI 10.1128/jb.170.9.4136-4140.1988; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA K, 1991, BIOCHIM BIOPHYS ACTA, V1089, P113, DOI 10.1016/0167-4781(91)90092-Z; TANAKA K, 1992, BIOCHIM BIOPHYS ACTA, V1132, P94, DOI 10.1016/0167-4781(92)90060-D; TANAKA K, 1988, SCIENCE, V242, P1040, DOI 10.1126/science.3194753; TILLER K, 1991, EUR J BIOCHEM, V198, P93, DOI 10.1111/j.1432-1033.1991.tb15990.x; TROXLER RF, 1994, PLANT PHYSIOL, V104, P753, DOI 10.1104/pp.104.2.753	29	97	99	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 28	1996	272	5270					1932	1935		10.1126/science.272.5270.1932	http://dx.doi.org/10.1126/science.272.5270.1932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658165				2022-12-24	WOS:A1996UV29400047
J	Dennehy, JA; Appleby, L; Thomas, CS; Faragher, EB				Dennehy, JA; Appleby, L; Thomas, CS; Faragher, EB			Case-control study of suicide by discharged psychiatric patients	BRITISH MEDICAL JOURNAL			English	Article							RISK		UNIV MANCHESTER,SCH PSYCHIAT & BEHAV SCI,MANCHESTER M20 8LR,LANCS,ENGLAND; UNIV S MANCHESTER HOSP,MANCHESTER,LANCS,ENGLAND	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital								ALLEBECK P, 1987, ACTA PSYCHIAT SCAND, V76, P414, DOI 10.1111/j.1600-0447.1987.tb05626.x; APPLEBY L, 1992, BRIT J PSYCHIAT, V161, P749, DOI 10.1192/bjp.161.6.749; *DEP HLTH, 1992, HLTH NAT; POKORNY AD, 1983, ARCH GEN PSYCHIAT, V40, P249; WILLIAMS P, 1986, SOC PSYCH PSYCH EPID, V21, P89, DOI 10.1007/BF00578748	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1580	1580		10.1136/bmj.312.7046.1580	http://dx.doi.org/10.1136/bmj.312.7046.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU806	8664668	Green Published			2022-12-24	WOS:A1996UU80600020
J	Legge, JS				Legge, JS			Peak-expiratory-flow meters and asthma self-management	LANCET			English	Editorial Material											Legge, JS (corresponding author), ABERDEEN ROYAL INFIRM,DEPT THORAC MED,ABERDEEN AB9 2ZB,SCOTLAND.							BOULET LP, 1994, THORAX, V49, P965, DOI 10.1136/thx.49.10.965; GIBSON PG, 1995, ANN INTERN MED, V123, P488, DOI 10.7326/0003-4819-123-7-199510010-00002; JONES KP, 1995, THORAX, V50, P851, DOI 10.1136/thx.50.8.851; KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P702, DOI 10.1016/0091-6749(93)90189-M; Miles JF, 1996, THORAX, V51, P403, DOI 10.1136/thx.51.4.403; VERSCHELDEN P, 1996, AM J RESP CRIT CARE, V153, pA777; 1994, BRIT MED J, V308, P564	8	13	13	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1709	1710		10.1016/S0140-6736(96)90802-8	http://dx.doi.org/10.1016/S0140-6736(96)90802-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656900				2022-12-24	WOS:A1996UT39600004
J	Nichols, CG; Shyng, SL; Nestorowicz, A; Glaser, B; Clement, JP; Gonzalez, G; AguilarBryan, L; Permutt, MA; Bryan, J				Nichols, CG; Shyng, SL; Nestorowicz, A; Glaser, B; Clement, JP; Gonzalez, G; AguilarBryan, L; Permutt, MA; Bryan, J			Adenosine diphosphate as an intracellular regulator of insulin secretion	SCIENCE			English	Article							ISOLATED MEMBRANE PATCHES; POTASSIUM CHANNELS; K+ CHANNELS; ATP; CELLS; ADP	Adenosine triphosphate (ATP)-sensitive potassium (K-ATP) channels couple the cellular metabolic state to electrical activity and are a critical link between blood glucose concentration and pancreatic insulin secretion. A mutation in the second nucleotide-binding fold (NBF2) of the sulfonylurea receptor (SUR) of an individual diagnosed with persistent hyperinsulinemic hypoglycemia of infancy generated K-ATP channels that could be opened by diazoxide but not in response to metabolic inhibition. The hamster SUR, containing the analogous mutation, had normal ATP sensitivity, but unlike wild-type channels, inhibition by ATP was not antagonized by adenosine diphosphate (ADP). Additional mutations in NBF2 resulted in the same phenotype, whereas an equivalent mutation in NBF1 showed normal sensitivity to MgADP. Thus, by binding to SUR NBF2 and antagonizing ATP inhibition of K-ATP channels, intracellular MgADP may regulate insulin secretion.	WASHINGTON UNIV,SCH MED,DIV ENDOCRINOL & METAB,ST LOUIS,MO 63110; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DIV ENDOCRINOL & METAB,IL-91010 JERUSALEM,ISRAEL; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Washington University (WUSTL); Hebrew University of Jerusalem; Baylor College of Medicine; Baylor College of Medicine	Nichols, CG (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110, USA.		Nichols, Colin/D-6336-2012; Glaser, Benjamin/F-8411-2017	Glaser, Benjamin/0000-0003-4711-5000				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; DUNNE MJ, 1986, FEBS LETT, V208, P59, DOI 10.1016/0014-5793(86)81532-0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; NICHOLS CG, 1991, BIOPHYS J, V60, P1164, DOI 10.1016/S0006-3495(91)82152-X; RAJAN AS, 1993, J BIOL CHEM, V268, P15221; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Zuppinger K, 1983, Prog Pediatr Surg, V16, P51	17	453	463	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1785	1787		10.1126/science.272.5269.1785	http://dx.doi.org/10.1126/science.272.5269.1785			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650576				2022-12-24	WOS:A1996UT11000042
J	Bortvin, A; Winston, F				Bortvin, A; Winston, F			Evidence that Spt6p controls chromatin structure by a direct interaction with histones	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PERIODIC TRANSCRIPTION; NUCLEAR-PROTEIN; ESSENTIAL GENE; YEAST; IDENTIFICATION; SNF2/SWI2; SUPPRESS; HOMOLOG; ENCODES	Genetic analysis has implicated SPT6, an essential gene of Saccharomyces cerevisiae, in the control of chromatin structure. Mutations in SPT6 and particular mutations in histone genes are able to overcome transcriptional defects in strains lacking the Snf/Swi protein complex. Here it is shown that an spt6 mutation causes changes in chromatin structure in vivo. In addition, both in vivo and in vitro experiments provide evidence that Spt6p interacts directly with histones and primarily with histone H3. Consistent with these findings, Spt6p is capable of nucleosome assembly in vitro.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School				Bortvin, Alex/0000-0003-0987-1905	NIGMS NIH HHS [GM32967] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032967, R37GM032967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBET FM, 1988, CURRENT PROTOCOLS MO; BORTVIN A, UNPUB; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CLARKADAMS CD, 1987, MOL CELL BIOL, V7, P679, DOI 10.1128/MCB.7.2.679; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; EDMONDSON DG, IN PRESS GENES DEV; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARTZOG GA, IN PRESS MOL CELL BI; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HEREFORD L, 1982, CELL, V30, P305, DOI 10.1016/0092-8674(82)90036-8; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1987, MOL CELL BIOL, V7, P672, DOI 10.1128/MCB.7.2.672; NISHIWAKI K, 1993, MOL GEN GENET, V239, P313, DOI 10.1007/BF00276929; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PRELICH G, 1993, GENETICS, V135, P665; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; Sherman F., 1978, METHODS YEAST GENETI; SWANSON MS, 1990, MOL CELL BIOL, V10, P4935, DOI 10.1128/MCB.10.9.4935; SWANSON MS, 1992, GENETICS, V132, P325; van Holde KE., 1989, SPRINGER SERIES MOL; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	40	282	282	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1473	1476		10.1126/science.272.5267.1473	http://dx.doi.org/10.1126/science.272.5267.1473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633238				2022-12-24	WOS:A1996UP89900045
J	Strelnitski, V; Haas, MR; Smith, HA; Erickson, EF; Colgan, SWJ; Hollenbach, DJ				Strelnitski, V; Haas, MR; Smith, HA; Erickson, EF; Colgan, SWJ; Hollenbach, DJ			Far-infrared hydrogen lasers in the peculiar star MWC 349A	SCIENCE			English	Article							RECOMBINATION LINE MASER; MWC-349	Far-infrared hydrogen recombination lines H15 alpha (169.4 micrometers), H12 alpha (88.8 micrometers), and H10 alpha (52.5 micrometers) were detected in the peculiar luminous star MWC 349A from the Kuiper Airborne Observatory. Here it is shown that at least H15 alpha is strongly amplified, with the probable amplification factor being greater than or about equal to 10(3) and a brightness temperature that is greater than or about equal to 10(7) kelvin. The other two lines also show signs of amplification, although to a lesser degree. Beyond H10 alpha the amplification apparently vanishes. The newly detected amplified lines fall into the laser wavelength domain. These lasers, as well as the previously detected hydrogen masers, may originate in the photoionized circumstellar disk of MWC 349A and constrain the disk's physics and structure.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; SEARCH EXTRATERR INTELLIGENCE INST,MT VIEW,CA 94043	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Strelnitski, V (corresponding author), SMITHSONIAN INST,NATL AIR & SPACE MUSEUM,ASTROPHYS LAB,WASHINGTON,DC 20560, USA.		Colgan, Sean W J/M-4742-2014					ALTENHOFF WJ, 1981, ASTRON ASTROPHYS, V93, P48; BEZARD B, 1986, ASTRON ASTROPHYS, V161, P387; CHEUNG AC, 1969, NATURE, V221, P626, DOI 10.1038/221626a0; COHEN M, 1985, ASTROPHYS J, V292, P249, DOI 10.1086/163154; DICKINSON RE, 1986, J GEOPHYS RES, V91, P70, DOI 10.1029/JA091iA01p00070; ERICKSON EF, 1995, P AIRB ASTR S GAL EC, P707; ERICKSON EF, 1984, P SOC PHOTOOPT INSTR, V509, P129; Gordiets B. F., 1983, Cosmic Research, V21, P725; GORDON MA, 1992, ASTROPHYS J, V387, P701, DOI 10.1086/171117; GWINN CR, 1992, ASTROPHYS J, V393, P149, DOI 10.1086/171493; HAAS MR, 1982, ICARUS, V51, P476, DOI 10.1016/0019-1035(82)90141-5; HAMANN F, 1986, ASTROPHYS J, V311, P909, DOI 10.1086/164828; HOLLENBACH D, 1994, ASTROPHYS J, V428, P654, DOI 10.1086/174276; KIM KJ, 1990, SCIENCE, V250, P88, DOI 10.1126/science.250.4977.88; KROLIK JH, 1978, ASTROPHYS J SUPPL S, V37, P459, DOI 10.1086/190538; MARTINPINTADO J, 1989, ASTRON ASTROPHYS, V215, pL13; MARTINPINTADO J, 1989, A A, V229, pL9; MASERS, 1984, ENCY AM; MATTHEWS S, 1977, 73204 X NASA, P1; MENTEN KM, 1995, ASTROPHYS J, V450, pL67, DOI 10.1086/316776; Merrill PW, 1933, ASTROPHYS J, V78, P87, DOI 10.1086/143490; Mumma M. J., 1993, ASTROPHYSICAL MASERS, P455; MUMMA MJ, 1981, SCIENCE, V212, P45, DOI 10.1126/science.212.4490.45; POPOULAR R, 1983, ASTRON ASTROPHYS, V117, P46; RODRIGUEZ LF, 1994, ASTROPHYS J, V428, P324, DOI 10.1086/174243; SCOVILLE N, 1983, ASTROPHYS J, V275, P201, DOI 10.1086/161526; SEATON MJ, 1959, MON NOT R ASTRON SOC, V119, P90, DOI 10.1093/mnras/119.2.90; SHU FH, 1993, ICARUS, V106, P92, DOI 10.1006/icar.1993.1160; SMITH H, UNPUB; SMITH HA, 1979, ASTROPHYS J, V233, P132, DOI 10.1086/157374; STEPANOVA GI, 1985, SOV ASTRON LETT, V11, P390; STOREY PJ, 1995, MON NOT R ASTRON SOC, V272, P41, DOI 10.1093/mnras/272.1.41; STRELENITSKI VS, 1994, P AIRB ASTR S GAL EC; STRELNITSKI VS, IN PRESS ASTROPHYS J; STRELNITSKI VS, 1996, AMAZING LIGHT, P603; THOMPSON RI, 1977, ASTROPHYS J, V218, P170, DOI 10.1086/155668; THUM C, 1995, ASTRON ASTROPHYS, V300, P843; THUM C, 1994, ASTRON ASTROPHYS, V283, P582; THUM C, 1992, ASTRON ASTROPHYS, V256, P507; THUM C, 1994, ASTRON ASTROPHYS, V288, pL25; WEAVER H, 1965, NATURE, V208, P29, DOI 10.1038/208029a0	41	42	42	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1459	1461		10.1126/science.272.5267.1459	http://dx.doi.org/10.1126/science.272.5267.1459			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633236	Green Published			2022-12-24	WOS:A1996UP89900040
J	Hiley, CMH; Morley, CJ				Hiley, CMH; Morley, CJ			Risk factors for sudden infant death syndrome: Further change in 1992-3	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT PAEDIAT,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge				Morley, Colin/0000-0001-5388-0214				HILEY CMH, 1994, BRIT MED J, V309, P703, DOI 10.1136/bmj.309.6956.703; 1994, OPCS MONITOR	2	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1996	312	7043					1397	1398						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP434	8646098	Green Published			2022-12-24	WOS:A1996UP43400025
J	Mamode, N; Scott, RN; McLaughlin, SC; McLelland, A; Pollock, JG				Mamode, N; Scott, RN; McLaughlin, SC; McLelland, A; Pollock, JG			Perioperative myocardial infarction in peripheral vascular surgery	BRITISH MEDICAL JOURNAL			English	Article									GLASGOW ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G31 2ER,LANARK,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT BIOCHEM,GLASGOW G31 2ER,LANARK,SCOTLAND	University of Glasgow; University of Glasgow	Mamode, N (corresponding author), GLASGOW ROYAL INFIRM,PERIPHERAL VASC UNIT,GLASGOW G31 2ER,LANARK,SCOTLAND.							KALRA M, 1993, BRIT J SURG, V80, P28, DOI 10.1002/bjs.1800800110; MAMODE N, 1995, BMJ-BRIT MED J, V310, P1215, DOI 10.1136/bmj.310.6989.1215; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; TAYLOR LM, 1991, J VASC SURG, V15, P52; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1996	312	7043					1396	1397		10.1136/bmj.312.7043.1396	http://dx.doi.org/10.1136/bmj.312.7043.1396			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP434	8646097	Green Published			2022-12-24	WOS:A1996UP43400024
J	Niemeyer, BA; Suzuki, E; Scott, K; Jalink, K; Zuker, CS				Niemeyer, BA; Suzuki, E; Scott, K; Jalink, K; Zuker, CS			The Drosophila light-activated conductance is composed of the two channels TRP and TRPL	CELL			English	Article							RETINAL-DEGENERATION; PHOTORECEPTOR DEACTIVATION; PROTEIN; GENE; MUTANT; PHOTOTRANSDUCTION; MELANOGASTER; RHODOPSIN; CA2+; MEMBRANE	Drosophila phototransduction is a G protein-coupled, calcium-regulated signaling cascade that serves as a model system for the dissection of phospholipase C (PLC) signaling in vivo. The Drosophila light-activated conductance is constituted in part by the transient receptor potential (trp) ion channel, yet trp mutants still display a robust response demonstrating the presence of additional channels. The transient receptor potential-like (trpl) gene encodes a protein displaying 40% amino acid identity with TRP. Mammalian homologs of TRP and TRPL recently have been isolated and postulated to encode components of the elusive I-crac conductance. We now show that TRP and TRPL localize to the membrane of the transducing organelle, together with rhodopsin and PLC, consistent with a role in PLC signaling during phototransduction. To determine the function of TRPL in vivo, we isolated trpl mutants and characterized them physiologically and genetically. We demonstrate that the light-activated conductance is composed of TRP and TRPL ion channels and that each can be activated on its own. We also use genetic and electrophysiological tools to study the contribution of each channel type to the light response and show that TRP and TRPL can serve partially overlapping functions.	UNIV TOKYO, INST MED SCI, TOKYO, JAPAN	University of Tokyo	Niemeyer, BA (corresponding author), UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, DEPT NEUROSCI, DEPT BIOL, LA JOLLA, CA 92093 USA.		Niemeyer, Barbara A./AAL-8972-2021	Jalink, Kees/0000-0001-7019-3440; Niemeyer, Barbara A./0000-0002-6963-0575; Suzuki, Emiko/0000-0002-4005-0542				BACIGALUPO J, 1990, SER CENT ES, P27; BACIGALUPO J, 1995, J NEUROSCI, V15, P7196; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BARASH S, 1988, J GEN PHYSIOL, V92, P307, DOI 10.1085/jgp.92.3.307; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; DECOUET HG, 1987, EUR J CELL BIOL, V44, P50; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DOLPH PJ, 1994, NATURE, V370, P59, DOI 10.1038/370059a0; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; HARDIE RC, 1993, P ROY SOC B-BIOL SCI, V252, P223, DOI 10.1098/rspb.1993.0069; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HARRIS WA, 1977, J GEN PHYSIOL, V69, P261, DOI 10.1085/jgp.69.3.261; HOCHSTRATE P, 1989, J COMP PHYSIOL A, V166, P179, DOI 10.1007/BF00193462; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kumar JP, 1995, DEVELOPMENT, V121, P4359; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; MINKE B, 1975, NATURE, V258, P84, DOI 10.1038/258084a0; MINKE B, 1991, PROG RETIN RES, V11, P99, DOI 10.1016/0278-4327(91)90026-X; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PAK WL, 1976, SCIENCE, V194, P956, DOI 10.1126/science.824732; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PERETZ A, 1994, J GEN PHYSIOL, V104, P1057, DOI 10.1085/jgp.104.6.1057; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; POLLOCK JA, 1995, J NEUROSCI, V15, P3747; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STIEVE H, 1986, MOL MECHANISM PHOTOR, P199; SUZUKI E, 1993, J ELECTRON MICROSC, V42, P178; SUZUKI E, 1994, J ELECTRON MICROSC, V43, P183; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; VIHTELIC TS, 1991, GENETICS, V127, P761; Wolff Tanya, 1993, P1277; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; YEANDLE S, 1957, THESIS J HOPKINS U; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	59	290	295	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 31	1996	85	5					651	659		10.1016/S0092-8674(00)81232-5	http://dx.doi.org/10.1016/S0092-8674(00)81232-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646774	Bronze			2022-12-24	WOS:A1996UP34400006
J	Subramaniam, VN; Peter, F; Philp, R; Wong, SH; Hong, WJ				Subramaniam, VN; Peter, F; Philp, R; Wong, SH; Hong, WJ			GS28, a 28-kilodalton Golgi SNARE that participates in ER-Golgi transport	SCIENCE			English	Article							VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; FUSION; RECEPTORS; PROTEIN; FAMILY	Little is known about the integral membrane proteins that participate in the early secretory pathway of mammalian cells. The complementary DNA encoding a 28-kilodalton protein (p28) of the cis-Golgi was cloned and sequenced. The protein was predicted to contain a central coiled-coil domain with a carboxyl-terminal membrane anchor. An in vitro assay for endoplasmic reticulum-Golgi transport was used to show that p28 participates in the docking and fusion stage of this transport event. Biochemical studies established that p28 is a core component of the Golgi SNAP receptor (SNARE) complex.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,MEMBRANE BIOL LAB,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Subramaniam, V. Nathan/A-1901-2010; HONG, Wanjin/E-9927-2010	Subramaniam, V. Nathan/0000-0002-4583-7790; 				ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MCMAHON HT, 1994, J CELL BIOL, V125, P1015; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOGAARD M, 1994, CELL, V78, P936; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TANG BL, 1994, EUR J CELL BIOL, V65, P298; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	22	122	127	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1996	272	5265					1161	1163		10.1126/science.272.5265.1161	http://dx.doi.org/10.1126/science.272.5265.1161			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638159				2022-12-24	WOS:A1996UM88900047
J	Subramanya, HS; Doherty, AJ; Ashford, SR; Wigley, DB				Subramanya, HS; Doherty, AJ; Ashford, SR; Wigley, DB			Crystal structure of an ATP-dependent DNA ligase from bacteriophage T7	CELL			English	Article							RNA CAPPING ENZYME; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; ESCHERICHIA-COLI; GENE; GUANYLYLTRANSFERASE; DOMAIN; CDNA	The crystal structure of the ATP-dependent DNA ligase from bacteriophage T7 has been solved at 2.6 Angstrom resolution. The protein comprises two domains with a deep cleft running between them. The structure of a complex with ATP reveals that the nucleotide binding pocket is situated on the larger N-terminal domain, at the base of the cleft between the two domains of the enzyme. Comparison of the overall domain structure with that of DNA methyltransferases, coupled with other evidence, suggests that DNA also binds in this cleft. Since this structure is the first of the nucleotidyl-transferase superfamily, which includes the eukaryotic mRNA capping enzymes, the relationship between the structure of DNA ligase and that of other nucleotidyl-transferases is also discussed.			Subramanya, HS (corresponding author), UNIV OXFORD,MOLEC BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND.			Doherty, Aidan/0000-0002-6370-1109	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BAYMILLER J, 1994, GENE, V142, P129, DOI 10.1016/0378-1119(94)90367-0; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHENG XD, 1995, CURR OPIN STRUC BIOL, V5, P4, DOI 10.1016/0959-440X(95)80003-J; CONG PJ, 1995, MOL CELL BIOL, V15, P6222; CONG PJ, 1993, J BIOL CHEM, V268, P7256; DOHERTY AJ, 1996, IN PRESS J BIOL CHEM; DOHERTY AJ, 1996, IN PRESS NUCL ACIDS; DUNN JJ, 1981, J MOL BIOL, V148, P303, DOI 10.1016/0022-2836(81)90178-9; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; GELLERT M, 1967, P NATL ACAD SCI USA, V57, P148, DOI 10.1073/pnas.57.1.148; HAMMOND JM, 1992, NUCLEIC ACIDS RES, V20, P2667, DOI 10.1093/nar/20.11.2667; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; LI Y, 1995, VIROLOGY, V212, P134, DOI 10.1006/viro.1995.1462; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; MODRICH P, 1973, J BIOL CHEM, V248, P7502; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OKAZAKI R, 1968, P NATL ACAD SCI USA, V59, P598, DOI 10.1073/pnas.59.2.598; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Sheldrick G. M., 1991, CRYSTALLOGRAPHIC COM, V5, P145; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1995, VIROLOGY, V211, P73, DOI 10.1006/viro.1995.1380; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; SODERHALL S, 1976, NATURE, V260, P640, DOI 10.1038/260640a0; Tan GT, 1996, BIOCHEM J, V314, P993, DOI 10.1042/bj3140993; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Wilson AJC, 1942, NATURE, V150, P151, DOI 10.1038/150152a0	44	206	209	1	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					607	615		10.1016/S0092-8674(00)81260-X	http://dx.doi.org/10.1016/S0092-8674(00)81260-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653795	Bronze			2022-12-24	WOS:A1996UM41500017
J	Petrie, KJ; Weinman, J; Sharpe, N; Buckley, J				Petrie, KJ; Weinman, J; Sharpe, N; Buckley, J			Role of patients' view of their illness in predicting return to work and functioning after myocardial infarction: Longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC REHABILITATION	Objective-To examine whether patients' initial perceptions of their myocardial infarction predict subsequent attendance at a cardiac rehabilitation course, return to work, disability, and sexual dysfunction. Design-Patients' perceptions of their illness were measured at admission with their first myocardial infarction and at follow up three and six months later. Setting-Two large teaching hospitals in Auckland, New Zealand. Subjects-143 consecutive patients aged under 65 with their first myocardial infarction. Main outcome measures-Attendance at rehabilitation course; time before returning to work; measures of disability with sickness impact profile questionnaire for sleep and rest, social interaction, recreational activity, and home management; and sexual dysfunction. Results-Attendance at the rehabilitation course was significantly related to a stronger belief during admission that the illness could be cured or controlled (t=2.08, P=0.04), Return to work within six weeks was significantly predicted by the perception that the illness would last a short time (t=-2.52, P=0.01) and have less grave consequences for the patient (t=-2.87, P=0.005), Patients' belief that their heart disease would have serious consequences was significantly related to later disability in work around the house, recreational activities, and social interaction, A strong illness identity was significantly related to greater sexual dysfunction at both three and six months. Conclusions-Patients' initial perceptions of illness are important determinants of different aspects of recovery after myocardial infarction, Specific illness perceptions need to be identified at an early stage as a basis for optimising outcomes from rehabilitation programmes.	UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,UNIT PSYCHOL,LONDON SE1 9RT,ENGLAND; UNIV AUCKLAND,SCH MED,DEPT MED,AUCKLAND,NEW ZEALAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Auckland	Petrie, KJ (corresponding author), UNIV AUCKLAND,SCH MED,DEPT PSYCHIAT & BEHAV SCI,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.			Buckley, Judith/0000-0003-0374-5369				ADES PA, 1992, ARCH INTERN MED, V152, P1033, DOI 10.1001/archinte.152.5.1033; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BYRNE DG, 1982, J PSYCHOSOM RES, V26, P105, DOI 10.1016/0022-3999(82)90028-9; DIEDERIKS JPM, 1991, J PSYCHOSOM RES, V35, P687, DOI 10.1016/0022-3999(91)90119-9; FLAPAN AD, 1994, BMJ-BRIT MED J, V309, P1129, DOI 10.1136/bmj.309.6962.1129; GARRITY TF, 1973, SOC SCI MED, V7, P705, DOI 10.1016/0037-7856(73)90004-8; GARRITY TF, 1975, PSYCHOL ASPECTS MYOC; GOBLE AJ, 1991, BRIT HEART J, V65, P126; Leventhal H., 1980, MED PSYCHOL, V2, P7; Ley P., 1988, COMMUNICATING PATIEN; LIPKIN DP, 1991, BRIT HEART J, V65, P237; LOGAN RL, 1986, NEW ZEAL MED J, V99, P368; MAELAND JG, 1987, J PSYCHOSOM RES, V31, P471, DOI 10.1016/0022-3999(87)90005-5; Skelton JA, 1991, MENTAL REPRESENTATIO; Stewart AL, 1992, MEASURING FUNCTIONIN; Weinman J, 1996, PSYCHOL HEALTH, V11, P114	16	464	472	0	28	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1191	1194						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UL058	8634561				2022-12-24	WOS:A1996UL05800016
J	Strachan, DP; Butland, BK; Anderson, HR				Strachan, DP; Butland, BK; Anderson, HR			Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort	BRITISH MEDICAL JOURNAL			English	Article							RISK FACTOR; NATURAL-HISTORY; BIRTH; PREMATURITY; CHILDREN	Objective-To describe the incidence and prognosis of wheezing illness from birth to age 33 and the relation of incidence to, perinatal, medical, social, environmental, and lifestyle factors. Design-Prospective longitudinal study. Setting-England, Scotland, and Wales. Subjects-18 559 people born on 3-9 March 1958. 5801 (31%) contributed information at ages 7, 11, 16, 23, and 33 years. Attrition bias was evaluated using information on 14 571 (79%) subjects. Main outcome measure-History of asthma, wheezy bronchitis, or wheezing obtained from interview with subjects' parents at ages 7, 11, and 16 and reported at interview by subjects at ages 23 and 33. Results-The cumulative incidence of wheezing illness was 18% by age 7, 24% by age 16, and 43% by age 33. Incidence during childhood was strongly and independently associated with pneumonia, hay fever, and eczema. There were weaker independent associations with male sex, third trimester antepartum haemorrhage, whooping cough, recurrent abdominal pain, and migraine. Incidence from age 17 to 33 was associated strongly with active cigarette smoking and a history of hay fever. There were weaker independent associations with female sex, maternal albuminuria during pregnancy, and histories of eczema and migraine. Maternal smoking during pregnancy was weakly and inconsistently related to childhood wheezing but was a stronger and significant independent predictor of incidence after age 16. Among 880 subjects who developed asthma or wheezy bronchitis from birth to age 7, 50% had attacks in the previous year at age 7; 18% at 11, 10% at 16, 10% at 23, and 27% at 33. Relapse at 33 after prolonged remission of childhood wheezing was more common among current smokers and atopic subjects. Conclusion-Atopy and active cigarette smoking are major influences on the incidence and recurrence of wheezing during adulthood.			Strachan, DP (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Anderson, Hugh R/A-7417-2016	Butland, Barbara/0000-0001-9952-3108				ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; ANDERSON HR, 1987, CHEST, V91, pS127, DOI 10.1378/chest.91.6.127S; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; BUTLER NR, 1969, PERINATAL PROBLEMS; Davie R., 1972, BIRTH 7 2 REPORT CHI; DOLOVICH J, 1981, THORAX, V36, P641, DOI 10.1136/thx.36.9.614; FERRI E, 1993, LIFE 33 5 FOLLOW UP; Fogelman K., 1976, BRITAINS 16 YEAR OLD; GILES GG, 1984, AUST NZ J MED, V14, P631, DOI 10.1111/j.1445-5994.1984.tb05015.x; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; JONES A, 1994, BRIT J GEN PRACT, V44, P127; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312, DOI 10.1164/ajrccm/143.2.312; RONA RJ, 1993, BMJ-BRIT MED J, V306, P817, DOI 10.1136/bmj.306.6881.817; *SAS SYST, 1990, SAS STAT US GUID VER; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1985, J ROY COLL GEN PRACT, V35, P182; VONMUTIUS E, 1993, J PEDIATR-US, V123, P223, DOI 10.1016/S0022-3476(05)81692-0	21	476	478	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1195	1199						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634562				2022-12-24	WOS:A1996UL05800018
J	Gash, DM; Zhang, ZM; Ovadia, A; Cass, WA; Yi, A; Simmerman, L; Russell, D; Martin, D; Lapchak, PA; Collins, F; Hoffer, BJ; Gerhardt, GA				Gash, DM; Zhang, ZM; Ovadia, A; Cass, WA; Yi, A; Simmerman, L; Russell, D; Martin, D; Lapchak, PA; Collins, F; Hoffer, BJ; Gerhardt, GA			Functional recovery in parkinsonian monkeys treated with GDNF	NATURE			English	Article							L-DOPA; NEURONS	PARKINSON's disease results from the progressive degeneration of dopamine neurons that innervate the striatum(1,2). In rodents, glial-cell-line-derived neurotrophic factor (GDNF) stimulates an increase in midbrain dopamine levels, protects dopamine neurons from some neurotoxins, and maintains injured dopamine neurons(3-9). Here we extend the rodent studies to an animal closer to the human in brain organization and function, by evaluating the effects of GDNF injected intracerebrally into rhesus monkeys that have had the symptomatology and pathophysiological features of Parkinson's disease induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)(10-14). The recipients of GDNF displayed significant improvements in three of the cardinal symptoms of parkinsonism: bradykinesia, rigidity and postural instability. GDNF administered every four weeks maintained functional recovery. On the lesioned side of GDNF-treated animals, dopamine levels in the midbrain and globus pallidus were twice as high, and nigral dopamine neurons were, on average, 20% larger, with an increased fibre density. The results indicate that GDNF may be of benefit in the treatment of Parkinson's disease.	AMGEN INC,THOUSAND OAKS,CA 91320; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,NEUROSCI TRAINING PROGRAM,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PSYCHIAT,NEUROSCI TRAINING PROGRAM,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,ROCKY MT CTR SENSOR TECHNOL,DENVER,CO 80262	Amgen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gash, DM (corresponding author), UNIV KENTUCKY,COLL MED,DEPT ANAT & NEUROBIOL,LEXINGTON,KY 40536, USA.		Lapchak, Paul/P-1845-2019	Lapchak, Paul/0000-0003-4413-7554; Gash, Don/0000-0002-2504-2528				BANKIEWICZ K, 1993, EXP NEUROL, V124, P140, DOI 10.1006/exnr.1993.1185; BANKIEWICZ KS, 1986, LIFE SCI, V39, P7, DOI 10.1016/0024-3205(86)90431-5; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DOUGLE KL, 1995, P NATL ACAD SCI USA, V92, P1669; GASH OM, 1995, J COMP NEUROL, V363, P345; GREENAMYRE JT, 1994, ANN NEUROL, V35, P655, DOI 10.1002/ana.410350605; HARDING AJ, 1994, J NEUROSCI METH, V51, P83, DOI 10.1016/0165-0270(94)90028-0; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; HOMYKIEWICZ O, 1986, ADV NEUROL, V45, P19; HUDSON J, 1995, BRAIN RES BULL, V36, P425, DOI 10.1016/0361-9230(94)00224-O; Jellinger K, 1986, ADV NEUROL, V45, P1; KEAMS CM, 1995, BRAIN RES, V672, P104; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; OVADIA A, 1995, NEUROBIOL AGING, V16, P931, DOI 10.1016/0197-4580(95)02012-8; ROBERTSON GS, 1988, NEUROSCI LETT, V89, P204, DOI 10.1016/0304-3940(88)90382-5; ROBERTSON GS, 1989, J NEUROSCI, V9, P3326; SMITH RD, 1993, NEUROSCIENCE, V52, P7, DOI 10.1016/0306-4522(93)90176-G; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O	22	809	852	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					252	255		10.1038/380252a0	http://dx.doi.org/10.1038/380252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637574				2022-12-24	WOS:A1996UB11700053
J	Bifani, PJ; Plikaytis, BB; Kapur, V; Stockbauer, K; Pan, X; Lutfey, ML; Moghazeh, SL; Eisner, W; Daniel, TM; Kaplan, MH; Crawford, JT; Musser, JM; Kreiswirth, BN				Bifani, PJ; Plikaytis, BB; Kapur, V; Stockbauer, K; Pan, X; Lutfey, ML; Moghazeh, SL; Eisner, W; Daniel, TM; Kaplan, MH; Crawford, JT; Musser, JM; Kreiswirth, BN			Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EPIDEMIOLOGY; POLYMORPHISM; TOOL	Objective.-To determine whether isolates of Mycobacterium tuberculosis from New York and elsewhere that are resistant to four or more primary antimicrobial agents and responsible for widespread disease in the 1990s represent a newly emerged clone or a heterogeneous array of unrelated organisms. Setting.-New York City area and selected locations in the United States. Patients.-M tuberculosis isolates from 1953 patients in New York and multidrug-resistant isolates from six patients from other US communities. Design.-Convenience sample of all M tuberculosis strains (M tuberculosis isolates resistant to rifampin, streptomycin, isoniazid, and ethambutol, and sometimes ethionamide, kanamycin, capreomycin, or ciprofloxacin) submitted to the Public Health Research Institute Tuberculosis Center since 1991 and samples submitted to the Centers for Disease Control and Prevention from throughout the United States, The samples submitted were representative of the New York City strains of M tuberculosis. Main Outcome Measure.-Characterization of resistant M tuberculosis strains studied by IS6110 and polymorphic CC-rich repetitive sequence (PGRS) hybridization patterns, multiplex polymerase chain reaction (PCR) analysis, and automated DNA sequencing of genes containing mutations associated with resistance to rifampin (rpoB), isoniazid (katG and inhA locus), and streptomycin (strA and rrs). Results.-Multidrug-resistant M tuberculosis isolates were recovered from 253 New York City patients and had the same or closely allied IS6110 and PGRS patterns, multiplex PCR type, and gene mutations associated with resistance to rifampin, isoniazid, and streptomycin. Isolates with these same molecular characteristics were recovered from patients in Florida and Nevada, health care workers in Atlanta, Ga, and Miami, Fla, and an individual who recently moved from New York City to Denver, Cole, and caused disease or skin test conversion in at least 12 people in a nursing home environment. Conclusions.-The results document the molecular origin and spread of progeny of a closely related family of multidrug-resistant M tuberculosis strains that have recently shared a common ancestor and undergone clonal expansion. The multidrug-resistant phenotype in these organisms arose by sequential acquisition of resistance-conferring mutations in several genes, most likely as a consequence of antibiotic selection of randomly occurring mutants in concert with inadequately treated infections. Dissemination of these difficult-to-treat bacteria throughout New York City and to at least four additional US cities has adverse implications for tuberculos control in the 21st century.	PUBL HLTH RES INST,TB CTR,NEW YORK,NY 10016; BAYLOR COLL MED,DEPT PATHOL,SECT MOLEC PATHOBIOL,HOUSTON,TX; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30341; N SHORE UNIV HOSP,MANHASSET,NY 11030; CASE WESTERN RESERVE UNIV,CTR INT HLTH,CLEVELAND,OH	Baylor College of Medicine; Centers for Disease Control & Prevention - USA; Northwell Health; North Shore University Hospital; Case Western Reserve University			Kapur, Vivek/F-7610-2013	Kapur, Vivek/0000-0002-9648-0138; Bifani, Pablo/0000-0001-9651-6439	NIAID NIH HHS [R01-AI37004] Funding Source: Medline; NIDA NIH HHS [R01-DA09238] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009238] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; HEWLETT D, 1995, INFECT DIS CLIN PRAC, V4, P389, DOI 10.1097/00019048-199509000-00020; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; HORN DL, IN PRESS INFECT DIS; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; LONGUET P, 1995, 35TH INT C ANT AG CH; MUSSER JM, 1995, CLIN MICROBIOL REV, V8, P496, DOI 10.1128/CMR.8.4.496; PLIKAYTIS BB, 1994, J CLIN MICROBIOL, V32, P1542, DOI 10.1128/JCM.32.6.1542-1546.1994; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SEPKOWITZ KA, 1994, CLIN INFECT DIS, V18, P755, DOI 10.1093/clinids/18.5.755; SIDDIQI S, 1989, BACTEC TB SYSTEMS PR; SMALL PM, 1993, INFECT AGENT DIS, V2, P132; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; 1991, MMWR MORBID MORTAL W, V40, P585; 1992, MMWR MORBID MORTAL W, V41, P507; 1990, NCCLS M24P NAT COMM	26	319	336	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					452	457		10.1001/jama.275.6.452	http://dx.doi.org/10.1001/jama.275.6.452			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627966				2022-12-24	WOS:A1996TU63800033
J	Goldberg, L				Goldberg, L			Adverse effects of anabolic steroids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ANDROGENIC STEROIDS; TESTOSTERONE; ATHLETE				Goldberg, L (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201, USA.							CREAGH TM, 1988, J CLIN PATHOL, V41, P441, DOI 10.1136/jcp.41.4.441; FRANKLE MA, 1988, ARCH PHYS MED REHAB, V69, P632; GRUNEWALD KK, 1993, SPORTS MED, V15, P90, DOI 10.2165/00007256-199315020-00003; HAUPT HA, 1984, AM J SPORT MED, V12, P469, DOI 10.1177/036354658401200613; HEYDENREICH G, 1989, ARCH DERMATOL, V125, P571, DOI 10.1001/archderm.1989.01670160119036; JOHNSON FL, 1975, LANCET, V1, P1294; MAUGHAN RJ, 1995, INT J SPORT NUTR, V5, P94, DOI 10.1123/ijsn.5.2.94; MCDONALD EC, 1978, JAMA-J AM MED ASSOC, V240, P243, DOI 10.1001/jama.240.3.243; MCNUTT RA, 1988, AM J CARDIOL, V62, P164, DOI 10.1016/0002-9149(88)91390-2; MESSERLI FH, 1979, ARCH INTERN MED, V139, P682, DOI 10.1001/archinte.139.6.682; MOKROHISKY ST, 1977, NEW ENGL J MED, V296, P1411; MOORE WV, 1988, JAMA-J AM MED ASSOC, V260, P3484, DOI 10.1001/jama.260.23.3484; OVERLY WL, 1984, ANN INTERN MED, V100, P158, DOI 10.7326/0003-4819-100-1-158_3; POPE HG, 1988, AM J PSYCHIAT, V145, P487; Ruden T. M., 1996, Medicine and Science in Sports and Exercise, V28, pS81; SCOTT MJ, 1989, JAMA-J AM MED ASSOC, V262, P207, DOI 10.1001/jama.1989.03430020049017; Shephard R J, 1977, Br J Sports Med, V11, P170; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001/jama.261.8.1165; WEBB OL, 1984, METABOLISM, V33, P971, DOI 10.1016/0026-0495(84)90222-1; [No title captured]	20	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					257	257						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667574				2022-12-24	WOS:A1996UW46900041
J	Horton, R				Horton, R			Playing with smoke, but not without fire	LANCET			English	Editorial Material																		Carnall D, 1996, BMJ-BRIT MED J, V312, P721; MASSING M, 1996, NEW YORK REV BO 0711, P32; Roberts J, 1996, BMJ-BRIT MED J, V312, P133; Szende B, 1996, EUR J CANCER, V32A, P1102, DOI 10.1016/0959-8049(96)00006-8	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1782	1782		10.1016/S0140-6736(96)91614-1	http://dx.doi.org/10.1016/S0140-6736(96)91614-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667920				2022-12-24	WOS:A1996UU46900007
J	Zenke, FT; Engels, R; Vollenbroich, V; Meyer, J; Hollenberg, CP; Breunig, KD				Zenke, FT; Engels, R; Vollenbroich, V; Meyer, J; Hollenberg, CP; Breunig, KD			Activation of Gal4p by galactose-dependent interaction of galactokinase and Gal80p	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; KLUYVEROMYCES-LACTIS; GLUCOSE REPRESSION; ESCHERICHIA-COLI; GENE-EXPRESSION; PROTEIN; YEAST; INDUCTION; REGULON; PHENOTYPE	Yeast galactokinase (Gal1p) is an enzyme and a regulator of transcription. In addition to phosphorylating galactose, Gal1p activates Gal4p, the activator of GAL genes, but the mechanism of this regulation has been unclear. Here, biochemical and genetic evidence is presented to show that Gal1p activates Gal4p by direct interaction with the Gal4p inhibitor Gal80p. interaction requires galactose, adenosine triphosphate, and the regulatory function of Gal1p. These data indicate that Gal1p-Gal80p complex formation results in the inactivation of Gal80p, thereby transmitting the galactose signal to Gal4p.	UNIV DUSSELDORF,INST MIKROBIOL,D-40225 DUSSELDORF,GERMANY	Heinrich Heine University Dusseldorf			Breunig, Karin D./B-1929-2009	Zenke, Frank/0000-0002-2226-3755				AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; BHAT PJ, 1990, GENETICS, V125, P281; BHAT PJ, 1992, MOL CELL BIOL, V12, P2701, DOI 10.1128/MCB.12.6.2701; BIANCHI MM, 1987, CURR GENET, V12, P185, DOI 10.1007/BF00436877; CROWE J, 1990, METHOD MOL BIOL, P371; FISHER JA, 1988, NATURE, V332, P853; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; MEYER J, 1991, MOL CELL BIOL, V11, P5454, DOI 10.1128/MCB.11.11.5454; MEYER J, 1993, THESIS H HEINE U DUS; MEYER JMM, UNPUB; RILEY MI, 1987, MOL CELL BIOL, V7, P780, DOI 10.1128/MCB.7.2.780; ROSE M, 1991, EUR J BIOCHEM, V199, P511, DOI 10.1111/j.1432-1033.1991.tb16149.x; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SALMERON JM, 1989, MOL CELL BIOL, V9, P2950, DOI 10.1128/MCB.9.7.2950; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; ZACHARIAE W, 1994, THESIS H HEINE U DUS; ZENKE FT, 1993, MOL CELL BIOL, V13, P7566, DOI 10.1128/MCB.13.12.7566; ZENKE FT, 1995, THESIS H HEINE U DUS	23	127	131	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1996	272	5268					1662	1665		10.1126/science.272.5268.1662	http://dx.doi.org/10.1126/science.272.5268.1662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658143				2022-12-24	WOS:A1996UR09300050
J	Vassar, MJ; Kizer, KW				Vassar, MJ; Kizer, KW			Hospitalizations for firearm-related injuries - A population-based study of 9562 patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URBAN TRAUMA CENTER; HOMICIDE	Objective.-To determine the incidence, nature, demographics, severity, and hospital charges associated with inpatient treatment of firearm-related injuries. Design.-A retrospective, 1-year, population-based study of firearm-related hospitalizations based on the 1991 California Hospital Discharge Abstract Data Tapes. Setting.-California acute care hospitals that reported firearm-related discharges. Patients.-A total of 9562 patients discharged with firearm-related injuries. Main Outcome Measures.-Per capita hospital discharge rates, according to age, race, and sex. Results.-A total of 9562 firearm-injured persons were discharged from California hospitals in 1991, representing a rate of 32 discharges per 100 000 population, Males aged 15 to 24 years accounted for 72% of the hospitalizations. For all causes of firearm-related injury, the highest age- and race-specific discharge rate was 439 per 100 000 for black persons aged 15 to 24 years, The highest county discharge rate was 55 per 100 000 for Los Angeles County. Statewide, there were 1.8 hospital discharges per firearm-related fatality (both in the hospital and in the community). Assaults accounted for 74% of cases, Among black males aged 15 to 24 years, assaults accounted for 598 discharges per 100 000 population. Hospital charges for 9193 patients exceeded $164 million; mean and median charges per patient discharged were $17 888 and $8535, respectively, Publicly financed health insurance programs sponsored 56% of patients; 25% had private insurance, and 19% were uninsured, Fifty-three percent of the discharges occurred at 13 of the 371 hospitals that discharged patients with firearm-related injuries. Conclusions.-Firearm-related violence is a major cause of hospitalization of young urban black males and represents a significant cost to publicly financed health care, The impact on individual hospitals is highly disproportionate, While hospital discharge data can be used for population-based surveillance of firearm-related trauma, there is need for improvement in local, state, and national surveillance of these injuries.	UNIV CALIF DAVIS,SCH MED,DAVIS,CA 95616	University of California System; University of California Davis			Vassar, Matt/AAD-5385-2020					ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; *CA DEP HLTH SERV, 1994, 4 EPIC CAL DEP HLTH; CLANCY TV, 1994, J TRAUMA, V37, P1, DOI 10.1097/00005373-199407000-00001; EASTMAN AB, 1994, J TRAUMA, V36, P835, DOI 10.1097/00005373-199406000-00014; FINE PR, 1994, J FORENSIC SCI, V39, P674; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; GRIFFITH EEH, 1989, JAMA-J AM MED ASSOC, V262, P2265, DOI 10.1001/jama.262.16.2265; HUTSON HR, 1994, NEW ENGL J MED, V330, P324, DOI 10.1056/NEJM199402033300506; *J HOPK HLTH SERV, 1989, DET INJ SEV HOSP DIS; KELLERMANN AL, 1992, J TRAUMA, V33, P1, DOI 10.1097/00005373-199207000-00001; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; KLEIN SR, 1991, AM SURGEON, V57, P793; LANGLOIS JA, 1995, AM J PUBLIC HEALTH, V85, P1261, DOI 10.2105/AJPH.85.9.1261; MARGANITT B, 1990, AM J PUBLIC HEALTH, V10, P1463; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; ORDOG GJ, 1995, J TRAUMA, V38, P291, DOI 10.1097/00005373-199502000-00029; OZONOFF V, 1995, MMWR-MORBID MORTAL W, V44, P160; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Rice DP, 1989, COST INJURY US REPOR; RIDDICK L, 1993, AM J FOREN MED PATH, V14, P216; ROPP L, 1992, JAMA-J AM MED ASSOC, V267, P2905, DOI 10.1001/jama.267.21.2905; RYAN M, 1993, AM SURGEON, V59, P831; SHELEY JF, 1995, PUBLIC HEALTH REP, V110, P18; SMITH RS, 1992, ARCH SURG-CHICAGO, V127, P668; SMITH SM, 1989, AM J PREV MED, V5, P296, DOI 10.1016/S0749-3797(18)31070-5; TARDIFF K, 1994, JAMA-J AM MED ASSOC, V272, P43, DOI 10.1001/jama.272.1.43; TARDIFF K, 1995, PUBLIC HEALTH REP, V110, P13; *US BUR CENS, 1990, 1990 CENS POP; *US DEP HHS, 1988, INT CLASS DIS 9 REV; *US GEN ACC OFF, 1991, TRAUM CAR LIF SYST; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; 1994, MONTHLY VITAL STAT R, V43, P1; 1994, MMWR-MORBID MORTAL W, V43, P37	37	35	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1734	1739		10.1001/jama.275.22.1734	http://dx.doi.org/10.1001/jama.275.22.1734			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637170				2022-12-24	WOS:A1996UP30700026
J	Pharoah, PDP; Hollingworth, W				Pharoah, PDP; Hollingworth, W			Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; MORTALITY; DEATH; TIME	Objectives-To estimate the cost effectiveness of statins in lowering serum cholesterol concentration in people at varying risk of fatal cardiovascular disease and to explore the implications of changing the criteria for intervention on cost and cost effectiveness for a purchasing authority. Design-A life table method was used to model the effect of treatment with a statin on survival over 10 years in men and women aged 45-64. The costs of intervention were estimated from the direct costs of treatment, offset by savings associated with a reduction in coronary angiographies, non-fatal myocardial infarctions, and revascularisation procedures. The robustness of the model to various assumptions was tested in a sensitivity analysis. Setting-Population of a typical district health authority. Main outcome measure-Cost per life year saved. Results-The average cost effectiveness of treating men aged 45-64 with no history of coronary heart disease and a cholesterol concentration >6,5 mmol/l for 10 years with a statin was pound 136 000 per life year saved. The average cost effectiveness for patients with pre-existing coronary heart disease and a cholesterol concentration >5.4 mmol/l was pound 32 000. These averages hide enormous differences in cost effectiveness between groups at different risk, ranging from pound 6000 per life year in men aged 55-64 who have had a myocardial infarction and whose cholesterol concentration is above 7.2 mmol/l to pound 361 000 per life year saved in women aged 45-54 with angina and a cholesterol concentration of 5.5-6.0 mmol/l. Conclusions-Lowering serum cholesterol concentration in patients with and without preexisting coronary heart disease is effective and safe, but treatment for all those in whom treatment is likely to be effective is not sustainable within current NHS resources. Data on cost effectiveness data should be taken into account when assessing who should be eligible for treatment.	FULBOURNE HOSP, CAMBRIDGE & HUNTINGDON HLTH COMMISS, CAMBRIDGE CB1 5EF, ENGLAND; UNIV CAMBRIDGE, INST PUBL HLTH, DEPT COMMUNITY MED, HLTH SERV RES GRP, CAMBRIDGE CB2 2SR, ENGLAND	University of Cambridge			Pharoah, Paul/V-6658-2019	Pharoah, Paul/0000-0001-8494-732X; Hollingworth, William/0000-0002-0840-6254				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; *BRIT MED ASS, 1995, ROYAL PHARM SOC GREA; BURR ML, 1989, LANCET, V2, P757; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *DEP HLTH, 1992, PUBL HLTH COMM DAT S; FROST PH, 1987, AM HEART J, V113, P1356, DOI 10.1016/0002-8703(87)90648-X; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GRODOS D, 1994, LANCET, V344, P1768; HAMILTON VH, 1995, JAMA-J AM MED ASSOC, V273, P1032, DOI 10.1001/jama.273.13.1032; Malik I., 1995, European Heart Journal, V16, P463; MARTENS LL, 1989, AM J MED, V87, pS54, DOI 10.1016/S0002-9343(89)80600-X; MARTENS LL, 1994, CLIN THER, V16, P1052; MARTIN MJ, 1986, LANCET, V2, P933; MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522; *NHS MAN EX, 1994, CAP INV MAN BUS CAS; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; ROSE G, 1977, LANCET, V1, P105; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SAWITZ E, 1988, JAMA-J AM MED ASSOC, V259, P2419, DOI 10.1001/jama.259.16.2419; SCULPHER MJ, 1994, LANCET, V344, P927, DOI 10.1016/S0140-6736(94)92274-8; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHELDON TA, 1992, J PUBLIC HEALTH MED, V14, P250; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1994, LANCET, V344, P1766; SUHONEN O, 1988, ACTA MED SCAND, V223, P19; ULVENSTAM G, 1984, PREV MED, V13, P355, DOI 10.1016/0091-7435(84)90027-6; White A, 1993, HLTH SURVEY ENGLAND	29	126	128	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	1996	312	7044					1443	1448		10.1136/bmj.312.7044.1443	http://dx.doi.org/10.1136/bmj.312.7044.1443			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664620	Green Published			2022-12-24	WOS:A1996UQ29600022
J	Chen, RT; Hausinger, S; Dajani, AS; Hanfling, M; Baughman, AL; Pallansch, MA; Patriarca, PA				Chen, RT; Hausinger, S; Dajani, AS; Hanfling, M; Baughman, AL; Pallansch, MA; Patriarca, PA			Seroprevalence of antibody against poliovirus in inner-city preschool children - Implications for vaccination policy in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARALYTIC POLIOMYELITIS; VACCINES; IMMUNOGENICITY; CHILDHOOD; RESPONSES; OUTBREAK; DISEASE; OMAN; LIVE	Objectives.-To assess susceptibility to poliomyelitis in selected inner-city preschool children in the United States and to estimate the contribution of secondary spread of live attenuated oral poliovirus vaccine virus to type-specific immunity, Design.-Cross-sectional seroprevalence study, Methods.-Serum neutralizing antibody levels against poliovirus types 1, 2, and 3 were analyzed according to vaccination status, agp, and other sociodemographic variables, Setting.-Hospital and satellite clinics serving inner-city populations in Houston, Tex, and Detroit, Mich, 1990 to 1991, Participants.-A total of 526 children aged 12 to 47 months seeking medical care were enrolled in the seroprevalence study; 144 children aged 12 to 35 months without a history of previous oral poliovirus vaccination were enrolled in the secondary spread study. Results.-Seropositive rates were similar in children in both cities, ranging from about 80% for types 1 and 3 in 12- to 23-month-old children to more than 90% in those aged 36 to 47 months. The most important predictor of seropositivity was the number of doses of oral poliovirus vaccine received (P<.01), with levels approximately 90% for all 3 serotypes among children who had received 3 or more doses. In children likely to have been unvaccinated, seropositive rates ranged from 9% to 18% for poliovirus types 1 and 3 and from 29% to 42% for type 2; secondary spread of vaccine virus appeared to have occurred among children who had previously received 1 dose or less but not those with 2 or more doses. Conclusions.-Levels of immunity to poliovirus among inner-city preschoolers are high and may be predicted by the number of doses of oral poliovirus vaccine received, Secondary spread of the vaccine virus plays a modest role in increasing polio immunity in inner-city populations, especially against types 1 and 3, This role will decrease in importance if the recently attained high levels of immunization coverage in the United States are sustained and if the risk of importation of wild poliovirus continues to diminish.	CTR DIS CONTROL & PREVENT, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA; BAYLOR COLL MED, SECT ACAD AMBULATORY PEDIAT, HOUSTON, TX 77030 USA; WAYNE STATE UNIV, SCH MED, DEPT PEDIAT, DETROIT, MI 48201 USA; CHILDRENS HOSP MICHIGAN, DIV INFECT DIS, DETROIT, MI 48201 USA	Centers for Disease Control & Prevention - USA; Wayne State University; Children's Hospital of Michigan	Chen, RT (corresponding author), CTR DIS CONTROL & PREVENT, NATL IMMUNIZATION PROGRAM E61, ATLANTA, GA 30333 USA.				PHS HHS [200-89-0735] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BENYESHMELNICK M, 1976, AM J EPIDEMIOL, V86, P112; BOTTIGER M, 1984, REV INFECT DIS, V6, pS548; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P337; CIRNE MD, 1995, J INFECT DIS, V171, P1097, DOI 10.1093/infdis/171.5.1097; COHENABBO A, 1995, PEDIATR INFECT DIS J, V14, P100, DOI 10.1097/00006454-199502000-00004; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; FADEN H, 1990, J INFECT DIS, V162, P1291, DOI 10.1093/infdis/162.6.1291; Finney D., 1964, STAT METHOD BIOL ASS, P524; Fleiss JL, 1981, STAT METHODS RATES P; FOX JP, 1960, PAN AM SANITARY BURE, V50, P144; Francis Thomas, 1957, EVALUATION 1954 FIEL; GARD S, 1959, 1 INT C LIV POL VACC, P350; GELFAND HM, 1959, PAN AM SANITARY BURE, V44, P203; HARDEGREE M C, 1970, Bulletin of the World Health Organization, V43, P461; HINMAN AR, 1988, AM J PUBLIC HEALTH, V78, P291, DOI 10.2105/AJPH.78.3.291; HINMAN AR, 1993, AM J DIS CHILD, V147, P536, DOI 10.1001/archpedi.1993.02160290042020; HORSTMANN DM, 1959, JAMA-J AM MED ASSOC, V170, P1; HOVI T, 1986, LANCET, V1, P1427; *I MED, 1988, PUBL IOM, V8804; KIMBALL AC, 1960, PAN AM SANITARY BURE, V50, P161; KOPROWSKI H, 1960, PAN AM SANITARY BURE, V44, P159; KUCHARSKA Z, 1982, J HYG EPID MICROB IM, V26, P74; MARWICK C, 1995, JAMA-J AM MED ASSOC, V274, P203, DOI 10.1001/jama.1995.03530030025009; MCBEAN AM, 1988, AM J EPIDEMIOL, V128, P615, DOI 10.1093/oxfordjournals.aje.a115009; MODLIN JF, 1993, 33 INT C ANT AG CHEM; MORINIERE BJ, 1993, LANCET, V341, P1545, DOI 10.1016/0140-6736(93)90693-B; *NAT IMM PROGR, 1994, BIOL SURV SUMM; NIGHTINGALE EO, 1977, NEW ENGL J MED, V297, P249, DOI 10.1056/NEJM197708042970505; OGRA PL, 1984, REV INFECT DIS, V6, pS361; ONORATO IM, 1991, J INFECT DIS, V163, P1, DOI 10.1093/infdis/163.1.1; OOSTVOGEL PM, 1994, LANCET, V344, P665, DOI 10.1016/S0140-6736(94)92091-5; PATRIARCA PA, 1988, LANCET, V1, P429; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; PAUL JR, 1960, 5TH INT POL C COP, P359; PETER G, 1995, AAP NEWS, V11, P13; PLOTKIN SA, 1995, PEDIATR INFECT DIS J, V14, P835, DOI 10.1097/00006454-199510000-00003; SABIN AB, 1961, AM J DIS CHILD, V101, P546, DOI 10.1001/archpedi.1961.04020060004002; SHALALA DE, 1993, JAMA-J AM MED ASSOC, V269, P1844, DOI 10.1001/jama.269.14.1844; SPRENT P, 1993, APPL NONPARAMETRIC S, P28; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; SUTTER RW, 1993, INT J EPIDEMIOL, V22, P936, DOI 10.1093/ije/22.5.936; Sutter RW, 1993, MEASLES POLIOMYELITI, P279; *US BUR CENS, 1994, COUNT CIT DAT BOOK 1; WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833; 1995, MMWR-MORBID MORTAL W, V44, P613; 1995, MMWR-MORBID MORTAL W, V44, P273; 1994, MMWR-MORBID MORTAL W, V43, P720	50	60	61	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1639	1645		10.1001/jama.275.21.1639	http://dx.doi.org/10.1001/jama.275.21.1639			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637136				2022-12-24	WOS:A1996UN25200025
J	Kiyokawa, H; Kineman, RD; ManovaTodorova, KO; Soares, VC; Hoffman, ES; Ono, M; Khanam, D; Hayday, AC; Frohman, LA; Koff, A				Kiyokawa, H; Kineman, RD; ManovaTodorova, KO; Soares, VC; Hoffman, ES; Ono, M; Khanam, D; Hayday, AC; Frohman, LA; Koff, A			Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1)	CELL			English	Article							MOUSE; FIBROBLASTS; THYMOCYTES; APOPTOSIS; MUTATION; G(1); P21	Disruption of the cyclin-dependent kinase-inhibitory domain of p27 enhances growth of mice. Growth is attributed to an increase in cell number, due to increased cell proliferation, most obviously in tissues that ordinarily express p27 at the highest levels. Disruption of p27 function leads to nodular hyperplasia in the intermediate lobe of the pituitary. However, increased growth occurs without an increase in the amounts of either growth hormone or IGF-I. In addition, female mice were infertile. Luteal cell differentiation is impaired, and a disordered estrus cycle is detected. These results reflect a disturbance of the hypothalamic-pituitary-ovarian axis. The phenotypes of these mice suggest that loss of p27 causes an alteration in cell proliferation that can lead to specific endocrine dysfunction.	UNIV ILLINOIS,DEPT MED,CHICAGO,IL 60612; YALE UNIV,DEPT BIOL,IMMUNOBIOL SECT,NEW HAVEN,CT 06511	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Yale University	Kiyokawa, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.		Kineman, Rhonda D/H-2221-2011	Kineman, Rhonda D/0000-0001-7322-1152; Kiyokawa, Hiroaki/0000-0002-7942-6455	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030667, R01DK030667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM052597, R01GM037759, R01GM052597] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK30667] Funding Source: Medline; NIGMS NIH HHS [GM37759, GM52597] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen IT, 1996, ONCOGENE, V12, P595; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COATS S, 1996, IN PRESS SCIENCE; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU NP, 1994, ONCOGENE, V9, P1021; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Koff A, 1995, Prog Cell Cycle Res, V1, P141; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORSTYN G, 1983, J CLIN INVEST, V72, P1877; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOSS TJ, 1996, CELL GROWTH DIFFER, V7, P135; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WILSON A, 1988, J IMMUNOL, V140, P1461; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; [No title captured]	43	1129	1153	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1996	85	5					721	732		10.1016/S0092-8674(00)81238-6	http://dx.doi.org/10.1016/S0092-8674(00)81238-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646780	hybrid			2022-12-24	WOS:A1996UP34400012
J	Wilkinson, P; Sayer, J; Laji, K; Grundy, C; Marchant, B; Kopelman, P; Timmis, AD				Wilkinson, P; Sayer, J; Laji, K; Grundy, C; Marchant, B; Kopelman, P; Timmis, AD			Comparison of case fatality in south Asian and white patients after acute myocardial infarction: Observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; MORTALITY; LONDON; MEN; HYPERINSULINEMIA; BANGLADESHIS; PROGNOSIS; ENGLAND; WALES	Objective-To compare mortality in south Asian (Indian, Pakistani, and Bangladeshi) and white patients in the six months after hospital admission for acute myocardial infarction. Design-Observational study. Setting-District general hospital in east London. Patients-149 south Asian and 313 white patients aged <65 years admitted to the coronary care unit with acute myocardial infarction from. 1 December 1988 to 31 December 1992. Main outcome measure-All cause mortality in the first six months after myocardial infarction. Results-The admission rate in the south Asians was estimated to be 2.04 times that in the white patients. Most aspects of treatment were similar in the two groups, except that a higher proportion of the south Asians received thrombolytic drugs (81.2% v 73.8%). After adjustment for age, sex, previous myocardial infarction, and treatment with thrombolysis or aspirin, or both, the south Asians had a poorer survival over the six months from myocardial infarction (hazard ratio 2.02 (95% cofidence interval 1.14 to 3.56), P=0.018), but a substantially higher proportion were diabetic (38% v 11%, P<0.001), and additional adjustment for diabetes removed much of their excess risk (adjusted hazard ratio 1.26 (0.68 to 2.33), P=0.47). Conclusion-South Asian patients had a higher risk of admission with myocardial infarction and a higher risk of death over the ensuing six months than the white patients. The higher case fatality among the south Asians, largely attributable to diabetes, may contribute to the increased risk of death from coronary heart disease in south Asians living in Britain.	LONDON CHEST HOSP, DEPT CARDIOL, LONDON, ENGLAND; NEWHAM DIST GEN HOSP, DEPT CARDIOL, LONDON, ENGLAND; NEWHAM DIST GEN HOSP, DEPT DIABET, LONDON, ENGLAND	University of London; Queen Mary University London	Wilkinson, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, ENVIRONM EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND.			Wilkinson, Paul/0000-0001-7456-259X				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BECKLES GLA, 1986, LANCET, V1, P1298; BHATNAGAR D, 1995, LANCET, V345, P405; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P109; COX DR, 1972, J R STAT SOC B, V34, P187; HUGHES LO, 1989, BRIT MED J, V298, P1345, DOI 10.1136/bmj.298.6684.1345; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; LOWTY PJ, 1984, BRIT HEART J, V52, P610; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1992, BRIT HEART J, V67, P341, DOI 10.1136/hrt.67.5.341; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MCKEIGUE PM, 1985, LANCET, V2, P1086; MCKEIGUE PM, 1989, BRIT MED J, V299, P179, DOI 10.1136/bmj.299.6692.179-a; MUKHTAR HT, 1995, BRIT HEART J, V73, P122; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; TUNSTALLPEDOE H, 1975, LANCET, V2, P833; 1986, LANCET, V1, P1307	24	94	95	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1996	312	7042					1330	1333		10.1136/bmj.312.7042.1330	http://dx.doi.org/10.1136/bmj.312.7042.1330			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646044	Green Published			2022-12-24	WOS:A1996UN47600019
J	Yamasaki, L; Jacks, T; Bronson, R; Goillot, E; Harlow, E; Dyson, NJ				Yamasaki, L; Jacks, T; Bronson, R; Goillot, E; Harlow, E; Dyson, NJ			Tumor induction and tissue atrophy in mice lacking E2F-1	CELL			English	Article							TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA PROTEIN; BINDING PROTEIN; GENE; EXPRESSION; CLONING; MOUSE; CELLS; SITE; TRANSACTIVATION	The retinoblastoma tumor suppressor protein (pRB) is a transcriptional repressor that regulates gene expression by physically associating with transcription factors such as E2F family members. Although pRB and its upstream regulators are commonly mutated in human cancer, the physiological role of the pRB-E2F pathway is unknown. To address the function of E2F-1 and pRB/E2F-1 complexes in vivo, we have produced mice homozygous for a nonfunctional E2F-1 allele. Mice lacking E2F-1 are viable and fertile, yet experience testicular atrophy and exocrine gland dysplasia. Surprisingly, mice lacking E2F-1 develop a broad and unusual spectrum of tumors. Although overexpression of E2F-1 in tissue culture cells can stimulate cell proliferation and be oncogenic, loss of E2F-1 in mice results in tumorigenesis, demonstrating that E2F-1 also functions as a tumor suppressor.	MIT,CTR CANC RES,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH VET MED,USDA,HUMAN NUTR RES CTR AGING,DEPT PATHOL,BOSTON,MA 02111	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Tufts University; United States Department of Agriculture (USDA)	Yamasaki, L (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 49,13TH ST,CHARLESTOWN,MA 02129, USA.			Goillot, Evelyne/0000-0003-0026-4690	NATIONAL CANCER INSTITUTE [P01CA042063, R01CA064402, R01CA060636] Funding Source: NIH RePORTER; NCI NIH HHS [CA64402, CA60636, CA42063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Bronson R., 1990, GENETIC EFFECTS AGIN, VII, P279; BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DUHL DMJ, 1994, DEVELOPMENT, V120, P1695; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Harlow E, 1988, ANTIBODIES LAB MANUA; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOROWITZ JM, 1996, IN PRESS MOL CELL DI; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HU NP, 1994, ONCOGENE, V9, P1021; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLACK RS, 1993, ONCOGENE, V8, P1585; SLANSKY JE, 1995, TRANSCRIPTIONAL CONT; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; Turusov V., 1994, PATHOLOGY TUMORS LAB; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420	75	636	648	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					537	548		10.1016/S0092-8674(00)81254-4	http://dx.doi.org/10.1016/S0092-8674(00)81254-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653789	Bronze			2022-12-24	WOS:A1996UM41500011
J	Wu, JR; Gilbert, DM				Wu, JR; Gilbert, DM			A distinct G(1) step required to specify the Chinese hamster DHFR replication origin	SCIENCE			English	Article							DNA-REPLICATION	Nuclei isolated from Chinese hamster ovary (CHO) cells at various times during the G(1) phase of the cell cycle were stimulated to enter S phase by incubation in Xenopus egg cytosol. Replication of DNA initiated within the dihydrofolate reductase (DHFR) origin locus in nuclei isolated late in G(1), but at random sites in nuclei isolated early in G(1). A discrete transition point occurred 3 to 4 hours after metaphase. Neither replication licensing nor nuclear assembly was sufficient for origin recognition. Thus, a distinct cell cycle-regulated event in the nucleus restricts the initiation of replication to specific sites downstream of the DHFR gene.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center								BURHANS WC, 1994, SCIENCE, V263, P639, DOI 10.1126/science.8303270; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIJKWEL PA, 1995, MOL CELL BIOL, V15, P3023; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; HAMLIN JL, 1994, BBA-REV CANCER, V1198, P85, DOI 10.1016/0304-419X(94)90008-6; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MADINE MA, 1995, NATURE, V375, P4221; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075	14	110	111	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1270	1272		10.1126/science.271.5253.1270	http://dx.doi.org/10.1126/science.271.5253.1270			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638106				2022-12-24	WOS:A1996TX69500033
J	Liu, JD; Schrank, B; Waterston, RH				Liu, JD; Schrank, B; Waterston, RH			Interaction between a putative mechanosensory membrane channel and a collagen	SCIENCE			English	Article							SENSITIVE NA+ CHANNEL; CAENORHABDITIS-ELEGANS; HAIR-CELLS; C-ELEGANS; MUTATIONS; SEQUENCE; GENE; IDENTIFICATION; CLONING; MUSCLE	The degenerin family of proteins in Caenorhabditis elegans is homologous to subunits of the mammalian amiloride-sensitive epithelial sodium channels. Mutations in nematode degenerins cause cell death, probably because of defects in channel function. Genetic evidence was obtained that the unc-105 gene product represents a degenerin homolog affecting C. elegans muscles and that this putative channel interacts with type IV collagen in the extracellular matrix underlying the muscle cell. This interaction may serve as a mechanism of stretch-activated muscle contraction, and this system could provide a molecular model for the activation of mechanosensitive ion channels.			Liu, JD (corresponding author), WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023883, R37GM023883] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23883] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; Crofton H. D., 1966, NEMATODES; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Du HP, 1996, NEURON, V16, P183, DOI 10.1016/S0896-6273(00)80035-5; EIDE D, 1985, GENETICS, V109, P67; FIRE A, COMMUNICATION; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; KAO G, COMMUNICATION; KRAMER JG, COMMUNICATION; KRAMER JM, 1994, ANNU REV GENET, V28, P95; Lai CC, 1996, J CELL BIOL, V133, P1071, DOI 10.1083/jcb.133.5.1071; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; PARK EC, 1986, GENETICS, V113, P821; PARK EC, 1986, GENETICS, V113, P853; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; SHREFFLER W, 1995, GENETICS, V139, P1261; SIBLEY MH, 1994, EMBO J, V13, P3278, DOI 10.1002/j.1460-2075.1994.tb06629.x; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; WATERSTON RH, 1988, NEMATODE CAENORHABDI, P261; WHITE JG, 1976, PHILOS R SOC LONDO B, V275, P326; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	38	124	135	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1996	273	5273					361	364		10.1126/science.273.5273.361	http://dx.doi.org/10.1126/science.273.5273.361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY202	8662524				2022-12-24	WOS:A1996UY20200041
J	Perkins, WR; Dause, RB; Parente, RA; Minchey, SR; Neuman, KC; Gruner, SM; Taraschi, TF; Janoff, AS				Perkins, WR; Dause, RB; Parente, RA; Minchey, SR; Neuman, KC; Gruner, SM; Taraschi, TF; Janoff, AS			Role of lipid polymorphism in pulmonary surfactant	SCIENCE			English	Article							RESPIRATORY-DISTRESS SYNDROME; PREMATURE BABIES; ALEC; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPIDS; VESICLES; THERAPY; PHASE	The development of artificial surfactants for the treatment of respiratory distress syndrome (RDS) requires lipid systems that can spread rapidly from solution to the air-water interface, Because hydration-repulsion forces stabilize liposomal bilayers and oppose spreading, liposome systems that undergo geometric rearrangement from the bilayer (lamellar) phase to the hexagonal II (H-II) phase could hasten lipid transfer to the air-water interface through unstable transition intermediates. A liposome system containing dipalmitoylphosphatidylcholine was designed; the system is stable at 23 degrees C but undergoes transformation to the H-II phase as the temperature increases to 37 degrees C. The spreading of lipid from this system to the air-water interface was rapid at 37 degrees C but slow at 23 degrees C, When tested in vivo in a neonatal rabbit model, such systems elicited an onset of action equal to that of native human surfactant. These findings suggest that lipid polymorphic phase behavior may have a crucial role in the effective functioning of pulmonary surfactant.	LIPOSOME CO INC, PRINCETON, NJ 08540 USA; PRINCETON UNIV, DEPT PHYS, PRINCETON, NJ 08544 USA; THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Princeton University; Jefferson University			Neuman, Keir C./F-7400-2011; Gruner, Sol/G-2924-2010	Neuman, Keir C./0000-0002-0863-5671; Gruner, Sol/0000-0002-1171-4426				AHLUWALIA JS, 1995, ARCH DIS CHILD-FETAL, V72, pF121, DOI 10.1136/fn.72.2.F121; AMIRKHANIAN JD, 1995, LUNG, V173, P243; BARROW RE, 1979, J PHYSIOL-LONDON, V295, P217, DOI 10.1113/jphysiol.1979.sp012963; BOONMAN A, 1987, J COLLOID INTERF SCI, V120, P456, DOI 10.1016/0021-9797(87)90372-9; Bourbon J.R., 1991, PULMONARY SURFACTANT; BOURBON JR, 1991, PULMONARY SURFACTANT, P257; BOURBON JR, 1991, PULMONARY SURFACTANT, P143; CASIRO O, 1995, J PEDIATR-US, V126, pS53, DOI 10.1016/S0022-3476(95)70008-0; CHUNG JB, 1990, LANGMUIR, V6, P1647, DOI 10.1021/la00101a005; CLEMENTS JA, 1977, AM REV RESPIR DIS, V115, P67; CORBET A, 1995, J PEDIATR-US, V126, pS5, DOI 10.1016/S0022-3476(95)70002-1; DEHAN M, 1991, PULMONARY SURFACTANT, P333; ENHORNING G, 1995, AM J RESP CRIT CARE, V151, P554, DOI 10.1164/ajrccm.151.2.7842219; EPAND RM, 1985, CHEM PHYS LIPIDS, V36, P387, DOI 10.1016/0009-3084(85)90046-5; GAULTIER C, 1991, PULMONARY SURFACTANT, P359; GIBSON AT, 1994, EUR J PEDIATR, V153, P495, DOI 10.1007/s004310050179; GRUNER SM, 1985, BIOCHEMISTRY-US, V24, P2833, DOI 10.1021/bi00333a004; HALLMAN M, 1977, PEDIATR RES, V11, P714, DOI 10.1203/00006450-197706000-00003; HILLS BA, 1990, BIOL SURFACTANT, P184; HOEKSTRA RE, 1994, EUR J PEDIATR, V153, pS12, DOI 10.1007/BF02179667; JANOFF AS, 1992, Patent No. 6703; KUINT J, 1994, ARCH DIS CHILD-FETAL, V71, pF170, DOI 10.1136/fn.71.3.F170; LI W, 1986, BIOCHEMISTRY-US, V25, P7477, DOI 10.1021/bi00371a033; MARSH D, 1990, HDB LIPID BILAYERS, P265; MICHAELSON DM, 1974, BIOCHEMISTRY-US, V13, P2605, DOI 10.1021/bi00709a021; MORLEY CJ, 1989, DEV PHARMACOL THERAP, V13, P182, DOI 10.1159/000457602; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P467, DOI 10.1136/adc.66.4.467; MORLEY CJ, 1988, EARLY HUM DEV, V17, P41, DOI 10.1016/S0378-3782(88)80056-2; MORLEY CJ, 1990, ARCH DIS CHILD-FETAL, V65, P667, DOI 10.1136/adc.65.7_Spec_No.667; MOYA FR, 1994, AM J RESP CRIT CARE, V150, P1672, DOI 10.1164/ajrccm.150.6.7952631; PERKINS W R, 1992, Biophysical Journal, V61, pA239; PHILLIPS MC, 1970, BIOCHIM BIOPHYS ACTA, V196, P35, DOI 10.1016/0005-2736(70)90163-X; PLOTZ FB, 1995, PEDIATR RES, V37, P476; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; REVAK SD, 1986, AM REV RESPIR DIS, V134, P1258; SAIGAL S, 1995, J PEDIATR-US, V126, pS61, DOI 10.1016/S0022-3476(95)70009-9; SCHURCH S, 1994, J APPL PHYSIOL, V77, P974, DOI 10.1152/jappl.1994.77.2.974; WATKINS JC, 1968, BIOCHIM BIOPHYS ACTA, V152, P293, DOI 10.1016/0005-2760(68)90037-4; WISEMAN LR, 1994, DRUGS, V48, P386, DOI 10.2165/00003495-199448030-00006; YU SH, 1984, BIOCHIM BIOPHYS ACTA, V776, P37, DOI 10.1016/0005-2736(84)90248-7	40	65	73	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	1996	273	5273					330	332		10.1126/science.273.5273.330	http://dx.doi.org/10.1126/science.273.5273.330			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY202	8662513				2022-12-24	WOS:A1996UY20200030
J	Karp, CL; Wysocka, M; Wahl, LM; Ahearn, JM; Cuomo, PJ; Sherry, B; Trinchieri, G; Griffin, DE				Karp, CL; Wysocka, M; Wahl, LM; Ahearn, JM; Cuomo, PJ; Sherry, B; Trinchieri, G; Griffin, DE			Mechanism of suppression of cell-mediated immunity by measles virus	SCIENCE			English	Article							PERMEABILITY-INCREASING PROTEIN; HUMAN-IMMUNODEFICIENCY-VIRUS; COMPLEMENT-SYSTEM; INFECTED-CELLS; INTERFERON-GAMMA; ACTIVATION; CD46; INDUCTION; HIV-1; INTERLEUKIN-12	The mechanisms underlying the profound suppression of cell-mediated immunity (CMI) accompanying measles are unclear. Interleukin-12 (IL-12), derived principally from monocytes and macrophages, is critical for the generation of CMI. Measles virus (MV) infection of primary human monocytes specifically down-regulated IL-12 production. Cross-linking of CD46, a complement regulatory protein that is the cellular receptor for MV, with antibody or with the complement activation product C3b similarly inhibited monocyte IL-12 production, providing a plausible mechanism for MV-induced immunosuppression. CD46 provides a regulatory link between the complement system and cellular Immune responses.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; NIDR,IMMUNOL LAB,NIH,BETHESDA,MD 20892; PICOWER INST MED RES,MANHASSET,NY 11030; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOLEC MICROBIOL & IMMUNOL,BALTIMORE,MD 21205	The Wistar Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Northwell Health; Johns Hopkins University	Karp, CL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21287, USA.		Sherry, Barbara/GSD-7179-2022; Trinchieri, Giorgio/F-9369-2015	Sherry, Barbara/0000-0003-3119-1463; Trinchieri, Giorgio/0000-0001-5892-7464; Karp, Christopher/0000-0002-0832-2659	NIAID NIH HHS [AI23047, AI01223, AI35149] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035149, R01AI023047] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS EM, 1991, J IMMUNOL, V147, P3005; ARNEBORN P, 1983, INFECT IMMUN, V39, P29, DOI 10.1128/IAI.39.1.29-37.1983; ASSAAD F, 1983, REV INFECT DIS, V5, P452; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; CHO SW, 1991, CLIN EXP IMMUNOL, V83, P257; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DENTENER MA, 1993, J IMMUNOL, V151, P4258; DIERICH MP, 1993, IMMUNOL TODAY, V14, P435, DOI 10.1016/0167-5699(93)90246-H; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Durum Scott K., 1993, P801; EBENBICHLER CF, 1991, J EXP MED, V174, P1417, DOI 10.1084/jem.174.6.1417; ESOLEN LM, 1993, J INFECT DIS, V168, P47, DOI 10.1093/infdis/168.1.47; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; GERLIER D, 1994, J GEN VIROL, V75, P2163, DOI 10.1099/0022-1317-75-9-2163; GRANT JP, 1990, STATE WORLDS CHILDRE; GRIFFIN DE, 1990, CLIN EXP IMMUNOL, V81, P218; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; HIRSCH MS, 1996, VIROLOGY, P1953; HIRSCH RL, 1981, CLIN IMMUNOL IMMUNOP, V21, P341, DOI 10.1016/0090-1229(81)90223-3; HIRSCH RL, 1984, CLIN IMMUNOL IMMUNOP, V31, P1, DOI 10.1016/0090-1229(84)90184-3; JAMES SL, 1995, MICROBIOL REV, V59, P533, DOI 10.1128/MMBR.59.4.533-547.1995; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KARP CL, 1993, J CLIN INVEST, V91, P1644, DOI 10.1172/JCI116372; KARP CL, UNPUB; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; MARRA MN, 1990, J IMMUNOL, V144, P662; MARSCHANG P, 1993, AIDS, V7, P903, DOI 10.1097/00002030-199307000-00001; MAYERNIK DG, 1984, J LEUKOCYTE BIOL, V36, P551, DOI 10.1002/jlb.36.4.551; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MESZAROS K, 1993, J LEUKOCYTE BIOL, V54, P558, DOI 10.1002/jlb.54.6.558; MOENCH TR, 1988, J INFECT DIS, V158, P433, DOI 10.1093/infdis/158.2.433; MULLER G, 1995, J IMMUNOL, V155, P4661; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NUSSBAUM O, 1995, J VIROL, V69, P3341, DOI 10.1128/JVI.69.6.3341-3349.1995; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; SOLDER BM, 1989, IMMUNOL LETT, V22, P135, DOI 10.1016/0165-2478(89)90180-6; SPEAR GT, 1990, J IMMUNOL, V144, P1490; STOIBER H, 1995, IMMUNOBIOLOGY, V193, P98, DOI 10.1016/S0171-2985(11)80158-0; TAMASHIRO VG, 1987, PEDIATR INFECT DIS J, V6, P451, DOI 10.1097/00006454-198705000-00007; THIEBLEMONT N, 1993, AIDS RES HUM RETROV, V9, P229, DOI 10.1089/aid.1993.9.229; THIELENS NM, 1993, J IMMUNOL, V151, P6583; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; VAINIONPAA R, 1978, ACTA PATH MICRO IM B, V86, P379; VONPIRQUET C, 1908, DEUT MED WOCHENSCHR, V30, P1297; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WAHL LM, 1981, MANUAL MACROPHAGE ME, P423; WARD BJ, 1993, CLIN IMMUNOL IMMUNOP, V67, P171, DOI 10.1006/clin.1993.1061; WEISS J, 1978, J BIOL CHEM, V253, P2664; WHITTLE HC, 1978, J CLIN INVEST, V62, P678, DOI 10.1172/JCI109175; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZWEIMAN B, 1971, INT ARCH ALLER A IMM, V40, P834, DOI 10.1159/000230466	55	451	454	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					228	231		10.1126/science.273.5272.228	http://dx.doi.org/10.1126/science.273.5272.228			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8662504				2022-12-24	WOS:A1996UW78700038
J	Corrigan, E; Mumford, SE; Hull, MGR				Corrigan, E; Mumford, SE; Hull, MGR			Posthumous storage and use of sperm and embryos: Survey of opinion of treatment centres	BRITISH MEDICAL JOURNAL			English	Article									UNIV BRISTOL,ST MICHAELS HOSP,DEPT OBSTET & GYNAECOL,CTR REPROD MED,BRISTOL BS2 8EG,AVON,ENGLAND; UNIV BRISTOL,DEPT LAW,BRISTOL BS8 1RT,AVON,ENGLAND	University of Bristol; University of Bristol								AZIZASHUSTER E, 1994, HUM REPROD, V9, P2182, DOI 10.1093/oxfordjournals.humrep.a138414; Warnock M, 1984, CMND9314	2	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					24	24		10.1136/bmj.313.7048.24	http://dx.doi.org/10.1136/bmj.313.7048.24			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664765	Green Published			2022-12-24	WOS:A1996UW66700026
J	Kerlikowske, K; Grady, D; Barclay, J; Sickles, EA; Ernster, V				Kerlikowske, K; Grady, D; Barclay, J; Sickles, EA; Ernster, V			Effect of age, breast density, and family history on the sensitivity of first screening mammography	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DUCTAL CARCINOMA INSITU; MEDICAL AUDIT; FOLLOW-UP; GROWTH-RATES; LOW-COST; CANCER; COMMUNITY	Objective.-To determine factors that influence the sensitivity of modern first screening mammography. Design.-Cross-sectional. Setting.-Nine counties in northern California. Participants.-A total of 28 271 women aged 30 years and older referred for first screening mammography to the Mobile Mammography Screening Program of the University of California, San Francisco, from April 1985 to March 1 992, of whom 238 were subsequently diagnosed as having breast cancer. Measurements.-Breast cancer risk profile, 2 standard mammographic views per breast, breast density, and follow-up of abnormal and normal mammography by contacting women's physicians and by linkage to the regional Surveillance, Epidemiology, and End Results tumor registry to determine the occurrence of any invasive cancer or ductal carcinoma in situ. Results tumor registry to determine the occurrence of any invasive cancer or ductal carcinoma in situ. Results.-For women aged 50 years and older, the sensitivity of first screening mammography was relatively high and decreased slightly with increasing length of follow-up after mammography: 98.5% for 7 months of follow-up, 93.2% for 13 months, and 85.7% for 25 months. Sensitivity was higher among women aged 50 years and older when breast density was primarily fatty rather than primarily dense (98.4% vs 83.7%; P<.01). For women younger than 50 years, the sensitivity of first screening mammography also decreased with increasing length of follow-up but was significantly lower than for older women: 87.5% for 7 months of follow-up, 83.6% for 13 months, and 71.4% for 25 months. For women younger than 50 years, breast density did not affect the sensitivity of mammography (81.8% for those with primarily fatty breasts vs 85.4% for those with primarily dense breasts) and was lower among those with a family history of breast cancer (68.8%). Conclusions.-The sensitivity of modem mammography is highest among women aged 50 years and older who have primarily fatty breast density. Sensitivity is lowest among women younger than 50 years and particularly low when the time between screenings is about 2 years or when women have a family history of breast cancer, possibly because of rapid tumor growth.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kerlikowske, K (corresponding author), VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,111A1,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NCI NIH HHS [UO1 CA 63740, CA 58207-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA063740, P50CA058207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American College of Radiology, 1982, POL STAT GUID MAMM; ARNESSON LG, 1989, BRIT J SURG, V76, P672, DOI 10.1002/bjs.1800760707; BARTOW SA, 1995, AM J EPIDEMIOL, V142, P813, DOI 10.1093/oxfordjournals.aje.a117720; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; BIRD RE, 1992, RADIOLOGY, V184, P613, DOI 10.1148/radiology.184.3.1509041; BREKELMANS CTM, 1992, EUR J CANCER, V28A, P893, DOI 10.1016/0959-8049(92)90144-Q; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; BURHENNE HJ, 1994, AM J ROENTGENOL, V162, P1067, DOI 10.2214/ajr.162.5.8165983; CALLE EE, 1993, AM J EPIDEMIOL, V138, P675, DOI 10.1093/oxfordjournals.aje.a116904; Canadian Task Force on the Periodic Health Examination, 1994, CAN GUID CLIN PREV H; DERSHAW DD, 1989, RADIOLOGY, V170, P411, DOI 10.1148/radiology.170.2.2536185; DORSI CJ, 1993, SEMIN ROENTGENOL, V28, P204, DOI 10.1016/S0037-198X(05)80080-X; ELWOOD JM, 1993, ONLINE J CURR CLIN T, V2; Farrow J H, 1970, Cancer, V25, P468, DOI 10.1002/1097-0142(197002)25:2<468::AID-CNCR2820250226>3.0.CO;2-0; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FRANKEL SD, 1995, AM J ROENTGENOL, V164, P1107, DOI 10.2214/ajr.164.5.7717214; HARRIS R, 1995, ANN INTERN MED, V122, P550; HETELEKIDIS S, 1995, CA-CANCER J CLIN, V45, P244, DOI 10.3322/canjclin.45.4.244; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; LINVER MN, 1992, RADIOLOGY, V184, P39, DOI 10.1148/radiology.184.1.1609100; MA L, 1992, J NATL CANCER I, V84, P781, DOI 10.1093/jnci/84.10.781; METTLIN C, 1994, CA-CANCER J CLIN, V44, P248, DOI 10.3322/canjclin.44.4.248; MONTICCIOLO DL, 1990, AM J ROENTGENOL, V155, P751, DOI 10.2214/ajr.155.4.2119104; MOSKOWITZ M, 1986, RADIOLOGY, V161, P37, DOI 10.1148/radiology.161.1.3532183; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PEETERS PHM, 1989, INT J CANCER, V43, P226, DOI 10.1002/ijc.2910430209; ROBERTSON CL, 1993, RADIOLOGY, V187, P75, DOI 10.1148/radiology.187.1.8451440; SHAPIRO S, 1994, AM J PUBLIC HEALTH, V84, P10, DOI 10.2105/AJPH.84.1.10; SICKLES EA, 1986, RADIOLOGY, V160, P95, DOI 10.1148/radiology.160.1.3715053; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SICKLES EA, 1987, RADIOL CLIN N AM, V25, P1015; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; SIENKO DG, 1993, CANCER-AM CANCER SOC, V71, P1801, DOI 10.1002/1097-0142(19930301)71:5<1801::AID-CNCR2820710515>3.0.CO;2-W; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; SMART CR, 1995, CANCER, V76, P2788; SOX HC, 1995, ANN INTERN MED, V122, P550, DOI 10.7326/0003-4819-122-7-199504010-00013; SPRATT JS, 1986, CANCER RES, V46, P970; STOMPER PC, 1992, AM J ROENTGENOL, V159, P483, DOI 10.2214/ajr.159.3.1323923; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1995, CANCER, V75, P2507, DOI 10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H	43	497	505	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					33	38		10.1001/jama.276.1.33	http://dx.doi.org/10.1001/jama.276.1.33			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667536				2022-12-24	WOS:A1996UU43900024
J	Levine, BL; Mosca, JD; Riley, JL; Carroll, RG; Vahey, MT; Jagodzinski, LL; Wagner, KF; Mayers, DL; Burke, DS; Weislow, OS; StLouis, DC; June, CH				Levine, BL; Mosca, JD; Riley, JL; Carroll, RG; Vahey, MT; Jagodzinski, LL; Wagner, KF; Mayers, DL; Burke, DS; Weislow, OS; StLouis, DC; June, CH			Antiviral effect and ex vivo CD4(+) T cell proliferation in HIV-positive patients as a result of CD28 costimulation	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; LYMPHOCYTES-T; REPLICATION; INFECTION; INDIVIDUALS; ACTIVATION; EXPRESSION; AIDS; INTERLEUKIN-2; RESPONSES	Because stimulation of CD4(+) lymphocytes leads to activation of human immunodeficiency virus-type 1 (HIV-1) replication, viral spread, and cell death, adoptive CD4(+) T cell therapy has not been possible. When antigen and CD28 receptors on cultured T cells were stimulated by monoclonal antibodies (mAbs) to CD3 and CD28 that had been immobilized, there was an increase in the number of polyclonal CD4(+) T cells from HIV-infected donors. Activated cells predominantly secreted cytokines associated with T helper cell type 1 function, The HIV-1 viral load declined in the absence of antiretroviral agents, Moreover, CD28 stimulation of CD4(+) T cells from uninfected donors rendered these cells highly resistant to HIV-I infection, Immobilization of CD28 mAb was crucial to the development of HIV resistance, as cells stimulated with soluble CD28 mAb were highly susceptible to HIV infection, The CD28-mediated antiviral effect occurred early in the viral life cycle, before HIV-1 DNA integration. These data may facilitate immune reconstitution and gene therapy approaches in persons with HIV infection.	USN,MED RES INST,BETHESDA,MD 20889; HENRY M JACKSON FDN ADVANCEMENT MIL MED,ROCKVILLE,MD 20850; WALTER REED ARMY INST RES,DIV RETROVIROL,ROCKVILLE,MD 20850; SRA TECHNOL,DIV LIFE SCI,ROCKVILLE,MD 20850	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)			Levine, Bruce L/D-1688-2009; Riley, James L/D-1255-2009	/0000-0002-5704-8094; June, Carl/0000-0003-0241-3557; Riley, James/0000-0002-1057-576X	NIAID NIH HHS [AI29331] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029331] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASJO B, 1993, J VIROL, V67, P4395; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BORTHWICK NJ, 1994, AIDS, V8, P431, DOI 10.1097/00002030-199404000-00004; BRINCHMANN JE, 1994, J INFECT DIS, V169, P730, DOI 10.1093/infdis/169.4.730; CAYOTA A, 1993, CLIN EXP IMMUNOL, V91, P241; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COSTELLO R, 1993, EUR J IMMUNOL, V23, P608, DOI 10.1002/eji.1830230304; DOBRESCU D, 1995, P NATL ACAD SCI USA, V92, P5563, DOI 10.1073/pnas.92.12.5563; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HOLTER W, 1992, EUR J IMMUNOL, V22, P2765, DOI 10.1002/eji.1830221047; JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KING CL, 1995, EUR J IMMUNOL, V25, P587, DOI 10.1002/eji.1830250242; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; LEDBETTER JA, 1990, BLOOD, V75, P1531; LEVINE B, UNPUB; LEVINE BL, 1995, INT IMMUNOL, V7, P891, DOI 10.1093/intimm/7.6.891; LEWIS DE, 1994, J IMMUNOL, V153, P412; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MAGGI E, 1987, EUR J IMMUNOL, V17, P1685, DOI 10.1002/eji.1830171202; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; MARGOLICK JB, 1985, J CLIN INVEST, V76, P709, DOI 10.1172/JCI112025; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PINCHUK LM, 1994, IMMUNITY, V1, P317, DOI 10.1016/1074-7613(94)90083-3; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; SMITHGALL MD, 1995, AIDS RES HUM RETROV, V11, P885, DOI 10.1089/aid.1995.11.885; STEIN DS, 1993, CLIN INFECT DIS, V17, P749, DOI 10.1093/clinids/17.4.749; THOMPSON CB, 1995, CELL, V81, P979, DOI 10.1016/S0092-8674(05)80001-7; Vahey Maryanne T., 1995, P17; VANDERPOUWKRAAN T, 1993, EUR J IMMUNOL, V23, P1, DOI 10.1002/eji.1830230102; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; WILSON CC, 1995, J INFECT DIS, V172, P88, DOI 10.1093/infdis/172.1.88	41	198	221	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1996	272	5270					1939	1943		10.1126/science.272.5270.1939	http://dx.doi.org/10.1126/science.272.5270.1939			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658167				2022-12-24	WOS:A1996UV29400049
J	Wang, ZX; Moran, MF				Wang, ZX; Moran, MF			Requirement for the adapter protein GRB2 in EGF receptor endocytosis	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; LIGAND-INDUCED INTERNALIZATION; SH3 DOMAINS; TYROSINE KINASE; DOWN-REGULATION; BINDING-SITE; RAS; DYNAMIN; SOS	Activated epidermal growth factor (EGF) receptors induce the formation of various complexes of intracellular signaling proteins that are mediated by SRC homology 2 (SH2) and SH3 domains. The activated receptors are also rapidly internalized into the endocytotic compartment and degraded in lysosomes. EGF stimulation of canine epithelial cells induced a rapid and transient association of the SH3-SH2-SH3 protein GRB2 with dynamin, a guanosine triphosphatase that regulates endocytosis. Disruption of GRB2 interactions by microinjection of a peptide corresponding to the GRB2 SH2 domain or its phosphopeptide ligand blocked EGF receptor endocytosis; other SH2 domains that bind EGF receptors or antibodies that neutralize RAS did not. Both activation and termination of EGF signaling appear to be regulated by the diverse interactions of GRB2.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1L6,CANADA	University of Toronto; University of Toronto			Moran, Michael/GYD-3631-2022					ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DAMKE H, 1994, J CELL BIOL, V127, P925; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22925; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HELIN K, 1991, J BIOL CHEM, V266, P8363; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MIKI H, 1994, J BIOL CHEM, V269, P5489; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOLER C, 1994, J BIOL CHEM, V269, P12320; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; TAKEI K, 1995, NATURE, V374, P86; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WANG Z, UNPUB; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	52	151	155	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1996	272	5270					1935	1939		10.1126/science.272.5270.1935	http://dx.doi.org/10.1126/science.272.5270.1935			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658166				2022-12-24	WOS:A1996UV29400048
J	Dragic, T; Litwin, V; Allaway, GP; Martin, SR; Huang, YX; Nagashima, KA; Cayanan, C; Maddon, PJ; Koup, RA; Moore, JP; Paxton, WA				Dragic, T; Litwin, V; Allaway, GP; Martin, SR; Huang, YX; Nagashima, KA; Cayanan, C; Maddon, PJ; Koup, RA; Moore, JP; Paxton, WA			HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS; FUNCTIONAL EXPRESSION; CD4-MEDIATED FUSION	The beta-chemokines MIP-1 alpha, MIP-1 beta and RANTES inhibit infection of CD4(+) T cells by primary, non-syncytium-inducing (NSI) HIV-1 strains at the virus entry stage, and also block env-mediated cell-cell membrane fusion. CD4(+) T cells from some HIV-1-exposed uninfected individuals cannot fuse with NSI HIV-1 strains and secrete high levels of beta-chemokines. Expression of the beta-chemokine receptor CC-CKR-5 in CD4(+), non-permissive human and non-human cells renders them susceptible to infection by NSI strains, and allows env-mediated membrane fusion. CC-CKR-5 is a second receptor for NSI primary viruses.	ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; PROGEN PHARMACEUT INC,TARRYTOWN,NY 10591	Rockefeller University			paxton, william/R-9747-2019	Paxton, William/0000-0002-2654-5186; Paxton, William/0000-0001-5200-0801				ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; COOCHI F, 1995, SCIENCE, V270, P1811; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; LITWIN V, IN PRESS J VIROL; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Moore J P, 1995, AIDS, V9 Suppl A, pS117; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Puri A, 1996, VIROLOGY, V219, P262, DOI 10.1006/viro.1996.0244; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53	29	2782	2926	0	162	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					667	673		10.1038/381667a0	http://dx.doi.org/10.1038/381667a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649512	Bronze			2022-12-24	WOS:A1996UR97900042
J	Hickok, G; Bellugi, U; Klima, ES				Hickok, G; Bellugi, U; Klima, ES			The neurobiology of sign language and its implications for the neural basis of language	NATURE			English	Article								THE left cerebral hemisphere is dominant for language, and many aspects of language use are more impaired by damage to the left than the right hemisphere, The basis for this asymmetry, however, is a matter of debate; the left hemisphere may be specialized for processing linguistic information(1-3) or for some more general function on which language depends, such as the processing of rapidly changing temporal information(4) or execution of complex motor patterns(5). To investigate these possibilities, we examined the linguistic abilities of 23 sign-language users with unilateral brain lesions. Despite the fact that sign language relies on visuospatial rather than rapid temporal information, the same left-hemispheric dominance emerged. Correlation analyses of the production of sign language versus non-linguistic hand gestures suggest that these processes are largely independent, Our findings support the view that the left-hemisphere dominance for language is not reducible solely to more general sensory or motor processes.	UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92186	University of California System; University of California San Diego	Hickok, G (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BELIUGI U, 1989, TRENDS NEUROSCI, V10, P380; CHIARELLO C, 1982, BRAIN, V105, P29, DOI 10.1093/brain/105.1.29; Corina D., 1993, PHONOLOGY, V10, P165, DOI [10.1017/S0952675700000038, DOI 10.1017/S0952675700000038]; Corina David P., 1993, PHONETICS PHONOLOGY, P63; CORINA DP, 1992, SCIENCE, V255, P1258, DOI 10.1126/science.1546327; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; GOODGLASS H, 1976, ASSESSMENT APHASIA R; KIMURA D, 1982, PHILOS T ROY SOC B, V298, P135, DOI 10.1098/rstb.1982.0077; Kimura D., 1993, NEUROMOTOR MECH HUMA; Klima E., 1979, SIGNS LANGUAGE; Liddell S.K., 1980, AM SIGN LANGUAGE SYN, DOI 10.1515/9783112418260; Lillo-Martin Diane., 1991, UNIVERSAL GRAMMAR AM; Osterrieth P., 1944, ARCH PSYCHOL-GENEVE, V30, P206; PERLMUTTER DM, 1992, LINGUIST INQ, V23, P407; POIZNER H, 1993, ANN NY ACAD SCI, V682, P192, DOI 10.1111/j.1749-6632.1993.tb22969.x; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; Siple Patricia, 1990, THEORETICAL ISSUES S, V1, P191, DOI DOI 10.1007/978-94-011-3468-2; TALLAL P, 1993, ANN NY ACAD SCI, V682, P27, DOI 10.1111/j.1749-6632.1993.tb22957.x; [No title captured]	19	114	116	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					699	702		10.1038/381699a0	http://dx.doi.org/10.1038/381699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649515				2022-12-24	WOS:A1996UR97900053
J	Roberts, I				Roberts, I			Safely to school?	LANCET			English	Editorial Material											Roberts, I (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL,CHILD HLTH MONITORING UNIT,LONDON WC1N 1EH,ENGLAND.							CHINN S, 1994, PAEDIATR PERINAT EP, V8, P90, DOI 10.1111/j.1365-3016.1994.tb00438.x; *DEP TRANSP, 1995, TRANSP STAT REP; Department of Health, 1996, STRAT STAT PHYS ACT; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; Preston B., 1992, CUTTING PEDESTRIAN C; ROBERTS I, 1995, EPIDEMIOLOGY, V6, P169, DOI 10.1097/00001648-199503000-00014; WOODROFFE C, 1993, CHILDREN TEENAGERS H	7	19	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1642	1642		10.1016/S0140-6736(96)91483-X	http://dx.doi.org/10.1016/S0140-6736(96)91483-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642954				2022-12-24	WOS:A1996UQ70100006
J	Shaw, M; Tomlinson, D; Higginson, I				Shaw, M; Tomlinson, D; Higginson, I			Survey of HIV patients' views on confidentiality and non-discrimination policies in general practice	BRITISH MEDICAL JOURNAL			English	Article							INFECTION; PRACTITIONER; ATTITUDES; AIDS		CHELSEA WESTMINSTER COMMISS AGCY,LONDON W2 6LX,ENGLAND		Shaw, M (corresponding author), ST MARYS NHS HOSP TRUST,DEPT GENITOURINARY MED,PRAED ST,LONDON W2 1NY,ENGLAND.		Higginson, Irene Julie/C-7309-2012	Higginson, Irene Julie/0000-0002-3687-1313				BROWNPETERSIDE P, 1991, BRIT J GEN PRACT, V41, P401; GUTHRIE B, 1995, INT J STD AIDS, V6, P84, DOI 10.1177/095646249500600204; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; KING MB, 1989, BMJ-BRIT MED J, V299, P713, DOI 10.1136/bmj.299.6701.713; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104	5	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1463	1464		10.1136/bmj.312.7044.1463	http://dx.doi.org/10.1136/bmj.312.7044.1463			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664629	Green Published			2022-12-24	WOS:A1996UQ29600032
J	Yamatsuji, T; Matsui, T; Okamoto, T; Komatsuzaki, K; Takeda, S; Fukumoto, H; Iwatsubo, T; Suzuki, N; AsamiOdaka, A; Ireland, S; Kinane, TB; Giambarella, U; Nishimoto, I				Yamatsuji, T; Matsui, T; Okamoto, T; Komatsuzaki, K; Takeda, S; Fukumoto, H; Iwatsubo, T; Suzuki, N; AsamiOdaka, A; Ireland, S; Kinane, TB; Giambarella, U; Nishimoto, I			G protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; MISSENSE MUTATION; ALPHA-SUBUNIT; GENE; CELLS; APOPTOSIS; INDUCTION; DEATH	Missense mutations in the 595-amino acid form of the amyloid precursor protein (APP(695)) cosegregate with disease phenotype in families with dominantly inherited Alzheimer's disease. These mutations convert valine at position 642 to isoleucine, phenylalanine, or glycine. Expression of these mutant proteins, but not of normal APP(695), was shown to induce nucleosomal DNA fragmentation in neuronal cells. Induction of DNA fragmentation required the cytoplasmic domain of the mutants and appeared to be mediated by heterotrimeric guanosine triphosphate-binding proteins (G proteins).	HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CARDIVASC RES CTR,DEPT MED,CHARLESTOWN,MA 02129; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT NEUROPATHOL & NEUROSCI,BUNKYO KU,TOKYO 113,JAPAN; TAKEDA CHEM IND LTD,TSUKUBA,IBARAKI 30042,JAPAN; ONCOR INC,GAITHERSBURG,MD 20877; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT PEDIAT,RENAL UNIT,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital; University of Tokyo; Takeda Chemical Industries; Harvard University; Massachusetts General Hospital								ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JOFFE I, 1993, CALCIFIED TISSUE INT, V53, P45, DOI 10.1007/BF01352014; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KINANE TB, 1993, J BIOL CHEM, V268, P24669; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; LEE VMY, 1986, J NEUROSCI, V6, P514; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; YAMATSUJI T, UNPUB; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	40	218	229	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1349	1352		10.1126/science.272.5266.1349	http://dx.doi.org/10.1126/science.272.5266.1349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650548				2022-12-24	WOS:A1996UN47200050
J	Graff, JM; Bansal, A; Melton, DA				Graff, JM; Bansal, A; Melton, DA			Xenopus Mad proteins transduce distinct subsets of signals for the TGF beta superfamily	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; MESODERM-INDUCING ACTIVITY; VENTRALIZING FACTOR; AXIAL MESODERM; EARLY RESPONSE; INDUCTION; EMBRYOS; RNA; EXPRESSION; EMBRYOGENESIS	Xenopus cDNAs homologous to the Drosophila Mad gene and C. elegans CEM genes have been cloned and functionally analyzed by microinjection into frog embryos. The results show that these genes (Xmad) encode intracellular proteins that act downstream of TGF beta superfamily ligands. Most interesting is the fact that different Xmad proteins produce distinct biological responses. Xmad1 produces ventral mesoderm, apparently transducing a signal for BMP2 and BMP4, whereas Xmad2 induces dorsal mesoderm like Vg1, activin, and nodal. These results suggest that an individual Xmad protein waits poised in the cytoplasm for instruction from a distinct subset of TGF beta ligands and then conveys specific information to the nucleus.	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1992, DEVELOPMENT, V115, P573; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JONES CM, 1992, DEVELOPMENT, V115, P639; JONES CM, 1995, DEVELOPMENT, V121, P3651; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NEWFELD SJ, 1996, IN PRESS DEVELOPMENT; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PIERCE SB, 1995, DEVELOPMENT, V121, P755; RAFTERY LA, 1995, GENETICS, V139, P241; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SAVAGE C, 1996, P NATL ACAD SCI USA, V93, P7790; SCHMIDT JE, 1995, DEV BIOL, V169, P37, DOI 10.1006/dbio.1995.1124; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH LD, 1991, METHOD CELL BIOL, V36, P45; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	56	396	409	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					479	487		10.1016/S0092-8674(00)81249-0	http://dx.doi.org/10.1016/S0092-8674(00)81249-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653784	Bronze			2022-12-24	WOS:A1996UM41500006
J	Tsang, SH; Gouras, P; Yamashita, CK; Kjeldbye, H; Fisher, J; Farber, DB; Goff, SP				Tsang, SH; Gouras, P; Yamashita, CK; Kjeldbye, H; Fisher, J; Farber, DB; Goff, SP			Retinal degeneration in mice lacking the gamma subunit of the rod cGMP phosphodiesterase	SCIENCE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; DOMINANT RETINITIS-PIGMENTOSA; BETA-SUBUNIT; OUTER SEGMENTS; RHODOPSIN MUTATIONS; PHOTORECEPTOR CELLS; NONSENSE MUTATION; MOUSE RETINA; G-PROTEIN; RDS GENE	The retinal cyclic guanosine 3',5'-monophosphate (cGMP) phosphodiesterase (PDE) is a key regulator of phototransduction in the vertebrate visual system, PDE consists of a catalytic core of alpha and beta subunits associated with two inhibitory gamma subunits. A gene-targeting approach was used to disrupt the mouse PDE gamma gene, This mutation resulted in a rapid retinal degeneration resembling human retinitis pigmentosa. In homozygous mutant mice, reduced rather than increased PDE activity was apparent; the PDE alpha beta dimer was formed but lacked hydrolytic activity, Thus, the inhibitory gamma subunit appears to be necessary for integrity of the photoreceptors and expression of PDE activity in vivo.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT OPHTHALMOL,EDWARD HARKNESS EYE INST,NEW YORK,NY 10032; UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT OPHTHALMOL,LOS ANGELES,CA 90095	Columbia University; Howard Hughes Medical Institute; Columbia University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547; Farber, Debora/0000-0002-3207-697X	NEI NIH HHS [R01 EY008285, K08 EY000408, K08 EY000408-01, EY08285] Funding Source: Medline; NIGMS NIH HHS [T32 GM 073667-14] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008285, K08EY000408] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAYES M, 1995, HUM MUTAT, V5, P228, DOI 10.1002/humu.1380050307; BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; DANCIGER M, 1995, GENOMICS, V3, P1; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; FARBER DB, 1976, J CYCLIC NUCL PROT, V2, P139; FARBER DB, 1974, SCIENCE, V186, P449, DOI 10.1126/science.186.4162.449; FARBER DB, 1992, NEURON, V9, P349, DOI 10.1016/0896-6273(92)90173-B; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GOURAS P, 1994, INVEST OPHTH VIS SCI, V35, P3145; HANH LB, 1994, INVEST OPHTH VIS SCI, V35, P1077; HUANG SH, 1995, INVEST OPHTH VIS SCI, V36, pS825; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KROLL S, 1989, J BIOL CHEM, V264, P4490; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MCINNES RR, 1992, NAT GENET, V1, P155, DOI 10.1038/ng0692-155; MCLAUGHLIN ME, 1995, P NATL ACAD SCI USA, V92, P3249, DOI 10.1073/pnas.92.8.3249; MIKI N, 1975, J BIOL CHEM, V250, P6320; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Papaioannou V., 1993, Gene targeting: a practical approach., P107; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; RAY K, 1994, INVEST OPHTH VIS SCI, V35, P4291; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SHEFFIELD VC, 1991, AM J HUM GENET, V49, P699; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; TSANG S, UNPUB; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; YAMAMOTO S, 1993, INVEST OPHTH VIS SCI, V34, P3068; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9	49	148	151	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1026	1029		10.1126/science.272.5264.1026	http://dx.doi.org/10.1126/science.272.5264.1026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638127	Green Accepted			2022-12-24	WOS:A1996UL61900050
J	Herlitze, S; Garcia, DE; Mackie, K; Hille, B; Scheuer, T; Catterall, WA				Herlitze, S; Garcia, DE; Mackie, K; Hille, B; Scheuer, T; Catterall, WA			Modulation of Ca2+ channels by G-protein beta gamma subunits	NATURE			English	Article							CALCIUM CHANNELS; SYNAPTIC TRANSMISSION; SYMPATHETIC NEURONS; RECEPTORS; INHIBITION	CALCIUM ions entering cells through voltage-gated Ca2+ channels initiate rapid release of neurotransmitters and secretion of hormones. Ca2+ currents can be inhibited in many cell types by neurotransmitters acting through G proteins via a membrane-delimited pathway independently of soluble intracellular messengers(1-4). Inhibition is typically caused by a positive shift in the voltage dependence and a slowing of channel activation and is relieved by strong depolarization resulting in facilitation of Ca2+ currents(1,4-6). This pathway regulates the activity of N-type and P/Q-type Ca2+ channels(1,2,7), which are localized in presynaptic terminals(8,9) and participate in neurotransmitter release(10-13). Synaptic transmission is inhibited by neurotransmitters through this mechanism(1,4). G-protein alpha subunits confer specificity in receptor coupling(1-4,14-17), but it is not known whether the G alpha or G beta gamma subunits are responsible for modulation of Ca2+ channels. Here we report that G beta gamma subunits can modulate Ca2+ channels. Transfection of G beta gamma into cells expressing P/Q-type Ca2+ channels induces modulation like that caused by activation of G protein-coupled receptors, but G alpha subunits do not. Similarly, injection or expression of G beta gamma subunits in sympathetic ganglion neurons induces facilitation and occludes modulation of N-type channels by noradrenaline, but G alpha subunits do not. In both cases, the G gamma subunit is ineffective by itself, but overexpression of exogenous G beta subunits is sufficient to cause channel modulation.	UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT ANESTHESIOL,SEATTLE,WA 98195; NATL AUTONOMOUS UNIV MEXICO,FAC MED,DEPT PHYSIOL,MEXICO CITY 04510,DF,MEXICO	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universidad Nacional Autonoma de Mexico	Herlitze, S (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.		Mackie, Kenneth P/B-7358-2011; Mackie, Ken/E-3715-2013; Garcia, David/A-7626-2008; Garcia, David/AAE-8176-2020	Mackie, Ken/0000-0001-8501-6199; 				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DOLPHIN AC, 1995, EXP PHYSIOL, V80, P1; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hescheler J, 1993, Curr Opin Neurobiol, V3, P360, DOI 10.1016/0959-4388(93)90129-M; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; HIMING LD, 1988, SCIENCE, V239, P57; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SHAPIRO MS, 1994, J NEUROSCI, V14, P7109; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILKBLASZCZAK MA, 1994, NEURON, V13, P1215, DOI 10.1016/0896-6273(94)90059-0; ZHU Y, 1994, NEURON, V13, P657, DOI 10.1016/0896-6273(94)90033-7	30	674	686	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					258	262		10.1038/380258a0	http://dx.doi.org/10.1038/380258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637576				2022-12-24	WOS:A1996UB11700055
J	Verkhovsky, MI; Morgan, JE; Puustinen, A; Wikstrom, M				Verkhovsky, MI; Morgan, JE; Puustinen, A; Wikstrom, M			Kinetic trapping of oxygen in cell respiration	NATURE			English	Article							CYTOCHROME-C-OXIDASE; LOW-SPIN HEME; ELECTRON-TRANSFER; ESCHERICHIA-COLI; FLOW-FLASH; SITE	CELL respiration in eukaryotes is catalysed by the mitochondri`al enzyme cytochrome c oxidase. In bacteria there are many variants of this enzyme, all of which have a binuclear haem iron-copper centre at which O-2 reduction occurs, and a low-spin haem, which serves as the immediate electron donor to this centre(1). It is essential that the components of the cell respiratory system have a high affinity for oxygen because of the low concentrations of dissolved O-2 in the tissues; however, the binding of O-2 to the respiratory haem-copper oxidases is very weak(2,3). This paradox has been attributed to kinetic trapping during fast reactions of O-2 bound within the enzyme's binuclear haem iron-copper centre(2). Our earlier work(3) indicated that electron transfer from the low-spin haem to the oxygen-bound binuclear centre may be necessary for such kinetic oxygen trapping. Here we show that a specific decrease of this haem-haem electron transfer rate in the respiratory haem-copper oxidase from Escherichia coli leads to a corresponding decrease in the enzyme's operational steady-state affinity for O-2. This demonstrates directly that fast electron transfer between the haem groups is a key process in achieving the high affinity for oxygen in cell respiration.	UNIV HELSINKI,BIOCENTRUM HELSINKI,SF-00014 HELSINKI,FINLAND	University of Helsinki	Verkhovsky, MI (corresponding author), UNIV HELSINKI,INST BIOMED SCI,DEPT MED CHEM,HELSINKI BIOENERGET GRP,PB 8,SF-00014 HELSINKI,FINLAND.		Wikstrom, Marten KF/A-4403-2008	Puustinen, Anne/0000-0002-0262-9975; Wikstrom, Marten/0000-0002-7527-4415				BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; CHANCE B, 1975, J BIOL CHEM, V250, P9226; CHANCE B, 1965, J GEN PHYSIOL, V49, P163, DOI 10.1085/jgp.49.1.163; HILL BC, 1984, BIOCHEM J, V218, P913, DOI 10.1042/bj2180913; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; MORGAN JE, 1993, BIOCHEMISTRY-US, V32, P11412; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; PETERSEN LC, 1974, BIOCHEM J, V142, P247, DOI 10.1042/bj1420247; PROVENCHER SW, 1983, PROGR SCI COMPUTING, V2, P304; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; SVENSSON M, 1993, BIOCHEMISTRY-US, V32, P5442, DOI 10.1021/bi00071a021; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042	14	91	91	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					268	270		10.1038/380268a0	http://dx.doi.org/10.1038/380268a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637579				2022-12-24	WOS:A1996UB11700058
J	Cole, NB; Smith, CL; Sciaky, N; Terasaki, M; Edidin, M; LippincottSchwartz, J				Cole, NB; Smith, CL; Sciaky, N; Terasaki, M; Edidin, M; LippincottSchwartz, J			Diffusional mobility of Golgi proteins in membranes of living cells	SCIENCE			English	Article							HUMAN KDEL RECEPTOR; ENDOPLASMIC-RETICULUM; BREFELDIN-A; ELECTRON-MICROSCOPY; RETROGRADE TRANSPORT; LATERAL DIFFUSION; COMPLEX; RETENTION; APPARATUS; FLUORESCENCE	The mechanism by which Golgi membrane proteins are retained with in the Golgi complex in the midst of a continuous flow of protein and lipid is not yet understood. The diffusional mobilities of mammalian Golgi membrane proteins fused with green fluorescent protein from Aequorea victoria were measured in living HeLa cells with the fluorescence photobleaching recovery technique. The diffusion coefficients ranged from 3 x 10(-9) square centimeters per second to 5 x 10(-9) square centimeters per second, with greater than 90 percent of the chimeric proteins mobile. Extensive lateral diffusion of the chimeric proteins occurred between Golgi stacks. Thus, the chimeras diffuse rapidly and freely in Golgi membranes, which suggests that Golgi targeting and retention of these molecules does not depend on protein immobilization.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA; NINCDS, NIH, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; UNIV CONNECTICUT, CTR HLTH, DEPT PHYSIOL, FARMINGTON, CT 06032 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Johns Hopkins University; University of Connecticut			Smith, Christina/GXG-6941-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014584] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI14584] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; Edidin M., 1994, MOBILITY PROXIMITY B, P109; GRIFFITHS G, 1989, J CELL BIOL, V108, P277, DOI 10.1083/jcb.108.2.277; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HSU VW, 1992, CELL, V69, P625, DOI 10.1016/0092-8674(92)90226-3; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JAFFE LA, 1993, DEV BIOL, V156, P566, DOI 10.1006/dbio.1993.1103; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; PETERS P, UNPUB; PRASHER DC, 1992, GENE, V15, P111; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; STORRIE B, 1994, J CELL SCI, V107, P1309; TANAKA K, 1986, J SUBMICR CYTOL PATH, V18, P1; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WEIDMAN PJ, 1995, TRENDS CELL BIOL, V5, P302, DOI 10.1016/S0962-8924(00)89046-7; WEY CL, 1981, BIOPHYS J, V33, P225, DOI 10.1016/S0006-3495(81)84883-7; WIER ML, 1986, J CELL BIOL, V103, P215, DOI 10.1083/jcb.103.1.215	36	394	407	3	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					797	801		10.1126/science.273.5276.797	http://dx.doi.org/10.1126/science.273.5276.797			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670420				2022-12-24	WOS:A1996VB42900043
J	Ginsburg, GS; Agil, A; OToole, M; Rimm, E; Douglas, PS; Rifai, N				Ginsburg, GS; Agil, A; OToole, M; Rimm, E; Douglas, PS; Rifai, N			Effects of a single bout of ultraendurance exercise on lipid levels and susceptibility of lipids to peroxidation in triathletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; DENSITY-LIPOPROTEIN; IRON; RISK; MEN; PLASMA; CELLS	Objective.-To determine the effects of a single bout of ultraendurance exercise, as a model for physiologic stress, on lipid and lipoprotein levels, and oxidative susceptibility of lipids in highly trained athletes. Design.-Observational trial. Population and Setting.-Thirty-nine volunteer subjects (26 men, 13 women; mean age, 38+/-10 years) who competed in and completed the 1994 Hawaii Ironman World Championship Triathlon consisting of a consecutive 3.9-km (2.4-mi) swim, 180.2-km (112-mi) bike ride, and a 42.2-km (26.2-mi) run. Subjects answered questionnaires and had blood samples obtained 2 days prior to and within 15 minutes of completion of the triathlon. Main Outcome Measures.-Prerace vs postrace changes in lipid and lipoprotein levels, and susceptibility of lipids to peroxidation. Results.-The mean duration of exercise was 753+/-128 minutes. With exercise, plasma volume-corrected levels of triglycerides decreased 39% from 1.58+/-0.83 to 0.97+/-0.68 mmol/L (139.6+/-73.6 to 85.8+/-60.5 mg/dL) (P<.001). Levels of total cholesterol decreased 9% from 4.94+/-0.88 to 4.50+/-0.79 mmol/L (190.8+/-33.8 to 173.8+/-30.6 mg/dL) (P<.001), low-density lipoprotein cholesterol decreased 11% from 2.59+/-0.77 to 2.30+/-0.86 mmol/L (100.1+/-29.9 to 88.7+/-33.3 mg/dL) (P=.02), and apolipoprotein B decreased 10% from 0.91+/-0.20 to 0.82+/-0.18 g/L (90.7+/-20.0 to 82.0+/-17.9 mg/dL) (P<.001). High-density lipoprotein cholesterol and apolipoprotein A-I increased with exercise but not significantly. The susceptibility of lipids to peroxidation decreased significantly (4.51+/-1.91 mu mol/L, preexercise, vs 2.42+/-2.27 mu mol/L, postexercise, P<.001), an effect that was not related to antioxidant use or levels of vitamins A, C, or E. Serum iron, a potential pro-oxidant, also decreased by 45% with exercise from 15.75+/-5.55 to 8.59+/-4.30 mu mol/L (88+/-31 to 48+/-24 mu g/dL) (P<.001), an effect that was weakly correlated with changes in lipid peroxidation (P=.05). Conclusions.-These data suggest that a single bout of prolonged exercise can reduce lipid and lipoprotein risk factors for developing cardiovascular disease. Moreover, susceptibility of lipids to peroxidation is reduced by exercise, thereby adding to the benefits of physical activity. This effect appears to be independent of antioxidant supplement use and may be mediated by induction of endogenous antioxidants. These observations may explain in part the reduced risk of developing vascular and other diseases in individuals who are physically active.	CHILDRENS HOSP,DEPT CARDIOL,BOSTON,MA 02115; CHILDRENS HOSP,DEPT LAB MED,BOSTON,MA 02115; UNIV GRANADA,DEPT PHARMACOL,E-18071 GRANADA,SPAIN; UNIV TENNESSEE,DEPT ORTHOPED,MEMPHIS,TN; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; University of Granada; University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ginsburg, GS (corresponding author), BETH ISRAEL HOSP,DIV CARDIOVASC,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Agil, Ahmad/D-9620-2014	Douglas, Pamela/0000-0001-9876-4049; Agil, Ahmad/0000-0003-0164-9648				AGIL A, 1995, CLIN CHEM, V41, P220; APPLEGATE E A, 1989, Medicine and Science in Sports and Exercise, V21, pS48; ASCHERIO A, 1994, CIRCULATION, V89, P969, DOI 10.1161/01.CIR.89.3.969; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CATIGNANI GL, 1983, CLIN CHEM, V29, P708; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DEMBACH AR, 1993, J APPL PHYSIOL, V74, P2140; DILL DB, 1974, J APPL PHYSIOL, V37, P247, DOI 10.1152/jappl.1974.37.2.247; Durstine J L, 1994, Exerc Sport Sci Rev, V22, P477; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; KANTER MM, 1994, INT J SPORT NUTR, V4, P205, DOI 10.1123/ijsn.4.3.205; Murray MJ, 1991, ARTERIOSCLER THROMB, V11, p1479A; OTOOLE ML, 1995, CLIN J SPORT MED, V5, P116, DOI 10.1097/00042752-199504000-00008; OTOOLE ML, 1989, MED SCI SPORT EXER, V21, pS209; OTTLINGER ME, 1995, CLIN CHEM, V41, pS158; PIOTROWSKI JJ, 1990, LIFE SCI, V46, P715, DOI 10.1016/0024-3205(90)90077-5; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALMINEN A, 1983, ACTA PHYSIOL SCAND, V117, P109, DOI 10.1111/j.1748-1716.1983.tb07184.x; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; Salonen Jukka T., 1993, Current Opinion in Lipidology, V4, P277, DOI 10.1097/00041433-199308000-00003; SAS Institute Inc, 1993, SAS US GUID STAT VER; SEMPOS CT, 1994, NEW ENGL J MED, V330, P1119, DOI 10.1056/NEJM199404213301604; SJODIN B, 1990, SPORTS MED, V10, P236; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; TAYLOR C, 1987, J APPL PHYSIOL, V62, P464, DOI 10.1152/jappl.1987.62.2.464; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WU LL, 1989, CLIN CHEM, V35, P1486; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5	30	59	59	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					221	225		10.1001/jama.276.3.221	http://dx.doi.org/10.1001/jama.276.3.221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667567				2022-12-24	WOS:A1996UW46900034
J	Shao, XG; Davletov, BA; Sutton, RB; Sudhof, TC; Rizo, J				Shao, XG; Davletov, BA; Sutton, RB; Sudhof, TC; Rizo, J			Bipartite Ca2+-binding motif in C-2 domains of synaptotagmin and protein kinase C	SCIENCE			English	Article							PHOSPHOLIPID-BINDING; ACTIVATION	C-2 domains are found in many proteins involved in membrane traffic or signal transduction. Although C-2 domains are thought to bind calcium ions, the structural basis for calcium binding is unclear. Analysis of calcium binding to C-2 domains of synaptotagmin I and protein kinase C-beta by nuclear magnetic resonance spectroscopy revealed a bipartite calcium-binding motif that involves the coordination of two calcium ions by five aspartate residues located on two separate loops. Sequence comparisons indicated that this may be a widely used calcium-binding motif, designated here as the C-2 motif.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275	NIMH NIH HHS [R01-MH52804-01] Funding Source: Medline; NINDS NIH HHS [R29 NS33731-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033731] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GRONENBORN AM, 1990, ANAL CHEM, V62, P2, DOI 10.1021/ac00200a003; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LUO JH, 1993, J BIOL CHEM, V268, P23580; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RIZO J, 1994, J BIOMOL NMR, V4, P741, DOI 10.1007/BF00398406; SHAO XF, UNPUB; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	22	284	296	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					248	251		10.1126/science.273.5272.248	http://dx.doi.org/10.1126/science.273.5272.248			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8662510				2022-12-24	WOS:A1996UW78700044
J	GalchevaGargova, Z; Konstantinov, KN; Wu, IH; Klier, FG; Barrett, T; Davis, RJ				GalchevaGargova, Z; Konstantinov, KN; Wu, IH; Klier, FG; Barrett, T; Davis, RJ			Binding of zinc finger protein ZPR1 to the epidermal growth factor receptor	SCIENCE			English	Article							SIGNAL TRANSDUCTION; TYROSINE KINASE; SH3 DOMAINS; A431 CELLS; MECHANISM; AFFINITY	ZPR1 is a zinc finger protein that binds to the cytoplasmic tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Deletion analysis demonstrated that this binding interaction is mediated by the zinc fingers of ZPR1 and subdomains X and XI of the EGFR tyrosine kinase. Treatment of mammalian cells with EGF caused decreased binding of ZPR1 to the EGFR and the accumulation of ZPR1 in the nucleus. The effect of EGF to regulate ZPR1 binding is dependent on tyrosine phosphorylation of the EGFR. ZPR1 therefore represents a prototype for a class of molecule that binds to the EGFR and is released from the receptor after activation.	UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Scripps Research Institute; Scripps Research Institute					NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRITZLER MJ, 1994, MOL BIOL CELL, V5, P1043; GALCHEVA Z, UNPUB; GREGORIOU M, 1994, EUR J BIOCHEM, V223, P455, DOI 10.1111/j.1432-1033.1994.tb19013.x; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P2198, DOI 10.1210/en.136.5.2198; GRONOWSKI AM, 1993, ENDOCRINOLOGY, V133, P2836; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HU HM, 1994, J BIOL CHEM, V269, P30069; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONSTANTINOV KN, UNPUB; KOTZIN BL, 1984, J IMMUNOL, V133, P2554; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROY LM, 1991, J CELL PHYSIOL, V146, P63, DOI 10.1002/jcp.1041460109; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WU RY, 1994, J BIOL CHEM, V269, P25085	35	92	100	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1797	1802		10.1126/science.272.5269.1797	http://dx.doi.org/10.1126/science.272.5269.1797			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650580				2022-12-24	WOS:A1996UT11000046
J	Xu, DM; Nouraini, S; Field, D; Tang, SJ; Friesen, JD				Xu, DM; Nouraini, S; Field, D; Tang, SJ; Friesen, JD			An RNA-dependent ATPase associated with U2/U6 snRNAs in pre-mRNA splicing	NATURE			English	Article							SMALL NUCLEAR-RNA; YEAST; PROTEIN; SPLICEOSOME; MECHANISM; SUGGESTS; FIDELITY; PATHWAY; ROLES; U2	THE hydrolysis of ATP by a group of RNA dependent ATPases (DEAD/H proteins(1)) is required for spliceosome assembly, but not for the subsequent transesterification reactions(2). Little is known about the function of these ATPases in relation to the RNA conformational changes that occur in formation of active structures, in which U2/U6 small nuclear RNA (snRNA) interactions(3,4) are essential for splicing to take place, Using a synthetic lethal genetic screen, we have isolated four yeast splicing factors involved in U2/U6 snRNA interactions (D.X. et al., manuscript in preparation). The RNA-dependent ATPase activity associated with one such factor, the Slt22 protein, is stimulated preferentially by annealed U2/U6 snRNAs. Both mutant slt22-1 and U2 snRNA cause a reduction in stimulation, The slt22-1 mutation blocks splicing at or before the first step, resulting in the accumulation of an unusual complex which lacks U5 snRNA. Our results indicate that the U2/U6 snRNA interactions facilitated by Slt22 are also Involved in the interaction of U5 snRNA with tire spliceosome.	HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; BURGESS SM, 1993, TRENDS BIOCHEM SCI, V18, P381, DOI 10.1016/0968-0004(93)90094-4; BURGESS SM, 1993, CELL, V73, P1377, DOI 10.1016/0092-8674(93)90363-U; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; Field DJ, 1996, GENE DEV, V10, P489, DOI 10.1101/gad.10.4.489; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; FULLERPACE FV, 1993, EMBO J, V12, P369; JONES MH, 1995, P NATL ACAD SCI USA, V92, P9687, DOI 10.1073/pnas.92.21.9687; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAUBER J, IN PRESS EMBO J; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; Moore M., 1993, RNA WORLD, P303; Newman AJ, 1995, RNA, V1, P968; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; TAM WY, 1993, P NATL ACAD SCI USA, V90, P10821; [No title captured]	25	70	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	1996	381	6584					709	713		10.1038/381709a0	http://dx.doi.org/10.1038/381709a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649518				2022-12-24	WOS:A1996UR97900056
J	Ernst, M; Zametkin, AJ; Matochik, JA; Pascualvaca, D; Jons, PH; Hardy, K; Hankerson, JG; Doudet, DJ; Cohen, RM				Ernst, M; Zametkin, AJ; Matochik, JA; Pascualvaca, D; Jons, PH; Hardy, K; Hankerson, JG; Doudet, DJ; Cohen, RM			Presynaptic dopaminergic deficits in Lesch-Nyhan disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; F-18 DOPA; PARKINSONS-DISEASE; BRAIN; MODEL; BEHAVIOR; NEUROTRANSMITTERS; CARBIDOPA; MONKEYS	Background. Lesch-Nyhan disease is a rare, devastating, X-linked recessive disorder of purine synthesis. Patients present with hyperuricemia, choreoathetosis, dystonia, and aggressive and self-injurious behavior. Although the genetic and biochemical abnormalities have been identified, the causes of the neuropsychiatric syndrome remain unclear. Methods. We used positron-emission tomography to measure presynaptic accumulation of fluorodopa F 18 tracer in the dopaminergic regions of the brains of 12 patients with Lesch-Nyhan disease (age, 10 to 20 years) and 15 healthy controls (age, 12 to 23). The results were expressed as ratios of specific to nonspecific radioactive counts. A low ratio indicates decreased dopa decarboxylase activity and dopamine storage. Results. The fluorodopa F 18 ratio was significantly lower in the putamen (31 percent of control values), caudate nucleus (39 percent), frontal cortex (44 percent), and ventral tegmental complex (substantia nigra and ventral tegmentum; 57 percent) in the patients with Lesch-Nyhan disease than in the controls. Uptake of the tracer was abnormally low even in the youngest patients tested, and there was no overlap in the values between patients and controls. Conclusions. Patients with Lesch-Nyhan disease have abnormally few dopaminergic nerve terminals and cell bodies. The abnormality involves all dopaminergic pathways and is not restricted to the basal ganglia. These dopaminergic deficits are pervasive and appear to be developmental in origin, which suggests that they contribute to the characteristic neuropsychiatric manifestations of the disease. (C) 1996, Massachusetts Medical Society.	NIMH,PSYCHOL & PSYCHOPATHOL LAB,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT ANESTHESIOL,BETHESDA,MD 20892; UNIV BRITISH COLUMBIA,VANCOUVER,BC V5Z 1M9,CANADA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of British Columbia	Ernst, M (corresponding author), NIMH,CEREBRAL METAB LAB,BLDG 36,CONVENT DR,MSC 4030,BETHESDA,MD 20892, USA.			Hardy, Kristina/0000-0002-5479-5043				ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDERSON LT, 1992, J AUTISM DEV DISORD, V22, P189, DOI 10.1007/BF01058150; ANDERSON LT, 1994, J AUTISM DEV DISORD, V24, P67, DOI 10.1007/BF02172213; BOYES BE, 1986, LIFE SCI, V39, P2243, DOI 10.1016/0024-3205(86)90403-0; BREESE GR, 1984, PHARMACOL BIOCHEM BE, V21, P459, DOI 10.1016/S0091-3057(84)80110-0; BROOKS DJ, 1990, ANN NEUROL, V28, P547, DOI 10.1002/ana.410280412; CASASBRUGE M, 1985, LANCET, V1, P991; DOUDET DJ, 1992, J NUCL MED, V33, P1383; DOUDET DJ, 1992, PSYCHIAT RES-NEUROIM, V45, P153, DOI 10.1016/0925-4927(92)90023-W; DUNNETT SB, 1989, BRAIN RES, V501, P401, DOI 10.1016/0006-8993(89)90659-8; FREEMAN TB, 1991, EXP NEUROL, V113, P344, DOI 10.1016/0014-4886(91)90025-8; GJEDDE A, 1986, SOC NEUROSCI, V12; GOLDSTEIN M, 1986, BRAIN RES, V367, P114, DOI 10.1016/0006-8993(86)91584-2; HARRIS J, 1991, SOC NEUROSCI, V17; HARRIS J, 1994, 41 ANN M AM AC CHILD, V10; HOLLINGSHEAD AB, 1958, SOCIAL CLASS MENTAL, P387; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JANKOVIC J, 1988, ANN NEUROL, V23, P466, DOI 10.1002/ana.410230507; JINNAH HA, 1994, J NEUROSCI, V14, P1164; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LAKE CR, 1977, SCIENCE, V196, P905, DOI 10.1126/science.860124; LEENDERS KL, 1990, ARCH NEUROL-CHICAGO, V47, P1290, DOI 10.1001/archneur.1990.00530120034007; LESCH M, 1964, AM J MED, V36, P561, DOI 10.1016/0002-9343(64)90104-4; LLOYD KG, 1981, NEW ENGL J MED, V305, P1106, DOI 10.1056/NEJM198111053051902; MATSUI T, 1978, ATLAS HUMAN BRAIN CO; MCLELLAN CA, 1991, APPL RADIAT ISOTOPES, V42, P847; OLSON L, 1973, Z ANAT ENTWICKLUNGS, V139, P259, DOI 10.1007/BF00519968; Reich W., 1988, DIAGNOSTIC INTERVIEW; Sattler, 1986, STANFORD BINET INTEL; SAWLE GV, 1992, ANN NEUROL, V32, P609, DOI 10.1002/ana.410320503; SEMPLE WE, 1993, IMAGING DRUG ACTION, P297; SILANI V, 1994, EXP NEUROL, V128, P59, DOI 10.1006/exnr.1994.1113; SILVERSTEIN FS, 1985, NEUROLOGY, V35, P907, DOI 10.1212/WNL.35.6.907; Tanner J.M., 1962, GROWTH ADOLESCENCE, V2nd ed.; WATTS RWE, 1982, Q J MED, V201, P43; WECHSLER D, 1974, WISC 3 WECHSLER INTE; Wechsler D., 1981, WAIS R WECHSLER ADUL; WONG DF, 1992, SOC NEUROSCI, V18	39	134	138	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1568	1572		10.1056/NEJM199606133342403	http://dx.doi.org/10.1056/NEJM199606133342403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP663	8628337	Bronze			2022-12-24	WOS:A1996UP66300003
J	Jiang, W; Babyak, M; Krantz, DS; Waugh, RA; Coleman, RE; Hanson, MM; Frid, DJ; McNulty, S; Morris, JJ; OConnor, CM; Blumenthal, JA				Jiang, W; Babyak, M; Krantz, DS; Waugh, RA; Coleman, RE; Hanson, MM; Frid, DJ; McNulty, S; Morris, JJ; OConnor, CM; Blumenthal, JA			Mental stress-induced myocardial ischemia and cardiac events	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; STABLE ANGINA-PECTORIS; SEGMENT DEPRESSION; PROGNOSTIC VALUE; SILENT ISCHEMIA; HEART-DISEASE; DAILY LIFE; INFARCTION; EXERCISE; ANGIOGRAPHY	Objective.-To assess the clinical significance of mental stress-induced myocardial ischemia in patients with coronary artery disease (CAD). Design and Setting.-Cohort study in outpatients in a tertiary care teaching hospital assessed at baseline and followed up for up to 5 years. Subjects.-A total of 126 volunteer patients (112 men, 14 women; mean age, 59 years) with documented CAD and exercise-induced myocardial ischemia. Outcome Measures.-Patients underwent baseline mental stress and exercise testing using radionuclide ventriculography and 48-hour Holter monitoring. Patients were subsequently contacted by mailed questionnaires or telephone to document cardiac events, including death, nonfatal myocardial infarction, and cardiac revascularization procedures, Logistic regression and Cox proportional hazards models were used to examine the prognostic value of the ischemic measures after adjusting for such potential confounding factors as age, baseline left ventricular ejection fraction (LVEF), and history of myocardial infarction. Results.-Twenty-eight patients (22%) experienced at least 1 cardiac event, Baseline mental stress-induced ischemia was associated with significantly higher rates of subsequent cardiac events (odds ratio, 2.8; 95% confidence interval [CI], 1.0-7.7; P<.05), The LVEF change during mental stress was significantly related to event-free survival (risk ratio [RR], 2.4; 95% CI, 1.12-5.14; P=.02), controlling for age, history of prior myocardial infarction, and baseline LVEF. This relationship remained significant after controlling for electrocardiogram (ECG)-defined ischemia during exercise (RR, 2.2; 95% CI, 1.01-4.81; P<.05). The RR for EGG-defined ischemia during exercise testing was 1,9 (95% CI, 0.95-3.96; P=.07) and the RR for ambulatory ECG ischemia was 0.75 (95% CI, 0.35-1.64; P=.47). Conclusions.-The presence of mental stress-induced ischemia is associated with significantly higher rates of subsequent fatal and nonfatal cardiac events, independent of age, baseline LVEF, and previous myocardial infarction, and predicted events over and above exercise-induced ischemia, These data suggest that the relationship between psychological stress and adverse cardiac events may be mediated by the occurrence of myocardial ischemia.	DUKE UNIV,CTR LIVING,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PSYCHIAT & BEHAV SCI,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT RADIOL,DURHAM,NC 27710; UNIFORMED SERV UNIV HLTH SCI,DEPT MED CLIN PSYCHOL,BETHESDA,MD 20814	Duke University; Duke University; Duke University; Duke University; Uniformed Services University of the Health Sciences - USA			Krantz, David S./L-5364-2015	Krantz, David/0000-0002-1671-1355	NHLBI NIH HHS [HL 43028, HL 49572, HL 47337] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047337, R01HL049572, R01HL043028] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM RD, 1986, AM J CARDIOL, V58, P423, DOI 10.1016/0002-9149(86)90008-1; BARRY J, 1988, AM J CARDIOL, V61, P989, DOI 10.1016/0002-9149(88)90112-9; BLUMENTHAL JA, 1995, CIRCULATION, V92, P2102, DOI 10.1161/01.CIR.92.8.2102; BLUMENTHAL JA, 1987, APPL BEHAV MED HLTH, P3; Burg MM, 1993, J AM COLL CARDIOL, V22, P440, DOI 10.1016/0735-1097(93)90048-6; CORBETT JR, 1981, CIRCULATION, V64, P535, DOI 10.1161/01.CIR.64.3.535; COX DR, 1972, J R STAT SOC B, V34, P187; DAKAK N, 1995, AM J CARDIOL, V76, P125, DOI 10.1016/S0002-9149(99)80043-5; DEANFIELD JE, 1984, LANCET, V2, P1001; DEANFIELD JE, 1983, LANCET, V2, P753; DEEDWANIA PC, 1990, CIRCULATION, V81, P748, DOI 10.1161/01.CIR.81.3.748; FRASURESMITH N, 1989, PSYCHOSOM MED, V51, P485, DOI 10.1097/00006842-198909000-00002; FRIEDMAN M, 1986, AM HEART J, V112, P653, DOI 10.1016/0002-8703(86)90458-8; FULLER CM, 1981, ANN INTERN MED, V94, P734, DOI 10.7326/0003-4819-94-6-734; Gabbay FH, 1996, J AM COLL CARDIOL, V27, P585, DOI 10.1016/0735-1097(95)00510-2; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; Gill JB, 1996, NEW ENGL J MED, V334, P65, DOI 10.1056/NEJM199601113340201; GOTTDIENER JS, 1994, J AM COLL CARDIOL, V24, P1645, DOI 10.1016/0735-1097(94)90169-4; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; IRONSON G, 1992, AM J CARDIOL, V70, P281, DOI 10.1016/0002-9149(92)90605-X; JAIN D, 1995, AM J CARDIOL, V76, P31, DOI 10.1016/S0002-9149(99)80796-6; JIANG W, 1995, AM J CARDIOL, V76, P350, DOI 10.1016/S0002-9149(99)80099-X; LEGAULT SE, 1995, AM J CARDIOL, V75, P1007, DOI 10.1016/S0002-9149(99)80713-9; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; MILLER TQ, 1994, J BEHAV MED, V17, P567, DOI 10.1007/BF01857598; NEWMAN GF, 1980, CIRCULATION, V62, P1204, DOI 10.1161/01.CIR.62.6.1204; PETERSON ED, 1995, CIRCULATION, V92, P272; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; STERN S, 1974, BRIT HEART J, V36, P481; TALIERCIO CP, 1988, MAYO CLIN PROC, V63, P573, DOI 10.1016/S0025-6196(12)64887-3; TAVAZZI L, 1990, ADV CARDIOL, V37, P53; Trauner Michael A., 1994, Annals of Behavioral Medicine, V16, P24; TZIVONI D, 1989, AM J CARDIOL, V63, P273, DOI 10.1016/0002-9149(89)90329-9; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205; YEUNG AC, 1991, CIRCULATION, V83, P1598, DOI 10.1161/01.CIR.83.5.1598	38	252	260	3	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1651	1656		10.1001/jama.275.21.1651	http://dx.doi.org/10.1001/jama.275.21.1651			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637138				2022-12-24	WOS:A1996UN25200027
J	Lecuit, T; Brook, WJ; Ng, M; Calleja, M; Sun, H; Cohen, SM				Lecuit, T; Brook, WJ; Ng, M; Calleja, M; Sun, H; Cohen, SM			Two distinct mechanisms for long-range patterning by decapentaplegic in the Drosophila wing	NATURE			English	Article							OPTOMOTOR-BLIND; GENE-EXPRESSION; MELANOGASTER; MORPHOGENESIS; THRESHOLDS; ACTIVIN; HOMOLOG	Secreted signalling molecules provide cells with positional information that organizes long-range pattern during the development of multicellular animals. Evidence is presented that localized expression of Decapentaplegic instructs cells about their position along the anterior-posterior axis of the Drosophila wing in two distinct ways. One mechanism is based on the local concentration of the secreted protein; the other is based on the ability of the cells to retain an instruction received at an earlier time when their progenitors were in close proximity to the signal. Both mechanisms are involved in axis formation.	EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV AUTONOMA MADRID, E-28029 MADRID, SPAIN; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	European Molecular Biology Laboratory (EMBL); Autonomous University of Madrid; Academia Sinica - Taiwan			Sun, Y. Henry/ABC-4614-2021; Cohen, Stephen M/G-9930-2011; Sun, Y. Henry/AAZ-7966-2021	Sun, Y. Henry/0000-0001-8279-5270; Cohen, Stephen M/0000-0003-2858-9163; 				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DURINBORKOWSKI OA, 1995, DEV BIOL, V168, P689; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Ng M, 1996, NATURE, V381, P316, DOI 10.1038/381316a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PFLUGFELDER GO, 1990, GENETICS, V126, P91; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; RAFTERY LA, 1995, GENETICS, V139, P241; SANICOLA M, 1995, GENETICS, V139, P745; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SIMMONDS AJ, 1995, NATURE, V376, P424, DOI 10.1038/376424a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; WIERSDORFF V, IN PRESS DEVELOPMENT; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WOLPERT L, 1989, DEVELOPMENT, V107, P3; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036; ZECCA M, 1995, DEVELOPMENT, V121, P2265	44	559	565	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 30	1996	381	6581					387	393		10.1038/381387a0	http://dx.doi.org/10.1038/381387a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632795				2022-12-24	WOS:A1996UN47900041
J	[Anonymous]				[Anonymous]			How not to act on good advice	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					351	351						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632781				2022-12-24	WOS:A1996UN47900001
J	Matsumine, A; Ogai, A; Senda, T; Okumura, N; Satoh, K; Baeg, GH; Kawahara, T; Kobayashi, S; Okada, M; Toyoshima, K; Akiyama, T				Matsumine, A; Ogai, A; Senda, T; Okumura, N; Satoh, K; Baeg, GH; Kawahara, T; Kobayashi, S; Okada, M; Toyoshima, K; Akiyama, T			Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein	SCIENCE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; IMMUNOELECTRON MICROSCOPY; SEPTATE JUNCTIONS; MEMBRANE-PROTEIN; GENE-PRODUCT; IDENTIFICATION; MUTATIONS; CHROMOSOME-5Q21; ASSOCIATION; CANCER	The adenomatous polyposis coli gene (APC) is mutated in familial adenomatous polyposis and in sporadic colorectal tumors, and its product binds to the adherens junction protein beta-catenin. Overexpression of APC blocks cell cycle progression, The APC-beta-catenin complex was shown to bind to DLG, the human homolog of the Drosophila discs large tumor suppressor protein, This interaction required the carboxyl-terminal region of APC and the DLG homology repeat region of DLG. APC colocalized with DLG at the lateral cytoplasm in rat colon epithelial cells and at the synapse in cultured hippocampal neurons. These results suggest that the APC-DLG complex may participate in regulation of both cell cycle progression and neuronal function.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,SCH MED,DEPT ANAT 1,NAGOYA,AICHI 466,JAPAN; OSAKA UNIV,INST PROT RES,DIV PROT METAB,SUITA,OSAKA 565,JAPAN; CTR ADULT DIS,OSAKA 537,JAPAN	Osaka University; Nagoya University; Osaka University			Baeg, Gyeong-Hun/A-2951-2008; Satoh, Kiyotoshi/M-3653-2017	Satoh, Kiyotoshi/0000-0001-6029-6534				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bartel PL, 1993, USING 2 HYBRID SYSTE, P153; BHAT RV, 1994, J NEUROSCI, V14, P3059; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MATSUMINE A, UNPUB; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; MUNEMITSU S, 1994, CANCER RES, V54, P3676; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SENDA T, UNPUB; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	36	399	410	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1020	1023		10.1126/science.272.5264.1020	http://dx.doi.org/10.1126/science.272.5264.1020			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638125				2022-12-24	WOS:A1996UL61900048
J	Rubinfeld, B; Albert, I; Porfiri, E; Fiol, C; Munemitsu, S; Polakis, P				Rubinfeld, B; Albert, I; Porfiri, E; Fiol, C; Munemitsu, S; Polakis, P			Binding of GSK3 beta to the APC-beta-catenin complex and regulation of complex assembly	SCIENCE			English	Article							CYTOPLASMIC DOMAIN; GENE-PRODUCT; E-CADHERIN; MUTATIONS; IDENTIFICATION; PROTEIN; CHROMOSOME-5Q21; PHOSPHORYLATION; ASSOCIATION; ANTIBODIES	The adenomatous polyposis coli gene (APC) is mutated in most colon cancers. The APC protein binds lo the cellular adhesion molecule beta-catenin, which is a mammalian homolog of ARMADILLO, a component of the WINGLESS signaling pathway in Drosophila development. Here it is shown that when beta-catenin is present in excess, APC binds to another component of the WINGLESS pathway, glycogen synthase kinase 3 beta (GSK3 beta), a mammalian homolog of Drosophila ZESTE WHITE 3. APC was a good substrate for GSK3 beta in vitro, and the phosphorylation sites were mapped to the central region of APC. Binding of beta-catenin to this region was dependent on phosphorylation by GSK3 beta.	ONYX PHARMACEUT,RICHMOND,CA 94806; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis				Rubinfeld, Bonnee/0000-0001-9861-6775				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, UNPUB; MUNEMITSU S, 1995, P NATL ACAD SCI US, V92; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; WANG QM, 1994, ANAL BIOCHEM, V220, P397, DOI 10.1006/abio.1994.1356	30	1234	1280	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1023	1026		10.1126/science.272.5264.1023	http://dx.doi.org/10.1126/science.272.5264.1023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638126				2022-12-24	WOS:A1996UL61900049
J	Nkata, M				Nkata, M			Rupture of the uterus: A review of 32 cases in a general hospital in Zambia	BRITISH MEDICAL JOURNAL			English	Article							MATERNAL MORTALITY				Nkata, M (corresponding author), MANSA GEN HOSP,POB 710156,MANSA,ZAMBIA.							CHIPHANGWI JD, 1992, E AFR MED J, V69, P675; FALEYIMU BL, 1990, TROP DOCT, V20, P188, DOI 10.1177/004947559002000425; SUNDARI TK, 1992, INT J HEALTH SERV, V22, P513, DOI 10.2190/91YH-A52T-AFBB-1LEA; VEALE DJH, 1992, J ETHNOPHARMACOL, V36, P185, DOI 10.1016/0378-8741(92)90043-Q	4	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1204	1205						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634565				2022-12-24	WOS:A1996UL05800022
J	Tokiwa, G; Dikic, I; Lev, S; Schlessinger, J				Tokiwa, G; Dikic, I; Lev, S; Schlessinger, J			Activation of Pyk2 by stress signals and coupling with JNK signaling pathway	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; RAS; CDC42HS; IDENTIFICATION; SUBFAMILY; DOMAIN; BINDS; CELLS; RAC1; ERK	The c-Jun amino-terminal kinase (JNK) is activated by various heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors, inflammatory cytokines, and stress signals. Yet, upstream mediators that link extracellular signals with the JNK signaling pathway are currently unknown. The tyrosine kinase Pyk2 was activated by tumor necrosis factor alpha, by ultraviolet irradiation, and by changes in osmolarity. Overexpression of Pyke led to activation of JNK, and a dominant-negative mutant of Pyk2 interfered with ultraviolet light- or osmotic shock-induced activation of JNK. Pyk2 represents a cell type-specific, stress-sensitive mediator of the JNK signaling pathway.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; SUGEN,REDWOOD CITY,CA 94063	New York University			Lev, Sima/AAP-7880-2020; Dikic, Ivan/O-4650-2015	Lev, Sima/0000-0002-2108-3330; Dikic, Ivan/0000-0001-8156-9511				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIKIC I, UNPUB; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOKIWA G, UNPUB	24	286	291	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					792	794		10.1126/science.273.5276.792	http://dx.doi.org/10.1126/science.273.5276.792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670418				2022-12-24	WOS:A1996VB42900041
J	Wang, FS; Wolenski, JS; Cheney, RE; Mooseker, MS; Jay, DG				Wang, FS; Wolenski, JS; Cheney, RE; Mooseker, MS; Jay, DG			Function of myosin-V in filopodial extension of neuronal growth cones	SCIENCE			English	Article							ASSISTED LASER INACTIVATION; GRASSHOPPER PIONEER NEURONS; UNCONVENTIONAL MYOSIN; NERVE GROWTH; PROTEIN FUNCTION; MOTOR-ACTIVITY; FASCICLIN-I; MOTILITY; CELLS; IDENTIFICATION	The molecular mechanisms underlying directed motility of growth cones have not been determined, The role of myosin-V, an unconventional myosin, in growth cone dynamics was examined by chromophore-assisted laser inactivation (CALI), CALI of purified chick brain myosin-V absorbed onto nitrocellulose-coated cover slips inhibited the ability of myosin-V to translocate actin filaments. CALI of myosin-V in growth cones of chick dorsal root ganglion neurons resulted in rapid filopodial retraction, The rate of filopodial extension was significantly decreased, whereas the rate of filopodial retraction was not affected, which suggests a specific role for myosin-V in filopodial extension.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Harvard University; Yale University				Cheney, Richard/0000-0001-6565-7888	NINDS NIH HHS [NS-34699, NS-29007] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS029007, R01NS029007, R01NS034699] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P11767; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; Bray D., 1991, CULTURING NERVE CELL, P119; BUETTNER HM, 1994, DEV BIOL, V163, P407, DOI 10.1006/dbio.1994.1158; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; DAVENPORT RW, 1993, NATURE, V361, P721, DOI 10.1038/361721a0; DIAMOND P, 1993, NEURON, V11, P409, DOI 10.1016/0896-6273(93)90146-I; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; JAY DG, 1988, P NATL ACAD SCI USA, V85, P5454, DOI 10.1073/pnas.85.15.5454; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; LIAO JC, 1995, PHOTOCHEM PHOTOBIOL, V62, P923; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; LINDEN KG, 1992, BIOPHYS J, V61, P956, DOI 10.1016/S0006-3495(92)81902-1; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NOVAK KD, 1992, MOL BIOL CELL, V3, pA3; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; SCHMUCKER D, 1994, P NATL ACAD SCI USA, V91, P2664, DOI 10.1073/pnas.91.7.2664; SCHROEDER R, IN PRESS DEV GENES F; SHEETZ MP, 1992, CELL MOTIL CYTOSKEL, V22, P160, DOI 10.1002/cm.970220303; SIMON VR, 1995, J CELL BIOL, V130, P345, DOI 10.1083/jcb.130.2.345; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; SPRINGER ML, 1994, DEVELOPMENT, V120, P2651; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; SYDOR AM, IN PRESS J CELL BIOL; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WOLENSKI JS, 1995, J CELL SCI, V108, P1489; WOLENSKI JS, 1993, J EXP ZOOL, V267, P33, DOI 10.1002/jez.1402670106; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	40	164	165	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					660	663		10.1126/science.273.5275.660	http://dx.doi.org/10.1126/science.273.5275.660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662560				2022-12-24	WOS:A1996VA24900052
J	OwenHughes, T; Utley, RT; Cote, J; Peterson, CL; Workman, JL				OwenHughes, T; Utley, RT; Cote, J; Peterson, CL; Workman, JL			Persistent site-specific remodeling of a nucleosome array by transient action of the SWI/SNF complex	SCIENCE			English	Article							TRANSCRIPTION FACTOR-BINDING; FACILITATED BINDING; YEAST; DNA; DISRUPTION; HISTONES; GAL4; ENHANCEMENT; ACTIVATORS; PROTEINS	The SWI/SNF complex participates in the restructuring of chromatin for transcription. The function of the yeast SWI/SNF complex in the remodeling oi a nucleosome array has now been analyzed in vitro. Binding of the purified SWI/SNF complex to a nucleosome array disrupted multiple nucleosomes in an adenosine triphosphate-dependent reaction. However, removal of SWI/SNF left a deoxyribonuclease I-hypersensitive site specifically at a nucleosome that was bound by derivatives of the transcription factor Gal4p. Analysis of individual nucleosomes revealed that the SWI/SNF complex catalyzed eviction of histones from the Gal4-bound nucleosomes. Thus, the transient action of the SWI/SNF complex facilitated irreversible disruption of transcription factor-bound nucleosomes.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester			Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X; Owen-Hughes, Tom/0000-0002-0618-8185	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047867, R01GM049650, R01GM047867, R37GM049650] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM049650, GM47867, R37 GM049650] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; COTE J, UNPUB; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KRUDE T, 1993, MOL CELL BIOL, V13, P1059, DOI 10.1128/MCB.13.2.1059; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; OWENHUGHES T, IN PRESS EMBO J; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SVAREN J, 1993, CURR OPIN GENET DEV, V3, P219, DOI 10.1016/0959-437X(93)90026-L; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	35	195	198	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1996	273	5274					513	516		10.1126/science.273.5274.513	http://dx.doi.org/10.1126/science.273.5274.513			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8662543				2022-12-24	WOS:A1996UY98300045
J	Wang, J; Walsh, K				Wang, J; Walsh, K			Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation	SCIENCE			English	Article							RETINOBLASTOMA PROTEIN; CELL-DEATH; COMMITMENT	Proliferating murine C2C12 myoblasts can undergo either terminal differentiation or programmed cell death under conditions of mitogen deprivation. Unlike myoblasts, differentiated myotubes were resistant to apoptosis. During myogenesis the appearance of the apoptosis-resistant phenotype was correlated with the induction of the cyclin-dependent kinase (Cdk) inhibitor p21(CIP1) but not with the appearance of myogenin, a marker expressed earlier in differentiation. Forced expression of the Cdk inhibitors p21(CIP1) or p16(INK4A) blocked apoptosis during myocyte differentiation. These data indicate that induction of Cdk inhibitors may serve to protect differentiating myocytes from programmed cell death as well as play a role in establishing the postmitotic state.	ST ELIZABETHS MED CTR,DIV CARDIOVASC RES,BOSTON,MA 02135; TUFTS UNIV,SCH MED,BOSTON,MA 02135	St. Elizabeth's Medical Center; Tufts University				Walsh, Kenneth/0000-0001-7580-2276	NHLBI NIH HHS [HL50692] Funding Source: Medline; NIAMS NIH HHS [R01 AR040197, AR40197] Funding Source: Medline; NIA NIH HHS [R01 AG015052] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COLLINS MKL, 1993, TRENDS BIOCHEM SCI, V18, P307, DOI 10.1016/0968-0004(93)90042-L; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HAUPT Y, 1995, ONCOGENE, V10, P1563; JEFFS P, 1992, ANAT EMBRYOL, V185, P589; JIANG HP, 1994, ONCOGENE, V9, P3397; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LOIS AF, 1995, CANCER RES, V55, P4010; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Poluha W, 1996, MOL CELL BIOL, V16, P1335; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; TORNEI LD, 1993, P NATL ACAD SCI USA, V90, P853; WANG JC, UNPUB; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	28	461	465	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1996	273	5273					359	361		10.1126/science.273.5273.359	http://dx.doi.org/10.1126/science.273.5273.359			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY202	8662523	Green Accepted			2022-12-24	WOS:A1996UY20200040
J	Rencken, ML; Chesnut, CH; Drinkwater, BL				Rencken, ML; Chesnut, CH; Drinkwater, BL			Bone density at multiple skeletal sites in amenorrheic athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINERAL-CONTENT; WOMEN	Objective.-To determine if there is a generalized loss of bone mass at multiple skeletal sites in amenorrheic athletes compared with a group of eumenorrheic athletes. Design.-A case-control study examining the differences in bone mineral density (BMD) between amenorrheic and eumenorrheic athletes. Setting.-Seattle, Wash, and surrounding communities. Participants.-Forty-nine athletes, aged 17 to 39 years, were selected from those responding to advertisements in local sporting-goods stores and track-and-field newsletter. Athletes were defined as amenorrheic if they had had fewer than 2 menstrual cycles in the last 12 months or none in the past 6 months, or eumenorrheic if they had had 10 to 13 cycles in the previous year. Only women who met these criteria, confirmed by tests for estradiol and progesterone levels, were enrolled in the study. Main Outcome Measures.-Bone mineral density measured by dual-energy x-ray absorptiometry. Results.-Amenorrheic athletes had significantly lower BMD (P<.01) at the lumbar spine, femoral neck, trochanter, Ward triangle, intertrochanteric region, femoral shaft, and tibia. No difference was noted at the fibula. Body weight combined with months of amenorrhea and age of menarche predicted the BMD of the lumbar spine far amenorrheic athletes. Duration of amenorrhea and body weight of amenorrheic athletes predicted BMD at the femoral neck, trochanter, intertrochanteric region, and tibia. Weight alone predicted BMD at the femoral shaft and tibia. Age plus weight predicted lumbar BMD of eumenorrheic women. Conclusion.-Extended periods of amenorrhea may result in low bone density at multiple skeletal sites including those subjected to impact loading during exercise.	UNIV WASHINGTON,MED CTR,DEPT RADIOL,DIV NUCL MED,SEATTLE,WA 98195; PACIFIC MED CTR,DEPT MED,SEATTLE,WA	University of Washington; University of Washington Seattle								BENNELL KL, 1995, CLIN J SPORT MED, V5, P229, DOI 10.1097/00042752-199510000-00004; CANN CE, 1984, JAMA-J AM MED ASSOC, V251, P626, DOI 10.1001/jama.251.5.626; DRINKWATER BL, 1984, NEW ENGL J MED, V311, P277, DOI 10.1056/NEJM198408023110501; DRINKWATER BL, 1990, JAMA-J AM MED ASSOC, V263, P545, DOI 10.1001/jama.263.4.545; FISHER EC, 1986, J CLIN ENDOCR METAB, V62, P1232, DOI 10.1210/jcem-62-6-1232; GULEKLI B, 1994, CLIN ENDOCRINOL, V41, P275, DOI 10.1111/j.1365-2265.1994.tb02545.x; HAENGGI W, 1994, OSTEOPOROSIS INT, V4, P99, DOI 10.1007/BF01623232; JOHNSTON CC, 1990, PRIMER METABOLIC BON, P93; JOHNSTON CC, 1991, AM J MED, V91, pB5; JONNAVITHULA S, 1993, OBSTET GYNECOL, V81, P669; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KEEN AD, 1995, J BONE MINER RES, V10, pS243; LINDBERG JS, 1984, ANN INTERN MED, V101, P647, DOI 10.7326/0003-4819-101-5-647; LLOYD T, 1986, MED SCI SPORT EXER, V18, P374; MARCUS R, 1985, ANN INTERN MED, V102, P158, DOI 10.7326/0003-4819-102-2-158; MYBURGH KH, 1990, ANN INTERN MED, V113, P754, DOI 10.7326/0003-4819-113-10-754; MYBURGH KH, 1993, MED SCI SPORT EXER, V25, P1197; NICHOLS DL, 1994, MED SCI SPORT EXER, V26, P1220; OKANO H, 1995, J ENDOCRINOL, V42, P271; ROBINSON TL, 1995, J BONE MINER RES, V10, P26; WILSON JH, 1994, BRIT J RHEUMATOL, V33, P480	21	116	117	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					238	240		10.1001/jama.276.3.238	http://dx.doi.org/10.1001/jama.276.3.238			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667570				2022-12-24	WOS:A1996UW46900037
J	Billeter, M; Guntert, P; Luginbuhl, P; Wuthrich, K				Billeter, M; Guntert, P; Luginbuhl, P; Wuthrich, K			Hydration and DNA recognition by homeodomains	CELL			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; ANTENNAPEDIA HOMEODOMAIN; MOLECULAR-DYNAMICS; AQUEOUS-SOLUTION; WATER-MOLECULES; AMINO-ACID; COMPLEX; PROTEIN; SPECIFICITY	A 2-nanosecond molecular dynamics (MD) simulation of an Antennapedia homeodomain-DNA complex in explicit solvent water at ambient temperature and pressure was performed to supplement experimental nuclear magnetic resonance (NMR) data on the structure and dynamics of this complex. In addition to direct protein-DNA contacts, the MD trajectory attributes an essential role for specific DNA recognition to hydration water molecules that mediate intermolecular contacts. The simulation provides a detailed description of the pathways of hydration water molecules exchanging in and out of the protein-DNA interface and indicates that the residence times of these ''interior'' waters are on the nanosecond time scale, near the lower end of the range determined by NMR.			Billeter, M (corresponding author), ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND.		Billeter, Martin/A-8293-2010; Güntert, Peter/L-5577-2013	Güntert, Peter/0000-0002-2911-7574				BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Billeter M, 1995, PROG NUCL MAG RES SP, V27, P635, DOI 10.1016/0079-6565(95)01015-7; BRAUN W, 1995, FASEB J, V9, P63, DOI 10.1096/fasebj.9.1.7529736; BRUNNE RM, 1993, J MOL BIOL, V231, P1040, DOI 10.1006/jmbi.1993.1350; DENISOV VP, 1995, J MOL BIOL, V245, P682, DOI 10.1006/jmbi.1994.0055; DOTSCH V, 1995, J AM CHEM SOC, V117, P6064; Drenth J, 1994, PRINCIPLES PROTEIN X; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; FREY M, 1994, ACTA CRYSTALLOGR D, V50, P663, DOI 10.1107/S0907444993013368; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEWIRTH DT, 1995, STRUCT BIOL, V2, P386; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; KARPLUS PA, 1994, CURR OPIN STRUC BIOL, V4, P770, DOI 10.1016/S0959-440X(94)90178-3; KORADI R, 1996, IN PRESS J MOL GRAPH, V27; OTTING G, 1991, J AM CHEM SOC, V113, P4363, DOI 10.1021/ja00011a068; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PERCIVALSMITH A, 1990, EMBO J, V11, P382; QIAN YQ, 1993, J MOL BIOL, V234, P1070, DOI 10.1006/jmbi.1993.1660; QIAN YQ, 1993, J AM CHEM SOC, V115, P1189, DOI 10.1021/ja00056a077; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SCHIFFER CA, 1995, BIOCHEMISTRY-US, V34, P15057, DOI 10.1021/bi00046a011; THANKI N, 1988, J MOL BIOL, V202, P637, DOI 10.1016/0022-2836(88)90292-6; TREISMAN J, 1989, CELL, V59, P553; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wiithrich K., 1995, NMR STRUCTURAL BIOL; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WUTHRICH K, 1993, COLD SPRING HARB SYM, V58, P149, DOI 10.1101/SQB.1993.058.01.019; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZHANG XJ, 1994, PROTEIN SCI, V3, P1031, DOI 10.1002/pro.5560030705	35	106	107	3	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1057	1065		10.1016/S0092-8674(00)81306-9	http://dx.doi.org/10.1016/S0092-8674(00)81306-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674112	Bronze			2022-12-24	WOS:A1996UV48400012
J	Sze, G				Sze, G			Contrast enhancement for cranial CT scanning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BRAIN METASTASES; MR				Sze, G (corresponding author), YALE UNIV,SCH MED,NEURORADIOL SECT,NEW HAVEN,CT 06520, USA.							JINKINS JR, 1986, NEUROSURGERY, V18, P664, DOI 10.1227/00006123-198605000-00027; LATCHAW RE, 1978, RADIOLOGY, V126, P681, DOI 10.1148/126.3.681; LEMAY M, 1986, AM J ROENTGENOL, V147, P963, DOI 10.2214/ajr.147.5.963; MITCHELL WG, 1988, PEDIATRICS, V82, P76; PRICE HI, 1982, RADIOGRAPHICS, V2, P7; SEARS ES, 1982, NEUROLOGY, V32, P815, DOI 10.1212/WNL.32.8.815; SZE G, 1989, AM J NEURORADIOL, V10, P965; SZE G, 1990, AM J NEURORADIOL, V11, P785; SZE G, 1988, RADIOLOGY, V168, P187, DOI 10.1148/radiology.168.1.3380956; SZE G, 1992, CRANIAL MRI CT, P539; SZE G, 1989, AJR AM J ROENTGENOL, V154, P1039	11	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1996	275	24					1875	1876						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR975	8648856				2022-12-24	WOS:A1996UR97500014
J	Prakash, N; CohenCory, S; Frostig, RD				Prakash, N; CohenCory, S; Frostig, RD			Rapid and opposite effects of BDNF and NGF on the functional organization of the adult cortex in vivo	NATURE			English	Article							INTRINSIC SIGNALS; MESSENGER-RNA; VISUAL-CORTEX; ARCHITECTURE	THE adult cortex is thought to undergo plastic changes that are closely dependent on neuronal activity (reviewed in ref. 1), although it is not yet known what molecules are involved. Neurotrophins and their receptors have been implicated in several aspects of developmental plasticity(2-4), and their expression in the adult cortex suggests additional roles in adult plasticity(5-9). To examine these potential roles in viva, we used intrinsic-signal optical imaging to quantify the effects of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) on the functional representation of a stimulated whisker in the 'barrel' subdivision of the rat somatosensory cortex. Topical application of BDNF resulted in a rapid and long-lasting decrease in the size of a whisker representation, and a decrease in the amplitude of the activity-dependent intrinsic signal, In contrast, NGF application resulted in a rapid but transient increase in the size of a representation, and an increase in the amplitude of the activity-dependent intrinsic signal. These results demonstrate that neurotrophins can rapidly modulate stimulus-dependent activity in adult cortex, and suggest a role for neurotrophins in regulating adult cortical plasticity.	UNIV CALIF IRVINE, DEPT PSYCHOBIOL, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, CTR LEARNING & MEMORY, IRVINE, CA 92717 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; California Institute of Technology				Prakash, Neal/0000-0003-0288-6573				ALTAR CA, 1994, EXP NEUROL, V130, P31, DOI 10.1006/exnr.1994.1182; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; Cellerino A., 1995, Society for Neuroscience Abstracts, V21, P2010; CHEN C, IN PRESS J NEUROSCIM; CUELLO AC, 1992, MOL NEUROBIOL, V6, P451, DOI 10.1007/BF02757946; Frostig R. D., 1994, Society for Neuroscience Abstracts, V20, P1384; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; Kaas Jon H., 1995, P51; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MALONEK D, 1990, Society for Neuroscience Abstracts, V16, P292; MASANA Y, 1993, J NEUROSCI RES, V35, P468, DOI 10.1002/jnr.490350503; Masino SA, 1996, P NATL ACAD SCI USA, V93, P4942, DOI 10.1073/pnas.93.10.4942; MASINO SA, 1993, P NATL ACAD SCI USA, V90, P9998, DOI 10.1073/pnas.90.21.9998; MIZUNO K, 1994, DEV BIOL, V165, P243, DOI 10.1006/dbio.1994.1250; NAWA H, 1994, J NEUROSCI, V14, P3751; Pitts AF, 1995, SOMATOSENS MOT RES, V12, P329, DOI 10.3109/08990229509093666; RACAMORA N, 1993, SOC NEUR ABSTR, V19, P259; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; ZHOU XF, 1993, BRAIN RES, V622, P63, DOI 10.1016/0006-8993(93)90802-T	30	96	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 20	1996	381	6584					702	706		10.1038/381702a0	http://dx.doi.org/10.1038/381702a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649516				2022-12-24	WOS:A1996UR97900054
J	Sadowski, LS; Munoz, SR				Sadowski, LS; Munoz, SR			Nonfatal and fatal firearm injuries in a rural county	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To measure the incidence of fatal and nonfatal firearm injuries in a rural setting. Design.-A prospective, population-based surveillance system using information from medical and legal records, newspapers, and members of the community. Setting.-A rural county in North Carolina. Main Outcome Measures.-Incidence rates and case-fatality ratios (fatal:nonfatal). Results.-Of the 114 firearm injuries detected by the surveillance system from January 1, 1990, through December 31, 1991, nearly two thirds were nonfatal, The overall age-adjusted annual incidence of firearm injuries was 66.4 per 100 000 population, and the incidence of nonfatal firearm injuries was 41.2 per 100 000 population, Subgroup annual incidence rates were greatest for African Americans. The overall case-fatality ratio was 1:1.8 (fatal:nonfatal). Conclusions.-Incidence rates and case-fatality ratios for firearm injury in this rural setting were greater than expected, based on national estimates, perhaps because of greater proportions of rifle injuries and self-inflicted injuries.	UNIV LA FRONTERA, SCH MED, CLIN EPIDEMIOL UNIT, TEMUCO, CHILE	Universidad de La Frontera	Sadowski, LS (corresponding author), UNIV N CAROLINA, DEPT MED, CB 7110, CHAPEL HILL, NC 27599 USA.				PHS HHS [R49/CCR402444] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXANDER GR, 1985, AM J PUBLIC HEALTH, V75, P165, DOI 10.2105/AJPH.75.2.165; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; Rothman K, 1986, MODERN EPIDEMIOLOGY; *STAT GRAPH DAT MA, 1992, STATA REF MAN REL 3, V3, P66; *US BUR CENS, 1987, 1987 CURR POP SURV; *US BUR CENS, 1992, 1990 COUNT POP AG SE; *US CTR HLTH STAT, 1988, 1988 US DET MORT DAT; *US NAT CTR HLTH S, 1976, VIT HLTH STAT, V10; WINTEMUTE GJ, 1987, J TRAUMA, V27, P530; ZWERLING C, 1993, AM J PREV MED, V9, P21, DOI 10.1016/S0749-3797(18)30674-3	13	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1762	1764		10.1001/jama.275.22.1762	http://dx.doi.org/10.1001/jama.275.22.1762			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637176				2022-12-24	WOS:A1996UP30700032
J	Seim, A; Sivertsen, B; Eriksen, BC; Hunskaar, S				Seim, A; Sivertsen, B; Eriksen, BC; Hunskaar, S			Treatment of urinary incontinence in women in general practice: Observational study	BRITISH MEDICAL JOURNAL			English	Article							URGE INCONTINENCE; PELVIC FLOOR; PREVALENCE	Objective-To examine what is attainable when treating urinary incontinence in women in general practice. Design-Observational study with 12 months' follow up. Interview and clinical examination before, during, and after treatment of women seeking help for urinary incontinence in general practice. Setting-General practice in the rural district of Rissa, Norway. Subjects-105 women aged 20 or more with urinary incontinence. Interventions-Treatment with pelvic floor exercises, electrostimulation, oestrogen, anticholinergic drugs, bladder training, and protective pads. Main outcome measures-Subjective and objective measures of urinary incontinence; number of patients referred to a specialist. Results-After 12 months' follow up 70% (69/99) of the women were cured or much better; the mean score on a 100 mm visual analogue scale decreased from 37 to 20 mm; and the proportion of women who were greatly bothered by their incontinence decreased by 62%. 20% (20/98) of women became continent, and the percentage of women with severe incontinence decreased from 64% (63/99) to 28% (27/98). Mean leakage per 24 hours measured by a pad test decreased from 28 g at the start of treatment to 13 g after 12 months. The number of light weight pads or sanitary towels decreased from 1.6 to 0.6 a day. In all, 17/105 (16%) patients were referred to a specialist. Conclusions-Urinary incontinence in women can be effectively managed ire general practice with fairly simple treatment. Most women will be satisfied with the results.	UNIV BERGEN,DEPT PUBL HLTH & PRIMARY HLTH CARE,DIV GEN PRACTICE,N-5009 BERGEN,NORWAY; UNIV TRONDHEIM HOSP,DEPT OBSTET & GYNAECOL,TRONDHEIM,NORWAY; MED OFF HLTH,RISSA,NORWAY	University of Bergen; Norwegian University of Science & Technology (NTNU)								Abrams P, 1988, Scand J Urol Nephrol Suppl, V114, P5; BO K, 1990, NEUROUROL URODYNAM, V9, P489, DOI 10.1002/nau.1930090505; BROCKLEHURST JC, 1993, BRIT MED J, V306, P832, DOI 10.1136/bmj.306.6881.832; BURGIO KL, 1991, J UROLOGY, V146, P1255, DOI 10.1016/S0022-5347(17)38063-1; ERIKSEN BC, 1989, NEUROUROL URODYNAM, V8, P219, DOI 10.1002/nau.1930080305; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; Flynn L, 1994, J Gerontol Nurs, V20, P23; JOLLEYS JV, 1989, J ROY COLL GEN PRACT, V39, P277; Klovning Atle, 1994, Tidsskrift for den Norske Laegeforening, V114, P3068; LAGROJANSSEN ALM, 1992, FAM PRACT, V9, P284, DOI 10.1093/fampra/9.3.284; LOSE G, 1990, ANN MED, V22, P449, DOI 10.3109/07853899009147285; NORTON PA, 1988, BRIT MED J, V297, P1187, DOI 10.1136/bmj.297.6657.1187; OBRIEN J, 1991, BRIT MED J, V303, P1308, DOI 10.1136/bmj.303.6813.1308; REKERS H, 1992, EUR J OBSTET GYN R B, V43, P229, DOI 10.1016/0028-2243(92)90178-2; SANDVIK H, 1990, Scandinavian Journal of Primary Health Care, V8, P3, DOI 10.3109/02813439008994922; Sandvik H, 1993, Scand J Caring Sci, V7, P53; SANDVIK H, 1993, J EPIDEMIOL COMMUN H, V47, P497, DOI 10.1136/jech.47.6.497; SANDVIK H, 1995, J AGING HEALTH, V7, P417, DOI 10.1177/089826439500700305; SEIM A, 1995, FAM PRACT, V12, P18, DOI 10.1093/fampra/12.1.18; U.S. Department of Health and Human Services, 1992, AHCPR PUBL, V92-0047	20	61	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1459	1462		10.1136/bmj.312.7044.1459	http://dx.doi.org/10.1136/bmj.312.7044.1459			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664627	Green Published			2022-12-24	WOS:A1996UQ29600030
J	Shigemoto, R; Kulik, A; Roberts, JDB; Ohishi, H; Nusser, Z; Kaneko, T; Somogyi, P				Shigemoto, R; Kulik, A; Roberts, JDB; Ohishi, H; Nusser, Z; Kaneko, T; Somogyi, P			Target-cell-specific concentration of a metabotropic glutamate receptor In the presynaptic active zone	NATURE			English	Article							SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; CALCIUM CURRENTS; MODULATION	THE probability of synaptic neurotransmitter release from nerve terminals is regulated by presynaptic receptors responding to transmitters released from the same nerve terminal or from terminals of other neurons. The release of glutamate, the major excitatory neurotransmitter, is suppressed by presynaptic autoreceptors(1-3). Here we show that a metabotropic glutamate receptor (mGluR7) in the rat hippocampus is restricted to the presynaptic grid, the site of synaptic vesicle fusion. Pyramidal cell terminals presynaptic to mGluR1 alpha-expressing interneurons have at least a ten-fold higher level of presynaptic mGluR7 than terminals making synapses with pyramidal cells and other types of interneuron. Distinct levels of mGluR7 are found at different synapses made by individual pyramidal axons or even single boutons. These results raise the possibility that presynaptic neurons could regulate the probability of transmitter release at individual synapses according to the postsynaptic target.	UNIV OXFORD,MRC,ANAT NEUROPHARMACOL UNIT,DEPT PHARMACOL,OXFORD OX1 3TH,ENGLAND; KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,SAKYO KU,KYOTO 606,JAPAN	University of Oxford; Kyoto University			Shigemoto, Ryuichi/E-3628-2013; Nusser, Zoltan/K-8587-2014	Shigemoto, Ryuichi/0000-0001-8761-9444; Nusser, Zoltan/0000-0001-7004-4111				BAUDE A, 1995, NEUROSCIENCE, V69, P1031, DOI 10.1016/0306-4522(95)00350-R; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BLASCOIBANEZ JM, 1995, EUR J NEUROSCI, V7, P2170, DOI 10.1111/j.1460-9568.1995.tb00638.x; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; CHARPAK S, 1995, EUR J NEUROSCI, V7, P1548, DOI 10.1111/j.1460-9568.1995.tb01150.x; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; GEREAU RW, 1995, J NEUROSCI, V15, P6879; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; KOERBER HR, 1991, J NEUROPHYSIOL, V65, P590, DOI 10.1152/jn.1991.65.3.590; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MACCAFERRI G, 1995, J NEURON, V15, P137; Manzoni O, 1995, EUR J NEUROSCI, V7, P2518, DOI 10.1111/j.1460-9568.1995.tb01051.x; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; Ohishi H, 1995, NEUROSCI LETT, V202, P85, DOI 10.1016/0304-3940(95)12207-9; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; SAHARA Y, 1993, J NEUROSCI, V13, P3041; Shigemoto R., 1995, Society for Neuroscience Abstracts, V21, P846; SOMOGYI P, 1984, J NEUROSCI, V4, P2590; TAREILUS E, 1995, NEUROCHEM INT, V26, P539, DOI 10.1016/0197-0186(94)00149-O; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; VIGNES M, 1995, NEUROPHARMACOLOGY, V34, P973, DOI 10.1016/0028-3908(95)00093-L	31	337	359	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					523	525		10.1038/381523a0	http://dx.doi.org/10.1038/381523a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632825				2022-12-24	WOS:A1996UP43500060
J	Yang, YS; Kochoyan, M; Burgstaller, P; Westhof, E; Famulok, M				Yang, YS; Kochoyan, M; Burgstaller, P; Westhof, E; Famulok, M			Structural basis of ligand discrimination by two related RNA aptamers resolved by NMR spectroscopy	SCIENCE			English	Article							CONFORMATION; HAIRPIN; LOOP; INVITRO; COMPLEX; DNA	In a previous study, an RNA aptamer for the specific recognition of arginine was evolved from a parent sequence that bound citrulline specifically. The two RNAs differ al only 3 positions out of 44. The solution structures df the two aptamers complexed to their cognate amino acids have now been determined by two-dimensional nuclear magnetic resonance spectroscopy, Both aptamers contain two asymmetrical internal loops that are not well ordered in the free RNA but that fold into a compact structure upon ligand binding. Those nucleotides common to both RNAs include a conserved cluster of purine residues, three of which form an uneven plane containing a G:G pair, and two other residues nearly perpendicular to that surface, Two of the three variant nucleotides are stacked on the cluster of purines and form a triple contact to the amino acid side chain, whereas the edge of the third variant nucleotide is capping the binding pocket.	CBS FAC PHARM,F-34060 MONTPELLIER,FRANCE; ECOLE POLYTECH,CNRS,UNITE RECH ASSOCIEE D1254,GRP BIOPHYS,F-91128 PALAISEAU,FRANCE; UNIV MUNICH,GENZENTRUM,INST BIOCHEM,D-81675 MUNICH,GERMANY; INST BIOL MOLEC & CELLULAIRE,CNRS,UNITE PROPRE RECH 9002,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris; University of Munich; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; BLINGTON AD, 1994, CURR BIOL, V4, P427; BRUNGER AT, 1992, X PLOR USER MANUAL V; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burgstaller P, 1995, NUCLEIC ACIDS RES, V23, P4769, DOI 10.1093/nar/23.23.4769; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; ELINGTON AD, 1990, NATURE, V346, P818; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HIRAO I, 1995, CURR BIOL, V5, P1017, DOI 10.1016/S0960-9822(95)00205-3; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; KELLOGG G, 1993, FEBS LETT, V327, P261; KLUG SJ, 1994, MOL BIOL REP, V20, P97, DOI 10.1007/BF00996358; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; MASSIRE C, 1994, J MOL GRAPHICS, V12, P201, DOI 10.1016/0263-7855(94)80088-X; NAGAL K, 1994, RNA PROTEIN INTERACT; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4508; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PRETTRE CG, 1976, BIOPOLYMERS, V15, P2277; PUGLISI EV, 1994, P NATL ACAD SCI USA, V91, P11467, DOI 10.1073/pnas.91.24.11467; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SANTALUCIA J, 1993, BIOCHEMISTRY-US, V32, P12612, DOI 10.1021/bi00210a009; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Wuthrich K., 1986, NMR PROTEINS NUCL AC; WYATT JR, 1991, BIOTECHNIQUES, V11, P764; Yang Y., UNPUB; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6	45	162	168	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1343	1347		10.1126/science.272.5266.1343	http://dx.doi.org/10.1126/science.272.5266.1343			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650546				2022-12-24	WOS:A1996UN47200048
J	OKeefe, J; Burgess, N				OKeefe, J; Burgess, N			Geometric determinants of the place fields of hippocampal neurons	NATURE			English	Article							FREELY-MOVING RATS; UNIT-ACTIVITY; CELLS; DIRECTION; POSITION; LESIONS; MEMORY	THE human hippocampus has been implicated in memory(1), in particular episodic(2,3) or declarative(4) memory. In rats, hippocampal lesions cause selective spatial deficits(2,5-7), and hippocampal complex spike cells (place cells) exhibit spatially localized firing(8,9), suggesting a role in spatial memory(2), although broader functions have also been suggested(10,11). Here we report the identification of the environmental features controlling the location and shape of the receptive fields (place fields) of the place cells. This was done by recording from the same cell in four rectangular boxes that differed solely in the length of one or both sides. Most of our results are explained by a model in which the place field is formed by the summation of gaussian tuning curves, each oriented perpendicular to a box wall and peaked at a fixed distance from it.			OKeefe, J (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.		Burgess, Neil/B-2420-2009	Burgess, Neil/0000-0003-0646-6584				[Anonymous], 1983, CANADIAN PSYCHOL; BURGESS N, 1994, NEURAL NETWORKS, V7, P1065, DOI 10.1016/S0893-6080(05)80159-5; CHENG K, 1986, COGNITION, V23, P149, DOI 10.1016/0010-0277(86)90041-7; COLLETT TS, 1986, J COMP PHYSIOL A, V158, P835, DOI 10.1007/BF01324825; EICHENBAUM H, 1992, J COGNITIVE NEUROSCI, V4, P217, DOI 10.1162/jocn.1992.4.3.217; Gothard KM, 1996, J NEUROSCI, V16, P823; GOTHARD KM, 1995, SOC NEUR ABSTR, V21, P911; KNIERIM JJ, 1995, J NEUROSCI, V15, P1648, DOI 10.1523/JNEUROSCI.15-03-01648.1995; MARGULES J, 1988, ANIM LEARN BEHAV, V16, P404, DOI 10.3758/BF03209379; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; MCNAUGHTON BL, 1994, COGNITIVE NEUROSCIEN, P585; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MULLER RU, 1987, J NEUROSCI, V7, P1951; MULLER RU, 1989, J NEUROSCI, V9, P4101; MULLER RU, 1994, J NEUROSCI, V14, P7235; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1975, EXP NEUROL, V48, P152, DOI 10.1016/0014-4886(75)90230-7; OKEEFE J, 1979, PROG NEUROBIOL, V13, P419, DOI 10.1016/0301-0082(79)90005-4; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; OKeefe J, 1991, BRAIN SPACE, P273, DOI DOI 10.1016/j.neuron.2015.06.011; REDISH AD, IN PRESS SYMBOLIC VI; Rudy JW, 1995, HIPPOCAMPUS, V5, P375, DOI 10.1002/hipo.450050502; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHARP PE, 1991, PSYCHOBIOLOGY, V19, P103; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TAUBE JS, 1990, J NEUROSCI, V10, P420; ZIPSER D, 1985, BEHAV NEUROSCI, V99, P1006, DOI 10.1037/0735-7044.99.5.1006	30	734	742	3	75	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					425	428		10.1038/381425a0	http://dx.doi.org/10.1038/381425a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632799				2022-12-24	WOS:A1996UN47900052
J	Ragent, B; Colburn, DS; Avrin, P; Rages, KA				Ragent, B; Colburn, DS; Avrin, P; Rages, KA			Results of the Galileo probe nephelometer experiment	SCIENCE			English	Article								The nephelometer experiment carried on the Galileo probe was designed to measure the jovian cloud structure and its microphysical characteristics from entry down to atmospheric pressure levels greater than 10 bars. Before this mission there was no direct evidence for the existence of the clouds below the uppermost cloud layer, and only theoretical models derived from remote sensing observations were available for describing such clouds. Only one significant cloud structure with a base at about 1.55 bars was found along the probe descent trajectory below an ambient pressure of about 0.4 bar, although many indications of small densities of particle concentrations were noted during much of the descent.	AEROSP CORP,COLORADO SPRINGS,CO 80912; SPACE PHYS RES INST,SUNNYVALE,CA 94087	Aerospace Corporation - USA	Ragent, B (corresponding author), SAN JOSE STATE UNIV FDN,SAN JOSE,CA 95172, USA.							ATREYA SK, 1985, PLANETARY METEOROLOG, P17; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; GIVENS JJ, 1983, P AIAA 21 AER SCI M, P1; JOHNSON TV, 1992, SPACE SCI REV, V60, P3, DOI 10.1007/BF00216848; MAROV MY, 1980, ICARUS, V44, P608, DOI 10.1016/0019-1035(80)90131-1; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; ONEILL WJ, 1983, P AIAA 21 AER SCI M, P1; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; RAGENT B, 1992, SPACE SCI REV, V60, P179, DOI 10.1007/BF00216854; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; Sromovsky LA, 1996, SCIENCE, V272, P851, DOI 10.1126/science.272.5263.851; WEIDENSCHILLING SJ, 1973, ICARUS, V61, P311	12	35	35	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					854	856		10.1126/science.272.5263.854	http://dx.doi.org/10.1126/science.272.5263.854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629019				2022-12-24	WOS:A1996UK75700052
J	Joneson, T; White, MA; Wigler, MH; BarSagi, D				Joneson, T; White, MA; Wigler, MH; BarSagi, D			Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; PROTEIN	The RAS guanine nucleotide binding proteins activate multiple signaling events that regulate cell growth and differentiation. In quiescent fibroblasts, ectopic expression of activated H-RAS (H-RAS(V12), where V12 indicates valine-12) induces membrane ruffling, mitogen-activated protein (MAP) kinase activation, and stimulation of DNA synthesis. A mutant of activated H-RAS, H-RAS(V12C40) (where C40 indicates cysteine-40), was identified that was defective for MAP kinase activation and stimulation of DNA synthesis, but retained the ability to induce membrane ruffling. Another mutant of activated H-RAS, H-RAS(V12S35) (where S35 indicates serine-35), which activates MAP kinase, was defective for stimulation of membrane ruffling and induction of DNA synthesis. Expression of both mutants resulted in a stimulation of DNA synthesis that was comparable to that induced by H-RAS(V12). These results indicate that membrane ruffling and activation of MAP kinase represent distinct RAS effector pathways and that input from both pathways is required for the mitogenic activity of RAS.	SUNY STONY BROOK,DEPT MICROBIOL & MOLEC GENET,STONY BROOK,NY 11794; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cold Spring Harbor Laboratory				Wigler, Michael/0000-0003-4396-1971; Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; JONESON T, UNPUB; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THORBURN J, 1994, J BIOL CHEM, V269, P30580; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITE MG, UNPUB	18	362	363	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					810	812		10.1126/science.271.5250.810	http://dx.doi.org/10.1126/science.271.5250.810			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628998				2022-12-24	WOS:A1996TU69400047
J	Kobayashi, K; Manabe, T; Takahashi, T				Kobayashi, K; Manabe, T; Takahashi, T			Presynaptic long-term depression at the hippocampal mossy fiber-CA3 synapse	SCIENCE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CA3 PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; VISUAL-CORTEX; AREA CA1; 2 FORMS; POTENTIATION; MECHANISMS; INDUCTION; EXPRESSION	Long-term potentiation (LTP) and long-term depression (LTD) of synaptic strength may underlie learning and memory in the brain. The induction of LTP occurs in postsynaptic cells in the hippocampal CA1 region but is presynaptic in CA3. LTD is also well characterized in CA1 but not in CA3. Low-frequency stimulation of mouse hippocampal slices caused homosynaptic LTD at the messy fiber-CA3 synapse, which may be induced presynaptically by activation of metabotropic glutamate receptors. Thus, the efficacy of messy fiber-CA3 synapses can be regulated bidirectionally, which may contribute to neuronal information processing.	UNIV TOKYO,FAC MED,INST BRAIN RES,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Kobayashi, Katsunori/V-5326-2018; Takahashi, Tomoyuki/G-5951-2015	Kobayashi, Katsunori/0000-0001-8537-8448; Takahashi, Tomoyuki/0000-0002-8771-7666				BATTISTIN T, 1994, EUR J NEUROSCI, V6, P1750, DOI 10.1111/j.1460-9568.1994.tb00567.x; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BRADLER JE, 1989, SYNAPSE, V4, P132, DOI 10.1002/syn.890040207; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; GUERINEAU NC, 1995, J NEUROSCI, V15, P4395; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HARUTA H, 1994, NEUROREPORT, V5, P1829, DOI 10.1097/00001756-199409080-00036; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; REGEHR WG, 1994, J NEUROSCI, V14, P523; SELIG DK, 1995, J NEUROPHYSIOL, V74, P1075, DOI 10.1152/jn.1995.74.3.1075; SHIGEMOTO R, 1995, INT BRAIN RES ORG AB, V4; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANABE Y, 1993, J NEUROSCI, V13, P1372; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; YAMAMOTO C, 1992, NEUROSCI LETT, V138, P111, DOI 10.1016/0304-3940(92)90484-O; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	33	130	136	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					648	650		10.1126/science.273.5275.648	http://dx.doi.org/10.1126/science.273.5275.648			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662556				2022-12-24	WOS:A1996VA24900048
J	EnriquezSarano, M; Klodas, E; Garratt, KN; Bailey, KR; Tajik, AJ; Holmes, DR				EnriquezSarano, M; Klodas, E; Garratt, KN; Bailey, KR; Tajik, AJ; Holmes, DR			Secular trends in coronary atherosclerosis - Analysis in patients with valvular regurgitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; HONOLULU HEART PROGRAM; ARTERY DISEASE; UNITED-STATES; RISK-FACTORS; VALVE REPLACEMENT; UNSTABLE ANGINA; ORIFICE AREA; FOLLOW-UP; AUTOPSY	Background Between 1980 and 1989, mortality due to coronary artery disease decreased considerably in the United States, suggesting a possible decrease in the prevalence of coronary atherosclerosis. We examined this possibility in patients with valvular regurgitation who, often in the absence of angina, underwent coronary angiography before valve-replacement surgery. Methods We studied 601 patients with isolated, nonischemic valvular regurgitation who were operated on between 1980 and 1989 and who had undergone preoperative coronary angiography. From the angiograms we determined the prevalence of clinically significant coronary artery disease and of multivessel disease, assessed the mean degree of stenosis, and analyzed the trends in the data over the years of the study. Results The prevalence of coronary artery disease (35 percent in 1980-1981, 37 percent in 1982-1983, 34 percent in 1984-1985, 37 percent in 1986-1987, and 35 percent in 1988-1989; P=0.97) did not change significantly during the study period. We found no significant change in the prevalence of multivessel disease (24 percent in 1980-1981 and 23 percent in 1988-1989, P=0.99) or in the mean (+/-SD) degree of stenosis (11+/-13 percent in 1980-1981 and 13+/-14 percent in 1988-1989, P=0.07). When these measures of coronary atherosclerosis were adjusted for age and sex, there were still no significant changes over time (P=0.39 for the prevalence of coronary artery disease, P=0.81 for that of multivessel disease, and P=0.57 for the mean degree of stenosis). The patients' mean total cholesterol level decreased from 219+/-48 mg per deciliter (5.66+/-1.24 mmol per liter) to 206+/-44 mg per deciliter (5.33+/-1.14 mmol per liter) between 1980 and 1989 (P=0.04). Conclusions From 1980 to 1989, no significant change was observed in angiographic measures of coronary atherosclerosis in patients with nonischemic valvular regurgitation, in contrast to the marked decrease in mortality due to coronary disease in the general population, These findings suggest that the well-documented reduction in mortality due to coronary disease may not be due to a reduction in the prevalence of coronary atherosclerosis. (C) 1996, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905	Mayo Clinic	EnriquezSarano, M (corresponding author), MAYO CLIN & MAYO FDN,DIV CARDIOVASC DIS & INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.							ACAR J, 1985, Z KARDIOL S2, V75, P53; ALDERMAN EL, 1993, J AM COLL CARDIOL, V22, P1141, DOI 10.1016/0735-1097(93)90429-5; AMBROSE JA, 1986, J AM COLL CARDIOL, V7, P472, DOI 10.1016/S0735-1097(86)80455-7; BEAGLEHOLE R, 1990, EPIDEMIOL REV, V12, P1; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; CUPPLES LA, 1992, CIRCULATION SI, V85, P1; CZER LSC, 1984, CIRCULATION, V70, P198; DAVIES MJ, 1989, EUR HEART J, V10, P203, DOI 10.1093/oxfordjournals.eurheartj.a059467; DAVIS K, 1979, CIRCULATION, V59, P1105, DOI 10.1161/01.CIR.59.6.1105; DEROUEN TA, 1977, CIRCULATION, V55, P324, DOI 10.1161/01.CIR.55.2.324; DESTEFANO F, 1993, ARCH INTERN MED, V153, P2489, DOI 10.1001/archinte.153.21.2489; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; EDLAVITCH SA, 1991, CIRCULATION, V83, P492, DOI 10.1161/01.CIR.83.2.492; ELVEBACK L, 1984, CIRCULATION, V70, P345, DOI 10.1161/01.CIR.70.3.345; ELVEBACK LR, 1986, MAYO CLIN PROC, V61, P896, DOI 10.1016/S0025-6196(12)62612-3; ENRIQUEZSARANO M, 1994, J AM COLL CARDIOL, V23, P443, DOI 10.1016/0735-1097(94)90432-4; FALK E, 1992, CIRCULATION, V86, P30; FEINLEIB M, 1979, ATHEROSCLEROSIS, V34, P145, DOI 10.1016/0021-9150(79)90136-9; FISHER LD, 1982, CATHETER CARDIO DIAG, V8, P565, DOI 10.1002/ccd.1810080605; FREEDMAN DS, 1993, ATHEROSCLEROSIS, V104, P37, DOI 10.1016/0021-9150(93)90174-S; FRIEDMAN M, 1966, AM J PATHOL, V48, P19; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; GILLUM RF, 1987, AM HEART J, V113, P804, DOI 10.1016/0002-8703(87)90723-X; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HIGGINS M, 1989, INT J EPIDEMIOL, V18, pS58; HUMPHRIE.JO, 1974, CIRCULATION, V49, P489, DOI 10.1161/01.CIR.49.3.489; Joseph A, 1993, J AM COLL CARDIOL, V22, P459, DOI 10.1016/0735-1097(93)90050-B; JUDKINS MP, 1967, RADIOLOGY, V89, P815, DOI 10.1148/89.5.815; KEREIAKES DJ, 1991, J AM COLL CARDIOL, V17, P304, DOI 10.1016/S0735-1097(10)80091-9; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; LIPTON RB, 1994, AM J EPIDEMIOL, V139, P964; LIPTON RB, 1993, AM J EPIDEMIOL, V138, P826, DOI 10.1093/oxfordjournals.aje.a116786; LOZNER EC, 1989, CATHETER CARDIO DIAG, V17, P11, DOI 10.1002/ccd.1810170104; LYTLE BW, 1983, CIRCULATION, V68, P1149, DOI 10.1161/01.CIR.68.6.1149; MACLEAN CJ, 1987, AM J EPIDEMIOL, V126, P226, DOI 10.1093/aje/126.2.226; MARTIN MJ, 1986, LANCET, V2, P933; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MULLANY CJ, 1987, J AM COLL CARDIOL, V10, P66, DOI 10.1016/S0735-1097(87)80161-4; NEWMAN WP, 1988, MODERN PATHOL, V1, P109; OLOFSSON BO, 1985, ACTA MED SCAND, V218, P365; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; PEARSON TA, 1989, INT J EPIDEMIOL, V18, pS217; PEARSON TA, 1991, AM J EPIDEMIOL, V134, P123, DOI 10.1093/oxfordjournals.aje.a116064; RAMSDALE DR, 1986, Z KARDIOL, V75, P61; RAMSDALE DR, 1984, EUR HEART J, V5, P716, DOI 10.1093/oxfordjournals.eurheartj.a061732; REED D, 1991, AM J EPIDEMIOL, V134, P111, DOI 10.1093/oxfordjournals.aje.a116063; RHOADS GG, 1978, LAB INVEST, V38, P304; RUMBERGER JA, 1994, AM J CARDIOL, V73, P1169, DOI 10.1016/0002-9149(94)90176-7; SCHWARTZ JN, 1975, AM J CARDIOL, V36, P174, DOI 10.1016/0002-9149(75)90522-6; SORLIE PD, 1981, AM J PATHOL, V103, P345; STEHBENS WE, 1993, J CLIN EPIDEMIOL, V46, P1337, DOI 10.1016/0895-4356(93)90133-L; SUTHERLAND JE, 1990, JAMA-J AM MED ASSOC, V264, P3178, DOI 10.1001/jama.264.24.3178; SUTHERLAND JE, 1993, JAMA-J AM MED ASSOC, V269, P991; VANDERVOORT PM, 1993, CIRCULATION, V88, P1150, DOI 10.1161/01.CIR.88.3.1150; WHITNEY EJ, 1992, AM J CARDIOL, V70, P738, DOI 10.1016/0002-9149(92)90551-9; WILLERSON JT, 1985, CIRCULATION, V72, P3; 1981, CIRCULATION SI, V63, P1	59	63	65	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					316	322		10.1056/NEJM199608013350504	http://dx.doi.org/10.1056/NEJM199608013350504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8663854	Bronze			2022-12-24	WOS:A1996UY98200004
J	Levy, JA				Levy, JA			Surrogate markers in AIDS research - Is there truth in numbers?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HIV; LYMPHOCYTES; INFECTION		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Levy, JA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143, USA.							BARKER E, 1995, P NATL ACAD SCI USA, V92, P11135, DOI 10.1073/pnas.92.24.11135; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CAMERON B, 1996, 3 C RETR OPP INF WAS; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; DAQUILA RT, 1994, CLIN LAB MED, V14, P393, DOI 10.1016/S0272-2712(18)30385-8; DELOES SK, 1995, NEW ENGL J MED, V333, P408; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; Lech WJ, 1996, J VIROL, V70, P2038, DOI 10.1128/JVI.70.3.2038-2043.1996; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LEVY JA, 1995, LANCET, V345, P1619, DOI 10.1016/S0140-6736(95)90121-3; Levy JA, 1996, SCIENCE, V271, P670, DOI 10.1126/science.271.5249.670; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; MACKEWICZ CE, 1994, LANCET, V344, P1671, DOI 10.1016/S0140-6736(94)90459-6; MACKEWICZ CE, 1994, CLIN IMMUNOL IMMUNOP, V73, P80, DOI 10.1006/clin.1994.1172; Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Pantaleo G, 1995, J ACQ IMMUN DEF SYND, V10, pS6; PHILLIPS AN, 1991, LANCET, V337, P389; Raboud JM, 1996, J ACQ IMMUN DEF SYND, V12, P46, DOI 10.1097/00042560-199605010-00007; RICHMAN DD, 1992, AIDS RES HUM RETROV, V8, P1065, DOI 10.1089/aid.1992.8.1065; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; VOLBERDING PA, 1995, NEW ENGL J MED, V333, P401, DOI 10.1056/NEJM199508173330701; VOLBERDING PA, 1988, MED MANAGEMENT AIDS, P353; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTERMANN J, 1990, IMMUNOL TODAY, V11, P406, DOI 10.1016/0167-5699(90)90160-B	31	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					161	162		10.1001/jama.276.2.161	http://dx.doi.org/10.1001/jama.276.2.161			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656510				2022-12-24	WOS:A1996UV48500034
J	Beer, JH; Vogt, A; Neftel, K; Cottagnoud, P				Beer, JH; Vogt, A; Neftel, K; Cottagnoud, P			False positive results for leucocytes in urine dipstick test with common antibiotics	BRITISH MEDICAL JOURNAL			English	Article									ZIEGLER CITY HOSP,BERN,SWITZERLAND		Beer, JH (corresponding author), UNIV HOSP BERN,DEPT MED,CH-3010 BERN,SWITZERLAND.			Beer, Jurg Hans/0000-0002-7199-0406				BONNARDEAUX A, 1994, CLIN NEPHROL, V41, P167; HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; MENDEZ R, 1992, CHEM PHARM BULL, V40, P3228, DOI 10.1248/cpb.40.3228; VERSTRAETEN L, 1992, CLIN CHEM, V38, P2557	4	25	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					25	25		10.1136/bmj.313.7048.25	http://dx.doi.org/10.1136/bmj.313.7048.25			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664766	Green Published			2022-12-24	WOS:A1996UW66700027
J	Graham, B				Graham, B			Diagnosis of closed wrist injuries	LANCET			English	Editorial Material											Graham, B (corresponding author), UNIV TORONTO,TORONTO HOSP,TORONTO,ON,CANADA.							BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; Lichtman D., 1988, WRIST ITS DISORDERS; Thorpe AP, 1996, BRIT J RADIOL, V69, P109, DOI 10.1259/0007-1285-69-818-109; WILKENS EW, 1989, EMERGENCY MED SCI FD	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1709	1709		10.1016/S0140-6736(96)90801-6	http://dx.doi.org/10.1016/S0140-6736(96)90801-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656899				2022-12-24	WOS:A1996UT39600003
J	Hollenberg, SM; Parrillo, JE				Hollenberg, SM; Parrillo, JE			Critical care medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK SURGICAL PATIENTS; OXYGEN DELIVERY				Hollenberg, SM (corresponding author), RUSH MED COLL, CHICAGO, IL 60612 USA.		Hollenberg, Steven/AAR-4522-2020	Hollenberg, Steven/0000-0003-1293-8496				ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; CIVETTA JM, 1990, ANN SURG, V212, P266, DOI 10.1097/00000658-199009000-00005; ESSERMAN L, 1995, JAMA-J AM MED ASSOC, V274, P1544, DOI 10.1001/jama.274.19.1544; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; SHOEMAKER WC, 1992, CHEST, V102, P208, DOI 10.1378/chest.102.1.208; SUFFREDINI AF, 1994, CRIT CARE MED, V22, pS12; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; 1996, JAMA-J AM MED ASSOC, V275, P1232	16	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1799	1800		10.1001/jama.275.23.1799	http://dx.doi.org/10.1001/jama.275.23.1799			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642716				2022-12-24	WOS:A1996UQ15200015
J	Schindelin, H; Kisker, C; Hilton, J; Rajagopalan, KV; Rees, DC				Schindelin, H; Kisker, C; Hilton, J; Rajagopalan, KV; Rees, DC			Crystal structure of DMSO reductase: Redox-linked changes in molybdopterin coordination	SCIENCE			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; DIMETHYLSULFOXIDE REDUCTASE; MOLYBDENUM COFACTOR; RHODOBACTER-SPHAEROIDES; FORMATE DEHYDROGENASE; BIOGENIC SULFUR; PROTEIN; DENITRIFICANS	The molybdoenzyme dimethylsulfoxide (DMSO) reductase contributes to the release of dimethylsulfide, a compound that has been implicated in cloud nucleation and global climate regulation, The crystal structure of DMSO reductase from Rhodobacter sphaeroides reveals a monooxo molybdenum cofactor containing two molybdopterin guanine dinucleotides that asymmetrically coordinate the molybdenum through their dithiolene groups, One of the pterins exhibits different coordination modes to the molybdenum between the oxidized and reduced states, whereas the side chain oxygen of Ser(147) coordinates the metal in both states. The change in pterin coordination between the Mo(VI) and Mo(IV) forms suggests a mechanism for substrate binding and reduction by this enzyme. Sequence comparisons of DMSO reductase with a family of bacterial oxotransferases containing molybdopterin guanine dinucleotide indicate a similar polypeptide fold and active site with two molybdopterins within this family.	CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	California Institute of Technology; Duke University			Kisker, Caroline/T-1724-2019; Schindelin, Hermann/Q-2697-2019	Kisker, Caroline/0000-0002-0216-6026	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050775] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50775, GM00091] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANEJA VP, 1989, ACS SYM SER, V393, P2; [Anonymous], 1993, ADV INORGANIC CHEM, DOI DOI 10.1016/S0898-8838(08)60181-6; AXELROD HL, 1994, ACTA CRYSTALLOGR D, V50, P596, DOI 10.1107/S0907444994001319; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASTIAN NR, 1991, J BIOL CHEM, V266, P45; BATES TS, 1987, NATURE, V329, P319, DOI 10.1038/329319a0; BERG BL, 1991, J BIOL CHEM, V266, P22380; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BRUNGER AT, 1992, XPLOR VERSION 3 1 SY, P187; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; DACEY JWH, 1986, SCIENCE, V233, P1314, DOI 10.1126/science.233.4770.1314; Davies GJ, 1996, ACTA CRYSTALLOGR D, V52, P7, DOI 10.1107/S0907444995009280; DAVIES GJ, 1993, NATURE, V365, P362, DOI 10.1038/365362a0; FINNEGAN MG, 1993, INORG CHEM, V32, P2616, DOI 10.1021/ic00064a005; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; Hilton JC, 1996, ARCH BIOCHEM BIOPHYS, V325, P139, DOI 10.1006/abbi.1996.0017; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KILPATRICK L, 1995, BIOCHEMISTRY-US, V34, P3032, DOI 10.1021/bi00009a034; KRAFFT T, 1992, EUR J BIOCHEM, V206, P503, DOI 10.1111/j.1432-1033.1992.tb16953.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUDVIGSEN S, 1992, BIOCHEMISTRY-US, V31, P8783, DOI 10.1021/bi00152a014; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCEWAN AG, 1991, BIOCHEM J, V274, P305, DOI 10.1042/bj2740305; MCEWAN AG, 1989, BIOCHIM BIOPHYS ACTA, V973, P308, DOI 10.1016/S0005-2728(89)80437-2; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NEVITT GA, 1995, NATURE, V376, P680, DOI 10.1038/376680ao; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PIERSON DE, 1990, J BACTERIOL, V172, P2194, DOI 10.1128/jb.172.4.2194-2198.1990; POLLOCK VV, 1995, ARCH BIOCHEM BIOPHYS, V318, P322, DOI 10.1006/abbi.1995.1236; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; SATOH T, 1987, J BIOCHEM-TOKYO, V102, P191, DOI 10.1093/oxfordjournals.jbchem.a122032; SCHULTZ BE, 1995, J AM CHEM SOC, V117, P827, DOI 10.1021/ja00107a031; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SHUBER AP, 1986, J BIOL CHEM, V261, P2942; STIEFEL EI, 1993, ACS SYM SER, V535, P1; STOWELL MHB, IN PRESS J APPL CRYS; TAYLOR BF, 1989, ACS SYM SER, V393, P202; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	52	441	448	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	1996	272	5268					1615	1621		10.1126/science.272.5268.1615	http://dx.doi.org/10.1126/science.272.5268.1615			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658134				2022-12-24	WOS:A1996UR09300035
J	Johnson, AP; Speller, DCE; George, RC; Warner, M; Domingue, G; Efstratiou, A				Johnson, AP; Speller, DCE; George, RC; Warner, M; Domingue, G; Efstratiou, A			Prevalence of antibiotic resistance and serotypes in Pneumococci in England and Wales: Results of observational surveys in 1990 and 1995	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the prevalence of antibiotic resistance and serotype distribution among pneumococci in England and Wales in 1990 and 1995. Design-Observational surveys in March 1990 and March 1995. During two weeks in each survey period all pneumococci isolated in public health laboratories in England and Wales were collected and assessed for sensitivity to antibiotics and the distribution of serogroups or serotypes. Setting-The network of public health laboratories throughout England and Wales. Subjects-1127 individual patient isolates of Streptococcus pneumoniae obtained during the two surveys. Main outcome measures-Sensitivity or resistance to a range of antibiotics; serogroup or serotype. Results-The prevalence of intermediate or full resistance to penicillin increased from 1.5% in 1990 to 3.9% in 1995 and resistance to erythromycin increased from 2.8% to 8.6%. About 92% of isolates belonged to serogroups or serotypes included in the currently available pneumococcal vaccine. Conclusion-Resistance to penicillin and erythromycin has increased among pneumococci in England and Wales. Continued surveillance to assess further increases in the prevalence of pneumococcal resistance to antibiotics is essential.	CENT PUBL HLTH LAB,STREPTOCOCCUS & DIPHTHERIA REFERENCE UNIT,RESP & SYST INFECT LAB,LONDON NW9 5HT,ENGLAND	Public Health England	Johnson, AP (corresponding author), CENT PUBL HLTH LAB,ANTIBIOT REFERENCE UNIT,LAB HOSP INFECT,LONDON NW9 5HT,ENGLAND.		Johnson, Alan P/F-4420-2014					APPLEBAUM PC, 1992, CLIN INFECT DIS, V15, P77; ASZKENASY OM, 1995, COMMUNICAB DIS REP, V5, P45; BARRY AL, 1995, ANTIMICROB AGENTS CH, V39, P238, DOI 10.1128/AAC.39.1.238; BOSWELL TC, 1994, J ANTIMICROB CHEMOTH, V34, P844, DOI 10.1093/jac/34.5.844; FRIEDLAND IR, 1995, CURR OPIN INFECT DIS, V8, P213; George R C, 1992, Commun Dis Rep CDR Rev, V2, pR37; JOHNSON AP, 1995, J ANTIMICROB CHEMOTH, V35, P443, DOI 10.1093/jac/35.3.443; JORGENSEN JH, 1994, J CLIN MICROBIOL, V32, P2448, DOI 10.1128/JCM.32.10.2448-2459.1994; Klein DL, 1995, MICROB DRUG RESIST, V1, P49, DOI 10.1089/mdr.1995.1.49; KLUGMAN KP, 1994, EUR J CLIN MICROBIOL, V13, P1, DOI 10.1007/BF02026115; KLUGMAN KP, 1995, ANTIMICROB AGENTS CH, V39, P1988, DOI 10.1128/AAC.39.9.1988; LONKS JR, 1993, ANTIMICROB AGENTS CH, V37, P1742, DOI 10.1128/AAC.37.9.1742; RIDGWAY EJ, 1991, J HOSP INFECT, V17, P15, DOI 10.1016/0195-6701(91)90073-H; 1989, MMWR-MORBID MORTAL W, V38, P64; 1991, J ANTIMICROB CHEM SD, V27; 1989, MMWR-MORBID MORTAL W, V38, P73; 1995, COMMUNICAB DIS REP, V5, P187	17	74	74	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1454	1456		10.1136/bmj.312.7044.1454	http://dx.doi.org/10.1136/bmj.312.7044.1454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664623	Green Published			2022-12-24	WOS:A1996UQ29600026
J	Baba, TW; Trichel, AM; An, L; Liska, V; Martin, LN; MurpheyCorb, M; Ruprecht, RM				Baba, TW; Trichel, AM; An, L; Liska, V; Martin, LN; MurpheyCorb, M; Ruprecht, RM			Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL BISEXUAL MEN; RHESUS-MONKEYS; HIV SEROCONVERSION; HTLV-III; ACID-SECRETION; DISEASE STAGE; RISK-FACTORS; HUMAN SALIVA; TRANSMISSION	Unprotected receptive anal intercourse is a well-recognized risk factor for infection with human immunodeficiency virus-type 1 (HIV-1). Isolated human case reports have implicated HIV-1 transmission by oral-genital exposure. Adult macaques exposed nontraumatically to cell-free simian immunodeficiency virus (SIV) through the oral route became infected and developed acquired immunodeficiency syndrome (AIDS). The minimal virus dose needed to achieve systemic infection after oral exposure was 6000 times lower than the minimal dose required to achieve systemic infection after rectal exposure. Thus, unprotected receptive oral intercourse, even in the absence of mucosal lesions, should be added to the list of risk behaviors for HIV-1 transmission.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, LAB VIRAL PATHOGENESIS, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, DEPT PEDIAT, DIV NEWBORN MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; TULANE UNIV, TULANE REG PRIMATE RES CTR, COVINGTON, LA 70433 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School; Tulane University					NIAID NIH HHS [U01-AI24345, R01-AI34266, R01-AI32330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024345, R01AI034266, R01AI032330, R37AI024345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; AMEDEE AM, 1995, J VIROL, V69, P7982, DOI 10.1128/JVI.69.12.7982-7990.1995; AMORY J, 1992, CLIN RES, V40, pA51; ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; ARCHIBALD DW, 1990, AIDS RES HUM RETROV, V6, P1425, DOI 10.1089/aid.1990.6.1425; BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BABA TW, 1993, J WOMENS HEALTH, V2, P231; BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; BASKIN GB, 1986, J NATL CANCER I, V77, P127; BERGEY EJ, 1994, J ACQ IMMUN DEF SYND, V7, P995; BERTHIER A, 1986, LANCET, V2, P598; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; CONWAY MD, 1991, J MED PRIMATOL, V20, P152; COPPENHAVER DH, 1994, NEW ENGL J MED, V330, P1314, DOI 10.1056/NEJM199405053301815; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; FRANCHINI G, 1989, ANN NY ACAD SCI, V554, P81, DOI 10.1111/j.1749-6632.1989.tb22412.x; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; FRIEDLAND G, 1990, AIDS, V4, P639, DOI 10.1097/00002030-199007000-00005; FULTZ PN, 1986, J INFECT DIS, V154, P896, DOI 10.1093/infdis/154.5.896; FULTZ PN, 1986, LANCET, V2, P1215; GIBB D, 1994, AIDS S1, V8, pS275; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1984, SCIENCE, V226, P451, DOI 10.1126/science.6208608; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; KINGSLEY LA, 1987, LANCET, V1, P345; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; LAIRMORE MD, 1993, AIDS RES HUM RETROV, V9, P565, DOI 10.1089/aid.1993.9.565; LANE HC, 1991, AM J PUBLIC HEALTH, V81, P658, DOI 10.2105/AJPH.81.5.658; LARSSON H, 1983, GASTROENTEROLOGY, V85, P900; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; Levy JA, 1994, HIV PATHOGENESIS AID; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; LIND T, 1983, GUT, V24, P270, DOI 10.1136/gut.24.4.270; MALAMUD D, 1993, AIDS RES HUM RETROV, V9, P633, DOI 10.1089/aid.1993.9.633; MARTHAS ML, 1992, J MED PRIMATOL, V21, P99; MARTIN LN, 1994, ANTIMICROB AGENTS CH, V38, P1277, DOI 10.1128/AAC.38.6.1277; MARTIN LN, 1993, J INFECT DIS, V168, P825, DOI 10.1093/infdis/168.4.825; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; MCTAVISH D, 1991, DRUGS, V42, P138, DOI 10.2165/00003495-199142010-00008; MILLER CJ, 1994, J VIROL, V68, P6391, DOI 10.1128/JVI.68.10.6391-6400.1994; MILLER CJ, 1990, J MED PRIMATOL, V19, P401; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; MILLER CJ, 1994, AM J REPROD IMMUNOL, V31, P52, DOI 10.1111/j.1600-0897.1994.tb00847.x; MILLER CJ, 1994, AM J REPROD IMMUNOL, V188, P107; MURRAY AB, 1991, LANCET, V338, P830, DOI 10.1016/0140-6736(91)90726-6; ONKAWA S, 1990, FASEB J, V4, pA2264; PAUZA CD, 1994, AIDS RES HUM RETROV, V10, pS7; PAUZA CD, 1993, J MED PRIMATOL, V22, P154; POURTOIS M, 1991, AIDS, V5, P598, DOI 10.1097/00002030-199105000-00022; ROGERS MF, 1990, PEDIATRICS, V85, P210; ROZENBAUM W, 1988, LANCET, V1, P1395; SPOUGE JL, 1992, P NATL ACAD SCI USA, V89, P7581, DOI 10.1073/pnas.89.16.7581; SU H, 1991, MOL IMMUNOL, V28, P811, DOI 10.1016/0161-5890(91)90044-K; VANGRIENSVEN GJP, 1987, AM J EPIDEMIOL, V125, P1048, DOI 10.1093/oxfordjournals.aje.a114620; VANVOORHIS BJ, 1991, FERTIL STERIL, V55, P588; WILLIAMSHERMANN D, 1993, INT C AIDS JUN; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607; ZHANG JY, 1988, J INFECT DIS, V158, P1277, DOI 10.1093/infdis/158.6.1277	66	130	133	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1486	1489		10.1126/science.272.5267.1486	http://dx.doi.org/10.1126/science.272.5267.1486			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633242				2022-12-24	WOS:A1996UP89900049
J	Hanneman, RL				Hanneman, RL			Intersalt: Hypertension rise with age revisited	BRITISH MEDICAL JOURNAL			English	Article											Hanneman, RL (corresponding author), SALT INST,700 N FAIRFAX ST,ALEXANDRIA,VA 22314, USA.							SWALES JD, 1988, BRIT MED J, V297, P307, DOI 10.1136/bmj.297.6644.307; 1988, BRIT MED J, V297, P319	2	30	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1283	1284		10.1136/bmj.312.7041.1283	http://dx.doi.org/10.1136/bmj.312.7041.1283			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634620	Green Published			2022-12-24	WOS:A1996UM40400026
J	Koh, JY; Suh, SW; Gwag, BJ; He, YY; Hsu, CY; Choi, DW				Koh, JY; Suh, SW; Gwag, BJ; He, YY; Hsu, CY; Choi, DW			The role of zinc in selective neuronal death after transient global cerebral ischemia	SCIENCE			English	Article							HISTOCHEMICALLY REACTIVE ZINC; FOREBRAIN ISCHEMIA; RAT HIPPOCAMPUS; ENDOGENOUS ZN-2+; CORTICAL-NEURONS; TEMPORAL PROFILE; CELL LOSS; BRAIN; NMDA; RELEASE	Zinc is present in presynaptic nerve terminals throughout the mammalian central nervous system and likely serves as an endogenous signaling substance. However, excessive exposure to extracellular zinc can damage central neurons. After transient forebrain ischemia in rats, chelatable zinc accumulated specifically in degenerating neurons in the hippocampal hilus and CA1, as well as in the cerebral cortex, thalamus, striatum, and amygdala. This accumulation preceded neurodegeneration, which could be prevented by the intraventricular injection of a zinc chelating agent. The toxic influx of zinc may be a key mechanism underlying selective neuronal death after transient global ischemic insults.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,CTR STUDY NERVOUS SYST INJURY,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Koh, Jae-Young/C-9014-2011	Koh, Jae-Young/0000-0002-4318-495X; Hsu, Chung Y./0000-0002-5632-2733	NINDS NIH HHS [NS30337] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030337] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BLOMQVIST P, 1985, J CEREBR BLOOD F MET, V5, P420, DOI 10.1038/jcbfm.1985.57; BUCHAN AM, 1991, NEUROSCI LETT, V132, P255, DOI 10.1016/0304-3940(91)90314-J; CHARTON G, 1985, EXP BRAIN RES, V58, P202; CHOI DW, 1988, NEUROSCIENCE, V24, P67, DOI 10.1016/0306-4522(88)90312-0; CHOW HS, 1994, BRAIN RES, V639, P102, DOI 10.1016/0006-8993(94)91769-8; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; CHUNG SH, 1984, PROC R SOC SER B-BIO, V221, P145, DOI 10.1098/rspb.1984.0028; CSERMELY P, 1988, J BIOL CHEM, V263, P6487; DANSCHER G, 1985, HISTOCHEMISTRY, V83, P419, DOI 10.1007/BF00509203; DESHPANDE J, 1992, EXP BRAIN RES, V88, P91, DOI 10.1007/BF02259131; DIEMER NH, 1992, ACTA NEUROL SCAND, V86, P45, DOI 10.1111/j.1600-0404.1992.tb08052.x; FREDENS K, 1973, HISTOCHEMISTRY, V37, P321, DOI 10.1007/BF00274968; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FREDERICKSON CJ, 1982, BRAIN RES, V246, P338, DOI 10.1016/0006-8993(82)91188-X; FREDERICKSON CJ, 1992, J CHEM NEUROANAT, V5, P521, DOI 10.1016/0891-0618(92)90007-D; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; FREDERICKSON CJ, 1984, MERITS DEMERITS ZINC, VA, P289; GILL R, 1987, J NEUROSCI, V7, P3343; Gwag B. J., 1995, Society for Neuroscience Abstracts, V21, P1585; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; JOHANSEN FF, 1990, ACTA NEUROPATHOL, V81, P14, DOI 10.1007/BF00662632; JOHANSEN FF, 1987, ACTA NEUROPATHOL, V73, P110, DOI 10.1007/BF00693775; KIRINO T, 1984, ACTA NEUROPATHOL, V64, P139, DOI 10.1007/BF00695577; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KRESS Y, 1981, BRAIN RES, V220, P139, DOI 10.1016/0006-8993(81)90217-1; LEES GJ, 1989, ACTA NEUROPATHOL, V7, P519; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; NOHL H, 1991, FREE RADICAL BIO MED, V11, P581, DOI 10.1016/0891-5849(91)90139-T; Perrin D.D., 1979, STABILITY CONSTANTS; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Rose K, 1993, IN VITRO BIOL METHOD, P46; ROSS T, 1995, BRAIN RES, V683, P117; SANDSTROM BE, 1994, FREE RADICAL BIO MED, V16, P177, DOI 10.1016/0891-5849(94)90141-4; SLOVITER RS, 1985, BRAIN RES, V330, P150, DOI 10.1016/0006-8993(85)90017-4; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WINEGAR BD, 1990, J PHYSIOL-LONDON, V425, P563, DOI 10.1113/jphysiol.1990.sp018118; YIM MB, 1994, J BIOL CHEM, V269, P1621	45	927	947	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1013	1016		10.1126/science.272.5264.1013	http://dx.doi.org/10.1126/science.272.5264.1013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638123				2022-12-24	WOS:A1996UL61900046
J	Thea, DM; Porat, R; Nagimbi, K; Baangi, M; StLouis, ME; Kaplan, G; Dinarello, CA; Keusch, GT				Thea, DM; Porat, R; Nagimbi, K; Baangi, M; StLouis, ME; Kaplan, G; Dinarello, CA; Keusch, GT			Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1	ANNALS OF INTERNAL MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; HUMAN MONONUCLEAR-CELLS; IMMUNODEFICIENCY-VIRUS TYPE-1; FACTOR-ALPHA; SOLUBLE RECEPTORS; HIV-1-INFECTED PATIENTS; BLOOD MONOCYTES; TNF-ALPHA; IL-1	Objectives: To examine the relation of circulating cytokines and cytokine antagonists to the progression of human immunodeficiency virus type 1 (HIV-1) disease. Design: Cross-sectional analysis. Setting: An ambulatory acquired immunodeficiency syndrome (AIDS) research clinic in Kinshasa, Zaire. Patients: 48 women with AIDS, 51 women with HIV infection who were clinically asymptomatic, and 11 female controls who did not have HIV infection, all from Zaire. Measurements: Plasma levels of interleukin-1 beta, tumor necrosis factor-alpha (TNF-alpha), interleukin-6, interleukin-8, interferon-gamma, interleukin-1 beta receptor antagonist (interleukin-1Ra), and TNF soluble receptor p55 (TNFsRp55) were assayed by specific radioimmunoassays. Plasma levels of interferon-gamma were assayed by commercial enzyme-linked immunosorbent assay. The Wilcoxon rank-sum test was used to assess the significance of mean and median differences between groups. Results: Of the 48 patients with AIDS, circulating interleukin-1 beta was detected in 2, TNF-alpha in 4, interleukin-6 in 3, and interleukin-8 in 12. None of these factors were seen in any of the 11 controls. Median values of interleukin-lp (320 pg/ml), TNF-alpha (210 pg/mL), and interleukin-8 (750 pg/mL) were elevated in HIV-infected asymptomatic patients compared with patients with AIDS (2-, 2.6-, and 18.7-fold higher, respectively; P < 0.001). Interleukin-1Ra and TNFsRp55 levels were substantially higher than interleukin-1 beta and TNF-alpha levels in HIV-infected asymptomatic patients (73- and 14-fold, respectively) and were higher than those in patients with AIDS (17.8- and 1.74-fold, respectively). Conclusion: High circulating levels of the proinflammatory cytokines interleukin-1 beta and TNF-alpha, combined with an excess of their natural inhibitors interleukin-1Ra and TNFsRp55, were seen in clinically asymptomatic HIV-1-positive African women but not in African women with AIDS or in HIV-negative controls. Circulating cytokine antagonists may play a clinical role in modulating cytokine-associated symptoms in the early phases of HIV infection.	TUFTS UNIV NEW ENGLAND MED CTR, DIV GEOGRAPH MED & INFECT DIS, BOSTON, MA 02111 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA 30333 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; MINIST HLTH, AIDS RES UNIT, KINSHASA, DEM REP CONGO	Tufts Medical Center; Centers for Disease Control & Prevention - USA; Rockefeller University				/0000-0001-5724-2965; Thea, Donald/0000-0002-6933-1030	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024755, R01AI024755, R37AI015614, P01AI026698, R01AI015614] Funding Source: NIH RePORTER; NIAID NIH HHS [P01-AI-26698, AI-24755, AI-15614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; BARGETZI MJ, 1993, CANCER RES, V53, P4010; BREEN EC, 1990, J IMMUNOL, V144, P480; CANNON JG, 1992, CRIT CARE MED, V20, P1414, DOI 10.1097/00003246-199210000-00009; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; DINARELLO CA, 1991, BLOOD, V77, P1627; FERRETTI M, 1994, J CLIN INVEST, V94, P449, DOI 10.1172/JCI117345; GIRARDIN E, 1992, IMMUNOLOGY, V76, P20; GODFRIED MH, 1994, J INFECT DIS, V169, P739, DOI 10.1093/infdis/169.4.739; GODFRIED MH, 1993, AIDS, V7, P33, DOI 10.1097/00002030-199301000-00005; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GRANOWITZ EV, 1992, BLOOD, V79, P2356; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; KAUFFMAN CA, 1986, AM J CLIN NUTR, V44, P449, DOI 10.1093/ajcn/44.4.449; KIKUTA H, 1990, J INFECT DIS, V162, P35, DOI 10.1093/infdis/162.1.35; LISI PJ, 1987, LYMPHOKINE RES, V6, P229; LOWRY SF, 1993, ARCH SURG-CHICAGO, V128, P1235; MILLER LC, 1993, LANCET, V341, P146, DOI 10.1016/0140-6736(93)90006-3; MOLINA JM, 1990, J INFECT DIS, V161, P888, DOI 10.1093/infdis/161.5.888; OKAMOTO T, 1989, AIDS RES HUM RETROV, V5, P131, DOI 10.1089/aid.1989.5.131; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POLI G, 1994, P NATL ACAD SCI USA, V91, P108, DOI 10.1073/pnas.91.1.108; PORAT R, 1992, FASEB J, V6, P2482, DOI 10.1096/fasebj.6.7.1532945; POUTSIAKA DD, 1991, BLOOD, V78, P1275; RAMBALDI A, 1991, BLOOD, V78, P3248; RAUTONEN J, 1991, AIDS, V5, P1319, DOI 10.1097/00002030-199111000-00006; REKA S, 1994, LYMPHOKINE CYTOK RES, V13, P391; ROUXLOMBARD P, 1989, CLIN IMMUNOL IMMUNOP, V50, P374, DOI 10.1016/0090-1229(89)90144-X; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCHINDLER R, 1990, BLOOD, V75, P40; SCOTTALGARA D, 1991, AIDS RES HUM RETROV, V7, P381, DOI 10.1089/aid.1991.7.381; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SHAPIRO L, 1993, J INFECT DIS, V167, P1344, DOI 10.1093/infdis/167.6.1344; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; SUTTMANN U, 1994, CLIN SCI, V86, P461; VANDERMEER JWM, 1988, J LEUKOCYTE BIOL, V43, P216, DOI 10.1002/jlb.43.3.216; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VONSYDOW M, 1991, AIDS RES HUM RETROV, V7, P375, DOI 10.1089/aid.1991.7.375; 1989, MMWR MORB MORT WK S7, V38, P1	40	72	74	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					757	762		10.7326/0003-4819-124-8-199604150-00009	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633837				2022-12-24	WOS:A1996UD93600009
J	Brenman, JE; Chao, DS; Gee, SH; McGee, AW; Craven, SE; Santillano, DR; Wu, ZQ; Huang, F; Xia, HH; Peters, MF; Froehner, SC; Bredt, DS				Brenman, JE; Chao, DS; Gee, SH; McGee, AW; Craven, SE; Santillano, DR; Wu, ZQ; Huang, F; Xia, HH; Peters, MF; Froehner, SC; Bredt, DS			Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha 1-syntrophin mediated by PDZ domains	CELL			English	Article							L-ARGININE; DYSTROPHIN; TISSUE; SYSTEM; BRAIN; CELLS	Neuronal nitric oxide synthase (nNOS) is concentrated at synaptic junctions in brain and motor endplates in skeletal muscle. Here, we show that the N-terminus of nNOS, which contains a PDZ protein motif, interacts with similar motifs in postsynaptic density-95 protein (PSD-95) and a related novel protein, PSD-93. nNOS and PSD-95 are coexpressed in numerous neuronal populations, and a PSD-95/nNOS complex occurs in cerebellum. PDZ domain interactions also mediate binding of nNOS to skeletal muscle syntrophin, a dystrophin-associated protein. nNOS isoforms lacking a PDZ domain, identified in nNOS(Delta/Delta) mutant mice, do not associate with PSD-95 in brain or with skeletal muscle sarcolemma. Interaction of PDZ-containing domains therefore mediates synaptic association of nNOS and may play a more general role in formation of macromolecular signaling complexes.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599	University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill	Brenman, JE (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.							ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AOKI C, 1993, BRAIN RES, V620, P97, DOI 10.1016/0006-8993(93)90275-R; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HALL AV, 1994, J BIOL CHEM, V269, P33082; HECKER M, 1994, J NEUROCHEM, V62, P1524; HIBBS JB, 1987, J IMMUNOL, V138, P550; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KIM E, 1995, IN PRESS NATURE; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242; YANG B, 1994, J BIOL CHEM, V269, P6040	37	1392	1454	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					757	767		10.1016/S0092-8674(00)81053-3	http://dx.doi.org/10.1016/S0092-8674(00)81053-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625413	Bronze			2022-12-24	WOS:A1996TZ99000013
J	Ehlers, MD; Zhang, S; Bernhardt, JP; Huganir, RL				Ehlers, MD; Zhang, S; Bernhardt, JP; Huganir, RL			Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit	CELL			English	Article							RAT HIPPOCAMPAL-NEURONS; SPINAL-CORD NEURONS; PROTEIN-KINASE-C; GLUTAMATE RECEPTORS; CALCIUM; CHANNELS; RESPONSES; CLONING; ACID	NMDA (N-methyl-D-aspartate) receptors are excitatory neurotransmitter receptors in the brain critical for synaptic plasticity and neuronal development. These receptors are Ca2+-permeable glutamate-gated ion channels whose physiological properties are regulated by intracellular Ca2+. We report here the purification of a 20 kDa protein identified as calmodulin that interacts with the NR1 subunit of the NMDA receptor. Calmodulin binding to the NR1 subunit is Ca2+ dependent and occurs with homomeric NR1 complexes, heteromeric NR1/NR2 subunit complexes, and NMDA receptors from brain. Furthermore, calmodulin binding to NR1 causes a 4-fold reduction in NMDA channel open probability. These results demonstrate that NMDA receptor function can be regulated by direct binding of calmodulin to the NR1 subunit, and suggest a possible mechanism for activity-dependent feedback inhibition and Ca2+-dependent inactivation of NMDA receptors.			Ehlers, MD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BAER MF, 1995, NEURON, V15, P1; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KATSUWADA T, 1992, NATURE, V358, P36; KINCAID RL, 1982, J BIOL CHEM, V267, P10638; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MEDINA I, 1995, J PHYSIOL-LONDON, V482, P567, DOI 10.1113/jphysiol.1995.sp020540; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; VYKLICKY L, 1993, J PHYSIOL-LONDON, V470, P575, DOI 10.1113/jphysiol.1993.sp019876; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; ZORUMSKI CF, 1989, CELL MOL NEUROBIOL, V9, P95, DOI 10.1007/BF00711446	41	462	479	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					745	755		10.1016/S0092-8674(00)81052-1	http://dx.doi.org/10.1016/S0092-8674(00)81052-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625412	hybrid			2022-12-24	WOS:A1996TZ99000012
J	Symons, M; Derry, JMJ; Karlak, B; Jiang, S; Lemahieu, V; McCormick, F; Francke, U; Abo, A				Symons, M; Derry, JMJ; Karlak, B; Jiang, S; Lemahieu, V; McCormick, F; Francke, U; Abo, A			Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; T-CELLS; GROWTH; LYMPHOCYTES; GENE; NCK; SH2	The Rho family of GTPases control diverse biological processes, including cell morphology and mitogenesis. We have identified WASP, the protein that is defective in Wiskott-Aldrich syndrome (WAS), as a novel effector for CDC42Hs, but not for the other Rho family members, Pac and Rho. This interaction is dependent on the presence of the G protein-binding domain. Cellular expression of epitope-tagged WASP produces clusters of WASP that are highly enriched in polymerized actin. This clustering is not observed with a C-terminally deleted WASP and is inhibited by coexpression with dominant negative CDC42Hs-N17, but not with dominant negative forms of Rac or Rho. Thus, WASP provides a novel link between CDC42Hs and the actin cytoskeleton, which suggests a molecular mechanism for many of the cellular abnormalities in WAS. The WASP sequence contains two novel domains that are homologous to other proteins involved in actin organization.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University	Symons, M (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.							Ammann AJ, 1989, IMMUNOLOGIC DISORDER, P257; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DERRY JMJ, 1995, GENOMICS, V29, P471, DOI 10.1006/geno.1995.9979; DERRY JMJ, 1995, HUM MOL GENET, V4, P1127, DOI 10.1093/hmg/4.7.1127; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DONNELLY SFH, 1993, MOL MICROBIOL, V10, P585, DOI 10.1111/j.1365-2958.1993.tb00930.x; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KENNEY D, 1986, BLOOD, V68, P1329; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOLLURI R, 1995, HUM MOL GENET, V4, P1119, DOI 10.1093/hmg/4.7.1119; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARTIN GA, 1995, EMBO J, V14, P4385, DOI 10.1002/j.1460-2075.1995.tb00113.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; MULLEN CA, 1993, BLOOD, V82, P2961; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCHS HD, 1980, BLOOD, V55, P243; PARSEY MV, 1993, J IMMUNOL, V151, P1881; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STEPHEN F, 1990, J MOL BIOL, V215, P403, DOI DOI 10.1006/JMBI.1990.9999; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; WENGLER GS, 1995, BLOOD, V86, P3684; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHU QL, 1995, BLOOD, V86, P3797, DOI 10.1182/blood.V86.10.3797.bloodjournal86103797	55	738	741	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					723	734		10.1016/S0092-8674(00)81050-8	http://dx.doi.org/10.1016/S0092-8674(00)81050-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625410	Bronze			2022-12-24	WOS:A1996TZ99000010
J	Wainberg, MA; Drosopoulos, WC; Salomon, H; Hsu, M; Borkow, G; Parniak, MA; Gu, ZX; Song, QB; Manne, J; Islam, S; Castriota, G; Prasad, VR				Wainberg, MA; Drosopoulos, WC; Salomon, H; Hsu, M; Borkow, G; Parniak, MA; Gu, ZX; Song, QB; Manne, J; Islam, S; Castriota, G; Prasad, VR			Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE INSERTION FIDELITY; HIGH-LEVEL RESISTANCE; INVITRO SELECTION; TYPE-1 RESISTANT; DNA-REPLICATION; INHIBITORS; EXTENSION; MUTATION; RNA	Monotherapy with (-)2',3'-dideoxy-3'-thiacytidine (3TC) leads to the appearance of a drug-resistant variant of human immunodeficiency virus-type 1 (HIV-1) with the methionine-184 --> valine (M184V) substitution in the reverse transcriptase (RT). Despite resulting drug resistance, treatment for more than 48 weeks is associated with a lower plasma viral burden than that at baseline. Studies to investigate this apparent contradiction revealed the following. (i) Titers of HIV-neutralizing antibodies remained stable in 3TC-treated individuals in contrast to rapid declines in those treated with azidothymidine (AZT). (ii) Unlike wild-type HIV, growth of M184V HIV in cell culture in the presence of d4T, AZT, Nevirapine, Delavirdine, or Saquinavir did not select for variants displaying drug resistance. (iii) There was an increase in fidelity of nucleotide insertion by the M184V mutant compared with wild-type enzyme.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; MCGILL UNIV,JEWISH GEN HOSP,MCGILL AIDS CTR,MONTREAL,PQ H3T 1E2,CANADA	Yeshiva University; Albert Einstein College of Medicine; McGill University			Borkow, Gadi/W-4294-2019; Prasad, Vinayaka R./A-1029-2011	Prasad, Vinayaka/0000-0002-9461-0189	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030861, P30AI027741, U01AI024845] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI-27741, R01 AI0-30861, UO1AI-24845] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; Bebenek K, 1993, REVERSE TRANSCRIPTAS, P85; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BOULERICE F, 1990, J VIROL, V64, P1745, DOI 10.1128/JVI.64.4.1745-1755.1990; Cleland W W, 1979, Methods Enzymol, V63, P103; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; DROSOPOULOS W, UNPUB; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUBNER A, 1992, J MOL BIOL, V223, P595, DOI 10.1016/0022-2836(92)90975-P; INGRAND D, 1995, AIDS, V9, P1323, DOI 10.1097/00002030-199512000-00004; KAVLICK MF, 1995, ANTIVIR RES, V28, P133, DOI 10.1016/0166-3542(95)00044-M; KEY Y, 1994, J BIOL CHEM, V269, P15331; LARDER BA, 1991, J VIROL, V65, P5232, DOI 10.1128/JVI.65.10.5232-5236.1991; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MEIER UC, 1995, SCIENCE, V270, P1360, DOI 10.1126/science.270.5240.1360; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; PILLAY D, 1995, REV MED VIROL, V5, P23, DOI 10.1002/rmv.1980050104; PLUDA JM, 1995, J INFECT DIS, V171, P1438, DOI 10.1093/infdis/171.6.1438; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; PRESTON BD, 1992, PHARM TECHNOL, V16, P34; PRINCE AM, 1987, J INFECT DIS, V156, P268, DOI 10.1093/infdis/156.2.268; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SALOMON H, 1995, ANTIVIR CHEM CHEMOTH, V6, P222, DOI 10.1177/095632029500600404; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TREMBLAY M, 1990, J INFECT DIS, V162, P735, DOI 10.1093/infdis/162.3.735; WAINBERG MA, 1995, AIDS, V9, P351, DOI 10.1097/00002030-199509040-00006; WAINBERG MA, 1995, AIDS RES HUM RETROV, V11, pS169; WAINBERG MA, 1994, AIDS, V8, P169; WAINBERG MA, 1991, AIDS, V5, P1061; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; YU H, 1992, J BIOL CHEM, V267, P10888; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	54	281	286	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1282	1285		10.1126/science.271.5253.1282	http://dx.doi.org/10.1126/science.271.5253.1282			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638110				2022-12-24	WOS:A1996TX69500037
J	Senkevich, TG; Bugert, JJ; Sisler, JR; Koonin, EV; Darai, G; Moss, B				Senkevich, TG; Bugert, JJ; Sisler, JR; Koonin, EV; Darai, G; Moss, B			Genome sequence of a human tumorigenic poxvirus: Prediction of specific host response-evasion genes	SCIENCE			English	Article							MOLLUSCUM-CONTAGIOSUM VIRUS; EPIDERMAL GROWTH-FACTOR; VACCINIA VIRUS; NUCLEOTIDE-SEQUENCE; RING FINGER; ZINC-FINGER; DNA; PROTEIN; VARIOLA; HOMOLOG	Molluscum contagiosum virus (MCV) commonly causes asymptomatic cutaneous neoplasms in children and sexually active adults as well as persistent opportunistic acquired immunodeficiency syndrome (AIDS)-associated disease. Sequencing the 190-kilobase pair genome of MCV has now revealed that the virus potentially encodes 163 proteins, of which 103 have homologs in the smallpox virus. MCV lacks counterparts to 83 genes of the smallpox virus, including those important in suppression of host responses to infection, nucleotide biosynthesis, and cell proliferation. MCV possesses 59 genes that are predicted to encode previously uncharacterized proteins, including major histocompatibility complex class I, chemokine, and glutathione peroxidase homologs, which suggests that there are MCV-specific strategies for coexistence with the human host.	NIAID, VIRAL DIS LAB, NIH, BETHESDA, MD 20892 USA; NIH, NATL CTR BIOTECHNOL INFORMAT, NATL LIB MED, BETHESDA, MD 20892 USA; UNIV HEIDELBERG, INST MED VIROL, D-69120 HEIDELBERG, GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Ruprecht Karls University Heidelberg			Bugert, Joachim/AAK-6459-2021; Bugert, Joachim J/D-1705-2012	Bugert, Joachim J/0000-0002-0556-3211; Moss, Bernard/0000-0002-2154-8564				AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; ALCAMI A, 1995, IMMUNOL TODAY, V16, P474, DOI 10.1016/0167-5699(95)80030-1; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECK S, 1988, NATURE, V331, P269, DOI 10.1038/331269a0; BLAKE NW, 1991, J VIROL, V65, P3583, DOI 10.1128/JVI.65.7.3583-3589.1991; BORODOVSKY M, 1994, NUCLEIC ACIDS RES, V22, P4756, DOI 10.1093/nar/22.22.4756; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BORODOVSKY M, COMMUNICATION; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BROWNE H, 1992, J VIROL, V66, P6784, DOI 10.1128/JVI.66.11.6784-6787.1992; Bugert J, 1989, Virus Genes, V3, P159; BUGERT JJ, 1993, VIROLOGY, V192, P391, DOI 10.1006/viro.1993.1050; BUGERT JJ, 1991, J MED VIROL, V33, P211, DOI 10.1002/jmv.1890330313; BULLER RML, 1995, VIROLOGY, V213, P655, DOI 10.1006/viro.1995.0037; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; DARAI G, 1986, J MED VIROL, V18, P29, DOI 10.1002/jmv.1890180105; FAHNESTOCK ML, 1995, IMMUNITY, V3, P583, DOI 10.1016/1074-7613(95)90129-9; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FENNER F, 1966, FIELDS VIROLOGY, P2703; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Goebel S.J., 1990, VIROLOGY, V179, P517; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOTTLIEB SL, 1994, INT J DERMATOL, V33, P453, DOI 10.1111/j.1365-4362.1994.tb02853.x; HADASCH RP, 1993, INTERVIROLOGY, V36, P32; Henderson DA, 1988, SMALLPOX ITS ERADICA; KELLEY WL, 1994, TRENDS BIOCHEM SCI, V19, P277, DOI 10.1016/0968-0004(94)90003-5; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.immunol.13.1.587; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; MOSS B, 1966, FIELDS VIROLOGY, P2637; Nielsen H, 1996, PROTEINS, V24, P165, DOI 10.1002/(SICI)1097-0134(199602)24:2<165::AID-PROT4>3.0.CO;2-I; PARR RP, 1977, VIROLOGY, V81, P247, DOI 10.1016/0042-6822(77)90141-6; PEARSON WR, 1991, GENOMICS, V11, P635, DOI 10.1016/0888-7543(91)90071-L; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEARSON WR, 1988, COMPUT APPL BIOSCI, V4, P11; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; Porter C D, 1992, Mol Cell Biol Hum Dis Ser, V1, P233; PORTER CD, 1987, J GEN VIROL, V68, P673, DOI 10.1099/0022-1317-68-3-673; RAULET DH, 1995, CELL, V82, P697, DOI 10.1016/0092-8674(95)90466-2; REMPEL RE, 1992, J VIROL, V66, P4413, DOI 10.1128/JVI.66.7.4413-4426.1992; ROST B, 1995, PROTEIN SCI, V4, P521; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SENKEVICH TG, 1994, VIROLOGY, V198, P118, DOI 10.1006/viro.1994.1014; SENKEVICH TG, 1995, J VIROL, V69, P4103, DOI 10.1128/JVI.69.7.4103-4111.1995; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P80, DOI 10.1016/0014-5793(93)80041-R; SHCHELKUNOV SN, 1995, VIRUS RES, V36, P107, DOI 10.1016/0168-1702(94)00113-Q; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SONNTAG KC, 1995, VIROLOGY, V210, P471, DOI 10.1006/viro.1995.1364; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; UPTON C, 1994, J VIROL, V68, P4186, DOI 10.1128/JVI.68.7.4186-4195.1994; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x	58	256	283	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					813	816		10.1126/science.273.5276.813	http://dx.doi.org/10.1126/science.273.5276.813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670425				2022-12-24	WOS:A1996VB42900048
J	Hansson, LE; Nyren, O; Hsing, AW; Bergstrom, R; Josefsson, S; Chow, WH; Fraumeni, JF; Adami, HO				Hansson, LE; Nyren, O; Hsing, AW; Bergstrom, R; Josefsson, S; Chow, WH; Fraumeni, JF; Adami, HO			The risk of stomach cancer in patients with gastric or duodenal ulcer disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HELICOBACTER-PYLORI; PEPTIC-ULCER; ASCORBIC-ACID; ASPIRIN USE; CARCINOMA; ALCOHOL; DRUGS	Background Helicobacter pylori infection, now considered to be a cause of gastric cancer, is also strongly associated with gastric and duodenal ulcer disease. The discovery of these relations has brought the long-controversial connection between peptic ulcers and gastric cancer into focus. Methods We estimated the risk of stomach cancer in a large cohort of hospitalized patients with gastric or duodenal ulcers, as recorded in the Swedish Inpatient Register between 1965 and 1983. Altogether, 57,936 patients were followed through 1989, for an average of 9.1 years. The standardized incidence ratio - the ratio of the observed number of cancers to the number expected on the basis of the incidence in the Swedish population at large - was used as a measure of relative risk. Results After peaking in the first 3 years of followup, the standardized incidence ratio for gastric cancer among 29,287 patients with gastric ulcers leveled off at 1.8 (95 percent confidence interval, 1.6 to 2.0) and remained significantly increased throughout followup, which was as long as 24 years for some patients. Prepyloric ulcer, diagnosed in 8646 patients, was not associated with a significant excess risk (standardized incidence ratio, 1.2; 95 percent confidence interval, 0.8 to 1.6). In the cohort of patients with duodenal ulcers (24,456 patients), the incidence of gastric cancer was significantly lower than expected. After the second year of follow-up, the standardized incidence ratio was only 0.6 (95 percent confidence interval, 0.4 to 0.7) and remained stable thereafter. Conclusions Gastric ulcer disease and gastric cancer have etiologic factors in common. A likely cause of both is atrophic gastritis induced by H. pylori. By contrast, there appear to be factors associated with duodenal ulcer disease that protect against gastric cancer. (C) 1996, Massachusetts Medical Society.	UNIV UPPSALA HOSP,DEPT CANC EPIDEMIOL,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT STAT,S-75185 UPPSALA,SWEDEN; MORA HOSP,DEPT SURG,MORA,SWEDEN; NCI,DIV CANC EPIDEMIOL & GENET,BETHESDA,MD 20892; INT EPIDEMIOL INST,ROCKVILLE,MD; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health					PHS HHS [85636-05] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMI HO, 1987, SCAND J GASTROENTERO, V22, P889, DOI 10.3109/00365528708991931; AGREUS L, 1995, SCAND J GASTROENTERO, V30, P752, DOI 10.3109/00365529509096323; BAILAR JC, 1964, BIOMETRICS, V20, P639; BARTSCH H, 1988, MUTAT RES, V202, P307, DOI 10.1016/0027-5107(88)90194-7; CAHILL RJ, 1993, ACTA GASTROENTER S61, V56; CAMELS S, 1991, IARC SCI PUBL, V105, P187; Cruveilhier J, 1835, ANATOMIE PATHOLOGIQU; DEKKER W, 1977, GASTROENTEROLOGY, V73, P710; DOOLEY CP, 1984, ANN INTERN MED, V101, P538, DOI 10.7326/0003-4819-101-4-538; DUTERTRE Y, 1993, ACTA GASTROENTEROL S, V56, P61; EIDT S, 1994, DIGESTION, V55, P13, DOI 10.1159/000201116; ELLIS DJ, 1979, BRIT J SURG, V66, P117, DOI 10.1002/bjs.1800660211; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; HANSSON LE, 1994, INT J CANCER, V57, P26, DOI 10.1002/ijc.2910570106; HIROHATA T, 1968, J NATL CANCER I, V41, P895; HOLE DJ, 1987, SCAND J GASTROENTERO, V22, P17, DOI 10.3109/00365528708991850; HSING AW, 1993, CANCER, V71, P745, DOI 10.1002/1097-0142(19930201)71:3<745::AID-CNCR2820710316>3.0.CO;2-1; IHRE B. J. E., 1964, GASTROENTEROLOGIA, V102, P78; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JACKSON JH, 1989, J CLIN INVEST, V84, P1644, DOI 10.1172/JCI114342; KATO I, 1992, AM J EPIDEMIOL, V135, P521, DOI 10.1093/oxfordjournals.aje.a116319; Kawashima T, 1991, Nihon Shokakibyo Gakkai Zasshi, V88, P1161; KEKKI M, 1990, GASTROEN CLIN BIOL, V14, P217; KRAUSE U, 1963, ACTA CHIR SCAND    S, V310, P1; KUIPERS EJ, 1995, LANCET, V345, P1525, DOI 10.1016/S0140-6736(95)91084-0; *KUNGL MED, 1965, INT STAT CLASS DIS I; LANAS A, 1992, GASTROENTEROLOGY, V103, P862, DOI 10.1016/0016-5085(92)90018-T; LECHAGO J, 1993, GASTROENTEROLOGY, V104, P1554, DOI 10.1016/0016-5085(93)90370-R; LEE S, 1990, SCAND J GASTROENTERO, V25, P1223, DOI 10.3109/00365529008998557; LEWIS JH, 1982, AM J GASTROENTEROL, V77, P368; LUNDEGARDH G, 1988, NEW ENGL J MED, V319, P195, DOI 10.1056/NEJM198807283190402; LUNDEGARDH G, 1994, GUT, V35, P946, DOI 10.1136/gut.35.7.946; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; MOLLER H, 1992, GUT, V33, P1166, DOI 10.1136/gut.33.9.1166; MUNOZ N, 1994, CANCER EPIDEM BIOMAR, V3, P445; NAGAYO T, 1986, HISTOGENESIS PRECURS, P115; *NAT BOARD HLTH WE, 1973, INT STAT CLASS DIS I; NORFLEET RG, 1989, J CLIN GASTROENTEROL, V11, P382, DOI 10.1097/00004836-198908000-00006; NYREN O, 1995, JNCI-J NATL CANCER I, V87, P28, DOI 10.1093/jnci/87.1.28; ROOD JC, 1994, NUTR CANCER, V22, P65, DOI 10.1080/01635589409514332; SCHRAGER J, 1967, GUT, V8, P497, DOI 10.1136/gut.8.5.497; SIMPSON EH, 1951, J ROY STAT SOC B, V13, P238; SIPPONEN P, 1992, EUR J GASTROEN HEPAT, V4, pS25; SOBALA GM, 1989, GASTROENTEROLOGY, V97, P357, DOI 10.1016/0016-5085(89)90071-1; SOMERVILLE K, 1986, LANCET, V1, P462; SPIRO HM, 1993, CLIN GASTROENTEROLOG; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; THUN MJ, 1993, CANCER RES, V53, P1322; TSUGANE S, 1993, CANCER CAUSE CONTROL, V4, P297, DOI 10.1007/BF00051331; WESTLUND K, 1963, MORTALITY PEPTIC ULC; WONG J, 1980, J SURG RES, V29, P446, DOI 10.1016/0022-4804(80)90058-X; World Health Organization, 1994, IARC MON EV CARC RIS, P177; Yamagata S, 1979, World J Surg, V3, P671	53	495	515	2	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1996	335	4					242	249		10.1056/NEJM199607253350404	http://dx.doi.org/10.1056/NEJM199607253350404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ532	8657240	Bronze			2022-12-24	WOS:A1996UZ53200004
J	Sharpley, A				Sharpley, A			Impact of daytime sleepiness underrated	LANCET			English	Editorial Material											Sharpley, A (corresponding author), LITTLEMORE HOSP,PSYCHOPHARMACOL RES UNIT,OXFORD OX4 4XN,ENGLAND.			Sharpley, Ann L/0000-0002-0623-1067				BINNIE GA, 1983, BRIT MED J, V287, P1349, DOI 10.1136/bmj.287.6402.1349; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Hublin C, 1996, J INTERN MED, V239, P417, DOI 10.1046/j.1365-2796.1996.475826000.x; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Ray W A, 1993, Clin Geriatr Med, V9, P413	6	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					71	71		10.1016/S0140-6736(05)64601-6	http://dx.doi.org/10.1016/S0140-6736(05)64601-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676715				2022-12-24	WOS:A1996UW67300003
J	Diacovo, TG; Puri, KD; Warnock, RA; Springer, TA; vonAndrian, UH				Diacovo, TG; Puri, KD; Warnock, RA; Springer, TA; vonAndrian, UH			Platelet-mediated lymphocyte delivery to high endothelial venules	SCIENCE			English	Article							NODE VASCULAR ADDRESSIN; L-SELECTIN; P-SELECTIN; HOMING RECEPTOR; MESENTERIC VENULES; LIGAND; MOLECULE; IDENTIFICATION; RECOGNIZE; ADHESION	Circulating lymphocytes gain access to lymph nodes owing to their ability to initiate rolling along specialized high endothelial venules (HEVs). One mechanism of rolling involves L-selectin binding to peripheral node addressin (PNAd) on HEVs. Activated platelets are shown to bind to circulating lymphocytes and to mediate rolling in HEVs, in vivo, through another molecule, P-selectin, which also interacts with PNAd. In vitro, activated platelets enhanced tethering of lymphocytes to PNAd and sustained lymphocyte rolling, even in the absence of functional L-selectin. Thus, a platelet pathway operating through P-selectin provides a second mechanism for lymphocyte delivery to HEVs.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CARDIOL,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT PEDIAT,DIV NEWBORN MED,BOSTON,MA 02111; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; STANFORD UNIV,DEPT PATHOL,STANFORD,CA 94305	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School; Stanford University			von Andrian, Ulrich H/A-5775-2008		NHLBI NIH HHS [HL48675, HL54936] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054936] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTTRUM SM, 1993, BLOOD, V82, P1165; COLLINS CE, 1994, GASTROENTEROLOGY, V106, P840, DOI 10.1016/0016-5085(94)90741-2; Diacovo TG, 1996, BLOOD, V88, P146; Diacovo TG, 1996, J EXP MED, V183, P1193, DOI 10.1084/jem.183.3.1193; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1994, J IMMUNOL, V153, P3917; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LEHR HA, 1994, P NATL ACAD SCI USA, V91, P7688, DOI 10.1073/pnas.91.16.7688; LEHR HA, 1994, LAB INVEST, V71, P380; LEY K, 1993, BLOOD, V82, P1632; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; LIAU F, 1995, J EXP MED, V182, P1337; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MEBIUS RE, 1993, J IMMUNOL, V151, P3252; MICHIE SA, 1993, AM J PATHOL, V143, P1688; MOORE KL, 1992, BIOCHEM BIOPH RES CO, V186, P173, DOI 10.1016/S0006-291X(05)80790-9; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PRIES AR, 1988, INT J MICROCIRC, V7, P327; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAVAGE B, 1996, CELL, V84; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; TURUNEN JP, 1994, EUR J IMMUNOL, V24, P1130, DOI 10.1002/eji.1830240518; VONADRIAN UH, 1995, CELL, V82, P1; VONADRIAN UH, 1992, AM J PHYSIOL, V263, pH1304; VONANDRIAN UH, 1993, BLOOD, V82, P182, DOI 10.1182/blood.V82.1.182.bloodjournal821182; VONANDRIAN UH, IN PRESS MICROCIRCUL; WARNOCK R, UNPUB	42	264	272	2	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					252	255		10.1126/science.273.5272.252	http://dx.doi.org/10.1126/science.273.5272.252			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8662511				2022-12-24	WOS:A1996UW78700045
J	Mansergh, G; Haddix, AC; Steketee, RW; Nieburg, PI; Hu, DJ; Simonds, RJ; Rogers, M				Mansergh, G; Haddix, AC; Steketee, RW; Nieburg, PI; Hu, DJ; Simonds, RJ; Rogers, M			Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS	Objective.-To evaluate the cost-effectiveness of a short-course zidovudine program to prevent perinatal transmission of human immunodeficiency virus (HIV) type 1 in sub-Saharan African country settings. Design and Setting.-Several clinical trials of short-course zidovudine during pregnancy for prevention of perinatal transmission of HIV are under way in developing countries in sub-Saharan Africa. A decision model was used to examine the cost-effectiveness of zidovudine programs in a hypothetical 1-year birth cohort in a sub-Saharan African setting from the perspective of the health care system and of society. A completed short course of zidovudine was assumed to reduce perinatal HIV transmission from 25% to 16.5%, approximately one half of the effect of the longer-course zidovudine. Estimates of program costs, lifetime HIV-related health care costs, and lost productivity costs were derived from the published literature and from preliminary data available from sites of planned clinical trials. Sensitivity analyses were conducted on all relevant parameters. Main Outcome Measures.-Medical costs, lost productivity costs, program costs, cost savings, and incremental cost-effectiveness, expressed as cost per infant HIV infection prevented. Results.-The model estimated that a national zidovudine program in a setting with 12.5% HIV seroprevalence would reduce perinatal HIV incidence by 12% (4.9 infections per 1000 births), The cost to the health care system would be $3748 per infant HIV infection prevented. When productivity losses were included in the model, the cost decreases to $1115 per infant HIV infection prevented. The cost to implement a national zidovudine program including the cost of counseling, testing, and drugs, would be $2 million per 100 000 births or $20 per pregnant woman. In the base case, decreases in the cost of counseling and testing and increases in maternal HIV prevalence, zidovudine efficacy, and medical and lost productivity costs improved cost-effectiveness of the zidovudine program. Conclusions.-Assuming demonstrable efficacy of short-course zidovudine prevention of perinatal HIV, a national perinatal HIV prevention program with zidovudine in most sub-Saharan African country settings would reduce the incidence of infant HIV infection and, in some settings, provide societal savings; however, substantial initial investment in such programs will be required. Where health care resources are limited, as in these regions, allocation of resources to a perinatal zidovudine program will need to be considered in the context of resources required for other pressing medical care needs.	CTR DIS CONTROL & PREVENT,OFF DIRECTOR,NATL CTR HIV AIDS STD & TB PREVENT,NCHSTP,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Mansergh, G (corresponding author), CTR DIS CONTROL & PREVENT,EPIDEMIOL BRANCH,DIV HIV AIDS PREVENT,NCHSTP,MSE-45,1600 CLIFTON RD,ATLANTA,GA 30333, USA.							ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; [Anonymous], 1992, Wkly Epidemiol Rec, V67, P145; CAMERON C, 1992, 8 INT C AIDS AMST; COHEN J, 1995, SCIENCE, V269, P624, DOI 10.1126/science.7624786; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; EKPINI E, 1994, 10TH INT C AIDS YOK; Gillespie S., 1989, Land Use Policy, V6, P301, DOI 10.1016/0264-8377(89)90022-7; Gorsky RD, 1996, PUBLIC HEALTH REP, V111, P335; HANSON K, 1992, HEALTH POLICY PLANN, V7, P315, DOI 10.1093/heapol/7.4.315; HEYMANN SJ, 1990, AM J PUBLIC HEALTH, V80, P1305, DOI 10.2105/AJPH.80.11.1305; HU DJ, 1992, AIDS, V6, P1505, DOI 10.1097/00002030-199212000-00014; *INT PROGR CTR POP, 1995, 20 INT PROGR CTR POP; *INT PROGR CTR POP, 1994, 15 US BUR CENS INT P; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; NORSE D, 1991, 7 INT C AIDS FLOR; OVER M, 1989, HEALTH POLICY, V11, P169, DOI 10.1016/0168-8510(89)90034-1; OVER M, 1988, GLOBAL IMPACT AIDS, P123; PARROTT RH, 1991, J ACQ IMMUN DEF SYND, V4, P122; SATO PA, 1994, B WORLD HEALTH ORGAN, V72, P129; SCITOVSKY AA, 1988, AIDS, V2, pS71, DOI 10.1097/00002030-198800001-00011; *UNICEF, 1995, STAT WORLDS CHILDR 1; VIRAVAIDYA M, 1993, EC IMPLICATIONS AIDS, P7; *WORLD BANK, 1994, 1994 WORLD BANK WORL; *WORLD BANK, 1992, TANZ AIDS ASS PLANN; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, MMWR-MORBID MORTAL W, V43, P1	29	63	63	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					139	145		10.1001/jama.276.2.139	http://dx.doi.org/10.1001/jama.276.2.139			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV485	8656506				2022-12-24	WOS:A1996UV48500029
J	Mallonee, S; Istre, GR; Rosenberg, M; ReddishDouglas, M; Jordan, F; Silverstein, P; Tunell, W				Mallonee, S; Istre, GR; Rosenberg, M; ReddishDouglas, M; Jordan, F; Silverstein, P; Tunell, W			Surveillance and prevention of residential-fire injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION	Background The majority of severe and fatal burn injuries result from residential fires. We studied the effectiveness of a smoke-alarm-giveaway program in the prevention of burn injuries in an area with a high rate of such injuries. Methods We collected data on burn injuries in Oklahoma City from September 1987 through April 1990. The target area for the intervention was an area of 24 square miles (62 km(2)) with the highest rate of injuries related to residential fires in the city. We distributed smoke alarms door to door in the target area and then surveyed alarm use and function in a sample of the homes that had received an alarm. We also calculated the rates of fire injury per 100,000 population and per 100 fires for both the target area and the rest of the city before and after the smoke-alarm giveaway. Results Before the intervention the rate of burn injuries per 100,000 population was 4.2 times higher in the target area than in the rest of Oklahoma City. An initial survey indicated that 11,881 of the 34,945 homes in the target area (34 percent) did not have smoke alarms. A total of 10,100 smoke alarms were distributed to 9291 homes; 45 percent were functioning four years later. The annualized fire-injury rates declined by 80 percent in the target area during the four years after the intervention (from 15.3 to 3.1 per 100,000 population), as compared with a small increase in the rest of the city (from 3.6 to 3.9 per 100,000 population). There was also a 74 percent de dine in the target area in the injury rate per 100 fires (from 5.0 to 1.3; rate ratio, 0.3; 95 percent confidence interval, 0.1 to 0.6), as compared with a small in crease in the rest of the city. Conclusions A targeted intervention involving a smoke-alarm-giveaway program can reduce the incidence of injuries from residential fires. (C)1996, Massachusetts Medical Society.	OKLAHOMA DEPT HLTH,EPIDEMIOL SERV,OKLAHOMA CITY,OK 73117; CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341; OFF CHIEF MED EXAMINER,OKLAHOMA CITY,OK; BAPTIST MED CTR OKLAHOMA,OKLAHOMA CITY,OK; CHILDRENS HOSP OKLAHOMA,OKLAHOMA CITY,OK	Centers for Disease Control & Prevention - USA	Mallonee, S (corresponding author), OKLAHOMA DEPT HLTH,INJURY PREVENT SERV 0307,1000 NE 10TH,OKLAHOMA CITY,OK 73117, USA.				PHS HHS [R49/CCR603696] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], COST INJURY US; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BALLARD JE, 1992, PUBLIC HEALTH REP, V107, P402; BARILLO DJ, 1986, AM SURGEON, V52, P641; BIRKY MM, 1979, FIRE MATER, V3, P211, DOI 10.1002/fam.810030406; Dean A. G., 1990, EPI INFO VERSION 5 W; HALL JR, 1983, FIRE SERV TODAY, V50, P18; HEMENWAY D, 1990, Q J ECON, V105, P1063, DOI 10.2307/2937886; ISTRE GR, 1992, PUBLIC HEALTH SURVEILLANCE, P42; JAMES KE, 1973, BIOMETRICS, V29, P121, DOI 10.2307/2529681; JERNIGAN W, 1987, FIRE J, V81, P57; Karter M J Jr, 1994, NFPA J, V88, P57; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LEVINE MS, 1977, AM J PUBLIC HEALTH, V67, P1077, DOI 10.2105/AJPH.67.11.1077; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MIERLEY MC, 1983, JAMA-J AM MED ASSOC, V249, P1466, DOI 10.1001/jama.249.11.1466; *NAT FIR PROT AG, 1990, 901 NFPA FIR FACTS; PATETTA MJ, 1990, AM J PUBLIC HEALTH, V80, P1116, DOI 10.2105/AJPH.80.9.1116; ROSSOMANDO C, 1995, COMMUNITY BASED FIRE; Rothman K, 1986, MODERN EPIDEMIOLOGY; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; Thacker SB, 1996, FIELD EPIDEMIOLOGY, P16; *US FIR ADM, 1990, FIR US 1983 1987; *US FIR ADM FED EM, 1980, EV RES SMOK DET PERF; 1987, JAMA-J AM MED ASSOC, V257, P1618; 1985, MMWR-MORBID MORTAL W, V34, P623; 1987, MMWR-MORBID MORTAL W, V36, P644	27	132	135	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					27	31		10.1056/NEJM199607043350106	http://dx.doi.org/10.1056/NEJM199607043350106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU479	8637539				2022-12-24	WOS:A1996UU47900006
J	Alkhatib, G; Combadiere, C; Broder, CC; Feng, Y; Kennedy, PE; Murphy, PM; Berger, EA				Alkhatib, G; Combadiere, C; Broder, CC; Feng, Y; Kennedy, PE; Murphy, PM; Berger, EA			CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1	SCIENCE			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; IMMUNODEFICIENCY-VIRUS; CD4-MEDIATED FUSION; VACCINIA VIRUS; MURINE CELLS; EXPRESSION; INFECTION; SYSTEM; GENES; CD4	Human immunodeficiency virus-type 1 (HIV-1) entry requires fusion cofactors on the CD4(+) target cell. Fusin, a heterotrimeric GTP-binding protein (G protein)-coupled receptor, serves as a cofactor for T cell line-tropic isolates. The chemokines RANTES, MIP-1 alpha, and MIP-1 beta, which suppress infection by macrophage-tropic isolates, selectively inhibited cell fusion mediated by the corresponding envelope glycoproteins (Envs). Recombinant CC CKR5, a G protein-coupled receptor for these chemokines, rendered CD4-expressing nonhuman cells fusion-competent preferentially with macrophage-tropic Envs. CC CKR5 messenger RNA was detected selectively in cell types susceptible to macrophage-tropic isolates. CC CKR5 is thus a fusion cofactor for macrophage-tropic HIV-1 strains.	NIAID,HOST DEF LAB,NIH,BETHESDA,MD 20892; NIAID,VIRAL DIS LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Broder, Christopher/E-1169-2013; Combadiere, Christophe/I-5639-2013	Combadiere, Christophe/0000-0002-1755-4531				ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992; Alkhatib G, 1996, J VIROL, V70, P5487, DOI 10.1128/JVI.70.8.5487-5494.1996; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BERGER EA, 1995, HIV PRACTICAL APPROA, V2, P123; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CALLEBAUT C, 1994, SCIENCE, V264, P1162, DOI 10.1126/science.264.5162.1162; CHAKRABARTI SK, COMMUNICATION; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COMBADIERE C, 1995, J BIOL CHEM, V270, P30235; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; COMBADIERE C, 1995, MOL BIOL CELL, V6, P224; COMBADIERE SK, 1996, J LEUKOCYTE BIOL, V60, P147; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Goudsmit J, 1995, J ACQ IMMUN DEF SYND, V10, pS15; KLEIN MR, 1995, TRENDS MICROBIOL, V3, P386, DOI 10.1016/S0966-842X(00)88984-2; LAZDINS JK, 1990, AIDS RES HUM RETROV, V6, P1157, DOI 10.1089/aid.1990.6.1157; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Planelles Vincente, 1993, P17; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SIMMONS G, 1995, VIROLOGY, V209, P696, DOI 10.1006/viro.1995.1307; VALENTIN A, 1994, J VIROL, V68, P6684, DOI 10.1128/JVI.68.10.6684-6689.1994; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679	32	2390	2513	0	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1996	272	5270					1955	1958		10.1126/science.272.5270.1955	http://dx.doi.org/10.1126/science.272.5270.1955			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658171				2022-12-24	WOS:A1996UV29400054
J	Graham, A; Green, L; Glasier, AF				Graham, A; Green, L; Glasier, AF			Teenagers' knowledge of emergency contraception: Questionnaire survey in south east Scotland	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCIES	Objective-To determine the level of knowledge of emergency contraception among 14 and 15 year olds. Design-Confidential questionnaire survey. Setting-10 secondary schools in Lothian, south east Scotland. Subjects-1206 pupils predominantly (98.7%) aged 14 and 15 in the fourth year of secondary school. Main outcome measures-Knowledge of the existence of emergency contraception; of its safety, efficacy, and time limits; and of where to obtain it. Results-1121 (93.0%) fourth year pupils aged 14-16 had heard of emergency contraception. 194 girls (32.7%) and 168 boys (27.5%) had experienced sexual intercourse. Of girls who had experienced sexual intercourse, 61 (31.4%) had used emergency contraception. Knowledge of correct time limits was poor, sexually active girls being the most knowledgeable. Pupils attending schools ranked lower than the national average for academic attainment were less likely to have heard of emergency contraception and more likely to have been sexually active. 861 (76.8%) pupils knew they could obtain emergency contraception from their doctor. 925 (82.5%) pupils believed emergency contraception to be effective but 398 (35.5%) thought it more dangerous than the oral contraceptive pill. Conclusions-One third of sexually active girls aged under 16 in Lothian have used emergency contraception. This may help explain the fairly constant teenage pregnancy rates despite increasing sexual activity. Scottish teenagers are well informed about the existence of emergency contraception. However, many do not know when and how to access it properly. Health education initiatives should target teenagers from less academic schools as they are more likely to be sexually active at a young age and are less well informed about emergency contraception.	EDINBURGH HEALTHCARE NHS TRUST,FAMILY PLANNING & WELL WOMAN SERV,EDINBURGH EH4 1NL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT OBSTET & GYNAECOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh								ALLABY MAK, 1995, BRIT MED J, V310, P1641, DOI 10.1136/bmj.310.6995.1641; *AUD UN HER MAJ IN, 1995, EX RES SCOTT SCH 199; BROMHAM DR, 1993, BRIT MED J, V306, P556, DOI 10.1136/bmj.306.6877.556; BURTON R, 1990, BRIT J GEN PRACT, V40, P326; BURTON R, 1990, BR J FAM PLANN, V15, P119; Department of Health, 1992, GEN HOUS SURV; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; GEORGE J, 1994, BRIT J GEN PRACT, V44, P451; JOHNSON AM, 1994, SEXUAL ATTITUDES LIF; MELLANBY A, 1993, BRIT MED J, V307, P25, DOI 10.1136/bmj.307.6895.25; MELLANBY AR, 1995, BRIT MED J, V311, P414, DOI 10.1136/bmj.311.7002.414; PEARSON VAH, 1995, BRIT MED J, V310, P1644, DOI 10.1136/bmj.310.6995.1644; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; SMITH T, 1993, BRIT MED J, V306, P1232, DOI 10.1136/bmj.306.6887.1232; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P269, DOI 10.2307/2135857	15	67	67	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1567	1569		10.1136/bmj.312.7046.1567	http://dx.doi.org/10.1136/bmj.312.7046.1567			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664665	Green Published			2022-12-24	WOS:A1996UU80600017
J	Zablackis, E; York, WS; Pauly, M; Hantus, S; Reiter, WD; Chapple, CCS; Albersheim, P; Darvill, A				Zablackis, E; York, WS; Pauly, M; Hantus, S; Reiter, WD; Chapple, CCS; Albersheim, P; Darvill, A			Substitution of L-fucose by L-galactose in cell walls of Arabidopsis mur1	SCIENCE			English	Article							XYLOGLUCAN-OLIGOSACCHARIDES; STRUCTURAL-ANALYSIS; SEED XYLOGLUCAN; GROWTH; PLANTS	An Arabidopsis thaliana mutant (mur1) has less than 2 percent of the normal amounts of L-fucose in the primary cell walls of aerial portions of the plant. The survival of mur1 plants challenged the hypothesis that fucose is a required component of biologically active oligosaccharides derived from cell wall xyloglucan. However, the replacement of L-fucose (that is, 6-deoxy-L-galactose) by L-galactose does not detectably alter the biological activity of the oligosaccharides derived from xyloglucan. Thus, essential structural and conformational features of xyloglucan and xyloglucan-derived oligosaccharides are retained when L-galactose replaces L-fucose.	UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602; UNIV GEORGIA,DEPT BIOCHEM & MOLEC BIOL,ATHENS,GA 30602; UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Connecticut; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Chapple, Clint CS/Q-5456-2017; Pauly, Markus/B-5895-2008	Chapple, Clint CS/0000-0002-5195-562X; Pauly, Markus/0000-0002-3116-2198				AUGUR C, 1992, PLANT PHYSIOL, V99, P180, DOI 10.1104/pp.99.1.180; BAUER WD, 1973, PLANT PHYSIOL, V51, P174, DOI 10.1104/pp.51.1.174; BAYDOUN EAH, 1988, J PLANT PHYSIOL, V132, P484, DOI 10.1016/S0176-1617(88)80068-3; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; DARVILL A, 1992, GLYCOBIOLOGY, V2, P181, DOI 10.1093/glycob/2.3.181; DARVILL A, 1980, BIOCH PLANTS, V1; Feingold D. S., 1982, ENCY PLANT PHYSL A, V13A, P3; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; FRY SC, 1993, PLANT PHYSIOL, V103, P1, DOI 10.1104/pp.103.1.1; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; HALLGREN C, 1995, J CARBOHYD CHEM, V14, P453, DOI 10.1080/07328309508005350; HAYASHI T, 1984, PLANT PHYSIOL, V75, P596, DOI 10.1104/pp.75.3.596; LORENCES EP, 1990, PHYSIOL PLANTARUM, V80, P109; MCDOUGALL GJ, 1989, J EXP BOT, V40, P233, DOI 10.1093/jxb/40.2.233; MCDOUGALL GJ, 1991, J PLANT PHYSIOL, V137, P332, DOI 10.1016/S0176-1617(11)80141-0; Pauly M, 1996, CARBOHYD RES, V282, P1, DOI 10.1016/0008-6215(95)00362-2; REITER WD, 1993, SCIENCE, V261, P1032, DOI 10.1126/science.261.5124.1032; ROBERTS RM, 1973, PHYTOCHEMISTRY, V12, P2679, DOI 10.1016/0031-9422(73)85079-4; ROBERTS RM, 1971, ARCH BIOCHEM BIOPHYS, V145, P685, DOI 10.1016/S0003-9861(71)80029-2; WATANABE T, 1980, AGR BIOL CHEM TOKYO, V44, P791, DOI 10.1080/00021369.1980.10864032; YORK WS, 1990, CARBOHYD RES, V200, P9, DOI 10.1016/0008-6215(90)84179-X; YORK WS, 1984, PLANT PHYSIOL, V75, P295, DOI 10.1104/pp.75.2.295; YORK WS, 1993, CARBOHYD RES, V248, P285, DOI 10.1016/0008-6215(93)84135-S; YORK WS, 1995, CARBOHYD RES, V267, P79, DOI 10.1016/0008-6215(94)00287-P; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1; ZABLACKIS E, 1995, PLANT PHYSIOL, V107, P1129, DOI 10.1104/pp.107.4.1129	26	117	119	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1808	1810		10.1126/science.272.5269.1808	http://dx.doi.org/10.1126/science.272.5269.1808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650583				2022-12-24	WOS:A1996UT11000049
J	Chemello, L; Cavalletto, L; Casarin, C; Bonetti, P; Bernardinello, E; Pontisso, P; Donada, C; Belussi, F; Martinelli, S; Alberti, A				Chemello, L; Cavalletto, L; Casarin, C; Bonetti, P; Bernardinello, E; Pontisso, P; Donada, C; Belussi, F; Martinelli, S; Alberti, A			Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED TRIAL; THERAPY; ALFA; RNA	Objective: To define long-term outcome in patients with chronic hepatitis C who remain viremic after sustained biochemical response to interferon-alpha therapy. Design: Prospective evaluation of an outpatient cohort. Setting: University hospital. Patients: 107 patients with chronic hepatitis C who maintained normal aminotransferase levels as long as 12 months after interferon-alpha therapy. Patients were followed prospectively for an additional 6 to 36 months. Measurements: Aminotransferase levels were monitored at 3-month intervals. Serum hepatitis C virus (HCV) RNA was tested by polymerase chain reaction before therapy, at the end of therapy, and 12 months after therapy. The HCV genotype was defined by spot hybridization using serum specimens obtained before treatment, Results: Hepatitis C virus RNA was detected in 27 (25%) patients with sustained biochemical response; 80 (75%) patients were negative for HCV RNA. Patients positive for HCV RNA were older (P < 0.001), had received a smaller interferon-a dose (P = 0.02), and were more frequently infected with HCV genotype 2 (P < 0.01). Liver histologic findings were active in 57% of patients positive for HCV RNA, despite normal alanine aminotransferase levels, compared with only 12% of patients who were negative for HCV RNA (P = 0.01). The estimated probability of hepatitis relapse by 4 years after therapy was 53% in viremic patients and 0% in patients negative for HCV RNA (P < 0.001). Conclusion: Patients with chronic hepatitis C should be tested for serum HCV RNA 1 year after a sustained biochemical response to interferon-alpha therapy to determine whether the response is complete and permanent.	UNIV PADUA, MED CLIN 2, I-35100 PADUA, ITALY; OSPED CIVILE, DIV MED 3, I-33170 PORDENONE, ITALY; OSPED LE GRAZIE, DIV MALATTIE INFETT, I-30124 VENICE, ITALY; OSPED CIVILE CITTADELLA, DIV MED, I-35013 CITTADELLA, PD, ITALY	University of Padua; ULSS 6 Euganea; Ospedale di Cittadella			chemello, liliana/AAU-9414-2020; PONTISSO, PATRIZIA/K-3574-2018	PONTISSO, PATRIZIA/0000-0003-2077-9202; ALBERTI, ALFREDO/0000-0001-9926-2382				Casarin C., 1994, Journal of Hepatology, V21, pS62; CHEMELLO L, 1995, J VIRAL HEPATITIS, V2, P91, DOI 10.1111/j.1365-2893.1995.tb00012.x; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; KASAHARA A, 1995, HEPATOLOGY, V21, P291, DOI 10.1016/0270-9139(95)90083-7; LAU JYN, 1993, LANCET, V342, P1208, DOI 10.1016/0140-6736(93)92187-X; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; TISMINETZKY SG, 1994, INT HEPATOL COMMUN, V2, P105, DOI 10.1016/0928-4346(94)90020-5	12	107	108	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1058	1060		10.7326/0003-4819-124-12-199606150-00005	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633819				2022-12-24	WOS:A1996UQ65800005
J	Kauffman, CA				Kauffman, CA			Quandary about treatment of aspergillomas persists	LANCET			English	Editorial Material							PULMONARY ASPERGILLOMA				Kauffman, CA (corresponding author), VET AFFAIRS MED CTR,INFECT DIS SECT,ANN ARBOR,MI 48105, USA.							DIOT P, 1995, EUR RESPIR J, V8, P1263, DOI 10.1183/09031936.95.08081263; ISRAEL HL, 1982, CHEST, V82, P430, DOI 10.1378/chest.82.4.430; JEWKES J, 1983, THORAX, V38, P572, DOI 10.1136/thx.38.8.572; MASSARD G, 1992, ANN THORAC SURG, V54, P1159, DOI 10.1016/0003-4975(92)90086-J; Rumbak M, 1996, THORAX, V51, P253, DOI 10.1136/thx.51.3.253; YAMADA H, 1993, CHEST, V103, P1421, DOI 10.1378/chest.103.5.1421	6	57	58	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1640	1640		10.1016/S0140-6736(96)91481-6	http://dx.doi.org/10.1016/S0140-6736(96)91481-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642952				2022-12-24	WOS:A1996UQ70100004
J	Marks, MB; McKendry, RJR				Marks, MB; McKendry, RJR			Orthoses for rheumatoid feet: Does it matter what's underfoot?	LANCET			English	Editorial Material									UNIV OTTAWA,RHEUMAT DIS UNIT,FAC MED,OTTAWA,ON,CANADA	University of Ottawa	Marks, MB (corresponding author), UNIV OTTAWA,PHYS MED & REHABIL UNIT,FAC MED,OTTAWA,ON,CANADA.							Budiman-Mak E, 1995, J Clin Rheumatol, V1, P313, DOI 10.1097/00124743-199512000-00001; BUDIMANMAK E, 1991, J CLIN EPIDEMIOL, V44, P561, DOI 10.1016/0895-4356(91)90220-4; Conrad KJ, 1996, J CLIN EPIDEMIOL, V49, P1, DOI 10.1016/0895-4356(96)00534-3; CRACCHIOLO A, 1988, FOOT BOOK, P239; CRAXFORD AD, 1982, CLIN ORTHOP RELAT R, P121; LANG LMG, 1987, BAILLIERE CLIN RHEUM, V1, P215, DOI 10.1016/S0950-3579(87)80001-8; MERRITT JL, 1987, J RHEUMATOL, V14, P62; Philps JW, 1990, FUNCTIONAL FOOT ORTH; SMIDT L, 1987, BAILLIERE CLIN RHEUM, V1, P275, DOI 10.1016/S0950-3579(87)80004-3; TINLEY P, 1987, BAILLIERE CLIN RHEUM, V1, P383, DOI 10.1016/S0950-3579(87)80009-2	10	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1639	1639		10.1016/S0140-6736(96)91480-4	http://dx.doi.org/10.1016/S0140-6736(96)91480-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642951				2022-12-24	WOS:A1996UQ70100003
J	Alam, SM; Travers, PJ; Wung, JL; Nasholds, W; Redpath, S; Jameson, SC; Gascoigne, NRJ				Alam, SM; Travers, PJ; Wung, JL; Nasholds, W; Redpath, S; Jameson, SC; Gascoigne, NRJ			T-cell-receptor affinity and thymocyte positive selection	NATURE			English	Article							MOLECULE	DEVELOPMENT Of thymocytes involves two distinct outcomes resulting from superficially similar events, Recognition by thymocytes of major histocompatibility complex (MHC) proteins plus peptide leads to their rescue from apoptosis (positive selection), and recognition of antigenic peptide induces cell death (negative selection)(1), Antigen analogues(1-3), and sometimes low concentrations of antigenic peptide(4,5), induce positive selection; such analogues are often antagonists of mature T-cell clones(1-3,6) Various models seek to explain how recognition of different peptide/MHC complexes leads to such different outcomes(1,7-10): quantitative models relate response to the affinity, avidity or kinetics of T cell-antigen receptor (TCR) binding, whereas qualitative models require conformational or spatial changes in the TCR or associated molecules to modulate signal transduction(7,9). We have used surface plasmon resonance(11) to measure the kinetics of TCR interactions with positively and negatively selecting ligands to distinguish between these models, and find that affinity correlates to the outcome of selection. A 'window' of affinity resulting in positive selection extends over a 1-log range starting threefold below the affinity for negative selection.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV LONDON BIRKBECK COLL, DEPT CRYSTALLOG, LONDON WC1E 7HX, ENGLAND; UNIV MINNESOTA, SCH MED, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA	Scripps Research Institute; University of London; Birkbeck University London; University of Minnesota System; University of Minnesota Twin Cities			Jameson, Stephen C/D-9892-2013; Alam, S. Munir/AAC-6711-2019	Jameson, Stephen C/0000-0001-9137-1146; 				AJITKUMAR P, 1988, CELL, V54, P47, DOI 10.1016/0092-8674(88)90178-X; ALRAMADI BK, 1995, J IMMUNOL, V155, P662; Arden Bernhard, 1995, Immunogenetics, V42, P501; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; GASCOIGNE NRJ, 1990, J BIOL CHEM, V265, P9296; GERMAIN RN, 1995, IMMUNOLOGIST, V3, P113; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JAMESON SC, 1994, NATURE, V369, P750, DOI 10.1038/369750a0; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JANEWAY CA, 1995, IMMUNOL TODAY, V16, P223, DOI 10.1016/0167-5699(95)80163-4; KAPPLER J, 1994, P NATL ACAD SCI USA, V91, P8462, DOI 10.1073/pnas.91.18.8462; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KELLY JM, 1993, EUR J IMMUNOL, V23, P3318, DOI 10.1002/eji.1830231239; KOOP BF, 1994, GENOMICS, V19, P478, DOI 10.1006/geno.1994.1097; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; SCORER CA, 1994, BIO-TECHNOL, V12, P181, DOI 10.1038/nbt0294-181; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	29	519	524	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					616	620		10.1038/381616a0	http://dx.doi.org/10.1038/381616a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637599				2022-12-24	WOS:A1996UQ65700054
J	Latronico, N; Fenzi, F; Recupero, D; Guarneri, B; Tomelleri, G; Tonin, P; DeMaria, G; Antonini, L; Rizzuto, N; Candiani, A				Latronico, N; Fenzi, F; Recupero, D; Guarneri, B; Tomelleri, G; Tonin, P; DeMaria, G; Antonini, L; Rizzuto, N; Candiani, A			Critical illness myopathy and neuropathy	LANCET			English	Article							MULTIPLE ORGAN FAILURE; SEPSIS; POLYNEUROPATHY; DEFINITIONS	Background Critically ill patients may develop muscle weakness or paralysis during the course of sepsis and multiple-organ failure. We studied peripheral nerve and muscle disorders (NMD) in comatose patients. Methods Comatose patients who developed paralysis associated with absent deep-tendon reflexes had electroneuromyography (ENMG) and muscle-nerve biopsy specimens taken. Onset and duration of sepsis, multiple-organ dysfunction and failure, biochemical alterations, and drugs potentially interfering with nerve-muscle function were recorded. Findings 24 patients became quadriparetic or quadriplegic; muscle changes were found in 23. Axonal neuropathy was found in eight of 22 patients examined. All patients had prolonged sepsis and multiple-organ dysfunction, but only 14 had multiple-organ failure. Drugs such as steroids, neuromuscular-blocking agents, and aminoglycosides were not responsible for paresis, and the part played by hyperglycaemia and hypoalbuminaemia is uncertain. Attending physicians predicted a fatal outcome in all cases, although six of seven survivors fully recovered within 115-210 days from the onset of paralysis. Interpretation Comatose patients may become completely paralysed because of NMD. The diagnosis is important to avoid unnecessary investigations and unreasonably pessimistic prognosis. ENMG is essential for the diagnosis and for planning further clinical management. Biopsy needs to be done only when it is necessary to properly classify NMD.	UNIV BRESCIA, SPEDALI CIVILE, SERV NEUROFISIOPATOL, BRESCIA, ITALY; UNIV VERONA, OSPED BORGO ROMA, I-37100 VERONA, ITALY	Hospital Spedali Civili Brescia; University of Brescia; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Latronico, N (corresponding author), UNIV BRESCIA, SPEDALI CIVILI, IST ANESTESIA & REANIMAZ, PIAZZALE OSPED CIVILI 1, I-25125 BRESCIA, ITALY.		LATRONICO, Nicola/F-1557-2010	LATRONICO, Nicola/0000-0002-2521-5871				BAUE AE, 1991, SURG CLIN N AM, V71, P549; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; BOLTON CF, 1986, J NEUROL NEUROSUR PS, V49, P563, DOI 10.1136/jnnp.49.5.563; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; COAKLEY JH, 1993, INTENS CARE MED, V19, P323, DOI 10.1007/BF01694705; DECOUL AAWO, 1991, CLIN NEUROL NEUROSUR, V93, P27, DOI 10.1016/0303-8467(91)90005-A; FIACCADORI E, 1991, RIV ITALIANA NUTR PA, V9, P187; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; JENNETT B, 1975, LANCET, V1, P480; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNOCHEL JP, 1982, AM J MED, V72, P521, DOI 10.1016/0002-9343(82)90522-8; KUPFER Y, 1992, ANN INTERN MED, V117, P484, DOI 10.7326/0003-4819-117-6-484; LACOMIS D, 1993, MUSCLE NERVE, V16, P84, DOI 10.1002/mus.880160114; LYCHLAMA A, 1987, HDB CLIN NEUROLOGY, V7, P575; MCQUILLE.MP, 1968, ARCH NEUROL-CHICAGO, V18, P402, DOI 10.1001/archneur.1968.00470340088008; SCHUSTER DP, 1992, CRITICAL CARE, P407; TEASDALE G, 1974, LANCET, V2, P81; WITT NJ, 1991, CHEST, V99, P176, DOI 10.1378/chest.99.1.176; ZOCHODNE DW, 1987, BRAIN, V110, P819, DOI 10.1093/brain/110.4.819; ZOCHODNE DW, 1994, MUSCLE NERVE, V17, P285, DOI 10.1002/mus.880170305	20	300	307	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 8	1996	347	9015					1579	1582		10.1016/S0140-6736(96)91074-0	http://dx.doi.org/10.1016/S0140-6736(96)91074-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667865				2022-12-24	WOS:A1996UP66100008
J	Cui, XQ; Wise, RP; Schnable, PS				Cui, XQ; Wise, RP; Schnable, PS			The rf2 nuclear restorer gene of male-sterile T-cytoplasm maize	SCIENCE			English	Article							ZEA-MAYS L; PROTEIN; PLANTS; MITOCHONDRIA; MICROSPOROGENESIS; DEHYDROGENASE; LOCALIZATION; DISEASE; ENCODES; T-URF13	The T cytoplasm of maize serves as a model for the nuclear restoration of cytoplasmic male sterility. The rf2 gene, one of two nuclear genes required for fertility restoration in male-sterile T-cytoplasm (cmsT) maize, was cloned. The protein predicted by the rf2 sequence is a putative aldehyde dehydrogenase, which suggests several mechanisms that might explain Rf2-mediated fertility restoration in cmsT maize. Aldehyde dehydrogenase may be involved in the detoxification of acetaldehyde produced by ethanolic fermentation during pollen development, may play a role in energy metabolism or may interact with URF13, the mitochondrial protein associated with male sterility in cmsT maize.	IOWA STATE UNIV SCI & TECHNOL, DEPT AGRON, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, DEPT ZOOL & GENET, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, DEPT PLANT PATHOL, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, USDA ARS, AMES, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University; Iowa State University; United States Department of Agriculture (USDA)				Wise, Roger/0000-0001-7786-1528; Schnable, Patrick/0000-0001-9169-5204; Cui, Xiangqin/0000-0003-0621-9313				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBROZIAK W, 1993, ADV EXP MED BIOL, V328, P5; ASKER H, 1985, PHYTOCHEMISTRY, V24, P689, DOI 10.1016/S0031-9422(00)84877-3; BARKAN A, COMMUNICATION; BUCHER M, 1994, EMBO J, V13, P2755, DOI 10.1002/j.1460-2075.1994.tb06569.x; BUCHER M, 1995, PLANT MOL BIOL, V28, P739, DOI 10.1007/BF00021197; COMSTOCK JC, 1973, PHYTOPATHOLOGY, V63, P1357, DOI 10.1094/Phyto-63-1357; DEAN C, 1985, EMBO J, V4, P3055, DOI 10.1002/j.1460-2075.1985.tb04045.x; DELONG A, 1993, CELL, V74, P757, DOI 10.1016/0092-8674(93)90522-R; DEWEY RE, 1987, P NATL ACAD SCI USA, V84, P5374, DOI 10.1073/pnas.84.15.5374; DEWEY RE, 1986, CELL, V44, P439, DOI 10.1016/0092-8674(86)90465-4; DUVICK DONALD N., 1965, ADVANCE GENET, V13, P1, DOI 10.1016/S0065-2660(08)60046-2; FLAVELL R, 1974, PLANT SCI LETT, V3, P259, DOI 10.1016/0304-4211(74)90096-0; FORDE BG, 1980, P NATL ACAD SCI-BIOL, V77, P418, DOI 10.1073/pnas.77.1.418; HACK E, 1991, PLANT PHYSIOL, V95, P861, DOI 10.1104/pp.95.3.861; HANSON MR, 1985, INT REV CYTOL, V94, P213, DOI 10.1016/S0074-7696(08)60398-8; HOOKER A L, 1970, Plant Disease Reporter, V54, P708; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; KENNELL JC, 1987, MOL GEN GENET, V210, P399, DOI 10.1007/BF00327189; KENNELL JC, 1989, MOL GEN GENET, V216, P16, DOI 10.1007/BF00332225; KORTH KL, 1991, P NATL ACAD SCI USA, V88, P10865, DOI 10.1073/pnas.88.23.10865; LASER KD, 1972, BOT REV, V38, P425, DOI 10.1007/BF02860010; LAUGHNAN JR, 1983, ANNU REV GENET, V17, P27, DOI 10.1146/annurev.ge.17.120183.000331; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVINGS CS, 1993, PLANT CELL, V5, P1285, DOI 10.2307/3869781; MACKENZIE S, 1994, PLANT PHYSIOL, V105, P775, DOI 10.1104/pp.105.3.775; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PRING DR, 1989, ANNU REV PHYTOPATHOL, V27, P483; PRING DR, 1988, PHILOS T ROY SOC B, V319, P187, DOI 10.1098/rstb.1988.0042; SCHNABLE PS, 1994, GENETICS, V136, P1171; TASAYCO ML, 1990, ARCH BIOCHEM BIOPHYS, V278, P444, DOI 10.1016/0003-9861(90)90283-5; ULLSTRUP AJ, 1972, ANNU REV PHYTOPATHOL, V10, P37, DOI 10.1146/annurev.py.10.090172.000345; VILLEMUR R, 1992, J MOL BIOL, V227, P81, DOI 10.1016/0022-2836(92)90683-B; WALLACE DC, 1989, TRENDS GENET, V5, P9, DOI 10.1016/0168-9525(89)90005-X; WARMKE HE, 1977, J HERED, V68, P213, DOI 10.1093/oxfordjournals.jhered.a108817; WISE RP, 1994, THEOR APPL GENET, V88, P785, DOI 10.1007/BF01253987; WISE RP, 1987, PLANT MOL BIOL, V9, P121, DOI 10.1007/BF00015644; WISE RP, IN PRESS GENETICS; YODER OC, 1973, PHYTOPATHOLOGY, V63, P1361, DOI 10.1094/Phyto-63-1361	39	301	381	3	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1334	1336		10.1126/science.272.5266.1334	http://dx.doi.org/10.1126/science.272.5266.1334			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650543				2022-12-24	WOS:A1996UN47200045
J	Taggart, AKP; Pugh, BF				Taggart, AKP; Pugh, BF			Dimerization of TFIID when not bound to DNA	SCIENCE			English	Article							BINDING-PROTEIN; TRANSCRIPTION	For unknown reasons, the eukaryotic transcription factor TFIID inefficiently recognizes promoters. Human TFIID was found to form highly specific homodimers that must dissociate before DNA binding. TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID. Chemical cross-linking experiments in HeLa cells revealed the presence of TBP dimers in vivo. These findings suggest that dimerization through TBP is the physiological state of TFIID when not bound to DNA. Thus, the inefficiency of TFIID binding to a promoter may be partly attributable to the competitive effect of dimerization.	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM47855] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PUGH BF, 1995, IN VITRO TRANSCRIPTI, V37, P359; TAGGART AK, 1994, NUCLEIC ACIDS RES, V22, P1179; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TJIAN R, 1994, CELL, V77, P55; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	16	56	56	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1331	1333		10.1126/science.272.5266.1331	http://dx.doi.org/10.1126/science.272.5266.1331			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650542				2022-12-24	WOS:A1996UN47200044
J	Jansen, RP; Dowzer, C; Michaelis, C; Galova, M; Nasmyth, K				Jansen, RP; Dowzer, C; Michaelis, C; Galova, M; Nasmyth, K			Mother cell-specific HO expression in budding yeast depends on the unconventional myosin myo4p and other cytoplasmic proteins	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CYCLE REGULATION; TRANSCRIPTION; GENE; ASYMMETRY; DIVISION	Certain cell types give rise to progeny that adopt different patterns of gene expression in the absence of any differences in their environment. Cells of budding yeast give birth to mother and daughter cells that differ in that only mother cells express the HO endonuclease gene and thereby switch mating types. We describe the identification of five genes, called SHE1-SHE5, that encode cytoplasmic proteins required for mother-specific HO expression. She1p, which is identical to the minimyosin Myo4p, and She3p are not, however, mother-specific proteins. On the contrary, they accumulate in growing buds. She proteins might be required for the transport of factors that promote HO repression from the mother cell into its bud. In an accompanying paper, we show that SHE genes are needed for the accumulation in daughter nuclei of Ash1p, a repressor of HO.			Jansen, RP (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				BECAM AM, 1994, YEAST, V10, P1; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; HAARER BK, 1994, J CELL SCI, V107, P1055; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SANDERS SL, 1994, CURR BIOL, V4, P907, DOI 10.1016/S0960-9822(00)00201-3; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927	36	260	262	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					687	697		10.1016/S0092-8674(00)81047-8	http://dx.doi.org/10.1016/S0092-8674(00)81047-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625407	Bronze			2022-12-24	WOS:A1996TZ99000007
J	Wiertz, EJHJ; Jones, TR; Sun, L; Bogyo, M; Geuze, HJ; Ploegh, HL				Wiertz, EJHJ; Jones, TR; Sun, L; Bogyo, M; Geuze, HJ; Ploegh, HL			The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol	CELL			English	Article							COMPLEX CLASS-I; TRANSLOCATION; EXPRESSION; STABILITY; ANTIGENS; SEC61P	Human cytomegalovirus (HCMV) down-regulates expression of MHC class I products by selective proteolysis. A single HCMV gene, US11, which encodes an endoplasmic reticulum (ER) resident type-I transmembrane glycoprotein, is sufficient to cause this effect. In US11(+) cells, MHC class I molecules are core-glycosylated and therefore inserted into the ER. They are degraded with a half-time of less than 1 min. A full-length breakdown intermediate that has lost the single N-linked glycan in an N-glycanase-catalyzed reaction transiently accumulates in cells exposed to the protease inhibitors LLnL, Cbz-LLL, and lactacystin, identifying the proteasome as a key protease. Subcellular fractionation experiments show this intermediate to be cytosolic. Thus, US11 dislocates newly synthesized class I molecules from the ER to the cytosol, where they are acted upon by an N-glycanase and the proteasome.	WYETH AYERST RES, DEPT BIOL MOLEC, INFECT DIS SECT, PEARL RIVER, NY 10965 USA; UNIV UTRECHT, SCH MED, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	Pfizer; Utrecht University	Wiertz, EJHJ (corresponding author), MIT, CTR CANC RES, DEPT BIOL, CAMBRIDGE, MA 02139 USA.			Bogyo, Matthew/0000-0003-3753-4412	NCI NIH HHS [5-P30-CA14501] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; DELVAL M, 1992, J EXP MED, V176, P729, DOI 10.1084/jem.176.3.729; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EICHHOLTZ T, 1992, J BIOL CHEM, V267, P22490; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HILL A, 1995, P NATL ACAD SCI USA, V92, P341, DOI 10.1073/pnas.92.2.341; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; JONES TR, 1994, J VIROL, V68, P3742, DOI 10.1128/JVI.68.6.3742-3752.1994; JONES TR, 1991, J VIROL, V65, P3742; KIM HJ, 1995, J VIROL, V69, P2565, DOI 10.1128/JVI.69.4.2565-2573.1995; KIM YJ, 1994, CELL, V78, P845; LARDY HENRY A., 1965, P245; LIOU W, 1994, IMPROVED FINE STRUCT, P1; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; NEEFJES JJ, 1993, EUR J IMMUNOL, V23, P840, DOI 10.1002/eji.1830230411; NEEFJES JJ, 1986, IMMUNOGENETICS, V23, P164, DOI 10.1007/BF00373817; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STAM NJ, 1986, J IMMUNOL, V137, P2299; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	43	898	919	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					769	779		10.1016/S0092-8674(00)81054-5	http://dx.doi.org/10.1016/S0092-8674(00)81054-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625414	Bronze			2022-12-24	WOS:A1996TZ99000014
J	Willett, WC; Stampfer, MJ; Manson, JE; Colditz, GA; Rosner, BA; Speizer, FE; Hennekens, CH				Willett, WC; Stampfer, MJ; Manson, JE; Colditz, GA; Rosner, BA; Speizer, FE; Hennekens, CH			Coffee consumption and coronary heart disease in women - A ten-year follow-up	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; DEATH; QUESTIONNAIRE; MEN	Objective.-To assess the relationship between coffee consumption and risk of coronary heart disease (CHD) among women. Design.-Prospective cohort study with coffee consumption measured in 1980, 1984, and 1986, and follow-up through 1990. Setting.-Female registered nurses in the United States. Participants.-A total of 85 747 US women 34 to 59 years of age in 1980 and without history of CHD, stroke, or cancer. Main Outcome Measure.-Ten-year incidence of CHD (defined as nonfatal myocardial infarction or fatal CHD). Results.-During 10 years of follow-up we documented 712 cases of CHD. After adjustment for age, smoking, and other CHD risk factors, we found no evidence for any positive association between coffee consumption and risk of subsequent CHD. For women drinking six or more cups of caffeine-containing coffee per day in 1980, the relative risk was 0.95 (95% confidence interval, 0.73 to 1.26) compared with women who did not consume this beverage. Similarly, there was no association when the first 4 years of follow-up were excluded, when nonfatal and fatal CHD end points were examined separately, or when we updated coffee consumption in 1984 or 1986 and examined only CHD during the next 2-year interval. Further, there was no association with caffeine intake from all sources combined or with decaffeinated coffee consumption. Conclusions.-These data indicate that coffee as consumed by US women is not an important cause of CHD.	BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Willett, WC (corresponding author), CHANNING LABS,818 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594, HL 24074] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		GABH Rose, 1982, WHO MONOGRAPH SERIES; GREENLAND S, 1993, EPIDEMIOLOGY, V4, P366, DOI 10.1097/00001648-199307000-00013; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HENNEKENS CH, 1976, NEW ENGL J MED, V294, P633, DOI 10.1056/NEJM197603182941203; KALANDIDI A, 1993, INT J EPIDEMIOL, V21, P174; KAWACHI I, 1994, BRIT HEART J, V72, P269; Klag Michael J., 1994, Annals of Epidemiology, V4, P425, DOI 10.1016/1047-2797(94)90001-9; KLATSKY AL, 1990, AM J EPIDEMIOL, V132, P479, DOI 10.1093/oxfordjournals.aje.a115684; MANN JI, 1975, LANCET, V2, P1215; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MYERS MG, 1992, ARCH INTERN MED, V152, P1767, DOI 10.1001/archinte.152.9.1767; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; TVERDAL A, 1990, BRIT MED J, V300, P566, DOI 10.1136/bmj.300.6724.566; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; ZOCK PL, 1990, LANCET, V335, P1235, DOI 10.1016/0140-6736(90)91302-Q	18	79	84	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					458	462		10.1001/jama.275.6.458	http://dx.doi.org/10.1001/jama.275.6.458			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627967				2022-12-24	WOS:A1996TU63800034
J	Thomas, C; DeVries, P; Hardin, J; White, J				Thomas, C; DeVries, P; Hardin, J; White, J			Four-dimensional imaging: Computer visualization of 3D movements in living specimens	SCIENCE			English	Article							FLUORESCENCE MICROSCOPY; TIME-LAPSE; EMBRYOS; ELEGANS; CELLS	The study of many biological processes requires the analysis of three-dimensional (3D) structures that change over time. Optical sectioning techniques can provide 3D data from living specimens; however, when 3D data are collected over a period of time, the quantity of Image information produced leads to difficulties in interpretation. A computer-based system is described that permits the analysis and archiving of 3D image data taken over time, The system allows a user to roam through the full range of time points and focal planes in the data set. The user can animate images as an aid to visualization and can append multicolored labels and text notes to identified structures during data analysis, The system provides a valuable tool for the study of embryogenesis and cytoplasmic movements within cells and has considerable potential as an educational tool.	UNIV WISCONSIN, DEPT ZOOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Thomas, C (corresponding author), UNIV WISCONSIN, INTEGRATED MICROSCOPY RESOURCE BIOMED RES, MADISON, WI 53706 USA.		DeVries, Peter/B-7014-2009	DeVries, Peter/0000-0003-4637-5281	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000570] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR00570-26] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DRIEBIN RA, 1988, COMPUT GRAPH, V22, P65; FIRE A, 1994, COMPUT APPL BIOSCI, V10, P443; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; INOUE S, 1994, BIOL BULL, V187, P232, DOI 10.1086/BBLv187n2p232; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41	11	95	97	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1996	273	5275					603	607		10.1126/science.273.5275.603	http://dx.doi.org/10.1126/science.273.5275.603			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662545	Green Submitted			2022-12-24	WOS:A1996VA24900032
J	Bloom, BR				Bloom, BR			A perspective on AIDS vaccines	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY				Bloom, BR (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,BRONX,NY 10461, USA.							ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; BAKSHI SS, 1995, PEDIATR INFECT DIS J, V14, P658, DOI 10.1097/00006454-199508000-00002; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLEMENTS ML, IN PRESS NEW GENERAT; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DESROSIERS RC, 1994, AIDS RES HUM RETROV, V10, P331, DOI 10.1089/aid.1994.10.331; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HAYNES BF, 1993, SCIENCE, V260, P1279, DOI 10.1126/science.8493572; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236; LOHMAN BL, 1994, J VIROL, V68, P7021, DOI 10.1128/JVI.68.11.7021-7029.1994; LONG RB, 1996, NY TIMES        0419, pA18; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; MARTIN HL, 1994, AIDS RES HUM RETROV, V10, pS235; MOORE J, 1994, NATURE, V372, P313, DOI 10.1038/372313a0; MORRIS OP, 1996, J INFECT DIS, V173, P68; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; Newell ML, 1996, LANCET, V347, P213, DOI 10.1016/S0140-6736(96)90401-8; *NIH OFF AIDS RES, 1996, NIH AIDS RES PROGR E; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PAUL WE, 1995, CELL, V82, P177, DOI 10.1016/0092-8674(95)90304-6; PLUMMER FA, 1993, 9 INT C AIDS STD WOR; ROQUES PA, 1995, AIDS, V9, pF19; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5; Ruprecht RM, 1996, AIDS RES HUM RETROV, V12, P459, DOI 10.1089/aid.1996.12.459; SHIRAMIZU B, 1994, CANCER RES, V54, P2069; TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936; WALKER MC, 1994, AIDS S1, V8, pS213; Weiss RA, 1996, AIDS RES HUM RETROV, V12, P465, DOI 10.1089/aid.1996.12.465; *WORLD BANK, 1993, INV HLTH, P62; [No title captured]; 1991, J AM VET MED ASSOC, V10, P1392	35	26	30	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1996	272	5270					1888	1890		10.1126/science.272.5270.1888	http://dx.doi.org/10.1126/science.272.5270.1888			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658160				2022-12-24	WOS:A1996UV29400029
J	Hakem, R; delaPompa, JL; Sirard, C; Mo, R; Woo, M; Hakem, A; Wakeham, A; Potter, J; Reitmair, A; Billia, F; Firpo, E; Hui, CC; Roberts, J; Rossant, J; Mak, TW				Hakem, R; delaPompa, JL; Sirard, C; Mo, R; Woo, M; Hakem, A; Wakeham, A; Potter, J; Reitmair, A; Billia, F; Firpo, E; Hui, CC; Roberts, J; Rossant, J; Mak, TW			The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse	CELL			English	Article							FAMILIAL BREAST; PROTEIN; MORPHOGENESIS; GASTRULATION; LINKAGE; ENCODES; COMPLEX; CANCER; GROWTH; ONSET	Mutations of the BRCA1 gene in humans are associated with predisposition to breast and ovarian cancers. We show here that Brca1(+/-) mice are normal and fertile and lack tumors by age eleven months. Homozygous Brca1(5-6) mutant mice die before day 7.5 of embryogenesis. Mutant embryos are poorly developed, with no evidence of mesoderm formation. The extraembryonic region is abnormal, but aggregation with wild-type tetraploid embryos does not rescue the lethality. In vivo, mutant embryos do not exhibit increased apoptosis but show reduced cell proliferation accompanied by decreased expression of cyclin E and mdm-2, a regulator of p53 activity. The expression of cyclin-dependent kinase inhibitor p21 is dramatically increased in the mutant embryos. Buttressing these in vivo observations is the fact that mutant blastocyst growth is grossly impaired in vitro. Thus, the death of Brca1(5-6) mutant embryos prior to gastrulation may be due to a failure of the proliferative burst required for the development of the different germ layers.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS & IMMUNOL, TORONTO, ON M5G 2C1, CANADA; UNIV TORONTO, DEPT MED & MOLEC GENET, TORONTO, ON M5S 1A1, CANADA; UNIV TORONTO, DEPT OBSTET & GYNECOL, TORONTO, ON M5S 1A1, CANADA; HOSP SICK CHILDREN, DIV ENDOCRINOL RES INST, PROGRAM DEV BIOL, TORONTO, ON M5G 1X8, CANADA; FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, SEATTLE, WA 98104 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Fred Hutchinson Cancer Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Hakem, R (corresponding author), UNIV TORONTO, AMGEN INST, 100 COLL ST, TORONTO, ON M5G 2C1, CANADA.		Billia, Filio/B-3011-2014; De La Pompa, José Luis/F-9719-2014	Billia, Filio/0000-0002-2824-1215; De La Pompa, José Luis/0000-0001-6761-7265; Hakem, Razqallah/0000-0001-5948-7931				BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARPER JW, 1993, CELL, V75, P805; HAYASHI Y, 1988, J HISTOCHEM CYTOCHEM, V36, P511, DOI 10.1177/36.5.3282006; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LUNA RMD, 1995, NATURE, V378, P203; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; Nagy A., 1993, Gene targeting: a practical approach., P147; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; POWER MA, 1993, ANAT EMBRYOL, V187, P493; Rao VN, 1996, ONCOGENE, V12, P523; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; VARMUZA S, 1988, DEVELOPMENT, V102, P127; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	49	550	560	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1996	85	7					1009	1023		10.1016/S0092-8674(00)81302-1	http://dx.doi.org/10.1016/S0092-8674(00)81302-1			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674108	Bronze			2022-12-24	WOS:A1996UV48400008
J	Durbec, P; MarcosGutierrez, CV; Kilkenny, C; Grigoriou, M; Wartiovaara, K; Suvanto, P; Smith, D; Ponder, B; Costantini, F; Saarma, M; Sariola, H; Pachnis, V				Durbec, P; MarcosGutierrez, CV; Kilkenny, C; Grigoriou, M; Wartiovaara, K; Suvanto, P; Smith, D; Ponder, B; Costantini, F; Saarma, M; Sariola, H; Pachnis, V			GDNF signalling through the Ret receptor tyrosine kinase	NATURE			English	Article							EXPRESSION	MUTATIONAL analysis in humans and mice has demonstrated that Ret, the product of the c-ret proto-oncogene, a member of the receptor tyrosine kinase (RTK) superfamily(1), is essential for development of the enteric nervous system and kidney(2-6). Despite the established role of Ret in mammalian embryogenesis, its cognate ligand(s) is currently unknown. Here we demonstrate, by using a Xenopus embryo bioassay, that glial-cell-line-derived neurotrophic factor (GDNF)(7), a distant member of the transforming growth factor(TGF)-beta superfamily, signals through the Ret RTK. Furthermore, using explant cultures from wild-type and Ret-deficient mouse embryos(4), we show that normal c-ret function is necessary for GDNF signalling in the peripheral nervous system, Our data strongly suggest that Ret is a functional receptor for GDNF, and that GDNF, in addition to its potential role in the differentiation and survival of central nervous system neurons(8-12), has profound effects on kidney organogenesis and the development of the peripheral nervous system.	NATL INST MED RES, DIV DEV NEUROBIOL, LONDON NW7 1AA, ENGLAND; UNIV HELSINKI, BIOCTR 1, INST BIOTECHNOL, FIN-00014 HELSINKI, FINLAND; UNIV CAMBRIDGE, ADDENBROOKES HOSP, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 2QQ, ENGLAND; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; HELSINKI UNIV, CHILDRENS HOSP, FIN-000290 HELSINKI, FINLAND	MRC National Institute for Medical Research; University of Helsinki; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Columbia University; University of Helsinki			Grigoriou, Maria/AAM-8332-2021	Grigoriou, Maria/0000-0001-6336-5523				BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Borrello MG, 1995, ONCOGENE, V11, P2419; BRIVANLOU AH, 1994, CELL, V77, P283; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; HEBENSTREIT PG, 1992, ONCOGENE, V7, P2499; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; RATHJEN FG, 1984, EMBO J, V3, P1; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SAIRIO K, 1994, INT J DEV BIOL, V38, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Suvanto P, 1996, EUR J NEUROSCI, V8, P816, DOI 10.1111/j.1460-9568.1996.tb01267.x; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	30	682	725	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					789	793		10.1038/381789a0	http://dx.doi.org/10.1038/381789a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657282				2022-12-24	WOS:A1996UU35600061
J	Morahan, G; Huang, DX; Tait, BD; Colman, PG; Harrison, LC				Morahan, G; Huang, DX; Tait, BD; Colman, PG; Harrison, LC			Markers on distal chromosome 2q linked to insulin-dependent diabetes mellitus	SCIENCE			English	Article							GENETIC-ANALYSIS; LOCALIZATION; MICE; IDENTIFICATION; LINKAGE; RECEPTOR; PROTEIN; GENOME; LOCUS	Insulin-dependent diabetes mellitus (IDDM) is a multigenic autoimmune disease. An IDDM susceptibility gene was mapped to chromosome 2q34. This gene may act early in diabetogenesis, because ''preclinical'' individuals also showed linkage, Human leukocyte antigen (HLA)-disparate, but not HLA-identical, sibs showed linkage, which was even stronger in families with affected females. The genes encoding insulin-like growth factor-binding proteins 2 and 5 were mapped to a 4-megabase pair interval near this locus, These results indicate the existence of a gene that acts at an early stage in IDDM development, screening for which may identify a specific subset of at-risk individuals.			Morahan, G (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Morahan, Grant/T-7501-2019	Colman, Peter/0000-0001-8718-6175				ALLANDER SV, 1994, J BIOL CHEM, V269, P10891; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BLUM WF, 1993, GROWTH REGULAT, V3, P100; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BUONAVISTA N, 1992, GENOMICS, V13, P856, DOI 10.1016/0888-7543(92)90169-S; CARTER RE, 1995, GENOMICS, V27, P196, DOI 10.1006/geno.1995.1025; COPEMAN JB, 1995, NAT GENET, V9, P80, DOI 10.1038/ng0195-80; CORNALL RJ, 1991, NATURE, V353, P262, DOI 10.1038/353262a0; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DEGOUYON B, 1993, P NATL ACAD SCI USA, V90, P1877, DOI 10.1073/pnas.90.5.1877; DUNCAN AMV, 1992, CYTOGENET CELL GENET, V60, P212, DOI 10.1159/000133340; EHRENBORG E, 1991, BIOCHEM BIOPH RES CO, V176, P1250, DOI 10.1016/0006-291X(91)90420-C; FIELD LL, 1994, NAT GENET, V8, P189, DOI 10.1038/ng1094-189; GARCHON HJ, 1991, NATURE, V353, P260, DOI 10.1038/353260a0; GIANNINI S, 1994, J CLIN ENDOCR METAB, V79, P1824, DOI 10.1210/jc.79.6.1824; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HOLMANS P, 1993, AM J HUM GENET, V52, P362; HONEYMAN MC, 1993, SPRINGER SEMIN IMMUN, V14, P253; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; KRUGLYAK L, 1995, NAT GENET, V11, P241; LUERSSEN H, 1990, GENOMICS, V8, P324, DOI 10.1016/0888-7543(90)90289-7; LUO DF, 1995, AM J HUM GENET, V57, P911; LUO DF, IN PRESS HUM MOL GEN; MORAHAN G, 1994, P NATL ACAD SCI USA, V91, P5898, DOI 10.1073/pnas.91.13.5898; MORAHAN G, UNPUB; OWERBACH D, 1995, DIABETES, V44, P132, DOI 10.2337/diabetes.44.1.132; POCIOT F, 1994, AUTOIMMUNITY, V19, P169, DOI 10.3109/08916939408995692; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; SERREZE DV, 1994, J EXP MED, V180, P1553, DOI 10.1084/jem.180.4.1553; STOFFEL M, 1993, DIABETOLOGIA, V36, P335, DOI 10.1007/BF00400237; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; THOMSON G, 1994, NAT GENET, V8, P108, DOI 10.1038/ng1094-108; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TODD JA, 1990, IMMUNOL TODAY, V11, P122, DOI 10.1016/0167-5699(90)90049-F; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHITE JK, 1994, GENOMICS, V24, P295, DOI 10.1006/geno.1994.1619; WILKIE TM, 1993, GENOMICS, V18, P175, DOI 10.1006/geno.1993.1452; WU BL, 1993, CYTOGENET CELL GENET, V63, P29, DOI 10.1159/000133495; YOUNG A, 1995, GAS MANUAL USER GUID; ZIMONJIC DB, 1995, ONCOGENE, V10, P1235	42	103	107	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1811	1813		10.1126/science.272.5269.1811	http://dx.doi.org/10.1126/science.272.5269.1811			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650584				2022-12-24	WOS:A1996UT11000050
J	Dobson, M; Peel, D; Khallaf, N				Dobson, M; Peel, D; Khallaf, N			Field trial of oxygen concentrators in upper Egypt	LANCET			English	Article							DEVELOPING-COUNTRIES	Technical problems in developing countries often require more than just technological solutions. Many small hospitals in rural areas are without a reliable oxygen supply; small oxygen concentrators offer a solution, but simply sending out machines is ineffective. This account details the setting up and first year's operation of a project to test oxygen concentrations in a developing country. A co-ordinated strategy has been developed to include machines, supplies, education, training, and feedback. Initial results are encouraging, and support the idea that suitably installed and maintained concentrations can have a valuable role in bringing oxygen therapy to patients and hospitals in countries which have so far been denied it.	NATL ARI PROGRAM,CAIRO,EGYPT		Dobson, M (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT ANAESTHET,OXFORD OX3 9DU,ENGLAND.							[Anonymous], 1981, LANCET, V1, P681; DOBSON MB, 1991, ANAESTHESIA, V46, P217, DOI 10.1111/j.1365-2044.1991.tb09413.x; FENTON PM, 1989, ANAESTHESIA, V44, P498, DOI 10.1111/j.1365-2044.1989.tb11380.x; GOULD GA, 1985, THORAX, V40, P811, DOI 10.1136/thx.40.11.811; PEDERSEN J, 1991, BRIT J ANAESTH, V66, P264, DOI 10.1093/bja/66.2.264; *WHO, 1991, 912 WHO ARI	6	40	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1597	1599		10.1016/S0140-6736(96)91080-6	http://dx.doi.org/10.1016/S0140-6736(96)91080-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667871				2022-12-24	WOS:A1996UP66100014
J	Noble, J				Noble, J			Influence of physician perceptions on putting knowledge into practice	LANCET			English	Editorial Material											Noble, J (corresponding author), BOSTON UNIV,SCH MED,GEN INTERNAL MED SECT,BOSTON,MA 02118, USA.							Friedmann PD, 1996, ANN INTERN MED, V124, P414, DOI 10.7326/0003-4819-124-4-199602150-00005; MEDALIE JH, 1976, AM J MED, V60, P910, DOI 10.1016/0002-9343(76)90921-9	2	1	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1571	1571		10.1016/S0140-6736(96)91071-5	http://dx.doi.org/10.1016/S0140-6736(96)91071-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667862				2022-12-24	WOS:A1996UP66100005
J	Yuvaniyama, J; Denu, JM; Dixon, JE; Saper, MA				Yuvaniyama, J; Denu, JM; Dixon, JE; Saper, MA			Crystal structure of the dual specificity protein phosphatase VHR	SCIENCE			English	Article							CDC25 PROTEIN; TYROSINE PHOSPHATASE; DETECTOR; P34CDC2	Dual specificity protein phosphatases (DSPs) regulate mitogenic signal transduction and control the cell cycle. Here, the crystal structure of a human DSP, vaccinia H1-related phosphatase (or VHR), was determined at 2.1 angstrom resolution. A shallow active site pocket in VHR allows for the hydrolysis of phosphorylated serine, threonine, or tyrosine protein residues, whereas the deeper active site of protein tyrosine phosphatases (PTPs) restricts substrate specificity to only phosphotyrosine. Positively charged crevices near the active site may explain the enzyme's preference for substrates with two phosphorylated residues. The VHR structure defines a conserved structural scaffold for both DSPs and PTPs. A ''recognition region,'' connecting helix alpha 1 to strand beta 1 may determine differences in substrate specificity between VHR, the PTPs, and other DSPs.	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Yuvaniyama, Jirundon/0000-0002-6800-8944	NIAID NIH HHS [AI 34095] Funding Source: Medline; NIDDK NIH HHS [DK18024, DK18849] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849, R01DK018024, R37DK018024] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROCA P, 1995, J BIOL CHEM, V270, P14229, DOI 10.1074/jbc.270.23.14229; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KWAK SP, 1994, J BIOL CHEM, V269, P3596; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P140; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STONE RL, 1994, J BIOL CHEM, V269, P31323; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; STUCKEY JH, UNPUB; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	35	299	306	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1996	272	5266					1328	1331		10.1126/science.272.5266.1328	http://dx.doi.org/10.1126/science.272.5266.1328			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN472	8650541				2022-12-24	WOS:A1996UN47200043
J	Nehls, M; Kyewski, B; Messerle, M; Waldschutz, R; Schuddekopf, K; Smith, AJH; Boehm, T				Nehls, M; Kyewski, B; Messerle, M; Waldschutz, R; Schuddekopf, K; Smith, AJH; Boehm, T			Two genetically separable steps in the differentiation of thymic epithelium	SCIENCE			English	Article							STROMAL CELL-TYPES; MICE; MICROENVIRONMENT; MATURATION; ALPHA	The development oi the thymus depends initially on epithelial-mesenchymal and subsequently on reciprocal lympho-stromal interactions. The genetic steps governing development and differentiation of the thymic microenvironment are unknown. With the use of a targeted disruption of the whn gene, which recapitulates the phenotype of the athymic nude mouse, the WHN transcription factor was shown to be the product of the nude locus. Formation of the thymic epithelial primordium before the entry of lymphocyte progenitors did not require the activity of WHN. However, subsequent differentiation of primitive precursor cells into subcapsular, cortical, and medullary epithelial cells of the postnatal thymus did depend on activity of the whn gene. These results define the first geneticallyd separable steps during thymic epithelial differentiation.	DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); MRC Laboratory Molecular Biology				Messerle, Martin/0000-0002-1227-3933				ALTEVOGT P, 1989, EUR J IMMUNOL, V19, P1509, DOI 10.1002/eji.1830190826; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; AUERBACH R, 1960, DEV BIOL, V2, P271, DOI 10.1016/0012-1606(60)90009-9; CORDIER AC, 1980, AM J ANAT, V157, P227, DOI 10.1002/aja.1001570303; HOLLANDER GA, 1995, NATURE, V373, P350, DOI 10.1038/373350a0; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; KISHIHARA K, 1987, EUR J IMMUNOL, V17, P477, DOI 10.1002/eji.1830170407; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KUBO RT, 1989, J IMMUNOL, V142, P2736; LASTER AJ, 1986, DIFFERENTIATION, V31, P67, DOI 10.1111/j.1432-0436.1986.tb00385.x; LEDOUARIN NM, 1984, AM J ANAT, V170, P261, DOI 10.1002/aja.1001700305; MACDONALD HR, 1981, J IMMUNOL, V126, P885; MESSERLE M, UNPUB; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; NEHLS M, 1995, MAMM GENOME, V6, P321, DOI 10.1007/BF00364794; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NEHLS M, 1994, BIOTECHNIQUES, V17, P770; RICH BE, 1995, J EXP MED, V181, P1223, DOI 10.1084/jem.181.3.1223; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; WARREN A, 1994, CELL, V15, P45; [No title captured]	28	368	437	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					886	889		10.1126/science.272.5263.886	http://dx.doi.org/10.1126/science.272.5263.886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629026				2022-12-24	WOS:A1996UK75700063
J	Dickason, RR; Huston, DP				Dickason, RR; Huston, DP			Creation of a biologically active interleukin-5 monomer	NATURE			English	Article							COLONY-STIMULATING FACTOR; BINDING	INTERLEUKIN-5 (IL-5) specifically induces the differentiation of eosinophils, which are important in host defence and the patho genesis of allergies and asthma(1,2). Structurally, IL-5 is a unique member of the short-chain helical-bundle subfamily of cytokines whose canonical motif contains four helices (A-D) arranged in an up-up-down-down topology(3,4). In contrast to other subfamily members, which fold unimolecularly into a single helical bundle(5-8), IL-5 forms a pair of helical bundles by the interdigitation of two identical monomers that contribute a D helix to the other's A-C helices(3). We predicted that the lack of bioactivity by an IL-5 monomer(9) was due to a short loop between helices C and D which physically prevents unimolecular folding of helix D into a functionally obligate structural motif. Here we report that, by lengthening this loop, we have engineered an insertional mutant of IL-5 that was expressed as a monomer with biological activity similar to that of native IL-5. These studies demonstrate that all of the structural features necessary for IL-5 to function are contained within a single helical bundle.	BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA	Baylor College of Medicine	Dickason, RR (corresponding author), BAYLOR COLL MED, DEPT MED, 1 BAYLOR PLAZA, FBRN B567, HOUSTON, TX 77030 USA.			Huston, David/0000-0002-2332-0010				BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; DICKASON RR, 1994, CYTOKINE, V6, P647, DOI 10.1016/1043-4666(94)90053-1; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KORKE M, 1994, INT ARCH ALLER A IMM, V104, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKENZIE ANJ, 1991, MOL IMMUNOL, V28, P155, DOI 10.1016/0161-5890(91)90099-6; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; Sanderson C J, 1992, Adv Pharmacol, V23, P163, DOI 10.1016/S1054-3589(08)60965-5; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; Summers MD, 1987, MANUAL METHODS BACUL; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194	19	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					652	655		10.1038/379652a0	http://dx.doi.org/10.1038/379652a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628400				2022-12-24	WOS:A1996TV68800056
J	Eidelman, LA; Putterman, D; Putterman, C; Sprung, CL				Eidelman, LA; Putterman, D; Putterman, C; Sprung, CL			The spectrum of septic encephalopathy - Definitions, etiologies, and mortalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEPSIS; SYSTEM; COMA	Objective.-To determine whether the severity of septic encephalopathy is correlated with gram-negative bacteremia and mortality and whether there exists a single or combination of metabolic derangement(s) that cause septic encephalopathy. Design and Setting.-Prospective case series in an academic medical center. Patients.-Fifty patients selected according to clinical and laboratory criteria for severe sepsis. The criteria included temperature, heart rate, respiratory rate, and hypotension and/or signs of systemic hypoperfusion. Main Outcome Measures.-A single or combination of metabolic and laboratory derangements and organ failures, three different methods to grade the severity of septic encephalopathy, Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, gram-negative bacteremia and infection, and mortality. Results.-Encephalopathy was associated with an increase in mortality when graded by the Glasgow Coma Score; a score of 15 had 16% mortality, 13 to 14 had 20%, 9 to 12 had 50%, and 3 to 8 had 63% mortality (P<.05). Bacteremia was associated with encephalopathy; 13% of septic patients without encephalopathy vs 59% of patients with encephalopathy had bacteremia (P<.001) when graded by altered mental status. Septic encephalopathic patients had elevated serum urea nitrogen and bilirubin levels, increased APACHE II scores, and a higher incidence of renal failure. Conclusions.-The severity of septic encephalopathy correlated with mortality, bacteremia, and renal and hepatic dysfunction. The Glasgow Coma Score is a useful tool for characterizing septic encephalopathy. Considerable variations can be found according to different criteria used to classify septic encephalopathy.	HEBREW UNIV JERUSALEM,HADASSAH UNIV HOSP,DEPT ANESTHESIOL & CRIT CARE MED,IL-91120 JERUSALEM,ISRAEL; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY	Hebrew University of Jerusalem; Yeshiva University; Albert Einstein College of Medicine								[Anonymous], 1992, CRIT CARE MED, V20, P864; BATES DW, 1995, ARCH INTERN MED, V155, P593, DOI 10.1001/archinte.155.6.593; Bleck Thomas P., 1993, P193; BLECK TP, 1993, CRIT CARE MED, V21, P98, DOI 10.1097/00003246-199301000-00019; Bolton CF, 1986, NEW HORIZONS PERSPEC, P157; BOLTON CF, 1993, ANN NEUROL, V33, P4; BOWTON DL, 1989, CRIT CARE CLIN, V5, P785; Freedman D. A., 1980, STATISTICS; JACKSON AC, 1985, CAN J NEUROL SCI, V12, P303, DOI 10.1017/S0317167100035381; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOPPEL JD, 1989, TXB NEPHROLOGY, P1238; KREGER BE, 1980, AM J MED, V68, P332, DOI 10.1016/0002-9343(80)90101-1; LUCE JM, 1987, CHEST, V91, P883, DOI 10.1378/chest.91.6.883; Martin M A, 1991, Infect Dis Clin North Am, V5, P739; MERRILL JP, 1953, AM J MED, V14, P519; MULLIE A, 1988, LANCET, V1, P137; PENDLEBURY WW, 1989, J NEUROPATH EXP NEUR, V48, P290, DOI 10.1097/00005072-198905000-00006; PINE RW, 1983, ARCH SURG-CHICAGO, V118, P242; Plum F, 1980, DIAGNOSIS STUPOR COM, Vthird; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; TEASDALE G, 1974, LANCET, V2, P81; WIJDICKS EFM, 1992, ARCH NEUROL-CHICAGO, V49, P653, DOI 10.1001/archneur.1992.00530300093015; YOUNG GB, 1990, CLIN INVEST MED, V13, P297; YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016; ZEIGLER EJ, 1991, NEW ENGL J MED, V324, P429	25	269	287	2	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					470	473		10.1001/jama.275.6.470	http://dx.doi.org/10.1001/jama.275.6.470			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627969				2022-12-24	WOS:A1996TU63800036
J	Rodewald, HR; Dessing, M; Dvorak, AM; Galli, SJ				Rodewald, HR; Dessing, M; Dvorak, AM; Galli, SJ			Identification of a committed precursor for the mast cell lineage	SCIENCE			English	Article							BONE-MARROW; PERIPHERAL-BLOOD; MICE; HYPERSENSITIVITY; INTERLEUKIN-4; ESTABLISHMENT; MATURATION; EXPRESSION; RECEPTORS; BASOPHILS	Mast cells originate from hematopoietic stem cells, but the mast cell-committed precursor has not been identified. In the study presented here, a cell population in murine fetal blood that fulfills the criteria of progenitor mastocytes was identified. It is defined by the phenotype Thy-1(lo)c-Kit(hi), contains cytoplasmic granules, and expresses RNAs encoding mast cell-associated proteases but lacks expression of the high-affinity immunoglobulin E receptor. Thy-1(lo)c-Kit(hi) cells generated functionally competent mast cells at high frequencies in vitro but lacked developmental potential for other hematopoietic lineages. When transferred intraperitoneally, this population reconstituted the peritoneal mast cell compartment of genetically mast cell-deficient W/W-v mice to wild-type levels.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rodewald, HR (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.				NCI NIH HHS [CA/AI-72074] Funding Source: Medline; NIAID NIH HHS [AI-33372, AI/CA-23990] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023990, R01AI023990, R01AI033372] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN JW, 1991, EUR J IMMUNOL, V21, P2559, DOI 10.1002/eji.1830211037; DVORAK AM, 1993, LAB INVEST, V68, P708; DVORAK AM, 1982, BLOOD, V59, P1279; DVORAK AM, 1994, AM J PATHOL, V144, P160; ENERBACK L, 1974, HISTOCHEMISTRY, V42, P301, DOI 10.1007/BF00492678; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GALLI SJ, 1982, J CELL BIOL, V95, P435, DOI 10.1083/jcb.95.2.435; HUFF TF, 1995, BIOLOGICAL AND MOLECULAR ASPECTS OF MAST CELL AND BASOPHIL DIFFERENTIATION AND FUNCTION, P105; ISCOVE NN, 1979, IMMUNOLOGICAL METHOD, P379; ISHIZAKA K, 1989, CURR OPIN IMMUNOL, V1, P625, DOI 10.1016/0952-7915(89)90031-9; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KINZER CA, 1995, J EXP MED, V182, P575, DOI 10.1084/jem.182.2.575; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P1085; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; KODAMA HA, 1982, J CELL PHYSIOL, V112, P89, DOI 10.1002/jcp.1041120114; KSUGAI T, 1995, BLOOD, V85, P1334; LANTZ CS, 1995, J IMMUNOL, V155, P4024; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Miller H. R. P., 1992, Allergy and immunity to helminths: common mechanisms or divergent pathways., P228; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; OGAWA M, 1991, J EXP MED, V174, P631; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; RA C, 1989, J BIOL CHEM, V264, P15323; RODEWALD HR, 1994, EMBO J, V13, P4229, DOI 10.1002/j.1460-2075.1994.tb06743.x; RODEWALD HR, 1995, CURR OPIN IMMUNOL, V7, P176, DOI 10.1016/0952-7915(95)80002-6; ROLINK A, 1993, BLOOD, V81, P2290; ROTTEM M, 1992, BLOOD, V79, P972; SCUDAMORE CL, 1995, J EXP MED, V182, P1871, DOI 10.1084/jem.182.6.1871; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SONODA T, 1982, J CELL PHYSIOL, V112, P136, DOI 10.1002/jcp.1041120120; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TSAI M, 1995, AM J PATHOL, V146, P335; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306; ZUCKERFRANKLIN D, 1981, BLOOD, V58, P544	45	283	287	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					818	822		10.1126/science.271.5250.818	http://dx.doi.org/10.1126/science.271.5250.818			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8629001				2022-12-24	WOS:A1996TU69400050
J	Leitges, M; Schmedt, C; Guinamard, R; Davoust, J; Schaal, S; Stabel, S; Tarakhovsky, A				Leitges, M; Schmedt, C; Guinamard, R; Davoust, J; Schaal, S; Stabel, S; Tarakhovsky, A			Immunodeficiency in protein kinase C beta-deficient mice	SCIENCE			English	Article							BRUTON TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; SIGNAL-TRANSDUCTION PATHWAYS; B-CELL-DIFFERENTIATION; CBA-N MICE; MEDIATED PROLIFERATION; SURFACE-IMMUNOGLOBULIN; T-LYMPHOCYTES; XID MICE; EXPRESSION	Cross-linking of the antigen receptor on lymphocytes by antigens or antibodies to the receptor results in activation of enzymes of the protein kinase C (PKC) family. Mice homozygous for a targeted disruption of the gene encoding the PKC-beta I and PKC-beta II isoforms develop an immunodeficiency characterized by impaired humoral immune responses and reduced cellular responses of B cells, which is similar to X-linked immunodeficiency in mice. Thus PKC-beta I and PKC-beta II play an important role in B cell activation and may be functionally linked to Bruton's tyrosine kinase in antigen receptor-mediated signal transduction.	MAX PLANCK GESELL, MAX DELBRUCK LAB, D-50829 COLOGNE, GERMANY; UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY; CNRS, INSERM MARSEILLE LUMINY, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	Max Planck Society; University of Cologne; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Leitges, M (corresponding author), MAX PLANCK INST IMMUNBIOL, STUBEWEG 51, D-79108 FREIBURG, GERMANY.		Leitges, Michael/AAN-1953-2021; Guinamard, Rodolphe/P-9804-2016	Davoust, Jean/0000-0002-3098-7665; Guinamard, Rodolphe/0000-0002-7400-582X				AMSBAUGH DF, 1972, J EXP MED, V136, P931, DOI 10.1084/jem.136.4.931; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BAIXERAS E, 1993, IMMUNOL REV, V132, P5, DOI 10.1111/j.1600-065X.1993.tb00836.x; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; COHEN DP, 1991, J IMMUNOL, V146, P2921; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; FRANCOIS DT, 1988, J IMMUNOL, V140, P3338; FREIREMOAR J, 1991, J IMMUNOL, V147, P405; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HASBOLD J, 1994, EUR J IMMUNOL, V24, P152, DOI 10.1002/eji.1830240123; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; HUBER B, 1979, EUR J IMMUNOL, V9, P827, DOI 10.1002/eji.1830091016; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KELLEHER D, 1992, FEBS LETT, V301, P310, DOI 10.1016/0014-5793(92)80264-H; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KLAUS GGB, 1990, EUR J IMMUNOL, V20, P2301, DOI 10.1002/eji.1830201020; KORETZKY GA, 1989, J IMMUNOL, V143, P1692; LEITGES M, UNPUB; LINDSBERG ML, 1991, J IMMUNOL, V147, P3774; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MOND JJ, 1995, CURR OPIN IMMUNOL, V7, P349, DOI 10.1016/0952-7915(95)80109-X; MOND JJ, 1983, J IMMUNOL, V131, P2107; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; PERLMUTTER RM, 1979, J EXP MED, V149, P993, DOI 10.1084/jem.149.4.993; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P2081, DOI 10.1002/eji.1830191117; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SCHER I, 1979, J IMMUNOL, V123, P477; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; SMITH CIE, 1994, J IMMUNOL, V152, P557; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TARANTINO N, 1994, FEBS LETT, V338, P339, DOI 10.1016/0014-5793(94)80295-5; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; VORECHOVSKY I, 1995, HUM MOL GENET, V4, P51, DOI 10.1093/hmg/4.1.51; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	51	393	404	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					788	791		10.1126/science.273.5276.788	http://dx.doi.org/10.1126/science.273.5276.788			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670417				2022-12-24	WOS:A1996VB42900040
J	Karpen, GH; Le, MH; Le, H				Karpen, GH; Le, MH; Le, H			Centric heterochromatin and the efficiency of achiasmate disjunction in Drosophila female meiosis	SCIENCE			English	Article							POSITION-EFFECT VARIEGATION; RNA GENES FUNCTION; CHROMOSOME SEGREGATION; MELANOGASTER FEMALES; SYNAPTONEMAL COMPLEX; WILD-TYPE; DNA; RECOMBINATION; PROTEINS; REPEATS	The chromosomal requirements for achiasmate (nonexchange) homolog disjunction in Drosophila female meiosis I have been identified with the use of a series of molecularly defined minichromosome deletion derivatives. Efficient disjunction requires 1000 kilobases of overlap in the centric heterochromatin and is not affected by homologous euchromatin or overall size differences. Disjunction efficiency decreases linearly as heterochromatic overlap is reduced from 1000 to 430 kilobases of overlap. Further observations, including rescue experiments with nod kinesin-like protein transgenes, demonstrate that heterochromatin does not act solely to promote chromosome movement or spindle attachment. Thus, it is proposed that centric heterochromatin contains multiple pairing elements that act additively to initiate or maintain the proper alignment of achiasmate chromosomes in meiosis I. How heterochromatin could act to promote chromosome pairing is discussed here.			Karpen, GH (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037, USA.							AFSHAR K, 1995, J CELL BIOL, V131, P833, DOI 10.1083/jcb.131.4.833; AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; ASHBURNER M, 1990, DROSOPHILA LAB HDB; BENFANTE R, 1990, GENE, V94, P217, DOI 10.1016/0378-1119(90)90390-D; CABOT EL, 1993, GENETICS, V135, P477; CARPENTER ATC, 1975, CHROMOSOMA, V51, P157, DOI 10.1007/BF00319833; CARPENTER ATC, 1979, GENETICS, V92, P511; Cook K. J., UNPUB; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; DERNBURG AF, IN PRESS CELL; DONALDSON KD, UNPUB; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; Grell R. F., 1976, GENET BIOL DROSOPHIL, VIa, P435; GRIGLIATTI T, 1991, METHOD CELL BIOL, V35, P587; HASSOLD T, 1993, CURR OPIN GENET DEV, V3, P398, DOI 10.1016/0959-437X(93)90111-2; HAWLEY RS, 1993, ANNU REV GENET, V27, P281; HAWLEY RS, 1993, DEV GENET, V13, P440; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; KARPEN GH, 1992, GENETICS, V132, P737; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KARPEN GH, 1990, CELL, V63, P97; KARPEN GH, UNPUB; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; LE MH, 1995, GENETICS, V141, P283; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOHE AR, 1993, GENETICS, V134, P1149; LOIDL J, 1994, P NATL ACAD SCI USA, V91, P331, DOI 10.1073/pnas.91.1.331; MCKEE BD, 1992, GENETICS, V132, P529; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOENS PB, 1994, BIOESSAYS, V16, P101, DOI 10.1002/bies.950160206; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; NIEDENTHAL RK, 1993, NUCLEIC ACIDS RES, V21, P4726, DOI 10.1093/nar/21.20.4726; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PIMPINELLI S, 1995, P NATL ACAD SCI USA, V92, P3804, DOI 10.1073/pnas.92.9.3804; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; Rabl C, 1885, MORPHOL JB, V10, P214; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; Ross LO, 1996, GENETICS, V142, P79; SUN X, UNPUB; THEURKAUF WE, 1992, J CELL BIOL, V118, P759; TOWER J, 1993, GENETICS, V133, P347; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; WOLF KW, 1994, BIOESSAYS, V16, P107, DOI 10.1002/bies.950160207; WURGLICS G, 1993, NATURWISSENSCHAFTEN, V80, P174, DOI 10.1007/BF01226377; YOOK K, UNPUB; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	52	173	177	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1996	273	5271					118	122		10.1126/science.273.5271.118	http://dx.doi.org/10.1126/science.273.5271.118			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8658180				2022-12-24	WOS:A1996UV47800054
J	Harding, C; Knox, WF; Faragher, EB; Baildam, A; Bundred, NJ				Harding, C; Knox, WF; Faragher, EB; Baildam, A; Bundred, NJ			Hormone replacement therapy and tumour grade in breast cancer: Prospective study in screening unit	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,UNIV S MANCHESTER HOSP,DEPT SURG,MANCHESTER M20 2LR,LANCS,ENGLAND; UNIV MANCHESTER,UNIV S MANCHESTER HOSP,DEPT HISTOPATHOL,MANCHESTER M20 2LR,LANCS,ENGLAND	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital								BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; GAMBRELL RD, 1992, AM FAM PHYSICIAN, V46, pS87; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x	5	59	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1996	312	7047					1646	1647		10.1136/bmj.312.7047.1646	http://dx.doi.org/10.1136/bmj.312.7047.1646			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV489	8664718	Green Published			2022-12-24	WOS:A1996UV48900023
J	James, M				James, M			Isotretinoin for severe acne	LANCET			English	Article																			0	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1749	1750		10.1016/S0140-6736(96)90814-4	http://dx.doi.org/10.1016/S0140-6736(96)90814-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656912				2022-12-24	WOS:A1996UT39600016
J	Deng, HK; Liu, R; Ellmeier, W; Choe, S; Unutmaz, D; Burkhart, M; DiMarzio, P; Marmon, S; Sutton, RE; Hill, CM; Davis, CB; Peiper, SC; Schall, TJ; Littman, DR; Landau, NR				Deng, HK; Liu, R; Ellmeier, W; Choe, S; Unutmaz, D; Burkhart, M; DiMarzio, P; Marmon, S; Sutton, RE; Hill, CM; Davis, CB; Peiper, SC; Schall, TJ; Littman, DR; Landau, NR			Identification of a major co-receptor for primary isolates of HIV-1	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; MONONUCLEAR PHAGOCYTES; AIDS VIRUS; INFECTION; TROPISM; DOMAIN; PHENOTYPE; SYSTEM; BRAIN	Entry of HIV-1 into target cells requires cell-surface CD4 and additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T-cell lines was recently identified and named fusin. However, fusin does not promote entry of macrophage-tropic viruses, which are believed to be the key pathogenic strains in vivo. The principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR-5, a receptor for the beta-chemokines RANTES, MIP-1 alpha and MIP-1 beta.	NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016; NYU,MED CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10016; ROCKEFELLER UNIV,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305; UNIV LOUISVILLE,SCH MED,JAMES GRAHAM BROWN CANC CTR,LOUISVILLE,KY 40207; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	New York University; Howard Hughes Medical Institute; New York University; Rockefeller University; Stanford University; University of Louisville; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.				Ellmeier, Wilfried/0000-0001-8192-8481				ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; COMELISSEN M, 1995, J VIROL, V69, P1810; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1995, VIROLOGY, V206, P936; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FISHER AG, 1988, NATURE, V334, P444, DOI 10.1038/334444a0; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; GAO JL, 1994, J BIOL CHEM, V269, P28539; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LIU ZQ, 1990, J VIROL, V64, P6148, DOI 10.1128/JVI.64.12.6148-6153.1990; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PAGE KA, 1990, J VIROL, V64, P5720; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; VEENSTRA J, 1995, CLIN INFECT DIS, V21, P556, DOI 10.1093/clinids/21.3.556; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	44	3118	3306	2	241	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1996	381	6584					661	666		10.1038/381661a0	http://dx.doi.org/10.1038/381661a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR979	8649511				2022-12-24	WOS:A1996UR97900041
J	Olshausen, BA; Field, DJ				Olshausen, BA; Field, DJ			Emergence of simple-cell receptive field properties by learning a sparse code for natural images	NATURE			English	Article							CORTEX	THE receptive fields of simple cells in mammalian primary visual cortex can be characterized as being spatially localized, oriented(1-4) and bandpass (selective to structure at different spatial scales), comparable to the basis functions of wavelet transforms(5,6), One approach to understanding such response properties of visual neurons has been to consider their relationship to the statistical structure of natural images in terms of efficient coding(7-12), Along these lines, a number of studies have attempted to train unsupervised learning algorithms on natural images in the hope of developing receptive fields with similar properties(13-18), but none has succeeded in producing a full set that spans the image space and contains all three of the above properties. Here we investigate the proposal(8,12) that a coding strategy that maximizes sparseness is sufficient to account for these properties, We show that a learning algorithm that attempts to find sparse linear codes for natural scenes will develop a complete family of localized, oriented, bandpass receptive fields, similar to those found in the primary visual cortex, The resulting sparse image code provides a more efficient representation for later stages of processing because it possesses a higher degree of statistical independence among its outputs.	CORNELL UNIV,DEPT PSYCHOL,ITHACA,NY 14853; UNIV CALIF DAVIS,CTR NEUROSCI,DAVIS,CA 95616	Cornell University; University of California System; University of California Davis			Field, David j/B-9211-2008					Aticky JJ, 2011, NETWORK-COMP NEURAL, V22, P4, DOI [10.1088/0954-898X/3/2/009, 10.3109/0954898X.2011.638888]; Barlow HB, 1989, NEURAL COMPUT, V1, P295, DOI 10.1162/neco.1989.1.3.295; BARROW HG, 1994, IEEE 1 INT C NEUR NE, V4, P115; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; DAUGMAN JG, 1989, IEEE T BIO-MED ENG, V36, P107, DOI 10.1109/10.16456; DAUGMAN JG, 1990, COMPUTATIONAL NEUROS, P403; DEVALOIS RL, 1982, VISION RES, V22, P545, DOI 10.1016/0042-6989(82)90113-4; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; Field DJ, 1993, WAVELETS FRACTALS FO, P151; FOLDIAK P, 1990, BIOL CYBERN, V64, P165, DOI 10.1007/BF02331346; FYFE C, 1995, NETWORK-COMP NEURAL, V6, P333, DOI 10.1088/0954-898X/6/3/002; HANCOCK PJB, 1992, NETWORK-COMP NEURAL, V3, P61, DOI 10.1088/0954-898X/3/1/008; Harpur GF, 1996, NETWORK-COMP NEURAL, V7, P277, DOI 10.1088/0954-898X/7/2/007; HINTON GE, 1995, SCIENCE, V268, P1158, DOI 10.1126/science.7761831; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; INTRATOR N, 1992, NEURAL COMPUT, V4, P98, DOI 10.1162/neco.1992.4.1.98; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; LAW CC, 1994, P NATL ACAD SCI USA, V91, P7797, DOI 10.1073/pnas.91.16.7797; LINSKER R, 1988, COMPUTER         MAR, P105; LU ZL, 1996, 9615 U CAL IRV I MAT; Olshausen BA, 1996, NETWORK-COMP NEURAL, V7, P333, DOI 10.1088/0954-898X/7/2/014; PARKER AJ, 1988, J OPT SOC AM A, V5, P598, DOI 10.1364/JOSAA.5.000598; RUDERMAN DL, 1994, NETWORK-COMP NEURAL, V5, P517, DOI 10.1088/0954-898X/5/4/006; Sanger T. D., 1989, ADV NEURAL INFORMATI, V1, P11; SAUND E, 1995, NEURAL COMPUT, V7, P51, DOI 10.1162/neco.1995.7.1.51; Schmidhuber J, 1996, NEURAL COMPUT, V8, P773, DOI 10.1162/neco.1996.8.4.773; SRINIVASAN MV, 1982, PROC R SOC SER B-BIO, V216, P427, DOI 10.1098/rspb.1982.0085; VANHATEREN JH, 1992, NATURE, V360, P68, DOI 10.1038/360068a0; Zemel R, 1993, THESIS U TORONTO	30	3389	3610	24	304	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					607	609		10.1038/381607a0	http://dx.doi.org/10.1038/381607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637596				2022-12-24	WOS:A1996UQ65700051
J	Peel, NFA; Smith, AG; Hannon, RA; Eastell, R				Peel, NFA; Smith, AG; Hannon, RA; Eastell, R			Rate of bone loss from lumbar spine in women with distal forearm fracture	BRITISH MEDICAL JOURNAL			English	Article									UNIV SHEFFIELD,DEPT HUMAN METAB & CLIN BIOCHEM,SHEFFIELD,S YORKSHIRE,ENGLAND	University of Sheffield			Eastell, Richard/G-5851-2011	Eastell, Richard/0000-0002-0323-3366				ALFFRAM PA, 1962, J BONE JOINT SURG AM, V44, P105, DOI 10.2106/00004623-196244010-00009; PARFITT AM, 1982, CONTINUING ED FA APR, P46; PEEL NFA, 1994, BRIT MED J, V308, P1543, DOI 10.1136/bmj.308.6943.1543; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919	5	4	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1457	1457		10.1136/bmj.312.7044.1457	http://dx.doi.org/10.1136/bmj.312.7044.1457			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664625	Green Published			2022-12-24	WOS:A1996UQ29600028
J	Dobner, T; Horikoshi, N; Rubenwolf, S; Shenk, T				Dobner, T; Horikoshi, N; Rubenwolf, S; Shenk, T			Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor	SCIENCE			English	Article							LATE GENE-EXPRESSION; WILD-TYPE; DNA-BINDING; EARLY REGION-4; TRANSFORMED-CELLS; PROTEIN; SEQUENCE; ANTIGEN; DOMAIN; TRANSACTIVATION	The adenovirus E4orf6 protein is shown here to interact with the cellular tumor suppressor protein p53 and to block p53-mediated transcriptional activation. The adenovirus protein inhibited the ability of p53 to bind to human TAF(II)31, a component of transcription factor IID (TFIID). Earlier work demonstrated that the interaction of p53 with TAF(II)31 involves a sequence near the NH2-terminus of p53, whereas the E4orf6-p53 interaction occurs within amino acids 318 to 360 of p53. Thus, the E4orf6 protein interacts at a site on p53 distinct from the domain that binds to TAF(II)31 but nevertheless inhibits the p53-TAF(II)31 interaction.	PRINCETON UNIV, DEPT MOLEC BIOL, HOWARD HUGHES MED INST, PRINCETON, NJ 08544 USA; UNIV REGENSBURG, INST MED MIKROBIOL & HYG, D-93042 REGENSBURG, GERMANY	Howard Hughes Medical Institute; Princeton University; University of Regensburg			Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178				BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BRAIN R, 1994, ONCOGENE, V9, P1775; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KAO CC, 1990, VIROLOGY, V52, P456; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	39	256	263	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1470	1473		10.1126/science.272.5267.1470	http://dx.doi.org/10.1126/science.272.5267.1470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633237				2022-12-24	WOS:A1996UP89900044
J	Thorpe, S; Fize, D; Marlot, C				Thorpe, S; Fize, D; Marlot, C			Speed of processing in the human visual system	NATURE			English	Article							EVENT-RELATED POTENTIALS; FACES; PICTURES; RECOGNITION; TIME	How long does it take for the human visual system to process a complex natural image? Subjectively, recognition of familiar objects and scenes appears to be virtually instantaneous, but measuring this processing time experimentally has proved difficult. Behavioural measures such as reaction times can be used(1), but these include not only visual processing but also the time required for response execution. However, event-related potentials (ERPs) can sometimes reveal signs of neural processing well before the motor output(2). Here we use a go/no-go categorization task in which subjects have to decide whether a previously unseen photograph, flashed on for just 20 ms, contains an animal. ERP analysis revealed a frontal negativity specific to no-go trials that develops roughly 150 ms after stimulus onset. We conclude that the visual processing needed to perform this highly demanding task can be achieved in under 150 ms.			Thorpe, S (corresponding author), CTR RECH CERVEAU & COGNIT,UMR 5549,F-31062 TOULOUSE,FRANCE.		Fize, Denis/F-4525-2011; THORPE, Simon J/A-5661-2008	THORPE, Simon J/0000-0003-4997-3367				ALLISON T, 1994, CEREB CORTEX, V4, P544, DOI 10.1093/cercor/4.5.544; ALLISON T, 1994, J NEUROPHYSIOL, V71, P821, DOI 10.1152/jn.1994.71.2.821; BARRETT SE, 1988, NEUROPSYCHOLOGIA, V26, P105, DOI 10.1016/0028-3932(88)90034-6; BARRETT SE, 1989, NEUROPSYCHOLOGIA, V27, P913, DOI 10.1016/0028-3932(89)90067-5; BARRETT SE, 1990, BRAIN COGNITION, V14, P201, DOI 10.1016/0278-2626(90)90029-N; BARRETT SE, 1990, BRAIN LANG, V38, P424, DOI 10.1016/0093-934X(90)90125-Z; BOBES MA, 1994, BRAIN COGNITION, V26, P1, DOI 10.1006/brcg.1994.1039; BULTHOFF HH, 1995, CEREB CORTEX, V5, P247, DOI 10.1093/cercor/5.3.247; CELEBRINI S, 1993, VISUAL NEUROSCI, V10, P811, DOI 10.1017/S0952523800006052; GEMBA DH, 1989, NEUROSCI LETT, V101, P263, DOI 10.1016/0304-3940(89)90543-0; HALGREN E, 1994, J PHYSIOL-PARIS, V88, P1, DOI 10.1016/0928-4257(94)90092-2; HOLCOMB PJ, 1994, BRAIN COGNITION, V24, P259, DOI 10.1006/brcg.1994.1014; HUMMEL JE, 1992, PSYCHOL REV, V99, P480, DOI 10.1037/0033-295X.99.3.480; INTRAUB H, 1981, J EXP PSYCHOL HUMAN, V7, P604, DOI 10.1037/0096-1523.7.3.604; JEFFREYS DA, 1992, EXP BRAIN RES, V91, P340; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; ORAM MW, 1992, J NEUROPHYSIOL, V68, P70, DOI 10.1152/jn.1992.68.1.70; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; POTTER MC, 1975, NATURE, V253, P437, DOI 10.1038/253437a0; PRATARELLI ME, 1994, BRAIN COGNITION, V24, P137, DOI 10.1006/brcg.1994.1008; ROLLS ET, 1994, P ROY SOC B-BIOL SCI, V257, P9, DOI 10.1098/rspb.1994.0087; RUDELL AP, 1992, ELECTROEN CLIN NEURO, V83, P77, DOI 10.1016/0013-4694(92)90135-5; RUGG MC, 1995, ELECTROPHYSIOLOGY MI; RUGG MD, 1995, J COGNITIVE NEUROSCI, V7, P209, DOI 10.1162/jocn.1995.7.2.209; SASAKI K, 1993, NEUROSCI RES, V18, P249, DOI 10.1016/0168-0102(93)90062-U; SEECK M, 1992, EXP BRAIN RES, V92, P338; THORPE SJ, 1989, CONNECTIONISM IN PERSPECTIVE, P63; VETTER T, 1995, CEREB CORTEX, V5, P261, DOI 10.1093/cercor/5.3.261	28	2359	2432	14	307	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					520	522		10.1038/381520a0	http://dx.doi.org/10.1038/381520a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UP435	8632824				2022-12-24	WOS:A1996UP43500059
J	MacGregor, GA; Sever, PS				MacGregor, GA; Sever, PS			Salt - Overwhelming evidence but still no action: Can a consensus be reached with the food industry?	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; ESSENTIAL-HYPERTENSION; ETIOLOGY; KIDNEY; TRIAL		UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,LONDON W2 7PG,ENGLAND	Imperial College London	MacGregor, GA (corresponding author), ST GEORGE HOSP,SCH MED,BLOOD PRESSURE UNIT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.							ANTONIOS TFT, IN PRESS LANCET; Cardiovascular Review Group Great Britain-Department of Health, 1994, NUTR ASP CARD DIS; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; DEWARDENER HE, 1990, CLIN SCI, V79, P193, DOI 10.1042/cs0790193; DEWARDENER HE, 1990, CLIN SCI, V79, P289, DOI 10.1042/cs0790289; FORTE JG, 1989, J HUM HYPERTENS, V3, P179; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; *ROWL CO, 1991, LIF FACTS SALT; SEVER PS, 1989, J HYPERTENS, V7, pS9, DOI 10.1097/00004872-198902001-00004; SINGER DRJ, 1995, HYPERTENSION, V25, P1042, DOI 10.1161/01.HYP.25.5.1042; UZODIKE VO, 1993, THESIS U LONDON LOND	14	64	68	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1287	1289		10.1136/bmj.312.7041.1287	http://dx.doi.org/10.1136/bmj.312.7041.1287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634621	Green Published			2022-12-24	WOS:A1996UM40400029
J	Field, SJ; Tsai, FY; Kuo, F; Zubiaga, AM; Kaelin, WG; Livingston, DM; Orkin, SH; Greenberg, ME				Field, SJ; Tsai, FY; Kuo, F; Zubiaga, AM; Kaelin, WG; Livingston, DM; Orkin, SH; Greenberg, ME			E2F-1 functions in mice to promote apoptosis and suppress proliferation	CELL			English	Article							TRANSCRIPTION FACTOR E2F; DNA-BINDING ACTIVITY; HUMAN MYC PROMOTER; RETINOBLASTOMA PROTEIN; CYCLIN-A; CELL-CYCLE; THYMIDINE KINASE; TRANS-ACTIVATION; S-PHASE; COMPLEX	Members of the E2F transcription factor family (E2F-1-E2F-5) are believed to be critical positive regulators of cell cycle progression in eukaryotes although the in vivo functions of the individual E2Fs have not been elucidated. Mice were generated that lack E2F-1 and, surprisingly, these mice develop and reproduce normally. However, E2F-1(-/-) mice exhibit a defect in T lymphocyte development leading to an excess of mature T cells due to a maturation stage-specific defect in thymocyte apoptosis. As E2F-1(-/-) mice age they exhibit a second phenotype marked by aberrant cell proliferation. These findings suggest that while certain members of the E2F family may positively regulate cell cycle progression, E2F-1 functions to regulate apoptosis and to suppress cell proliferation.	CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115; CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute			zubiaga, ana/S-3457-2019	zubiaga, ana/0000-0002-2132-9708; Field, Seth/0000-0002-8893-4806	NIDDK NIH HHS [DK49216] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049216, P30DK049216] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLD R, 1993, J HISTOCHEM CYTOCHEM, V41, P1023, DOI 10.1177/41.7.8515045; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KISIELOW P, 1991, ADV EXP MED BIOL, V292, P31; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEUMAN E, 1995, MOL CELL BIOL, V15, P4660; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OWEN JJT, 1988, IMMUNOLOGY, V63, P639; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P104; SALA A, 1994, CANCER RES, V54, P1402; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHI YF, 1991, J IMMUNOL, V146, P3340; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yang Xiao-He, 1995, Gene Expression, V4, P195	64	696	709	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					549	561		10.1016/S0092-8674(00)81255-6	http://dx.doi.org/10.1016/S0092-8674(00)81255-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653790	Bronze			2022-12-24	WOS:A1996UM41500012
J	Glass, DJ; Bowen, DC; Stitt, TN; Radziejewski, C; Bruno, J; Ryan, TE; Gies, DR; Shah, S; Mattsson, K; Burden, SJ; DiStefano, PS; Valenzuela, DM; DeChiara, TM; Yancopoulos, GD				Glass, DJ; Bowen, DC; Stitt, TN; Radziejewski, C; Bruno, J; Ryan, TE; Gies, DR; Shah, S; Mattsson, K; Burden, SJ; DiStefano, PS; Valenzuela, DM; DeChiara, TM; Yancopoulos, GD			Agrin acts via a MuSK receptor complex	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; CULTURED MUSCLE-CELLS; ACETYLCHOLINE-RECEPTORS; NGF; PHOSPHORYLATION; AGGREGATION; COMPONENTS; PROTEINS; NEURONS; SURFACE	Formation of the neuromuscular junction depends upon reciprocal inductive interactions between the developing nerve and muscle, resulting in the precise juxtaposition of a differentiated nerve terminal with a highly specialized patch on the muscle membrane, termed the motor endplate. Agrin is a nerve-derived factor that can induce molecular reorganizations at the motor endplate, but the mechanism of action of agrin remains poorly understood. MuSK is a receptor tyrosine kinase localized to the motor endplate, seemingly well positioned to receive a key nerve-derived signal. Mice lacking either agrin or MUSK have recently been generated and exhibit similarly profound defects in their neuromuscular junctions. Here we demonstrate that agrin acts via a receptor complex that includes MuSK as well as a myotube-specific accessory component.	NYU,MED CTR,SKIRBALL INST,MOL NEUROBIOL PROGRAM,NEW YORK,NY 10016	New York University	Glass, DJ (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Burden, Steven/0000-0002-3550-6891; Glass, David/0000-0001-6187-4164	NINDS NIH HHS [R01 NS036193-01A1S1, R01 NS036193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036193] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BARBACID M, 1993, ONCOGENE, V8, P2033; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BURDEN SJ, 1995, DEV BIOL, V6, P59; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; PENG HB, 1991, NEURON, V6, P237; QU Z, 1994, J NEUROSCI, V14, P6834; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEALOCK R, 1994, CELL, V77, P617, DOI 10.1016/0092-8674(94)90045-0; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1995, J CELL BIOL, V128, P1121, DOI 10.1083/jcb.128.6.1121; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661	47	548	572	2	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1996	85	4					513	523		10.1016/S0092-8674(00)81252-0	http://dx.doi.org/10.1016/S0092-8674(00)81252-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653787	hybrid			2022-12-24	WOS:A1996UM41500009
J	Meydan, N; Grunberger, T; Dadi, H; Shahar, M; Arpaia, E; Lapidot, Z; Leeder, JS; Freedman, M; Cohen, A; Gazit, A; Levitzki, A; Roifman, CM				Meydan, N; Grunberger, T; Dadi, H; Shahar, M; Arpaia, E; Lapidot, Z; Leeder, JS; Freedman, M; Cohen, A; Gazit, A; Levitzki, A; Roifman, CM			Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor	NATURE			English	Article							PROTEIN-TYROSINE KINASES; DEFICIENT SCID MICE; SRC FAMILY; LEUKEMIA; LYMPHOCYTES; CELLS; PHOSPHORYLATION; INTERLEUKIN-7; EXPRESSION; ACTIVATION	ACUTE lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Despite the progress achieved in its treatment, 20% of cases relapse and no longer respond to chemotherapy. The most common phenotype of ALL cells share surface antigens with very early precursors of B cells and are therefore believed to originate from this lineage(1,3). Characterization of the growth requirement of ALL cells indicated that they were dependent on various cytokines, suggesting paracrine and/or autocrine growth regulation(4-6). Because many cytokines induce tyrosine phosphorylation in lymphoid progenitor cells, and constitutive tyrosine phosphorylation is commonly observed in B-lineage leukaemias(7,8), attempts have been made to develop protein tyrosine kinase (PTK) blockers of leukaemia cell growth(9,10). Here we show that leukaemic cells from patients in relapse have constitutively activated Jak-2 PTK. Inhibition of Jak-2 activity by a specific tyrosine kinase blocker, AG-490, selectively blocks leukaemic cell growth in vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal haematopoiesis.	HOSP SICK CHILDREN, DIV ALLERGY IMMUNOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DIV HAEMATOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DIV PHARMACOL, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT PEDIAT, TORONTO, ON M5G 1X8, CANADA; WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL; HEBREW UNIV JERUSALEM, INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Weizmann Institute of Science; Hebrew University of Jerusalem			Leeder, James Steven/ABD-5438-2021	Leeder, James Steven/0000-0001-6688-0504				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKE TR, 1993, J MED CHEM, V36, P425, DOI 10.1021/jm00056a001; COHEN A, 1991, BLOOD, V78, P94; CUSHMAN M, 1994, J MED CHEM, V37, P3353, DOI 10.1021/jm00046a020; DADI HK, 1993, BIOCHEM BIOPH RES CO, V192, P459, DOI 10.1006/bbrc.1993.1437; ESTROV Z, 1991, EXP HEMATOL, V19, P221; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; GRIMALDI JC, 1989, BLOOD, V73, P2081; HARPUR AG, 1992, ONCOGENE, V7, P1347; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAMELREID S, 1992, LEUKEMIA, V6, P8; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; NADLER LM, 1983, J IMMUNOL, V131, P244; OSAMU M, 1994, BLOOD, V84, P1501; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; ROIFMAN CM, 1992, J IMMUNOL, V148, P1136; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1993, NEW ENGL J MED, V329, P1296, DOI 10.1056/NEJM199310283291802; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	30	841	932	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					645	648		10.1038/379645a0	http://dx.doi.org/10.1038/379645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628398				2022-12-24	WOS:A1996TV68800054
J	Oliver, SG				Oliver, SG			From DNA sequence to biological function	NATURE			English	Article							HUMAN GENOME PROJECT; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-III; YEAST; GENE; PROTEINS; GROWTH; SYSTEM; CELL	Genome sequencing is leading to the discovery of new genes at a rate 50-100 times greater than that achieved by classical genetics, but the biological function of almost half of these genes is completely unknown. In order fully to exploit genome sequence data, a systematic approach to the discovery of gene function is required. Possible strategies are discussed here in the context of functional analysis in the yeast Saccharomyces cerevisiae, a model eukaryote whose genome sequence will soon be completed.			Oliver, SG (corresponding author), UMIST, DEPT BIOCHEM & APPL MOLEC BIOL, POB 88, MANCHESTER M60 1QD, LANCS, ENGLAND.							ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BLATTNER FR, 1993, JOHN INN S, P43; BODMER W, 1994, NAT GENET, V6, P217, DOI 10.1038/ng0394-217; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHADWICK DJ, 1992, CIBA F S, V171; CHATER KF, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P277; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DANG VD, 1994, YEAST, V10, P1273, DOI 10.1002/yea.320101004; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DEVINE KM, 1995, TRENDS BIOTECHNOL, V13, P210, DOI 10.1016/S0167-7799(00)88948-9; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DULBECCO R, 1993, GENE, V135, P259, DOI 10.1016/0378-1119(93)90074-D; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; Hammond J. R. M., 1993, YEASTS, P7; HAVUKKALA I, 1995, J BIOTECHNOL, V41, P139, DOI 10.1016/0168-1656(95)00038-R; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; JIA Y, 1993, THESIS U P M CURIE P; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KABACK DB, 1979, NUCLEIC ACIDS RES, V6, P2499, DOI 10.1093/nar/6.7.2499; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KREUDTZFELDT C, 1991, BIOTECH HDB, V4, P5; LALO D, 1993, CR HEBD ACAD SCI, V316, P137; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LEONGMORGENTHALER P, 1994, BIOCHIMIE, V76, P45, DOI 10.1016/0300-9084(94)90061-2; LIN YS, 1993, MOL MICROBIOL, V10, P923, DOI 10.1111/j.1365-2958.1993.tb00964.x; MEHTA PK, 1993, EUR J BIOCHEM, V211, P373, DOI 10.1111/j.1432-1033.1993.tb19907.x; MORTIMER RK, 1986, GENETICS, V113, P35; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLIVER SG, 1993, JOHN INN S, P233; Olson M., 1991, MOL CELLULAR BIOL YE, P1; OLSON MV, 1993, P NATL ACAD SCI USA, V90, P4338, DOI 10.1073/pnas.90.10.4338; OUZOUNIS C, 1993, FEBS LETT, V322, P159, DOI 10.1016/0014-5793(93)81559-I; QUANT PA, 1993, TRENDS BIOCHEM SCI, V18, P26; RENDUELES PS, 1988, FEMS MICROBIOL LETT, V54, P17; RIEGER K, IN PRESS YEAST; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMIDT R, 1993, BIOESSAYS, V15, P63, DOI 10.1002/bies.950150110; SCHWARTZ K, 1994, NAT GENET, V8, P110, DOI 10.1038/ng1094-110; SHORT N, 1995, NATURE, V377, P1; SMITH HO, 1995, SCIENCE, V269, P538, DOI 10.1126/science.7542802; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; TANAKA S, 1993, NUCLEIC ACIDS RES, V21, P1149, DOI 10.1093/nar/21.5.1149; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WARD R, 1990, HYPERTENSION PATHOPH, P81; WATERSTON B, 1995, NATURE, V376, P111, DOI 10.1038/376111d0; Weinstock Keith G., 1994, Current Opinion in Biotechnology, V5, P599, DOI 10.1016/0958-1669(94)90081-7; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOSHIKAWA A, 1990, YEAST, V6, P383, DOI 10.1002/yea.320060504; ZHENG L, 1958, P NATL ACAD SCI USA, V90, P2754	61	245	249	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					597	600		10.1038/379597a0	http://dx.doi.org/10.1038/379597a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628394				2022-12-24	WOS:A1996TV68800040
J	Hilgetag, CC; ONeill, MA; Young, MP				Hilgetag, CC; ONeill, MA; Young, MP			Indeterminate organization of the visual system	SCIENCE			English	Editorial Material							CORTICAL CONNECTIONS; AREAS				Hilgetag, CC (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT PSYCHOL,NEURAL SYST GRP,RIDLEY BLDG,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND.		Hilgetag, Claus C/L-7282-2013; Hilgetag, Claus C/AAH-1760-2020	Hilgetag, Claus C/0000-0003-2129-8910; Hilgetag, Claus C/0000-0003-2129-8910				BOUSSAOUD D, 1990, J COMP NEUROL, V296, P462, DOI 10.1002/cne.902960311; COOGAN TA, 1993, J NEUROSCI, V13, P3749; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; MANUNSELL JHR, 1983, ANN REV NEUROSCI, V10, P363; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; ROCKLAND KS, 1979, BRAIN RES, V179, P3, DOI 10.1016/0006-8993(79)90485-2; VANLAARHOVEN PJM, 1987, SIMULATED ANNEALING	7	123	125	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					776	777		10.1126/science.271.5250.776	http://dx.doi.org/10.1126/science.271.5250.776			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628990				2022-12-24	WOS:A1996TU69400035
J	Kimura, K; Ito, M; Amano, M; Chihara, K; Fukata, Y; Nakafuku, M; Yamamori, B; Feng, JH; Nakano, T; Okawa, K; Iwamatsu, A; Kaibuchi, K				Kimura, K; Ito, M; Amano, M; Chihara, K; Fukata, Y; Nakafuku, M; Yamamori, B; Feng, JH; Nakano, T; Okawa, K; Iwamatsu, A; Kaibuchi, K			Regulation of myosin phosphatase by Rho and Rho-Associated kinase (Rho-kinase)	SCIENCE			English	Article							SMOOTH-MUSCLE; PHOSPHORYLATION; SENSITIVITY; SYSTEM; CELLS; RAS	The small guanosine triphosphatase Rho is implicated in myosin light chain (MLC) phosphorylation, which results in contraction of smooth muscle and interaction of actin and myosin in nonmuscle cells. The guanosine triphosphate (GTP)-bound, active form of RhoA (GTP . RhoA) specifically interacted with the myosin-binding subunit (MBS) of myosin phosphatase, which regulates the extent of phosphorylation of MLC. Rho-associated kinase (Rho-kinase), which is activated by GTP . RhoA, phosphorylated MBS and consequently inactivated myosin phosphatase. Overexpression of RhoA or activated RhoA in NIH 3T3 cells increased phosphorylation of MBS and MLC. Thus, Rho appears to inhibit myosin phosphatase through the action of Rho-kinase.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; MIE UNIV,SCH MED,DEPT INTERNAL MED 1,TSU,MIE 514,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	Nara Institute of Science & Technology; Mie University; Kirin Brewery Company Limited			Kimura, Kazushi/ABB-4007-2020; Amano, Mutsuki/M-4820-2014; Nakafuku, Masato/J-3068-2013	Amano, Mutsuki/0000-0002-0662-1524; Nakafuku, Masato/0000-0001-7783-9005; Fukata, Yuko/0000-0001-7724-8643				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; AMANO M, UNPUB; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIULIANO KA, 1995, CURR OPIN CELL BIOL, V7, P4, DOI 10.1016/0955-0674(95)80038-7; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KIMURA K, UNPUB; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MORELAND S, 1992, AM J PHYSIOL, V263, pC540, DOI 10.1152/ajpcell.1992.263.2.C540; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATOH T, 1992, J BIOL CHEM, V267, P24149; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WYBORSKI DL, 1991, NUCLEIC ACIDS RES, V19, P4647, DOI 10.1093/nar/19.17.4647; YAMAMORI B, UNPUB; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557	32	2336	2406	0	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					245	248		10.1126/science.273.5272.245	http://dx.doi.org/10.1126/science.273.5272.245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8662509				2022-12-24	WOS:A1996UW78700043
J	Williams, K; Chambers, M; Logan, S; Robinson, D				Williams, K; Chambers, M; Logan, S; Robinson, D			Association of common health symptoms with bullying in primary school children	BRITISH MEDICAL JOURNAL			English	Article							MIDDLE	Objectives-To estimate the prevalence of bullying in primary school children and to examine its association with common symptoms in childhood. Design-Semistructured health interview conducted by school nurses as part of a school medical. Setting-Newham, east London. Subjects-All children in year 4 of school during the academic year 1992-93. Main outcome measures-Reported bullying and common health symptoms. Results-2962 children (93.1% of those on the school roll) were interviewed (ages 7.6 to 10.0 years). Information about bullying was not recorded for 114 children. 22.4% (95% confidence interval 20.9 to 24.0) of children for whom information was available reported that they had been bullied. There was an association between children reporting being bullied sometimes or more often and reporting not sleeping well (odds ratio 3.6, 2.5 to 5.2), bed wetting (1.7, 1.3 to 2.4), feeling sad (3.6, 1.9 to 6.8), and experiencing more than occasional headaches (2.4, 1.8 to 3.4) and tummy aches (2.4, 1.8 to 3.3). A significant trend for increasing risk of symptoms with increased frequency of bullying was shown for all reported health symptoms (P<0.001). Conclusions-Health professionals seeing primary schoolchildren who present with headaches, tummy ache, feeling sad or very sad, bed wetting, and sleeping difficulties should consider bullying as a possible contributory factor.	INST CHILD HLTH,DEPT EPIDEMIOL,LONDON WC1N 1EH,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT,LONDON E1 4NS,ENGLAND; NEWHAM HLTH CARE,LONDON E15 4EE,ENGLAND	University of London; University College London; University of London; Queen Mary University London			Williams, Katrina/B-6828-2015	Williams, Katrina/0000-0002-1686-4458; Logan, Stuart/0000-0002-9279-261X				AHMAD YS, 1990, NEWSLETTER ASS CHILD, V15, P26; BOULTON MJ, 1992, BRIT J EDUC PSYCHOL, V62, P73, DOI 10.1111/j.2044-8279.1992.tb01000.x; CORNFIELD J, 1956, P 3 BERK S BERK, V4; Dean A.G., 1994, EPI INFO VERSION 6 W; ERLING R, 1994, BULLYING SCH, P21; GARDNER SB, 1991, CIA CONFIDENCE INTER; Olweus D., 1993, AGGRESSIVE BEHAV CUR; OMOORE AM, 1989, IRISH J PSYCHOL, V10, P426, DOI 10.1080/03033910.1989.10557759; SHARP S, 1992, EARLY CHILD DEV CARE, V77, P47; WHITNEY I, 1993, EDUC RES, V35, P3, DOI 10.1080/0013188930350101	10	234	238	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1996	313	7048					17	19		10.1136/bmj.313.7048.17	http://dx.doi.org/10.1136/bmj.313.7048.17			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UW667	8664762	Green Published			2022-12-24	WOS:A1996UW66700024
J	Haigh, S				Haigh, S			12 years on: Co-proxamol revisited	LANCET			English	Letter							PROPOXYPHENE HYDROCHLORIDE				Haigh, S (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT PHARM,NOTTINGHAM NG7 2UH,ENGLAND.							Beaver W T, 1984, Hum Toxicol, V3 Suppl, p191S; Drug and Therapeutics Bulletin, 1983, DRUG THER B, V21, P17; HOPKINSON JH, 1973, J CLIN PHARMACOL, V13, P251, DOI 10.1002/j.1552-4604.1973.tb00265.x; HOPKINSON JH, 1976, CURR THER RES CLIN E, V19, P622; MILLER RR, 1970, J AMER MED ASSOC, V213, P996, DOI 10.1001/jama.213.6.996	5	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 29	1996	347	9018					1840	1841		10.1016/S0140-6736(96)91665-7	http://dx.doi.org/10.1016/S0140-6736(96)91665-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU469	8667959				2022-12-24	WOS:A1996UU46900065
J	Weiss, RA				Weiss, RA			HIV receptors and the pathogenesis of AIDS	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; IMMUNE-SYSTEM; RETROVIRUS; INFECTION; TROPISM				Weiss, RA (corresponding author), INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BOYD MT, 1993, J VIROL, V67, P3649, DOI 10.1128/JVI.67.6.3649-3652.1993; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DENG HK, IN PRESS NATURE; DRAGIC T, IN PRESS NATURE; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Hilleman MR, 1995, VACCINE, V13, P1733, DOI 10.1016/0264-410X(95)00114-G; HILLEMAN MR, 1994, AIDS RES HUM RETROV, V10, P3, DOI 10.1089/aid.1994.10.3; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Levy JA, 1994, HIV PATHOGENESIS AID; LUBASHOV VV, 1995, J VIROL, V69, P6911; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCKNIGHT A, 1995, TRENDS MICROBIOL, V3, P356, DOI 10.1016/S0966-842X(00)88975-1; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MCKNIGHT A, 1995, J VIROL, V69, P3167, DOI 10.1128/JVI.69.5.3167-3170.1995; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; McLean Angela R., 1993, Trends in Microbiology, V1, P9, DOI 10.1016/0966-842X(93)90018-M; Miedema F, 1996, SCIENCE, V272, P505, DOI 10.1126/science.272.5261.505; NARAYAN O, 1993, RETROVIRIDAE, V2, P229; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; NOWAK MA, 1993, AIDS, V7, P53; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; SMITHERS DW, 1962, LANCET, V1, P493; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TSAI WP, 1992, AIDS RES HUM RETROV, V8, P1749, DOI 10.1089/aid.1992.8.1749; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571; WEISS RA, 1993, RETROVIRIDAE, V1, P1; WEISS RA, IN PRESS ADV NEW AGE; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537	40	53	61	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1996	272	5270					1885	1886		10.1126/science.272.5270.1885	http://dx.doi.org/10.1126/science.272.5270.1885			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV294	8658158				2022-12-24	WOS:A1996UV29400027
J	Trupp, M; Arenas, E; Fainzilber, M; Nilsson, AS; Sieber, BA; Grigoriou, M; Kilkenny, C; SalazarGrueso, E; Pachnis, V; Arumae, U; Sariola, H; Saarma, M; Ibanez, CF				Trupp, M; Arenas, E; Fainzilber, M; Nilsson, AS; Sieber, BA; Grigoriou, M; Kilkenny, C; SalazarGrueso, E; Pachnis, V; Arumae, U; Sariola, H; Saarma, M; Ibanez, CF			Functional receptor for GDNF encoded by the c-ret proto-oncogene	NATURE			English	Article							LINE	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF) promotes the survival and phenotype of central dopaminergic(1,2), noradrenergic(3) and motor neurons(4-6), as well as various subpopulations of peripheral sensory and sympathetic neurons(7,8). GDNF is structurally related to members of the transforming growth factor (TGF)-beta superfamily(9), several members of which have well-characterized receptor systems(10,11); however, GDNF receptors still remain undefined. Here we show that GDNF binds to, and induces tyrosine phosphorylation of, the product of the c-ret proto-oncogene, an orphan receptor tyrosine kinase, in a GDNF-responsive motor-neuron cell line. Ret protein could also bind GDNF and mediate survival and growth responses to GDNF upon transfection into naive fibroblasts. Moreover, high levels of c-ret mRNA expression were found in dopaminergic neurons of the adult substantia nigra, where exogenous GDNF protected Ret-positive neurons from 6-hydroxydopamine-induced cell death, Thus the product of the c-ret proto-oncogene encodes a functional receptor for GDNF that may mediate its neurotrophic effects on motor and dopaminergic neurons.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MOLEC NEUROBIOL LAB,S-17177 STOCKHOLM,SWEDEN; NATL INST MED RES,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND; UNIV CHICAGO,BRAIN RES INST,DEPT NEUROL,CHICAGO,IL 60637; UNIV HELSINKI,INST BIOTECHNOL,PROGRAM MOL NEUROBIOL,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,INST BIOTECHNOL,PROGRAM DEV BIOL,FIN-00014 HELSINKI,FINLAND	Karolinska Institutet; MRC National Institute for Medical Research; University of Chicago; University of Helsinki; University of Helsinki			Grigoriou, Maria/AAM-8332-2021; Arumäe, Urmas/E-8290-2016; Arenas, Ernest/AAO-5231-2020	Grigoriou, Maria/0000-0001-6336-5523; Arumäe, Urmas/0000-0003-3658-6464; Arenas, Ernest/0000-0003-0197-6577; Fainzilber, Mike/0000-0001-8173-8557; Pachnis, Vassilis/0000-0001-9733-7686				Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DOW E, 1994, AM J MED GENET, V53, P75, DOI 10.1002/ajmg.1320530116; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Neveu I, 1996, J CELL BIOL, V133, P631, DOI 10.1083/jcb.133.3.631; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SUVANTO P, 1996, EUR J NEUROSCI, V8, P116; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; TSUZUKI T, 1995, ONCOGENE, V10, P191; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	24	686	718	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					785	789		10.1038/381785a0	http://dx.doi.org/10.1038/381785a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657281				2022-12-24	WOS:A1996UU35600060
J	Bhattacharya, I; Sack, EM				Bhattacharya, I; Sack, EM			Screening colonoscopy: The cost of common sense	LANCET			English	Editorial Material							OCCULT BLOOD-TESTS; COLORECTAL-CANCER; MORTALITY				Bhattacharya, I (corresponding author), MICHAEL REESE HOSP & MED CTR,2929 S ELLIS,CHICAGO,IL 60616, USA.							ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; BHATTACHARYA I, 1996, IN PRESS GASTROENTER; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; LIEBERMAN DA, 1995, GASTROENTEROLOGY, V109, P1781, DOI 10.1016/0016-5085(95)90744-0; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MULLER AD, 1995, ARCH INTERN MED, V108, P402; Parker S. L., 1996, CA CANC J CLIN, V65, P5; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; ROGGE JD, 1994, AM J GASTROENTEROL, V89, P1775; SACK EM, 1996, IN PRESS GASTROENTER; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; STJOHN DJB, 1993, GASTROENTEROLOGY, V104, P1661, DOI 10.1016/0016-5085(93)90643-Q; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	14	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1744	1745		10.1016/S0140-6736(96)90812-0	http://dx.doi.org/10.1016/S0140-6736(96)90812-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656910				2022-12-24	WOS:A1996UT39600014
J	Virmani, R; Farb, A; Burke, A				Virmani, R; Farb, A; Burke, A			Contraction-band necrosis: New use for an old friend	LANCET			English	Editorial Material											Virmani, R (corresponding author), ARMED FORCES INST PATHOL,DEPT CARDIOVASC PATHOL,WASHINGTON,DC 20306, USA.							ARBUSTINI E, 1993, CORONARY ARTERY DIS, V4, P751, DOI 10.1097/00019501-199309000-00001; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; FARB A, 1993, J MOL CELL CARDIOL, V25, P343, DOI 10.1006/jmcc.1993.1041; Hopster DJ, 1996, J CLIN PATHOL, V49, P403, DOI 10.1136/jcp.49.5.403; KARCH SB, 1986, HUM PATHOL, V17, P9, DOI 10.1016/S0046-8177(86)80150-2	5	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1710	1711		10.1016/S0140-6736(96)90803-X	http://dx.doi.org/10.1016/S0140-6736(96)90803-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656901				2022-12-24	WOS:A1996UT39600005
J	Torres, RM; Flaswinkel, H; Reth, M; Rajewsky, K				Torres, RM; Flaswinkel, H; Reth, M; Rajewsky, K			Aberrant B cell development and immune response in mice with a compromised BCR complex	SCIENCE			English	Review							X-LINKED AGAMMAGLOBULINEMIA; ANTIGEN RECEPTOR COMPLEX; PROTEIN-TYROSINE KINASES; IG-BETA COMPONENTS; MOUSE BONE-MARROW; SIGNAL-TRANSDUCTION; IMMUNOGLOBULIN HEAVY; SRC FAMILY; ALPHA; EXPRESSION	The immunoglobulin alpha (Ig-alpha)-Ig-beta heterodimer is the signaling component of the antigen receptor complex on B cells (BCR) and B cell progenitors (pre-BCR). A mouse mutant that lacks most of the Ig-alpha cytoplasmic tail exhibits only a small impairment in early B cell development but a severe block in the generation of the peripheral B cell pool, revealing a checkpoint in B cell maturation that ensures the expression of a functional BCR on mature B cells. B cells that do develop demonstrate a differential dependence on Ig-alpha signaling in antibody responses such that a signaling-competent Ig-alpha appears to be critical for the response to T-independent, but not T-dependent, antigens.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY; MAX PLANCK INST IMMUNOBIOL,D-79108 FREIBURG,GERMANY	University of Cologne; Max Planck Society				Rajewsky, Klaus/0000-0002-6633-6370				ALLMAN DM, 1993, J IMMUNOL, V151, P4431; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; BLUM JH, 1993, J BIOL CHEM, V268, P27236; BONNEROT C, 1995, IMMUNITY, V3, P335, DOI 10.1016/1074-7613(95)90118-3; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; BROWN VK, 1994, J BIOL CHEM, V269, P17238; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CONLEY ME, 1992, J CLIN IMMUNOL, V12, P139, DOI 10.1007/BF00918144; CONLEY ME, 1994, IMMUNOL REV, V138, P5, DOI 10.1111/j.1600-065X.1994.tb00844.x; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; GILFILLAN S, 1994, INT IMMUNOL, V6, P1681, DOI 10.1093/intimm/6.11.1681; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HINSHELWOOD S, 1995, EUR J IMMUNOL, V25, P1113, DOI 10.1002/eji.1830250439; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; JACK RS, 1977, EUR J IMMUNOL, V7, P559, DOI 10.1002/eji.1830070813; KAHN WN, 1995, IMMUNITY, V3, P283; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; LIN JJ, 1992, J IMMUNOL, V149, P1548; Loffert D, 1996, IMMUNITY, V4, P133, DOI 10.1016/S1074-7613(00)80678-0; LOFFERT D, 1994, IMMUNOL REV, V137, P135, DOI 10.1111/j.1600-065X.1994.tb00662.x; MATSUO T, 1993, J IMMUNOL, V150, P3766; MATSUUCHI L, 1992, P NATL ACAD SCI USA, V89, P3404, DOI 10.1073/pnas.89.8.3404; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; PAPAVASILIOU F, 1995, SCIENCE, V268, P408, DOI 10.1126/science.7716544; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; RAJEWSKY K, 1974, EUR J IMMUNOL, V4, P111, DOI 10.1002/eji.1830040210; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TORRES RM, 1996, IN PRESS LAB PROTOCO; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WICKER LS, 1986, CURR TOP MICROBIOL, V124, P87; WIENANDS J, 1990, THESIS U FREIBURG GE; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; [No title captured]	60	243	249	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1804	1808		10.1126/science.272.5269.1804	http://dx.doi.org/10.1126/science.272.5269.1804			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650582				2022-12-24	WOS:A1996UT11000048
J	Stoeckle, MY; Douglas, RG				Stoeckle, MY; Douglas, RG			Infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MERCK & CO INC, WHITE HOUSE STN, NJ USA	Merck & Company	Stoeckle, MY (corresponding author), CORNELL UNIV MED COLL, NEW YORK, NY 10021 USA.							CAMERON B, 1996, 3 C RETR OPP INF WAS; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P590; CHANG YF, 1995, INFECT IMMUN, V63, P3543, DOI 10.1128/IAI.63.9.3543-3549.1995; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; GUIBERT M, 1995, ACTA PAEDIATR, V84, P831, DOI 10.1111/j.1651-2227.1995.tb13771.x; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; Lederberg J, 1996, JAMA-J AM MED ASSOC, V275, P243, DOI 10.1001/jama.275.3.243; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; MARWICK C, 1995, JAMA-J AM MED ASSOC, V274, P12, DOI 10.1001/jama.274.1.12; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; RAMSAY ME, 1994, PEDIATR INFECT DIS J, V13, P1117, DOI 10.1097/00006454-199412000-00009; 1995, MMWR-MORBID MORTAL W, V44, P273; 1995, AM SOC MICROBIOL NEW, V61, P620; 1995, MMWR-MORBID MORTAL W, V44, P399; 1995, MMWR-MORBID MORTAL W, V44, P468; 1995, MMWR-MORBID M      S, V44, P1; 1995, MMWR-MORBID MORTAL W, V44, P625	19	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1816	1817		10.1001/jama.275.23.1816	http://dx.doi.org/10.1001/jama.275.23.1816			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642726				2022-12-24	WOS:A1996UQ15200025
J	Egan, KM; Newcomb, PA; Longnecker, MP; TrenthamDietz, A; Baron, JA; Trichopoulos, D; Stampfer, MJ; Willett, WC				Egan, KM; Newcomb, PA; Longnecker, MP; TrenthamDietz, A; Baron, JA; Trichopoulos, D; Stampfer, MJ; Willett, WC			Jewish religion and risk of breast cancer	LANCET			English	Article								Background The excess risk of breast cancer among Jewish women has been attributed to the effects of difference in lifestyle and reproductive patterns, but there is now evidence that Jewish women may be more likely than other women to inherit mutations in breast-cancer genes. We investigated whether any excessive risk among Jewish women is confined to those with a family history of breast cancer. Methods We assessed the effect of Jewish religion on breast cancer in a large population-based case-control study (6611 women with breast cancer and 9026 controls) in USA. Participants were given telephone interviews and asked about known and suspected risk factors for breast cancer. Findings Overall, Jewish women had only a slightly raised relative risk of breast cancer (1 . 10 [95% CI 0 . 84-1 . 44]; p=0 . 49). However, the relative risk was much higher for Jewish women with a first-degree relative who had breast cancer (3 . 78 [1 . 74-8 . 16]; p<0 . 001). The effect of family history was greater in Jewish women than in women of other religions (p interaction=0 . 05). Interpretation These results are consistent with data suggesting that certain groups of Jewish women have a higher than expected rate of mutation in the breast-cancer gene BRCA1.	UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI; NIEHS,EPIDEMIOL BRANCH,RES TRIANGLE PK,NC; DARTMOUTH COLL SCH MED,DEPT MED,HANOVER,NH; DARTMOUTH COLL SCH MED,DEPT FAMILY & COMMUNITY MED,HANOVER,NH; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Dartmouth College; Dartmouth College; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Egan, KM (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115, USA.			Longnecker, Matthew/0000-0001-6073-5322	NATIONAL CANCER INSTITUTE [R01CA047305, R01CA047147] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47147, CA 47305] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP DT, 1994, EUR J CANCER, V30A, P1738, DOI 10.1016/0959-8049(94)00455-E; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; LONGNECKER MP, 1995, JNCI-J NATL CANCER I, V87, P923, DOI 10.1093/jnci/87.12.923; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; NEWILL VA, 1961, J NATL CANCER I, V26, P405; SALBER EJ, 1969, JNCI-J NATL CANCER I, V43, P1013; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198	8	51	51	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1645	1646		10.1016/S0140-6736(96)91485-3	http://dx.doi.org/10.1016/S0140-6736(96)91485-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642956	hybrid			2022-12-24	WOS:A1996UQ70100008
J	More, MI; Finger, LD; Stryker, JL; Fuqua, C; Eberhard, A; Winans, SC				More, MI; Finger, LD; Stryker, JL; Fuqua, C; Eberhard, A; Winans, SC			Enzymatic synthesis of a quorum-sensing autoinducer through use of defined substrates	SCIENCE			English	Article							ACYL CARRIER PROTEIN; ESCHERICHIA-COLI; VIBRIO-FISCHERI; TI-PLASMID; LUMINESCENCE; BIOSYNTHESIS; CONJUGATION; THIOESTERS	Many bacteria, including several pathogens of plants and humans, use a pheromone called an autoinducer to regulate gene expression in a cell density-dependent manner. Agrobacterium autoinducer [AAI, N-(3-oxo-octanoyl)-L-homoserine lactone] of A. tumefaciens is synthesized by the TraI protein, which is encoded by the tumor-inducing plasmid. Purified hexahistidinyl-TraI (H-6-TraI) used S-adenosylmethionine to make the homoserine lactone moiety of AAI, but did not use related compounds. H-6-TraI used 3-oxo-octanoyl-acyl carrier protein to make the 3-oxo-octanoyl moiety of AAI, but did not use 3-oxo-octanoyl-coenzyme A. These results demonstrate the enzymatic synthesis of an autoinducer through the use of purified substrates.	CORNELL UNIV,MICROBIOL SECT,ITHACA,NY 14853; ITHACA COLL,DEPT CHEM,ITHACA,NY 14850; TRINITY UNIV,DEPT BIOL,SAN ANTONIO,TX 78212	Cornell University; Trinity University				Finger, L. David/0000-0002-2342-9569; More, Margret/0000-0002-3672-521X	NIGMS NIH HHS [GM42893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042893, R29GM042893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAR YY, 1993, J BIOLUM CHEMILUM, V8, P261, DOI 10.1002/bio.1170080506; BASSLER BL, 1995, 2 COMPONENT SIGNAL T, pCH28; CAO JG, 1993, J BACTERIOL, V175, P3856, DOI 10.1128/JB.175.12.3856-3862.1993; CRONAN JE, 1981, P NATL ACAD SCI-BIOL, V78, P5440, DOI 10.1073/pnas.78.9.5440; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DAGNOLO G, 1975, J BIOL CHEM, V250, P5283; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; EBERHARD A, 1991, ARCH MICROBIOL, V155, P294, DOI 10.1007/BF00252215; Fuqua C, 1996, J BACTERIOL, V178, P435, DOI 10.1128/jb.178.2.435-440.1996; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; FUQUA WC, 1994, J BACTERIOL, V176, P2796, DOI 10.1128/JB.176.10.2796-2806.1994; FUQUA WC, IN PRESS MOL MICROBI; HANZELKA BL, 1995, J BACTERIOL, V177, P815, DOI 10.1128/jb.177.3.815-817.1995; HUISMAN GW, 1994, SCIENCE, V265, P537, DOI 10.1126/science.7545940; HWANG IY, 1994, P NATL ACAD SCI USA, V91, P4639, DOI 10.1073/pnas.91.11.4639; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MORE MB, UNPUB; OUYANG T, 1991, J ORG CHEM, V56, P3752, DOI 10.1021/jo00011a067; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; SALMOND GPC, 1995, MOL MICROBIOL, V16, P615, DOI 10.1111/j.1365-2958.1995.tb02424.x; SIGGAARDANDERSEN M, 1994, P NATL ACAD SCI USA, V91, P11027, DOI 10.1073/pnas.91.23.11027; SITNIKOV DM, 1995, MOL MICROBIOL, V17, P801, DOI 10.1111/j.1365-2958.1995.mmi_17050801.x; TEMPE J, 1977, P NATL ACAD SCI USA, V74, P2848, DOI 10.1073/pnas.74.7.2848; Wirth R, 1996, TRENDS MICROBIOL, V4, P96, DOI 10.1016/0966-842X(96)81525-3; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0	28	301	318	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1996	272	5268					1655	1658		10.1126/science.272.5268.1655	http://dx.doi.org/10.1126/science.272.5268.1655			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658141				2022-12-24	WOS:A1996UR09300048
J	Fried, M; Duffy, PE				Fried, M; Duffy, PE			Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta	SCIENCE			English	Article							INFECTED ERYTHROCYTES; MALARIA; PREGNANCY; AFRICA; ICAM-1	Women are particularly susceptible to malaria during first and second pregnancies, even though they may have developed immunity over years of residence in endemic areas. Plasmodium falciparum-infected red blood cells (IRBCs) were obtained from human placentas. These IRBCs bound to purified chondroitin sulfate A (CSA) but not to other extracellular matrix proteins or to other known IRBC receptors. IRBCs from nonpregnant donors did not bind to CSA. Placental IRBCs adhered to sections of fresh-frozen human placenta with an anatomic distribution similar to that of naturally infected placentas, and this adhesion was competitively inhibited by purified CSA. Thus, adhesion to CSA appears to select for a subpopulation of parasites that causes maternal malaria.	KENYA GOVT MED RES CTR,KISUMU,KENYA	Kenya Medical Research Institute	Fried, M (corresponding author), USA,MED RES UNIT KENYA,POB 54,KISUMU,KENYA.							Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BRABIN BJ, 1985, REV INFECT DIS, V7, P579; BRABIN BJ, 1990, ANN TROP MED PARASIT, V84, P1; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; FRIED M, UNPUB; GUPTA S, 1994, P NATL ACAD SCI USA, V91, P3715, DOI 10.1073/pnas.91.9.3715; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; McGregor I A, 1987, Parassitologia, V29, P153; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; RASHEED FN, 1993, AM J TROP MED HYG, V48, P154, DOI 10.4269/ajtmh.1993.48.154; REILLY K, 1993, PRIMARY CARE, V20, P665; RIGANTI M, 1990, IMMUNOL LETT, V25, P199, DOI 10.1016/0165-2478(90)90115-7; RINDWALD P, 1993, INFECT IMMUN, V61, P5198; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; WALTER PR, 1982, AM J PATHOL, V109, P330; WEINBERG ED, 1984, REV INFECT DIS, V6, P814; ZHU ZL, 1995, P NATL ACAD SCI USA, V92, P3546, DOI 10.1073/pnas.92.8.3546	26	874	884	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1502	1504		10.1126/science.272.5267.1502	http://dx.doi.org/10.1126/science.272.5267.1502			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633247				2022-12-24	WOS:A1996UP89900054
J	Nakayama, K; Ishida, N; Shirane, M; Inomata, A; Inoue, T; Shishido, N; Hori, I; Loh, DY; Nakayama, K				Nakayama, K; Ishida, N; Shirane, M; Inomata, A; Inoue, T; Shishido, N; Hori, I; Loh, DY; Nakayama, K			Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors	CELL			English	Article							GROWTH-FACTOR-BETA; CELL; MOUSE; DISRUPTION; INHIBITOR; ONCOGENE; MUTATIONS; KINASES; GENES; P21	Mice lacking p27(Kip1) have been created by gene targeting in embryonic stem cells. These mice are larger than the control animals, with thymus, pituitary, and adrenal glands and gonadal organs exhibiting striking enlargement. CDK2 activity is elevated about 10-fold in p27(-/-) thymocytes. Development of ovarian follicles seems to be impaired, resulting in female sterility. Similar to mice with the Rb mutation, the p27(-/-) mice often develop pituitary tumors spontaneously. The retinas of the mutant mice show a disturbed organization of the normal cellular layer pattern. These findings indicate that p27(Kip1) acts to regulate the growth of a variety of cells. Unexpectedly, the cell cycle arrest mediated by TGF beta, rapamycin, or contact inhibition remained intact in p27(-/-) cells, suggesting that p27(Kip1) is not required in these pathways.	NIPPON ROCHE RES CTR,DEPT TOXICOL & PATHOL,KAMAKURA,KANAGAWA 247,JAPAN; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED GENET & MOL MICROBIOL,ST LOUIS,MO 63110	Roche Holding; Howard Hughes Medical Institute; Washington University (WUSTL)	Nakayama, K (corresponding author), NIPPON ROCHE RES CTR,DEPT BIOL,KAMAKURA,KANAGAWA 247,JAPAN.			Shirane, Michiko/0000-0002-8297-9245				AHUJA SS, 1993, J IMMUNOL, V150, P3109; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BULLRICH F, 1995, CANCER RES, V55, P1199; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHAN LC, 1992, CANCER GENET CYTOGEN, V62, P47, DOI 10.1016/0165-4608(92)90037-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECKER HJH, 1990, CANCER GENET CYTOGEN, V46, P135, DOI 10.1016/0165-4608(90)90021-2; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GILLETT C, 1994, CANCER RES, V54, P1812; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KAWAMATA N, 1995, CANCER RES, V55, P2266; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE KP, 1979, TOXICOL APPL PHARM, V51, P219, DOI 10.1016/0041-008X(79)90464-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MORI T, 1994, CANCER RES, V54, P3396; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHINOHARA M, 1994, BLOOD, V84, P3781; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAHL SM, 1989, IMMUNOL TODAY, V10, P258, DOI 10.1016/0167-5699(89)90136-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	65	1362	1400	0	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1996	85	5					707	720		10.1016/S0092-8674(00)81237-4	http://dx.doi.org/10.1016/S0092-8674(00)81237-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646779	Bronze			2022-12-24	WOS:A1996UP34400011
J	Feller, MB; Wellis, DP; Stellwagen, D; Werblin, FS; Shatz, CJ				Feller, MB; Wellis, DP; Stellwagen, D; Werblin, FS; Shatz, CJ			Requirement for cholinergic synaptic transmission in the propagation of spontaneous retinal waves	SCIENCE			English	Article							GABA-LIKE IMMUNOREACTIVITY; GANGLION-CELL DENDRITES; MAMMALIAN RETINA; CAT RETINA; ACETYLCHOLINE; RESPONSES; BUNGAROTOXIN; PATTERNS; SYSTEMS	Highly correlated neural activity in the form of spontaneous waves of action potentials is present in the developing retina weeks before vision. Optical imaging revealed that these waves consist of spatially restricted domains of activity that form a mosaic pattern over the entire retinal ganglion cell layer. Whole-cell recordings indicate that wave generation requires synaptic activation of neuronal nicotinic acetylcholine receptors on ganglion cells. The only cholinergic cells in these immature retinas are a uniformly distributed, bistratified population of amacrine cells, as assessed by antibodies to choline acetyltransferase. The results indicate that the major source of synaptic input to retinal ganglion cells is a system of cholinergic amacrine cells, whose activity is required for wave propagation in the developing retina.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Feller, MB (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,221 LIFE SCI ADDIT,BERKELEY,CA 94720, USA.				NATIONAL EYE INSTITUTE [R01EY000561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NEI NIH HHS [EY00561] Funding Source: Medline; NIGMS NIH HHS [GM07048] Funding Source: Medline; NIMH NIH HHS [NIMH 48108] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AIZENMAN E, 1990, BRAIN RES, V517, P209, DOI 10.1016/0006-8993(90)91028-F; BODNARENKO SR, 1993, NATURE, V364, P144, DOI 10.1038/364144a0; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DONG CJ, 1994, J NEUROSCI, V14, P2648; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HAMASSAKIBRITTO DE, 1994, J COMP NEUROL, V347, P161, DOI 10.1002/cne.903470202; HEAULME M, 1986, BRAIN RES, V384, P224, DOI 10.1016/0006-8993(86)91158-3; Kandler Karl, 1995, Current Opinion in Neurobiology, V5, P98, DOI 10.1016/0959-4388(95)80093-X; KEYSER KT, 1993, J NEUROSCI, V13, P442; KITTILA CA, 1995, J NEUROPHYSIOL, V73, P703, DOI 10.1152/jn.1995.73.2.703; LEBEDA FJ, 1982, J NEUROPHYSIOL, V48, P622, DOI 10.1152/jn.1982.48.3.622; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8390, DOI 10.1073/pnas.83.21.8390; LIPPE WR, 1994, J NEUROSCI, V14, P1486, DOI 10.1523/JNEUROSCI.14-03-01486.1994; LUKASIEWICZ PD, 1990, J NEUROSCI, V10, P210; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MASLAND RH, 1976, J NEUROPHYSIOL, V39, P1220, DOI 10.1152/jn.1976.39.6.1220; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; Mooney R., UNPUB; MOSINGER JL, 1986, EXP EYE RES, V42, P631, DOI 10.1016/0014-4835(86)90052-7; ODONOVAN M, 1992, J EXP ZOOL, V261, P261, DOI 10.1002/jez.1402610306; PENN AA, 1994, J NEUROSCI, V14, P3805; Pourcho RG, 1980, BRAIN RES, V198, P33; RORIG B, 1994, NEUROREPORT, V5, P1197; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; Sernagor E., 1994, Society for Neuroscience Abstracts, V20, P1470; SERNAGOR E, 1994, INVEST OPHTH VIS SCI, V35, P2125; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SPITZER NC, 1994, TRENDS NEUROSCI, V17, P115, DOI 10.1016/0166-2236(94)90120-1; TOOTLE JS, 1993, J NEUROPHYSIOL, V69, P1645, DOI 10.1152/jn.1993.69.5.1645; von der Malsburg C, 1973, Kybernetik, V14, P85; WASSLE H, 1989, J COMP NEUROL, V279, P43, DOI 10.1002/cne.902790105; WELLIS DP, UNPUB; Wong R O, 1993, Curr Opin Neurobiol, V3, P595, DOI 10.1016/0959-4388(93)90061-3; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; WONG ROL, 1995, J NEUROSCI, V15, P2696; WONG ROL, 1995, NATURE, V374, P716, DOI 10.1038/374716a0; WOTRING VE, 1995, NEUROSCIENCE, V67, P293, DOI 10.1016/0306-4522(95)00011-7; Yazulla S, 1985, Neurosci Res Suppl, V2, pS147, DOI 10.1016/0921-8696(85)90014-3; YUSTE R, 1995, NEURON, V14, P7, DOI 10.1016/0896-6273(95)90236-8; ZHANG ZW, 1994, NEURON, V12, P167, DOI 10.1016/0896-6273(94)90161-9; ZHANG ZW, 1991, BRIT J PHARMACOL, V102, P19, DOI 10.1111/j.1476-5381.1991.tb12125.x	47	419	425	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1996	272	5265					1182	1187		10.1126/science.272.5265.1182	http://dx.doi.org/10.1126/science.272.5265.1182			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638165				2022-12-24	WOS:A1996UM88900054
J	Elliott, P; Stamler, J; Nichols, R; Dyer, AR; Stamler, R; Kesteloot, H; Marmot, M				Elliott, P; Stamler, J; Nichols, R; Dyer, AR; Stamler, R; Kesteloot, H; Marmot, M			Intersalt revisited: Further analyses of 24 hour sodium excretion and blood pressure within and across populations	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIETARY SALT; OBSERVATIONAL DATA; REDUCTION; POTASSIUM; CORONARY	Objectives-To assess further the relation in Intersalt of 24 hour urinary sodium to blood pressure of individuals and populations, and the difference it blood pressure from young adulthood into middle age. Design-Standardised cross sectional study within and across populations. Setting-52 population samples in 32 countries. Subjects-10 074 men and women aged 20-59. Main outcome measures-Association of sodium and blood pressure from within population and cross population multiple linear regression analyses with multivariate correction for regression dilution bias. Relation of sample median daily urinary sodium excretion to difference in blood pressure with age. Results-In within population analyses (n=10 074), individual 24 hour urinary sodium excretion higher by 100 mmol (for example, 170 v 70 mmol) was associated with systolic/diastolic blood pressure higher on average by 3/0 to 6/3 mm Hg (with and without body mass in analyses). Associations were larger at ages 40-59. In cross population analyses (n=52), sample median 24 hour sodium excretion higher by 100 mmol was associated with median systolic/diastolic pressure higher on average by 5-7/2-4 mm Hg, and estimated mean difference in systolic/diastolic pressure at age 55 compared with age 25 greater by 10-11/6 mm Hg. Conclusions-The strong, positive association of urinary sodium with systolic pressure of individuals concurs with Intersalt cross population findings and results of other studies. Higher urinary sodium is also associated with substantially greater differences in blood pressure in middle age compared with young adulthood. These results support recommendations for reduction of high salt intake in populations for prevention and control of adverse blood pressure levels.	NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, CHICAGO, IL 60611 USA; ST RAPHAEL UNIV HOSP, DEPT EPIDEMIOL, LOUVAIN, BELGIUM; UNIV LONDON UNIV COLL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND	Northwestern University; University of London; University College London; UCL Medical School	Elliott, P (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON W2 1PG, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; Department of Health, 1994, 46 DEP HLTH CARD REV; DYER AR, 1994, AM J EPIDEMIOL, V139, P927, DOI 10.1093/oxfordjournals.aje.a117099; DYER AR, 1989, J HUM HYPERTENS, V3, P299; DYER AR, 1995, NAT MED, V1, P994, DOI 10.1038/nm1095-994; DYER AR, 1994, HYPERTENSION, V23, P729, DOI 10.1161/01.HYP.23.6.729; DYER AR, 1994, AM J EPIDEMIOL, V139, P940, DOI 10.1093/oxfordjournals.aje.a117100; ELLIOTT P, 1988, BRIT MED J, V297, P319; ELLIOTT P, 1989, J HUM HYPERTENS, V3, P289; ELLIOTT P, 1988, CONTROL CLIN TRIALS, V9, pS1, DOI 10.1016/0197-2456(88)90028-1; ELLIOTT P, 1989, J HUM HYPERTENS, V3, P323; ELLIOTT P, 1991, HYPERTENSION, V17, pI3, DOI 10.1161/01.HYP.17.1_Suppl.I3; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GELEIJNSE JM, 1994, BRIT MED J, V309, P436, DOI 10.1136/bmj.309.6952.436; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; JOOSSENS JV, 1994, J AM COLL NUTR, V13, P179; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; KLEINBAUM DG, 1987, APPLIED REGRESSION A; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LIU K, 1988, AM J EPIDEMIOL, V127, P864, DOI 10.1093/oxfordjournals.aje.a114870; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; *NAT RES COUNC COM, 1989, DIET HLTH IMPL RED C, V15, P413; PAFFENBARGER RS, 1968, AM J EPIDEMIOL, V88, P25, DOI 10.1093/oxfordjournals.aje.a120864; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; PRIOR IAM, 1980, EPIDEMIOLOGY ARTERIA, P243; ROSE G, 1986, J HYPERTENS, V4, P781; SANCHEZCASTILLO CP, 1987, CLIN SCI, V72, P95, DOI 10.1042/cs0720095; Snedecor GW, 1980, STAT METHODS, V7th; STAMLER J, 1989, HYPERTENSION, V14, P570, DOI 10.1161/01.HYP.14.5.570; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; STAMLER J, 1960, PATHOGENESIS ESSENTI, P67; STAMLER J, 1967, LECTURES PREVENTIVE, P242; STAMLER J, 1979, HYPERTENSION UPDATE, P23; *US DHHS, 1991, DHHS PUBL; [No title captured]; [No title captured]	39	631	648	1	39	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 18	1996	312	7041					1249	1253		10.1136/bmj.312.7041.1249	http://dx.doi.org/10.1136/bmj.312.7041.1249			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634612	Green Published			2022-12-24	WOS:A1996UM40400016
J	Feng, Y; Broder, CC; Kennedy, PE; Berger, EA				Feng, Y; Broder, CC; Kennedy, PE; Berger, EA			HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BACTERIOPHAGE-T7 RNA-POLYMERASE; MOLECULAR-CLONING; HUMAN CD4; REGULATED EXPRESSION; CD4-MEDIATED FUSION; MEMBRANE-FUSION; VACCINIA VIRUS; HUMAN HOMOLOG; MURINE CELLS	A cofactor for HIV-1 (human immunodeficiency virus-type 1) fusion and entry was identified with the use of a novel functional complementary DNA (cDNA) cloning strategy. This protein, designated ''fusin,'' is a putative G protein-coupled receptor with seven transmembrane segments. Recombinant fusin enabled CD4-expressing nonhuman cell types to support HIV-1 Env-mediated cell fusion and HIV-1 infection. Antibodies to fusin blocked cell fusion and infection with normal CD4-positive human target cells. Fusin messenger RNA levels correlated with HIV-1 permissiveness in diverse human cell types. Fusin acted preferentially for T cell line-tropic isolates, in comparison to its activity with macrophage-tropic HIV-1 isolates.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Broder, Christopher/E-1169-2013					ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992; ALKHATIB G, IN PRESS J VIROL; [Anonymous], COMMUNICATION; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BERGER EA, 1996, KEYST S CELL BIOL VI, P8; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHAKRABARTI SK, COMMUNICATION; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; Cho SG, 1995, AIDS RES HUM RETROV, V11, P1487, DOI 10.1089/aid.1995.11.1487; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DRAGIC T, 1993, J VIROL, V67, P2355, DOI 10.1128/JVI.67.4.2355-2359.1993; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; DUNN CS, 1995, J GEN VIROL, V76, P1327, DOI 10.1099/0022-1317-76-6-1327; EARL PL, 1991, CURRENT PROTOCOL S15, V2; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; FENG Y, 1996, KEYST S IMM HIV INF, P21; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GILLESPIE FP, 1993, MOL CELL BIOL, V13, P2952, DOI 10.1128/MCB.13.5.2952; HANNA Z, 1994, MOL CELL BIOL, V14, P1084, DOI 10.1128/MCB.14.2.1084; HARRINGTON RD, 1993, J VIROL, V67, P5939, DOI 10.1128/JVI.67.10.5939-5947.1993; HERZOG H, 1993, DNA CELL BIOL, V12, P465, DOI 10.1089/dna.1993.12.465; HOXIE JA, 1988, J VIROL, V62, P2557, DOI 10.1128/JVI.62.8.2557-2568.1988; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOENIG S, 1989, P NATL ACAD SCI USA, V86, P2443, DOI 10.1073/pnas.86.7.2443; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Planelles Vincente, 1993, P17; RAMARLI D, 1993, AIDS RES HUM RETROV, V9, P1269, DOI 10.1089/aid.1993.9.1269; Richardson TM, 1996, J VIROL, V70, P753, DOI 10.1128/JVI.70.2.753-762.1996; SNYDER BW, 1995, MOL REPROD DEV, V40, P419, DOI 10.1002/mrd.1080400405; TRONO D, 1994, CLIN LAB MED, V14, P203, DOI 10.1016/S0272-2712(18)30375-5; VALENTIN A, 1994, J VIROL, V68, P6684, DOI 10.1128/JVI.68.10.6684-6689.1994; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679	44	3535	3779	1	202	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					872	877		10.1126/science.272.5263.872	http://dx.doi.org/10.1126/science.272.5263.872			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629022				2022-12-24	WOS:A1996UK75700059
J	Bochkarev, A; Barwell, JA; Pfuetzner, RA; Bochkareva, E; Frappier, L; Edwards, AM				Bochkarev, A; Barwell, JA; Pfuetzner, RA; Bochkareva, E; Frappier, L; Edwards, AM			Crystal structure of the DNA-Binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA	CELL			English	Article							NUCLEAR ANTIGEN EBNA-1; REPLICATION ORIGIN; HUMAN-CELLS; SITES; ORIP; PLASMIDS; ENHANCER; REFINEMENT; TARGET	The Epstein-Barr virus nuclear antigen 1 (EBNA1) protein binds to and activates DNA replication from oriP, the latent origin of DNA replication in Epstein-Barr virus. The crystal structure of the DNA-binding domain of EBNA1 bound to an 18 bp binding site was solved at 2.4 Angstrom resolution. EBNA1 comprises two domains, a flanking and a core domain. The flanking domain, which includes a helix that projects into the major groove and an extended chain that travels along the minor groove, makes all of the sequence-determining contacts with the DNA. The core domain, which is structurally homologous to the complete DNA-binding domain of the bovine papilloma virus E2 protein, makes no direct contacts with the DNA bases. A model for origin unwinding is proposed that incorporates the known biochemical and structural features of the EBNA1-origin interaction.	MCMASTER UNIV,DEPT PATHOL,CANC RES GRP,INST MOLEC BIOL & BIOTECHNOL,HAMILTON,ON L8N 3Z5,CANADA	McMaster University				Edwards, Aled/0000-0002-4782-6016				AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FUREY W, 1995, MACROMOLECULAR CRYST; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEIMAN Z, 1994, CURR OPIN GENE DEV, V4, P185; Kornberg A., 1992, DNA REPLICATION; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	30	183	192	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					791	800		10.1016/S0092-8674(00)81056-9	http://dx.doi.org/10.1016/S0092-8674(00)81056-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625416	Bronze			2022-12-24	WOS:A1996TZ99000016
J	Lewis, M; Chang, G; Horton, NC; Kercher, MA; Pace, HC; Schumacher, MA; Brennan, RG; Lu, PZ				Lewis, M; Chang, G; Horton, NC; Kercher, MA; Pace, HC; Schumacher, MA; Brennan, RG; Lu, PZ			Crystal structure of the lactose operon repressor and its complexes with DNA and inducer	SCIENCE			English	Article							LAC REPRESSOR; ESCHERICHIA-COLI; MOLECULAR-DYNAMICS; RNA-POLYMERASE; OPERATOR; PROTEIN; MUTATIONS; SEQUENCE; REGION; GENE	The lac operon of Escherichia coli is the paradigm for gene regulation. Its key component is the lac repressor, a product of the lad gene. The three-dimensional structures of the intact lac repressor, the lac repressor bound to the gratuitous inducer isopropyl-beta-D-1-thiogalactoside (IPTG) and the lac repressor complexed with a 21-base pair symmetric operator DNA have been determined. These three structures show the conformation of the molecule in both the induced and repressed states and provide a framework for understanding a wealth of biochemical and genetic information. The DNA sequence of the lac operon has three lac repressor recognition sites in a stretch of 500 base pairs. The crystallographic structure of the complex with DNA suggests that the tetrameric repressor functions synergistically with catabolite gene activator protein (CAP) and participates in the quaternary formation of repression loops in which one tetrameric repressor interacts simultaneously with two sites on the genomic DNA.	UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	University of Pennsylvania; University of Pennsylvania; Oregon Health & Science University	Lewis, M (corresponding author), UNIV PENN,JOHNSON RES FDN,PHILADELPHIA,PA 19104, USA.		Horton, Nancy C/E-7881-2011	Horton, Nancy C/0000-0003-2710-8284; Brennan, Richard/0000-0001-7647-485X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044617] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR06017] Funding Source: Medline; NIGMS NIH HHS [GM44617, 2-T32-GM082745] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P207; ALBERTI S, 1991, NEW BIOL, V3, P57; BELLOMY GR, 1988, BIOCHEMISTRY-US, V27, P3900, DOI 10.1021/bi00411a002; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BEYREUTHER K, 1973, P NATL ACAD SCI USA, V70, P3576, DOI 10.1073/pnas.70.12.3576; Bourgeois S, 1976, Adv Protein Chem, V30, P1, DOI 10.1016/S0065-3233(08)60478-7; BRENOWITZ M, 1991, BIOCHEMISTRY-US, V30, P5986, DOI 10.1021/bi00238a024; BRENOWITZ M, 1991, J BIOL CHEM, V286, P1281; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURSTEIN C, 1965, BIOCHIM BIOPHYS ACTA, V95, P634, DOI 10.1016/0005-2787(65)90517-4; CARUTHERS MH, 1980, ACCOUNTS CHEM RES, V13, P155, DOI 10.1021/ar50149a005; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG G, 1994, ACTA CRYSTALLOGR D, V50, P667, DOI 10.1107/S0907444994000727; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHEN J, 1994, J BIOL CHEM, V269, P12482; CHEN J, 1994, BIOCHEMISTRY-US, V33, P8728, DOI 10.1021/bi00195a014; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; EISMANN ER, 1990, J MOL BIOL, V213, P763, DOI 10.1016/S0022-2836(05)80262-1; FAIRMAN R, 1995, PROTEIN SCI, V4, P1457, DOI 10.1002/pro.5560040803; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FICKERT R, 1992, J MOL BIOL, V226, P59, DOI 10.1016/0022-2836(92)90124-3; FLASHNER Y, 1988, P NATL ACAD SCI USA, V85, P8968, DOI 10.1073/pnas.85.23.8968; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GEISLER N, 1978, FEBS LETT, V87, P215, DOI 10.1016/0014-5793(78)80335-4; GILBERT W, 1973, P NATL ACAD SCI USA, V70, P3581, DOI 10.1073/pnas.70.12.3581; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GILBERT W, 1975, PROTEIN LIGAND INTER, P193; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAUROWITZ F, 1938, HOPPESEYLERS Z PHYSL, V254, P268; HUDSON JM, 1990, J MOL BIOL, V214, P381, DOI 10.1016/0022-2836(90)90188-R; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JACOB F, 1961, COLD SPRING HARB SYM, V26, P193, DOI 10.1101/SQB.1961.026.01.024; JAREMA MAC, 1981, P NATL ACAD SCI-BIOL, V78, P2707, DOI 10.1073/pnas.78.5.2707; JOBE A, 1972, J MOL BIOL, V69, P397, DOI 10.1016/0022-2836(72)90253-7; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIM R, 1982, COLD SPRING HARB SYM, V47, P451, DOI 10.1101/SQB.1983.047.01.053; KORNBERG RD, 1981, SCI AM, V244, P48, DOI 10.1038/scientificamerican0281-52; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWIS MA, UNPUB; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; Miller J. H., 1980, OPERON; MILLER JH, 1984, J MOL BIOL, V180, P205, DOI 10.1016/0022-2836(84)90438-8; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; MILLER JH, 1970, LACTOSE OPERON; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MONOD J, 1942, THESIS U PARIS; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MULLERHILL B, 1964, J MOL BIOL, V10, P303, DOI 10.1016/S0022-2836(64)80049-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OTWINOWSKI Z, UNPUB HKL PROGRAM SU; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; PERUTZ MF, 1964, NATURE, V203, P687, DOI 10.1038/203687a0; PLATT T, 1973, J BIOL CHEM, V248, P110; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; ROYER CA, 1990, BIOCHEMISTRY-US, V29, P4959, DOI 10.1021/bi00472a028; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SADLER JR, 1983, P NATL ACAD SCI-BIOL, V80, P6785, DOI 10.1073/pnas.80.22.6785; SCHLEIF R, 1988, SCIENCE, V240, P127, DOI 10.1126/science.3353710; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHIGETA R, 1994, ACTA CRYSTALLOGR D, V50, P71, DOI 10.1107/S0907444993009382; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIMONS A, 1984, P NATL ACAD SCI-BIOL, V81, P1624, DOI 10.1073/pnas.81.6.1624; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; Voet D VJ, 1990, BIOCHEMISTRY; WADEJARDETZKY N, 1978, J MOL BIOL, V128, P259; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; ZUBAY G, 1970, P NATL ACAD SCI USA, V66, P104, DOI 10.1073/pnas.66.1.104	75	651	666	1	184	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1247	1254		10.1126/science.271.5253.1247	http://dx.doi.org/10.1126/science.271.5253.1247			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638105				2022-12-24	WOS:A1996TX69500027
J	White, K; Tahaoglu, E; Steller, H				White, K; Tahaoglu, E; Steller, H			Cell killing by the Drosophila gene reaper	SCIENCE			English	Article							DEATH	The reaper gene (rpr) is important for the activation of apoptosis in Drosophila. To investigate whether rpr expression is sufficient to induce apoptosis, transgenic flies were generated that express rpr complementary DNA or the rpr open reading frame in cells that normally live. Transcription of rpr from a heat-inducible promoter rapidly caused widespread ectopic apoptosis and organismal death. Ectopic overexpression of rpr in the developing retina resulted in eye ablation. The occurrence of cell death was highly sensitive to the dosage of the transgene. Because cell death induced by the protein encoded by rpr(RPR)could be blocked by the baculovirus p35 protein, RPR appears to activate a death program mediated by a ced-3/ICE (interleukin-1 converting enzyme)-like protease.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	White, K (corresponding author), MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129, USA.		White, Kristin/D-7936-2013					ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CLEM RJ, 1994, APOPTOSIS, V2, P89; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; NEWCOMBCARBOY C, UNPUB; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; SONG HY, 1994, J BIOL CHEM, V269, P22492; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WHITE K, 1995, TRENDS CELL BIOL, V5, P74, DOI 10.1016/S0962-8924(00)88950-3; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	20	326	340	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					805	807		10.1126/science.271.5250.805	http://dx.doi.org/10.1126/science.271.5250.805			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628996				2022-12-24	WOS:A1996TU69400045
J	Brezina, V; Orekhova, IV; Weiss, KR				Brezina, V; Orekhova, IV; Weiss, KR			Functional uncoupling of linked neurotransmitter effects by combinatorial convergence	SCIENCE			English	Article							CHOLINERGIC MOTOR NEURONS; RADULA CLOSER MUSCLE; PEPTIDE COTRANSMITTERS; APLYSIA-CALIFORNICA; NEUROPEPTIDE COTRANSMITTERS; ARC MUSCLE; K-CURRENT; CONTRACTIONS; MODULATION; NEUROMODULATORS	Physiological signaling pathways both diverge and converge-a single neurotransmitter can have multiple effects acid multiple transmitters can have the same effects-in the same target cell. Divergence couples the effects of a transmitter together in a relatively fixed ratio. Different physiological circumstances may require a different ratio, however, the coupling must be made modifiable. This can be achieved through convergence. If two transmitters couple the effects in different ratios, then combinations of the transmitters can yield all intermediate ratios of the effects, thus functionally uncoupling them. This mechanism is analyzed in a well-understood, simple invertebrate neuromuscular circuit.	MT SINAI SCH MED,FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai	Brezina, V (corresponding author), MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,BOX 1218,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000987, R01MH036730, R37MH036730] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM320099] Funding Source: Medline; NIMH NIH HHS [MH36730, K21 MH00987] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLOOM FE, 1988, FASEB J, V2, P32, DOI 10.1096/fasebj.2.1.2891578; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; Brezina V., 1995, Biophysical Journal, V68, pA277; Brezina V., 1993, Society for Neuroscience Abstracts, V19, P1262; BREZINA V, 1995, J NEUROPHYSIOL, V74, P54, DOI 10.1152/jn.1995.74.1.54; BREZINA V, 1994, J NEUROSCI, V14, P4412; BREZINA V, 1994, J NEUROSCI, V14, P4393; BREZINA V, 1995, J NEUROPHYSIOL, V73, P993, DOI 10.1152/jn.1995.73.3.993; BYGRAVE FL, 1995, FASEB J, V9, P1297, DOI 10.1096/fasebj.9.13.7557019; CHURCH PJ, 1994, J NEUROPHYSIOL, V72, P1794, DOI 10.1152/jn.1994.72.4.1794; COHEN JL, 1978, J NEUROPHYSIOL, V41, P157, DOI 10.1152/jn.1978.41.1.157; CROPPER EC, 1991, PEPTIDES, V12, P683, DOI 10.1016/0196-9781(91)90120-E; CROPPER EC, 1994, J NEUROPHYSIOL, V72, P2181, DOI 10.1152/jn.1994.72.5.2181; CROPPER EC, 1990, BRAIN RES, V522, P176, DOI 10.1016/0006-8993(90)91598-B; CROPPER EC, 1988, P NATL ACAD SCI USA, V85, P6177, DOI 10.1073/pnas.85.16.6177; CROPPER EC, 1987, P NATL ACAD SCI USA, V84, P3486, DOI 10.1073/pnas.84.10.3486; CROPPER EC, 1990, P NATL ACAD SCI USA, V87, P933, DOI 10.1073/pnas.87.3.933; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HOOPER SL, 1994, BRAIN RES, V657, P337, DOI 10.1016/0006-8993(94)90988-1; HOOPER SL, 1994, NEUROSCI LETT, V179, P167, DOI 10.1016/0304-3940(94)90960-1; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; KUPFERMANN I, 1991, PHYSIOL REV, V71, P683, DOI 10.1152/physrev.1991.71.3.683; KUPFERMANN I, IN PRESS NEURONS NET; LLOYD PE, 1984, P NATL ACAD SCI-BIOL, V81, P2934, DOI 10.1073/pnas.81.9.2934; LLOYD PE, 1986, TRENDS NEUROSCI, V9, P428, DOI 10.1016/0166-2236(86)90138-4; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PROBST WC, 1994, P NATL ACAD SCI USA, V91, P8487, DOI 10.1073/pnas.91.18.8487; SUSSWEIN AJ, 1978, J COMP PHYSIOL, V123, P31, DOI 10.1007/BF00657341; WEISS KR, 1979, J NEUROPHYSIOL, V42, P791, DOI 10.1152/jn.1979.42.3.791; WEISS KR, 1978, J NEUROPHYSIOL, V41, P181, DOI 10.1152/jn.1978.41.1.181; WEISS KR, 1993, J PHYSIOLOGY-PARIS, V87, P141, DOI 10.1016/0928-4257(93)90025-O; WHIM MD, 1989, P NATL ACAD SCI USA, V86, P9034, DOI 10.1073/pnas.86.22.9034; WHIM MD, 1990, J NEUROSCI, V10, P3313; 1992, TRENDS BIOCH SCI, V17	34	70	71	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					806	810		10.1126/science.273.5276.806	http://dx.doi.org/10.1126/science.273.5276.806			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670423				2022-12-24	WOS:A1996VB42900046
J	Yokoi, M; Kobayashi, K; Manabe, T; Takahashi, T; Sakaguchi, I; Katsuura, G; Shigemoto, R; Ohishi, H; Nomura, S; Nakamura, K; Nakao, K; Katsuki, M; Nakanishi, S				Yokoi, M; Kobayashi, K; Manabe, T; Takahashi, T; Sakaguchi, I; Katsuura, G; Shigemoto, R; Ohishi, H; Nomura, S; Nakamura, K; Nakao, K; Katsuki, M; Nakanishi, S			Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2	SCIENCE			English	Article							LONG-TERM POTENTIATION; METABOTROPIC GLUTAMATE RECEPTORS; GUINEA-PIG; SYNAPTIC TRANSMISSION; TARGETED DISRUPTION; 2 FORMS; RAT; LOCALIZATION; MODULATION; RESPONSES	Subtype 2 of the metabotropic glutamate receptor (mGluR2) is expressed in the presynaptic elements of hippocampal messy fiber-GAS synapses. Knockout mice deficient in mGluR2 showed no histological changes and no alterations in basal synaptic transmission, paired-pulse facilitation, or tetanus-induced long-term potentiation (LTP) al the messy fiber-CA3 synapses. Long-term depression (LTD) induced by low-frequency stimulation, however, was almost fully abolished. The mutant mice performed normally in water maze learning tasks. Thus, the presynaptic mGluR2 is essential for inducing LTD at the mossy fiber-CA3 synapses, but this hippocampal LTD does not seem to be required for spatial learning.	KYOTO UNIV, FAC MED, DEPT BIOL SCI, KYOTO 606, JAPAN; UNIV TOKYO, FAC MED, BRAIN RES INST, DEPT NEUROPHYSIOL, TOKYO 113, JAPAN; SHIONOGI & CO LTD, ABURAHI LABS, SHIGA 52034, JAPAN; KYOTO UNIV, FAC MED, DEPT MORPHOL BRAIN SCI, KYOTO 606, JAPAN; KYOTO UNIV, COLL MED TECHNOL, KYOTO 606, JAPAN; KYUSHU UNIV, MED INST BIOREGULAT, FUKUOKA 812, JAPAN	Kyoto University; University of Tokyo; Shionogi & Company Limited; Kyoto University; Kyoto University; Kyushu University			Kobayashi, Katsunori/V-5326-2018; Takahashi, Tomoyuki/G-5951-2015; Shigemoto, Ryuichi/E-3628-2013	Kobayashi, Katsunori/0000-0001-8537-8448; Takahashi, Tomoyuki/0000-0002-8771-7666; Shigemoto, Ryuichi/0000-0001-8761-9444				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Kobayashi K, 1996, SCIENCE, V273, P648, DOI 10.1126/science.273.5275.648; LANTHORN TH, 1984, BRAIN RES, V290, P174, DOI 10.1016/0006-8993(84)90750-9; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MANZONI OJ, 1995, NEUROPHARMACOLOGY, V34, P965, DOI 10.1016/0028-3908(95)00060-J; MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X; SHIGEMOTO R, 1995, INT BRAIN RES ORG AB, V4; SHIGEMOTO R, 1995, SOC NEUR ABSTR, V21, P33820; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	24	291	313	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1996	273	5275					645	647		10.1126/science.273.5275.645	http://dx.doi.org/10.1126/science.273.5275.645			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662555				2022-12-24	WOS:A1996VA24900047
J	Cuervo, AM; Dice, JF				Cuervo, AM; Dice, JF			A receptor for the selective uptake and degradation of proteins by lysosomes	SCIENCE			English	Article							RAT-LIVER LYSOSOMES; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE	Multiple pathways of protein degradation operate within cells, A selective protein import pathway exists for the uptake and degradation of particular cytosolic proteins by lysosomes. Here, the lysosomal membrane glycoprotein LGP96 was identified as a receptor for the selective import and degradation of proteins within lysosomes. Specific substrates of this proteolytic pathway bound to the cytosolic tail of a 96-kilodalton lysosomal membrane protein in two different binding assays, Overexpression of human LGP96 in Chinese hamster ovary cells increased the activity of the selective lysosomal proteolytic pathway in vivo and in vitro.	TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111	Tufts University				Cuervo, Ana Maria/0000-0002-0771-700X	NATIONAL INSTITUTE ON AGING [R37AG006116, R01AG006116] Funding Source: NIH RePORTER; NIA NIH HHS [AG06116] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANIENTO F, 1993, J BIOL CHEM, V268, P10463; AUTERI JS, 1983, J CELL PHYSL, V115, P159; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; CUERVO AM, UNPUB; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; NOGUCHI Y, 1989, BIOCHEM BIOPH RES CO, V164, P1113, DOI 10.1016/0006-291X(89)91784-1; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; TERLECKY L, UNPUB; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1994, EXPERIENTIA, V50, P1021, DOI 10.1007/BF01923456	15	667	696	4	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1996	273	5274					501	503		10.1126/science.273.5274.501	http://dx.doi.org/10.1126/science.273.5274.501			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8662539				2022-12-24	WOS:A1996UY98300041
J	Noll, KS; Johnson, RE; Lane, AL; Domingue, DL; Weaver, HA				Noll, KS; Johnson, RE; Lane, AL; Domingue, DL; Weaver, HA			Detection of ozone on Ganymede	SCIENCE			English	Article							ION-BOMBARDMENT; SATELLITES; LIFE; REFLECTANCE; SPECTRA; SEARCH; H2O	An absorption band at 260 nanometers on the trailing hemisphere of Ganymede, identified as the Hartley band of ozone (O-3), was measured with the Hubble Space Telescope, The column abundance of ozone, 4.5 x 10(16) per square centimeter, can be produced by ion impacts or by photochemical equilibrium with previously detected molecular oxygen (O-2). An estimated number density ratio of [O-3]/[O-2] approximate to 10(-4) to 10(-3) requires an atmospheric density orders of magnitude higher than upper limits from spacecraft occultation experiment's. Apparently, this O-2-O-3 ''atmosphere'' is trapped in Ganymede's surface ice, an inference consistent with the shift and broadening of the band compared with the gas-phase O-3 band.	UNIV VIRGINIA, CHARLOTTESVILLE, VA 22901 USA; CALTECH, JET PROP LAB, PASADENA, CA 91109 USA; LUNAR & PLANETARY INST, HOUSTON, TX 77058 USA; JOHNS HOPKINS UNIV, DEPT PHYS & ASTRON, BALTIMORE, MD 21218 USA	University of Virginia; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Johns Hopkins University	Noll, KS (corresponding author), SPACE TELESCOPE SCI INST, 3700 SAN MARTIN DR, BALTIMORE, MD 21218 USA.		Weaver, Harold A/D-9188-2016; Noll, Keith/C-8447-2012	Weaver, Harold A/0000-0003-0951-7762; 				BAGENAL F, 1992, GEOPHYS RES LETT, V19, P79, DOI 10.1029/92GL00070; BROADFOOT AL, 1979, SCIENCE, V204, P979, DOI 10.1126/science.204.4396.979; BURATTI BJ, 1990, ICARUS, V87, P339, DOI 10.1016/0019-1035(90)90138-Y; BURKE BF, 1986, NATURE, V322, P340, DOI 10.1038/322340a0; Calvin WM, 1996, GEOPHYS RES LETT, V23, P673, DOI 10.1029/96GL00450; CHAMBERLAIN J.W., 1987, THEORY PLANETARY ATM; CLARK RN, 1984, ICARUS, V58, P265, DOI 10.1016/0019-1035(84)90043-5; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; HAMILTON DC, 1981, J GEOPHYS RES-SPACE, V86, P8301, DOI 10.1029/JA086iA10p08301; Johnson R.E., 1990, ENERGETIC CHARGED PA, DOI [10.1007/978-3-642-48375-2, DOI 10.1007/978-3-642-48375-2]; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LANE AL, 1994, B AM ASTRON SOC, V26, P1159; LEGER A, 1994, ASTROPHYS SPACE SCI, V212, P327, DOI 10.1007/BF00984536; MATICH AJ, 1993, J PHYS CHEM-US, V97, P10539, DOI 10.1021/j100143a007; NELSON RM, 1987, ICARUS, V72, P358, DOI 10.1016/0019-1035(87)90180-1; NOLL KS, 1995, J GEOPHYS RES-PLANET, V100, P19057, DOI 10.1029/94JE03294; ROTTMAN GJ, COMMUNICATION; ROUSH TL, 1995, VOLATILES EARTH SOLA, V341, P143; SACK NJ, 1992, ICARUS, V100, P534, DOI 10.1016/0019-1035(92)90116-O; SACK NJ, 1991, J GEOPHYS RES-PLANET, V96, P17535, DOI 10.1029/91JE01681; SAGAN C, 1993, NATURE, V365, P715, DOI 10.1038/365715a0; SCHLEICHER DG, 1988, ASTROPHYS J, V331, P1058, DOI 10.1086/166622; SEDLACEK AJ, 1989, J PHYS CHEM-US, V93, P509, DOI 10.1021/j100339a004; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; TAUBE H, 1957, T FARADAY SOC, V53, P656, DOI 10.1039/tf9575300656; VAIDA V, 1989, J PHYS CHEM-US, V93, P506, DOI 10.1021/j100339a003	26	139	141	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 19	1996	273	5273					341	343		10.1126/science.273.5273.341	http://dx.doi.org/10.1126/science.273.5273.341			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY202	8662517				2022-12-24	WOS:A1996UY20200034
J	Kujala, UM; Sarna, S; Kaprio, J; Koskenvuo, M				Kujala, UM; Sarna, S; Kaprio, J; Koskenvuo, M			Hospital care in later life among former world-class Finnish athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; PHYSICAL-ACTIVITY; EXPECTANCY; MORTALITY; LONGEVITY; HEALTH	Objective.-To investigate the use of hospital care from all causes among former top-level athletes from different vigorous sports to determine whether health benefits or adverse effects have the greater influence. Design.-National, population-based cohort study with a 21-year follow-up. Setting.-Finland. Subjects.-A total of 2049 male athletes who had represented Finland during 1920 to 1965, and 1403 male controls classified healthy at 20 years of age. Main Outcome Measure.-In-hospital care from all causes was extracted from the national hospital discharge registry for the period 1970 through 1990 expressed as hospital days per person-yeats of exposure, Results.-Compared with controls, the rate ratios (RRs) for all-cause hospital days per person-years of exposure were lower in athletes from endurance sports (RR, 0.71; 95% confidence interval [CI], 0.70-0.73), mixed sports (including endurance and weight training) (RR, 0.86; 95% CI, 0.85-0.87), and power sports(RR, 0.95; 95% CI, 0.94-0.96) (P<.001 for all comparisons) after adjustment for age and occupational group. The lower RR among athletes from endurance sports and other sports involving aerobic activity was largely explained by lower rates of hospital care for heart disease, respiratory disease, and neoplasms, but not for musculoskeletal disorders, Conclusions.-Former elite athletes, particularly those in aerobic sports, use less hospital care. Other beneficial health habits are known to be associated with a physically active lifestyle.	UNIV HELSINKI,DEPT PUBL HLTH,HELSINKI,FINLAND; UNIV TURKU,DEPT PUBL HLTH,SF-20500 TURKU,FINLAND	University of Helsinki; University of Turku	Kujala, UM (corresponding author), UNIV HELSINKI,INST BIOMED,UNIT SPORTS & EXERCISE MED,TOOLO SPORTS HALL,MANNERHEIMINTIE 17,FIN-00250 HELSINKI,FINLAND.		Kaprio, Jaakko/A-1820-2008; Kujala, Urho/AAP-2547-2020	Kaprio, Jaakko/0000-0002-3716-2455; Sarna, Seppo/0000-0003-3458-1627; Kujala, Urho/0000-0002-9262-1992				ANTONOVSKY A, 1967, MILBANK FUND Q, V45, P31, DOI 10.2307/3348839; Astrand P.O., 1986, TXB WORK PHYSL PHYSL; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; *FINLAND CENTR STA, 1972, ALPH LIST OCC CLASS; FOGELHOLM M, 1994, MED SCI SPORT EXER, V26, P224, DOI 10.1249/00005768-199402000-00013; GORNICK M, 1993, HLTH AFF, V12, P999; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Howard D.R., 1992, J SPORT MANAGE, V6, DOI [10.1123/jsm.6.3.191, DOI 10.1123/JSM.6.3.191]; KAPRIO J, 1988, J CLIN EPIDEMIOL, V41, P139, DOI 10.1016/0895-4356(88)90088-1; KARVONEN MJ, 1974, MED SCI SPORT EXER, V6, P49; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; KOSKENVUO M, 1979, SOC SCI MED-MED SOC, V13, P691, DOI 10.1016/0271-7123(79)90114-7; KUJALA UM, 1995, ARTHRITIS RHEUM, V38, P539, DOI 10.1002/art.1780380413; KUJALA UM, 1994, BRIT MED J, V308, P231, DOI 10.1136/bmj.308.6923.231; KUJALA UM, 1994, METABOLISM, V43, P1255, DOI 10.1016/0026-0495(94)90219-4; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SARNA S, 1994, SPORTS MED, V17, P149, DOI 10.2165/00007256-199417030-00001; SARNA S, 1993, MED SCI SPORT EXER, V25, P237; SCHNOHR P, 1971, LANCET, V2, P1364; *WHO, 1977, WHO ICD9; *WHO, 1969, WHO ICD8; YAMAJI K, 1977, Journal of Human Ergology, V6, P15; 1990, EGRET STAT SOFTWARE	28	58	58	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					216	220		10.1001/jama.276.3.216	http://dx.doi.org/10.1001/jama.276.3.216			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667566				2022-12-24	WOS:A1996UW46900033
J	Mauskopf, JA; Paul, JE; Wichman, DS; White, AD; Tilson, HH				Mauskopf, JA; Paul, JE; Wichman, DS; White, AD; Tilson, HH			Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine - Implications for HIV screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; COST-BENEFIT-ANALYSIS; INFECTION; ANTIBODY; PERFORMANCE; KNOWLEDGE; CONTINUE; HEALTH; CARE	Objectives.-To estimate the economic impact of (1) treating pregnant women who are human immunodeficiency virus (HIV)-positive with zidovudine and (2) voluntary screening programs for pregnant women for HIV infection and offering treatment with zidovudine to those found to be HIV-positive. Main Outcome Measures.-Number of cases of pediatric HIV infection and costs of screening, zidovudine treatment, and pediatric HIV infection treatment. Design.-Health care costs associated with treatment of HIV-positive pregnant women and their newborns are estimated as the costs of zidovudine and its administration and the reduction in costs of treating pediatric HIV infection. The lifetime costs of pediatric HIV infection are derived from the published literature. Estimates of the reduction in maternal-to-fetal transmission rates are taken from the AIDS [acquired immunodeficiency syndrome] Clinical Trials Group (ACTG) Protocol 076, Costs of a voluntary screening program include costs of screening tests and counseling. Sensitivity and threshold analyses are performed to determine the impact of changes in input parameter values including zidovudine treatment costs, efficacy of treatment, costs of pediatric HIV infection, prevalence of HIV infection in pregnant women, screening test sensitivity and specificity, and pregnancy termination rates on the results. Results.-Assuming transmission rates are reduced from 25.5% to 8.3% as found in the ACTG 076 trial, treatment costs of $104 502 for 100 HIV-positive pregnant women and their newborns are offset by the reduction of $1 701 333 associated with fewer cases of pediatric HIV infection for a net savings of $1 596 831. The sensitivity and threshold analyses show that overall cost savings from treatment of HIV-positive pregnant women and their newborns are achieved for a wide range of possible maternal treatment costs, efficacy rates, and lifetime pediatric HIV treatment costs. In the base-case analysis for the voluntary screening program, overall cost savings are seen when the HIV prevalence rate among pregnant women is greater than 4.6 per 1000. However, this threshold prevalence rate is sensitive to changes in parameter values-especially pediatric HIV treatment costs, counseling costs, efficacy of treatment, and years of additional HIV treatment for the pregnant women. Conclusions.-Offering zidovudine treatment to pregnant women known to be HIV-positive will decrease the number of cases of pediatric HIV infection and reduce health care costs. Voluntary screening programs for pregnant women will further decrease the number of cases of pediatric HIV infection. The effect of a screening program on health care costs varies according to HIV prevalence and the costs associated with the screening program.			Mauskopf, JA (corresponding author), GLAXO WELLCOME INC,5 MOORE DR,RES TRIANGLE PK,NC 27709, USA.			Mauskopf, Josephine/0000-0002-6098-5548				ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BARBACCI MB, 1990, SEX TRANSM DIS, V17, P122, DOI 10.1097/00007435-199007000-00002; BARNHART H, 1995, 2 C RETR OPP INF WAS; BLOOM DE, 1991, SCIENCE, V252, P1798, DOI 10.1126/science.1829547; BRANDEAU ML, 1992, ARCH INTERN MED, V152, P2229, DOI 10.1001/archinte.152.11.2229; BROWN AE, 1995, NEW ENGL J MED, V332, P963, DOI 10.1056/NEJM199504063321419; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; *CDCP, 1994, NAT HIV SER SUMM RES, V3; CHAVEY WE, 1994, J FAM PRACTICE, V38, P249; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COZEN W, 1993, J ACQ IMMUN DEF SYND, V6, P95; Faden R R, 1993, Womens Health Issues, V3, P216, DOI 10.1016/S1049-3867(05)80067-2; FEHRS LJ, 1991, AM J PUBLIC HEALTH, V81, P619, DOI 10.2105/AJPH.81.5.619; FREDERICK T, 1994, PEDIATR INFECT DIS J, V13, P1091, DOI 10.1097/00006454-199412000-00004; GARRETT HM, 1994, RED BOOK, P48; GWINN M, 1992, J ACQ IMMUN DEF SYND, V5, P505; GWINN M, 1993, 9TH INT C AIDS BERL; HARDY LM, 1991, HIV SCREENING PREGNA; HAVENS PL, 1996, 3 C ANT OPP INF WASH; HEDLUND K, 1990, 6 INT C AIDS SAN FRA; HEGARTY JD, 1988, JAMA-J AM MED ASSOC, V260, P1901; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOLTGRAVE DR, 1993, ARCH INTERN MED, V153, P1225, DOI 10.1001/archinte.153.10.1225; HSIA DC, 1995, ARCH PEDIAT ADOL MED, V149, P489, DOI 10.1001/archpedi.1995.02170180019003; JOHNSTONE FD, 1990, BRIT MED J, V300, P23, DOI 10.1136/bmj.300.6716.23; LINDSAY MK, 1991, OBSTET GYNECOL, V77, P599; LINDSAY MK, 1989, OBSTET GYNECOL, V78, P678; LURIE P, 1994, JAMA-J AM MED ASSOC, V272, P1832, DOI 10.1001/jama.272.23.1832; MACDONALD KL, 1989, ANN INTERN MED, V110, P617, DOI 10.7326/0003-4819-110-8-617; MCCARTHY BD, 1993, ARCH INTERN MED, V153, P1107, DOI 10.1001/archinte.153.9.1107; PARROTT RH, 1991, J ACQ IMMUN DEF SYND, V4, P122; PHILLIPS KA, 1994, JAMA-J AM MED ASSOC, V271, P851, DOI 10.1001/jama.271.11.851; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P3567, DOI 10.1001/jama.261.24.3567; STEIN Z, 1993, AM J PUBLIC HEALTH, V83, P1379, DOI 10.2105/AJPH.83.10.1379; The European Collaborative Study, 1994, PEDIATRICS, V94, P815; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P3415, DOI 10.1001/jama.261.23.3415; *US BUR CENS, 1995, 1995 STAT ABSTR US, P494; VENTURA SJ, 1995, VITAL HLTH STAT S, V3; WEBER B, 1993, J VIROL METHODS, V44, P251, DOI 10.1016/0166-0934(93)90060-5; YOGEV R, 1992, MANAGEMENT HIV INFEC, P8; 1994, MMWR-MORBID MORTAL W, V43, P1	42	63	63	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					132	138		10.1001/jama.276.2.132	http://dx.doi.org/10.1001/jama.276.2.132			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656505				2022-12-24	WOS:A1996UV48500028
J	Chen, CR; Cheng, TO; Huang, T; Zhou, UL; Chen, JY; Huang, YG; Li, HJ				Chen, CR; Cheng, TO; Huang, T; Zhou, UL; Chen, JY; Huang, YG; Li, HJ			Percutaneous balloon valvuloplasty for pulmonic stenosis in adolescents and adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VALVE STENOSIS	Background Percutaneous balloon valvuloplasty has been the accepted first-line treatment for congenital pulmonic stenosis in children. Its efficacy in adolescents and adults is less well defined. Methods Between December 1985 and July 1995 we performed percutaneous pulmonic valvuloplasty with a single Inoue balloon catheter in 53 adolescent or adult patients 13 to 55 years of age (mean [+/-SD], 26+/-11). Follow-up studies were performed 0.2 to 9.8 years after the procedure (mean, 6.9+/-3.1) by Doppler echocardiography (in all the patients) and by cardiac catheterization and angiography (in nine patients). Results After balloon valvuloplasty, the systolic pressure gradient across the pulmonic valve decreased from 91+/-46 mm Hg to 38+/-32 mm Hg (P<0.001), and the diameter of the pulmonic-valve orifice increased from 8.9+/-3.6 mm to 17.4+/-4.6 mm (P<0.001). In the nine patients catheterized at followup, the systolic gradient decreased from 107+/-48 mm Hg before valvuloplasty to 50+/-29 mm Hg after valvuloplasty and to 30+/-16 mm Hg at follow-up (P<0.001 for the comparison of the gradient before and after valvuloplasty; P<0.001 for the comparison before valvuloplasty and at follow-up; and P<0.05 for the comparison after valvuloplasty and at followup). In the same nine patients, the diameter of the pulmonic valve, as measured by right ventricular angiography, increased from 8.3+/-1.4 mm before valvuloplasty to 17.2+/-2.0 mm after valvuloplasty (P<0.001) and to 18.4+/-1.4 mm at follow-up (P=0.08). Incompetence of the pulmonic valve was noted in 7 of the 53 patients (13 percent) after balloon valvuloplasty, but it had disappeared at followup in all of them. Conclusions Patients with congenital pulmonic stenosis who present in late adolescence or adult life can be treated with percutaneous balloon valvuloplasty with excellent short-term and long-term results that are similar to those in young children. (C)1996, Massachusetts Medical Society.	GUANGDONG CARDIOVASC INST,DEPT CARDIOL,GUANGZHOU,PEOPLES R CHINA; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT MED,DIV CARDIOL,WASHINGTON,DC 20052	George Washington University								ALKASAB S, 1988, AM J CARDIOL, V62, P822, DOI 10.1016/0002-9149(88)91234-9; BARRAUD P, 1992, ARCH MAL COEUR VAISS, V85, P435; BENSHACHAR G, 1985, J AM COLL CARDIOL, V5, P754, DOI 10.1016/S0735-1097(85)80407-1; BOUTAUD P, 1990, ARCH MAL COEUR VAISS, V83, P969; Carminati M, 1993, Cardiologia, V38, P361; CHEN CR, 1988, CATHETER CARDIO DIAG, V15, P55, DOI 10.1002/ccd.1810150113; CHEN CR, 1995, AM HEART J, V129, P1197, DOI 10.1016/0002-8703(95)90404-2; CHEN CR, 1987, CHIN J CARDIOL, V15, P234; CHENG TO, 1994, CIRCULATION, V89, P896, DOI 10.1161/01.CIR.89.2.896; Eckert S., 1994, European Heart Journal, V15, P265; FAIT F, 1995, J INFASIVE CARDIO SC, V7, pC16; FAWZY ME, 1990, CATHETER CARDIO DIAG, V21, P77, DOI 10.1002/ccd.1810210204; GUTGESELL HP, 1992, J AM COLL CARDIOL, V20, P174, DOI 10.1016/0735-1097(92)90155-G; HERRMANN HC, 1991, AM J CARDIOL, V68, P1111, DOI 10.1016/0002-9149(91)90510-R; KAN JS, 1984, CIRCULATION, V69, P554, DOI 10.1161/01.CIR.69.3.554; KAN JS, 1982, NEW ENGL J MED, V307, P540, DOI 10.1056/NEJM198208263070907; KAUL UA, 1993, AM HEART J, V126, P1152, DOI 10.1016/0002-8703(93)90668-Y; LANDZBERG MJ, 1993, CIRCULATION, V88, P341; Lau K W, 1993, J Heart Valve Dis, V2, P321; LAU KW, 1993, CATHETER CARDIO DIAG, V29, P99, DOI 10.1002/ccd.1810290203; MAATOUK F, 1995, ARCH MAL COEUR VAISS, V88, P63; MCCRINDLE BW, 1991, CIRCULATION, V83, P1915, DOI 10.1161/01.CIR.83.6.1915; NUGENT EW, 1977, CIRCULATION, V56, P38; OCONNOR BK, 1992, J AM COLL CARDIOL, V20, P169, DOI 10.1016/0735-1097(92)90154-F; PRESBITERO P, 1988, Giornale Italiano di Cardiologia, V18, P155; RAO PS, 1988, AM J CARDIOL, V62, P979, DOI 10.1016/0002-9149(88)90909-5; RAO PS, 1992, PERCUTANEOUS BALLOON, P365; SADRAMELI MA, 1995, J AM COLL CARDIOL, P25; SHERMAN W, 1990, AM HEART J, V119, P186, DOI 10.1016/S0002-8703(05)80100-0; SIEVERT H, 1989, EUR HEART J, V10, P712, DOI 10.1093/oxfordjournals.eurheartj.a059555; STANGER P, 1990, AM J CARDIOL, V65, P775, DOI 10.1016/0002-9149(90)91387-L; TEUPE CHJ, 1995, CIRCULATION S1, V92, P357	32	100	109	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					21	25		10.1056/NEJM199607043350104	http://dx.doi.org/10.1056/NEJM199607043350104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637537				2022-12-24	WOS:A1996UU47900004
J	Dresser, R				Dresser, R			Mentally disabled research subjects - The enduring policy issues	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSENT; DEMENTIA	Mentally disabled adults often serve as subjects in research on mental illness, developmental disabilities, dementia, and other conditions associated with mental impairment. Since US regulatory policy fails to resolve many ethical issues presented by such research, investigators and institutional review boards must determine the appropriate standards and procedures for studies involving adults with mental disabilities. Procedures for capacity assessment and information disclosure should enhance the autonomy of capable subjects and accurately identify subjects incapable of independent choice. Research teams should inform proxy decision makers of their ethical responsibilities. Decisionally incapable adults objecting to research involvement should rarely be included in studies. Researchers, institutional review boards, advocacy groups, and federal officials should collaborate to improve evaluation of risks and potential benefits to decisionally incapable subjects. These groups should also seek consensus on appropriate risk limits in studies presenting no prospect of direct benefit to decisionally incapable subjects; Finally, subject populations should be represented in research planning and review activities.	CASE WESTERN RESERVE UNIV, SCH MED, CTR BIOMED ETH, CLEVELAND, OH 44106 USA	Case Western Reserve University	Dresser, R (corresponding author), CASE WESTERN RESERVE UNIV, SCH LAW, 11075 EAST BLVD, CLEVELAND, OH 44106 USA.							ADDINGTON D, 1995, CAN J PSYCHIAT, V40, P171, DOI 10.1177/070674379504000403; *ADV COMM HUM RAD, 1995, FIN REP, P705; ANNAS GJ, 1986, NEW ENGL J MED, V315, P1157, DOI 10.1056/NEJM198610303151809; Appelbaum Paul S, 1996, IRB, V18, P1, DOI 10.2307/3563910; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; APPELBAUM PS, 1995, LAW HUMAN BEHAV, V19, P105, DOI 10.1007/BF01499321; BIROS MH, 1995, JAMA-J AM MED ASSOC, V273, P1283, DOI 10.1001/jama.273.16.1283; BUCHANAN AE, 1989, DECIDING OTHERS ETHI, P50; Caplan Arthur L, 1994, J Calif Alliance Ment Ill, V5, P36; CAPRON AM, 1986, BIOLAW; COOKDEEGAN RM, 1992, NEW ENGL J MED, V327, P61; COTRELL V, 1993, GERONTOLOGIST, V33, P205, DOI 10.1093/geront/33.2.205; DERENZO E, 1994, CAMB Q HEALTHC ETHIC, V3, P539, DOI 10.1017/S0963180100005429; DERENZO EG, 1994, IRB REV HUM SUBJECT, V16, P11; DeRenzo Evan Gaines, 1994, IRB, V16, P7, DOI 10.2307/3563879; ERIKSON J, 1995, SCIENCE, V269, P1508, DOI 10.1126/science.7667631; FLETCHER JC, 1987, PSYCHOPHARMACOL BULL, V23, P382; FREEDMAN B, 1993, HASTINGS CENT REP, V23, P13, DOI 10.2307/3562813; GOSTIN LO, 1995, JAMA-J AM MED ASSOC, V274, P844; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P127, DOI 10.1007/BF01499322; hhs, 1979, BELM REP ETH PRINC G; HIGH DM, 1994, ALZ DIS ASSOC DIS, V8, P66, DOI 10.1097/00002093-199400000-00008; Jonas H., 1970, EXPT HUMAN SUBJECTS, P1; Katz Jay, 1993, St Louis Univ Law J, V38, P7; KEYSERLINGK EW, 1995, PERSPECT BIOL MED, V38, P319; KOPELMAN LM, 1995, ENCY BIOETHICS, P2291; LEVINE C, 1995, ENCY BIOETHICS, P2296; LEVINE RJ, 1995, JAMA-J AM MED ASSOC, V273, P1300, DOI 10.1001/jama.273.16.1300; Levine RJ, 1986, ETHICS REGULATION CL, V2nd; LOEWY EH, 1987, NEW ENGL J MED, V317, P1465, DOI 10.1056/NEJM198712033172308; MELNICK VL, 1984, J AM GERIATR SOC, V32, P531, DOI 10.1111/j.1532-5415.1984.tb02240.x; *NAT COMM PROT HUM, 1978, REP REC RES INV THOS; Nelson H.L., 1995, PATIENT FAMILY, P55; *OFF PROT RES RISK, 1994, EV HUM SUBJ PROT SCH; Sachs G A, 1990, Law Med Health Care, V18, P234; SACHS GA, 1994, CLIN RES, V42, P403; SACHS GA, 1994, ALZ DIS ASSOC DIS, V8, P19, DOI 10.1097/00002093-199400000-00003; WARREN JW, 1986, NEW ENGL J MED, V315, P1124, DOI 10.1056/NEJM198610303151804; WHITE LJ, 1989, ANN INTERN MED, V111, P843, DOI 10.7326/0003-4819-111-10-843; 1995, FED REG         1003, V60, P52063; 1991, FED REG         0618, V56, P28012	42	88	89	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					67	72		10.1001/jama.276.1.67	http://dx.doi.org/10.1001/jama.276.1.67			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU439	8667543				2022-12-24	WOS:A1996UU43900031
J	Prandoni, P; Lensing, AWA; Cogo, A; Cuppini, S; Villalta, S; Carta, M; Cattelan, AM; Polistena, P; Bernardi, E; Prins, MH				Prandoni, P; Lensing, AWA; Cogo, A; Cuppini, S; Villalta, S; Carta, M; Cattelan, AM; Polistena, P; Bernardi, E; Prins, MH			The long-term clinical course of acute deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						thrombophlebitis; thromboembolism; blood coagulation disorders; recurrence; neoplasms	VEIN THROMBOSIS; PULMONARY-EMBOLISM; LOWER-EXTREMITY; STANDARD; SEQUELAE	Background: In patients who have symptomatic deep venous thrombosis, the long-term risk for recurrent venous thromboembolism and the incidence and severity of post-thrombotic sequelae have not been well documented. Objective: To determine the clinical course of patients during the 8 years after their first episode of symptomatic deep venous thrombosis. Design: Prospective cohort study. Setting: University outpatient thrombosis clinic. Patients: 355 consecutive patients with a first episode of symptomatic deep venous thrombosis. Measurements: Recurrent venous thromboembolism, the post-thrombotic syndrome, and death. Potential risk factors for these outcomes were also evaluated. Results: The cumulative incidence of recurrent venous thromboembolism was 17.5% after 2 years of follow-up (95% CI, 13.6% to 22.2%), 24.6% after 5 years (CI, 19.6% to 29.7%), and 30.3% after 8 years (CI, 23.6% to 37.0%). The presence of cancer and of impaired coagulation inhibition increased the risk for recurrent venous thromboembolism (hazard ratios, 1.72 [CI, 1.31 to 2.25] and 1.44 [CI, 1.02 to 2.01], respectively). In contrast, surgery and recent trauma or fracture were associated with a decreased risk for recurrent venous thromboembolism (hazard ratios, 0.36 [CI, 0.21 to 0.62] and 0.51 [CI, 0.32 to 0.87], respectively). The cumulative incidence of the post-thrombotic syndrome was 22.8% after 2 years (CI, 18.0% to 27.5%), 28.0% after 5 years (CI, 22.7% to 33.3%), and 29.1% after 8 years (CI, 23.4% to 34.7%). The development of ipsilateral recurrent deep venous thrombosis was strongly associated with the risk for the post-thrombotic syndrome (hazard ratio, 6.4; CI, 3.1 to 13.3). Survival after 8 years was 70.2% (CI, 64.7% to 75.6%). The presence of cancer increased the risk for death (hazard ratio, 8.1; CI, 3.6 to 18.1). Conclusion: Patients with symptomatic deep venous thrombosis, especially those without transient risk factors for deep venous thrombosis, have a high risk for recurrent venous thromboembolism that persists for many years. The post-thrombotic syndrome occurs in almost one third of these patients and is strongly related to ipsilateral recurrent deep venous thrombosis. These findings challenge the widely adopted use of short-course anticoagulation therapy in patients with symptomatic deep venous thrombosis.	UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, 1105 AZ AMSTERDAM, NETHERLANDS; UNIV HOSP PADUA, PADUA, ITALY	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; Azienda Ospedaliera - Universita di Padova	Prandoni, P (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & I, F-4, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, NETHERLANDS.		Carta, Mariarosa/ABF-9677-2021	Carta, Mariarosa/0000-0002-7143-4928; Cattelan, Anna Maria/0000-0003-2869-2945				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; [Anonymous], 1994, HAEMOSTASIS S1; BEYTH RJ, 1995, ARCH INTERN MED, V155, P1031, DOI 10.1001/archinte.155.10.1031; BRANDJES DPM, 1991, THROMB HAEMOSTASIS, V65, pA1568; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; GJORES J E, 1956, Acta Chir Scand Suppl, V206, P1; HELDAL M, 1993, J INTERN MED, V234, P71, DOI 10.1111/j.1365-2796.1993.tb00707.x; HIRSH J, 1993, HEMOSTASIS THROMBOSI, P1322; HIRSH J, 1993, HEMOSTASIS THROMBOSI, P1543; IMMELMAN EJ, 1984, CLIN CHEST MED, V5, P537; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI, P1; KIERKEGAARD A, 1980, ACTA CHIR SCAND, V146, P267; LENSING AWA, 1992, THROMB HAEMOSTASIS, V67, P8; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1993, HEMOSTASIS THROMBOSI, P1297; LINDNER DJ, 1986, J VASC SURG, V4, P436, DOI 10.1067/mva.1986.avs0040436; MONREAL M, 1993, J INTERN MED, V233, P233, DOI 10.1111/j.1365-2796.1993.tb00981.x; ODONNELL TF, 1977, J SURG RES, V22, P483, DOI 10.1016/0022-4804(77)90030-0; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Salzman E. X., 1993, HEMOSTASIS THROMBOSI, P1275; Salzmann E, 1993, HEMOSTASIS THROMBOSI, P1346; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; STRANDNESS DE, 1983, JAMA-J AM MED ASSOC, V250, P1289, DOI 10.1001/jama.250.10.1289; WIDMER LK, 1985, VASA-J VASCULAR DIS, V14, P264	27	1603	1658	0	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1996	125	1					1	+		10.7326/0003-4819-125-1-199607010-00001	http://dx.doi.org/10.7326/0003-4819-125-1-199607010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT399	8644983				2022-12-24	WOS:A1996UT39900001
J	Arroyo, AG; Yang, JT; Rayburn, H; Hynes, RO				Arroyo, AG; Yang, JT; Rayburn, H; Hynes, RO			Differential requirements for alpha 4 integrins during fetal and adult hematopoiesis	CELL			English	Article							MARROW STROMAL CELLS; BONE-MARROW; B-CELL; PROGENITOR CELLS; MOUSE THYMUS; VLA-4; MICE; FIBRONECTIN; ADHESION; BINDING	Mice chimeric for the expression of alpha 4 integrins were used to dissect the roles of these receptors in development and traffic of lymphoid and myeloid cells. During fetal life, T cell development is alpha 4 independent, but after birth further production of T cells becomes alpha 4 dependent. Precursors for both T and B cells require alpha 4 integrins for normal development within the bone marrow. In contrast, monocytes and natural killer cells can develop normally without alpha 4 integrins. Thus, there are lymphocyte-specific, developmentally regulated requirements for alpha 4 integrins in hematopoiesis in the bone marrow. We also show that alpha 4 integrins are essential for T cell homing to Peyer's patches, but not to other secondary lymphoid organs, including spleen, lymph nodes, and intestinal epithelium.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Arroyo, AG (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.		Arroyo, Alicia G./L-2796-2014; Arroyo, Alicia G/M-2507-2018	Arroyo, Alicia G./0000-0002-1536-3846; Arroyo, Alicia G/0000-0002-1536-3846	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTEVOGT P, 1995, J EXP MED, V182, P345, DOI 10.1084/jem.182.2.345; Boismenu R, 1996, SCIENCE, V271, P198, DOI 10.1126/science.271.5246.198; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; GEORGE EL, 1994, METHOD ENZYMOL, V245, P386; GISLER RH, 1987, J IMMUNOL, V138, P2427; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; HAMANN A, 1994, J IMMUNOL, V152, P3282; HARDIN JA, 1995, CELL IMMUNOL, V161, P50, DOI 10.1006/cimm.1995.1008; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JARVIS LJ, 1995, J IMMUNOL, V155, P2359; JOTEREAU F, 1987, J IMMUNOL, V138, P1026; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KERST JM, 1993, BLOOD, V81, P344; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEDBETTER JA, 1979, IMMUNOGENETICS, V8, P347, DOI 10.1007/BF01561445; LEE MG, 1994, J IMMUNOL, V152, P5653; LEVESQUE JP, 1995, J EXP MED, V181, P1805, DOI 10.1084/jem.181.5.1805; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; Merville P, 1996, J EXP MED, V183, P227, DOI 10.1084/jem.183.1.227; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PAPAYANNOPOULOU T, 1993, P NATL ACAD SCI USA, V90, P9374, DOI 10.1073/pnas.90.20.9374; PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; ROLDAN E, 1992, J EXP MED, V175, P1739, DOI 10.1084/jem.175.6.1739; RUIZ P, 1995, EUR J IMMUNOL, V25, P2034, DOI 10.1002/eji.1830250735; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; SALOMON DR, 1994, J EXP MED, V179, P1573, DOI 10.1084/jem.179.5.1573; SANCHEZMADRID F, 1992, SEMIN CELL BIOL, V8, P1735; SAWADA M, 1992, J IMMUNOL, V149, P3517; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCOLLAY R, 1986, IMMUNOL REV, V91, P129, DOI 10.1111/j.1600-065X.1986.tb01487.x; SHEPPARD AM, 1994, CELL ADHES COMMUN, V2, P27, DOI 10.3109/15419069409014200; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SIMMONS PJ, 1992, BLOOD, V80, P388; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STRASSER A, 1989, J EXP MED, V170, P1973, DOI 10.1084/jem.170.6.1973; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; TELXIDO J, 1992, J CLIN INVEST, V90, P358; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UTSUMI K, 1991, P NATL ACAD SCI USA, V88, P5685, DOI 10.1073/pnas.88.13.5685; VELS DJ, 1993, CELL, V75, P229; WEISSMAN IL, 1994, CELL, V76, P207, DOI 10.1016/0092-8674(94)90329-8; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; YANG JT, 1995, DEVELOPMENT, V121, P549; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	65	278	287	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					997	1008		10.1016/S0092-8674(00)81301-X	http://dx.doi.org/10.1016/S0092-8674(00)81301-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674127	Bronze, Green Submitted			2022-12-24	WOS:A1996UV48400007
J	Leuther, KK; Bushnell, DA; Kornberg, RD				Leuther, KK; Bushnell, DA; Kornberg, RD			Two-dimensional crystallography of TFIIB- and IIE-RNA polymerase II complexes: Implications for start site selection and initiation complex formation	CELL			English	Article							TRANSCRIPTION FACTOR-TFIIB; TATA-BINDING-PROTEIN; CRYSTAL-STRUCTURE; ELECTRON-MICROSCOPY; 3-DIMENSIONAL STRUCTURE; 2-DIMENSIONAL CRYSTALS; FUNCTIONAL DOMAINS; YEAST; DNA; RESOLUTION	Transcription factors IIB (TFIIB) and IIE (TFIIE) bound to RNA polymerase II have been revealed by electron crystallography in projection at 15.7 Angstrom resolution. The results lead to simple hypotheses for the roles of these factors in the initiation of transcription. TFIIB is suggested to define the distance from TATA box to transcription start site by bringing TATA DNA in contact with polymerase at that distance from the active center of the enzyme. TFIIE is suggested to participate in a key conformational switch occurring at the active center upon polymerase-DNA interaction.			Leuther, KK (corresponding author), STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21144] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; ASTURIAS FJ, 1995, J STRUCT BIOL, V114, P60, DOI 10.1006/jsbi.1995.1005; BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BRISSON A, 1994, BIOL CELL, V80, P221, DOI 10.1016/0248-4900(94)90045-0; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1991, J MOL BIOL, V221, P347, DOI 10.1016/0022-2836(91)80223-H; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; JAP BK, 1992, ULTRAMICROSCOPY, V46, P45, DOI 10.1016/0304-3991(92)90007-7; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOMBERG RD, 1991, CURR OPIN STRUC BIOL, V1, P642; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SCHULTZ P, 1990, J MOL BIOL, V216, P353, DOI 10.1016/S0022-2836(05)80326-2; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1994, J MOL BIOL, V244, P6, DOI 10.1006/jmbi.1994.1699; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUN ZW, 1995, P NATL ACAD SCI USA, V92, P3127, DOI 10.1073/pnas.92.8.3127; SVEJSTRUP JQ, 1996, J BIOL CHEM, V2, P643; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; XIAO H, 1994, MOL CELL BIOL, V14, P7507, DOI 10.1128/MCB.14.11.7507; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	69	87	86	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1996	85	5					773	779		10.1016/S0092-8674(00)81242-8	http://dx.doi.org/10.1016/S0092-8674(00)81242-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646784	Bronze			2022-12-24	WOS:A1996UP34400016
J	Fey, R; Pearson, N				Fey, R; Pearson, N			Statins and coronary heart disease	LANCET			English	Editorial Material									AVON HLTH, DIST HLTH AUTHOR, BRISTOL BS2 8EE, AVON, ENGLAND		Fey, R (corresponding author), AVON HLTH, AVON FAMILY HLTH SERV AUTHOR, 10 DIGHTON ST, BRISTOL BS2 8EE, AVON, ENGLAND.							ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; DEAN M, 1995, LANCET, V346, P1415, DOI 10.1016/S0140-6736(95)92414-0; FOULDS J, 1995, BRIT MED J, V311, P1152, DOI 10.1136/bmj.311.7013.1152; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; *OFF POP CENS SURV, 1995, SER PP2, V19; OLIVER MF, 1995, LANCET, V346, P1378, DOI 10.1016/S0140-6736(95)92399-3; *OPCS SOC SURV DIV, 1995, 1993 HLTH SURV ENGL; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDERSEN TR, 1995, NEW ENGL J MED, V333, P1350, DOI 10.1056/NEJM199511163332010; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SHEPHERD J, 1995, AM J CARDIOL, V76, P485; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; 1996, ANN INTERN MED, V14, P515; 1995, BRIT NATL FORMUL SEP	17	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1996	347	9012					1389	1390		10.1016/S0140-6736(96)91019-3	http://dx.doi.org/10.1016/S0140-6736(96)91019-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637349				2022-12-24	WOS:A1996UL90400018
J	Geiger, JH; Hahn, S; Lee, S; Sigler, PB				Geiger, JH; Hahn, S; Lee, S; Sigler, PB			Crystal structure of the yeast TFIIA/TBP/DNA complex	SCIENCE			English	Article							TRANSCRIPTION INITIATION SITES; SACCHAROMYCES-CEREVISIAE; FACTOR-IIA; TFIIA; SUBUNITS; ACTIVATION; CDNA; GENE	The crystal structure of the yeast TFIIA/TBP/TATA promoter complex was solved to 3 angstrom resolution by double-edge multiple wavelength anomalous diffraction from two different species of anomalous scattering elements in the same crystal. The large and small subunits of TFIIA associate intimately to form both domains of a two-domain folding pattern. TFIIA binds as a heterodimer to the side of the TBP/TATA complex opposite to the side that binds TFIIB and does not alter the TBP/DNA interaction. The six-stranded beta-sandwich domain interacts with the amino-terminal end of TBP through a stereospecific parallel beta-strand interface and with the backbone of the TATA box and the 5'-flanking B-DNA segment. The four-helix-bundle domain projects away from the TBP/TATA complex, thereby presenting a substantial surface for further protein-protein interactions.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Yale University; Howard Hughes Medical Institute; Yale University; Fred Hutchinson Cancer Center				Geiger, James/0000-0002-9443-4488				AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BRYANT GW, COMMUNICATION; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; GE H, 1994, J BIOL CHEM, V269, P17136; GuzikevichGuerstein G, 1996, NAT STRUCT BIOL, V3, P32, DOI 10.1038/nsb0196-32; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; LAGRANGE T, COMMUNICATION; LEE DK, 1992, MOL CELL BIOL, V12, P96; MA D, COMMUNICATION; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Ozer J, 1996, J BIOL CHEM, V271, P11182, DOI 10.1074/jbc.271.19.11182; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RANISH J, COMMUNICATION; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; RANISH JA, UNPUB; RANISH JA, IN PRESS CURR OPIN G; REED RJ, 1986, ACTA CRYSTALLOGR A, V42, P140; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313	46	233	236	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					830	836		10.1126/science.272.5263.830	http://dx.doi.org/10.1126/science.272.5263.830			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629014				2022-12-24	WOS:A1996UK75700043
J	Voloshin, ON; Wang, LJ; CameriniOtero, RD				Voloshin, ON; Wang, LJ; CameriniOtero, RD			Homologous DNA pairing promoted by a 20-amino acid peptide derived from RecA	SCIENCE			English	Article							SINGLE-STRANDED FRAGMENTS; ESCHERICHIA-COLI; SUPERHELICAL DNA; BRANCH MIGRATION; UVSX PROTEIN; BACTERIOPHAGE-T4; RECOMBINATION; BINDING; YEAST	The molecular structure of the Escherichia coli RecA protein in the absence of DNA revealed two disordered or mobile loops that were proposed to be DNA binding sites. A short peptide spanning one of these loops was shown to carry out the key reaction mediated by the whole RecA protein: pairing (targeting) of a single-stranded DNA to its homologous site on a duplex DNA. In the course of the reaction the peptide bound to both substrate DNAs, unstacked the single-stranded DNA, and assumed a beta structure. These events probably recapitulate the underlying molecular pathway or mechanism used by homologous recombination proteins.	NIDDKD,GENET BIOMED BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; COX MM, 1995, J BIOL CHEM, V270, P26021, DOI 10.1074/jbc.270.44.26021; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARRIS LD, 1988, BIOCHEMISTRY-US, V27, P6954, DOI 10.1021/bi00418a042; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; KANSY JW, 1986, J BIOMOL STRUCT DYN, V3, P1079, DOI 10.1080/07391102.1986.10508487; KASLIN E, 1994, J BIOL CHEM, V269, P14103; KMIEC EB, 1994, J BIOL CHEM, V269, P10163; KOLLER T, 1983, MECHANISMS DNA REPLI, P723; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KOWALCZYKOWSKI C, 1994, ANN REV BIOCH, V63, P991; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P538; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; MARABOEUF O, 1995, J BIOL CHEM, V270, P30927; Maxam A M, 1980, Methods Enzymol, V65, P499; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; RADDING CM, 1977, J MOL BIOL, V116, P825, DOI 10.1016/0022-2836(77)90273-X; RAO BJ, 1995, TRENDS BIOCHEM SCI, V20, P109, DOI 10.1016/S0968-0004(00)88976-8; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIKORAV JL, 1991, J MOL BIOL, V222, P1085, DOI 10.1016/0022-2836(91)90595-W; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; VOLOSHIN ON, UNPUB; Wang L., UNPUB; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YU X, 1993, J MOL BIOL, V232, P1, DOI 10.1006/jmbi.1993.1363; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	42	75	88	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					868	872		10.1126/science.272.5263.868	http://dx.doi.org/10.1126/science.272.5263.868			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629021				2022-12-24	WOS:A1996UK75700058
J	Tarn, WY; Steitz, JA				Tarn, WY; Steitz, JA			A novel spliceosome containing U11, U12, and U5 snRNPs excises a minor class (AT-AC) intron in vitro	CELL			English	Article							SMALL NUCLEAR-RNA; CROSS-LINKING; ACTIVE-SITE; U6 SNRNA; RIBONUCLEOPROTEIN; MUTATIONS; PROBES; U4/U6; YEAST; CAP	A minor class of introns with noncanonical splice (AT-AC) and branch site sequences exists in metazoan protein coding genes. We have established a HeLa cell in vitro system that accurately splices a pre-mRNA substrate containing such an intron from the human P120 gene. Splicing occurs via a lariat intermediate whose branch site A residue is predicted to bulge from a duplex formed with the low abundance U12 small nuclear ribonucleoprotein (snRNP), which we confirm by psoralen cross-linking. Native gel electrophoresis reveals that U11, U12, and U5 snRNPs assemble onto the P120 pre-mRNA to form splicing complexes. Inhibition of P120 splicing by 2'-O-methyl oligonucleotides complementary to U12 or U5 demonstrates that U12 and U5 snRNPs perform essential roles in the AT-AC spliceosome.			Tarn, WY (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW HAVEN, CT 06536 USA.		Tarn, Woan-Yuh/N-8464-2018		NIGMS NIH HHS [GM26154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026154, R37GM026154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CHANFREAU G, 1994, NUCLEIC ACIDS RES, V22, P1981, DOI 10.1093/nar/22.11.1981; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; CRISPINO JD, 1995, GENE DEV, V9, P2314, DOI 10.1101/gad.9.18.2314; GILLIAM AC, 1993, P NATL ACAD SCI USA, V90, P6781, DOI 10.1073/pnas.90.14.6781; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; HALL SL, 1986, IN PRESS SCIENCE; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1989, METHOD ENZYMOL, V180, P442; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LARSON RG, 1990, CANCER COMMUN, V2, P63, DOI 10.3727/095535490820874704; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; LINGNER J, 1993, NUCLEIC ACIDS RES, V21, P2917, DOI 10.1093/nar/21.12.2917; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; RUSKIN B, 1990, METHOD ENZYMOL, V181, P180; SCADDEN ADJ, 1995, EMBO J, V14, P3236; SONTHEIMER EJ, 1992, MOL CELL BIOL, V12, P734, DOI 10.1128/MCB.12.2.734; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; TARN WY, 1995, RNA, V1, P644; TARN WY, 1994, P NATL ACAD SCI USA, V8, P2704; WASSARMAN DA, 1993, MOL BIOL REP, V17, P143, DOI 10.1007/BF00996222; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542	41	185	188	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					801	811		10.1016/S0092-8674(00)81057-0	http://dx.doi.org/10.1016/S0092-8674(00)81057-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625417	hybrid			2022-12-24	WOS:A1996TZ99000017
J	Matsumoto, M; Mariathasan, S; Nahm, MH; Baranyay, F; Peschon, JJ; Chaplin, DD				Matsumoto, M; Mariathasan, S; Nahm, MH; Baranyay, F; Peschon, JJ; Chaplin, DD			Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; BETA; MONOCYTOGENES; ACTIVATION; RESOLUTION; RESPONSES; RESISTANT; INFECTION; SURFACE; COMPLEX	In mice deficient in either lymphotoxin-alpha (LT-alpha) or the type I tumor necrosis factor (TNF) receptor, but not the type II TNF receptor, germinal centers failed to develop in peripheral lymphoid organs. Germinal center formation was restored in LT-alpha-deficient mice by transplantation of normal bone marrow, indicating that the LT-alpha-expressing cells required to establish this lymphoid structure are derived from bone marrow.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)				Chaplin, David/0000-0002-1354-3069; Nahm, Moon/0000-0002-6922-1042				BANKS TA, 1995, J IMMUNOL, V155, P1685; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BROWNING J, 1989, J IMMUNOL, V143, P1859; BROWNING JL, 1991, J IMMUNOL, V147, P1230; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; HAKOSHIMA T, 1988, J MOL BIOL, V201, P455, DOI 10.1016/0022-2836(88)90153-2; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KRAAL G, 1986, IMMUNOLOGY, V58, P665; MARIATHASAN S, 1995, J INFLAMM, V45, P72; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PESCHON JJ, UNPUB; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAMESH N, 1994, IMMUNOL REV, V138, P87, DOI 10.1111/j.1600-065X.1994.tb00848.x; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; RUDDLE NH, 1992, CURR OPIN IMMUNOL, V4, P327, DOI 10.1016/0952-7915(92)90084-R; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; STEFFEN M, 1988, J IMMUNOL, V140, P2621; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; WORM M, 1994, INT IMMUNOL, V6, P1883, DOI 10.1093/intimm/6.12.1883; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	33	332	348	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1289	1291		10.1126/science.271.5253.1289	http://dx.doi.org/10.1126/science.271.5253.1289			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638112				2022-12-24	WOS:A1996TX69500039
J	Cluzel, P; Lebrun, A; Heller, C; Lavery, R; Viovy, JL; Chatenay, D; Caron, F				Cluzel, P; Lebrun, A; Heller, C; Lavery, R; Viovy, JL; Chatenay, D; Caron, F			DNA: An extensible molecule	SCIENCE			English	Article							RECA PROTEIN; SINGLE	The force-displacement response of a single duplex DNA molecule was measured. The force saturates at a plateau around 70 piconewtons, which ends when the DNA has been stretched about 1.7 times its contour length. This behavior reveals a highly cooperative transition to a state here termed S-DNA. Addition of an intercalator suppresses this transition. Molecular modeling of the process also yields a force plateau and suggests a structure for the extended form. These results may shed light on biological processes involving DNA extension and open the route for mechanical studies on individual molecules in a previously unexplored range.	ECOLE NORMALE SUPER,CNRS,URA 1302,GENET MOLEC LAB,F-75230 PARIS,FRANCE; INST CURIE,CNRS,URA 448,F-75005 PARIS,FRANCE; INST CURIE,CNRS,URA 1379,F-75005 PARIS,FRANCE; INST BIOL PHYSICOCHIM,CNRS,URA 77,LAB BIOCHIM THEOR,F-75005 PARIS,FRANCE; INST PHYS,LUDFC,F-67084 STRASBOURG,FRANCE; MAX PLANCK INST MOLEC GENET,D-14195 BERLIN,GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Max Planck Society			Lavery, Richard/G-1422-2011	Lavery, Richard/0000-0001-9901-6640; Viovy, Jean-Louis/0000-0002-8223-4040; Heller, Christoph/0000-0002-9434-8192				BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; Cox R. G., 1970, Journal of Fluid Mechanics, V44, P791, DOI 10.1017/S002211207000215X; CRICK FHC, 1954, PROC R SOC LON SER-A, V223, P80, DOI 10.1098/rspa.1954.0101; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRASER MJ, 1951, NATURE, V167, P760; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HILL TL, 1959, J CHEM PHYS, V30, P383, DOI 10.1063/1.1729961; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; LAVERY R, 1995, COMPUT PHYS COMMUN, V91, P135, DOI 10.1016/0010-4655(95)00046-I; LAVERY R, 1994, ADV COMP BIOL, V1, P69; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Smith Steven B., 1995, Biophysical Journal, V68, pA250; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; Sundaralingam M., 1988, STRUCTURE EXPRESSION, P191; VIOVY JL, 1994, CR ACAD SCI III-VIE, V317, P795; WILKINS MHF, 1951, NATURE, V167, P759, DOI 10.1038/167759a0; WILKINS MHF, 1953, NATURE, V171, P738, DOI 10.1038/171738a0; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	23	859	892	1	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					792	794		10.1126/science.271.5250.792	http://dx.doi.org/10.1126/science.271.5250.792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628993				2022-12-24	WOS:A1996TU69400041
J	Vortkamp, A; Lee, K; Lanske, B; Segre, GV; Kronenberg, HM; Tabin, CJ				Vortkamp, A; Lee, K; Lanske, B; Segre, GV; Kronenberg, HM; Tabin, CJ			Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein	SCIENCE			English	Article							HORMONE-RELATED PEPTIDE; TERMINAL CLEAVAGE PRODUCT; DROSOPHILA PATCHED GENE; MOTOR-NEURON INDUCTION; SONIC-HEDGEHOG; PARATHYROID-HORMONE; SCLEROTOME INDUCTION; POLARIZING ACTIVITY; VERTEBRATE HOMOLOG; RETROVIRAL VECTORS	Proper regulation of chondrocyte differentiation is necessary for the morphogenesis of skeletal elements, yet little is known about the molecular regulation of this process, A chicken homolog of Indian hedgehog (Ihh), a member of the conserved Hedgehog family of secreted proteins that is expressed during bone formation, has now been isolated. Ihh has biological properties similar to those of Sonic hedgehog (Shh), including the ability to regulate the conserved targets Patched (Ptc) and Gli. Ihh is expressed in the prehypertrophic chondrocytes of cartilage elements, where it regulates the rate of hypertrophic differentiation, Misexpression of Ihh prevents proliferating chondrocytes from initiating the hypertrophic differentiation process, The direct target of Ihh signaling is the perichondrium, where Gli and Ptc flank the expression domain of Ihh, Ihh induces the expression of a second signal, parathyroid hormone-related protein (PTHrP), in the periarticular perichondrium, Analysis of PTHrP (-/-) mutant mice indicated that the PTHrP protein signals to its receptor in the prehypertrophic chondrocytes, thereby blocking hypertrophic differentiation, In vitro application of Hedgehog or PTHrP protein to normal or PTHrP (-/-) limb explants demonstrated that PTHrP mediates the effects of Ihh through the formation of a negative feedback loop that modulates the rate of chondrocyte differentiation.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Lanske, Beate/0000-0003-4638-804X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047038] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47038, DK4723] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abou-Samra A B, 1994, Adv Nephrol Necker Hosp, V23, P247; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Broadus Arthur E., 1994, P259; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CURRIE P, IN PRESS NATURE; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; FORBES AJ, 1993, DEVELOPMENT, P115; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HINCHLIFFE JR, 1980, DEV VERTEBRATE LIMB, P76; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEE K, ENDOCRINOLOGY; Lee K. T., UNPUB; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LINSENMAYER TF, 1991, DEVELOPMENT, V111, P191; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARIGO V, IN PRESS P NATL ACAD; MARIGO V, UNPUB; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORENIC T, 1990, GENE DEV, V124, P50; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; THIEDE MA, 1990, NUCLEIC ACIDS RES, V18, P3062, DOI 10.1093/nar/18.10.3062; VORTKAMP A, UNPUB	65	1557	1632	2	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					613	622		10.1126/science.273.5275.613	http://dx.doi.org/10.1126/science.273.5275.613			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662546				2022-12-24	WOS:A1996VA24900038
J	Cheng, H; Cao, YH; Olson, L				Cheng, H; Cao, YH; Olson, L			Spinal cord repair in adult paraplegic rats: Partial restoration of hind limb function	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; CORTICOSPINAL TRACT; INJURY; REGENERATION; GRAFTS; ELONGATION; EXPRESSION; AXONS; BRAIN	Complete spinal cord gaps in adult rats were bridged with multiple intercostal nerve grafts that redirected specific pathways from white to gray matter. The grafted area was stabilized with fibrin glue containing acidic fibroblast growth factor and by compressive wiring of posterior spinal processes. Hind limb function improved progressively during the first 6 months, as assessed by two scoring systems. The corticospinal tract regenerated through the grafted area to the lumbar enlargement, as did several bulbospinal pathways. These data suggest a possible repair strategy for spinal cord injury.	NATL YANG MING UNIV, TAIPEI, TAIWAN; VET GEN HOSP, NEUROL INST, DEPT NEUROSURG, TAIPEI, TAIWAN; KAROLINSKA INST, DEPT MOLEC & CELL BIOL, S-17177 STOCKHOLM, SWEDEN	National Yang Ming Chiao Tung University; Karolinska Institutet	Cheng, H (corresponding author), KAROLINSKA INST, DEPT NEUROSCI, S-17177 STOCKHOLM, SWEDEN.							ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; BEATTIE MS, 1989, C P CRITERIA ASSESSI, P16; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BENFEY M, 1982, NATURE, V296, P150, DOI 10.1038/296150a0; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; BROWN LT, 1971, EXP BRAIN RES, V13, P432; Bunge R P, 1993, Curr Opin Neurobiol, V3, P805, DOI 10.1016/0959-4388(93)90157-T; CAO Y, 1993, THESIS KAROLINSKA I; CHENG H, 1995, EXP NEUROL, V136, P149, DOI 10.1006/exnr.1995.1092; CHENG H, 1994, J NEURAL TRANSP PLAS, V5, P233, DOI 10.1155/NP.1994.233; CHENG H, 1995, EXP BRAIN RES, V104, P199; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; ELDE R, 1991, NEURON, V7, P349, DOI 10.1016/0896-6273(91)90288-B; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GIACOBINI MMJ, 1991, EXP BRAIN RES, V86, P73; Grillner S., 1973, CONTROL POSTURE LOCO, P515; Heimer L, 1989, NEUROANATOMICAL TRAC; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; KOSHINAGA M, 1993, EXP NEUROL, V120, P32, DOI 10.1006/exnr.1993.1038; KUANG RZ, 1994, DEVELOPMENT, V120, P1937; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; NYGREN LG, 1974, BRAIN RES, V78, P377, DOI 10.1016/0006-8993(74)90922-6; OLSON L, 1982, BRAIN RES BULL, V9, P519, DOI 10.1016/0361-9230(82)90160-5; PUCHALA E, 1977, EXP NEUROL, V55, P1, DOI 10.1016/0014-4886(77)90155-8; SAVIO T, 1990, P NATL ACAD SCI USA, V87, P4130, DOI 10.1073/pnas.87.11.4130; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SCHWAB ME, 1990, TRENDS NEUROSCI, V13, P452, DOI 10.1016/0166-2236(90)90098-U	27	636	734	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1996	273	5274					510	513		10.1126/science.273.5274.510	http://dx.doi.org/10.1126/science.273.5274.510			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8662542				2022-12-24	WOS:A1996UY98300044
J	Khan, AA; Soloski, MJ; Sharp, AH; Schilling, G; Sabatini, DM; Li, SH; Ross, CA; Snyder, SH				Khan, AA; Soloski, MJ; Sharp, AH; Schilling, G; Sabatini, DM; Li, SH; Ross, CA; Snyder, SH			Lymphocyte apoptosis: Mediation by increased type 3 inositol 1,4,5-trisphosphate receptor	SCIENCE			English	Article							T-CELL ACTIVATION; CEREBELLAR PURKINJE-CELLS; PLASMA-MEMBRANE; FLOW-CYTOMETRY; ENDOPLASMIC-RETICULUM; SIGNAL TRANSDUCTION; DNA FRAGMENTATION; ANTIGEN RECEPTOR; CYTOSOLIC CA-2+; SUICIDE PROCESS	B and T lymphocytes undergoing apoptosis in response to anti-immunoglobulin M antibodies and dexamethasone, respectively, were found to have increased amounts of messenger RNA for the inositol 1,4,5-trisphosphate receptor (IP(3)R) and increased amounts of IP(3)R protein. Immunohistochemical analysis revealed that the augmented receptor population was localized to the plasma membrane. Type 3 IP(3)R (IP(3)R3) was selectively increased during apoptosis, with no enhancement of type 1 IP(3)R (IP(3)R1). Expression of IP(3)R3 antisense constructs in S49 T cells blocked dexamethasone-induced apoptosis, whereas IP(3)R3 sense, IP(3)R1 sense, or IP(3)R1 antisense control constructs did not block cell death. Thus, the increases in IP(3)R3 may be causally related to apoptosis.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037934, R01AI020922, R23AI020922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043040, R29MH043040] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20922, AI-37934] Funding Source: Medline; NIMH NIH HHS [MH43040] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASHERSON GL, 1970, J PHYSIOL-LONDON, V206, P32; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOYD AW, 1981, J IMMUNOL, V126, P2466; CARONLESLIE LAM, 1991, MOL ENDOCRINOL, V5, P1169, DOI 10.1210/mend-5-8-1169; Cohen J J, 1992, Semin Immunol, V4, P363; COHEN JJ, 1984, J IMMUNOL, V132, P38; CUNNINGHAM AM, 1993, NEUROSCIENCE, V57, P339, DOI 10.1016/0306-4522(93)90067-P; DANIELSEN M, 1983, MOL CELL BIOL, V3, P1310, DOI 10.1128/MCB.3.7.1310; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEFFERT DM, 1986, BIOCHEM J, V236, P37; DEFRANCO AL, 1982, B T CELL TUMORS BIOL, P445; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FENG L, 1992, CELL CALCIUM, V13, P79, DOI 10.1016/0143-4160(92)90001-9; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GARDNER P, 1990, ANNU REV IMMUNOL, V8, P231, DOI 10.1146/annurev.iy.08.040190.001311; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; Harlow E, 1988, ANTIBODIES LAB MANUA; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HARRIS AW, 1970, EXP CELL RES, V60, P341, DOI 10.1016/0014-4827(70)90527-6; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; KAISER N, 1977, P NATL ACAD SCI USA, V74, P638, DOI 10.1073/pnas.74.2.638; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KHAN AT, UNPUB; KIZAKI H, 1989, J IMMUNOL, V143, P1790; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KUNO M, 1994, BIOCHEM BIOPH RES CO, V199, P1128, DOI 10.1006/bbrc.1994.1348; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; MAYRLEITNER M, 1995, CELL CALCIUM, V17, P141, DOI 10.1016/0143-4160(95)90083-7; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RALPH P, 1973, BIOCHEM BIOPH RES CO, V55, P1085, DOI 10.1016/S0006-291X(73)80006-3; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SCOTT DW, 1987, J IMMUNOL, V139, P3924; SCREPANTI I, 1989, J IMMUNOL, V142, P3378; SHARP AH, 1992, J BIOL CHEM, V267, P7444; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUN XM, 1992, BIOCHEM PHARMACOL, V44, P2131; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; VANDERBILT JN, 1982, J BIOL CHEM, V257, P3009; VEDECKIS WV, 1983, MOL CELL ENDOCRINOL, V30, P215, DOI 10.1016/0303-7207(83)90049-7; WARNER NL, 1975, MEMBRANE RECEPTORS L, P203; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WHITFIELD JF, 1966, EXP CELL RES, V43, P602, DOI 10.1016/0014-4827(66)90031-0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	66	230	233	3	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1996	273	5274					503	507		10.1126/science.273.5274.503	http://dx.doi.org/10.1126/science.273.5274.503			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8662540				2022-12-24	WOS:A1996UY98300042
J	Blair, SN; Kampert, JB; Kohl, HW; Barlow, CE; Macera, CA; Paffenbarger, RS; Gibbons, LW				Blair, SN; Kampert, JB; Kohl, HW; Barlow, CE; Macera, CA; Paffenbarger, RS; Gibbons, LW			Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; EXERCISE; PROTOCOLS	Objective.-To quantify the relation of cardiorespiratory fitness to cardiovascular disease (CVD) mortality and to all-cause mortality within strata of other personal characteristics that predispose to early mortality. Design.-Observational cohort study. We calculated CVD and all-cause death rates for low (least fit 20%), moderate (next 40%), and high (most fit 40%) fitness categories by strata of smoking habit, cholesterol level, blood pressure, and health status. Setting.-Preventive medicine clinic. Study Participants.-Participants were 25 341 men and 7080 women who completed preventive medical examinations, including a maximal exercise test. Main Outcome Measures.-Cardiovascular disease and all-cause mortality. Results.-There were 601 deaths during 211 996 man-years of follow-up, and 89 deaths during 52 982 woman-years of follow-up. Independent predictors of mortality among men, with adjusted relative risks (RRs) and 95% confidence intervals (Cls), were low fitness (RR, 1.52; 95% CI, 1.28-1.82), smoking (RR, 1.65; 95% CI, 1.39-1.97), abnormal electrocardiogram (RR, 1.64; 95% CI, 1.34-2.01), chronic illness (RR, 1.63; 95% CI, 1.37-1.95), increased cholesterol level (RR, 1.34; 95% CI, 1.13-1.59), and elevated systolic blood pressure (RR, 1.34; 95% CI, 1.13-1.59), The only statistically significant independent predictors of mortality in women were low fitness (RR, 2.10; 95% CI, 1.36-3.21) and smoking (RR, 1.99; 95% CI, 1.25-3.17). Inverse gradients were seen for mortality across fitness categories within strata of other mortality predictors for both sexes. Fit persons with any combination of smoking, elevated blood pressure, or elevated cholesterol level had lower adjusted death rates than low-fit persons with none of these characteristics. Conclusions.-Low fitness is an important precursor of mortality. The protective effect of fitness held for smokers and nonsmokers, those with and without elevated cholesterol levels or elevated blood pressure, and unhealthy and healthy persons. Moderate fitness seems to protect against the influence of these other predictors on mortality. Physicians should encourage sedentary patients to become physically active and thereby reduce the risk of premature mortality.	COOPER CLIN, DALLAS, TX USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV S CAROLINA, SCH PUBL HLTH, COLUMBIA, SC 29208 USA; STANFORD UNIV, SCH MED, PALO ALTO, CA 94304 USA	Cooper Institute; Baylor College of Medicine; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Stanford University	Blair, SN (corresponding author), COOPER INST AEROB RES, 12330 PRESTON RD, DALLAS, TX 75230 USA.		wright, beth/V-7496-2019		NIA NIH HHS [AG06945] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG006945, R01AG006945] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1990, MED SCI SPORT EXER, V22, P265; [Anonymous], 1993, Med Sci Sports Exerc, V25, P1; BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bouchard C, 1994, PHYSICAL ACTIVITY FI, P569; COX DR, 1972, J R STAT SOC B, V34, P187; FAGARD RH, 1994, PHYSICAL ACTIVITY FI, P633; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Kriska A M, 1994, Exerc Sport Sci Rev, V22, P121; MORRIS JN, 1990, BRIT HEART J, V63, P325; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; POLLOCK ML, 1982, AM HEART J, V103, P363, DOI 10.1016/0002-8703(82)90275-7; Stefanovic-Racic M., 1994, P417	18	1251	1276	3	136	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					205	210		10.1001/jama.276.3.205	http://dx.doi.org/10.1001/jama.276.3.205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667564				2022-12-24	WOS:A1996UW46900031
J	Klesges, RC; Ward, KD; Shelton, ML; Applegate, WB; Cantler, ED; Palmieri, GMA; Harmon, K; Davis, J				Klesges, RC; Ward, KD; Shelton, ML; Applegate, WB; Cantler, ED; Palmieri, GMA; Harmon, K; Davis, J			Changes in bone mineral content in male athletes - Mechanisms of action and intervention effects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY ABSORPTIOMETRY; LONG-DISTANCE RUNNERS; BODY-COMPOSITION; DENSITY; EXERCISE; MASS	Objectives.-To determine changes in bane mineral content (BMC) in male athletes, to examine the mechanisms of changes, and to evaluate the effects of intervention. Design.-Dual-energy x-ray absorptiometry (DEXA) tests were administered over a 2-year period, and calcium loss during training was determined by analysis of sweat and urine. Calcium supplementation was administered during year 2. Setting.-A midsouth university. Participants.-Eleven members of a college Division I-A basketball team. Intervention.-Based on observed calcium loss, athletes received differential levels of calcium supplementation. intervention commenced the week prior to the fall training season and continued through postseason play. Main Outcome Measure.-Changes in BMC. Results.-Total body BMC decreased 3.8% from preseason to midseason of year 1 (mean decrease, 133.4 g, P=.02), increased nonsignificantly by 1.1% (mean increase, 35.3 g, P=.22) during the offseason, but decreased an additional 3.3% during summer months when practices resumed (mean decrease, 113.1 g, P=.01). Dermal calcium loss averaged 422 mg per training session, From preseason to late summer, there was an overall decrease of 6.1% in total BMC and a 10.5% decrease in BMC of the legs, Calcium supplementation was associated with significant increases in BMC and lean body mass. Conclusions.-Bone loss is calcium related and exercise is positively related to BMC provided that calcium intake is sufficient to offset dermal loss.	MEMPHIS UNIV,DEPT ATHLET,MEMPHIS,TN 38152; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN; UNIV TENNESSEE,DEPT UNIV PHARM,MEMPHIS,TN	University of Memphis; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Klesges, RC (corresponding author), MEMPHIS UNIV,DEPT PSYCHOL,UNIV PREVENT CTR,MEMPHIS,TN 38152, USA.							BILANIN JE, 1989, MED SCI SPORT EXER, V21, P66, DOI 10.1249/00005768-198902000-00012; CHARLES P, 1991, AM J CLIN NUTR, V54, pS266, DOI 10.1093/ajcn/54.1.266S; CHU JY, 1979, AM J CLIN NUTR, V32, P1699, DOI 10.1093/ajcn/32.8.1699; CUMMINGS SR, 1995, AM J MED S2A, V98, P245; GOING SB, 1993, AM J CLIN NUTR, V57, P845, DOI 10.1093/ajcn/57.6.845; GUTIN B, 1992, OSTEOPOROSIS INT, V2, P55, DOI 10.1007/BF01623838; Hertzler A. A., 1994, Topics in Clinical Nutrition, V9, P76; HETLAND ML, 1993, J CLIN ENDOCR METAB, V77, P770, DOI 10.1210/jc.77.3.770; JOHNSON AW, 1994, AM J SPORT MED, V22, P248, DOI 10.1177/036354659402200216; KELLIE SE, 1992, JAMA-J AM MED ASSOC, V267, P286; KIRBY CR, 1986, J APPL PHYSIOL, V61, P969; MACDOUGALL JD, 1992, J APPL PHYSIOL, V73, P1165, DOI 10.1152/jappl.1992.73.3.1165; MARCUS R, 1988, ADV SPORTS MED FITNE, V1, P63; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MYBURGH KH, 1990, ANN INTERN MED, V113, P754, DOI 10.7326/0003-4819-113-10-754; NELSON ME, 1991, AM J CLIN NUTR, V53, P1303; PALMIERI GMA, 1995, MINER ELECTROL METAB, V21, P236; PATTEN BM, 1974, ANN INTERN MED, V80, P182, DOI 10.7326/0003-4819-80-2-182; RICO H, 1993, J SPORT MED PHYS FIT, V33, P278; ROUBENOFF R, 1993, AM J CLIN NUTR, V58, P589, DOI 10.1093/ajcn/58.5.589; Scrimshaw NS, 1988, AM J CLIN NUTR S, V48, P1086; SUOMINEN H, 1993, SPORTS MED, V16, P316, DOI 10.2165/00007256-199316050-00003; TIPTON K, 1993, INT J SPORT NUTR, V3, P261, DOI 10.1123/ijsn.3.3.261; VOELLKOPF W, 1995, ATOM SPECTROSC, V16, P19; Williams M H, 1989, Int J Vitam Nutr Res Suppl, V30, P163; 1994, JAMA-J AM MED ASSOC, V272, P1942	26	109	113	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					226	230		10.1001/jama.276.3.226	http://dx.doi.org/10.1001/jama.276.3.226			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667568				2022-12-24	WOS:A1996UW46900035
J	Nudler, E; Avetissova, E; Markovtsov, V; Goldfarb, A				Nudler, E; Avetissova, E; Markovtsov, V; Goldfarb, A			Transcription processivity: Protein-DNA interactions holding together the elongation complex	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; CHAIN ELONGATION; GENE-EXPRESSION; TERMINATION; KINETICS; PROMOTER; SUBUNITS	The elongation of RNA chains during transcription occurs in a ternary complex containing RNA polymerase (RNAP), DNA template, and nascent RNA. It is shown here that elongating RNAP from Escherichia coli can switch DNA templates by means of end-to-end transposition without loss of the transcript. After the switch, transcription continues on the new template. With the use of defined short DNA fragments as switching templates, RNAP-DNA interactions were dissected into two spatially distinct components, each contributing to the stability of the elongating complex. The front (F) interaction occurs ahead of the growing end of RNA. This interaction is non-ionic and requires 7 to 9 base pairs of intact DNA duplex. The rear (R) interaction is ionic and requires approximately six nucleotides of the template DNA strand behind the active site and one nucleotide ahead of it. The nontemplate strand is not involved. With the use of protein DNA crosslinking, the F interaction was mapped to the conserved zinc finger motif in the NH2-terminus of the beta' subunit and the R interaction, to the COOH-terminal catalytic domain of the beta subunit. Mutational disruption of the zinc finger selectively destroyed the F interaction and produced a salt-sensitive ternary complex with diminished processivity. A model of the ternary complex is proposed here that suggests that trilateral contacts in the active center maintain the nonprocessive complex, whereas a front-end domain including the zinc finger ensures processivity.			Nudler, E (corresponding author), PUBL HLTH RES INST,NEW YORK,NY 10016, USA.			Nudler, Evgeny/0000-0002-8811-3071	NIGMS NIH HHS [GM49242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERGSLAND KJ, 1991, J BACTERIOL, V173, P3446, DOI 10.1128/jb.173.11.3446-3455.1991; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CLERGET M, 1995, J MOL BIOL, V248, P768, DOI 10.1006/jmbi.1995.0259; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; GIEDROC DP, 1986, BIOCHEMISTRY-US, V25, P4969, DOI 10.1021/bi00365a037; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MARKOVTSOV V, 1996, P NATL ACAD SCI USA, V93, P3231; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; NUDLER E, 1995, CELL, V81, P353; NUDLER E, UNPUB; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TELESNITSKY APW, 1992, J MOL BIOL, V225, P239; TREICH I, 1991, J BIOL CHEM, V266, P21971; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	40	175	177	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1996	273	5272					211	217		10.1126/science.273.5272.211	http://dx.doi.org/10.1126/science.273.5272.211			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW787	8662499				2022-12-24	WOS:A1996UW78700033
J	Jones, E; Jarvis, P; Lewis, JA; Ebbutt, AF				Jones, E; Jarvis, P; Lewis, JA; Ebbutt, AF			Trials to assess equivalence: The importance of rigorous methods	BMJ-BRITISH MEDICAL JOURNAL			English	Article								The aim of an equivalence trial Is to show the therapeutic equivalence of two treatments, usually a new drug under development and an existing drug for the same disease used as a standard active comparator. Unfortunately the principles that govern the design, conduct, and analysis of equivalence trials are not as well understood as they should be. Consequently such trials often include too few patients or have intrinsic design biases which tend towards the conclusion of no difference. In addition the application of hypo; thesis testing in analysing and interpreting data from such trials sometimes compounds the drawing of inappropriate conclusions, and the inclusion and exclusion of patients from analysis may be poorly managed. The design of equivalence trials should mirror that of earlier successful trials of the active comparator as closely as possible, Patient losses and other deviations from the protocol should be minimised; analysis strategies to deal with unavoidable problems should not centre on an ''intention to treat'' analysis but should seek to show the similarity of results from a range of approaches, Analysis should be based on confidence intervals, and this also carries implications for the estimation of the required numbers of patients at the design stage.	DE MONTFORT UNIV, SCH COMP SCI, DEPT MED STAT, LEICESTER LE1 9BH, LEICS, ENGLAND; GLAXO WELLCOME LTD, GREENFORD UB6 0HE, MIDDX, ENGLAND	De Montfort University; GlaxoSmithKline								ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; CAMPBELL MJ, 1995, BRIT MED J, V311, P1145, DOI 10.1136/bmj.311.7013.1145; HENRY D, 1995, BMJ-BRIT MED J, V310, P1279, DOI 10.1136/bmj.310.6990.1279; LEWIS JA, 1995, STAT MED, V14, P1655, DOI 10.1002/sim.4780141506; LEWIS JA, 1993, BRIT J CANCER, V68, P647, DOI 10.1038/bjc.1993.402; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MAKUCH RW, 1990, STAT ISSUES DRUG RES, P225; Pocock SJ, 1983, CLIN TRIALS PRACTICA; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SALSBURG D, 1994, PHARMACOEPIDEM DR S, V3, P329; TAUBES G, 1995, SCIENCE, V267, P25, DOI 10.1126/science.7809605; Temple R, 1982, DRUG INF J, V10-17, DOI DOI 10.1177/009286158201600102; 1995, STAT MED, V14, P1658; 1995, NEW ENGL J MED, V332, P60	14	744	757	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	1996	313	7048					36	39		10.1136/bmj.313.7048.36	http://dx.doi.org/10.1136/bmj.313.7048.36			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW667	8664772	Green Published			2022-12-24	WOS:A1996UW66700031
J	Moore, MW; Klein, RD; Farinas, I; Sauer, H; Armanini, M; Phillips, H; Reichardt, LF; Ryan, AM; CarverMoore, K; Rosenthal, A				Moore, MW; Klein, RD; Farinas, I; Sauer, H; Armanini, M; Phillips, H; Reichardt, LF; Ryan, AM; CarverMoore, K; Rosenthal, A			Renal and neuronal abnormalities in mice lacking GDNF	NATURE			English	Article							DOPAMINERGIC-NEURONS	GLIAL cell-line derived neurotrophic factor (GDNF) is a potent survival factor for embryonic midbrain dopaminergic(1), spinal motor(2), cranial sensory(3), sympathetic, and hindbrain noradrenergic(4) neurons, and is available to these cells in vivo. It is therefore considered a physiological trophic factor and a potential therapeutic agent for Parkinson's disease(5,6), amyotrophic lateral sclerosis(7), and Alzheimer's disease(4). Here we show that at postnatal day 0 (P0), GDNF-deficient mice have deficits in dorsal root ganglion, sympathetic and nodose neurons, but not in hindbrain noradrenergic or midbrain dopaminergic neurons. These mice completely lack the enteric nervous system (ENS), ureters and kidneys. Thus GDNF is important for the development and/or survival of enteric, sympathetic and sensory neurons and the renal system, but is not essential for catecholaminergic neurons in the central nervous system (CNS).	GENENTECH INC, DEPT NEUROSCI, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT PATHOBIOL, S SAN FRANCISCO, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco			Farinas, Isabel/L-7118-2014	Farinas, Isabel/0000-0003-2903-4960				Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; COYLE JT, 1976, J NEUROCHEM, V27, P673, DOI 10.1111/j.1471-4159.1976.tb10393.x; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Durbec PL, 1996, DEVELOPMENT, V122, P349; GERSHON MD, 1993, J NEUROBIOL, V24, P199, DOI 10.1002/neu.480240207; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HIRANO A, 1991, ADV NEUROL, V56, P91; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; HORNYKIEWICZ O, 1988, MT SINAI J MED, V55, P11; HUMPEL C, 1994, NEUROSCIENCE, V59, P791, DOI 10.1016/0306-4522(94)90284-4; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LICHING L, 1995, NEURON, V15, P527; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; SAUER H, 1995, P NATL ACAD SCI USA, V92, P8935, DOI 10.1073/pnas.92.19.8935; Saxen L., 1987, ORGANOGENESIS KIDNEY, V19; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SCHMIDTKASTNER R, 1994, MOL BRAIN RES, V26, P325, DOI 10.1016/0169-328X(94)90106-6; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	30	1036	1079	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 4	1996	382	6586					76	79		10.1038/382076a0	http://dx.doi.org/10.1038/382076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV473	8657308				2022-12-24	WOS:A1996UV47300057
J	Nightingale, SL				Nightingale, SL			Comments requested on direct-to-consumer promotion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKLAND,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					14	14						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667525				2022-12-24	WOS:A1996UU43900005
J	Orwar, O; Jardemark, K; Jacobson, I; Moscho, A; Fishman, HA; Scheller, RH; Zare, RN				Orwar, O; Jardemark, K; Jacobson, I; Moscho, A; Fishman, HA; Scheller, RH; Zare, RN			Patch-clamp detection of neurotransmitters in capillary electrophoresis	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; METHYL-D-ASPARTATE; CEREBELLAR GRANULE CELLS; FRESHLY ISOLATED NEURONS; RAT OLFACTORY-BULB; SYNAPTIC TRANSMISSION; GROWTH CONES; CURRENTS; GLUTAMATE; CHANNELS	Gamma-aminobutyrate acid, L-glutamate, and N-methyl-D-aspartate were separated by capillary electrophoresis and detected by the use of whole-cell and outside-out patch-clamp techniques on freshly dissociated rat olfactory interneurons. These neuroactive compounds could be identified from their electrophoretic migration times, unitary channel conductances, and power spectra that yielded corner frequencies and mean single-channel conductances characteristic for each of the different agonist-receptor interactions. This technique has the sensitivity to observe the opening of a single ion channel for agonists separated by capillary electrophoresis.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; GOTHENBURG UNIV,DEPT ANAT & CELL BIOL,S-41390 GOTHENBURG,SWEDEN; STANFORD UNIV,HOWARD HUGHES INST,DEPT MOL & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University; University of Gothenburg; Howard Hughes Medical Institute; Stanford University			Zare, Richard N./A-8410-2009	Zare, Richard/0000-0001-5266-4253	NIDA NIH HHS [DA 09873-01] Funding Source: Medline; NIMH NIH HHS [R01 MH112188, MH 45423-06] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045423, R01MH112188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009873] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; ANDINE P, 1991, J NEUROCHEM, V57, P230, DOI 10.1111/j.1471-4159.1991.tb02120.x; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; BUCH RM, 1989, ANAL CHEM, V61, pA533, DOI 10.1021/ac00183a001; BUFLER J, 1992, J COMP PHYSIOL A, V170, P153; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLQUHOUN D, 1977, PROC R SOC SER B-BIO, V199, P231, DOI 10.1098/rspb.1977.0137; COPENHAGEN DR, 1989, NATURE, V341, P536, DOI 10.1038/341536a0; CULLCANDY S, 1995, CURR BIOL, V5, P841, DOI 10.1016/S0960-9822(95)00168-0; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DO KQ, 1986, J NEUROCHEM, V46, P779, DOI 10.1111/j.1471-4159.1986.tb13040.x; FISHMAN HA, 1995, P NATL ACAD SCI USA, V92, P7877, DOI 10.1073/pnas.92.17.7877; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; HU YB, 1994, BRAIN RES, V659, P117, DOI 10.1016/0006-8993(94)90870-2; HUME RI, 1983, NATURE, V305, P632, DOI 10.1038/305632a0; JACOBSON I, 1991, NEUROSCI RES COMMUN, V8, P11; JACOBSON I, 1992, NEUROSCI RES COMMUN, V10, P177; Jahr C E, 1992, Curr Opin Neurobiol, V2, P270, DOI 10.1016/0959-4388(92)90114-Z; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KANEDA M, 1995, J PHYSIOL-LONDON, V485, P419, DOI 10.1113/jphysiol.1995.sp020739; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; KILIC G, 1993, EUR J NEUROSCI, V5, P65, DOI 10.1111/j.1460-9568.1993.tb00206.x; KIMURA M, 1995, NEUROSCIENCE, V66, P609, DOI 10.1016/0306-4522(95)00023-C; LEAL WS, 1995, P NATL ACAD SCI USA, V92, P1033, DOI 10.1073/pnas.92.4.1033; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LI XY, 1993, NEUROSCI LETT, V155, P42, DOI 10.1016/0304-3940(93)90669-C; MA GH, 1995, MOL PHARMACOL, V47, P1035; MAEDA T, 1995, NEURON, V15, P253, DOI 10.1016/0896-6273(95)90031-4; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MELDRUM B, 1995, DIVERSITY INTERACTIN, V757, P492; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; OLNEY JW, 1975, J NEUROPATH EXP NEUR, V34, P167, DOI 10.1097/00005072-197503000-00005; ORWAR O, 1994, J NEUROCHEM, V63, P1371; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; RECHNITZ GA, 1978, SCIENCE, V199, P440, DOI 10.1126/science.619467; Sakmann B., 1995, SINGLE CHANNEL RECOR; SANDBERG M, 1986, J NEUROCHEM, V47, P178; SCHONROCK B, 1993, EUR J NEUROSCI, V5, P1042, DOI 10.1111/j.1460-9568.1993.tb00957.x; SHEAR JB, 1995, SCIENCE, V267, P74, DOI 10.1126/science.7809609; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; Trombley P Q, 1993, Curr Opin Neurobiol, V3, P540, DOI 10.1016/0959-4388(93)90053-2; TROMBLEY PQ, 1994, J NEUROPHYSIOL, V71, P761, DOI 10.1152/jn.1994.71.2.761; TROMBLEY PQ, 1990, J NEUROPHYSIOL, V64, P598, DOI 10.1152/jn.1990.64.2.598; WALLINGFORD RA, 1987, ANAL CHEM, V59, P1762, DOI 10.1021/ac00141a005; WEISS JH, 1988, SCIENCE, V241, P973, DOI 10.1126/science.3136549; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0; ZOLLINGER M, 1994, J NEUROCHEM, V63, P1133	51	39	42	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1779	1782		10.1126/science.272.5269.1779	http://dx.doi.org/10.1126/science.272.5269.1779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650575				2022-12-24	WOS:A1996UT11000040
J	Sabbert, D; Engelbrecht, S; Junge, W				Sabbert, D; Engelbrecht, S; Junge, W			Intersubunit rotation in active F-ATPase	NATURE			English	Article							GAMMA-SUBUNIT; SYNTHASE; MECHANISM; DELTA	THE enzyme ATP synthase, or F-ATPase, is present in the membranes of bacteria, chloroplasts and mitochondria, Its structure is bipartite, with a proton-conducting, integral membrane portion, F-0, and a peripheral portion, F-1. Solubilized F-1 is composed of five different subunits, (alpha beta)(3) gamma delta epsilon, and is active as an ATPase(1,2). The function of F-ATPase is to couple proton translocation through F-0 with ATP synthesis in F-1 (ref. 3), Several fines of evidence support the spontaneous formation of ATP on F-1 (refs 4, 5) and its endergonic release(6) at cooperative and rotating (or at feast alternating) sites(7). The release of ATP at the expense of protonmotive force might involve mechanical energy transduction from F-0 into F-1 by rotation of the smaller subunits (mainly gamma) within (alpha beta)(3), the catalytic hexagon of F-1 as suggested by electron microscopy(8), by X-ray crystal structure analysis(9) and by the use of cleavable crosslinkers(10). Here we record an intersubunit rotation in real time in the functional enzyme by applying polarized absorption relaxation after photobleaching to immobilized F-1 with eosin-labelled gamma, We observe the rotation of gamma relative to immobilized (alpha beta)(3) in a timespan of 100 ms, compatible with the rate of ATP hydrolysis by immobilized F-1. Its angular range, which is of at least 200 degrees, favours a triple-site mechanism of catalysis(7,11), with gamma acting as a crankshaft in (alpha beta)(3). The rotation of gamma is blocked when ATP is substituted with its non-hydrolysable analogue AMP-PNP.	UNIV OSNABRUCK,FACHBEREICH BIOL CHEM,BIOPHYS ABT,D-49069 OSNABRUCK,GERMANY	University Osnabruck								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; ENGELBRECHT S, 1989, EUR J BIOCHEM, V179, P117, DOI 10.1111/j.1432-1033.1989.tb14528.x; ENGELBRECHT S, 1986, EUR J BIOCHEM, V160, P635, DOI 10.1111/j.1432-1033.1986.tb10085.x; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; Jablonski A, 1935, Z PHYS, V96, P236, DOI 10.1007/BF01341525; JUNGE W, 1977, BIOCHIM BIOPHYS ACTA, V462, P73, DOI 10.1016/0005-2728(77)90190-6; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; PARKER CA, 1961, T FARADAY SOC, V57, P1894, DOI 10.1039/tf9615701894; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; Perrin F, 1936, J PHYS-PARIS, V7, P1, DOI 10.1051/jphysrad:01936007010100; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; WAGNER R, 1982, BIOCHEMISTRY-US, V21, P1890, DOI 10.1021/bi00537a029; WAHL P, 1975, CHEM PHYS, V7, P210, DOI 10.1016/0301-0104(75)87003-0; WALKER JE, 1994, BIOCHEMIST, V16, P31; WEBER J, 1994, J BIOL CHEM, V269, P20462	22	458	466	1	44	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					623	625		10.1038/381623a0	http://dx.doi.org/10.1038/381623a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637601				2022-12-24	WOS:A1996UQ65700056
J	Wokke, JHJ				Wokke, JHJ			Diseases that masquerade as motor neuron disease	LANCET			English	Editorial Material											Wokke, JHJ (corresponding author), UNIV UTRECHT HOSP,DEPT NEUROL,UTRECHT,NETHERLANDS.							BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BLEXRUD MD, 1993, ANN NEUROL, V34, P622, DOI 10.1002/ana.410340419; BRAAKMAN R, 1994, J NEUROL NEUROSUR PS, V57, P257, DOI 10.1136/jnnp.57.3.257; Davenport RJ, 1996, J NEUROL NEUROSUR PS, V60, P147, DOI 10.1136/jnnp.60.2.147; NIGHTINGALE SL, 1995, JAMA-J AM MED ASSOC, V274, P292; SWASH M, 1992, NEUROMUSCULAR DISORD, V2, P7, DOI 10.1016/0960-8966(92)90020-7; SWASH M, 1988, J NEUROL NEUROSUR PS, V51, P165, DOI 10.1136/jnnp.51.2.165; VANDENBERG LH, 1995, NEUROLOGY, V45, P987, DOI 10.1212/WNL.45.5.987; 1992, J NEUROL NEUROSUR PS, V55, P536	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1347	1348		10.1016/S0140-6736(96)91005-3	http://dx.doi.org/10.1016/S0140-6736(96)91005-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637336	Bronze			2022-12-24	WOS:A1996UL90400004
J	Sromovsky, LA; Best, FA; Collard, AD; Fry, PM; Revercomb, HE; Freedman, RS; Orton, GS; Hayden, JL; Tomasko, MG; Lemmon, MT				Sromovsky, LA; Best, FA; Collard, AD; Fry, PM; Revercomb, HE; Freedman, RS; Orton, GS; Hayden, JL; Tomasko, MG; Lemmon, MT			Solar and thermal radiation in Jupiter's atmosphere: Initial results of the Galileo probe net flux radiometer	SCIENCE			English	Article								The Galileo probe net flux radiometer measured radiation within Jupiter's atmosphere over the 125-kilometer altitude range between pressures of 0.44 bar and 14 bars. Evidence for the expected ammonia cloud was seen in solar and thermal channels down to 0.5 to 0.6 bar. Between 0.6 and 10 bars large thermal fluxes imply very low gaseous opacities and provide no evidence for a deep water cloud. Near 8 bars the water vapor abundance appears to be about 10 percent of what would be expected for a solar abundance of oxygen. Below 8 bars, measurements suggest an increasing water abundance with depth or a deep cloud layer. Ammonia appears to follow a significantly subsaturated profile above 3 bars. Unexpectedly high absorption of sunlight was found at wavelengths greater than 600 nanometers.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; CALTECH,JET PROP LAB,PASADENA,CA 91109; LOCKHEED MARTIN ASTRONAUT,DENVER,CO 80201; UNIV ARIZONA,TUCSON,AZ 85721	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Lockheed Martin; University of Arizona	Sromovsky, LA (corresponding author), UNIV WISCONSIN,MADISON,WI 53706, USA.		Lemmon, Mark/X-2333-2019; Orton, Glenn/AAD-9862-2020; Lemmon, Mark T/E-9983-2010	Lemmon, Mark/0000-0002-4504-5136; Lemmon, Mark T/0000-0002-4504-5136				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; DEPATER I, 1993, J GEOPHYS RES-PLANET, V98, P5471, DOI 10.1029/92JE02810; GIVER LP, 1989, B AM ASTRON SOC, V21, P947; KARKOSCHKA E, 1994, ICARUS, V111, P174, DOI 10.1006/icar.1994.1139; LANZEROTTI LJ, COMMUNICATION; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; RAGENT B, 1996, SCIENCE, V272, P855; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; SROMOVSKY LA, 1992, SPACE SCI REV, V60, P233, DOI 10.1007/BF00216856; SROMOVSKY LA, 1994, P 4 INFR SENS CAL S; WEST RA, 1986, ICARUS, V65, P161, DOI 10.1016/0019-1035(86)90135-1; Young RE, 1996, SCIENCE, V272, P837, DOI 10.1126/science.272.5263.837	14	34	34	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					851	854		10.1126/science.272.5263.851	http://dx.doi.org/10.1126/science.272.5263.851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629018				2022-12-24	WOS:A1996UK75700051
J	Jaegle, M; Mandemakers, W; Broos, L; Zwart, R; Karis, A; Visser, P; Grosveld, F; Meijer, D				Jaegle, M; Mandemakers, W; Broos, L; Zwart, R; Karis, A; Visser, P; Grosveld, F; Meijer, D			The POU factor Oct-6 and Schwann cell differentiation	SCIENCE			English	Article							TRANSCRIPTION FACTOR SCIP; EXPRESSION; GENE; MYELINATION; AXONS	The POU transcription factor Oct-6, also known as SCIP or Tst-1, has been implicated as a major transcriptional regulator in Schwann cell differentiation. Microscopic and immunochemical analysis of sciatic nerves of Oct-6(-/-) mice at different stages of postnatal development reveals a delay in Schwann cell differentiation, with a transient arrest at the promyelination stage. Thus, Oct-6 appears to be required for the transition of promyelin cells to myelinating cells. Once these cells progress past this point, Oct-6 is no longer required, and myelination occurs normally.	ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, NL-3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam			Meijer, Dies/C-7786-2012	Meijer, Dies/0000-0002-8461-6341; Mandemakers, Wim/0000-0003-2673-5972				HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; Jessen K R, 1992, Curr Opin Neurobiol, V2, P575, DOI 10.1016/0959-4388(92)90021-C; JESSEN KR, 1994, NEURON, V12, P509, DOI 10.1016/0896-6273(94)90209-7; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; Lemke G., 1992, INTRO MOL NEUROBIOLO, P281; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; SCHERER SS, 1994, J NEUROSCI, V14, P1930; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; WEINBERG HJ, 1975, J NEUROCYTOL, V4, P395, DOI 10.1007/BF01261372; WEINSTEIN DE, 1995, MOL CELL NEUROSCI, V6, P212, DOI 10.1006/mcne.1995.1018; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Zwart R, 1996, MECH DEVELOP, V54, P185, DOI 10.1016/0925-4773(95)00472-6; ZWART R, 1996, THESIS ERASMUS U ROT	20	228	231	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1996	273	5274					507	510		10.1126/science.273.5274.507	http://dx.doi.org/10.1126/science.273.5274.507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8662541				2022-12-24	WOS:A1996UY98300043
J	Lai, RS; Chiang, AA; Wu, MT; Wang, JS; Lai, NS; Lu, JY; Ger, LP; Roggli, V				Lai, RS; Chiang, AA; Wu, MT; Wang, JS; Lai, NS; Lu, JY; Ger, LP; Roggli, V			Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan	LANCET			English	Article								Background In August, 1995, there was an outbreak in Taiwan of rapidly progressive respiratory distress associated with consumption of uncooked Sauropus androgynus, a vegetable with a claimed yet unconfirmed effect on weight control. We report on 23 patients with strikingly similar clinical presentations. Methods A structured questionnaire for clinical manifestations was completed. Radiographic findings, pulmonary physiological changes, immunological and microbiological studies, and pathological examination were evaluated. Findings All patients were young and middle-aged women (mean age 39 years [range 21-52]). They took uncooked S androgynus juice, generally mixed with guava or pineapple juice, for a mean duration of 10 weeks. Progressive dyspnoea and persistent cough were the main symptoms on presentation. Pulmonary function testing uniformly revealed moderate to severe airflow obstruction with mean forced expiratory volume in 1 s (FEV(1)) of 0 . 66 L (26% of predicted). No bronchodilator response was observed. Room-air arterial blood gas analysis showed hypoxaemia (mean PaO2 9 . 6 [SD 1 . 6] kPa). Chest radiographs were essentially normal. High-resolution computed tomography showed bilateral bronchiectasis and patchy low attenuation of lung parenchyma with mosaic perfusion. Ventilation-perfusion scintigraphic findings were compatible with obstructive lung disease. Histopathology of open lung biopsy specimens in four patients confirmed the presence of bronchiolitis obliterans. Immunohistochemical stains of the open lung biopsy specimens showed predominance of T cells over B cells. Immunofluorescent stains for IgG, IgM, IgA, C1q, C3, and C4 were negative. Serum concentrations of tumour necrosis factor a were higher than those of normal controls. Clinical response to prednisolone was limited. Interpretation We describe an unusual association between bronchiolitis obliterans and ingestion of the vegetable S androgynus. T-cell mediated immunity may be involved in the pathogenesis.	VET GEN HOSP, DEPT RADIOL, KAOHSIUNG, TAIWAN; VET GEN HOSP, DEPT PATHOL, KAOHSIUNG, TAIWAN; VET GEN HOSP, DEPT MED RES, KAOHSIUNG, TAIWAN; VET GEN HOSP, DIV RHEUMATOL & IMMUNOL, TAICHUNG, TAIWAN; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	Duke University	Lai, RS (corresponding author), VET GEN HOSP, DEPT MED, DIV CHEST MED, 386 TACHUNG 1ST RD, KAOHSIUNG, TAIWAN.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P1299; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Bender A. E., 1975, Plant Foods for Man, V1, P139; COLBY TV, 1992, SEMIN RESPIR MED, V13, P119, DOI 10.1055/s-2007-1006264; KING TE, 1993, CLIN CHEST MED, V14, P607; MULLER NL, 1995, RADIOLOGY, V196, P3; PADMAVATHI P, 1990, PLANT FOOD HUM NUTR, V40, P107, DOI 10.1007/BF02193767; WEBB WR, 1995, HIGH RESOLUTION CT L, P206; WRIGHT JL, 1992, AM REV RESPIR DIS, V146, P240, DOI 10.1164/ajrccm/146.1.240; YANG SC, 1993, J FORMOS MED ASS S3, V92, P152; YUNG C-H, 1990, Chinese Journal of Microbiology and Immunology (Taipei), V23, P312	11	66	66	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	1996	348	9020					83	85		10.1016/S0140-6736(96)00450-3	http://dx.doi.org/10.1016/S0140-6736(96)00450-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676721				2022-12-24	WOS:A1996UW67300009
J	Soll, RF				Soll, RF			Neonatal extracorporeal membrane oxygenation - A bridging technique	LANCET			English	Editorial Material							RESPIRATORY-FAILURE; CIRCULATION				Soll, RF (corresponding author), UNIV VERMONT,DEPT PEDIAT,BURLINGTON,VT 05405, USA.							BARTLETT RH, 1985, PEDIATRICS, V76, P479; BARTLETT RH, 1982, SURGERY, V92, P425; BARTLETT RH, 1976, T AM SOC ART INT ORG, V22, P80; GREER AL, 1993, NIH PUBLICATION; KANTO WP, 1994, J PEDIATR, V124, P35; WALSHSUKYS M, 1994, J PEDIATR-US, V124, P427; WARE JH, 1985, PEDIATRICS, V76, P849; 1988, LANCET, V2, P1289	8	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					70	71						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676714				2022-12-24	WOS:A1996UW67300002
J	Mummenbrauer, T; Janus, F; Muller, B; Wiesmuller, L; Deppert, W; Grosse, F				Mummenbrauer, T; Janus, F; Muller, B; Wiesmuller, L; Deppert, W; Grosse, F			p53 protein exhibits 3'-to-5' exonuclease activity	CELL			English	Article							WILD-TYPE P53; POLYMERASE-ALPHA-PRIMASE; DNA MISMATCH CORRECTION; NUCLEAR ACCUMULATION; GENE-EXPRESSION; BINDING-SITE; CALF THYMUS; REPLICATION; GROWTH; REPAIR	Highly purified p53 protein from different sources was able to degrade DNA with a 3'-to-5' polarity, yielding deoxynucleoside monophosphates as reaction products. This exonuclease activity was dependent on Mg2+ and inhibited by addition of 5 mM nucleoside monophosphates. This exonuclease activity is intrinsic to the wild-type p53 protein: it copurified with p53 during p53 preparation; only purified wild-type p53, but not identically purified mutant p53 proteins displayed exonuclease activity; the exonuclease activity could be reconstituted from SDS gel-purified and urea-renatured p53 protein and mapped to the core domain of the p53 molecule; and finally, purified p53 protein could be UV cross-linked to GMP. A p53-intrinsic exonuclease activity should substantially extend our view on the role of p53 as a ''guardian of the genome.''	INST MOL BIOTECHNOL,BIOCHEM ABT,D-07745 JENA,GERMANY		Mummenbrauer, T (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,D-20251 HAMBURG,GERMANY.							BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BIALEK G, 1993, J BIOL CHEM, V268, P6024; BODMER W, 1994, NAT GENET, V6, P217, DOI 10.1038/ng0394-217; BRAIN R, 1994, ONCOGENE, V9, P1775; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Grosse Frank, 1993, V16, P95; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HOHN KT, 1987, BIOCHEMISTRY-US, V26, P2870, DOI 10.1021/bi00384a031; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kornberg A., 1991, DNA REPLICATION; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linn S.M., 1993, NUCLEASES; MARX J, 1993, SCIENCE, V262, P1644, DOI 10.1126/science.8259506; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P371; MIYASHITA T, 1995, CELL, V80, P293; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; MODRICH P, 1989, J BIOL CHEM, V264, P6597; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; MULLER B, 1996, IN PRESS ONCOGENE; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RADMAN M, 1993, NATURE, V366, P722, DOI 10.1038/366722a0; ROLLEY N, 1995, ONCOGENE, V11, P763; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STEINMEYER K, 1988, ONCOGENE, V3, P501; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wiesmuller L, 1996, J VIROL, V70, P737; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	82	238	239	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1089	1099		10.1016/S0092-8674(00)81309-4	http://dx.doi.org/10.1016/S0092-8674(00)81309-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674115	Bronze			2022-12-24	WOS:A1996UV48400015
J	Sharp, D				Sharp, D			Gun deaths in schools, in the USA	LANCET			English	Editorial Material																		Ash P, 1996, JAMA-J AM MED ASSOC, V275, P1754, DOI 10.1001/jama.275.22.1754; Burns R, 1996, JAMA-J AM MED ASSOC, V275, P1775; Kachur SP, 1996, JAMA-J AM MED ASSOC, V275, P1729, DOI 10.1001/jama.275.22.1729	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 22	1996	347	9017					1712	1712		10.1016/S0140-6736(96)90805-3	http://dx.doi.org/10.1016/S0140-6736(96)90805-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT396	8656903				2022-12-24	WOS:A1996UT39600007
J	Sieratzki, JS; Woll, B				Sieratzki, JS; Woll, B			Why do mothers cradle babies on their left?	LANCET			English	Article							CARRYING NEWBORN-INFANTS; LEFT-SIDE PREFERENCE; HANDEDNESS; LATERALITY; PERCEPTION; HEARTBEAT; LANGUAGE; CHILD	Many explanations have been put forward for the observed preference of mothers to cradle babies on the left side. These include handedness, the importance of the maternal heartbeat, left breast sensitivity, socio-psychological factors, and advantages in monitoring the infant. We propose that protection and facilitation of affective communication Is at the core of cradling; and explore the relation between left-cradling and the role of the right hemisphere in early mother-infant interaction. Left-cradling not only directs maternal communication to the infant's right hemisphere but also facilitates affective feedback to the maternal right brain. The underlying neuro-linguistic mechanisms proposed in this article may be important in the early course of child language development and may also serve to illuminate our understanding of the evolution of human language.	CITY UNIV LONDON, DEPT CLIN COMMUN STUDIES, LONDON EC1V 0HB, ENGLAND	City University London	Sieratzki, JS (corresponding author), HAMMERSMITH HOSP, DEPT PAEDIAT & NEONATOL, LONDON, ENGLAND.		Woll, Bencie/C-2040-2008	Woll, Bencie/0000-0002-3300-4775				BERTONCINI J, 1989, BRAIN LANG, V37, P591, DOI 10.1016/0093-934X(89)90113-2; BOGREN LY, 1984, ACTA PSYCHIAT SCAND, V69, P13, DOI 10.1111/j.1600-0447.1984.tb04512.x; BOROD JC, 1990, BRAIN COGNITION, V13, P167, DOI 10.1016/0278-2626(90)90048-S; BRYDEN MP, 1991, CORTEX, V27, P229, DOI 10.1016/S0010-9452(13)80127-X; CODE C, 1984, EXPT CLIN PHONETICS, P166; Cruttenden A., 1994, INPUT INTERACTION LA, P135, DOI 10.1017/cbo9780511620690.008; DAVIDSON RJ, 1995, CURR OPIN NEUROBIOL, V5, P217, DOI 10.1016/0959-4388(95)80029-8; DECHATEAU P, 1987, ACTA PSYCHIAT SCAND, V75, P283; DECHATEAU P, 1976, DEV MED CHILD NEUROL, V18, P738; DIENSKE H, 1995, BEHAVIOUR, V132, P801, DOI 10.1163/156853995X00153; FERNALD A, 1989, J CHILD LANG, V16, P477, DOI 10.1017/S0305000900010679; FIFER WP, 1994, ACTA PAEDIATR, V83, P86, DOI 10.1111/j.1651-2227.1994.tb13270.x; FINGER S, 1975, CHILD DEV, V46, P267; GINSBURG HJ, 1979, CHILD DEV, V50, P280, DOI 10.2307/1129073; Hellige J. B., 1993, HEMISPHERIC ASYMMETR; HUHEEY JE, 1977, BEHAV GENET, V7, P29; Kupfermann I., 1991, PRINCIPLES NEURAL SC, P823; LUCAS MD, 1993, J GENET PSYCHOL, V154, P347; MANNING JT, 1990, ANIM BEHAV, V39, P1224, DOI 10.1016/S0003-3472(05)80800-0; MANNING JT, 1994, J COMP PSYCHOL, V108, P262, DOI 10.1037/0735-7036.108.3.262; PALMQVIST H, 1975, CHILD DEV, V46, P292; ROSS ED, 1993, NEUROL CLIN, V11, P9, DOI 10.1016/S0733-8619(18)30168-3; SALING MM, 1984, CURR ANTHROPOL, V25, P333, DOI 10.1086/203140; SALK L, 1973, SCI AM, V228, P24, DOI 10.1038/scientificamerican0573-24; SHIPLEYBROWN F, 1988, BRAIN LANG, V33, P16, DOI 10.1016/0093-934X(88)90051-X; SOLMS KLK, 1988, PERCEPT MOTOR SKILL, V67, P55; THOMPSON AM, 1993, CORTEX, V29, P649, DOI 10.1016/S0010-9452(13)80288-2; TREHUB SE, 1993, ADV CHILD DEV BEHAV, V24, P1, DOI 10.1016/S0065-2407(08)60298-0; WEILAND JH, 1970, J GENET PSYCHOL, V117, P157; WEINSTEIN S, 1963, AM J PSYCHOL, V76, P475, DOI 10.2307/1419791; Woll B., 1989, SOCIAL COGNITIVE ASP, P129	31	67	69	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 22	1996	347	9017					1746	1748		10.1016/S0140-6736(96)90813-2	http://dx.doi.org/10.1016/S0140-6736(96)90813-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UT396	8656911				2022-12-24	WOS:A1996UT39600015
J	Jackson, SR; Avery, NC; Tarlton, JF; Echford, SD; Abrams, P; Bailey, AJ				Jackson, SR; Avery, NC; Tarlton, JF; Echford, SD; Abrams, P; Bailey, AJ			Changes in metabolism of collagen in genitourinary	LANCET			English	Article								Background Genitourinary prolapse is a common problem, the pathophysiology of which is unknown. Methods We analysed vaginal-epithelial tissue from premenopausal women with genitourinary prolapse and compared them with controls. Findings We found that genitourinary prolapse is associated with a reduction in total collagen content and a decrease in collagen solubility. Both intermediate intermolecular cross-links acid advanced glycation crosslinks were increased in prolapse tissue. Collagen turnover, as indicated by matrix metalloproteinase activity, was up to four times higher in prolapse tissue. Collagen-type ratios, mature cross-link pyridinoline and total elastin content were similar in both prolapse and control tissues. Increased collagenolytic activity causes loss of collagen from prolapse tissue. Interpretation Based on these findings, we have identified a probable mechanism for genitourinary prolapse. Development of agents to inhibit collagenolytic activity may help in the treatment of this condition.	UNIV BRISTOL, COLLLAGEN RES GRP, BRISTOL, AVON, ENGLAND	University of Bristol	Jackson, SR (corresponding author), SOUTHMEAD GEN HOSP, BRISTOL UROL INST, BRISTOL BS10 5NB, AVON, ENGLAND.							AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; BAILEY AJ, 1995, BIOCHEM J, V305, P385, DOI 10.1042/bj3050385; BAILEY AJ, 1994, J HAND SURG-BRIT EUR, V19B, P522, DOI 10.1016/0266-7681(94)90220-8; BANNISTER DW, 1970, ANALYST, V95, P596, DOI 10.1039/an9709500596; BRINCAT M, 1983, BRIT MED J, V287, P1337, DOI 10.1136/bmj.287.6402.1337; el-Kholi G Y, 1975, J Egypt Med Assoc, V58, P196; Keane D, 1992, NEUROUROL URODYNAM, V11, P308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHT ND, 1982, BIOCHIM BIOPHYS ACTA, V702, P30, DOI 10.1016/0167-4838(82)90024-3; LIGHT ND, 1982, STRUCTURAL CONTRACTI; MAKINEN J, 1986, ARCH GYNECOL OBSTET, V239, P17, DOI 10.1007/BF02134283; MATRISIAN LM, 1994, CONTRIB NEPHROL, V107, P94; NAGASE H, 1994, CONTRIB NEPHROL, V107, P85; NORTON DP, 1990, MATER LETT, V9, P321, DOI 10.1016/0167-577X(90)90170-Q; SAYER TR, 1990, NEUROUROL URODYNAM, V9, P319; SELL DR, 1989, J BIOL CHEM, V264, P21597; SIMS TJ, 1992, J CHROMATOGR-BIOMED, V582, P49, DOI 10.1016/0378-4347(92)80301-6	17	273	286	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1658	1661		10.1016/S0140-6736(96)91489-0	http://dx.doi.org/10.1016/S0140-6736(96)91489-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642960				2022-12-24	WOS:A1996UQ70100012
J	Wang, G; Tanaka, K; Tanifuji, M				Wang, G; Tanaka, K; Tanifuji, M			Optical imaging of functional organization in the monkey inferotemporal cortex	SCIENCE			English	Article							ORIENTATION SELECTIVITY; INTRINSIC SIGNALS; NEURONAL-ACTIVITY; STRIATE CORTEX; VISUAL-CORTEX; MACAQUE; ARCHITECTURE; OBJECTS	To investigate the functional organization of object recognition, the technique of optical imaging was applied to the primate inferotemporal cortex, which is thought to be essential for object recognition. The features critical for the activation of single cells were first determined in unit recordings with electrodes. In the subsequent optical imaging, presentation of the critical features activated patchy regions around 0.5 millimeters in diameter, covering the site of the electrode penetration at which the critical feature had been determined. Because signals in optical imaging reflect average neuronal activities in the regions, the result directly indicates the regional clustering of cells responding to similar features.	RIKEN,FRONTIER RES PROGRAM,LAB NEURAL INFORMAT PROC,WAKO,SAITAMA 35101,JAPAN; RIKEN,INFORMAT SCI LAB,WAKO,SAITAMA 35101,JAPAN; KAGOSHIMA UNIV,FAC MED,DEPT PHYSIOL 2,KAGOSHIMA 890,JAPAN; FUKUI UNIV,DEPT INFORMAT SCI,FUKUI 910,JAPAN; RES DEV CORP JAPAN,PRECURSORY RES EMBRYON SCI & TECHNOL,FUKUI 910,JAPAN	RIKEN; RIKEN; Kagoshima University; University of Fukui; Japan Science & Technology Agency (JST)			Tanifuji, Manabu/H-1744-2019; Wang, Gang/Y-4549-2019; Tanaka, Keiji/N-5917-2015	Tanifuji, Manabu/0000-0001-7754-7774; Wang, Gang/0000-0002-4512-634X; Tanaka, Keiji/0000-0002-1910-3427				BALLARD DH, 1986, BEHAV BRAIN SCI, V9, P67, DOI 10.1017/S0140525X00021555; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; BLASDEL GG, 1992, J NEUROSCI, V12, P3115, DOI 10.1523/JNEUROSCI.12-08-03115.1992; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0; DESIMONE R, 1984, J NEUROSCI, V4, P2051; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; FUJITA I, 1992, NATURE, V360, P343, DOI 10.1038/360343a0; GOCHIN PM, 1991, EXP BRAIN RES, V84, P505; GOCHIN PM, 1992, P NATL ACAD SCI USA, V89, P8381, DOI 10.1073/pnas.89.17.8381; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; GRINVALD A, 1991, P NATL ACAD SCI USA, V88, P11559, DOI 10.1073/pnas.88.24.11559; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HAGLUND MM, 1992, NATURE, V358, P668, DOI 10.1038/358668a0; ITO M, 1995, J NEUROPHYSIOL, V73, P218, DOI 10.1152/jn.1995.73.1.218; ITO M, 1994, CEREB CORTEX, V5, P499; KIM DS, 1994, NATURE, V370, P370, DOI 10.1038/370370a0; KOBATAKE E, 1994, J NEUROPHYSIOL, V71, P856, DOI 10.1152/jn.1994.71.3.856; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; MALONEK D, 1994, P ROY SOC B-BIOL SCI, V258, P109, DOI 10.1098/rspb.1994.0150; MASINO SA, 1993, P NATL ACAD SCI USA, V90, P9998, DOI 10.1073/pnas.90.21.9998; Mountcastle V.B., 1978, MINDFUL BRAIN CORTIC, P7; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630	25	249	252	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1996	272	5268					1665	1668		10.1126/science.272.5268.1665	http://dx.doi.org/10.1126/science.272.5268.1665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658144				2022-12-24	WOS:A1996UR09300051
J	DErchia, AM; Gissi, C; Pesole, G; Saccone, C; Arnason, U				DErchia, AM; Gissi, C; Pesole, G; Saccone, C; Arnason, U			The guinea-pig is not a rodent	NATURE			English	Article							MITOCHONDRIAL-DNA; NUCLEOTIDE-SEQUENCE; EVOLUTION; PHYLOGENY; MAMMALS; GENE; SEAL	IN 1991 Graur et al. raised the question of whether the guinea-pig, Cavia porcellus, is a rodent(1). They suggested that the guinea-pig and myomorph rodents diverged before the separation between myormorph rodents and a lineage leading to primates and artiodactyls. Several findings have since been reported, both for and against this phylogeny, thereby highlighting the issue of the validity of molecular analysis in mammalian phylogeny. Here we present findings based on the sequence of the complete mitochondrial genome of the guinea-pig, which strongly contradict rodent monophyly. The conclusions are based on the cumulative evidence provided by orthologically inherited genes and the use of three different analytic al methods, none of which joins the guinea-pig with myomorph rodents. In addition to the phylogenetic conclusions, we also draw attention to several factors that are important for the validity of phylogenetic analysis based on molecular data.	UNIV BARI, DIPARTMENTO BIOCHIM & BIOL MOLEC, I-70125 BARI, ITALY; LUND UNIV, DEPT EVOLUTIONARY MOL SYSTEMAT, S-22362 LUND, SWEDEN; UNIV BASILICATA, DIPARTIMENTO BIOL DBAF, I-30100 POTENZA, ITALY; CNR, CTR STUDIO MITOCONDRI & METAB ENERGET, I-70125 BARI, ITALY	Universita degli Studi di Bari Aldo Moro; Lund University; University of Basilicata; Consiglio Nazionale delle Ricerche (CNR)			Pesole, Graziano/K-5283-2019; D'Erchia, Anna maria/K-9001-2016; Pesole, Graziano/E-9051-2014; Pesole, Graziano/C-1408-2009	Pesole, Graziano/0000-0003-3663-0859; Pesole, Graziano/0000-0003-3663-0859; D'ERCHIA, Anna Maria/0000-0002-4627-0626; Gissi, Carmela/0000-0002-2269-079X				ARNASON U, 1993, J MOL EVOL, V37, P323; Arnason U, 1996, J MOL EVOL, V42, P145, DOI 10.1007/BF02198840; ARNASON U, 1991, J MOL EVOL, V33, P556, DOI 10.1007/BF02102808; ARNASON U, 1992, J MOL EVOL, V34, P493, DOI 10.1007/BF00160463; CAO Y, 1994, MOL BIOL EVOL, V11, P593; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Felsestein J., 1993, PHYLIP PHYLOGENY INF; FRYE MS, 1995, MOL BIOL EVOL, V12, P168, DOI 10.1093/oxfordjournals.molbev.a040186; GRAUR D, 1992, COMP BIOCHEM PHYS B, V101, P495, DOI 10.1016/0305-0491(92)90327-N; GRAUR D, 1994, MOL BIOL EVOL, V11, P357; Graur D, 1996, NATURE, V379, P333, DOI 10.1038/379333a0; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; GRAUR D, 1993, FEBS LETT, V325, P152, DOI 10.1016/0014-5793(93)81432-Y; Hasegawa, 1992, COMPUTER SCI MONOGRA, V27; HASEGAWA M, 1992, NATURE, V355, P595, DOI 10.1038/355595a0; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; Krettek A, 1995, J MOL EVOL, V41, P952; KUMA K, 1994, JPN J GENET, V69, P555, DOI 10.1266/jjg.69.555; LI WH, 1992, J HERED, V83, P174, DOI 10.1093/oxfordjournals.jhered.a111188; MA DP, 1993, J MOL EVOL, V36, P327; MARTIGNETTI JA, 1993, P NATL ACAD SCI USA, V90, P9698, DOI 10.1073/pnas.90.20.9698; NOGUCHI T, 1994, COMP BIOCHEM PHYS B, V107, P179, DOI 10.1016/0305-0491(94)90037-X; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; SACCONE C, 1990, METHOD ENZYMOL, V183, P570; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Swofford D., 1998, PAUP PHYLOGENETIC AN; WOLF B, 1993, BIOL CHEM H-S, V374, P641, DOI 10.1515/bchm3.1993.374.7-12.641; XU XF, 1994, GENE, V148, P357, DOI 10.1016/0378-1119(94)90713-7	28	272	280	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					597	600		10.1038/381597a0	http://dx.doi.org/10.1038/381597a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637593				2022-12-24	WOS:A1996UQ65700048
J	Diem, SJ; Lantos, JD; Tulsky, JA				Diem, SJ; Lantos, JD; Tulsky, JA			Cardiopulmonary resuscitation on television - Miracles and misinformation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; PARAMEDIC SERVICES; METROPOLITAN-AREA; SURVIVAL; OUTCOMES; YOUNGER; OLDER; AGE	Background. Responsible, shared decision making on the part of physicians and patients about the potential use of cardiopulmonary resuscitation (CPR) requires patients who are educated about the procedure's risks and benefits, Television is an important source of information about CPR for patients, We analyzed how three popular television programs depict CPR, Methods. We watched all the episodes of the television programs ER and Chicago Hope during the 1994-1995 viewing season and 50 consecutive episodes of Rescue 911 broadcast over a three-month period in 1995, We identified all occurrences of CPR in each episode and recorded the causes of cardiac arrest, the identifiable demographic characteristics of the patients, the underlying illnesses, and the outcomes. Results. There were 60 occurrences of CPR in the 97 television episodes - 31 on ER, 11 on Chicago Hope, and 18 on Rescue 911, In the majority of cases, cardiac arrest was caused by trauma; only 28 percent were due to primary cardiac causes, Sixty-five percent of the cardiac arrests occurred in children, teenagers, or young adults, Seventy-five percent of the patients survived the immediate arrest, and 67 percent appeared to have survived to hospital discharge. Conclusions. The survival rates in our study are significantly higher than the most optimistic survival rates in the medical literature, and the portrayal of CPR on television may lead the viewing public to have an unrealistic impression of CPR and its chances for success, Physicians discussing the use of CPR with patients and families should be aware of the images of CPR depicted on television and the misperceptions these images may foster. (C) 1996, Massachusetts Medical Society.	DUKE UNIV,MED CTR,CTR HLTH POLICY RES & EDUC,DURHAM,NC; DUKE UNIV,MED CTR,CTR STUDY AGING & HUMAN DEV,DURHAM,NC; UNIV CHICAGO,MACLEAN CTR MED ETH,CHICAGO,IL	Duke University; Duke University; University of Chicago	Diem, SJ (corresponding author), VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,508 FULTON ST,DURHAM,NC 27705, USA.		Diem, Susan/B-6479-2013					ANNAS GJ, 1995, HASTINGS CENT REP, V25, P40, DOI 10.2307/3562794; APRAHAMIAN C, 1985, ANN EMERG MED, V14, P583, DOI 10.1016/S0196-0644(85)80785-X; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; COPASS MK, 1984, AM J SURG, V148, P20, DOI 10.1016/0002-9610(84)90284-8; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1980, LANCET, V1, P812; GUZY PM, 1983, AM J PUBLIC HEALTH, V73, P766, DOI 10.2105/AJPH.73.7.766; KARETZKY M, 1995, ARCH INTERN MED, V155, P1277, DOI 10.1001/archinte.155.12.1277; LAVELLE JM, 1993, CRIT CARE MED, V21, P368, DOI 10.1097/00003246-199303000-00013; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; PONS PT, 1985, J TRAUMA, V25, P828, DOI 10.1097/00005373-198509000-00003; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC REP; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TRESCH DD, 1988, AM J CARDIOL, V61, P1120, DOI 10.1016/0002-9149(88)90141-5; TRESCH DD, 1990, AM J CARDIOL, V65, P453, DOI 10.1016/0002-9149(90)90809-F; Turow Joseph, 1989, PLAYING DOCTOR TELEV; VERTESI L, 1983, CAN MED ASSOC J, V128, P809; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	315	323	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1578	1582		10.1056/NEJM199606133342406	http://dx.doi.org/10.1056/NEJM199606133342406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP663	8628340				2022-12-24	WOS:A1996UP66300006
J	Rhodes, CJ; Anderson, RM				Rhodes, CJ; Anderson, RM			Power laws governing epidemics in isolated populations	NATURE			English	Article							FOREST-FIRE MODEL; MEASLES DYNAMICS; TIME-SERIES; CHAOS; ERROR	TEMPORAL changes in the incidence of measles virus infection within large urban communities in the developed world have been the focus of much discussion in the context of the identification and analysis of nonlinear and chaotic patterns in biological time series(1-11). In contrast, the measles records for small isolated island populations are highly irregular, because of frequent fade-outs of infection(12-14), and traditional analysis(15) does not yield useful insight. Here we use measurements of the distribution of epidemic sizes and duration to show that regularities in the dynamics of such systems do become apparent. Specifically, these biological systems are characterized by well-defined power laws in a manner reminiscent of other nonlinear, spatially extended dynamical systems in the physical sciences(16-19). We further show that the observed power-law exponents are well described by a simple lattice-based model which reflects the social interaction between individual hosts.			Rhodes, CJ (corresponding author), UNIV OXFORD, DEPT ZOOL, CTR EPIDEMIOL INFECT DIS, S PARKS RD, OXFORD OX1 3PS, ENGLAND.			Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364; BAK P, 1990, PHYS LETT A, V147, P297, DOI 10.1016/0375-9601(90)90451-S; BARTLETT MS, 1960, J R STAT SOC SER A-G, V123, P37, DOI 10.2307/2343186; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; BLACK FL, 1966, J THEOR BIOL, V11, P207, DOI 10.1016/0022-5193(66)90161-5; BOLKER BM, 1993, P ROY SOC B-BIOL SCI, V251, P75, DOI 10.1098/rspb.1993.0011; CHEN K, 1991, PHYS REV A, V43, P625, DOI 10.1103/PhysRevA.43.625; CLAR S, 1994, PHYS REV E, V50, P1009, DOI 10.1103/PhysRevE.50.1009; Cliff Andrew, 1993, HIST GEOGRAPHY MAJOR; DROSSEL B, 1992, PHYS REV LETT, V69, P1629, DOI 10.1103/PhysRevLett.69.1629; FERGUSON N, IN PRESS PRINCETON M; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1994, PHILOS T R SOC A, V348, P515, DOI 10.1098/rsta.1994.0108; Gutenberg B., 1956, ANN GEOFIS, V9, P1, DOI DOI 10.4401/AG-5590; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MAY RM, 1987, PROC R SOC LON SER-A, V413, P27, DOI 10.1016/0920-5632(87)90020-X; OLSEN LF, 1988, THEOR POPUL BIOL, V33, P344, DOI 10.1016/0040-5809(88)90019-6; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; SOMETTE A, 1989, EPL-EUROPHYS LETT, V9, P197; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; SUGIHARA G, 1990, PHILOS T R SOC B, V330, P235, DOI 10.1098/rstb.1990.0195; TIDD CW, 1993, P ROY SOC B-BIOL SCI, V254, P257, DOI 10.1098/rspb.1993.0155	24	132	140	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					600	602		10.1038/381600a0	http://dx.doi.org/10.1038/381600a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637594				2022-12-24	WOS:A1996UQ65700049
J	Plas, DR; Johnson, R; Pingel, JT; Matthews, RJ; Dalton, M; Roy, G; Chan, AC; Thomas, ML				Plas, DR; Johnson, R; Pingel, JT; Matthews, RJ; Dalton, M; Roy, G; Chan, AC; Thomas, ML			Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling	SCIENCE			English	Article							PHOSPHATASE; SPECIFICITY	The threshold at which antigen triggers lymphocyte activation is set by the enzymes that regulate tyrosine phosphorylation. Upon T cell activation, the protein tyrosine phosphatase SHP-1 was found to bind to the protein tyrosine kinase ZAP-70. This interaction resulted in an increase in SHP-1 phosphatase activity and a decrease in ZAP-70 kinase activity. Expression of a dominant negative mutant of SHP-1 in T cells increased the sensitivity of the antigen receptor. Thus, SHP-1 functions as a negative regulator of the T cell antigen receptor and in setting the threshold of activation.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Roy, Garbiñe/AAG-2570-2021	Roy, Garbiñe/0000-0001-6124-7574				BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DECHERT U, 1995, EUR J BIOCHEM, V231, P673, DOI 10.1111/j.1432-1033.1995.0673d.x; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; EVAVOLD BD, 1992, J IMMUNOL, V148, P3471; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCFARLAND EDC, 1995, J BIOL CHEM, V270, P28103; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLAS DR, UNPUB; ROY G, 1995, ADV PROTEIN PHOSPHAT, V9, P121; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	22	327	333	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1996	272	5265					1173	1176		10.1126/science.272.5265.1173	http://dx.doi.org/10.1126/science.272.5265.1173			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638162				2022-12-24	WOS:A1996UM88900051
J	Oliet, SHR; Malenka, RC; Nicoll, RA				Oliet, SHR; Malenka, RC; Nicoll, RA			Bidirectional control of quantal size by synaptic activity in the hippocampus	SCIENCE			English	Article							LONG-TERM POTENTIATION; TRANSMITTER RELEASE; NEUROMUSCULAR-JUNCTION; NEURONS; CA1; STRONTIUM; CURRENTS; SLICES; CA2+	Analysis of strontium-induced asynchronous release of quanta from stimulated synapses revealed that long-term potentiation and long-term depression in the CA1 region of the mammalian hippocampus are associated with an increase and a decrease, respectively, in quantal size. At a single set of synapses, the increase in quantal size seen with long-term potentiation was completely reversed by depotentiating stimuli. Long-term potentiation and depression are also associated with an increase and decrease, respectively, in the frequency of quantal events, consistent with an all-or-none regulation (up or down) of clusters of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, a change in the release of transmitter, or both.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Oliet, SHR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143, USA.			Oliet, Stephane/0000-0003-0595-9029				ASZTELY F, 1991, BRAIN RES, V558, P153, DOI 10.1016/0006-8993(91)90734-D; BAIN AI, 1992, J PHYSIOL-LONDON, V450, P63, DOI 10.1113/jphysiol.1992.sp019116; BEKKERS JM, 1995, J NEUROPHYSIOL, V73, P1145, DOI 10.1152/jn.1995.73.3.1145; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DODGE FA, 1969, J PHYSIOL-LONDON, V200, P267, DOI 10.1113/jphysiol.1969.sp008692; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GROVER LM, 1995, SYNAPSE, V19, P121, DOI 10.1002/syn.890190208; HANSE E, 1994, J NEUROSCI, V14, P5028; HUBER KM, 1995, J NEUROPHYSIOL, V73, P270, DOI 10.1152/jn.1995.73.1.270; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Katz B., 1966, NERVE MUSCLE SYNAPSE; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MEIRI U, 1971, J PHYSIOL-LONDON, V215, P709, DOI 10.1113/jphysiol.1971.sp009493; MILEDI R, 1966, NATURE, V212, P1233, DOI 10.1038/2121233a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; WYLLIE DJA, 1994, NEURON, V13, P635, DOI 10.1016/0896-6273(94)90031-0; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175	34	171	171	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1294	1297		10.1126/science.271.5253.1294	http://dx.doi.org/10.1126/science.271.5253.1294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638114				2022-12-24	WOS:A1996TX69500041
J	Maruyama, H; Raphael, JH; Djerassi, C				Maruyama, H; Raphael, JH; Djerassi, C			Why Japan ought to legalize the pill	NATURE			English	Editorial Material											Maruyama, H (corresponding author), STANFORD UNIV, ASIA PACIFIC RES CTR, STANFORD, CA 94305 USA.							ANDERSON A, 1985, NATURE, V317, P760, DOI 10.1038/317760c0; Coleman Samuel, 1983, FAMILY PLANNING JAPA; JITSUKAWA M, 1994, SCIENCE, V265, P1048, DOI 10.1126/science.8066442; MURAMATSU M, 1973, B I PUBL HLTH, V22, P228; MURAMATSU M, 1974, ABORTION RES INT EXP, P133; NATHAN R, 1995, NAT MED, V1, P1115, DOI 10.1038/nm1195-1115; RIPHAGEN FE, 1987, WIEN MED WOCHENSCHR, V137, P488; TRUSSELL J, 1990, STUD FAMILY PLANN, V21, P51, DOI 10.2307/1966591; WEINSTEIN M, 1990, POP STUD-J DEMOG, V44, P447, DOI 10.1080/0032472031000144846; 1993, 1992 YUSEI HOGO TOKE, P20; 1994, SUMMARY 22ND NATIONA; 1992, SUMMARY 21ST NATIONA; 1995, NIKKEI UERUNESU, V12, P10; 1995, WORLD POPULATION DAT	14	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					579	580		10.1038/379579a0	http://dx.doi.org/10.1038/379579a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TV688	8628389				2022-12-24	WOS:A1996TV68800021
J	Rawlings, DJ; Scharenberg, AM; Park, H; Wahl, MI; Lin, SQ; Kato, RM; Fluckiger, AC; Witte, ON; Kinet, JP				Rawlings, DJ; Scharenberg, AM; Park, H; Wahl, MI; Lin, SQ; Kato, RM; Fluckiger, AC; Witte, ON; Kinet, JP			Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; TYROSINE KINASE; B-CELLS; CHROMOSOME; PP60C-SRC; MUTATION; GENES; MICE	Bruton's tyrosine kinase (BTK) is pivotal in B cell activation and development through its participation in the signaling pathways of multiple hematopoietic receptors. The mechanisms controlling BTK activation were studied here by examination of the biochemical consequences of an interaction between BTK and SRC family kinases. This interaction of BTK with SRC kinases transphosphorylated BTK on tyrosine at residue 551, which led to BTK activation. BTK then autophosphorylated at a second site. The same two sites were phosphorylated upon B cell antigen receptor cross-linking. The activated BTK was predominantly membrane-associated, which suggests that BTK integrates distinct receptor signals resulting in SRC kinase activation and BTK membrane targeting.	BETH ISRAEL HOSP, LAB ALLERGY & IMMUNOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036834, K11AR001912] Funding Source: NIH RePORTER; NCI NIH HHS [CA09120-20] Funding Source: Medline; NIAMS NIH HHS [AR36834, AR01912] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P4204, DOI 10.1073/pnas.91.10.4204; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER MD, 1993, PROGR IMMUNOLOGY, P535; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; EARL PL, 1987, CURRENT PROTOCOLS MO; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; Harian J. E., 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASBOLD J, 1994, EUR J IMMUNOL, V24, P152, DOI 10.1002/eji.1830240123; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HITOSHI Y, 1993, INT IMMUNOL, V5, P1183, DOI 10.1093/intimm/5.9.1183; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOIKE M, 1995, INT IMMUNOL, V7, P21, DOI 10.1093/intimm/7.1.21; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Park H., UNPUB; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SCRIBNER CL, 1987, J IMMUNOL, V138, P3611; SHIMAOKA J, UNPUB; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; YAMASHITA Y, 1995, IMMUNOLOGY, V85, P248; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	45	378	384	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	1996	271	5250					822	825		10.1126/science.271.5250.822	http://dx.doi.org/10.1126/science.271.5250.822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8629002				2022-12-24	WOS:A1996TU69400051
J	Marshall, FF				Marshall, FF			Is nephron-sparing surgery appropriate for a small renal-cell carcinoma?	LANCET			English	Editorial Material											Marshall, FF (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BRADY UROL INST,BALTIMORE,MD 21287, USA.							BELL ET, 1950, RENAL DISEASES, P435; Eschwege P, 1996, J UROLOGY, V155, P1196, DOI 10.1016/S0022-5347(01)66213-X; LICHT MR, 1993, J UROLOGY, V149, P1; POLASCIK TJ, 1995, J UROLOGY, V154, P1312, DOI 10.1016/S0022-5347(01)66845-9; POLASCIK TJ, 1995, J UROLOGY, V154, P1676, DOI 10.1016/S0022-5347(01)66748-X; ROBSON CJ, 1969, J UROLOGY, V101, P297, DOI 10.1016/S0022-5347(17)62331-0; STEINBACH F, 1992, J UROLOGY, V148, P24, DOI 10.1016/S0022-5347(17)36499-6; STOCKLE M, 1996, PARENCHYMA SAVING SU	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					72	73						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676717				2022-12-24	WOS:A1996UW67300005
J	Leshner, AI				Leshner, AI			Molecular mechanisms of cocaine addiction	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Leshner, AI (corresponding author), NIDA,ROCKVILLE,MD 20857, USA.							CARRERA MRA, 1995, NATURE, V378, P727, DOI 10.1038/378727a0; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586	3	31	32	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	1996	335	2					128	129		10.1056/NEJM199607113350211	http://dx.doi.org/10.1056/NEJM199607113350211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW353	8649475				2022-12-24	WOS:A1996UW35300011
J	Deyton, L				Deyton, L			Importance of surrogate markers in evaluation of antiviral therapy for HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; CLINICAL-TRIALS; END-POINTS; AIDS				Deyton, L (corresponding author), NIAID, DIV AIDS,HIV RES BRANCH,NIH,SOLAR BLDG ROOM 2C16, 6003 EXECUT BLVD MSC 7620, BETHESDA, MD 20892 USA.							CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAQUILA RT, 1995, P 2 NAT C HUM RETR R; DEGRUTTOLA V, 1994, J INFECT DIS, V169, P713, DOI 10.1093/infdis/169.4.713; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FLEMING TR, 1994, STAT MED, V13, P955, DOI 10.1002/sim.4780130906; FLEMING TR, 1994, STAT MED, V13, P1423, DOI 10.1002/sim.4780131318; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; GAZZARD B, 1996, P 3 C RETR OPP INF W; HAMMER SM, 1996, P 3 C RETR OPP INF W; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUGHES MD, 1995, J ACQ IMMUN DEF SYND, V10, pS1; *I MED, 1990, SURR ENDP EV EFF DRU; KAPPES JC, 1995, J ACQ IMMUN DEF SYND, V10, P139, DOI 10.1097/00042560-199510020-00005; LIN DY, 1993, STAT MED, V12, P835, DOI 10.1002/sim.4780120904; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; REICHELDERFER PS, 1995, J ACQ IMMUN DEF SYND, V10, pS19; SARAVOLATZ L, 1996, P 3 C RETR OPP INF W; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; THOMPSON M, 1995, CPCRA036 HIV RNA PRO; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	28	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1996	276	2					159	160		10.1001/jama.276.2.159	http://dx.doi.org/10.1001/jama.276.2.159			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV485	8656509				2022-12-24	WOS:A1996UV48500033
J	Kerlikowske, K; Grady, D; Barclay, J; Sickles, EA; Ernster, V				Kerlikowske, K; Grady, D; Barclay, J; Sickles, EA; Ernster, V			Likelihood ratios for modern screening mammography - Risk of breast cancer based on age and mammographic interpretation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILY HISTORY; MEDICAL AUDIT; COMMUNITY	Objective.-To determine the sensitivity, specificity, and likelihood ratios (LRs) for modern screening mammography by decade of age and mammographic interpretation. Design.-Cross-sectional. Setting.-Nine counties in northern California. Participants.-A total of 26 057 women aged 30 years and older who underwent a total of 41 747 first and subsequent screening mammographic examinations at the Mobile Mammography Screening Program of the University of California, San Francisco, from April 1985 to September 1991. Measurements.-Breast cancer risk profile, 2 standard mammographic views per breast, and follow-up of abnormal and normal mammograms by contacting women's physicians and by linkage to the regional Surveillance, Epidemiology, and End Results tumor registry. False-negative examinations were normal examinations that occurred within 13 months of a diagnosis of invasive breast cancer or ductal carcinoma in situ. Results.-The sensitivity of first screening mammography increased with age: 77.3% for ages 30 to 39 years, 86.7% for ages 40 to 49 years, 93.6% for ages 50 to 59 years, 94.1% for ages 60 to 69 years, and 91.?% for ages 70 years and older (P=.04). Specificity was similar for all ages, ranging from 92.6% to 95.2%. Of all abnormal first screening examinations, 92.9% were reported as ''additional evaluation needed.'' The LRs for that category ranged from 5.2 to 8.8 and did not vary with age. Based on the risk of breast cancer before mammography, which increases with age, the risk of breast cancer after mammography associated with these LRs were 0.01 for ages 30 to 39 years, 0.02 for ages 40 to 49 years, 0.05 for ages 50 to 59 years, 0.07 for ages 60 to 69 years, and 0.07 for ages 70 years and older. The LRs for mammography reported as ''suspicious for malignancy'' ranged from 88 to 144 and did not vary across age groups. These LRs were associated with a risk of breast cancer about 10 times greater than when mammography was reported as ''additional evaluation needed.'' Conclusions.-Most abnormal first screening mammography are interpreted as ''additional evaluation needed'' and are associated with LRs of about 7. Given this low LR, the risk of breast cancer after mammography is primarily influenced by a woman's age-specific risk of breast cancer before mammography. The LRs for screening mammography interpreted as ''suspicious for malignancy'' are high (about 124) and are associated with a substantial increase in the risk of breast cancer irrespective of age, but these interpretations comprise only a small proportion of abnormal mammagraphy.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS,GEN INTERNAL MED SECT,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [1 O1 CA63740, CA58207-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA063740, P50CA058207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; BURHENNE HJ, 1994, AM J ROENTGENOL, V162, P1067, DOI 10.2214/ajr.162.5.8165983; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; DORSI CJ, 1993, SEMIN ROENTGENOL, V28, P204, DOI 10.1016/S0037-198X(05)80080-X; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FRANKEL SD, 1995, AM J ROENTGENOL, V164, P1107, DOI 10.2214/ajr.164.5.7717214; GIARD RWM, 1993, CYTOPATHOLOGY, V4, P131, DOI 10.1111/j.1365-2303.1993.tb00078.x; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HARRIS R, 1995, ANN INTERN MED, V122, P550; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; LINVER MN, 1992, RADIOLOGY, V184, P39, DOI 10.1148/radiology.184.1.1609100; ROBERTSON CL, 1993, RADIOLOGY, V187, P75, DOI 10.1148/radiology.187.1.8451440; RUSSELL LB, 1994, SCREENING PROSTATE C, P30; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SHAPIRO S, 1994, AM J PUBLIC HEALTH, V84, P10, DOI 10.2105/AJPH.84.1.10; SICKLES EA, 1995, ANN INTERN MED, V122, P534, DOI 10.7326/0003-4819-122-7-199504010-00010; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; SIENKO DG, 1993, CANCER-AM CANCER SOC, V71, P1801, DOI 10.1002/1097-0142(19930301)71:5<1801::AID-CNCR2820710515>3.0.CO;2-W; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; SMART CR, 1995, CANCER, V76, P2788; SOX HC, 1995, ANN INTERN MED, V122, P550, DOI 10.7326/0003-4819-122-7-199504010-00013; 1992, BRIT MED J, V304, P346; 1992, MMWR-MORBID MORTAL W, V41, P17	26	127	129	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					39	43		10.1001/jama.276.1.39	http://dx.doi.org/10.1001/jama.276.1.39			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667537				2022-12-24	WOS:A1996UU43900025
J	Nightingale, SL				Nightingale, SL			HIV home test system approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKLAND,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					14	14						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667525				2022-12-24	WOS:A1996UU43900007
J	Schreiber, GB; Busch, MP; Kleinman, SH; Korelitz, JJ				Schreiber, GB; Busch, MP; Kleinman, SH; Korelitz, JJ			The risk of transfusion-transmitted viral infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; NON-B-HEPATITIS; STATES BLOOD-DONORS; NON-A-HEPATITIS; UNITED-STATES; LONG-TERM; RECIPIENTS; ANTIBODY; TRANSMISSION	Background. Accurate estimates of the risk of transfusion-transmitted infectious disease are essential for monitoring the safety of the blood supply and evaluating the potential effect of new screening tests. We estimated the risk of transmitting the human immunodeficiency virus (HIV), the human T-cell lymphotropic virus (HTLV), the hepatitis C virus (HCV), and the hepatitis B virus (HBV) from screened blood units donated during the window period following a recent, undetected infection. Methods. Using data on 586,507 persons who each donated blood more than once between 1991 and 1993 at five blood centers (for a total of 2,318,356 allogeneic blood donations), we calculated the incidence rates of seroconversion among those whose donations passed all the screening tests used. We adjusted these rates for the estimated duration of the infectious window period for each virus. We then estimated the further reductions in risk that would result from the use of new and more sensitive viral-antigen or nucleic acid screening tests. Results. Among donors whose units passed all screening tests, the risks of giving blood during an infectious window period were estimated as follows: for HIV, 1 in 493,000 (95 percent confidence interval, 202,000 to 2,778,000); for HTLV, 1 in 641,000 (256,000 to 2,000,000); for HCV, 1 in 103,000 (28,000 to 288,000); and for HBV, 1 in 63,000 (31,000 to 147,000). HBV and HCV accounted for 88 percent of the aggregate risk of 1 in 34,000. New screening tests that shorten the window periods for the four viruses should reduce the risks by 27 to 72 percent. Conclusions. The risk of transmitting HIV, HTLV, HCV, or HBV infection by the transfusion of screened blood is very small, and new screening tests will reduce the risk even further. (C) 1996, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; IRWIN MEM BLOOD CTR, SAN FRANCISCO, CA USA; UNIV CALIF LOS ANGELES, BLOOD & PLATELET CTR, LOS ANGELES, CA USA	University of California System; University of California San Francisco; University of California System; University of California Los Angeles	Schreiber, GB (corresponding author), WESTAT CORP, 1650 RES BLVD, ROCKVILLE, MD 20850 USA.				DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097078, N01HB097077] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-97077, N01-HB-97114, N01-HB-97078] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Aubuchon J. P., 1995, Transfusion (Bethesda), V35, p43S; BUSCH MP, 1994, BLOOD, V83, P1143; BUSCH MP, 1993, TRANSFUSION, V33, P84, DOI 10.1046/j.1537-2995.1993.33193142316.x; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; Busch MP, 1995, TRANSFUSION, V35, P903, DOI 10.1046/j.1537-2995.1995.351196110893.x; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DODD RY, 1994, BLOOD SUPPLY RISKS P, P1; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; HJELLE B, 1993, BLOOD, V81, P1641; HOOFNAGLE JH, 1978, VIRAL HEPATITIS, P219; HUGHES W, 1995, TRANSFUSION MED, V5, P225, DOI 10.1111/j.1365-3148.1995.tb00232.x; IWARSON S, 1995, CLIN INFECT DIS, V20, P1361, DOI 10.1093/clinids/20.5.1361; JAGODZINSKI L, 1994, TRANSFUSION, V34, pS37; KLEINMAN S, 1992, TRANSFUSION, V32, P805, DOI 10.1046/j.1537-2995.1992.32993110750.x; KLEINMAN S, 1992, BLOOD SAFETY CURRENT, P169; KLEINMAN SH, 1994, J CLIN MICROBIOL, V32, P603, DOI 10.1128/JCM.32.3.603-607.1994; KLEINMAN SH, 1996, CLIN PRACTICE TRANSF, P809; KORELITZ JJ, 1994, TRANSFUSION, V34, P870, DOI 10.1046/j.1537-2995.1994.341095026972.x; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; LELIE PN, 1992, J MED VIROL, V37, P203, DOI 10.1002/jmv.1890370310; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; MIMMS LT, 1993, BRIT MED J, V307, P1095, DOI 10.1136/bmj.307.6912.1095; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; RENZULLO PO, 1995, J ACQ IMMUN DEF SYND, V10, P177, DOI 10.1097/00042560-199510020-00011; Sayre KR, 1996, TRANSFUSION, V36, P45, DOI 10.1046/j.1537-2995.1996.36196190514.x; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; STRAUSS D, 1994, TRANSFUSION, V34, pS34; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x; 1994, MMWR-MORBID MORTAL W, V42, P1	41	1367	1444	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1685	1690		10.1056/NEJM199606273342601	http://dx.doi.org/10.1056/NEJM199606273342601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT400	8637512				2022-12-24	WOS:A1996UT40000001
J	Tong, SL; Baghurst, P; McMichael, A; Sawyer, M; Mudge, J				Tong, SL; Baghurst, P; McMichael, A; Sawyer, M; Mudge, J			Lifetime exposure to environmental lead and children's intelligence at 11-13 years: The Port Pirie cohort study	BRITISH MEDICAL JOURNAL			English	Article							NEUROPSYCHOLOGICAL DEVELOPMENT; COGNITIVE-DEVELOPMENT; ADULT MONKEYS; BLOOD LEAD; CHILDHOOD; AGE; DEFICITS	Objective-To examine the association between environmental exposure to lead and children's intelligence at age 11-13 years, and to assess the implications of exposure in the first seven years of life for later childhood development. Design-Prospective cohort study. Subjects-375 children born in or around the lead smelting town of Port Pirie, Australia, between 1979 and 1982. Main outcome measure-Children's intelligence quotient (IQ) measured at 11-13 years of age. Results-IQ was inversely associated with both antenatal and postnatal blood lead concentrations, Verbal, performance, and full scale IQ were inversely related to blood lead concentration with no apparent threshold, Multivariate analyses indicated that after adjustment for a wide range of confounders, the postnatal blood lead concentrations (particularly within the age range 15 months to 7 years) exhibited inverse associations with IQ, Strong associations with IQ were observed for lifetime average blood lead concentrations at various ages. The expected mean full scale IQ declined by 3.0 points (95% confidence interval 0.07 to 5.93) for an increase in lifetime average blood lead concentration from 0.48 to 0.96 mu mol/l (10 to 20 mu g/dl). Conclusions-Exposure to environmental lead during the first seven years of life is associated with cognitive deficits that seem to persist into later childhood.	CSIRO,DIV HUMAN NUTR,ADELAIDE,SA 5000,AUSTRALIA; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND; WOMENS & CHILDRENS HOSP,EVALUAT UNIT,ADELAIDE,SA 5000,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of London; London School of Hygiene & Tropical Medicine; Womens & Childrens Hospital Australia								*AUSTR COMM DEP HU, 1994, RED LEAD EXP AUSTR A; BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Caldwell BM, 1985, HOME OBSERVATION MEA; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; COONEY GH, 1989, DEV MED CHILD NEUROL, V31, P640; DANIEL A, 1984, COMMUNITY HLTH STUDI, V3, P218; DIETRICH KN, 1993, PEDIATRICS, V91, P301; DIETRICH KN, 1991, NEUROTOXICOL TERATOL, V13, P203, DOI 10.1016/0892-0362(91)90012-L; DIETRICH KN, 1987, PEDIATRICS, V80, P721; ERNHART CB, 1989, NEUROTOXICOL TERATOL, V11, P161, DOI 10.1016/0892-0362(89)90055-X; FERGUSSON DM, 1993, INT J EPIDEMIOL, V22, P891, DOI 10.1093/ije/22.5.891; FULTON M, 1987, LANCET, V1, P1221; GILBERT SG, 1987, TOXICOL APPL PHARM, V91, P484, DOI 10.1016/0041-008X(87)90070-6; GOLDBERG DP, 1978, MANUAL GENERAL HLTH; GOLDSTEIN GW, 1992, PEDIATR ANN, V21, P384, DOI 10.3928/0090-4481-19920601-11; KAUFMAN AS, 1979, INTELLIGENT TESTING, P1; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LEVIN ED, 1987, PSYCHOPHARMACOLOGY, V91, P334, DOI 10.1007/BF00518187; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; MCMICHAEL AJ, 1992, NEUROTOXICOL TERATOL, V14, P321, DOI 10.1016/0892-0362(92)90038-C; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; POCOCK SJ, 1994, BRIT MED J, V309, P1189, DOI 10.1136/bmj.309.6963.1189; POCOCK SJ, 1987, LANCET, V2, P53; RICE DC, 1988, NEUROTOXICOL TERATOL, V10, P207, DOI 10.1016/0892-0362(88)90019-0; RIUS RA, 1988, SCI TOTAL ENVIRON, V71, P441, DOI 10.1016/0048-9697(88)90216-1; RONNBACK L, 1992, BRIT J IND MED, V49, P233; SATTLER JM, 1988, ASSESSMENT CHILDREN, P61; Silbergeld EK, 1983, LEAD VERSUS HLTH, P191; SMITH M, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P3; SMITH RE, 1983, SOIL SCI SOC AM J, V47, P1; *STAND ASS AUSTR, 1985, WHOLE BLOOD DET LEAD; *US EPA, 1986, EPA600883028AFDF; Wechsler D., 1997, WAIS 3 WECHSLER ADUL, V3rd, DOI 10.1111/j.1749-6632.1989.tb21005.x; Wechsler DW., 1999, INTELLIGENCE SCALE C; WIGG NR, 1988, J EPIDEMIOL COMMUN H, V42, P213, DOI 10.1136/jech.42.3.213	44	138	140	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1996	312	7046					1569	1575		10.1136/bmj.312.7046.1569	http://dx.doi.org/10.1136/bmj.312.7046.1569			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU806	8664666	Green Published			2022-12-24	WOS:A1996UU80600018
J	Hofmann, E; Wrench, PM; Sharples, FP; Hiller, RG; Welte, W; Diederichs, K				Hofmann, E; Wrench, PM; Sharples, FP; Hiller, RG; Welte, W; Diederichs, K			Structural basis of light harvesting by carotenoids: Peridinin-chlorophyll-protein from Amphidinium carterae	SCIENCE			English	Article							BACTERIOCHLOROPHYLL-A-PROTEIN; PROSTHECOCHLORIS-AESTUARII; MARINE DINOFLAGELLATE; LOCATION; COMPLEX	Peridinin-chlorophyll-protein, a water-soluble light-harvesting complex that has a blue-green absorbing carotenoid as its main pigment, is present in most photosynthetic dinoflagellates, Its high-resolution (2.0 angstrom) x-ray structure reveals a noncrystallographic trimer in which each polypeptide contains an unusual jellyroll fold of the alpha-helical amino- and carboxyl-terminal domains, These domains constitute a scaffold with pseudo-twofold symmetry surrounding a hydrophobic cavity filled by two lipid, eight peridinin, and two chlorophyll a molecules, The structural basis for efficient excitonic energy transfer from peridinin to chlorophyll is found in the clustering of peridinins around the chlorophylls at van der Waals distances.	UNIV KONSTANZ,FAK BIOL,D-78434 CONSTANCE,GERMANY; MACQUARIE UNIV,SCH BIOL SCI,N RYDE,NSW 2109,AUSTRALIA	University of Konstanz; Macquarie University			Hofmann, Eckhard/GPF-5024-2022	Hofmann, Eckhard/0000-0003-4874-372X				BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, XPLOR VERSION 3 1; CARBONERA D, 1995, SPECTROCHIM ACTA A, V51, P115, DOI 10.1016/0584-8539(94)00204-O; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; DIEDERICHS K, 1994, JT CCP4 ESF EACBM NE, V31, P23; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; Frank H. A., 1993, CAROTENOIDS PHOTOSYN; FUJIOSHI Y, 1994, NATURE, V367, P614; FUREY W, IN PRESS METHODS ENZ; GILLBRO T, 1993, PHOTOCHEM PHOTOBIOL, V57, P44, DOI 10.1111/j.1751-1097.1993.tb02253.x; HAXO FT, 1976, PLANT PHYSIOL, V57, P297, DOI 10.1104/pp.57.2.297; HILLER RG, 1995, FEBS LETT, V363, P175, DOI 10.1016/0014-5793(95)00297-M; HILLER RG, 1993, PHOTOCHEM PHOTOBIOL, V57, P125, DOI 10.1111/j.1751-1097.1993.tb02267.x; HILLER RG, 1995, PHOTOSYNTHESIS LIGHT, V1, P24; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; IGLESIASPRIETO R, 1991, P ROY SOC B-BIOL SCI, V246, P275, DOI 10.1098/rspb.1991.0155; IGLESIASPRIETO R, 1993, PHILOS T ROY SOC B, V340, P381, DOI 10.1098/rstb.1993.0080; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOKA P, 1977, BIOCHIM BIOPHYS ACTA, V495, P220, DOI 10.1016/0005-2795(77)90379-8; Koyama Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P243, DOI 10.1111/j.1751-1097.1996.tb03021.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P127; MATTHEWS BW, 1979, J MOL BIOL, V131, P259, DOI 10.1016/0022-2836(79)90076-7; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MIMURO M, 1990, BIOCHIM BIOPHYS ACTA, V1016, P280, DOI 10.1016/0005-2728(90)90070-K; NORRIS BJ, 1994, PLANT MOL BIOL, V24, P673, DOI 10.1007/BF00023563; RAWLYER A, 1995, BIOCHIM BIOPHYS ACTA, V1233, P122; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SONG PS, 1976, BIOCHEMISTRY-US, V15, P4422, DOI 10.1021/bi00665a012; STECK K, 1990, FEBS LETT, V268, P48, DOI 10.1016/0014-5793(90)80969-P; Triplett Edward L., 1993, Molecular Marine Biology and Biotechnology, V2, P246; TRONRUD DE, 1986, J MOL BIOL, V188, P443, DOI 10.1016/0022-2836(86)90167-1; [No title captured]	38	369	389	4	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1996	272	5269					1788	1791		10.1126/science.272.5269.1788	http://dx.doi.org/10.1126/science.272.5269.1788			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UT110	8650577	Green Submitted			2022-12-24	WOS:A1996UT11000043
J	Heilek, GM; Noller, HF				Heilek, GM; Noller, HF			Site-directed hydroxyl radical probing of the rRNA neighborhood of ribosomal protein S5	SCIENCE			English	Article							ESCHERICHIA-COLI; CROSS-LINKING; TRANSLATIONAL FIDELITY; ELECTRON-MICROSCOPY; PRIMER EXTENSION; SMALL SUBUNIT; 16S RNA; LOCALIZATION; NUCLEOTIDES; MUTATIONS	Cysteine residues were introduced into three different positions distributed on the surface of ribosomal protein S5, to serve as targets for derivatization with an Fe(II)-ethyl-enediaminetetraacetic acid linker, Hydroxyl radicals generated locally from the tethered Fe(II) in intermediate ribonucleoprotein particles or in 30S ribosomal subunits reconstituted from derivatized S5 caused cleavage of the RNA, resulting in characteristically different cleavage patterns for the three different tethering positions. These findings provide constraints for the three-dimensional folding of 16S ribosomal RNA (rRNA) and for the orientation of S5 in the 30S subunit, and they further suggest that antibiotic resistance and accuracy mutations in S5 may involve perturbation of 16S rRNA.			Heilek, GM (corresponding author), UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, CTR MOL BIOL RNA, SANTA CRUZ, CA 95064 USA.							BILGIN N, 1990, EMBO J, V9, P735, DOI 10.1002/j.1460-2075.1990.tb08167.x; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRIMACOMBE R, 1990, RIBOSOME, P93; BRIMACOMBE R, 1992, BIOCHIMIE, V74, P319, DOI 10.1016/0300-9084(92)90109-R; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; DERIEMER LH, 1981, J LABELLED COMPD RAD, V18, P1517, DOI 10.1002/jlcr.2580181017; GUTHRIE C, 1969, P NATL ACAD SCI USA, V63, P384, DOI 10.1073/pnas.63.2.384; HEILEK GM, 1995, P NATL ACAD SCI USA, V92, P1113, DOI 10.1073/pnas.92.4.1113; HELD WA, 1974, J BIOL CHEM, V249, P3103; JOHANSON U, 1995, NUCLEIC ACIDS RES, V23, P464, DOI 10.1093/nar/23.3.464; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYRIATSOULIS A, 1986, NUCLEIC ACIDS RES, V14, P1171, DOI 10.1093/nar/14.3.1171; LASATER LS, 1990, NUCLEIC ACIDS RES, V18, P477, DOI 10.1093/nar/18.3.477; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MARSH RC, 1973, P NATL ACAD SCI USA, V70, P151, DOI 10.1073/pnas.70.1.151; MATKOVIC B, 1980, MOL GEN GENET, V179, P135, DOI 10.1007/BF00268455; MIAN S, UNPUB; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MONTANDON PE, 1986, EMBO J, V5, P3705, DOI 10.1002/j.1460-2075.1986.tb04703.x; NOLLER HF, UNPUB; OAKES MI, 1986, P NATL ACAD SCI USA, V83, P275, DOI 10.1073/pnas.83.2.275; OAKES MI, 1990, RIBOSOME, P180; OSSWALD M, 1987, NUCLEIC ACIDS RES, V15, P3221, DOI 10.1093/nar/15.8.3221; PIEPERSBERG W, 1975, MOL GEN GENET, V143, P43, DOI 10.1007/BF00269419; PIEPERSBERG W, 1975, MOL GEN GENET, V140, P91, DOI 10.1007/BF00329777; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; POWERS T, 1994, TRENDS GENET, V10, P27, DOI 10.1016/0168-9525(94)90016-7; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; RINKEAPPEL J, 1991, EMBO J, V10, P2195, DOI 10.1002/j.1460-2075.1991.tb07755.x; SAMAHA RR, 1994, P NATL ACAD SCI USA, V91, P7884, DOI 10.1073/pnas.91.17.7884; SCHEINMAN A, 1992, BIOCHIMIE, V74, P307, DOI 10.1016/0300-9084(92)90108-Q; SIGMUND CD, 1984, NUCLEIC ACIDS RES, V12, P4653, DOI 10.1093/nar/12.11.4653; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; STERN S, 1988, J MOL BIOL, V201, P683, DOI 10.1016/0022-2836(88)90467-6; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TREMPE MR, 1982, J BIOL CHEM, V257, P9822; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WOESE CR, 1989, P NATL ACAD SCI USA, V86, P3119, DOI 10.1073/pnas.86.9.3119; ZWIEB C, 1978, NUCLEIC ACIDS RES, V5, P1189, DOI 10.1093/nar/5.4.1189	47	85	86	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	1996	272	5268					1659	1662		10.1126/science.272.5268.1659	http://dx.doi.org/10.1126/science.272.5268.1659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658142				2022-12-24	WOS:A1996UR09300049
J	Johnson, RL; Rothman, AL; Xie, JW; Goodrich, LV; Bare, JW; Bonifas, JM; Quinn, AG; Myers, RM; Cox, DR; Epstein, EH; Scott, MP				Johnson, RL; Rothman, AL; Xie, JW; Goodrich, LV; Bare, JW; Bonifas, JM; Quinn, AG; Myers, RM; Cox, DR; Epstein, EH; Scott, MP			Human homolog of patched, a candidate gene for the basal cell nevus syndrome	SCIENCE			English	Article							CARCINOMA SYNDROME; SEGMENT POLARITY; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; KRUPPEL FAMILY; GLI GENE; PROTEIN; MUTATIONS; SEQUENCES; SUNLIGHT	The basal cell nevus syndrome (BCNS) is characterized by developmental abnormalities and by the postnatal occurrence of cancers, especially basal cell carcinomas (BCCs), the most common human cancer. Heritable mutations in BCNS patients and a somatic mutation in a sporadic BCC were identified in a human homolog of the Drosophila patched (ptc) gene. The ptc gene encodes a transmembrane protein that in Drosophila acts in opposition to the Hedgehog signaling protein, controlling cell fates, patterning, and growth in numerous tissues. The human PTC gene appears to be crucial for proper embryonic development and for tumor suppression.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DEPT DERMATOL, SAN FRANCISCO, CA 94110 USA; STANFORD UNIV, SCH MED, DEPT GENET & DEV BIOL, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University; Stanford University					NIAMS NIH HHS [AR3995] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BINKLEY GW, 1951, AMA ARCH DERM SYPH, V63, P73, DOI 10.1001/archderm.1951.01570010076006; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BONIFAS JM, 1994, HUM MOL GENET, V3, P447, DOI 10.1093/hmg/3.3.447; BONIFAS JM, UNPUB; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHEN H, 1995, J INVEST DERMATOL, V105, P629, DOI 10.1111/1523-1747.ep12323846; CHENEVIXTRENCH G, 1993, AM J HUM GENET, V53, P760; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; FELSENFELD AL, 1995, DEVELOPMENT, V121, P1; FORBES AJ, 1993, DEVELOPMENT, P115; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1960, NEW ENGL J MED, V262, P908, DOI 10.1056/NEJM196005052621803; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HABUCHI T, 1995, INCOGENE, V11, P1671; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWELL JB, 1984, J AM ACAD DERMATOL, V11, P98, DOI 10.1016/S0190-9622(84)70141-1; HOWELL JB, 1959, ARCH DERMATOL, V79, P67, DOI 10.1001/archderm.1959.01560130069008; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson R. M., UNPUB; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KOJIMA T, 1994, GENE, V148, P211; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; Marigo V, 1996, DEVELOPMENT, V122, P1225; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MORRIS DJ, 1994, GENOMICS, V23, P23, DOI 10.1006/geno.1994.1454; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SAMPEDRO J, 1991, NATURE, V353, P187, DOI 10.1038/353187a0; SLUSARSKI DC, 1995, GENETICS, V139, P229; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WICKING C, 1994, GENOMICS, V22, P505, DOI 10.1006/geno.1994.1423; Xie J., UNPUB; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	65	1477	1553	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	1996	272	5268					1668	1671		10.1126/science.272.5268.1668	http://dx.doi.org/10.1126/science.272.5268.1668			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658145				2022-12-24	WOS:A1996UR09300052
J	Oda, N; Levin, JD; Spoonde, AY; Frank, EG; Levine, AS; Woodgate, R; Ackerman, EJ				Oda, N; Levin, JD; Spoonde, AY; Frank, EG; Levine, AS; Woodgate, R; Ackerman, EJ			Arrested DNA replication in Xenopus and release by Escherichia coli mutagenesis proteins	SCIENCE			English	Article							REPAIR; OOCYTES; EXTRACT; GENES; UMUD'; EGGS; RECA	Xenopus oocytes and oocyte nuclear extracts repair ultraviolet photoproducts on double-stranded (ds) DNA and replicate single-stranded (ss) to ds DNA, M13 ss DNA molecules containing cyclobutane pyrimidine dimers were maintained but not replicated in Xenopus oocytes, yet were replicated in progesterone-matured oocytes, The replication arrest functioned only in cis, The replication arrest was alleviated by injection into oocytes of messenger RNAs encoding the prokaryotic mutagenesis proteins UmuD'C or MucA'B, These results may help explain how cells stabilize repair or replication events on DNA with unrepairable lesions.	NIDDKD,NIH,BETHESDA,MD 20892; NICHHD,SECT DNA REPLICAT REPAIR & MUTAGENESIS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Woodgate, Roger/0000-0001-5581-4616; Spunde, Alexander/0000-0001-8805-9100				BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BJURSELL G, 1979, NATURE, V280, P420, DOI 10.1038/280420a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; CORTESE R, 1980, P NATL ACAD SCI-BIOL, V77, P4147, DOI 10.1073/pnas.77.7.4147; DOREE M, 1993, CELL CYCLE PRACTICAL, P285; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORD CC, 1975, DEV BIOL, V43, P189, DOI 10.1016/0012-1606(75)90140-2; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; FRIEDBERG EC, 1995, DNA REPAIR; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEYER WD, 1994, EXPERIENTIA, V50, P223, DOI 10.1007/BF01924005; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KAISERMAN HB, 1990, EUKARYOTIC NUCLEUS M, V2, P783; KAY BK, 1991, PRACTICAL USES CELL, V36; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; MAESHIMA K, 1995, GENE, V160, P195, DOI 10.1016/0378-1119(95)00148-Y; MURLI S, 1993, CURR OPIN GENET DEV, V3, P719, DOI 10.1016/S0959-437X(05)80089-9; ODA N, UNPUB; ODA N, IN PRESS J BIOL CHEM; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; SEDGWICK SG, 1991, J BACTERIOL, V173, P5604, DOI 10.1128/jb.173.18.5604-5611.1991; SEDGWICK SG, 1991, MOL GEN GENET, V229, P428, DOI 10.1007/BF00267466; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WITKIN EM, 1987, P NATL ACAD SCI USA, V84, P6805, DOI 10.1073/pnas.84.19.6805; WOODGATE R, 1992, MOL MICROBIOL, V6, P2213, DOI 10.1111/j.1365-2958.1992.tb01397.x	31	13	13	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1996	272	5268					1644	1646		10.1126/science.272.5268.1644	http://dx.doi.org/10.1126/science.272.5268.1644			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658137				2022-12-24	WOS:A1996UR09300044
J	Tobutt, C; Oppenheimer, E; Laranjeira, R				Tobutt, C; Oppenheimer, E; Laranjeira, R			Health of cohort of heroin addicts from London clinics: 22 year follow up	BRITISH MEDICAL JOURNAL			English	Article									INST PSYCHIAT,NATL ADDICT CTR,ADDICT RES UNIT,LONDON SE5 8AF,ENGLAND	University of London; King's College London								LEHMAN WEK, 1990, OPIOID ADDICTION TRE; OPPENHEIMER E, 1994, ADDICTION, V89, P1299, DOI 10.1111/j.1360-0443.1994.tb03309.x; SIMPSON DD, 1986, ADDICTION CAREERS SU; Stimson G., 1982, HEROIN ADDICTION TRE; VAILLANT GE, 1973, ARCH GEN PSYCHIAT, V29, P237	5	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1458	1458		10.1136/bmj.312.7044.1458	http://dx.doi.org/10.1136/bmj.312.7044.1458			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UQ296	8664626	Green Published			2022-12-24	WOS:A1996UQ29600029
J	Jayaraman, T; Ondrias, K; Ondriasova, E; Marks, AR				Jayaraman, T; Ondrias, K; Ondriasova, E; Marks, AR			Regulation of the inositol 1,4,5-trisphosphate receptor by tyrosine phosphorylation	SCIENCE			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; PROTEIN-KINASE; BINDING-SITE; MUTANT MICE; CHANNELS; TRANSDUCTION; CEREBELLUM	Tyrosine kinases indirectly raise intracellular calcium concentration ([Ca2+](i)) by activating phospholipases that generate inositol 1,4,5-trisphosphate (IP3). IP3 activates the IP3 receptor (IP(3)R), an intracellular calcium release channel on the endoplasmic reticulum. T cell receptor stimulation triggered a physical association between the nonreceptor protein tyrosine kinase Fyn and the IP(3)R, which induced tyrosine phosphorylation of the IP(3)R. Fyn activated an IP3-gated calcium channel in vitro, and tyrosine phosphorylation of the IP(3)R during T cell activation was reduced in thymocytes from fyn(-/-) mice. Thus, activation of the IP(3)R by tyrosine phosphorylation may play a role in regulating [Ca2+](i).	CUNY MT SINAI SCH MED,DEPT MED,MOLEC CARDIOL LAB,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Ondriasova, Elena/0000-0002-2990-990X; Ondrias, Karol/0000-0001-8329-3563	PHS HHS [N529814] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; JAYARAMAN T, UNPUB; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKADE S, 1994, J BIOL CHEM, V269, P6735; ONDRIAS K, UNPUB; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; WATRAS J, 1991, J NEUROSCI, V11, P3239; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	27	190	197	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1492	1494		10.1126/science.272.5267.1492	http://dx.doi.org/10.1126/science.272.5267.1492			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633244				2022-12-24	WOS:A1996UP89900051
J	Allison, MC; Mills, PR				Allison, MC; Mills, PR			Controversies in management: Screening asymptomatic people at high risk for hepatitis C - The case against	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTTRANSFUSION HEPATITIS		GARTNAVEL ROYAL HOSP, GLASGOW G12 0YN, LANARK, SCOTLAND	Gartnavel Royal Hospital	Allison, MC (corresponding author), ROYAL GWENT HOSP, NEWPORT NP9 2UB, GWENT, WALES.							ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; BOOTH JCL, 1995, GUT, V37, P449, DOI 10.1136/gut.37.4.449; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; DUSHEIKO GM, 1994, ALIMENT PHARM THER, V8, P229; GORDON SC, 1993, HEPATOLOGY, V18, P1338, DOI 10.1002/hep.1840180609; LAU JYN, 1993, LANCET, V342, P1208, DOI 10.1016/0140-6736(93)92187-X; MCMAHON RFT, 1994, HISTOPATHOLOGY, V24, P517; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; SANGIOVANNI A, 1995, HEPATOLOGY, V22, P734; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHIELL A, 1994, MED J AUSTRALIA, V160, P268, DOI 10.5694/j.1326-5377.1994.tb125830.x; THOMAS DL, 1995, J INFECT DIS, V171, P768, DOI 10.1093/infdis/171.4.768; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; ZANETTI AR, 1995, LANCET, V345, P289, DOI 10.1016/S0140-6736(95)90277-5	16	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1996	312	7042					1349	1350		10.1136/bmj.312.7042.1349	http://dx.doi.org/10.1136/bmj.312.7042.1349			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646053	Green Published			2022-12-24	WOS:A1996UN47600028
J	Tsukihara, T; Aoyama, H; Yamashita, E; Tomizaki, T; Yamaguchi, H; ShinzawaItoh, K; Nakashima, R; Yaono, R; Yoshikawa, S				Tsukihara, T; Aoyama, H; Yamashita, E; Tomizaki, T; Yamaguchi, H; ShinzawaItoh, K; Nakashima, R; Yaono, R; Yoshikawa, S			The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 angstrom	SCIENCE			English	Article							CARBON-MONOXIDE BINDING; PARACOCCUS-DENITRIFICANS; SUBUNITS; RESOLUTION; CONFORMERS; PROTEINS; ENERGY	The crystal structure of bovine heart cytochrome c oxidase at 2.8 Angstrom resolution with an R Value of 19.9 percent reveals 13 subunits, each different from the other, five phosphatidyl ethanolamines, three phosphatidyl glycerols and two cholates, two hemes A, and three copper, one magnesium, and one zinc. Of 3606 amino acid residues in the dimer, 3560 have been converged to a reasonable structure by refinement, A hydrogen-bonded system, including a propionate of a heme A (heme a), part of peptide backbone, and an imidazole ligand of Cu-A, could provide an electron transfer pathway between Cu-A and heme a, Two possible proton pathways for pumping, each spanning from the matrix to the cytosolic surfaces, were identified, including hydrogen bonds, internal cavities likely to contain water molecules, and structures that could form hydrogen bonds with small possible conformational change of amino acid side chains. Possible channels for chemical protons to produce H2O, for removing the produced water, and for O-2, respectively, were identified.	OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN; HIMEJI INST TECHNOL,DEPT LIFE SCI,KAMIGOHRI AKOH,HYOGO 67812,JAPAN	Osaka University; University of Hyogo			Yamashita, Eiki/V-6758-2019	Yamashita, Eiki/0000-0002-4278-0039; Aoyama, Hiroshi/0000-0001-7915-8975				ANDYMARK WH, 1994, NATURE, V367, P750; ANTHONY G, 1993, P NATL ACAD SCI USA, V90, P1652, DOI 10.1073/pnas.90.5.1652; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BLOOMER AC, 1978, NATURE, V276, P362, DOI 10.1038/276362a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAUGHEY WS, 1981, P NATL ACAD SCI-BIOL, V78, P2903, DOI 10.1073/pnas.78.5.2903; CHOTHIA C, 1977, P NATL ACAD SCI USA, V74, P4130, DOI 10.1073/pnas.74.10.4130; FETTER JR, 1995, P NATL ACAD SCI USA, V92, P1604, DOI 10.1073/pnas.92.5.1604; GARAVITO R M, 1990, Methods (Orlando), V1, P57, DOI 10.1016/S1046-2023(05)80147-1; GARCIAHORSMAN JA, 1995, BIOCHEMISTRY-US, V34, P4428, DOI 10.1021/bi00013a035; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HILL BC, 1994, J BIOL CHEM, V269, P2419; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1983, TRENDS BIOCHEM SCI, V8, P398, DOI 10.1016/0968-0004(83)90302-X; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MORGAN JE, 1994, J BIOENERG BIOMEMBR, V26, P599, DOI 10.1007/BF00831534; MULLER M, 1988, BIOCHEM BIOPH RES CO, V154, P1260, DOI 10.1016/0006-291X(88)90275-6; PALMER G, 1991, LONG RANGE ELECT TRA; Perutz M. F., 1990, MECH COOPERATIVITY; POTTER WT, 1990, BIOCHEMISTRY-US, V29, P6283, DOI 10.1021/bi00478a025; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; ROBINSON NC, 1982, BIOCHEMISTRY-US, V21, P184, DOI 10.1021/bi00530a031; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VASSILEV AO, 1995, P NATL ACAD SCI USA, V92, P8680, DOI 10.1073/pnas.92.19.8680; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Warburg O, 1929, BIOCHEM Z, V214, P64; WIKSTROM MKF, 1976, FEBS LETT, V65, P259, DOI 10.1016/0014-5793(76)80127-5; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412; ZHANG YZ, 1991, BIOCHEMISTRY-US, V30, P3674, DOI 10.1021/bi00229a012	33	1884	1920	4	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1996	272	5265					1136	1144		10.1126/science.272.5265.1136	http://dx.doi.org/10.1126/science.272.5265.1136			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638158				2022-12-24	WOS:A1996UM88900040
J	Wonderling, D; McDermott, C; Buxton, M; Kinmonth, AL; Pyke, S; Thompson, S; Wood, D				Wonderling, D; McDermott, C; Buxton, M; Kinmonth, AL; Pyke, S; Thompson, S; Wood, D			Costs and cost effectiveness of cardiovascular screening and intervention: The British family heart study	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure costs and cost effectiveness of the British family heart study cardiovascular screening and intervention programme. Design-Cost effectiveness analysis of randomised controlled trial. Clinical and resource use data taken from trial and unit cost data from external estimates. Setting-13 general practices across Britain. Subjects-4185 men aged 40-59 and their 2827 partners. Intervention-Nurse led programme using a family centred approach, with follow up according to degree of risk. Main outcome measures-Cost of the programme itself; overall short term cost to NHS; cost per 1% reduction in coronary risk at one year. Results-Estimated cost of putting the programme into practice for one year was pound 63 per person (95% confidence interval pound 60 to pound 65). The overall short term cost to the health service was pound 77 per man (pound 29 to pound 124) but only pound 13 per woman (-pound 48 to pound 74), owing to differences in utilisation of other health service resources. The cost per 1% reduction in risk was pound 5.08 per man (pound 5.92 including broader health service costs) and pound 5.78 per woman (pound 1.28 taking into account wider health service savings). Conclusions-The direct cost of the programme to a four partner practice of 7500 patients would be approximately pound 58 000. Annually, pound 8300 would currently be paid to a practice of this size working to the ma target on the health promotion bands, plus any additional reimbursement of practice staff salaries for which the practice qualified. The broader short term costs to the NHS may augment these costs for men but offset them considerably for women.	BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND; UNIV SOUTHAMPTON,FAC MED,SOUTHALL SO16 5ST,MIDDX,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON WC1E 7HT,ENGLAND; NATL HEART & LUNG INST,DEPT CLIN EPIDEMIOL,LONDON SW3 6LY,ENGLAND	Brunel University; University of Southampton; University of London; London School of Hygiene & Tropical Medicine; Imperial College London				Wonderling, David/0000-0003-0315-6273				[Anonymous], 1995, COMP HLTH STAT; BRYAN S, 1995, J EPIDEMIOL COMMUN H, V49, P70, DOI 10.1136/jech.49.1.70; *CHAR I PUBL FIN A, 1994, HLTH DATABASE 994, V1; *DEP EMPL, 1994, 1994 DEP EMPL A; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Langham S, 1996, BRIT MED J, V312, P1265, DOI 10.1136/bmj.312.7041.1265; NETTEN A, 1994, UNIT COSTS COMMUNITY; *OFF POP CENS SURV, 1994, OPCS MON 1994; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274; 1994, BRIT MED J, V308, P313; 1995, BRIT MED J, V310, P1099; 1994, BR J GEN PRACT, V44, P62	13	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1269	1273		10.1136/bmj.312.7041.1269	http://dx.doi.org/10.1136/bmj.312.7041.1269			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634617	Green Published, Green Submitted			2022-12-24	WOS:A1996UM40400023
J	Kurten, RC; Cadena, DL; Gill, GN				Kurten, RC; Cadena, DL; Gill, GN			Enhanced degradation of EGF receptors by a sorting nexin, SNX1	SCIENCE			English	Article								The vectorial movement of proteins requires specific recognition by components of the vesicular trafficking machinery. A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code, SNX1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation. Thus, SNX1 is likely to play a role in sorting EGFR to lysosomes.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008666] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline; NIDDK NIH HHS [F32DK08666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CADENA DL, 1994, J BIOL CHEM, V269, P260; EKENA K, 1995, MOL CELL BIOL, V15, P1671; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KURTEN RC, UNPUB; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Moore DD, 1995, GLOB MOB SURV; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	11	308	317	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1008	1010		10.1126/science.272.5264.1008	http://dx.doi.org/10.1126/science.272.5264.1008			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638121				2022-12-24	WOS:A1996UL61900044
J	Li, KJ; Kaufman, TC				Li, KJ; Kaufman, TC			The homeotic target gene centrosomin encodes an essential centrosomal component	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; DROSOPHILA EMBRYO; SEGMENTAL DETERMINATION; BITHORAX COMPLEX; GAMMA-TUBULIN; ULTRABITHORAX; RECOMBINASE; EXPRESSION; MUTATIONS; PROTEINS	The centrosomin (cnn) gene encodes a protein associated with mitotic centrosomes in Drosophila melanogaster and is a target of homeotic gene regulation. Here we report that CNN is an essential component of the centrosome. Loss of zygotic cnn expression disrupts the development of the second midgut constriction, the gastric caeca, and the nervous system. Embryos that lack maternal as well as zygotic cnn expression display defects in nuclear division, chromosome alignment, and microtubule organization, while adult flies that are mosaic for cnn(-) cells exhibit defects indicative of a block in cell proliferation. We propose that cnn provides an example of homeotic genes directly regulating the accumulation of essential cellular proteins to carry out segment-specific morphogenetic functions.	INDIANA UNIV, HOWARD HUGHES MED INST, DEPT BIOL, BLOOMINGTON, IN 47405 USA	Howard Hughes Medical Institute; Indiana University System; Indiana University Bloomington								AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; AHMAD FJ, 1994, NEURON, V12, P271, DOI 10.1016/0896-6273(94)90270-4; ANDREW DJ, 1992, NEW BIOL, V4, P5; Ashburner M., 1989, DROSOPHILA LAB HDB; BAAS PW, 1992, J CELL BIOL, V119, P171, DOI 10.1083/jcb.119.1.171; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BOOKER R, 1989, DEVELOPMENT, V105, P621; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; BRYANT PJ, 1971, DEV BIOL, V26, P606, DOI 10.1016/0012-1606(71)90146-1; BRYANT PJ, 1973, GENETICS, V75, P623; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CHOU TB, 1992, GENETICS, V131, P643; CHOU TB, 1993, DEVELOPMENT, V119, P1359; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Fuller M.T., 1993, SPERMATOGENESIS DEV; GHYSEN A, 1985, CELL, V40, P943, DOI 10.1016/0092-8674(85)90354-X; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GONZALEZ C, 1990, J CELL SCI, V96, P605; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Goodman Corey S., 1993, P1131; GOULD AP, 1992, DEVELOPMENT, V116, P1163; GRABA Y, 1995, DEVELOPMENT, V121, P209; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; HEUER JG, 1995, DEVELOPMENT, V121, P3861; HINZ U, 1992, DEVELOPMENT, V116, P543; JIJAKLI H, 1992, INT J DEV BIOL, V36, P93; JONES B, 1993, GENE DEV, V7, P229, DOI 10.1101/gad.7.2.229; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KELLOGG DR, 1995, MOL BIOL CELL, V6, P1673, DOI 10.1091/mbc.6.12.1673; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; MASTICK GS, 1995, GENETICS, V139, P349; OEGEMA K, 1995, J CELL BIOL, V131, P1261, DOI 10.1083/jcb.131.5.1261; RAFF JW, 1993, J CELL BIOL, V121, P823, DOI 10.1083/jcb.121.4.823; REUTER R, 1990, DEVELOPMENT, V109, P289; RUSSELL MA, 1974, DEV BIOL, V40, P24, DOI 10.1016/0012-1606(74)90104-3; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; SULLIVAN W, 1995, CURR OPIN CELL BIOL, V7, P18, DOI 10.1016/0955-0674(95)80040-9; SULLIVAN W, 1990, DEVELOPMENT, V110, P311; SUNKEL CE, 1988, J CELL SCI, V89, P25; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; THEURKAUF WE, 1994, DROSOPHILA MELANOGAS, P489; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; VERHEYEN E, 1994, DROSOPHILA MELANOGAS, P545; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WHITFIELD WGF, 1995, J CELL SCI, V108, P3377; XU T, 1993, DEVELOPMENT, V117, P1223; XU T, 1994, METHOD CELL BIOL, V44, P655, DOI 10.1016/S0091-679X(08)60937-1; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	56	111	113	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1996	85	4					585	596		10.1016/S0092-8674(00)81258-1	http://dx.doi.org/10.1016/S0092-8674(00)81258-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653793	Bronze			2022-12-24	WOS:A1996UM41500015
J	Sheng, HZ; Zhadanov, AB; Mosinger, B; Fujii, T; Bertuzzi, S; Grinberg, A; Lee, EJ; Huang, SP; Mahon, KA; Westphal, H				Sheng, HZ; Zhadanov, AB; Mosinger, B; Fujii, T; Bertuzzi, S; Grinberg, A; Lee, EJ; Huang, SP; Mahon, KA; Westphal, H			Specification of pituitary cell lineages by the LIM homeobox gene Lhx3	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; EXPRESSION; ONTOGENESIS; MESENCHYME; LETHALITY; INVITRO	During pituitary organogenesis, the progressive differentiation of distinct pituitary-specific cell lineages from a common primordium involves a series of developmental decisions and inductive interactions. Targeted gene disruption in mice showed that Lhx3, a LIM homeobox gene expressed in the pituitary throughout development, is essential for differentiation and proliferation of pituitary cell lineages, In mice homozygous for the Lhx3 mutation, Rathke's pouch formed but failed to grow and differentiate; such mice lacked both the anterior and intermediate robes of the pituitary. The determination of all pituitary cell lineages, except the corticotrophs, was affected, suggesting that a distinct, Lhx3-independent ontogenetic pathway exists for the initial specification of this lineage.	NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CHIN WW, 1981, P NATL ACAD SCI-BIOL, V78, P5329, DOI 10.1073/pnas.78.9.5329; DAIKOKU S, 1983, DEV BIOL, V97, P81, DOI 10.1016/0012-1606(83)90065-9; DIAKOKU S, 1982, DEV BIOL, V90, P198; ELKABES S, 1989, DEV BRAIN RES, V46, P85, DOI 10.1016/0165-3806(89)90145-4; ETKIN W, 1967, NEUROENDOCRINOLOGY, P261; FERRAND R, 1972, Archives de Biologie, V83, P297; Hermesz E, 1996, DEVELOPMENT, V122, P41; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P1117, DOI 10.1177/42.8.8027530; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KAWAMURA K, 1995, CELL TISSUE RES, V279, P233, DOI 10.1007/s004410050278; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; KIKUYAMA S, 1993, J EXP ZOOL, V266, P216, DOI 10.1002/jez.1402660307; KUSAKABE M, 1984, DEV GROWTH DIFFER, V26, P263; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINZER DIH, 1985, J BIOL CHEM, V260, P9574; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; OFFIELD MF, IN PRESS DEVELOPMENT; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; ROBINSON GW, 1991, NEW BIOL, V3, P1183; Schwind JL, 1928, AM J ANAT, V41, P295, DOI 10.1002/aja.1000410206; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; SHENG H, UNPUB; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WATANABE YG, 1982, CELL TISSUE RES, V227, P257, DOI 10.1007/BF00210884; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; ZHADANOV AB, 1995, GENOMICS, V27, P27, DOI 10.1006/geno.1995.1004; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	33	369	375	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1004	1007		10.1126/science.272.5264.1004	http://dx.doi.org/10.1126/science.272.5264.1004			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638120				2022-12-24	WOS:A1996UL61900043
J	Ikeda, SR				Ikeda, SR			Voltage-dependent modulation of N-type calcium channels by G-protein beta gamma subunits	NATURE			English	Article							RAT SYMPATHETIC NEURONS; CA2+ CHANNELS; BINDING; INHIBITION; MUTATIONS; CURRENTS	THE most commonly used signal transduction pathway for receptor-mediated N-type Ca2+-channel modulation involves activation of a heterotrimeric G protein to produce voltage-dependent inhibition(1). Although it is widely assumed that G alpha mediates this effect, experiments to address this hypothesis directly are lacking. Here I show that transient overexpression of G beta gamma in sympathetic neurons mimics and occludes the voltage-dependent Ca2+ channel modulation produced by noradrenaline (NA). Conversely, overexpression of G alpha produces minimal effects on basal Ca2+ channel behaviour but attenuates NA-mediated inhibition in a manner consistent with the buffering of G beta gamma. These observations indicate that it is G beta gamma, and not G alpha, that mediates voltage-dependent inhibition of N-type Ca2+ channels. The identification of G beta gamma as the mediator of this pathway has broad implications as G-protein-coupled receptors, many of which are implicated in disease or are targets of therapeutic agents, couple to N-type Ca2+ channels(2) and may modulate synaptic transmission by this mechanism(3,4).			Ikeda, SR (corresponding author), MED COLL GEORGIA, DEPT PHARMACOL & TOXICOL, AUGUSTA, GA 30912 USA.			Ikeda, Stephen/0000-0002-4088-9508				ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bourinet E., 1995, Society for Neuroscience Abstracts, V21, P515; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; HELM R, 1995, NATURE, V373, P663; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; IKEDA SR, 1995, NEURON, V14, P1029, DOI 10.1016/0896-6273(95)90341-0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MULLER S, 1995, BIOCHEM SOC T, V23, P141; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; ROCHE JP, 1995, FEBS LETT, V371, P43, DOI 10.1016/0014-5793(95)00860-C; SCHOFIELD GG, 1990, EUR J PHARMACOL, V180, P37, DOI 10.1016/0014-2999(90)90590-3; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; ZHU Y, 1994, NEURON, V13, P657, DOI 10.1016/0896-6273(94)90033-7	30	652	663	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	1996	380	6571					255	258		10.1038/380255a0	http://dx.doi.org/10.1038/380255a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637575				2022-12-24	WOS:A1996UB11700054
J	Fields, PE; Gajewski, TF; Fitch, FW				Fields, PE; Gajewski, TF; Fitch, FW			Blocked ras activation in anergic CD4(+) T cells	SCIENCE			English	Article							CLONAL ANERGY; ANTIGEN RECEPTOR; IL-2; STIMULATION; INVITRO; P21RAS	T cell anergy is a state of functional unresponsiveness characterized by the inability to produce interleukin-2 (IL-2) upon T cell receptor stimulation. The mitogen-activated protein kinases ERK-1 and ERK-2 and the guanosine triphosphate-binding protein p21(Ras) were found to remain unactivated upon stimulation of anergic murine T helper cell 1 clones. The inability to activate the Ras pathway did not result from a defect in association among Shc, Grb-2, and murine Son of Sevenless, nor from a defect in their tyrosine phosphorylation. This block in Ras activation may lead to defective transactivation at activator protein 1 sites in anergic cells and may enable T cells to shut down IL-2 production selectively during anergy.	UNIV CHICAGO,COMM IMMUNOL,BEN MAY INST,DEPT PATHOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,HEMATOL ONCOL SECT,CHICAGO,IL 60637	University of Chicago; University of Chicago			Fields, Patrick E/G-4878-2012	Fields, Patrick/0000-0002-6797-4139				BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BHANDOOLA A, 1993, J IMMUNOL, V151, P2355; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIELDS PI, UNPUB; GAJEWSKI TF, 1995, EUR J IMMUNOL, V25, P1836, DOI 10.1002/eji.1830250707; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; QUILL H, 1992, J IMMUNOL, V149, P2887; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; STACK RM, 1994, J IMMUNOL, V152, P5723; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WOODROW M, 1993, J IMMUNOL, V150, P1	26	352	359	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1996	271	5253					1276	1278		10.1126/science.271.5253.1276	http://dx.doi.org/10.1126/science.271.5253.1276			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TX695	8638108				2022-12-24	WOS:A1996TX69500035
J	Arkin, MR; Stemp, EDA; Holmlin, RE; Barton, JK; Hormann, A; Olson, EJC; Barbara, PF				Arkin, MR; Stemp, EDA; Holmlin, RE; Barton, JK; Hormann, A; Olson, EJC; Barbara, PF			Rates of DNA-mediated electron transfer between metallointercalators	SCIENCE			English	Article							PHENANTHRENEQUINONE DIIMINE COMPLEXES; AQUEOUS-SOLUTION; MOLECULAR WIRES; INTERCALATED ETHIDIUM; DONOR PROPERTIES; METAL-COMPLEXES; LIGHT SWITCH; CHARGE; MIGRATION; DISTANCE	Ultrafast emission and absorption spectroscopies were used to measure the kinetics of DNA-mediated electron transfer reactions between metal complexes intercalated into DNA, In the presence of rhodium(III) acceptor, a substantial fraction of photoexcited donor exhibits fast oxidative quenching (>3 x 10(10) per second). Transient-absorption experiments indicate that, for a series of donors, the majority of back electron transfer is also very fast (similar to 10(10) per second). This rate is independent of the loading of accepters on the helix, but is sensitive to sequence and pi stacking. The cooperative binding of donor and acceptor is considered unlikely on the basis of structural models and DNA photocleavage studies of binding. These data show that the DNA double helix differs significantly from proteins as a bridge for electron transfer.	CALTECH,BECKMAN INST,PASADENA,CA 91125; UNIV MINNESOTA,DEPT CHEM,MINNEAPOLIS,MN 55455	California Institute of Technology; University of Minnesota System; University of Minnesota Twin Cities			Arkin, Michelle/AAO-2009-2021		NIGMS NIH HHS [GM49216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amouyal E., 1990, J CHEM SOC DA, V6, DOI [10.1039/dt9900001841, DOI 10.1039/DT9900001841]; Arkin MR, 1996, J AM CHEM SOC, V118, P2267, DOI 10.1021/ja9532998; Arkin MR, 1995, ADV CHEM SER, V246, P449; ATHERTON SJ, 1987, J PHYS CHEM-US, V91, P3137, DOI 10.1021/j100296a008; ATHERTON SJ, 1995, J PHYS CHEM-US, V99, P12025, DOI 10.1021/j100031a035; ATHERTON SJ, 1987, J PHYS CHEM-US, V91, P3993, DOI 10.1021/j100299a014; BAGULEY BC, 1984, BIOCHEMISTRY-US, V23, P37; BARTON JK, 1986, J AM CHEM SOC, V108, P6391, DOI 10.1021/ja00280a047; BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894; BOXER SG, 1990, ANNU REV BIOPHYS BIO, V19, P267; BRUN AM, 1992, J AM CHEM SOC, V114, P3656, DOI 10.1021/ja00036a013; BRUN AM, 1994, J AM CHEM SOC, V116, P10383, DOI 10.1021/ja00102a004; CANDEIAS LP, 1993, J AM CHEM SOC, V115, P2437, DOI 10.1021/ja00059a044; CHAMBRON JC, 1985, NOUV J CHIM, V9, P527; CHOW CS, 1992, METHOD ENZYMOL, V212, P219; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; COLLINS JG, 1994, J AM CHEM SOC, V116, P9840, DOI 10.1021/ja00101a004; CREUTZ C, 1980, J AM CHEM SOC, V102, P1309, DOI 10.1021/ja00524a014; CROTHERS DM, 1968, BIOPOLYMERS, V6, P575, DOI 10.1002/bip.1968.360060411; CULLIS PM, 1990, J CHEM SOC FARADAY T, V86, P591, DOI 10.1039/ft9908600591; DAVID SS, 1993, J AM CHEM SOC, V115, P2984, DOI 10.1021/ja00060a060; DAVIS LM, 1987, CHEM-BIOL INTERACT, V62, P45, DOI 10.1016/0009-2797(87)90078-0; DEE D, 1974, J CHEM PHYS, V60, P541, DOI 10.1063/1.1681073; DUPUREUR CM, 1994, J AM CHEM SOC, V116, P10286, DOI 10.1021/ja00101a053; FARAGGI M, 1994, J CHIM PHYS PCB, V91, P1054, DOI 10.1051/jcp/1994911054; FELTS AK, 1995, J PHYS CHEM-US, V99, P2929, DOI 10.1021/j100009a057; FRIEDMAN AE, 1991, NUCLEIC ACIDS RES, V19, P2595; FRIEDMAN AE, 1990, J AM CHEM SOC, V112, P4960, DOI 10.1021/ja00168a052; FROMHERZ P, 1986, J AM CHEM SOC, V108, P5361, DOI 10.1021/ja00277a060; HARTSHORN RM, 1992, J AM CHEM SOC, V114, P919; HIORT C, 1993, J AM CHEM SOC, V115, P3448, DOI 10.1021/ja00062a007; HOLMLIN RE, 1995, INORG CHEM, V34, P7, DOI 10.1021/ic00105a004; Holmlin RE, 1996, J AM CHEM SOC, V118, P5236, DOI 10.1021/ja953941y; HORMANN A, UNPUB; HOUEELEVIN C, 1991, BIOCHEMISTRY-US, V30, P8216, DOI 10.1021/bi00247a018; HUDSON BP, 1995, J AM CHEM SOC, V117, P9379, DOI 10.1021/ja00141a041; HUNTER CA, 1993, J MOL BIOL, V230, P1025, DOI 10.1006/jmbi.1993.1217; HUSH NS, 1975, CHEM PHYS LETT, V34, P11, DOI 10.1016/0009-2614(75)80190-4; JENKINS Y, 1992, BIOCHEMISTRY-US, V31, P10809, DOI 10.1021/bi00159a023; JOVANOVIC SV, 1986, J PHYS CHEM-US, V90, P974, DOI 10.1021/j100277a053; KARTHA S, 1991, MET IONS BIOL SYST, V27, P323; KEMP M, 1994, J CHEM PHYS, V101, P5172, DOI 10.1063/1.467373; Kittler L., 1980, J ELECTROANAL CHEM I, V116, P503; LANGEN R, 1995, SCIENCE, V268, P1733, DOI 10.1126/science.7792598; Lipscomb LA, 1996, BIOCHEMISTRY-US, V35, P2818, DOI 10.1021/bi952443z; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARKOVITSI D, 1992, J CHEM SOC FARADAY T, V88, P1275, DOI 10.1039/ft9928801275; MARKS TJ, 1990, ANGEW CHEM INT EDIT, V29, P857, DOI 10.1002/anie.199008571; MCCONNELL H, 1961, J CHEM PHYS, V35, P508, DOI 10.1063/1.1731961; MEADE TJ, 1995, ANGEW CHEM INT EDIT, V34, P352, DOI 10.1002/anie.199503521; MEADE TJ, 1996, MET IONS BIOL SYST, V33, P453; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; MUJICA V, 1994, J CHEM PHYS, V101, P6849, DOI 10.1063/1.468314; MUJICA V, 1994, J CHEM PHYS, V101, P6856, DOI 10.1063/1.468315; MURPHY CJ, 1994, P NATL ACAD SCI USA, V91, P5315, DOI 10.1073/pnas.91.12.5315; MURPHY CJ, 1993, SCIENCE, V262, P1025, DOI 10.1126/science.7802858; NALEWAY CA, 1991, J PHYS CHEM-US, V95, P8434, DOI 10.1021/j100175a005; O'KONSKI C. T., 1964, BIOPOLYMERS SYMP, V1, P479; Olson E. J., UNPUB; PURUGGANAN MD, 1988, SCIENCE, V241, P1645, DOI 10.1126/science.3420416; QUIRION G, 1991, SYNTHETIC MET, V42, P2653, DOI 10.1016/0379-6779(91)91445-G; RISSER SM, 1993, J AM CHEM SOC, V115, P2508, DOI 10.1021/ja00059a057; SCHMECHEL DE, 1971, BIOPOLYMERS, V10, P465, DOI 10.1002/bip.360100304; SCHOUTEN PG, 1994, J AM CHEM SOC, V116, P6880, DOI 10.1021/ja00094a048; SHIELDS TP, 1995, BIOCHEMISTRY-US, V34, P15049, DOI 10.1021/bi00046a010; SHIELDS TP, 1995, BIOCHEMISTRY-US, V34, P15037, DOI 10.1021/bi00046a009; SITLANI A, 1993, J AM CHEM SOC, V115, P12589, DOI 10.1021/ja00079a050; SITLANI A, 1992, J AM CHEM SOC, V114, P2303, DOI 10.1021/ja00033a003; SITLANI A, 1994, BIOCHEMISTRY-US, V33, P12100, DOI 10.1021/bi00206a013; SNART RS, 1973, BIOPOLYMERS, V12, P1493, DOI 10.1002/bip.1973.360120705; STEENKEN S, 1992, J AM CHEM SOC, V114, P4701, DOI 10.1021/ja00038a037; STEMP EDA, 1995, J AM CHEM SOC, V117, P2375, DOI 10.1021/ja00113a037; Stemp EDA, 1996, MET IONS BIOL SYST, V33, P325; SZENTGYORGYI A, 1960, P NATL ACAD SCI USA, V46, P1444, DOI 10.1073/pnas.46.11.1444; TERBRUEGGEN RH, 1995, BIOCHEMISTRY-US, V34, P8227, DOI 10.1021/bi00026a003; TURRO C, 1995, J AM CHEM SOC, V117, P9026, DOI 10.1021/ja00140a020; UCHIDA K, 1989, NUCLEIC ACIDS RES, V17, P10259, DOI 10.1093/nar/17.24.10259; ULLMANN GM, 1995, J AM CHEM SOC, V117, P4766, DOI 10.1021/ja00122a005; VORLICKOVA M, 1985, J BIOMOL STRUCT DYN, V3, P67, DOI 10.1080/07391102.1985.10508399; WARMAN JM, 1992, RAD RES 20TH CENTURY, V2, P93; WELCH TW, 1995, J PHYS CHEM-US, V99, P11757, DOI 10.1021/j100030a021; WHILLANS DW, 1975, BIOCHIM BIOPHYS ACTA, V414, P193, DOI 10.1016/0005-2787(75)90223-3; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007; YANAGI K, 1991, J MOL BIOL, V217, P201, DOI 10.1016/0022-2836(91)90620-L; [No title captured]	85	422	434	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1996	273	5274					475	480		10.1126/science.273.5274.475	http://dx.doi.org/10.1126/science.273.5274.475			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY983	8662532				2022-12-24	WOS:A1996UY98300034
J	Hubbard, EJA; Dong, Q; Greenwald, I				Hubbard, EJA; Dong, Q; Greenwald, I			Evidence for physical and functional association between EMB-5 and LIN-12 in Caenorhabditis elegans	SCIENCE			English	Article							C-ELEGANS; CELL LINEAGE; YEAST; GENE; EXPRESSION; MUTANTS; GLP-1; MUTATIONS; DECISION; PROTEINS	The Caenorhabditis elegans LIN-12 and GLP-1 proteins are members of the LIN-12/Notch family of receptors for intercellular signals that specify cell fate. Evidence presented here suggests that the intracellular domains of LIN-12 and GLP-1-interact with the C. elegans EMB-5 protein and that the emb-5 gene functions in the same pathway as the lin-12 and glp-1 genes. EMB-5 is similar in sequence to a yeast protein that controls chromatin structure. Hence, a direct consequence of LIN-12 or GLP-1 activation may be an alteration of chromatin structure that produces changes in transcriptional activity.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute				Hubbard, E. Jane Albert/0000-0001-5893-7232	NIGMS NIH HHS [GM37602] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037602] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AUSTIN CP, 1995, DEVELOPMENT, V121, P3637; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BARSTEAD R, COMMUNICATION; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; CASSADA R, 1981, DEV BIOL, V84, P193, DOI 10.1016/0012-1606(81)90383-3; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; Christensen S, 1996, DEVELOPMENT, V122, P1373; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; Dong Q., UNPUB; DURFEE T, 1993, GENE DEV, V7, P1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FITZGERALD K, 1993, DEVELOPMENT, V119, P1019; Fitzgerald K, 1995, DEVELOPMENT, V121, P4275; FITZGERALD K, COMMUNICATION; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HEDGECOCK EM, 1995, GENETICS, V141, P989; HUBBARD EL, UNPUB; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; MACLENNAN AJ, 1993, TRENDS BIOCHEM SCI, V18, P464; Miller J.H., 1972, EXPT MOL GENETICS; MIWA J, 1980, DEV BIOL, V76, P160, DOI 10.1016/0012-1606(80)90369-3; NAGASE T, D79984 GEN BANK; NISHIWAKI K, 1993, MOL GEN GENET, V239, P313, DOI 10.1007/BF00276929; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SCHWEISGUTH F, 1995, DEVELOPMENT, V121, P1875; SCHWEISGUTH F, 1994, CELL, V69, P199; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SUNDARAM M, 1993, GENETICS, V135, P755; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	46	52	60	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1996	273	5271					112	115		10.1126/science.273.5271.112	http://dx.doi.org/10.1126/science.273.5271.112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8658178				2022-12-24	WOS:A1996UV47800052
J	Zaychikov, E; Martin, E; Denissova, L; Kozlov, M; Markovtsov, V; Kashlev, M; Heumann, H; Nikiforov, V; Goldfarb, A; Mustaev, A				Zaychikov, E; Martin, E; Denissova, L; Kozlov, M; Markovtsov, V; Kashlev, M; Heumann, H; Nikiforov, V; Goldfarb, A; Mustaev, A			Mapping of catalytic residues in the RNA polymerase active center	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; OPEN COMPLEXES; MG2+; SITE	When the Mg2+ ion in the catalytic center of Escherichia coli RNA polymerase (RNAP) is replaced with Fe2+, hydroxyl radicals are generated. In the promoter complex, such radicals cleave template DNA near the transcription start site, whereas the beta' subunit is cleaved at a conserved motif NADFDGD (Asn-Ala-Asp-Phe-Asp-Gly-Asp). Substitution of the three aspartate residues with alanine creates a dominant lethal mutation. The mutant RNAP is catalytically inactive but can bind promoters and form an open complex, The mutant fails to support Fe2+-induced cleavage of DNA or protein. Thus, the NADFDGD motif is involved in chelation of the active center Mg2+.	PUBL HLTH RES INST,NEW YORK,NY 10016; RUSSIAN ACAD SCI,INST LIMNOL,IRKUTSK 664033,RUSSIA; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,MUNCHEN,GERMANY	Irkutsk Science Centre of the Russian Academy of Sciences; Russian Academy of Sciences; Limnological Institute SB RAS; Max Planck Society			Kozlov, Maxim/GLN-3047-2022	Kozlov, Maxim/0000-0002-5994-9099				BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; CHOU WY, 1995, J BIOL CHEM, V270, P25935, DOI 10.1074/jbc.270.43.25935; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; ETTNER N, 1995, BIOCHEMISTRY-US, V34, P22, DOI 10.1021/bi00001a004; FARBER JM, 1986, J BIOL CHEM, V261, P4574; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KNORRE DG, 1993, RUSS CHEM REV, V62, P65; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MARKOVTSOV V, UNPUB; MARTIN E, 1992, THESIS RUSSIAN ACAD; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; SCHULTZ P, 1993, EMBO J, V12, P2607; SEVERINOV K, 1995, J BIOL CHEM, V270, P29428, DOI 10.1074/jbc.270.49.29428; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; SUH WC, 1992, BIOCHEMISTRY-US, V31, P7815, DOI 10.1021/bi00149a011; WEI CH, 1994, BIOCHEMISTRY-US, V33, P7931, DOI 10.1021/bi00191a021; WEI CH, 1995, BIOCHEMISTRY-US, V34, P7949, DOI 10.1021/bi00024a020; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	26	149	153	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1996	273	5271					107	109		10.1126/science.273.5271.107	http://dx.doi.org/10.1126/science.273.5271.107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8658176				2022-12-24	WOS:A1996UV47800050
J	Liu, MY; Simon, MI				Liu, MY; Simon, MI			Regulation by cAMP-dependent protein kinase of a G-protein-mediated phospholipase C	NATURE			English	Article							TRACHEAL SMOOTH-MUSCLE; BETA-GAMMA; SUBUNITS; PHOSPHORYLATION; STIMULATION; ACTIVATION; FORSKOLIN; CALCIUM; ISOZYME	THE heterotrimeric G proteins mediate a variety of cellular processes by coupling transmembrane receptors to different effector molecules, including adenylyl cyclases and inositol-phospholipid-specific phospholipase C (PLC)(1-3). Activation of adenylyl cyclases results in the production of cyclic AMP and activation of cAMP-dependent protein kinase (PKA), Phospholipase C catalyses the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PtdInsP(2)) to generate diacylglycerol and inositol-1,4,5-triphosphate (InsP(3)), leading to the activation of protein kinase C (PKC) and the mobilization of intracellular calcium(4). The various PLC isoforms appear to be activated by different receptors, and in some cases by different G-protein components(5). There are four well-characterized forms of PLC-beta and all of them are activated to various extents by the G alpha(q) family of G proteins(6-9). Specific activation of PLC isoforms beta 2 and beta 3 by G-protein beta gamma subunits has also been reported(10,11). Although it has been suggested that PLC activity might be modulated by the adenylyl cyclase pathway, no clear link has been established between the two pathways. Here we report that cAMP-dependent protein kinase specifically inhibits G beta gamma-activated PLC-beta 2 activity but not that of the G alpha-activated PLC isoforms, and that the effect of PKA is not mimicked by PKC isozymes. Furthermore, we show that PKA directly phosphorylates serine residues of the PLC-beta 2 protein both in vivo and in vitro. Our results provide an insight into the specificity and nature of the crosstalk between the two G-protein coupled signal transduction pathways.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology				Liu, Mingyao/0000-0002-9188-8417				ANWER K, 1989, ENDOCRINOLOGY, V124, P2995, DOI 10.1210/endo-124-6-2995; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL IP, 1990, BRIT J PHARMACOL, V100, P646, DOI 10.1111/j.1476-5381.1990.tb15861.x; JHON DY, 1993, J BIOL CHEM, V268, P6654; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIM UH, 1989, J BIOL CHEM, V264, P20167; MADISON JM, 1988, J CLIN INVEST, V82, P1462, DOI 10.1172/JCI113752; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEYLON CB, 1988, EUR J PHARMACOL, V148, P441, DOI 10.1016/0014-2999(88)90124-0; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OKAJIMA F, 1995, J BIOL CHEM, V270, P26332, DOI 10.1074/jbc.270.44.26332; PERNEY TM, 1989, J BIOL CHEM, V264, P7317; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; RYU SH, 1990, J BIOL CHEM, V265, P17941; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SNYDERMAN R, 1990, ADP RIBOSYLATING TOX, P295; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WATSON SP, 1984, J BIOL CHEM, V259, P3199; WEN YS, 1992, ENDOCRINOLOGY, V131, P1377, DOI 10.1210/en.131.3.1377; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1993, J BIOL CHEM, V268, P3704	30	184	195	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1996	382	6586					83	87		10.1038/382083a0	http://dx.doi.org/10.1038/382083a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV473	8657310				2022-12-24	WOS:A1996UV47300059
J	Jing, SQ; Wen, DZ; Yu, YB; Holst, PL; Luo, Y; Fang, M; Tamir, R; Antonio, L; Hu, Z; Cupples, R; Louis, JC; Hu, S; Altrock, BW; Fox, GM				Jing, SQ; Wen, DZ; Yu, YB; Holst, PL; Luo, Y; Fang, M; Tamir, R; Antonio, L; Hu, Z; Cupples, R; Louis, JC; Hu, S; Altrock, BW; Fox, GM			GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF	CELL			English	Article							NEUROTROPHIC FACTOR; EXPRESSION SYSTEM; SIGNAL SEQUENCE; PROTOONCOGENE; CLONING; CDNA; MUTATIONS; NEURONS	We report the expression cloning and characterization of GDNFR-alpha, a novel glycosylphosphatidylinositol-linked cell surface receptor for glial cell line-derived neurotrophic factor (GDNF). GDNFR-alpha binds GDNF specifically and mediates activation of the Ret protein-tyrosine kinase (PTK). Treatment of Neuro-2a cells expressing GDNFR-alpha with GDNF rapidly stimulates Ret autophosphorylation. Ret is also activated by treatment with a combination of GDNF and soluble GDNFR-alpha in cells lacking GDNFR-alpha, and this effect is blocked by a soluble Ret-Fc fusion protein. Ret activation by GDNF was also observed in cultured embryonic rat spinal cord motor neurons, a cell type that responds to GDNF in vivo. A model for the stepwise formation of a GDNF signal-transducing complex including GDNF, GDNFR-alpha, and the Ret PTK is proposed.	AMGEN INC,DEPT MAMALIAN CELL MOL BIOL,THOUSAND OAKS,CA 91320; AMGEN INC,DEPT NEUROBIOL,THOUSAND OAKS,CA 91320; AMGEN INC,DEPT DEV BIOL,THOUSAND OAKS,CA 91320	Amgen; Amgen; Amgen	Jing, SQ (corresponding author), AMGEN INC,DEPT IMMUNOL,THOUSAND OAKS,CA 91320, USA.							ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; CAMU W, 1992, J NEUROSCI METH, V44, P59, DOI 10.1016/0165-0270(92)90114-S; Choi-Lundberg D L, 1995, Brain Res Dev Brain Res, V85, P80; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Harlow E, 1988, ANTIBODIES LAB MANUA; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LOUIS JC, 1992, J PHARMACOL EXP THER, V262, P1274; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANCHEZ M, 1996, IN PRESS NATURE; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Saxen L, 1987, DEV CELL BIOL SERIES; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; TSUZUKI T, 1995, ONCOGENE, V10, P191; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909	40	990	1069	1	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1996	85	7					1113	1124		10.1016/S0092-8674(00)81311-2	http://dx.doi.org/10.1016/S0092-8674(00)81311-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UV484	8674117	Bronze			2022-12-24	WOS:A1996UV48400017
J	Eberhart, CG; Maines, JZ; Wasserman, SA				Eberhart, CG; Maines, JZ; Wasserman, SA			Meiotic cell cycle requirement for a fly homologue of human Deleted in Azoospermia	NATURE			English	Article							CDC25 HOMOLOG; DROSOPHILA; SPERMATOGENESIS; TWINE; GENE	INFERTILITY resulting from a severe defect in sperm production affects 2% of men worldwide(1,2). Of these men with azoospermia, the absence of sperm in semen, one in eight carry de novo deletions for a specific region of the Y chromosome(3-5). A candidate gene for the Y-chromosome azoospermia factor (AZF) has been identified and named Deleted in Azoospermia (DAZ)(5). Here we describe the cloning and characterization of the Drosophila gene boule, which is a homologue of DAZ. The two genes encode closely related proteins that contain a predicted RNA-binding motif, and both loci are expressed exclusively in the testis. Loss of bottle function results in azoospermia; meiotic divisions are blocked, although limited spermatid differentiation occurs. Histological examination of boule testes with cell-cycle markers indicates that the primary defect is at the meiotic G2/M transition. These results support the hypothesis that DAZ is the human AZF, and indicate that Boule and DAZ have an essential meiotic function in fly and human spermatogenesis.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; CASTRILLON DH, 1993, GENETICS, V135, P489; CENCI G, 1994, J CELL SCI, V107, P3521; COMHAIRE FH, 1987, INT J ANDROL S, V7, P3; Cooke HJ, 1996, HUM MOL GENET, V5, P513, DOI 10.1093/hmg/5.4.513; COURTOT C, 1992, DEVELOPMENT, V116, P405; EBERHART CG, 1995, DEVELOPMENT, V121, P3477; FULLER M, 1993, DEV DROSOPHILA, P61; GONCZY P, 1994, CELL, V77, P1015, DOI 10.1016/0092-8674(94)90441-3; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; HEGER RW, 1914, GERM CELL CYCLE ANIM; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; KARSCHMIZRACHI I, 1993, NUCLEIC ACIDS RES, V21, P2229, DOI 10.1093/nar/21.9.2229; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lindsley D.L., 1980, Genetics and Biology of Drosophila, V2d, P225; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MCKEARIN D, 1995, DEVELOPMENT, V121, P2937; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; SILBER SJ, 1995, HUM REPROD, V10, P1031, DOI 10.1093/oxfordjournals.humrep.a136085; SODERSTROM KO, 1980, ARCH PATHOL LAB MED, V104, P476; STEM C, 1941, J EXP ZOOL, V87, P113; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; WHITECOOPER H, 1993, J CELL SCI, V106, P1035	30	337	361	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					783	785		10.1038/381783a0	http://dx.doi.org/10.1038/381783a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657280				2022-12-24	WOS:A1996UU35600059
J	Bloor, K; Freemantle, N				Bloor, K; Freemantle, N			Lessons from international experience in controlling pharmaceutical expenditure .2. Influencing doctors	BRITISH MEDICAL JOURNAL			English	Article							COSTS	This is the second of three papers that review international policies to control spending on drugs and to improve the efficiency of drug use. This paper reviews policies influencing doctors' prescribing of drugs-particularly the use of budgetary restrictions, information and feedback, and guidelines-and evaluates the impact of these policies. Studies evaluating incentive systems are Limited, but evidence suggests that providing information on its own will not lead to substantial changes in practice and that more active strategies should be evaluated.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	Bloor, K (corresponding author), UNIV YORK,DEPT HLTH SCI & CLIN EVALUAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.			Freemantle, Nick/0000-0001-5807-5740; Bloor, Karen/0000-0003-4852-9854				*AG HLTH CAR POL R, 1992, CLIN PRACT GUID, V3; *AG HLTH CAR POL R, 1994, CLIN PRACT GUID, V8; [Anonymous], 1994, EFF HLTH CAR B; Bloor K, 1993, PURCHASING PROVIDING; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BROWN SS, 1995, BRIT MED J, V311, P1543; Cook T.C., 1979, QUASIEXPERIMENTATION; MALING TJB, 1994, PHARMACOECONOMICS, V6, P5, DOI 10.2165/00019053-199406010-00002; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; Maynard A, 1996, NEW ENGL J MED, V334, P604, DOI 10.1056/NEJM199602293340918; *MIN WELF HLTH CUL, 1994, V8E MIN WELF HLTH CU; PELC A, 1994, PHARMACOECONOMICS, V6, P28, DOI 10.2165/00019053-199400061-00009; SCHULENBURG JM, 1994, HEALTH ECON, V3, P301; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; SOUMERAI SB, 1987, AM J PUBLIC HEALTH, V77, P1518, DOI 10.2105/AJPH.77.12.1518; SOUMERAI SB, 1989, MILBANK Q, V67, P296; Stryer D. B., 1995, JGIM, V10, P114; *U LEEDS, 1993, EFF HLTH CAR B, V5; 1994, SCRIP           1129, P3; 1995, SCRIP           0314, P3; 1995, SCRIP           0310, P3; 1995, SCRIP           0530, P16	22	77	78	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 15	1996	312	7045					1525	1527		10.1136/bmj.312.7045.1525	http://dx.doi.org/10.1136/bmj.312.7045.1525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UR823	8646148	Green Published			2022-12-24	WOS:A1996UR82300026
J	Rothwell, PM; Staines, A; Smail, P; Wadsworth, E; McKinney, P				Rothwell, PM; Staines, A; Smail, P; Wadsworth, E; McKinney, P			Seasonality of birth of patients with childhood diabetes in Britain	BRITISH MEDICAL JOURNAL			English	Article							MELLITUS; CHILDREN		UNIV LEEDS,LEUKAEMIA RES FUND CTR CLIN EPIDEMIOL,LEEDS LS2 9NG,W YORKSHIRE,ENGLAND; ROYAL ABERDEEN CHILDRENS HOSP,ABERDEEN AB9 2ZG,SCOTLAND; INST CHILD HLTH,BRISTOL BS8 8BJ,AVON,ENGLAND; UNIV LEEDS,PAEDIAT EPIDEMIOL GRP,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND	University of Leeds; University of Aberdeen; University of Bristol; University of Leeds	Rothwell, PM (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Wadsworth, Emma/D-1679-2009; Staines, Anthony/AFQ-7565-2022; Rothwell, Peter/ABE-5913-2020	Staines, Anthony/0000-0001-9161-1357; Rothwell, Peter/0000-0001-9739-9211				LESLIE RDG, 1994, DIABETES, V43, P843, DOI 10.2337/diabetes.43.7.843; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; PATTERSON CC, 1988, DIABETIC MED, V5, P160, DOI 10.1111/j.1464-5491.1988.tb00964.x; STAINES A, 1993, DIABETOLOGIA, V36, P1282, DOI 10.1007/BF00400806; WALTER SD, 1975, BRIT J PREV SOC MED, V29, P18	5	70	70	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1456	1457		10.1136/bmj.312.7044.1456	http://dx.doi.org/10.1136/bmj.312.7044.1456			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664624	Green Published			2022-12-24	WOS:A1996UQ29600027
J	Martyn, CN; Gale, CR; Sayer, AA; Fall, C				Martyn, CN; Gale, CR; Sayer, AA; Fall, C			Growth in utero and cognitive function in adult life: Follow up study of people born between 1920 and 1943	BRITISH MEDICAL JOURNAL			English	Article							WEIGHT; BIRTH; CIRCUMFERENCE; INFANTS; DISEASE; BRAIN; FETAL; DEATH; HEAD	Objectives-To examine the relation between fetal growth and cognitive function in adult life. Design-A follow up study of men and women whose birth weights and other measurements of body size had been recorded at birth. Setting-Hertfordshire, Preston, and Sheffield. Subjects-1576 men and women born in Hertfordshire, Sheffield, or Preston between 1920 and 1943. Main outcome measures-Intelligence quotient as measured by the AH4 test and amount of decline in cognitive function with age as estimated by the difference between score on the Mill Hill vocabulary test and score on the AH4 test. Results-Score on the intelligence test was higher in people who had a large biparietal head diameter at birth, but it was not related to any other measure of body size or proportions. No association was found between decline in cognitive function and any measure of size or proportions at birth. Conclusion-Impaired fetal growth was not associated with poorer cognitive performance in adult life. Adaptations made by the fetus in response to conditions that retard its growth seem to be largely successful in maintaining brain development.			Martyn, CN (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Sayer, Avan Aihie/A-4359-2012; Gale, Catharine R/B-1653-2012	Aihie Sayer, Avan/0000-0003-1283-6457; Gale, Catharine/0000-0002-3361-8638; Fall, Caroline/0000-0003-4402-5552	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], [No title captured]; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; BERK LE, 1991, CHILD DEV; CAMPBELL S, 1977, BRIT J OBSTET GYNAEC, V84, P165, DOI 10.1111/j.1471-0528.1977.tb12550.x; COOKE RWI, 1977, EARLY HUM DEV, V1, P145, DOI 10.1016/0378-3782(77)90015-9; CRAVIOTO J, 1975, PERCEPTUAL LEARNING, V2, P3; DAVIES PA, 1975, BRIT MED BULL, V31, P85, DOI 10.1093/oxfordjournals.bmb.a071248; FANCOURT R, 1976, BMJ-BRIT MED J, V1, P1435, DOI 10.1136/bmj.1.6023.1435; FOULDS GA, 1948, J MENT SCI, V94, P133, DOI 10.1192/bjp.94.394.133; GORMAN KS, 1992, INFANT BEHAV DEV, V15, P279, DOI 10.1016/0163-6383(92)80001-B; HOLLAND CA, 1991, REV CLIN GERONTOLOGY, V1, P81, DOI DOI 10.1017/S0959259800002598; HORN JL, 1967, ACTA PSYCHOL, V26, P107, DOI 10.1016/0001-6918(67)90011-X; KLINE J, 1976, CONCEPTION BIRTH EPI; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; MORGANE PJ, 1992, VULNERABLE BRAIN ENV, V1, P3; NELSON KB, 1970, DEV MED CHILD NEUROL, V12, P487; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Osofsky H J, 1975, Obstet Gynecol Surv, V30, P227, DOI 10.1097/00006254-197504000-00001; RABBITT P, 1993, Q J EXP PSYCHOL-A, V46, P385, DOI 10.1080/14640749308401055; RABBITT P, 1990, APPL COGNITIVE PSYCH, V4, P225, DOI 10.1002/acp.2350040402; RABBITT P, 1993, Z GERONTOL, V26, P176; SCHERJON SA, 1993, THESIS U AMSTERDAM A; SMART JL, 1977, GENETICS ENV INTELLI, P215; STEIN Z, 1975, PEDIATR RES, V9, P70, DOI 10.1203/00006450-197509020-00003; Stein Z., 1975, FAMINE HUM DEV DUTCH; VILLAR J, 1984, PEDIATRICS, V74, P783; WARSHAW JB, 1985, PEDIATRICS, V6, P998; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300; Winick M., 1972, Lipids, malnutrition and the developing brain. A Ciba Foundation Symposium jointly with the Nestle Foundation in memory of Sir Norman Wright., P199	32	73	78	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1996	312	7043					1393	1396						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP434	8646096				2022-12-24	WOS:A1996UP43400023
J	Cash, S; Zucker, RS; Poo, MM				Cash, S; Zucker, RS; Poo, MM			Spread of synaptic depression mediated by presynaptic cytoplasmic signaling	SCIENCE			English	Article							LONG-TERM POTENTIATION; NEURONS; INVITRO; CULTURE; CELLS; INDUCTION; TRANSPORT; SYNAPSES; CURRENTS; RELEASE	Postsynaptic activity may modulate presynaptic functions by transsynaptic retrograde signals, At developing neuromuscular synapses in Xenopus nerve-muscle cultures, a brief increase in the cytosolic calcium ion (Ca2+) concentration in postsynaptic myocytes induced persistent depression of presynaptic transmitter secretion, This depression spread to distant synapses formed by the same neuron, Clearance of extracellular fluid did not prevent the spread of depression, and depression could not be induced by increasing the Ca2+ concentration in a nearby myocyte not in contact with the presynaptic neuron, Thus, the spread of depression is mediated by signaling in the presynaptic cytoplasm, rather than by a retrograde factor in the extracellular space.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; UNIV CALIF BERKELEY,DIV NEUROBIOL,BERKELEY,CA 94720	Columbia University; University of California System; University of California Berkeley			Zucker, Robert S/J-9995-2012	Zucker, Robert S/0000-0003-1068-2343	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015114] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15114] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM WC, 1983, NATURE, V305, P717, DOI 10.1038/305717a0; ALLEN RD, 1982, SCIENCE, V218, P1127, DOI 10.1126/science.6183744; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BOURNE HR, 1993, NEURON S, V10, P65; BRADLER JE, 1990, NEUROSCIENCE, V35, P265, DOI 10.1016/0306-4522(90)90080-N; CASH S, IN PRESS NEURON; CHOW I, 1984, J PHYSIOL-LONDON, V346, P181, DOI 10.1113/jphysiol.1984.sp015015; CHRISTIE BR, 1992, SYNAPSE, V10, P1, DOI 10.1002/syn.890100102; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; EVERS J, 1989, J NEUROSCI, V9, P1523; GOODMAN CS, 1993, NEURON S, V10, P77; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRSCH JC, 1992, SYNAPSE, V12, P82, DOI 10.1002/syn.890120110; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KAO JPY, 1989, J BIOL CHEM, V264, P8179; LANDO L, 1994, J NEUROPHYSIOL, V72, P825, DOI 10.1152/jn.1994.72.2.825; Linden D J, 1993, Curr Opin Neurobiol, V3, P401, DOI 10.1016/0959-4388(93)90133-J; LO YJ, 1994, J NEUROSCI, V14, P4684; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MARTY A, 1995, CURR OPIN NEUROBIOL, V5, P335, DOI 10.1016/0959-4388(95)80046-8; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; NICOLL RA, 1995, NATURE, V377, P155; OTANI S, 1995, LEARN MEMORY, V2, P101, DOI 10.1101/lm.2.2.101; POPOV S, 1992, J NEUROSCI, V12, P77; PURVES D, 1985, PRINCIPLES NEURAL DE; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; Tabti N., 1991, CULTURING NERVE CELL, P137; VINCENT P, 1993, NEURON, V11, P885, DOI 10.1016/0896-6273(93)90118-B; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0; ZUCKER RS, 1993, CELL CALCIUM, V14, P87, DOI 10.1016/0143-4160(93)90079-L	34	37	38	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					998	1001		10.1126/science.272.5264.998	http://dx.doi.org/10.1126/science.272.5264.998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638143				2022-12-24	WOS:A1996UL61900041
J	Lau, HT; Yu, M; Fontana, A; Stoeckert, CJ				Lau, HT; Yu, M; Fontana, A; Stoeckert, CJ			Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice	SCIENCE			English	Article							SYSTEMIC DELIVERY	Allogeneic transplantation of islets of Langerhans was facilitated by the cotransplantation of syngeneic myoblasts genetically engineered to express the Fas ligand (FasL). Composite grafting of allogeneic islets with syngeneic myoblasts expressing Fast protected the islet graft from immune rejection and maintained normoglycemia for more than 80 days in mice with streptozotocin-induced diabetes. Graft survival was not prolonged with composite grafts of unmodified myoblasts or Fas-expressing myoblasts. Islet allografts transplanted separately from FasL-expressing myoblasts into the contralateral kidney were rejected, as were similarly transplanted third-party thyroid allografts. Thus, the FasL signal provided site- and immune-specific protection of islet allografts.	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT SURG,PHILADELPHIA,PA 19104; UNIV ZURICH HOSP,DEPT INTERNAL MED,CLIN IMMUNOL SECT,CH-8044 ZURICH,SWITZERLAND; CHILDRENS HOSP PHILADELPHIA,DEPT HEMATOL,ABRAMSON CTR,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Zurich; University Zurich Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia								BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; CANTINI M, 1994, IN VITRO CELL DEV-AN, V30A, P131; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLSTEIN P, 1995, IMMUNOL REV, V146, P45, DOI 10.1111/j.1600-065X.1995.tb00683.x; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LYNCH DH, 1995, IMMUNOL TODAY, V16, P570; MILLER RA, 1993, CURRENT PROTOCOLS IM, V1; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; YAGITA H, 1995, IMMUNOL REV, V146, P223, DOI 10.1111/j.1600-065X.1995.tb00691.x	19	407	443	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1996	273	5271					109	112		10.1126/science.273.5271.109	http://dx.doi.org/10.1126/science.273.5271.109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8658177				2022-12-24	WOS:A1996UV47800051
J	Goldstein, KP; Philipson, TJ; Joe, H; Daum, RS				Goldstein, KP; Philipson, TJ; Joe, H; Daum, RS			The effect of epidemic measles on immunization rates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MISSED OPPORTUNITIES; UNITED-STATES; VACCINATION	Objective.-To evaluate whether immunization against a vaccine-preventable disease is sought to avoid the naturally occurring disease itself, we hypothesized that the rate of ''on-time'' measles immunization would increase during an epidemic of that disease. If such an effect occurred, we wondered whether it would have an impact on on-time administration of other recommended immunizations. Design.-Retrospective evaluation of immunization rates of children at their second birthday with the use of computerized health records for children entering kindergarten in an 8-year interval spanning the onset of epidemic measles in Chicago, III, in 1989 and 1990. Setting.-Children entering Chicago public schools. Main Outcome Measures.-Rates of receipt of measles-containing vaccine (MCV), 1 to 4 doses of a diphtheria toxoid-tetanus toxoid-pertussis (DTP) or diphtheria toxoid-tetanus toroid (DT) vaccine, 1 to 3 doses of oral or inactivated polio vaccine (OPV/IPV), and the full series of these vaccines (4:3:1) that are required to be ''up-to-date'' by the second birthday. Results.-The rate of on-time MCV receipt increased from 56% to 58% in the years prior to the epidemic to 70% during the epidemic (1989 and 1990). A similar increase did not occur for DTP/DT 4 or OPV/IPV 3. Moreover, among older children delayed in MCV receipt, evidence of catch-up immunization also occurred during the epidemic years; similar catch-up for delayed DTP/DT 4 or OPV/IPV 3 immunization did not occur. Conclusions.-Dramatic increases in on-time and catch-up MCV receipt occurred during the Chicago measles epidemic of 1989 and 1990. The lack of similar increases in DTP/DT 4 and OPV/IPV 3 suggests MCV receipt was not associated with receipt of other recommended immunizations during that time.	UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT ECON,CHICAGO,IL 60637	University of Chicago; University of Chicago								ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; BATES AS, 1994, JAMA-J AM MED ASSOC, V272, P1105, DOI 10.1001/jama.272.14.1105; BOBO JK, 1991, PEDIATRICS, V92, P308; BRUNELL P, 1984, NEWS COMM AM ACAD PE, V35, P12; *COMM INF DIS, 1991, REP COMM INF DIS; CUTTS FT, 1992, ANNU REV PUBL HEALTH, V13, P385, DOI 10.1146/annurev.pu.13.050192.002125; FARIZO KM, 1992, PEDIATRICS, V89, P589; GUYER B, 1994, PEDIATRICS, V94, P53; LIEU TA, 1994, PEDIATRICS, V93, P373; MCCONNOCHIE KM, 1992, PEDIATRICS, V89, P1019; MILLER LA, 1994, PEDIATRICS, V94, P213; MURPHY TV, 1995, PEDIATR INFECT DIS J, V14, P561, DOI 10.1097/00006454-199507000-00002; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; SAS, 1996, SAS STAT SOFTW REL 6; *STATA CORP, 1995, STATA STAT SOFTW REL; SZILAGYI PG, 1994, PEDIATRICS, V94, P517; SZILAGYI PG, 1993, PEDIATRICS, V91, P1; WOOD D, 1995, PEDIATRICS, V96, P295; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833; 1989, MMWR-MORBID MORTAL W, V38, P219; 1984, MMWR-MORBID MORTAL W, V33, P695; 1989, MMWR-MORBID MORTAL W, V39, P317; 1989, MMWR-MORBID MORTAL W, V38, P205; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1995, MMWR-MORBID MORTAL W, V444, P613; 1989, PEDIATRICS, V84, P110	26	22	24	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1996	276	1					56	58		10.1001/jama.276.1.56	http://dx.doi.org/10.1001/jama.276.1.56			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU439	8667540				2022-12-24	WOS:A1996UU43900028
J	Gurley, RJ; Lum, N; Sande, M; Lo, B; Katz, MH				Gurley, RJ; Lum, N; Sande, M; Lo, B; Katz, MH			Persons found in their homes helpless or dead	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPPORT	Background. Healthcare providers and providers of emergency services are sometimes Galled to help with people who are found alone in their homes either helpless or dead. It is not known who is at risk for being found helpless or dead, what the mortality rates are among those found alive, or how frequently this situation occurs. Methods. We conducted a population-based study of patients who were found in their homes either helpless or dead. Over 12 weeks, paramedics employed by the city of San Francisco identified 387 such events involving 367 persons. We obtained information on these patients from the emergency-medical-services department or the hospitals to which they were taken and determined their outcomes. Results. The median age of the persons found helpless or dead was 73 years; 51 percent were women. The frequency of such incidents increased sharply with age, from a rate of 3 per 1000 per year among those 60 to 64 years of age to 27 per 1000 per year among those 85 years of age or older. The highest rate was among men 85 years and older who were living alone (123 per 1000 per year). In 23 percent of the cases, the person was found dead, an additional 5 percent died in the hospital. Thus, total mortality was 28 percent, Of the patients found alive, 62 percent were admitted to the hospital. The average hospital stay was eight days, and 52 percent of those admitted required intensive care. Of the survivors, 62 percent were unable to return to living independently. The total mortality was 67 percent for patients who were estimated to have been helpless for more than 72 hours, as compared with 12 percent for those who had been helpless for less than 1 hour. Conclusions. For elderly people who live alone, becoming incapacitated and unable to Set help is a common event, which usually marks the end of their ability to live independently. (C) 1996, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA; SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110; CITY & CTY SAN FRANCISCO,DEPT PUBL HLTH,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO & BERKELEY,JOINT MED SCH PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; San Francisco Department of Public Health; University of California System; University of California San Francisco								Cantor M., 1985, HDB AGING SOCIAL SCI, P745; CRIMMINS EM, 1990, RES AGING, V12, P3, DOI 10.1177/0164027590121001; CUMMINGS SR, 1994, NEW ENGL J MED, V331, P872, DOI 10.1056/NEJM199409293311310; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; Hennon C. B., 1983, FAM RELAT, P149; JACOBSEN SJ, 1990, AM J PUBLIC HEALTH, V80, P871, DOI 10.2105/AJPH.80.7.871; STEINBACH U, 1992, J GERONTOL, V47, pS183, DOI 10.1093/geronj/47.4.S183; TREAS J, 1977, GERONTOLOGIST, V17, P486, DOI 10.1093/geront/17.6.486; TREAS J, 1981, GERONTOLOGIST, V21, P98; 1993, STAT B METROP INSUR, V74, P2	10	142	143	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1710	1716		10.1056/NEJM199606273342606	http://dx.doi.org/10.1056/NEJM199606273342606			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UT400	8637517				2022-12-24	WOS:A1996UT40000006
J	Merson, MH				Merson, MH			Returning home: Reflections on the USA's response to the HIV AIDS epidemic	LANCET			English	Editorial Material											Merson, MH (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,POB 20834,NEW HAVEN,CT 06520, USA.							BRANDT A, 1987, NO MAGIC BULLET; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; FRANCIS DP, 1992, JAMA-J AM MED ASSOC, V268, P1444, DOI 10.1001/jama.268.11.1444; GROSECLOSE SL, 1995, J ACQ IMMUN DEF SYND, V10, P82; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; KIRBY D, 1994, PUBLIC HEALTH REP, V109, P339; NORMAND J, 1995, PREVENTING HIV TRANS; *OFF TECHN ASS, 1995, EFF AIDS PREV EFF; PHILLIPS KA, 1995, NEW ENGL J MED, V332, P1308, DOI 10.1056/NEJM199505113321918; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; STRYKER J, 1995, JAMA-J AM MED ASSOC, V273, P1143, DOI 10.1001/jama.273.14.1143; 1993, MMWR MORBID MORTAL W, V42, P337; 1993, INVESTING HLTH, P99; 1993, MMWR MORBID MORTAL W, V42, P329; 1995, MMWR MORBID MORTAL W, V44, P849	16	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 15	1996	347	9016					1673	1676		10.1016/S0140-6736(96)91494-4	http://dx.doi.org/10.1016/S0140-6736(96)91494-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ701	8642965	hybrid			2022-12-24	WOS:A1996UQ70100017
J	Brunet, A; Pouyssegur, J				Brunet, A; Pouyssegur, J			Identification of MAP kinase domains by redirecting stress signals into growth factor responses	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHORYLATION; PROLIFERATION; FAMILY; S6	Mitogen-activated protein kinase (MAPK) cascades, termed MAPK modules, channel extracellular signals into specific cellular responses. Chimeric molecules were constructed between p38 and p44 MAPKs, which transduce stress and growth factor signals, respectively. A discrete region of 40 residues located in the amino-terminal p38MAPK lobe directed the specificity of response to extracellular signals, whereas the carboxyl-terminal half of the molecule specified Substrate recognition. One p38-p44MAPK chimera, expressed in vivo, redirected stress signals into early mitogenic responses, demonstrating the functional independence of these domains.			Brunet, A (corresponding author), FAC SCI,CTR BIOCHIM,CNRS,UMR134,PARC VALROSE,F-06108 NICE 2,FRANCE.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNET A, 1994, ONCOGENE, V9, P3379; BRUNET A, UNPUB; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAVOIE J, IN PRESS PROGR CELL, V2; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	28	124	128	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1996	272	5268					1652	1655		10.1126/science.272.5268.1652	http://dx.doi.org/10.1126/science.272.5268.1652			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658140				2022-12-24	WOS:A1996UR09300047
J	Dominguez, M; Brunner, M; Hafen, E; Basler, K				Dominguez, M; Brunner, M; Hafen, E; Basler, K			Sending and receiving the Hedgehog signal: Control by the Drosophila Gli protein Cubitus interruptus	SCIENCE			English	Article							ENGRAILED GENE; EXPRESSION; COMPARTMENT; DOMINANT; REGION; CELL; RECOMBINATION; TRANSCRIPTION; MELANOGASTER; REPRESSION	Drosophila limb development is organized by interactions between anterior and posterior compartment cells. Posterior cells continuously express and require engrailed (en) and secrete Hedgehog (Hh) protein. Anterior cells express the zinc-finger protein Cubitus interruptus (Ci). It is now shown that anterior cells lacking ci express hh and adopt posterior properties without expressing en. Increased levels of Ci can induce the expression of the Hh target gene decapentaplegic (dpp) in a Hh-independent manner. Thus, expression of Ci in anterior cells controls limb development (i) by restricting hh secretion to posterior cells and (ii) by conferring competence to respond to Hh by mediating the transduction of this signal.			Dominguez, M (corresponding author), UNIV ZURICH,INST ZOOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.		Dominguez, Maria/G-2171-2014	Dominguez, Maria/0000-0002-3329-7862; Basler, Konrad/0000-0003-3534-1529				Ashburner M., 1989, DROSOPHILA LAB HDB; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWER DL, 1986, EMBO J, V5, P2649, DOI 10.1002/j.1460-2075.1986.tb04547.x; BROWER DL, 1984, NATURE, V319, P496; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FORBES AJ, 1993, DEVELOPMENT, P115; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GUBB D, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P236, DOI 10.1007/BF00848252; GUILLEN I, 1995, DEVELOPMENT, V121, P3447; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HIDALGO A, 1994, CURR BIOL, V4, P1087, DOI 10.1016/S0960-9822(00)00247-5; HOCHMAN B, 1973, COLD SPRING HARB SYM, V38, P581, DOI 10.1101/SQB.1974.038.01.062; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE TC, 1994, ONCOGENE, V9, P1047; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOCKE J, 1994, MOL GEN GENET, V243, P234, DOI 10.1007/BF00280321; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; ORENIC T, 1987, DEV BIOL, V124, P50, DOI 10.1016/0012-1606(87)90458-1; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; POOLE SJ, 1985, CELL, V40, P31; SANICOLA M, 1995, GENETICS, V139, P745; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHIMMANG T, 1993, PROG CLIN BIOL RES, V383, P153; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; SLUSARSKI DC, 1995, GENETICS, V139, P229; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; ZECCA M, 1995, DEVELOPMENT, V121, P2265	58	268	278	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1996	272	5268					1621	1625		10.1126/science.272.5268.1621	http://dx.doi.org/10.1126/science.272.5268.1621			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658135				2022-12-24	WOS:A1996UR09300036
J	Sherman, DR; Mdluli, K; Hickey, MJ; Arain, TM; Morris, SL; Barry, CE; Stover, CK				Sherman, DR; Mdluli, K; Hickey, MJ; Arain, TM; Morris, SL; Barry, CE; Stover, CK			Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis	SCIENCE			English	Article							OXIDATIVE STRESS	Mutations that eliminate KatG catalase-peroxidase activity prevent activation of isoniazid and are a major mechanism of resistance to this principal drug for the treatment of Mycobacterium tuberculosis infections. However, the loss of KatG activity in clinical isolates seemed paradoxical because KatG is considered an important factor for the survival of the organism. Expression of either KatG or the recently identified alkyl hydroperoxidase AhpC was sufficient to protect bacilli against the toxic effects of organic peroxides. To survive during infection, isoniazid-resistant KatG mutants have apparently compensated for the loss of KatG catalase-peroxidase activity by a second mutation, resulting in hyperexpression of AhpC.	PATHOGENESIS CORP, LAB TB & MOL MICROBIOL, SEATTLE, WA 98119 USA; NIAID, TB RES UNIT, INTRACELLULAR PARASITES LAB, ROCKY MT LABS, HAMILTON, MT 59840 USA; US FDA, LAB MYCOBACTERIA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA)			Barry, III, Clifton/H-3839-2012; Barry, Clifton E/ABE-7992-2020	Barry, III, Clifton/0000-0002-2927-270X; Barry, Clifton E/0000-0002-2927-270X; Stover, Charles/0000-0002-7406-1696	Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; COLE ST, COMMUNICATION; DEMPLE B, 1983, NATURE, V304, P466, DOI 10.1038/304466a0; DERETIC V, 1995, MOL MICROBIOL, V17, P889, DOI 10.1111/j.1365-2958.1995.mmi_17050889.x; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; Hickey MJ, 1996, ANTIMICROB AGENTS CH, V40, P400, DOI 10.1128/AAC.40.2.400; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; MORRIS S, 1995, J INFECT DIS, V171, P954, DOI 10.1093/infdis/171.4.954; ROSNER JL, 1994, ANTIMICROB AGENTS CH, V38, P1829, DOI 10.1128/AAC.38.8.1829; SHERMAN DH, UNPUB; SHERMAN DR, 1995, P NATL ACAD SCI USA, V92, P6625, DOI 10.1073/pnas.92.14.6625; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; WIELES B, 1995, INFECT IMMUN, V63, P4946, DOI 10.1128/IAI.63.12.4946-4948.1995; WILSON TM, 1995, MOL MICROBIOL, V15, P1009, DOI 10.1111/j.1365-2958.1995.tb02276.x; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	21	341	362	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	1996	272	5268					1641	1643		10.1126/science.272.5268.1641	http://dx.doi.org/10.1126/science.272.5268.1641			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658136				2022-12-24	WOS:A1996UR09300043
J	Long, AF; Fairfield, G				Long, AF; Fairfield, G			Confusion of levels in monitoring outcomes and/or process	LANCET			English	Editorial Material											Long, AF (corresponding author), NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND.							BECKINGHAM A, 1994, HLTH SUMMARY, V11, P11; DAVIES HTO, 1995, BRIT MED J, V311, P766, DOI 10.1136/bmj.311.7008.766; Dixon P, 1995, OUTCOMES BRIEFING, V6, P4; KALRA L, 1993, STROKE, V24, P1462, DOI 10.1161/01.STR.24.10.1462; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; Sackett D. L., 1995, EVIDENCE BASED MED, V1, P5; Sheldon T A, 1993, Qual Health Care, V2, P149, DOI 10.1136/qshc.2.3.149; *STROK UN TRIAL CO, 1995, SYST REV SPEC MULT T; WEN SW, 1995, JAMA-J AM MED ASSOC, V274, P1687, DOI 10.1001/jama.274.21.1687; WIEBERS DO, 1995, EVIDENCE BASED MED, V1, P11	11	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1572	1572		10.1016/S0140-6736(96)91072-7	http://dx.doi.org/10.1016/S0140-6736(96)91072-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667863				2022-12-24	WOS:A1996UP66100006
J	Wong, VS; Wreghitt, TG; Alexander, GJM				Wong, VS; Wreghitt, TG; Alexander, GJM			Prospective study of hepatitis B vaccination in patients with chronic hepatitis C	BRITISH MEDICAL JOURNAL			English	Article							STRATEGIES		UNIV CAMBRIDGE,SCH CLIN MED,ADDENBROOKES NHS TRUST,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES NHS TRUST,DEPT VIROL,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital								ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; CATTERALL AP, 1992, GUT, V33, P576, DOI 10.1136/gut.33.5.576; ESTEBAN R, 1993, J HEPATOL, V17, P567; ILAN Y, 1994, ISRAEL J MED SCI, V30, P259; 1987, UPDATE HEPATITIS B P, V107, P353	5	21	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1996	312	7042					1336	1337		10.1136/bmj.312.7042.1336	http://dx.doi.org/10.1136/bmj.312.7042.1336			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN476	8646046	Green Published			2022-12-24	WOS:A1996UN47600021
J	Niemann, HB; Atreya, SK; Carignan, GR; Donahue, TM; Haberman, JA; Harpold, DN; Hartle, RE; Hunten, DM; Kasprzak, WT; Mahaffy, PR; Owen, TC; Spencer, NW; Way, SH				Niemann, HB; Atreya, SK; Carignan, GR; Donahue, TM; Haberman, JA; Harpold, DN; Hartle, RE; Hunten, DM; Kasprzak, WT; Mahaffy, PR; Owen, TC; Spencer, NW; Way, SH			The Galileo probe mass spectrometer: Composition of Jupiter's atmosphere	SCIENCE			English	Article							GIANT PLANETS; ABUNDANCES; SATURN; SOLAR; RATIO	The composition of the jovian atmosphere from 0.5 to 21 bars along the descent trajectory was determined by a quadrupole mass spectrometer on the Galileo probe. The mixing ratio of He (helium) to H-2 (hydrogen), 0.156, is close to the solar ratio. The abundances of methane, water, argon, neon, and hydrogen sulfide were measured; krypton and xenon were detected. As measured in the jovian atmosphere, the amount of carbon is 2.9 times the solar abundance relative to H-2, the amount of sulfur is greater than the solar abundance, and the amount of oxygen is much less than the solar abundance. The neon abundance compared with that of hydrogen is about an order of magnitude less than the solar abundance. Isotopic ratios of carbon and the noble gases are consistent with solar values. The measured ratio of deuterium to hydrogen (D/H) of (5 +/- 2) x 10(-5) indicates that this ratio is greater in solar-system hydrogen than in local interstellar hydrogen, and the He-3/He-4 ratio of (1.1 +/- 0.2) x 10(-4) provides a new value for protosolar (solar nebula) helium isotopes. Together, the D/H and He-3/He-4 ratios are consistent with conversion in the sun of protosolar deuterium to present-day He-3.	UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721; UNIV HAWAII,INST ASTRON,HONOLULU,HI 96822	University of Michigan System; University of Michigan; University of Arizona; University of Hawaii System	Niemann, HB (corresponding author), NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771, USA.		Mahaffy, Paul/E-4609-2012; Harpold, Dan/I-3345-2013	Mahaffy, Paul/0000-0003-1896-1726; 				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; CONRATH BJ, 1984, ASTROPHYS J, V282, P807, DOI 10.1086/162267; DEPATER I, 1985, ICARUS, V62, P143, DOI 10.1016/0019-1035(85)90177-0; GAUTIER D, 1989, ORIGIN EVOLUTION PLA, P504; Geiss J., 1993, ORIGIN EVOLUTION ELE, V89; Hubbard WB, 1989, ORIGIN EVOLUTION PLA, P539; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; LINSKY JL, 1993, ASTROPHYS J, V402, P694, DOI 10.1086/172170; LINSKY JL, 1995, LIGHT ELEMENT ABUNDA, P215; LUNINE JI, 1985, ASTROPHYS J SUPPL S, V58, P493, DOI 10.1086/191050; MARTEN A, 1980, ICARUS, V41, P410, DOI 10.1016/0019-1035(80)90225-0; Mason B., 1962, METEORITES; NIEMANN HB, 1992, SPACE SCI REV, V60, P111, DOI 10.1007/BF00216852; NOLL KS, 1991, ICARUS, V89, P168, DOI 10.1016/0019-1035(91)90096-C; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; POLLACK JB, 1989, ORIGIN EVOLUTION PLA, P564; RAGENT B, 1996, SCIENCE, V272, P855; Roulston M. S, 1995, EOS ABSTR AGU FALL M, V76, P343; SMITH WH, 1989, ASTROPHYS J, V336, P967, DOI 10.1086/167067; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; SPRAGUE AL, IN PRESS ICARUS; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P221, DOI 10.1086/190478; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P239, DOI 10.1086/190479; STEVENSON DJ, 1982, ANNU REV EARTH PL SC, V10, P257, DOI 10.1146/annurev.ea.10.050182.001353; vonZahn U, 1996, SCIENCE, V272, P849, DOI 10.1126/science.272.5263.849; WIIK HB, 1956, GEOCHIM COSMOCHIM AC, V9, P279, DOI 10.1016/0016-7037(56)90028-X; [No title captured]	29	207	211	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					846	849		10.1126/science.272.5263.846	http://dx.doi.org/10.1126/science.272.5263.846			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629016				2022-12-24	WOS:A1996UK75700049
J	Nelson, KE; Celentano, DD; Eiumtrakol, S; Hoover, DR; Beyrer, C; Suprasert, S; Kuntolbutra, S; Khamboonruang, C				Nelson, KE; Celentano, DD; Eiumtrakol, S; Hoover, DR; Beyrer, C; Suprasert, S; Kuntolbutra, S; Khamboonruang, C			Changes in sexual behavior and a decline in HIV infection among young men in Thailand	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; CHIANG-MAI; TRANSMITTED DISEASES; NORTHERN THAILAND; COMMERCIAL SEX; WORKERS	Background In Thailand the epidemic of human immunodeficiency virus (HIV) infection is of recent origin. Because of the high seroprevalence of HIV among sex workers, the Ministry of Public Health began a program in 1990 and 1991 to promote the use of condoms during commercial sex. We evaluated the effect of this and other programs to prevent HIV infection in Thailand. Methods Using direct interviews, we studied five cohorts of 21-year-old men from northern Thailand who were conscripted into the army by a lottery in 1991, 1993, and 1995. In all, 4311 men were tested for HIV antibodies by enzyme-linked immunosorbent assay, with confirmation by Western blot assay. Results In the 1991 and 1993 cohorts, the prevalence of HIV infection was 10.4 to 12.5 percent. In 1995, it fell to 6.7 percent (P<0.001). The seroprevalence was only 0.7 percent among men who did not have sexual relations with a sex worker before 1992. Over the study period, the proportion of men who reported having sexual relations with a sex worker fell from 81.4 percent to 63.8 percent (P<0.001). From 1991 to 1995, the men's reported use of condoms during the most recent sexual contacts with sex workers increased from 61.0 percent to 92.5 percent (P<0.001); and in 1995, 15.2 percent of men had a history of a sexually transmitted disease, as compared with 42.2 percent in 1991 (P<0.001). Conclusions Public health programs in Thailand have led to substantial changes in sexual behavior among young men, especially an increased use of condoms, and the rate of new HIV infections has declined. (C) 1996, Massachusetts Medical Society.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; ROYAL THAI ARMY,KAVILA ARMY HOSP,CHIANG MAI,THAILAND; CHIANG MAI UNIV,FAC MED,DEPT FAMILY MED,CHIANG MAI 50000,THAILAND; CHIANG MAI UNIV,RES INST HLTH SCI,CHIANG MAI 50000,THAILAND	Johns Hopkins University; Chiang Mai University; Chiang Mai University	Nelson, KE (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI035173] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI35173] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEYRER C, 1995, AIDS, V9, P171, DOI 10.1097/00002030-199509020-00009; Beyrer C, 1996, AIDS, V10, P113, DOI 10.1097/00002030-199601000-00023; BEYRER C, 1994, 10 INT C AIDS INT C, V2, P25; BROWN T, 1994, AIDS, V8, pS131; CARAEL M, 1995, AIDS, V9, P1171, DOI 10.1097/00002030-199510000-00009; Celentano DD, 1996, JAMA-J AM MED ASSOC, V275, P122, DOI 10.1001/jama.275.2.122; CELENTANO DD, 1994, AIDS, V8, P533, DOI 10.1097/00002030-199404000-00018; CHOOPANYA K, 1991, AIDS, V5, P1509, DOI 10.1097/00002030-199112000-00014; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HOOVER DR, 1991, AM J EPIDEMIOL, V134, P1190, DOI 10.1093/oxfordjournals.aje.a116022; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; LIMANONDA B, 1994, AM J PUBLIC HEALTH, V84, P2026, DOI 10.2105/AJPH.84.12.2026; MASON CJ, 1995, AIDS, V9, P1061, DOI 10.1097/00002030-199509000-00012; MORRIS M, 1995, AIDS, V9, P507, DOI 10.1097/00002030-199509050-00014; NELSON KE, 1994, AIDS RES HUM RETROV, V10, pS243; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NELSON KE, 1994, AIDS, V8, P951, DOI 10.1097/00002030-199407000-00012; PYNE HH, 1992, THESIS MIT CAMBRIDGE; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; RUGPAO S, 1993, CONTRACEPTION, V48, P537, DOI 10.1016/0010-7824(93)90116-O; Shilts R., 1987, BAND PLAYED POLITICS; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; STONE AB, 1994, AIDS S1, V8, pS285; Strickler Howard, 1995, Annals of Epidemiology, V5, P447, DOI 10.1016/1047-2797(95)00070-4; Sweat M D, 1995, AIDS, V9 Suppl A, pS251; TAWIL O, 1995, AIDS, V9, P1299, DOI 10.1097/00002030-199512000-00001; Ungchusak K., 1989, Thai AIDS Journal, V1, P57; Vanichseni S., 1989, Thai AIDS Journal, V1, P75; WANGROONGSARB Y, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P517; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	32	277	282	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	1996	335	5					297	303		10.1056/NEJM199608013350501	http://dx.doi.org/10.1056/NEJM199608013350501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY982	8663861				2022-12-24	WOS:A1996UY98200001
J	Harding, SM				Harding, SM			Racing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1996	276	3					176	176						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW469	8667547				2022-12-24	WOS:A1996UW46900001
J	Burnstock, G				Burnstock, G			A unifying purinergic hypothesis for the initiation of pain	LANCET			English	Article							RHEUMATOID-ARTHRITIS; ATP; STIMULATION; ADENOSINE; GUANETHIDINE; MECHANISMS; RECEPTORS; NEURONS; TISSUES; TUMOR	There have been hints over the years about the involvement of purines in pain, and we now have direct evidence with the cloning and characterisation of extracellular receptors for ATP (P2X-purinoceptors) on nociceptive sensory neurons. In this article, a hypothesis is put forward about the sources of ATP released to activate these receptors in three different pain conditions-as a cotransmitter from sympathetic nerves in causalgia and reflex sympathetic dystrophy; from endothelial cells in vascular pain, including migraine and angina; and from tumour cells in cancer. These findings are leading to an active search for selective PZ-purinoceptor antagonists to alleviate pain.			Burnstock, G (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.							ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; BLEEHEN T, 1977, PAIN, V3, P367, DOI 10.1016/0304-3959(77)90066-5; BLEEHEN T, 1978, BRIT J PHARMACOL, V62, P573, DOI 10.1111/j.1476-5381.1978.tb07764.x; BODIN P, 1995, EXPERIENTIA, V51, P256, DOI 10.1007/BF01931108; BOULTON AJM, 1986, CLIN ENDOCRINOL META, V15, P917, DOI 10.1016/S0300-595X(86)80080-9; BOUVIER MM, 1991, EUR J NEUROSCI, V3, P285, DOI 10.1111/j.1460-9568.1991.tb00090.x; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P31; BURNSTOCK G, 1989, BIOMED PHARMACOTHER, V43, P727, DOI 10.1016/0753-3322(89)90161-3; BURNSTOCK G, 1990, NEUROCHEM INT, V17, P357, DOI 10.1016/0197-0186(90)90158-P; BURNSTOCK G, 1993, DRUG DEVELOP RES, V28, P195, DOI 10.1002/ddr.430280303; BURNSTOCK G, 1981, LANCET, V1, P1397; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; COUTTS AA, 1981, EUR J PHARMACOL, V76, P391, DOI 10.1016/0014-2999(81)90110-2; CREA F, 1990, CIRCULATION, V81, P164, DOI 10.1161/01.CIR.81.1.164; DRIESSEN B, 1994, BRAIN RES, V666, P182, DOI 10.1016/0006-8993(94)90770-6; FYFFE REW, 1984, P NATL ACAD SCI-BIOL, V81, P6890, DOI 10.1073/pnas.81.21.6890; HANNINGTONKIFF JG, 1974, LANCET, V1, P1019; HILTON BP, 1971, J CLIN PATHOL, V24, P250, DOI 10.1136/jcp.24.3.250; JANIG W, 1984, RECENT RESULTS CANC, V89, P45; KHAKH BS, 1995, J PHYSIOL-LONDON, V484, P385, DOI 10.1113/jphysiol.1995.sp020672; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; LEVINE JD, 1987, RHEUM DIS CLIN N AM, V13, P369; LEVINE JD, 1986, J RHEUMATOL, V13, P1040; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; MAEHARA Y, 1987, CLIN CHIM ACTA, V169, P341, DOI 10.1016/0009-8981(87)90337-8; MCMAHON SB, 1991, BRIT MED BULL, V47, P584, DOI 10.1093/oxfordjournals.bmb.a072494; NEEDLEMAN P, 1974, CIRC RES, V34, P455, DOI 10.1161/01.RES.34.4.455; SAWYNOK J, 1989, NEUROSCIENCE, V32, P557, DOI 10.1016/0306-4522(89)90278-9; SCHOTT GD, 1992, AUTONOMIC FAILURE TX, P904; SIEMS WG, 1993, CANCER RES, V53, P5143; SYLVEN C, 1993, CARDIOVASC DRUG THER, V7, P745, DOI 10.1007/BF00878926; TRAMS EG, 1980, J THEOR BIOL, V87, P609, DOI 10.1016/0022-5193(80)90239-8; WANG YT, 1991, ARCH INT PHARMACOD T, V309, P160; YASUDA JM, 1994, ANN PHARMACOTHER, V28, P338	34	205	213	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 8	1996	347	9015					1604	1605		10.1016/S0140-6736(96)91082-X	http://dx.doi.org/10.1016/S0140-6736(96)91082-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP661	8667873				2022-12-24	WOS:A1996UP66100016
J	Lavoie, BD; Shaw, GS; Millner, A; Chaconas, G				Lavoie, BD; Shaw, GS; Millner, A; Chaconas, G			Anatomy of a flexer-DNA complex inside a higher-order transposition intermediate	CELL			English	Article							HISTONE-LIKE PROTEIN; SITE-SPECIFIC RECOMBINATION; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; NUCLEOPROTEIN STRUCTURES; EDTA-IRON; HU-ALPHA; BINDING; IHF; REPLICATION	Escherichia coli HU, a nonsequence-specific histone- and HMG-like DNA-binding protein, was chemically converted into a series of HU-nucleases with an iron-EDTA-based cleavage moiety positioned at 16 rationally selected sites. Specific DNA cleavage patterns from each of these HU-nucleases allowed us to determine the precise localization, stoichiometry, and orientation of HU binding in the Mu transpososome, a multiprotein structure that mediates the chemical reactions in DNA transposition. Correlation of the DNA cleavage data with the position of the cleavage moiety in the HU three-dimensional structure indicates the presence of a dramatic DNA bend, for which the bend center, direction, and magnitude were assessed. The data, which directly localize selected HU amino acids with respect to DNA in the transpososome, were used as constraints for computer-based molecular modeling to derive the first snapshot of an HU-DNA interaction.			Lavoie, BD (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON,ON N6A 5C1,CANADA.		Shaw, Gary S./C-7656-2009	Shaw, Gary S./0000-0002-4685-9625				AKI T, 1996, IN PRESS GENES CELLS, V2; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BIANCHI ME, 1994, MOL MICROBIOL, V14, P1, DOI 10.1111/j.1365-2958.1994.tb01261.x; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; Calladine CR., 1992, UNDERSTANDING DNA; CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; EBRIGHT YW, 1992, BIOCHEMISTRY-US, V31, P10664, DOI 10.1021/bi00159a004; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ERMACORA MR, 1992, P NATL ACAD SCI USA, V89, P6383, DOI 10.1073/pnas.89.14.6383; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GOSHIMA N, 1990, GENE, V96, P141, DOI 10.1016/0378-1119(90)90355-U; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HWANG DS, 1992, J BIOL CHEM, V267, P23083; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KAO LR, 1993, P NATL ACAD SCI USA, V90, P5598, DOI 10.1073/pnas.90.12.5598; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LAVOIE BD, 1995, CURR TOP MICROBIOL I, V204, P83; LEE EC, 1992, EMBO J, V11, P305, DOI 10.1002/j.1460-2075.1992.tb05053.x; MAZZARELLI JM, 1993, BIOCHEMISTRY-US, V32, P2979, DOI 10.1021/bi00063a008; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; Nash Howard A., 1996, P149; NER SS, 1994, TRENDS BIOCHEM SCI, V19, P185, DOI 10.1016/0968-0004(94)90017-5; NUNESDUBY SE, 1995, J MOL BIOL, V253, P228, DOI 10.1006/jmbi.1995.0548; OBERTO J, 1994, BIOCHIMIE, V76, P901, DOI 10.1016/0300-9084(94)90014-0; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SHINDO H, 1993, BIOL PHARM BULL, V16, P437; SHINDO H, 1992, NUCLEIC ACIDS RES, V20, P1553, DOI 10.1093/nar/20.7.1553; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; TANAKA H, 1993, J BIOCHEM-TOKYO, V113, P568, DOI 10.1093/oxfordjournals.jbchem.a124084; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VIS H, 1995, J MOL BIOL, V254, P692, DOI 10.1006/jmbi.1995.0648; Wang ZG, 1996, J BIOL CHEM, V271, P9619, DOI 10.1074/jbc.271.16.9619; Watson MA, 1996, CELL, V85, P435, DOI 10.1016/S0092-8674(00)81121-6; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WERNER MH, 1994, CURR BIOL, V4, P477, DOI 10.1016/S0960-9822(00)00108-1; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	55	90	91	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1996	85	5					761	771		10.1016/S0092-8674(00)81241-6	http://dx.doi.org/10.1016/S0092-8674(00)81241-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UP344	8646783	Bronze			2022-12-24	WOS:A1996UP34400015
J	Deshpande, AM; Newlon, CS				Deshpande, AM; Newlon, CS			DNA replication fork pause sites dependent on transcription	SCIENCE			English	Article							RNA POLYMERASE-III; SACCHAROMYCES-CEREVISIAE; CONSENSUS SEQUENCE; YEAST CHROMOSOME; GENE; INVIVO; INITIATION; ORIGIN	Replication fork pause (RFP) sites transiently arresting replication fork movement were mapped to transfer RNA (tRNA) genes of Saccharomyces cerevisiae in vivo, RFP sites are polar, stalling replication forks only when they oppose the direction of tRNA transcription, Mutant tRNA genes defective in assembly of transcription initiation complexes and a temperature-sensitive RNA polymerase III mutant (rpc160-41) defective in initiation of transcription do not stall replication forks, suggesting that transcription is required for RFP activity.	UNIV MED & DENT NEW JERSEY, SCH MED, DEPT MICROBIOL & MOLEC GENET, NEWARK, NJ 07103 USA; UNIV MED & DENT NEW JERSEY, GRAD SCH BIOMED SCI, NEWARK, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NIGMS NIH HHS [GM35679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; COLLINS I, 1994, MOL CELL BIOL, V14, P3524, DOI 10.1128/MCB.14.5.3524; DESHPANDE AM, 1992, MOL CELL BIOL, V12, P4305, DOI 10.1128/MCB.12.10.4305; DESHPANDE AS, UNPUB; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; FRIEDMAN KL, COMMUNICATION; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GREENFEDER SA, 1992, MOL BIOL CELL, V3, P999, DOI 10.1091/mbc.3.9.999; GUDENUS R, 1988, GENETICS, V119, P517; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU B, 1994, P NATL ACAD SCI USA, V91, P10660, DOI 10.1073/pnas.91.22.10660; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; ROTHSTEIN R, 1987, MOL CELL BIOL, V7, P1198, DOI 10.1128/MCB.7.3.1198; SHAW KJ, 1984, MOL CELL BIOL, V4, P657, DOI 10.1128/MCB.4.4.657; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STROBEL MC, 1986, MOL CELL BIOL, V6, P2663, DOI 10.1128/MCB.6.7.2663; THEIS JF, 1992, YEAST, V8, P223, DOI 10.1002/yea.320080308; THURIAUX P, 1992, MOL CELLULAR BIOL YE, P1; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917	34	275	279	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	1996	272	5264					1030	1033		10.1126/science.272.5264.1030	http://dx.doi.org/10.1126/science.272.5264.1030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638128				2022-12-24	WOS:A1996UL61900051
J	Downing, AK; Knott, V; Werner, JM; Cardy, CM; Campbell, ID; Handford, PA				Downing, AK; Knott, V; Werner, JM; Cardy, CM; Campbell, ID; Handford, PA			Solution structure of a pair of calcium-binding epidermal growth factor-like domains: Implications for the Marfan syndrome and other genetic disorders	CELL			English	Article							HETERONUCLEAR NMR-SPECTROSCOPY; HUMAN FACTOR-IX; CONNECTIVE-TISSUE MICROFIBRILS; EGF-LIKE DOMAINS; COUPLING-CONSTANTS; FACTOR-X; PROTEINS; FIBRILLIN; ALPHA; RESIDUES	The nuclear magnetic resonance structure of a covalently linked pair of calcium-binding (cb) epidermal growth factor-like (EGF) domains from human fibrillin-1, the protein defective in the Marfan syndrome, is described. The two domains are in a rigid, rod-like arrangement, stabilized by interdomain calcium binding and hydrophobic interactions. We propose a model for the arrangement of fibrillin monomers in microfibrils that reconciles structural and antibody binding data, and we describe a set of disease-causing mutations that provide the first clues to the specificity of cbEGF interactions. The residues involved in stabilizing the domain linkage are highly conserved in fibrillin, fibulin, thrombomodulin, and the low density lipoprotein receptor. We propose that the relative orientation of tandem cbEGF domains in these proteins is similar, but that in others, including Notch, pairs adopt a completely different conformation.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND	University of Oxford; University of Oxford	Downing, AK (corresponding author), UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND.		Werner, Joern/E-1148-2013	Werner, Jorn/0000-0002-4712-1833	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BARON M, 1992, PROTEIN SCI, V1, P81; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BORK P, 1996, IN PRESS Q REV BIOPH; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GANDRILLE S, 1995, BLOOD, V85, P130, DOI 10.1182/blood.V85.1.130.bloodjournal851130; *GEN COMP GROUP, 1994, PROGR MAN GCG PACK; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; KIELTY CM, 1993, FEBS LETT, V336, P323, DOI 10.1016/0014-5793(93)80829-J; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PERSSON E, 1989, J BIOL CHEM, V264, P16897; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1991, BLOOD, V78, P1637; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WY US, 1995, CHEM BIOL, V2, P91; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8; [No title captured]	53	369	385	0	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1996	85	4					597	605		10.1016/S0092-8674(00)81259-3	http://dx.doi.org/10.1016/S0092-8674(00)81259-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UM415	8653794	Bronze			2022-12-24	WOS:A1996UM41500016
J	Fremont, DH; Hendrickson, WA; Marrack, P; Kappler, J				Fremont, DH; Hendrickson, WA; Marrack, P; Kappler, J			Structures of an MHC class II molecule with covalently bound single peptides	SCIENCE			English	Article							PH; PROLIFERATION; T-HELPER-1; SEPARATION; BINDING	The high-resolution x-ray crystal structures of the murine major histocompatibility complex (MHC) class II molecule, I-E(k), occupied by either of two antigenic peptides were determined. They reveal the structural basis for the I-E(k) peptide binding motif and suggest general principles for additional alleles. A buried cluster of acidic amino acids in the binding groove predicted to be conserved among all murine I-E and human DR MHC class II molecules suggests how pH may influence MHC binding or exchange of peptides. These structures also complement mutational studies on the importance of individual peptide residues to T cell receptor recognition.	NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,DIV BASIC IMMUNOL,DENVER,CO 80206	Howard Hughes Medical Institute; National Jewish Health	Fremont, DH (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687; Fremont, Daved/0000-0002-8544-2689				BENTAL N, UNPUB; BONIFACE JJ, 1993, BIOCHEMISTRY-US, V32, P11761, DOI 10.1021/bi00095a003; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUSIC V, 1994, NUCLEIC ACIDS RES, V22, P3663, DOI 10.1093/nar/22.17.3663; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; IGNATOWICZ L, 1995, J IMMUNOL, V154, P3852; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KOZONO H, 1995, IMMUNITY, V3, P187, DOI 10.1016/1074-7613(95)90088-8; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6; REAY PA, 1994, J IMMUNOL, V152, P3946; REAY PA, 1992, EMBO J, V11, P2829, DOI 10.1002/j.1460-2075.1992.tb05350.x; Schild H, 1995, INT IMMUNOL, V7, P1957, DOI 10.1093/intimm/7.12.1957; SETTE A, 1992, J IMMUNOL, V148, P844; SPAIN LM, 1994, J IMMUNOL, V152, P1709; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0	30	319	326	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1996	272	5264					1001	1004		10.1126/science.272.5264.1001	http://dx.doi.org/10.1126/science.272.5264.1001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL619	8638119				2022-12-24	WOS:A1996UL61900042
J	Dockerty, JD; Cox, B; Borman, B; Sharples, K				Dockerty, JD; Cox, B; Borman, B; Sharples, K			Population mixing and the incidence of childhood leukaemias: Retrospective comparison in rural areas of New Zealand	BRITISH MEDICAL JOURNAL			English	Article									CENT REG HLTH AUTHOR,WELLINGTON,NEW ZEALAND		Dockerty, JD (corresponding author), UNIV OTAGO,SCH MED,DEPT PREVENT & SOCIAL MED,POB 913,DUNEDIN,NEW ZEALAND.			Dockerty, John/0000-0002-5644-9398				ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; BRESLOW NE, 1984, INT J EPIDEMIOL, V13, P112, DOI 10.1093/ije/13.1.112; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; MUIR KR, 1990, BRIT MED J, V300, P676, DOI 10.1136/bmj.300.6725.676-b	5	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1203	1204						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634564				2022-12-24	WOS:A1996UL05800020
J	Coats, S; Flanagan, WM; Nourse, J; Roberts, JM				Coats, S; Flanagan, WM; Nourse, J; Roberts, JM			Requirement of p27(Kip1) for restriction point control of the fibroblast cell cycle	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; MAMMALIAN FIBROBLASTS; ACTIVATING KINASE; DEPENDENT KINASE; GROWTH-FACTOR; 3T3 CELLS; PHOSPHORYLATION; G1; OLIGONUCLEOTIDES; INHIBITION	Cells deprived of serum mitogens will either undergo immediate cell cycle arrest or complete mitosis and arrest in the next cell cycle. The transition from mitogen dependence to mitogen independence occurs in the mid- to late G(1) phase of the cell cycle and is called the restriction point. Murine Balb/c-3T3 fibroblasts deprived of serum mitogens accumulated the cyclin-dependent kinase (CDK) inhibitor p27(Kip1). This was correlated with inactivation of essential G(1) cyclin-CDK complexes and with cell cycle arrest in G(1). The ability of specific mitogens to allow transit through the restriction point paralleled their ability to down-regulate p27, and antisense inhibition of p27 expression prevented cell cycle arrest in response to mitogen depletion. Therefore, p27 is an essential component of the pathway that connects mitogenic signals to the cell cycle at the restriction point.	GILEAD SCI,FOSTER CITY,CA 94404; STANFORD UNIV,SCH MED,PROGRAM CANC BIOL,STANFORD,CA 94305	Gilead Sciences; Stanford University	Coats, S (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; ELDEIRY W, 1993, CELL, V75, P89; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; FROEHLER BC, 1992, TETRAHEDRON LETT, V33, P5307, DOI 10.1016/S0040-4039(00)79079-4; FROEHLER BC, 1993, TETRAHEDRON LETT, V34, P1003, DOI 10.1016/S0040-4039(00)77476-4; FROEHLER BC, 1993, PROTOCOLS OLIGONUCLE; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARVEY JC, 1992, SCIENCE, V258, P1481; HERRERA R, UNPUB; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LARSSON O, 1989, J CELL PHYSIOL, V139, P477, DOI 10.1002/jcp.1041390305; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEOF EB, 1983, EXP CELL RES, V147, P202, DOI 10.1016/0014-4827(83)90285-9; LEWIS J, 1996, P NATL ACAD SCI USA, V93, P2400; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOULDS C, 1995, BIOCHEMISTRY-US, V34, P5044, DOI 10.1021/bi00015a015; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, NATURE, V78, P67; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAVIPRAKASH K, 1995, J VIROL, V69, P69, DOI 10.1128/JVI.69.1.69-74.1995; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TEMIN HM, 1971, J CELL PHYSIOL, V78, P161, DOI 10.1002/jcp.1040780202; TOYASHIMA H, 1994, CELL, V78, P67; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	48	635	669	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					877	880		10.1126/science.272.5263.877	http://dx.doi.org/10.1126/science.272.5263.877			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629023				2022-12-24	WOS:A1996UK75700060
J	vonZahn, U; Hunten, DM				vonZahn, U; Hunten, DM			The helium mass fraction in Jupiter's atmosphere	SCIENCE			English	Article							VOYAGER MEASUREMENTS; ABUNDANCE; SOLAR; SATURN	On 7 December 1995, the NASA Galileo probe provided in situ measurements of the helium abundance in the atmosphere of Jupiter. A Jamin interferometer measured the refractive index of the jovian atmosphere in the pressure region from 2 to 14 bars. These measurements indicate that the atmospheric helium mole fraction is 0.136 +/- 0.004. The corresponding helium mass fraction is slightly below the presolar value, which suggests that separation of helium from hydrogen in Jupiter's interior is only in its early stages.	UNIV ARIZONA, DEPT PLANETARY SCI, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA	University of Arizona	vonZahn, U (corresponding author), UNIV ROSTOCK, INST ATMOSPHARENPHYS, SCHLOSS STR 4-6, KUHLUNGSBORN, GERMANY.							ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BAHCALL JN, 1992, REV MOD PHYS, V64, P885, DOI 10.1103/RevModPhys.64.885; BASU S, 1995, ESA SPECIAL PUBLICAT, V376, P35; CHABRIER G, 1992, ASTROPHYS J, V391, P817, DOI 10.1086/171390; CONRATH B, 1987, J GEOPHYS RES, V92, P15003, DOI 10.1029/JA092iA13p15003; CONRATH BJ, 1984, ASTROPHYS J, V282, P807, DOI 10.1086/162267; GUILLOT T, 1994, ICARUS, V112, P354, DOI 10.1006/icar.1994.1189; Hubbard WB, 1989, ORIGIN EVOLUTION PLA, P539; Jenkins FA, 1976, FUNDAMENTALS OPTICS; KOSOVICHEV AG, 1992, MON NOT R ASTRON SOC, V259, P536, DOI 10.1093/mnras/259.3.536; LEWIS JS, 1974, SCI AM, V230, P51, DOI 10.1038/scientificamerican0374-50; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; OLIVE KA, 1995, ASTROPHYS J SUPPL S, V97, P49, DOI 10.1086/192134; Perez Hernandez F., 1994, Monthly Notices of the Royal Astronomical Society, V269, P475; PODOLAK M, 1975, ICARUS, V25, P627, DOI 10.1016/0019-1035(75)90044-5; PROFFITT CR, 1994, ASTROPHYS J, V425, P849, DOI 10.1086/174030; Roulston M. S, 1995, EOS ABSTR AGU FALL M, V76, P343; SALPETER EE, 1973, ASTROPHYS J LETT, V181, pL183; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P221, DOI 10.1086/190478; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P239, DOI 10.1086/190479; Stix M., 1989, SUN; VONZAHN U, 1992, SPACE SCI REV, V60, P263, DOI 10.1007/BF00216857	23	57	57	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					849	851		10.1126/science.272.5263.849	http://dx.doi.org/10.1126/science.272.5263.849			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629017				2022-12-24	WOS:A1996UK75700050
J	Cook, DJ; Schlemmer, S; Balucani, N; Wagner, DR; Steiner, B; Saykally, RJ				Cook, DJ; Schlemmer, S; Balucani, N; Wagner, DR; Steiner, B; Saykally, RJ			Infrared emission spectra of candidate interstellar aromatic molecules	NATURE			English	Article							MICRON EMISSION; IRAS SOURCES; FEATURES; SPECTROSCOPY; HYDROCARBONS; CATIONS; BANDS; STATE	INTERSTELLAR dust is responsible, through surface reactions, for the creation of molecular hydrogen, the main component of the interstellar clouds in which new stars form, Intermediate between small, gas-phase molecules and dust are the polycyclic aromatic hydrocarbons (PAHs). Such molecules could account for 2-30% of the carbon in the Galaxy(1), and may provide nucleation sites for the formation of carbonaceous dust(2,3). Although PAHs have been proposed(4,5) as the sources of the unidentified infrared emission bands that are observed in the spectra of a variety of interstellar sources(6-11), the emission characteristics of such molecules are sources still poorly understood. Here we report laboratory emission spectra of several representative PAHs, obtained in conditions approximating those of the interstellar medium, and measured over the entire spectral region spanned by the unidentified infrared bands. We find that neutral PAHs of small and moderate size can at best make only a minor contribution to these emission bands, Cations of these molecules, as well as much larger PAHs and their cations, remain viable candidates for the sources of these bands.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Balucani, Nadia/GPX-7659-2022; Schlemmer, Stephan/E-2903-2015; Balucani, Nadia/B-8211-2011	Balucani, Nadia/0000-0001-5121-5683; Schlemmer, Stephan/0000-0002-1421-7281; Balucani, Nadia/0000-0001-5121-5683; SAYKALLY, RICHARD/0000-0001-8942-3656				ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; Allamandola LJ, 1995, ASTR SOC P, V73, P23; ALLAMANDOLA LJ, 1985, ASTROPHYS J, V290, pL25, DOI 10.1086/184435; ALLAMANDOLA LJ, 1989, ASTROPHYS J, V345, pL59, DOI 10.1086/185552; BRENNER JD, 1992, ASTROPHYS J, V388, pL39, DOI 10.1086/186325; CADWELL BJ, 1994, ASTROPHYS J, V429, P285, DOI 10.1086/174318; CHERCHNEFF I, 1989, ASTROPHYS J, V341, pL21, DOI 10.1086/185448; COHEN M, 1989, ASTROPHYS J, V341, P246, DOI 10.1086/167489; DEMUIZON MJ, 1990, ASTRON ASTROPHYS, V235, P367; FLICKINGER GC, 1991, ASTROPHYS J, V380, pL43, DOI 10.1086/186169; GEBALLE TR, 1985, ASTROPHYS J, V292, P500, DOI 10.1086/163182; HUDGINS DM, 1995, J PHYS CHEM-US, V99, P3033, DOI 10.1021/j100010a011; JOBLIN C, 1994, ASTRON ASTROPHYS, V281, P923; JOBLIN C, 1995, ASTRON ASTROPHYS, V299, P835; LANGHOFF SR, IN PRESS J PHYS CHEM; LEGER A, 1989, ANN PHYS-PARIS, V14, P181, DOI 10.1051/anphys:01989001402018100; LEGER A, 1984, ASTRON ASTROPHYS, V137, pL5; OMONT A, 1986, ASTRON ASTROPHYS, V164, P159; PETROFF MD, 1987, APPL PHYS LETT, V51, P406, DOI 10.1063/1.98404; SCHLEMMER S, 1994, SCIENCE, V265, P1686, DOI 10.1126/science.11539830; SCHUTTE WA, 1990, ASTROPHYS J, V360, P577, DOI 10.1086/169146; SHAN J, 1991, ASTROPHYS J, V383, P459, DOI 10.1086/170803; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SZCZEPANSKI J, 1993, ASTROPHYS J, V414, P646, DOI 10.1086/173110; SZCZEPANSKI J, 1993, CHEM PHYS LETT, V205, P434, DOI 10.1016/0009-2614(93)87147-U; TIELENS AGGM, 1990, NASA CONF P, V3061, P59; VALA M, 1994, J PHYS CHEM-US, V98, P9187, DOI 10.1021/j100088a017; WILLIAMS RM, 1995, ASTROPHYS J, V443, P675, DOI 10.1086/175559; WITTEBORN FC, 1989, ASTROPHYS J, V341, P270, DOI 10.1086/167490	29	100	101	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					227	229		10.1038/380227a0	http://dx.doi.org/10.1038/380227a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637570				2022-12-24	WOS:A1996UB11700044
J	Oh, KJ; Zhan, HJ; Cui, C; Hideg, K; Collier, RJ; Hubbell, WL				Oh, KJ; Zhan, HJ; Cui, C; Hideg, K; Collier, RJ; Hubbell, WL			Organization of diphtheria toxin T domain in bilayers: A site-directed spin labeling study	SCIENCE			English	Article							MEMBRANE TRANSLOCATION; TRANSMEMBRANE DOMAIN; PLASMA-MEMBRANE; B-FRAGMENT; LOW PH; CHANNELS; ENTRY; BACTERIORHODOPSIN; INSERTION; RECEPTOR	The diphtheria toxin transmembrane (T) domain was spin-labeled at consecutive residues in a helical segment, TH9. After binding of the T domain to membranes at low pH, the nitroxide side chains generated by spin labeling were measured with respect to their frequency of collision with polar and nonpolar reagents. The data showed that the helical structure of TH9 in solution is conserved, with one face exposed to water and the other to the hydrophobic interior of the bilayer. Measurement of the depth of the nitroxide side chains from the membrane surfaces revealed an incremental change of about 5 angstroms perturn, which is consistent with a transmembrane orientation of an alpha helix. These results indicate that the helix forms the lining of a transmembrane water-filled channel.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90095; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115; UNIV PECS,CENT RES LAB,H-7643 PECS,HUNGARY	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Harvard Medical School; University of Pecs				OH, KYOUNG JOON/0000-0002-4729-9674; Collier, R John/0000-0002-2427-4239	NATIONAL EYE INSTITUTE [R37EY005216, R01EY005216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022021, R01AI022021, R01AI022848] Funding Source: NIH RePORTER; NEI NIH HHS [EY-05216] Funding Source: Medline; NIAID NIH HHS [AI-22848, AI-22021] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; CABIAUX V, 1994, MOL MICROBIOL, V11, P43, DOI 10.1111/j.1365-2958.1994.tb00288.x; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HONJO T, 1968, J BIOL CHEM, V243, P3553; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; HUBBELL WL, 1994, MEMBRANE PROTEIN STR, P00224; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCHAOURAB H, IN PRESS BIOCHEMISTR; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P29; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; MONTECUCCO C, 1992, FEMS MICROBIOL IMMUN, V105, P101; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSS J, 1995, BACTERIAL TOXINS VIR, V8; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SHIN YK, 1992, BIOPHYS J, V61, P1443, DOI 10.1016/S0006-3495(92)81950-1; SILVERMAN JA, 1994, J MEMBRANE BIOL, V137, P17; SILVERMAN JA, 1994, J BIOL CHEM, V269, P22524; TORTORELLA D, 1995, J BIOL CHEM, V270, P27446, DOI 10.1074/jbc.270.46.27446; VANNESS BG, 1980, J BIOL CHEM, V255, P717; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043	34	113	114	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					810	812		10.1126/science.273.5276.810	http://dx.doi.org/10.1126/science.273.5276.810			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8670424				2022-12-24	WOS:A1996VB42900047
J	Li, H; Helling, R; Tang, C; Wingreen, N				Li, H; Helling, R; Tang, C; Wingreen, N			Emergence of preferred structures in a simple model of protein folding	SCIENCE			English	Article							GLOBULAR-PROTEINS; STABILITY; FORCES	Protein structures in nature often exhibit a high degree of regularity (for example, secondary structure and tertiary symmetries) that is absent from random compact conformations. With the use of a simple lattice model of protein folding, it was demonstrated that structural regularities are related to high ''designability'' and evolutionary stability. The designability of each compact structure is measured by the number oi sequences that can design the structure-that is, sequences that possess the structure as their nondegenerate ground state. Compact structures differ markedly in terms of their designability; highly designable structures emerge with a number of associated sequences much larger than the average. These highly designable structures possess ''proteinlike'' secondary structure and even tertiary symmetries. In addition, they are thermodynamically more stable than other structures. These results suggest that protein structures arg selected in nature because they are readily designed and stable against mutations, and that such a selection simultaneously leads to thermodynamic stability.	NEC RES INST,PRINCETON,NJ 08540	NEC Corporation				Tang, Chao/0000-0003-1474-3705				ABKEVICH VI, 1995, J MOL BIOL, V252, P460, DOI 10.1006/jmbi.1995.0511; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Chan HS, 1996, PROTEINS, V24, P335, DOI 10.1002/(SICI)1097-0134(199603)24:3<335::AID-PROT6>3.0.CO;2-F; CHAN HS, 1991, J CHEM PHYS, V95, P3775, DOI 10.1063/1.460828; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; CREIGHTON TE, 1992, PROTEIN FOLDING; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; GOVINDARAJAN S, 1995, BIOPOLYMERS, V36, P43, DOI 10.1002/bip.360360105; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; LAU KF, 1990, P NATL ACAD SCI USA, V87, P638, DOI 10.1073/pnas.87.2.638; LAU KF, 1989, MACROMOLECULES, V22, P3986, DOI 10.1021/ma00200a030; Li H., COMMUNICATION; Melin R., UNPUB; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; YUE K, 1995, P NATL ACAD SCI USA, V92, P146, DOI 10.1073/pnas.92.1.146	21	551	576	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1996	273	5275					666	669		10.1126/science.273.5275.666	http://dx.doi.org/10.1126/science.273.5275.666			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA249	8662562	Green Submitted			2022-12-24	WOS:A1996VA24900054
J	Gao, SJ; Kingsley, L; Hoover, DR; Spira, TJ; Rinaldo, CR; Saah, A; Phair, J; Detels, R; Parry, P; Chang, Y; Moore, PS				Gao, SJ; Kingsley, L; Hoover, DR; Spira, TJ; Rinaldo, CR; Saah, A; Phair, J; Detels, R; Parry, P; Chang, Y; Moore, PS			Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR VIRUS; AIDS; INFECTION; SYPHILIS; HIV; RESPONSES; PROTEINS; MEN	Background If Kaposi's sarcoma-associated herpesvirus (KSHV) is the cause of Kaposi's sarcoma, serologic evidence of infection should be present in patients before the disease develops. M Methods Using an immunoblot assay for two latent nuclear antigens of KSHV, we tested serum samples from homosexual male patients with the acquired immunodeficiency syndrome (AIDS) with and without Kaposi's sarcoma, HIV-infected men with hemophilia, HIV-seronegative blood donors, and HIV-seronegative patients with high titers of antibodies against Epstein-Barr virus (EBV). Serial serum samples obtained from patients with Kaposi's sarcoma before the diagnosis of the disease were tested for evidence of seroconversion. Results Of 40 patients with Kaposi's sarcoma, 32 (80 percent) were positive for antibodies against KSHV antigens by the immunoblot assay, as compared with only 7 of 40 homosexual men (18 percent) without Kaposi's sarcoma immediately before the onset of AIDS. Of 122 blood donors, 22 EBV-infected patients, and 20 HIV-infected men with hemophilia, none were seropositive. When studied by the immunoblot assay over a period of 13 to 103 months, 21 of the 40 patients with Kaposi's sarcoma (52 percent) seroconverted 6 to 75 months before the clinical appearance of Kaposi's sarcoma. The median duration of antibody seropositivity for KSHV-related latent nuclear antigens before the diagnosis of Kaposi's sarcoma was 33 months. Conclusions In most patients with Kaposi's sarcoma and AIDS, seroconversion to positivity for antibodies against KSHV-related nuclear antigens occurs before the clinical appearance of Kaposi's sarcoma. This supports the hypothesis that Kaposi's sarcoma results from infection with KSHV. (C) 1996, Massachusetts Medical Society.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10027; UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT INFECT DIS & MICROBIOL,PITTSBURGH,PA 15260; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,BALTIMORE,MD 21218; CTR DIS CONTROL & PREVENT,DIV AIDS SEXUALLY TRANSMITTED DIS,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,TB LAB RES,NATL CTR INFECT DIS,ATLANTA,GA 30341; NORTHWESTERN UNIV,SCH MED,COMPREHENS AIDS CTR,CHICAGO,IL 60611; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024	Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Northwestern University; University of California System; University of California Los Angeles	Gao, SJ (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,P&S 14-442,630 W 168TH ST,NEW YORK,NY 10032, USA.		Moore, Patrick/GVR-8294-2022; Gao, Shou-Jiang/B-8641-2012; Chang, Yuan/F-4146-2011; Moore, Patrick S./F-3960-2011	Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; Gao, Shou-Jiang/0000-0001-6194-1742; Kingsley, Lawrence/0000-0002-7000-8556	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035040, U01AI035039] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI35040, U01-AI35039] Funding Source: Medline; PHS HHS [U64CCU210852-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams V, 1995, LANCET, V346, P1715, DOI 10.1016/S0140-6736(95)92887-1; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BOSHOFF C, 1995, LANCET, V345, P1043; Boshoff C, 1996, LANCET, V347, P338, DOI 10.1016/S0140-6736(96)90524-3; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P186; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; GUPTA P, IN PRESS AIDS; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE W, 1987, P NATL ACAD SCI USA, V84, P570, DOI 10.1073/pnas.84.2.570; HICKS CB, 1987, ANN INTERN MED, V107, P492, DOI 10.7326/0003-4819-107-4-492; HICKS CB, 1987, ANN INTERN MED, V107, P946, DOI 10.7326/0003-4819-107-6-946_4; JOHNSON PDR, 1991, AIDS, V5, P419, DOI 10.1097/00002030-199104000-00010; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNETTE ET, 1993, EUR J CANCER, V29A, P1584, DOI 10.1016/0959-8049(93)90299-U; LEVY JA, 1995, LANCET, V346, P786, DOI 10.1016/S0140-6736(95)91611-3; Liebowitz David, 1993, P107; LIN JC, 1995, LANCET, V346, P1602; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; MILLER G, 1974, J INFECT DIS, V130, P187, DOI 10.1093/infdis/130.2.187; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PAGANO JS, 1995, ANTIVIRAL CHEMOTHERA, P155; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; RAHMAN MA, 1989, J INFECT DIS, V159, P472, DOI 10.1093/infdis/159.3.472; RANGAN SRS, 1977, J NATL CANCER I, V59, P165, DOI 10.1093/jnci/59.1.165; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; ROIZMAN B, 1995, NEW ENGL J MED, V332, P1227, DOI 10.1056/NEJM199505043321810; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SEIGNEURIN JM, 1987, INT J CANCER, V40, P349, DOI 10.1002/ijc.2910400311; Strathdee S A, 1996, AIDS, V10 Suppl A, pS51, DOI 10.1097/00002030-199601001-00008; TAPPERO JW, 1993, J AM ACAD DERMATOL, V28, P371, DOI 10.1016/0190-9622(93)70057-Z; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; ZALKA A, 1991, ANN INTERN MED, V114, P521, DOI 10.7326/0003-4819-114-6-521_2; ZURHAUSEN H, 1978, NATURE, V272, P373	44	482	494	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1996	335	4					233	241		10.1056/NEJM199607253350403	http://dx.doi.org/10.1056/NEJM199607253350403			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ532	8657239				2022-12-24	WOS:A1996UZ53200003
J	Mittal, R; Ahmadian, MR; Goody, RS; Wittinghofer, A				Mittal, R; Ahmadian, MR; Goody, RS; Wittinghofer, A			Formation of a transition-state analog of the Ras GTPase reaction by Ras center dot GDP, tetrafluoroaluminate, and GTPase-activating proteins	SCIENCE			English	Article							ESCHERICHIA-COLI; MECHANISM; GAP; HYDROLYSIS; BINDING; DOMAIN; SITE; FLUORIDE; P21; FLUORESCENCE	Unlike the alpha subunits of heterotrimeric guanosine triphosphate (GTP)-binding proteins, Ras-related GTP-binding proteins have hitherto been considered not to bind or become activated by tetrafluoroaluminate (AlF4-). However, the product of the proto-oncogene ras in its guanosine diphosphate (GDP)-bound form interacted with AlF4- in the presence of stoichiometric amounts of either of the guanosine triphosphatase (GTPase)-activating proteins (GAPs) p120(GAP) and neurofibromin. Neither oncogenic Ras nor a GAP mutant without catalytic activity produced such a complex. Together with the finding that the Ras-binding domain of the protein kinase c-Raf, whose binding site on Ras overlaps that of the GAPs, did not induce formation of such a complex, this result suggests that GAP and neurofibromin stabilize the transition state of the GTPase reaction of Ras.	MAX PLANCK INST MOLEK PHYSIOL, ABT STRUKTURELLE BIOL, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MOLEK PHYSIOL, PHYS BIOCHEM ABT, D-44139 DORTMUND, GERMANY	Max Planck Society; Max Planck Society			Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444				AHMADIAN MR, UNPUB; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CARLIER MF, 1989, BIOCHEMISTRY-US, V28, P1783, DOI 10.1021/bi00430a054; CODINA J, 1994, J BIOL CHEM, V269, P29339; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUTMANN DH, 1993, ONCOGENE, V8, P761; HAZLETT TL, 1991, FEBS LETT, V278, P225, DOI 10.1016/0014-5793(91)80122-J; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; JOHN J, 1989, NATO ADV SCI I A-LIF, V165, P209; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KAHN RA, 1991, J BIOL CHEM, V266, P15595; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MESTERS JR, 1993, FEBS LETT, V321, P149, DOI 10.1016/0014-5793(93)80097-E; MITTAL R, UNPUB; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; RENSLAND H, 1992, THESIS RUPRECHT KARL; SCHLICHTING I, UNPUB; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDOP C, 1984, J BIOL CHEM, V259, P696; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; WITTINGHOFER A, 1993, HDB EXPT PHARM, V108, P195	46	194	196	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 5	1996	273	5271					115	117		10.1126/science.273.5271.115	http://dx.doi.org/10.1126/science.273.5271.115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UV478	8658179				2022-12-24	WOS:A1996UV47800053
J	Cuvillier, O; Pirianov, G; Kleuser, B; Vanek, PG; Coso, OA; Gutkind, JS; Spiegel, S				Cuvillier, O; Pirianov, G; Kleuser, B; Vanek, PG; Coso, OA; Gutkind, JS; Spiegel, S			Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate	NATURE			English	Article							PROLIFERATION	CERAMIDE is an important regulatory participant of programmed cell death (apoptosis) induced by tumour-necrosis factor (TNF)-alpha and Fas ligand, members of the TNF superfamily(1-6). Conversely, sphingosine and sphingosine-1-phosphate, which are metabolites of ceramide, induce mitogenesis(7) and have been implicated as second messengers in cellular proliferation induced by platelet-derived growth factor and serum(8,9). Here we report that sphingosine-1-phosphate prevents the appearance of the key features of apoptosis, namely intranucleosomal DNA fragmentation and morphological changes, which result from increased concentrations of ceramide. Furthermore, inhibition of ceramide-mediated apoptosis by activation of protein kinase C results from stimulation of sphingosine kinase and the concomitant increase in intracellular sphingosine-l-phosphate. Finally sphingosine-1-phosphate not only stimulates the extracellular signal-regulated kinase (ERK) pathway(10), it counteracts the ceramide-induced activation of stress-activated protein kinase (SAPK/JNK). Thus, the balance between the intracellular levels of ceramide and sphingosine-1-phosphate and their regulatory effects on different family members of mitogen-activated protein kinases determines the fate of the cell.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007; TREVIGEN INC,GAITHERSBURG,MD 20877; NIDR,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			CUVILLIER, Olivier/B-2567-2009; Gutkind, J. Silvio/A-1053-2009; CUVILLIER, Olivier/S-1631-2019; Gutkind, J. Silvio/J-1201-2016	CUVILLIER, Olivier/0000-0003-3346-375X; CUVILLIER, Olivier/0000-0003-3346-375X; Gutkind, J. Silvio/0000-0002-5150-4482; Kleuser, Burkhard/0000-0002-1888-9595				BOMFELDT KE, 1995, J CELL BIOL, V130, P193; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUKE RC, 1992, CURRENT PROTOCOLS IM; GILL BM, 1994, IMMUNOL REV, V142, P113, DOI 10.1111/j.1600-065X.1994.tb00885.x; GULBINS E, 1995, IMMUNITY, V2, P1; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, CANCER RES, V54, P1707; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YATOMI T, 1995, ANAL BIOCHEM, V230, P315; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	30	1280	1330	2	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1996	381	6585					800	803		10.1038/381800a0	http://dx.doi.org/10.1038/381800a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UU356	8657285				2022-12-24	WOS:A1996UU35600064
J	Russell, RM				Russell, RM			Nutrition	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Russell, RM (corresponding author), TUFTS UNIV,JEAN MAYER USDA HUMAN NUTR RES CTR AGING,BOSTON,MA 02111, USA.							BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; *DIET GUID ADV COM, 1996, REP DIET GUID ADV CO, P1; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; IRIBARREN C, 1995, NEW ENGL J MED, V333, P686, DOI 10.1056/NEJM199509143331102; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MORGANTI CM, 1995, MED SCI SPORT EXER, V27, P906; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461	16	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1996	275	23					1828	1829		10.1001/jama.275.23.1828	http://dx.doi.org/10.1001/jama.275.23.1828			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ152	8642733				2022-12-24	WOS:A1996UQ15200032
J	Nelson, JR; Lawrence, CW; Hinkle, DC				Nelson, JR; Lawrence, CW; Hinkle, DC			Thymine-thymine dimer bypass by yeast DNA polymerase zeta	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CIS-SYN; INVITRO; GENE; MUTAGENESIS; REPLICATION; PROTEIN	The REV3 and REV7 genes of the yeast Saccharomyces cerevisiae are required for DNA damage-induced mutagenesis. The Rev3 and Rev7 proteins were shown to form a complex with DNA polymerase activity. This polymerase replicated past a thymine-thymine cis-syn cyclobutane dimer, a lesion that normally severely inhibits replication, with an efficiency of similar to 10 percent. In contrast, bypass replication efficiency with yeast DNA polymerase a was no more than 1 percent. The Rev3-Rev7 complex is the sixth eukaryotic DNA polymerase to be described, and is therefore called DNA polymerase zeta.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	University of Rochester; University of Rochester					NIGMS NIH HHS [GM21858, GM29686] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029686, R01GM021858] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAN GL, 1985, BIOCHEMISTRY-US, V24, P5723, DOI 10.1021/bi00342a006; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIEDBERG EC, 1995, DNA REPAIR; GEITZ RD, 1988, GENE, V74, P527; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LARSON KL, 1987, BIOCHEMISTRY-US, V26, P2471, DOI 10.1021/bi00383a011; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; NELSON J, UNPUB; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; RABKIN SD, 1983, P NATL ACAD SCI-BIOL, V80, P1541, DOI 10.1073/pnas.80.6.1541; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; SHIMIZU K, 1993, J BIOL CHEM, V268, P27148; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P1624, DOI 10.1021/bi00458a038; TORPEY LE, 1994, YEAST, V10, P1503, DOI 10.1002/yea.320101115	17	583	598	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1996	272	5268					1646	1649		10.1126/science.272.5268.1646	http://dx.doi.org/10.1126/science.272.5268.1646			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UR093	8658138				2022-12-24	WOS:A1996UR09300045
J	vonMutius, E; Illi, S; Nicolai, T; Martinez, FD				vonMutius, E; Illi, S; Nicolai, T; Martinez, FD			Relation of indoor heating with asthma, allergic sensitisation, and bronchial responsiveness: Survey of children in south Bavaria	BRITISH MEDICAL JOURNAL			English	Article							WOOD-BURNING STOVES; AIR	Objective-To investigate the relation between different types of heating and the prevalence of atopic diseases, skin test reactivity, and bronchial hyperresponsiveness. Design-Cross sectional survey-among school-children aged 9-11 years. Skin prick tests, pulmonary function tests, and bronchial challenge in the children and self completion of a written questionnaire by the children's parents. Subjects-1958 children in a rural area in southern Bavaria, Germany. Main outcome measures-Prevalence of asthma, hay fever, and atopic dermatitis as determined by parents' answers to a questionnaire; the atopic status of the child assessed by skin prick tests; and bronchial responsiveness to cold air challenge in the children. Resuls-After possible confounders were controlled for, the risk of developing hay fever (odds ratio=0.57; 95% confidence interval 0.34 to 0.98), atopy defined as at least one positive reaction to a panel of common aeroallergens (0.67; 0.49 to 0.93), sensitisation to pollen (0.60; 0.41 to 0.87), and of bronchial hyperresponsiveness (0.55;0.34-0.90) was significantly lower in children living in homes where coal or wood was used for heating than in children living in homes with other heating systems. Conclusions-Factors directly or indirectly related to the heating systems used in rural Bavarian homes decrease the susceptibility of children to becoming atopic and to developing bronchial hyperresponsiveness.	UNIV MUNICH,CHILDRENS HOSP,D-80337 MUNICH,GERMANY; UNIV ARIZONA,RESP SCI CTR,DEPT PEDIAT,TUCSON,AZ 85724	University of Munich; University of Arizona					NHLBI NIH HHS [HL15136] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BUTTERFIELD P, 1989, J ENVIRON HEALTH, V52, P172; COLLOFF MJ, 1994, CLIN EXP ALLERGY, V24, P94, DOI 10.1111/j.1365-2222.1994.tb00202.x; GOLD DR, 1992, CLIN CHEST MED, V13, P215; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; HONICKY RE, 1985, PEDIATRICS, V75, P587; KOSSOVE D, 1982, S AFR MED J, V61, P622; LARSON TV, 1994, ANNU REV PUBL HEALTH, V15, P133, DOI 10.1146/annurev.pu.15.050194.001025; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MORRIS K, 1990, AM J DIS CHILD, V144, P105, DOI 10.1001/archpedi.1990.02150250117047; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; PANDEY MR, 1987, INDOOR AIR QUALITY 1, V3, P25; SAMET JM, 1991, INDOOR AIR POLLUTION, P170; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VOLKMER RE, 1995, J PAEDIATR CHILD H, V31, P116, DOI 10.1111/j.1440-1754.1995.tb00758.x; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	18	82	83	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 8	1996	312	7044					1448	1450		10.1136/bmj.312.7044.1448	http://dx.doi.org/10.1136/bmj.312.7044.1448			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ296	8664621	Green Published			2022-12-24	WOS:A1996UQ29600023
J	Lohse, PA; Szostak, JW				Lohse, PA; Szostak, JW			Ribozyme-catalysed amino-acid transfer reactions	NATURE			English	Article							RNA	THE 'RNA world' hypothesis proposes an early stage in the evolution of life in which both genomic and catalytic functions were fulfilled by RNA(1). The evolution of RNA-catalysed protein synthesis would have been a necessary step in the transition from such an RNA world to modern protein-dominated biology, For this to have been possible, RNA must be capable of catalysing amide-bond formation using acylated carrier RNA substrates as amino-acid donors. We have used in vitro selection and evolution to isolate ribozymes with acyl transferase activity from a pool of random RNA sequences. One of these acyl transferases with a 5'-amino group transfers an amino acid to itself in a reaction that we propose to be analogous to peptidyl transfer on the ribosome.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHUNAG NM, 1971, BIOCHIM BIOPHYS ACTA, V228, P536, DOI 10.1016/0005-2787(71)90059-1; FAHNESTOCK S, 1970, BIOCHEMISTRY-US, V9, P2477, DOI 10.1021/bi00814a013; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; SYNETOS D, 1987, BIOCHIM BIOPHYS ACTA, V923, P275, DOI 10.1016/0304-4165(87)90014-6; ULANOVSKY L, 1990, NATURE, V343, P190, DOI 10.1038/343190a0; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0	10	175	211	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 30	1996	381	6581					442	444		10.1038/381442a0	http://dx.doi.org/10.1038/381442a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632803				2022-12-24	WOS:A1996UN47900056
J	Shibuya, H; Yamaguchi, K; Shirakabe, K; Tonegawa, A; Gotoh, Y; Ueno, N; Irie, K; Nishida, E; Matsumoto, K				Shibuya, H; Yamaguchi, K; Shirakabe, K; Tonegawa, A; Gotoh, Y; Ueno, N; Irie, K; Nishida, E; Matsumoto, K			TAB1: An activator of the TAK1 MAPKKK in TGF-beta signal transduction	SCIENCE			English	Article							GENE	Transforming growth factor-beta (TGF-B) regulates many aspects of cellular function. A member of the mitogen-activated protein kinase kinase kinase (MAPKKK) family, TAK1, was previously identified as a mediator in the signaling pathway of TGF-beta superfamily members. The yeast two-hybrid system has now revealed two human proteins, termed TAB1 and TAB2 (for TAK1 binding protein), that interact with TAK1. TAB1 and TAK1 were co-immunoprecipitated from mammalian cells. Overproduction of TAB1 enhanced activity of the plasminogen activator inhibitor 1 gene promoter, which is regulated by TGF-beta, and increased the kinase activity of TAK1. TAB1 may function as an activator of the TAK1 MAPKKK in TGF-beta signal transduction.	NAGOYA UNIV, FAC SCI, DEPT MOLEC BIOL, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN; RES DEV CORP JAPAN, PRECURSORY RES EMBRYON SCI & TECHNOL, HIKARI, KYOTO 61902, JAPAN; HOKKAIDO UNIV, FAC PHARMACEUT SCI, SAPPORO, HOKKAIDO 060, JAPAN; KYOTO UNIV, INST VIRUS RES, DEPT GENET & MOL BIOL, SAKYO KU, KYOTO 60601, JAPAN	Nagoya University; Japan Science & Technology Agency (JST); Hokkaido University; Kyoto University				Ueno, Naoto/0000-0002-8375-2317				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BANNO H, 1993, MOL CELL BIOL, V13, P4745, DOI 10.1128/MCB.13.8.4745; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JOHNSON AD, 1994, GENE, V147, P223, DOI 10.1016/0378-1119(94)90070-1; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OHTA S, 1992, FEBS LETT, V314, P356, DOI 10.1016/0014-5793(92)81505-G; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMAGUCHI K, UNPUB	24	509	538	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1996	272	5265					1179	1182		10.1126/science.272.5265.1179	http://dx.doi.org/10.1126/science.272.5265.1179			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM889	8638164				2022-12-24	WOS:A1996UM88900053
J	Rimm, EB; Ascherio, A; Giovannucci, E; Spiegelman, D; Stampfer, MJ; Willett, WC				Rimm, EB; Ascherio, A; Giovannucci, E; Spiegelman, D; Stampfer, MJ; Willett, WC			Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOTAL DIETARY FIBER; FOOD FREQUENCY QUESTIONNAIRE; BLOOD-LIPIDS; PRODUCTS; FAT; MORTALITY; REPRODUCIBILITY; CHOLESTEROL; VALIDITY; CANCER	Objective.-To examine prospectively the relationship between dietary fiber and risk of coronary heart disease. Design.-Cohort study. Setting.-In 1986, a total of 43 757 US male health professionals 40 to 75 years of age and free from diagnosed cardiovascular disease and diabetes completed a detailed 131-item dietary questionnaire used to measure usual intake of total dietary fiber and specific food sources of fiber. Main Outcome Measure.-Fatal and nonfatal myocardial infarction (MI). Results.-During 6 years of follow-up, we documented 734 cases of MI (229 were fatal coronary heart disease). The age-adjusted relative risk (RR) for total MI was 0.59 (95% confidence interval [CI], 0.46 to 0.76) among men in the highest quintile of total dietary fiber intake (median, 28.9 g/d) compared with men in the lowest quartile (median, 12.4 g/d). The inverse association was strongest for fatal coronary disease (RR, 0.45; 95% CI, 0.28 to 0.72). After controlling for smoking, physical activity and other known nondietary cardiovascular risk factors, dietary saturated fat, vitamin E, total energy intake, and alcohol intake, the RRs were only modestly attenuated. A 10-g increase in total dietary fiber corresponded to an RR for total MI of 0.81 (95% CI, 0.70 to 0.93). Within the three main food contributors to total fiber intake (vegetable, fruit, and cereal), cereal fiber was most strongly associated with a reduced risk of total MI (RR, 0.71; 95% CI, 0.55 to 0.91 for each 10-g increase in cereal fiber per day). Conclusions.-Our results suggest an inverse association between fiber intake and MI. These results support current national dietary guidelines to increase dietary fiber intake and suggest that fiber, independent of fat intake, is an important dietary component for the prevention of coronary disease.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Rimm, EB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JW, 1986, AM J GASTROENTEROL, V81, P907; ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; ASCHERIO A, 1995, AM J EPIDEMIOL, V141, pS65; BURR ML, 1989, LANCET, V2, P757; CARA L, 1992, AM J CLIN NUTR, V55, P81, DOI 10.1093/ajcn/55.1.81; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FESKENS EJM, 1994, AM J EPIDEMIOL, V140, P350, DOI 10.1093/oxfordjournals.aje.a117257; GABH Rose, 1982, WHO MONOGRAPH SERIES; HALLFRISCH J, 1995, AM J CLIN NUTR, V61, P379, DOI 10.1093/ajcn/61.2.379; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HOLLAND GWA, 1991, MCCANCE WIDDOWSONS C; HUMBLE CG, 1993, AM J PREV MED, V9, P197, DOI 10.1016/S0749-3797(18)30715-3; HUNNINGHAKE DB, 1994, AM J CLIN NUTR, V59, P1050, DOI 10.1093/ajcn/59.5.1050; JENKINS DJA, 1993, NEW ENGL J MED, V329, P21, DOI 10.1056/NEJM199307013290104; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KROMHOUT D, 1982, LANCET, V2, P518; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARCKMANN P, 1990, ATHEROSCLEROSIS, V80, P227, DOI 10.1016/0021-9150(90)90030-M; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; PAUL AA, 1978, MCCANCE WIDDOWSONS C, P37; PROSKY L, 1985, J ASSOC OFF ANA CHEM, V68, P677; PROSKY L, 1984, J ASSOC OFF ANA CHEM, V67, P1044; PROSKY L, 1988, J ASSOC OFF ANA CHEM, V71, P1017; RABEN A, 1994, AM J CLIN NUTR, V59, P1386, DOI 10.1093/ajcn/59.6.1386; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; ROTHMANN K, 1986, MODERN EPIDEMIOLOGY; SMITH U, 1994, AM J CLIN NUTR, V59, p686S, DOI 10.1093/ajcn/59.3.686S; SUNDELL IB, 1993, HAEMOSTASIS, V23, P45; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; Trowell HC, 1981, W DIS THEIR EMERGENC; VAHOUNY GV, 1980, LIPIDS, V15, P1012, DOI 10.1007/BF02534316; Vollendorf Nicholas W., 1993, Journal of Food Composition and Analysis, V6, P203, DOI 10.1006/jfca.1993.1023; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037; 1990, NIH903046 US DEP HLT; 1989, RECOMMENDED DIETARY; 1992, USDA HOME GARDEN B, V252	46	623	661	0	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					447	451		10.1001/jama.275.6.447	http://dx.doi.org/10.1001/jama.275.6.447			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627965				2022-12-24	WOS:A1996TU63800032
